PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ablooglu, AJ; Till, JH; Kim, K; Parang, K; Cole, PA; Hubbard, SR; Kohanski, RA				Ablooglu, AJ; Till, JH; Kim, K; Parang, K; Cole, PA; Hubbard, SR; Kohanski, RA			Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYL-TRANSFER-REACTIONS; TYROSINE KINASE; TRANSITION-STATE; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ACTIVE-SITE; AUTOPHOSPHORYLATION; SUBUNIT; DOMAIN	The interaction of a synthetic tetrafluorotyrosyl peptide substrate with the activated tyrosine kinase domain of the insulin receptor was studied by steady-state kinetics and x-ray crystallography. The pH-rate profiles indicate that the neutral phenol, rather than the chemically more reactive phenoxide ion, is required for enzyme-catalyzed phosphorylation. The pK(alpha) of the tetrafluorotyrosyl hydroxyl is elevated 2 pH units on the enzyme compared with solution, whereas the phenoxide anion species behaves as a weak competitive inhibitor of the tyrosine kinase. A structure of the binary enzyme-substrate complex shows the tetrafluorotyrosyl OH group at hydrogen bonding distances from the side chains of Asp(1132) and Arg(1136), consistent with elevation of the pK(alpha). These findings strongly support a reaction mechanism favoring a dissociative transition state.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University; New York University; Johns Hopkins University	Kohanski, RA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.		Parang, Keykavous/F-9236-2010; Parang, Keykavous/ABC-1584-2021	Parang, Keykavous/0000-0001-8600-0893; Hubbard, Stevan/0000-0002-2707-9383	NCI NIH HHS [CA74305] Funding Source: Medline; NIDDK NIH HHS [DK52916, DK50074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074305, R01CA074305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050074, R01DK052916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 1996, BIOCHEMISTRY-US, V35, P10949, DOI 10.1021/bi960613h; ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; Admiraal SJ, 2000, J AM CHEM SOC, V122, P2145, DOI 10.1021/ja993942g; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; Cann AD, 1997, ANAL BIOCHEM, V247, P327, DOI 10.1006/abio.1997.2077; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; Cole PA, 1999, PHARMACOL THERAPEUT, V82, P219, DOI 10.1016/S0163-7258(98)00046-1; COLE PA, 1994, J BIOL CHEM, V269, P30880; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EPSTEIN J, 1964, J AM CHEM SOC, V86, P3075, DOI 10.1021/ja01069a021; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Florian J, 1997, J AM CHEM SOC, V119, P5473, DOI 10.1021/ja964270m; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; GRANOT J, 1980, BIOCHEMISTRY-US, V19, P3537, DOI 10.1021/bi00556a019; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7587, DOI 10.1021/ja00201a048; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7597; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3624; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHAN SA, 1970, J CHEM SOC B, P1172, DOI 10.1039/j29700001172; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; KIRBY AJ, 1968, J CHEM SOC B, P135, DOI 10.1039/j29680000135; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KOHANSKI RA, 1991, BIOCHEMISTRY-US, V30, P2406, DOI 10.1021/bi00223a016; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRAFNY EAM, 1994, PROTEIN SCI, V3, P176; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	50	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30394	30398		10.1074/jbc.M003524200	http://dx.doi.org/10.1074/jbc.M003524200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869355	hybrid			2022-12-25	WOS:000089577900065
J	Battistutta, R; Sarno, S; De Moliner, E; Papinutto, E; Zanotti, G; Pinna, LA				Battistutta, R; Sarno, S; De Moliner, E; Papinutto, E; Zanotti, G; Pinna, LA			The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; TYROSINE KINASE; ZEA-MAYS; II-ALPHA; SUBUNIT; ENZYME; CLASSIFICATION; TRANSFORMATION; PROLIFERATION; PURIFICATION	The structure of a complex between the catalytic subunit of Zea mays CK2 and the nucleotide binding site-directed inhibitor emodin (3-methyl-1,6,8-trihydroxyanthraquinone) was solved at 2.6-Angstrom resolution. Emodin enters the nucleotide binding site of the enzyme, filling a hydrophobic pocket between the N-terminal and the C-terminal lobes, in the proximity of the site occupied by the base rings of the natural co-substrates. The interactions between the inhibitor and CK2 alpha are mainly hydrophobic. Although the C-terminal domain of the enzyme is essentially identical to the ATP-bound form, the beta-sheet in the N-terminal domain is altered by the presence of emodin. The structural data presented here highlight the flexibility of the kinase domain structure and provide information for the design of selective ATP competitive inhibitors of protein kinase CK2.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, CNR, Biomembrane Res Ctr, I-35121 Padua, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Padua, CNR, Biopolymer Res Ctr, I-35131 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Zanotti, G (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	zanotti@chor.unipd.it		Zanotti, Giuseppe/0000-0002-0945-6501				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; FREDENHAGEN A, 1995, J ANTIBIOT, V48, P1355, DOI 10.7164/antibiotics.48.1355; Guerra B, 1998, ACTA CRYSTALLOGR D, V54, P143, DOI 10.1107/S0907444997010184; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIVAK KJ, 1990, GENETICS, V124, P303; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STIGARE J, 1994, CELL MOL BIOL RES, V40, P463; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zhang LS, 1998, ONCOGENE, V16, P2855, DOI 10.1038/sj.onc.1201813	28	132	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29618	29622		10.1074/jbc.M004257200	http://dx.doi.org/10.1074/jbc.M004257200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882732	hybrid			2022-12-25	WOS:000089439800059
J	Nusrat, A; Chen, JA; Foley, CS; Liang, TW; Tom, J; Cromwell, M; Quan, C; Mrsny, RJ				Nusrat, A; Chen, JA; Foley, CS; Liang, TW; Tom, J; Cromwell, M; Quan, C; Mrsny, RJ			The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; POSSIBLE INVOLVEMENT; MEMBRANE-PROTEIN; ZO-1; CELLS; PERMEABILITY; INTERACTS; RECEPTOR	Occludin is an integral membrane protein that has been suggested to play a role in the organization and dynamic function of the epithelial tight junction (TJ). A number of other proteins have also been described to localize to the TJ, We have used a novel bait peptide method to investigate potential protein-protein interactions of the putative coiled-coil domain of occludin with some of these other TJ proteins. A 27-amino acid peptide of the human occludin sequence was synthesized, biotinylated at the N terminus, and modified to contain a photoactive moiety at either its hydrophobic or hydrophilic surface. These bait peptides were alpha-helical in solution, characteristic of coiled-coil structures. Photoactivation studies in the presence and absence of control peptides were used to assess the potential interactions in polarized sheets of a human intestinal cell line T84. Although a large number of proteins associated with the TJ or that are known to be involved in regulatory events of epithelial cells failed to be specifically labeled, occludin itself, ZO-1, protein kinase C-zeta c-Yes, the regulatory subunit of phosphatidylinositol 3-kinase, and the gap junction component connexin 26 were specifically labeled. Our data demonstrate the potential of one specific domain of occludin, contained within 27 amino acids, to coordinate the binding of proteins that have been previously suggested to modulate TJ structure and function.	Genentech Inc, Dept Pharmaceut Res & Dev, Drug Delivery Biol Grp, S San Francisco, CA 94080 USA; Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Bioorgan Chem, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Emory University; Roche Holding; Genentech; Roche Holding; Genentech	Mrsny, RJ (corresponding author), Genentech Inc, Dept Pharmaceut Res & Dev, Drug Delivery Biol Grp, MS 6,1 DNA Way, S San Francisco, CA 94080 USA.		Nusrat, Asma/B-3887-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK055679] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK55679] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED ARH, 1992, BIOCHEM J, V286, P377, DOI 10.1042/bj2860377; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; Chanson M, 1996, AM J PHYSIOL-CELL PH, V271, pC533, DOI 10.1152/ajpcell.1996.271.2.C533; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Furuse M, 1996, J CELL SCI, V109, P429; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1996, EUR J IMMUNOL, V26, P1781, DOI 10.1002/eji.1830260818; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; GORRY PA, 1990, ANAL CHEM, V62, P570, DOI 10.1021/ac00205a007; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KAOUTZANI P, 1993, AM J PHYSIOL, V264, pC1327, DOI 10.1152/ajpcell.1993.264.5.C1327; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Rasenick Mark M., 1993, Methods (Orlando), V5, P252, DOI 10.1006/meth.1993.1031; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SCHONBRUNN A, 1993, ENDOCRINOLOGY, V132, P146, DOI 10.1210/en.132.1.146; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SINGER KL, 1994, J BIOL CHEM, V269, P16108; STADDON JM, 1995, J CELL SCI, V108, P609; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; VanItallie CM, 1997, J CELL SCI, V110, P1113; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; WONG V, 1997, AM J PHYSIOL, V42, pC1859; Yap AS, 1998, J MEMBRANE BIOL, V163, P159, DOI 10.1007/s002329900380	55	153	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29816	29822		10.1074/jbc.M002450200	http://dx.doi.org/10.1074/jbc.M002450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887180	hybrid			2022-12-25	WOS:000089439800087
J	Roman, LJ; Martasek, P; Miller, RT; Harris, DE; de la Garza, MA; Shea, TM; Kim, JJP; Masters, BSS				Roman, LJ; Martasek, P; Miller, RT; Harris, DE; de la Garza, MA; Shea, TM; Kim, JJP; Masters, BSS			The C termini of constitutive nitric-oxide synthases control electron flow through the flavin and heme domains and affect modulation by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RELAXING FACTOR; BINDING DOMAIN; REDUCTASE; ISOFORMS; IDENTIFICATION; MACROPHAGES; ACTIVATION; EXPRESSION; ARGININE	The sequences of nitric-oxide synthase flavin domains closely resemble that of NADPH-cytochrome P450 reductase (CPR). However, all nitric-oxide synthase (NOS) isoforms are 20-40 residues longer in the C terminus, forming a "tail" that is absent in CPR. To investigate its function, we removed the 33 and 42 residue C termini from neuronal NOS (nNOS) and endothelial NOS (eNOS), respectively. Both truncated enzymes exhibited cytochrome c reductase activities without calmodulin that were 7-21-fold higher than the nontruncated forms. With calmodulin, the truncated and wild-type enzymes reduced cytochrome c at approximately equal rates. Therefore, calmodulin functioned as a nonessential activator of the wild-type enzymes and a partial noncompetitive inhibitor of the truncated mutants. Truncated nNOS and eNOS plus calmodulin catalyzed NO formation at rates that were 45 and 33%, respectively, those of their intact forms. Without calmodulin, truncated nNOS and eNOS synthesized NO at rates 14 and 20%, respectively, those with calmodulin. By using stopped-flow spectrophotometry, we demonstrated that electron transfer into and between the two flavins is faster in the absence of the C terminus. Although both CPR and intact NOS can exist in a stable, one-electron-reduced semiquinone form, neither of the truncated enzymes do so. We propose negative modulation of FAD-FMN interaction by the C termini of both constitutive NOSs.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Health San Antonio; Medical College of Wisconsin	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419, R01GM052682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52682, GM52419] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ALEXANDER LM, 1980, MICROSOMES DRUG OXID, P285; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; IGNARRO L J, 1988, P427; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Martasek P, 1999, METHOD ENZYMOL, V301, P70; MASTERS BSS, 2000, IN PRESS NITRIC OXID; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; XIE QW, 1994, J BIOL CHEM, V269, P28500; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	40	109	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29225	29232		10.1074/jbc.M004766200	http://dx.doi.org/10.1074/jbc.M004766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871625	hybrid			2022-12-25	WOS:000089439800008
J	Lesage, F; Terrenoire, C; Romey, G; Lazdunski, M				Lesage, F; Terrenoire, C; Romey, G; Lazdunski, M			Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and G(s), G(i), and G(q) protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; CLONING; LOCALIZATION; ACTIVATION; NEURONS; CELLS; TASK; PH	Mechano-sensitive and fatty acid-activated K+ belong to the structural class of K+ channel with two pore domains. Here, we report the isolation and the characterization of a novel member of this family. This channel, called TREK2, is closely related to TREK1 (78% of homology), Its gene is located on chromosome 14q31. TREK2 is abundantly expressed in pancreas and kidney and to a lower level in brain, testis, colon, and small intestine. In the central nervous system, TREK2 has a widespread distribution with the highest levels of expression in cerebellum, occipital lobe, putamen, and thalamus. In transfected cells, TREK2 produces rapidly activating and non-inactivating outward rectifier K+ currents. The single-channel conductance is 100 picosiemens at +40 mV in 150 mM K+, The currents can be strongly stimulated by polyunsaturated fatty acid such as arachidonic, docosahexaenoic, and linoleic acids and by lysophosphatidylcholine, The channel is also activated by acidification of the intracellular medium. TREK2 is blocked by application of intracellular cAMP. As with TREK1, TREK2 is activated by the volatile general anesthetics chloroform, halothane, and isoflurane and by the neuroprotective agent riluzole. TREK2 can be positively or negatively regulated by a variety of neurotransmitter receptors, Stimulation of the G(s)-coupled receptor 5HT4sR or the G(q)-coupled receptor mGluR1 inhibits channel activity, whereas activation of the G(1)-coupled receptor mGluR2 increases TREK2 currents. These multiple types of regulations suggest that TREK2 plays an important role as a target of neurotransmitter action.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arrighi I, 1998, FEBS LETT, V425, P310, DOI 10.1016/S0014-5793(98)00260-9; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; CARMAN WF, 1989, LANCET, V2, P588; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Duprat F, 2000, MOL PHARMACOL, V57, P906; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1998, GENOMICS, V51, P478, DOI 10.1006/geno.1998.5397; Lesage F, 1999, CURR TOP MEMBR, V46, P199; Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LOPES CM, 1994, NATURE, V367, P607; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V242, P17, DOI 10.1098/rspb.1990.0097; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 2000, NEUROSCIENCE, V95, P893; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x	34	257	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28398	28405		10.1074/jbc.M002822200	http://dx.doi.org/10.1074/jbc.M002822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880510	hybrid			2022-12-25	WOS:000089330700010
J	Sabatino, DE; Wong, C; Cline, AP; Pyle, L; Garrett, LJ; Gallagher, PG; Bodine, DM				Sabatino, DE; Wong, C; Cline, AP; Pyle, L; Garrett, LJ; Gallagher, PG; Bodine, DM			A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; BETA-GLOBIN; HYPERSENSITIVE SITE; HEREDITARY SPHEROCYTOSIS; DEVELOPMENTAL REGULATION; INDEPENDENT EXPRESSION; MESSENGER-RNA; CELLS; SEQUENCE	In red blood cells ankyrin (ANK-1) provides the primary linkage between the erythrocyte membrane skeleton and the plasma membrane. We have previously demonstrated that a 2-71-bp 5'-flanking region of the ANK-1 gene has promoter activity in erythroid, but not non-erythroid, cell lines. To determine whether the ankyrin promoter could direct erythroid-specific expression in vivo, we analyzed transgenic mice containing the ankyrin promoter fused to the human (A)gamma-globin gene. Sixteen of 17 lines expressed the transgene in erythroid cells indicating nearly position-independent expression. We also observed a significant correlation between the level of Ank/(A)gamma-globin mRNA and transgene copy number. The level of Ank/(A)gamma mRNA averaged 11% of mouse alpha-globin mRNA per gene copy at all developmental stages. The addition of the HS2 enhancer from the beta-globin locus control region to the Ank/(A)gamma-globin transgene resulted in Ank/(A)gamma-globin mRNA expression in embryonic and fetal erythroid cells in six of eight lines but resulted in absent or dramatically reduced levels of Ank/(A)gamma-globin mRNA in adult erythroid cells in eight of eight transgenic lines. These data indicate that the minimal ankyrin promoter contains all sequences necessary and sufficient for erythroid-specific, copy number-dependent, position-independent expression of the human (A)gamma-globin gene.	NHGRI, Hematopoiesis Sect, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); George Washington University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Bodine, DM (corresponding author), NHGRI, Hematopoiesis Sect, Genet & Mol Biol Branch, Bldg 49,Room 3A14 MSC 4442, Bethesda, MD 20892 USA.		Pyle, Louise C/AAR-3513-2021	Pyle, Louise C/0000-0002-8933-9320				BENZ EJ, 1993, MOL BASIS BLOOD DIS, P257; Birkenmeier CS, 1998, GENOMICS, V50, P79, DOI 10.1006/geno.1998.5305; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; Maniatis T., 1989, MOL CLONING LAB MANU; MORROW JS, 1996, HDB PHYSL, P485; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; ORKIN SH, 1992, BLOOD, V80, P575; PAWLIK KM, 1995, DEV BIOL, V169, P728, DOI 10.1006/dbio.1995.1182; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PORCHER C, 1995, J BIOL CHEM, V270, P17368, DOI 10.1074/jbc.270.29.17368; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; SAVVIDES P, 1993, BLOOD, V82, P2953; STAMATOYANNOPOU.G, 1993, MOL BASIS BLOOD DISE, P107; STARCK J, 1994, BLOOD, V84, P1656; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; Vyas P, 1999, DEVELOPMENT, V126, P2799; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812	40	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28549	28554		10.1074/jbc.M004043200	http://dx.doi.org/10.1074/jbc.M004043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878017	hybrid			2022-12-25	WOS:000089330700030
J	Shiina, T; Kawasaki, A; Nagao, T; Kurose, H				Shiina, T; Kawasaki, A; Nagao, T; Kurose, H			Interaction with beta-arrestin determines the difference in internalization behavior between beta(1)- and beta(2)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; DESENSITIZATION; SEQUESTRATION; TRAFFICKING; PHOSPHORYLATION; ENDOCYTOSIS; DOMAINS	The beta(1)-adrenergic receptor (beta(1)AR) shows the resistance to agonist-induced internalization. As beta-arrestin is important for internalization, we examine the interaction of beta-arrestin with beta(1)AR with three different methods: intracellular trafficking of beta-arrestin, binding of in vitro translated beta-arrestin to intracellular domains of beta(1)- and beta(2)ARs, and inhibition of beta AR-stimulated adenylyl cyclase activities by beta-arrestin. The green fluorescent protein-tagged beta-arrestin 2 translocates to and stays at the plasma membrane by beta(2)AR stimulation. Although green fluorescent protein-tagged beta-arrestin 2 also translocates to the plasma membrane, it returns to the cytoplasm 10-30 min after beta(1)AR stimulation. The binding of in vitro translated beta-arrestin 1 and beta-arrestin 2 to the third intracellular loop and the carboxyl tail of beta(1)AR is lower than that of beta(2)AR, The fusion protein of beta-arrestin 1 with glutathione S-transferase inhibits the beta(1)- and beta(2)AR-stimulated adenylyl cyclase activities, although inhibition of the beta(1)AR-stimulated activity requires a higher concentration of the fusion protein than that of the beta(1)AR-stimulated activity. These results suggest that weak interaction of beta(1)AR with beta-arrestins explains the resistance to agonist-induced internalization. This is further supported by the finding that beta-arrestin can induce internalization of beta(1)AR when beta-arrestin 1 does not dissociate from beta(1)AR by fusing to the carboxyl tail of beta(1)AR.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kurose, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kurose@mol.f.u-tokyo.ac.jp						Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohm SK, 1997, BIOCHEM J, V322, P1; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Furukawa H, 2000, J BIOCHEM-TOKYO, V127, P151, DOI 10.1093/oxfordjournals.jbchem.a022577; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Krueger KM, 1997, J BIOL CHEM, V272, P5; KUROSE H, 1993, MOL PHARMACOL, V43, P444; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; NANOFF C, 1989, J CARDIOVASC PHARM, V13, P198, DOI 10.1097/00005344-198902000-00004; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; Rousseau G, 1996, MOL PHARMACOL, V49, P752; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sato Y, 1996, EUR J PHARMACOL, V315, P363, DOI 10.1016/S0014-2999(96)00648-6; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; ZHOU XM, 1991, J BIOL CHEM, V266, P7462; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	32	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29082	29090		10.1074/jbc.M909757199	http://dx.doi.org/10.1074/jbc.M909757199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862778	hybrid			2022-12-25	WOS:000089330700096
J	Yamaguchi, K; von Knoblauch, K; Subramanian, AR				Yamaguchi, K; von Knoblauch, K; Subramanian, AR			The plastid ribosomal proteins - Identification of all the proteins in the 30 S subunit of an organelle ribosome (chloroplast)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; NUCLEOTIDE-SEQUENCE; AMINO-ACID; BACTERIAL-RIBOSOMES; GENE-EXPRESSION; BINDING-PROTEIN; MESSENGER-RNAS; IN-VIVO; TRANSLATION; TRANSCRIPTION	Identification of all the protein components of a plastid (chloroplast) ribosomal 30 S subunit has been achieved, using two-dimensional gel electropholesis, high performance liquid chromatography purification, N-terminal sequencing, polymerase chain reaction-based screening of cDNA library, nucleotide sequencing, and mass spectrometry (electrospray ionization, matrixassisted laser desorption/ionization time-of-flight, and reversed-phase HPLC coupled with electrospray ionization mass spectrometry), 25 proteins were identified, of which 21 are orthologues of all Escherichia coli 30 S ribosomal proteins (S1-S21), and 4 are plastid-specific ribosomal proteins (PSRPs) that have no homologues in the mitochondrial, archaebacterial, or cytosolic ribosomal protein sequences in data bases. 12 of the 25 plastid 30 S ribosomal proteins (PRPs) are encoded in the plastid genome, whereas the remaining 13 are encoded by the nuclear genome. Post-translational transit peptide cleavage sites for the maturation of the 13 cytosolically synthesized PRPs, and post-translational N-terminal processing in the maturation of the 12 plastid synthesized PRPs are described. Post-translational modifications in several PRPs were observed: alpha-N-acetylation of S9, N-terminal processings leading to five mature forms of S6 and two mature forms of S10, C-terminal and/or internal modifications in S1, 514, S18, and S19, leading to two distinct forms differing in mass and/or charge (the corresponding modifications are not observed in E, coli). The four PSRPs in spinach plastid 30 S ribosomal subunit (PSRP-1, 26.8 kDa, pi 6.2; PSRP-2, 21.7 kDa, pi 5.0; PSRP-3, 13.8 kDa, pI 4.9; PSRP-4, 5.2 kDa, pI 11.8) comprise 16% (67.6 kDa) of the total protein mass of the 30 S subunit (429.3 kDa), PSRP-1 and PSRP-3 show sequence similarities with hypothetical photosynthetic bacterial proteins, indicating their possible origins in photosynthetic bacteria. We propose the hypothesis that PSRPs form a ''plastid translational regulatory module" on the 30 S ribosomal subunit structure for the possible mediation of nuclear factors on plastid translation.	Univ Arizona, Dept Biochem Biosci W, Tucson, AZ 85721 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University of Arizona; Max Planck Society	Subramanian, AR (corresponding author), Univ Arizona, Dept Biochem Biosci W, Tucson, AZ 85721 USA.							Agalarov SC, 2000, SCIENCE, V288, P107, DOI 10.1126/science.288.5463.107; Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSCH M, 1985, J BIOL CHEM, V260, P237; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BUBUNENKO MG, 1994, J BIOL CHEM, V269, P18223; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; CUMBERLIDGE AG, 1979, J MOL BIOL, V25, P169; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V20, P4153, DOI 10.1093/nar/20.16.4153; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; *GEN COMP GROUP, 1998, WISC PACK VERS 10 0; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HITZ H, 1977, EUR J BIOCHEM, V75, P497, DOI 10.1111/j.1432-1033.1977.tb11551.x; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KAMP RM, 1983, H-S Z PHYSIOL CHEM, V364, P1777, DOI 10.1515/bchm2.1983.364.2.1777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MALONE P, 1988, J CELL BIOL, V106, P609; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Nakamura T, 1999, FEBS LETT, V460, P437, DOI 10.1016/S0014-5793(99)01390-3; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Price CA, 1996, PLANT MOL BIOL, V30, P225, DOI 10.1007/BF00020109; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; SCHMIDT J, 1992, PLANT MOL BIOL, V20, P459, DOI 10.1007/BF00040605; SCHMIDT J, 1993, BIOCHEM MOL BIOL INT, V29, P25; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1974, EUR J BIOCHEM, V45, P541, DOI 10.1111/j.1432-1033.1974.tb03579.x; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1990, MOL BIOL PLASTIDS, P191; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; TAN XL, 1994, J BIOL CHEM, V269, P20905; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; WEGLOHNER W, 1991, FEBS LETT, V279, P193, DOI 10.1016/0014-5793(91)80147-U; Weglohner W, 1995, BIOCHEM MOL BIOL INT, V36, P265; Weglohner W, 1997, EUR J BIOCHEM, V249, P383, DOI 10.1111/j.1432-1033.1997.00383.x; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WITTMANN HG, 1982, ANNU REV BIOCHEM, V51, P155, DOI 10.1146/annurev.bi.51.070182.001103; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; ZHOU DX, 1989, MOL GEN GENET, V219, P204, DOI 10.1007/BF00261178	52	152	188	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28455	28465		10.1074/jbc.M004350200	http://dx.doi.org/10.1074/jbc.M004350200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874039	hybrid			2022-12-25	WOS:000089330700018
J	Fontaine, T; Simenel, C; Dubreucq, G; Adam, O; Delepierre, M; Lemoine, J; Vorgias, CE; Diaquin, M; Latge, JP				Fontaine, T; Simenel, C; Dubreucq, G; Adam, O; Delepierre, M; Lemoine, J; Vorgias, CE; Diaquin, M; Latge, JP			Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; PH-REGULATED GENE; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; 1,3-BETA-D-GLUCAN SYNTHASE; MASS-SPECTROMETRY; BETA-GLUCAN; GLYCOPROTEIN GLYCANS; METHYL GLYCOSIDES; BGL2 GENE	Physical and biological properties of the fungal cell wall are determined by the composition and arrangement of the structural polysaccharides. Cell wall polymers of fungi are classically divided into two groups depending on their solubility in hot alkali. We have analyaed the alkali-insoluble fraction of the Aspergillus fumigatus cell wall, which is the fraction believed to be responsible for fungal cell wall rigidity. Using enzymatic digestions with recombinant endo-beta-1,3-glucanase and chitinase, fractionation by gel filtration, affinity chromatography with immobilized lectins, and high performance liquid chromatography, Several fractions that contained specific interpolysaccharide covalent linkages were isolated. Unique features of the A. fumigatus cell wall are (i) the absence of beta-1,6-glucan and (ii) the presence of a linear beta-1,3/1,4-glucan, never previously described in fungi. Galactomannan, chitin, and beta-1,3-glucan were also found in the alkali-insoluble fraction. The beta-1,3-glucan is a branched polymer with 4% of beta-1,6 branch points. Chitin, galactomannan, and the Linear beta-1,3/1,4-glucan were covalently linked to the nonreducing end of beta-1,3-glucan side chains. As in Saccharomyces cerevisiae, chitin was linked via a beta-1,4 linkage to beta-1,3-glucan. The data obtained suggested that the branching of beta-1,3-glucan is an early event in the construction of the cell wall, resulting in an increase of potential acceptor sites for chitin, galactomannan, and the linear beta-1,3/1,4-glucan.	Inst Pasteur, Lab Aspergillus, F-75724 Paris 15, France; Inst Pasteur, Lab Resonance Magnet Nucl, F-75724 Paris 15, France; Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Univ Athens, Dept Biol, Div Biochem & Mol Biol, GR-15701 Athens, Greece	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; Universite de Lille; National & Kapodistrian University of Athens	Fontaine, T (corresponding author), Inst Pasteur, Lab Aspergillus, 25 Rue Dr Roux, F-75724 Paris 15, France.	tfontain@pasteur.fr	Fontaine, thierry/Q-2201-2018; lemoine, jerome/C-4272-2014; Fontaine, Thierry/F-8227-2011; latge, jean paul/F-3581-2011; Latge, Jean Paul/C-9846-2014	Fontaine, thierry/0000-0002-8184-789X; lemoine, jerome/0000-0002-5497-6880; 				ARAKI Y, 1979, EUR J BIOCHEM, V102, P35, DOI 10.1111/j.1432-1033.1979.tb06260.x; ARONSON JM, 1981, BIOL CONIDIAL FUNGI, V2, P459; AufauvreBrown A, 1997, FUNGAL GENET BIOL, V21, P141, DOI 10.1006/fgbi.1997.0959; BARRETOBERGTER E, 1981, CARBOHYD RES, V95, P205, DOI 10.1016/S0008-6215(00)85577-9; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BEAUVAIS A, 1993, J GEN MICROBIOL, V139, P3071, DOI 10.1099/00221287-139-12-3071; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BOYD J, 1985, CARBOHYD RES, V139, P35; BULIGA GS, 1986, CARBOHYD RES, V157, P139, DOI 10.1016/0008-6215(86)85065-0; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Delay C, 1997, CARBOHYD RES, V302, P67, DOI 10.1016/S0008-6215(97)00101-8; DESVAUX H, 1994, J MAGN RESON SER A, V108, P219, DOI 10.1006/jmra.1994.1114; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; Fleet G.H., 1991, YEASTS, VVol. 4, P199, DOI [10.1002/jobm.19720120411, DOI 10.1002/JOBM.19720120411]; Fontaine T, 1997, EUR J BIOCHEM, V243, P315, DOI 10.1111/j.1432-1033.1997.0315a.x; FONTAINE T, 1991, ANAL BIOCHEM, V199, P154, DOI 10.1016/0003-2697(91)90083-6; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HARTLAND RP, 1991, P ROY SOC B-BIOL SCI, V246, P155, DOI 10.1098/rspb.1991.0138; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; Hartland RP, 1996, J BIOL CHEM, V271, P26843, DOI 10.1074/jbc.271.43.26843; HEARN VM, 1994, MICROBIOL-UK, V140, P789, DOI 10.1099/00221287-140-4-789; JOHNSON AR, 1971, ANAL BIOCHEM, V44, P628, DOI 10.1016/0003-2697(71)90252-1; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAPTEYN JC, 1994, EUR J CELL BIOL, V65, P402; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; LATGE JP, 1994, INFECT IMMUN, V62, P5424; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MELLADO E, 1995, MOL GEN GENET, V246, P353, DOI 10.1007/BF00288608; MOL PC, 1987, FEMS MICROBIOL LETT, V41, P95; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Mouyna I, 1998, MICROBIOL-SGM, V144, P3171, DOI 10.1099/00221287-144-11-3171; MSRA V, 1997, YEAST, V13, P1145; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; Nakazawa T, 1998, J BACTERIOL, V180, P2079, DOI 10.1128/JB.180.8.2079-2086.1998; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PERLIN AS, 1962, CAN J CHEM, V40, P50, DOI 10.1139/v62-009; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; QODATA H, 1996, SCIENCE, V272, P279; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; Sarthy AV, 1997, MICROBIOL-SGM, V143, P367, DOI 10.1099/00221287-143-2-367; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; SIETSMA JH, 1979, J GEN MICROBIOL, V114, P99, DOI 10.1099/00221287-114-1-99; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TAKADA H, 1981, J BIOCHEM-TOKYO, V89, P1265; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VORGIAS CE, 1993, CHITIN ENZYMOLOGY, P417; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WILLKER W, 1993, MAGN RESON CHEM, V31, P287, DOI 10.1002/mrc.1260310315; YU LP, 1993, J BIOMOL NMR, V3, P429	68	255	275	1	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27594	27607						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869365				2022-12-25	WOS:000089197100012
J	Belaaouaj, AA; Li, AG; Wun, TC; Welgus, HG; Shapiro, SD				Belaaouaj, AA; Li, AG; Wun, TC; Welgus, HG; Shapiro, SD			Matrix metalloproteinases cleave tissue factor pathway inhibitor - Effects on coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; DEPENDENT BLOOD-COAGULATION; SKIN FIBROBLAST COLLAGENASE; SUBSTRATE-SPECIFICITY; MACROPHAGE ELASTASE; UNSTABLE ANGINA; FACTOR XA; EXPRESSION; IDENTIFICATION; LOCALIZATION	The capacity of inflammatory cell-derived matrix metalloproteinases (MMPs) to cleave tissue factor pathway inhibitor (TFPI) and alter its activity was investigated. MMP-7 (matrilysin) rapidly cleaved TFPI to a major 35-kDa product. In contrast, MMP-1 (collagenase-1), MMP-9 (gelatinase B), and MMP-12 (macrophage elastase) cleaved TFPI into several fragments including the 35-kDa band. However, rates of cleavage were most rapid for MMP-7 and MMP-9. NH2-terminal amino acid sequencing revealed that MMP-12 cleaved TFPI at Lys(20)-Leu(21)(close to Kunitz I domain and producing a 35-kDa band), Arg(83)-Ile(84) (between Kunitz I and II domains), and Ser(174)-Thr(175) (between Kunitz II and III domains). MMP-7 and MMP-9 cleaved TFPI at Lys20-Leu21 with additional COOH-terminal processing. These MMPs did not cleave tissue factor (TF), factor VII, and factor Xa. Proteolytic cleavage by MMP-1, MMP-7, MMP-9, and MMP-12 resulted in considerable loss of TFPI activity. These observations indicate specific cleavage of TFPI by MMPs, which broadens their substrate profile. Go-localization of MMPs, TF, and TFPI in atherosclerotic tissues suggests that release of MMPs from inflammatory cell leukocytes may effect TF-mediated coagulation.	Washington Univ, Sch Med, Div Pulm & Crit Care Med, Barnes Jewish Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Monsanto Corp Res, St Louis, MO 63198 USA	Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Monsanto	Belaaouaj, AA (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care Med, Barnes Jewish Hosp, 216 S Kingshighway, St Louis, MO 63110 USA.		Bentaher, Abderrazzaq/M-4424-2017; A, Bentaher/F-6531-2018	A, Bentaher/0000-0001-6001-5456				BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BELAAOUAJ A, 1993, THROMB RES, V69, P547, DOI 10.1016/0049-3848(93)90059-W; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Brophy C M, 1991, Ann Vasc Surg, V5, P229, DOI 10.1007/BF02329378; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; Drew AF, 1997, LAB INVEST, V77, P291; GALLIS ZS, 1994, J CLIN INVEST, V94, P2493; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HAUST M D, 1960, Heart Bull, V9, P90; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIGUCHI DA, 1992, BLOOD, V79, P1712; KETTNER C, 1981, BIOCHEM J, V195, P369, DOI 10.1042/bj1950369; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Li A, 1998, THROMB HAEMOSTASIS, V80, P423, DOI 10.1055/s-0037-1615224; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; PARKS WC, 1998, MATRIX METALLOPROTEI; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; SIRES UI, 1993, J BIOL CHEM, V268, P2069; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WUN TC, 1992, THROMB HAEMOSTASIS, V68, P54	44	96	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27123	27128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859319				2022-12-25	WOS:000089144800062
J	Miconnet, I; Servis, C; Cerottini, JC; Romero, P; Levy, F				Miconnet, I; Servis, C; Cerottini, JC; Romero, P; Levy, F			Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A*0201-restricted peptide tumor antigen MAGE-3(271-279)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC T-LYMPHOCYTES; HUMAN GENE MAGE-3; 20S PROTEASOME; BETA-SUBUNITS; CELL-PROTEINS; YEAST; DEGRADATION; GENERATION; MELANOMA; SEQUENCE	The proteasome plays a crucial role in the proteolytic processing of antigens presented to T cells in the context of major histocompatibility complex class I molecules. However, the rules governing the specificity of cleavage sites are still largely unknown. We have previously shown that a cytolytic T lymphocyte-defined antigenic peptide derived from the MAGE-3 tumor-associated antigen (MAGE-3(271-279) FLWGPRALV in one-letter code) is not presented at the surface of melanoma cell lines expressing the MAGE-3 protein. By using purified proteasome and MAGE-3(271-279) peptides extended at the C terminus by 6 amino acids, we identified predominant cleavages after residues 278 and 280 but no detectable cleavage after residue Val(279), the C terminus of the antigenic peptide. In the present study, we have investigated the influence of Pro(275), Leu(278), and Glu(280) On the proteasomal digestion of MAGE-3(271-285) substituted at these positions. We show that positions 278 and 280 are major proteasomal cleavage sites because they tolerate most amino acid substitutions. In contrast, the peptide bond after Val(279) is a minor cleavage site, influenced by both distal and proximal amino acid residues.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne	Levy, F (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, Ch Des Boveresses 155, CH-1066 Epalinges, Switzerland.							Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Herman J, 1996, IMMUNOGENETICS, V43, P377, DOI 10.1007/s002510050078; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; NOPPEN C, 2000, IN PRESS INT J CANC; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; SHASTRI N, 1995, J IMMUNOL, V155, P4339; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Theobald M, 1998, J EXP MED, V188, P1017, DOI 10.1084/jem.188.6.1017; Valmori D, 1999, J EXP MED, V189, P895, DOI 10.1084/jem.189.6.895; Valmori D, 1997, CANCER RES, V57, P735; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; YellenShaw AJ, 1997, J IMMUNOL, V158, P1727	30	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26892	26897						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859301				2022-12-25	WOS:000089144800032
J	Tanimura, A; Tojyo, Y; Turner, RJ				Tanimura, A; Tojyo, Y; Turner, RJ			Evidence that type I, II, and III inositol 1,4,5-trisphosphate receptors can occur as integral plasma membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; OPERATED HTRP3 CHANNELS; IP3 RECEPTOR; CARCINOMA-CELLS; RAT-LIVER; LOCALIZATION; ACTIVATION; IDENTIFICATION; RETICULUM; NEURONS	A number of previous reports have suggested that inositol 1,4,5-trisphosphate receptors (IP(3)Rs) are present in the plasma membranes of cells. We confirm this directly in the present study by demonstrating that a significant proportion of the IP,Rs found in A431 cells, Jurkat cells, and rat parotid acini can be biotinylated by the extracellular application of sulfo-N-hydroxysuccinimide-biotin to intact cells. This labeling cannot be accounted for by the reaction of sulfo-N-hydroxysuccinimide-biotin with intracellular IP(3)Rs since calnexin and the SERCA2 ATPase, both integral membrane proteins of the endoplasmic reticulum, are not labeled under the same experimental conditions. individual IP3R subtypes were detected using subtype-specific antibodies. A431 cells expressed only the type-3 IP3R, and 23% of this protein was in the biotinylated (plasma membrane) fraction. Jurkat cells and rat parotid cells expressed all three IP3R subtypes. Contrary to earlier results suggesting that only the type-3 IP3R might localize to the plasma membrane, we found that significant amounts (5-14%) of all three subtypes could be identified in the biotinylated fractions of Jurkat and rat parotid cells. Our results suggest a role for IP,Rs in plasma membrane as well as intracellular membrane function.	Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan; NIDCR, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	Health Sciences University of Hokkaido; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Tanimura, A (corresponding author), Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan.	tanimura@hoku-iryo-u.ac.jp			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000415, ZIADE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FADOOL DA, 1994, P NATL ACAD SCI USA, V91, P9471, DOI 10.1073/pnas.91.20.9471; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HURLEY WL, 1985, J IMMUNOL METHODS, V85, P195, DOI 10.1016/0022-1759(85)90287-X; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; Lischka FW, 1999, BIOPHYS J, V76, P1410, DOI 10.1016/S0006-3495(99)77302-9; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SHARP AH, 1992, J BIOL CHEM, V267, P7444; TANIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1055, P273, DOI 10.1016/0167-4889(90)90043-D; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Ueda H, 2000, MOL PHARMACOL, V57, P108; Ueda H, 1996, J NEUROSCI, V16, P2891; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	32	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27488	27493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874040				2022-12-25	WOS:000089144800108
J	Tulk, BM; Schlesinger, PH; Kapadia, SA; Edwards, JC				Tulk, BM; Schlesinger, PH; Kapadia, SA; Edwards, JC			CLIC-1 functions as a chloride channel when expressed and purified from bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SUBCELLULAR-DISTRIBUTION; CYSTIC-FIBROSIS; PROTEIN; P64; PURIFICATION; EPITHELIA; KIDNEY	CLIC-1 is a member of a family of proteins related to the bovine intracellular chloride channel p64 which has been proposed to function as a chloride channel. We expressed CLIC-1 as a glutathione S-transferase fusion protein in bacteria. The fusion protein was purified by glutathione affinity, and CLIC-1 was released from its fusion partner by digestion with thrombin. After further purification, CLIC-1 was reconstituted into phospholipid vesicles by detergent dialysis. Chloride permeability of reconstituted vesicles was assessed using a valinomycin dependent chloride efflux assay, demonstrating increased vesicular chloride permeability with CLIC-1 compared with control. CLIC-1-dependent chloride permeability was inhibited by indanyloxyacetic acid-94 with an apparent IC50 of 8.6 mu M. The single channel properties of CLIC-1 were determined using the planar lipid bilayer technique. We found that CLIC-1 forms a voltage-dependent, Cl-selective channel with a rectifying current-voltage relationship and single channel conductances of 161 +/- 7.9 and 67.5 +/- 6.9 picosiemens in symmetric 300 and 150 mM KCI, respectively. The anion selectivity of this activity is Pr approximate to Cl > I. The open probability of CLIC-1 channels in planar bilayers was decreased by indanyloxyacetic acid-94 with an apparent IC50 of 86 mu M at 50 mV. These data convincingly demonstrate that CLIC-1 is capable of forming a novel, chloride-selective channel in the absence of other subunits or proteins.	St Louis VA Med Ctr, Renal Div 657111JC, St Louis, MO 63106 USA; St Louis Univ, Dept Internal Med, St Louis, MO 63106 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63106 USA	Saint Louis University; Washington University (WUSTL)	Edwards, JC (corresponding author), St Louis VA Med Ctr, Renal Div 657111JC, 915 N Grand Blvd, St Louis, MO 63106 USA.		Schlesinger, Paul H/C-6049-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR44838] Funding Source: Medline; NIDDK NIH HHS [R29 DK46212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ARMITAGE P, 1971, STATISTICAL METHODS, P189; Chuang JZ, 1999, J NEUROSCI, V19, P2919; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; Colombini M., 1986, ION CHANNEL RECONSTI, P533; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; FRENCH RJ, 1986, ION CHANNEL RECONSTI, P363; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR, P635; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; HILLE B, 1992, ION CHANNELS EXCITAB, P183; Hosie AM, 1997, TRENDS NEUROSCI, V20, P578, DOI 10.1016/S0166-2236(97)01127-2; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482, P19; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LEHNINGER AL, 1976, BIOCHEMISTRY; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; Sambrook J., 2002, MOL CLONING LAB MANU; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; TILMANN M, 1991, PFLUG ARCH EUR J PHY, V418, P556, DOI 10.1007/BF00370571; TULK BM, 1998, AM J PHYSIOL, V274, pF1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391	34	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26986	26993						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874038				2022-12-25	WOS:000089144800043
J	Huang, XP; Kagami, N; Inoue, H; Kojima, M; Kimura, T; Makabe, O; Suzuki, K; Takahashi, K				Huang, XP; Kagami, N; Inoue, H; Kojima, M; Kimura, T; Makabe, O; Suzuki, K; Takahashi, K			Identification of a glutamic acid and an aspartic acid residue essential for catalytic activity of aspergillopepsin II, a non-pepsin type acid proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	8th International Conference on Aspartic Proteinases	SEP 07-12, 1999	FUNCHAL, PORTUGAL				INSENSITIVE CARBOXYL PROTEINASE; SITE-DIRECTED MUTAGENESIS; SCYTALIDIUM-LIGNICOLUM; PROTEASE-B; NUCLEOTIDE-SEQUENCE; PEPSTATIN; NIGER; GENE; PURIFICATION; EXPRESSION	Aspergillopepsin II from Aspergillus niger var. mac rosporus is a non-pepsin type or pepstatin-insensitive acid proteinase. To identify the catalytic residues of the enzyme, all acidic residues that are conserved in the homologous proteinases of family A4 were replaced with Asn, Gin, or Ala using site-directed mutagenesis. The wild-type and mutant pro-enzymes were heterologously expressed in Escherichia coli and refolded in vitro. The wild-type pro-enzyme was shown to be processed into a two-chain active enzyme under acidic conditions. Most of the recombinant mutant pro-enzymes showed significant activity under acidic conditions because of autocatalytic activation except for the D123N, D123A, E219Q, and E219A mutants. The D123A, E219Q, and E219A mutants showed neither enzymatic activity nor autoprocessing activity under acidic conditions. The circular dichroism spectra of the mutant pro- and mature enzymes were essentially the same as those of the wildtype pro- and mature enzyme, respectively, indicating that the mutant pro-enzymes were correctly folded. In addition, two single and one double mutant pro-enzyme, D123E, E219D, and D123E/E219D, did not show enzymatic activity under acidic conditions. Taken together, Glu-219 and Asp-123 are deduced to be the catalytic residues of aspergillopepsin II.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1138654, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2220002, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo University of Pharmacy & Life Sciences; University of Tokyo; Meiji Holdings Co., Ltd.; University of Tokyo	Takahashi, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	kenjitak@ls.toyaku.ac.jp						ANSON ML, 1939, J GEN PHYSIOL, V22, P77; AOYAGI T, 1971, J ANTIBIOT, V24, P687, DOI 10.7164/antibiotics.24.687; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BROEKHUIJSEN MP, 1993, J BIOTECHNOL, V31, P135, DOI 10.1016/0168-1656(93)90156-H; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Dunn BM, 1991, STRUCTURE FUNCTION A; FUSEK M, 1990, J BIOL CHEM, V265, P1496; INOUE H, 1991, J BIOL CHEM, V266, P19484; Inoue H, 1996, EUR J BIOCHEM, V237, P719, DOI 10.1111/j.1432-1033.1996.0719p.x; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; James MNG, 1998, ASPARTIC PROTEINASES; Jara P, 1996, MOL GEN GENET, V250, P97, DOI 10.1007/BF02191829; JOHNSON JE, 1998, HDB PROTEOLYTIC ENZY, P963; Kakimori T, 1996, BIOSCI BIOTECH BIOCH, V60, P1210; KOAZE Y, 1964, AGR BIOL CHEM TOKYO, V28, P216, DOI 10.1080/00021369.1964.10858233; Kojima M, 2000, BIOCHEMISTRY-US, V39, P1364, DOI 10.1021/bi991584o; KOSTKA V, 1985, ASPARTIC PROTEINASES; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XL, 1990, J BIOL CHEM, V265, P1490; LIN XL, 1991, STRUCTURE FUNCTION A, P1; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; ODA K, 1994, J BIOL CHEM, V269, P26518; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; Oyama H, 1999, J BIOL CHEM, V274, P27815, DOI 10.1074/jbc.274.39.27815; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI K, 1991, J BIOL CHEM, V266, P19480; TAKAHASHI K, 1995, METHOD ENZYMOL, V248, P146; Takahashi K, 1997, BIOSCI BIOTECH BIOCH, V61, P381, DOI 10.1271/bbb.61.381; TAKAHASHI K, 1994, ASPARTIC PROTEINASES; TANG J, 1971, J BIOL CHEM, V246, P4510; TANG J, 1998, HDB PROTEOLYTIC ENZY, P802; Tang J, 1977, ACID PROTEASES STRUC; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P1305, DOI 10.1080/00021369.1989.10869464	39	18	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26607	26614		10.1074/jbc.M910243199	http://dx.doi.org/10.1074/jbc.M910243199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	348RF	10854444	hybrid			2022-12-25	WOS:000088999700099
J	Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM				Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM			Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice	ONCOGENE			English	Article						medullary thyroid carcinoma; multiple endocrine neoplasia type 2B; human RET transgenic mice	TYROSINE KINASE; SOMATIC MUTATIONS; PROTOONCOGENE; 2A; ACTIVATION; GERMLINE; RECEPTOR; GENE	Multiple endocrine neoplasia type 2B (MEN 2B) is a familial cancer syndrome, in which the cardinal feature is medullary thyroid carcinoma (MTC), a malignant tumor arising from the calcitonin producing thyroid C-cells, MEN 2B is associated with a germline point mutation in the RET proto-oncogene, leading to a Met-->Thr substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein. we used the human calcitonin gene (CALC-1) promoter to generate transgenic mice expressing either the human RET oncogene with the MEN2B-specific 918 Met-->Thr mutation (CALC-MEN2B-RET) or the human nonmutated RET proto-oncogene (CALC-WT-AET) in the C-cells, At 20-22 months of age three out of eight CALC-MEN2B-RET transgenic founders presented with macroscopic bilateral MTC, In two founders nodular C-cell hyperplasia (CCH) was observed. Thyroid abnormalities were never observed in CALC-WT-RET transgenic mice or control non-transgenic mice analysed at this age. In some mice from established CALC-MEN2B-RET transgenic lines nodular CCH was observed from 8 months on whereas MTC was detected in 13% of mice from one CALC-MEN2B-RET line, from the age of 11 months on. These results show for the first time that the MEN2B mutation in the RET oncogene predisposes mice for MTC.	Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University	Acton, DS (corresponding author), Univ Utrecht, Med Ctr, Dept Internal Med, POB 85500, NL-3508 GA Utrecht, Netherlands.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P793; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; DONISKELLER H, 1993, HUM MOL GENET, V2, P1579; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HORN RC, 1951, CANCER, V4, P697, DOI 10.1002/1097-0142(195107)4:4<697::AID-CNCR2820040407>3.0.CO;2-8; Landsvater RM, 1996, CANCER RES, V56, P4853; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CANCER RES, V56, P1241; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; STEINER AL, 1968, MEDICINE, V47, P371, DOI 10.1097/00005792-196809000-00001; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0	23	64	65	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3121	3125		10.1038/sj.onc.1203648	http://dx.doi.org/10.1038/sj.onc.1203648			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871866				2022-12-25	WOS:000087903900011
J	Jin, YH; Yoo, KJ; Lee, YH; Lee, SK				Jin, YH; Yoo, KJ; Lee, YH; Lee, SK			Caspase 3-mediated cleavage of p21(WAF1/CIP1) associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CARCINOMA CELLS; ACTIVATION; P21(CIP1/WAF1); P27(KIP1); DEATH; CDK2	Apoptosis of SK-HEP-1 human hepatoma cells induced by treatment with ginsenoside Rh2 (G-Rh2) is associated with rapid and selective activation of cyclin A-associated cyclin-dependent kinase 2 (Cdk2). Here, we show that in apoptotic cells, the Cdk inhibitory protein p21(WAF1/CIP1), which is associated with the cyclin A-Cdk2 complex, undergoes selective proteolytic cleavage. In contrast, another Cdk inhibitory protein, p27(KIP1), which is associated with cyclin A-Cdk2 and cyclin E-Cdk2 complexes, remained unaltered during apoptosis, Ectopic overexpression of p21(WAF1/CIP1) suppressed apoptosis as well as cyclin A-Cdk2 activity induced by treatment of SK-HEP-1 cells with G-Rh2. The suppressive effects of p21(WAF1/CIP1) were much higher in the cells transfected with p21D112N, an expression vector that encodes a p21(WAF1/CIP1) mutant resistant to caspase 3 cleavage. Overexpression of cyclin A in SK-HEP-1 cells dramatically up-regulated cyclin A-Cdk2 activity and accordingly enhances apoptosis induced by treatment with G-Rh2. These up-regulating effects were blocked by coexpression of a dominant negative allele of cdk2. Furthermore, olomoucine, a specific inhibitor of Cdks, also blocked G-Rh2-induced apoptosis. These data suggest that the induction of apoptosis in human hepatoma cells treated with G-Rh2 occurs by a mechanism that involves the activation of cyclin A-Cdk2 by caspase 3-mediated cleavage of p21(WAF1/CIP1).	Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Korea Ginseng & Tobacco Res Inst, Taejon 305345, South Korea	Seoul National University (SNU)	Lee, SK (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.		jin, yun/GQZ-6618-2022					CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Lee KY, 1996, CANCER LETT, V110, P193, DOI 10.1016/S0304-3835(96)04502-8; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; OTTA T, 1997, LIFE SCI, V60, pPL39; Park JA, 1997, CANCER LETT, V121, P73, DOI 10.1016/S0304-3835(97)00333-9; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shi LF, 1996, J IMMUNOL, V157, P2381; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	17	132	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30256	30263		10.1074/jbc.M001902200	http://dx.doi.org/10.1074/jbc.M001902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10884382	hybrid			2022-12-25	WOS:000089577900048
J	Kratzmeier, M; Albig, W; Hanecke, K; Doenecke, D				Kratzmeier, M; Albig, W; Hanecke, K; Doenecke, D			Rapid dephosphorylation of H1 histones after apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; PROTEIN-KINASE-C; PHOSPHORYLATION SITES; CAPILLARY ELECTROPHORESIS; PHORBOL ESTER; HL60 CELLS; EXPRESSION; PHOSPHATASE; SEPARATION; CHROMATIN	H1 histones are involved in the formation of higher order chromatin structures and in the modulation of gene expression. Changes in chromatin structure are a characteristic initial feature of apoptosis. We therefore have investigated the histone H1 pattern of the human leukemic cell line HL60 undergoing programmed cell death, as induced by topoisomerase I inhibition. Histone H1 proteins were isolated and analyzed by high performance liquid chromatography and capillary zone electrophoresis. DNA fragmentation after apoptosis induction was monitored by agarose gel electrophoresis. The patterns of the three H1 histone subtypes extractable from apoptotic HL60 cells significantly differed from those of control cells in showing a decrease of phosphorylated H1 subtypes and an increase of the respective dephosphorylated forms. This dephosphorylation of H1 histones could be observed already 45 min after apoptosis induction and preceded internucleosomal DNA cleavage by approximately 2 h. We conclude that during apoptotic DNA fragmentation, the H1 histones become rapidly dephosphorylated by a yet unknown protein phosphatase.	Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	University of Gottingen	Doenecke, D (corresponding author), Univ Gottingen, Inst Biochem & Mol Cell Biol, Humboldtallee 23, D-37073 Gottingen, Germany.	ddoenec@gwdg.de						AIBIG W, 1998, FEBS LETT, V435, P245; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; DAWSON JF, 1994, ANAL BIOCHEM, V220, P340, DOI 10.1006/abio.1994.1347; DOENECKE D, 1994, J CELL BIOCHEM, V54, P423, DOI 10.1002/jcb.240540409; DRABENT B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P311, DOI 10.1016/0167-4781(93)90162-7; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Gamble TN, 1999, ANAL CHEM, V71, P3469, DOI 10.1021/ac990276t; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; HUANG HC, 1985, FEBS LETT, V183, P270, DOI 10.1016/0014-5793(85)80791-2; JERZMANOWSKI A, 1992, J BIOL CHEM, V267, P8514; Kaneko YS, 1999, LIFE SCI, V65, P2251, DOI 10.1016/S0024-3205(99)00490-7; Kantarjian H, 1999, SEMIN HEMATOL, V36, P16; Kratzmeier M, 1999, BIOCHEM J, V337, P319, DOI 10.1042/0264-6021:3370319; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; Meergans T, 1997, DNA CELL BIOL, V16, P1041, DOI 10.1089/dna.1997.16.1041; Mills JC, 1998, J CELL SCI, V111, P625; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLINS DE, 1978, AM SCI, V66, P704; Paulson JR, 1996, J CELL SCI, V109, P1437; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schmitt CA, 1999, J PATHOL, V187, P127; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Swank RA, 1997, BIOCHEMISTRY-US, V36, P13761, DOI 10.1021/bi9714363; Talasz H, 1998, J BIOL CHEM, V273, P32236, DOI 10.1074/jbc.273.48.32236; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Wei J, 1998, ELECTROPHORESIS, V19, P2356, DOI 10.1002/elps.1150191316; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Wolffe A. P., 1999, CHROMATIN STRUCTURE; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhu WH, 1996, BIOCHEM PHARMACOL, V51, P1229	45	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30478	30486		10.1074/jbc.M003956200	http://dx.doi.org/10.1074/jbc.M003956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10874037	hybrid			2022-12-25	WOS:000089577900077
J	Lee, JY; Hannun, YA; Obeid, LM				Lee, JY; Hannun, YA; Obeid, LM			Functional dichotomy of protein kinase C (PKC) in tumor necrosis factor-alpha (TNF-alpha) signal transduction in L929 cells - Translocation and inactivation of PKC by TNF-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DNA-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; GROWTH-INHIBITION; INDUCED APOPTOSIS; ARACHIDONIC-ACID; CYTOTOXIC ACTION; RAT FIBROBLASTS; PHOSPHOLIPASE-D; AKT KINASE	Tumor necrosis factor-alpha (TNF-alpha) is capable of inducing a variety of biologic responses through multiple signaling pathways. Because of the potential role of protein kinase C (PKC) in apoptosis, we examined the effects and mechanisms of TNF-alpha on PKC regulation, specifically on PKC alpha. In L929 murine fibroblasts, TNF-alpha (0.55 nM) caused potent inhibition of PBC alpha activity and induced translocation of PKC alpha from the cytosol to the membrane. Treatment of cells with TNF-alpha also induced dephosphorylation of PKC alpha as detected by a mobility shift on SDS-polyacrylamide gel and inhibition of PKC phosphorylation as probed by anti-phospho-PKC antibodies. Since PKC is activated directly by diacylglycerol and inactivated indirectly by ceramide, we next examined the roles of these lipid mediators in the regulation of PKC alpha, Addition of TNF-alpha led to accumulation of both ceramide and diacylglycerol, Fumonisin B-1, an inhibitor of ceramide synthase, and glutathione, an inhibitor of neutral sphingomyelinase, both reversed the effect of TNF-alpha on PKC alpha activity, suggesting that ceramide production is necessary for the action of TNF-alpha. The diacylglycerol mimic phorbol 12-myristate 13-acetate was sufficient to cause translocation of PKC alpha, but not the mobility shift. Okadaic acid at 2 nM, a potent protein phosphatase inhibitor, blocked the effects of TNF-alpha on PKC alpha activity, but not on PKC alpha translocation, thus demonstrating that dephosphorylation and translocation are independent processes. These results demonstrate that PKC alpha acts as a downstream target for TNF-alpha and that different lipid-mediated pathways in TNF-alpha signaling lead to opposing signals in the regulation of PKC alpha activity.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 602 Strom Thurmond Bldg,114 Doughty St, Charleston, SC 29403 USA.			obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG-16853-0, 1R29-AG-12467, 5T32 AG00029] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012467, T32AG000029] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CACACE AM, 1993, ONCOGENE, V8, P2095; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KARIYA K, 1987, FEBS LETT, V219, P119, DOI 10.1016/0014-5793(87)81202-4; KARIYA K, 1987, FEBS LETT, V217, P69, DOI 10.1016/0014-5793(87)81245-0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WANG E, 1991, J BIOL CHEM, V266, P14486; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; ZHOU W, 1993, J BIOL CHEM, V268, P23041; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	68	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29290	29298		10.1074/jbc.M000170200	http://dx.doi.org/10.1074/jbc.M000170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887171	hybrid			2022-12-25	WOS:000089439800017
J	Rauen, M; Burtelow, MA; Dufault, VM; Karnitz, LM				Rauen, M; Burtelow, MA; Dufault, VM; Karnitz, LM			The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; DNA-DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE RAD1(+); SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; CONTROL GENE; STRUCTURAL HOMOLOG; CDC25 PHOSPHATASE; ATPASE ACTIVITY; MOUSE HOMOLOGS	DNA damage activates cell cycle checkpoints that prevent progression through the cell cycle. In yeast, the DNA damage checkpoint response is regulated by a series of genes that have mammalian homologs, including rad1, rad9, hus1, and rad17. On the basis of sequence homology, yeast and human Rad1, Rad9, and Hus1 protein homologs are predicted to structurally resemble the sliding clamp PCNA. Likewise, Rad17 homologs have extensive homology with replication factor C (RFC) subunits (p36, p37, p38, p40, and p140), which form a clamp loader for PCNA. These observations predict that Rad1, Hus1, and Rad9 might interact with Rad17 as a clamp-clamp loader pair during the DNA damage response. In this report, we demonstrate that endogenous human Rad17 (hRad17) interacts with the PCNA-related checkpoint proteins hRad1, hRad9, and hHus1. Mutational analysis of hRad1 and hRad17 demonstrates that this interaction has properties similar to the interaction between RFC and PCNA, a well characterized clamp-clamp loader pair. Moreover, we show that DNA damage affects the association of hRad17 with the clamp-like checkpoint proteins. Collectively, these data provide the first experimental evidence that hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9 in manner similar to the interaction between RFC and PCNA.	Mayo Clin, Div Dev Oncol Res, Rochester, MN 55902 USA; Mayo Clin, Div Radiat Oncol, Rochester, MN 55902 USA; Mayo Clin, Dept Immunol, Rochester, MN 55902 USA; Mayo Clin, Dept Mol Pharmacol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Guggenheim 13, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu						Bao SD, 1998, CELL GROWTH DIFFER, V9, P961; Bao SD, 1999, CANCER RES, V59, P2023; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Bluyssen HAR, 1999, GENOMICS, V55, P219, DOI 10.1006/geno.1998.5642; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; CASPARI T, 2000, MOL CELL BIOL, V74, P1264; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	47	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29767	29771		10.1074/jbc.M005782200	http://dx.doi.org/10.1074/jbc.M005782200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884395	hybrid			2022-12-25	WOS:000089439800080
J	Runge, S; Nielsen, FC; Nielsen, J; Lykke-Andersen, J; Wewer, UM; Christiansen, J				Runge, S; Nielsen, FC; Nielsen, J; Lykke-Andersen, J; Wewer, UM; Christiansen, J			H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASH1 MESSENGER-RNA; ROUGH ENDOPLASMIC-RETICULUM; LARGE RIBOSOMAL-RNA; XENOPUS-OOCYTES; GERM PLASM; NUCLEAR-LOCALIZATION; STRUCTURAL ELEMENTS; VEGETAL CORTEX; HNRNP-I; GENE	H19 RNA is a major oncofetal 2.5-kilobase untranslated RNA of unknown function. The maternally expressed H19 gene is located 90 kilobase pairs downstream from the paternally expressed insulin-like growth factor II (IGF-II) gene on human chromosome 11 and mouse chromosome 7; and due to their reciprocal imprinting and identical spatiotemporal expression, it is assumed that the two genes are functionally coupled. Here we show that human H19 RNA contains four attachment sites for the oncofetal IGF-II mRNA-binding protein (IMP) with apparent K-d values in the 0.4-1.3 nM range. The multiple attachment sites are clustered within a 700-nucleotide segment encoded by exons 4 and 5. This 3'-terminal segment targets H19 RNA to lamellipodia and perinuclear regions in dispersed fibroblasts where IMP is also localized. The results suggest that IMP participates in H19 RNA localization and provides a link between the IGF-II and H19 genes at post-transcriptional events during mammalian development.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, RNA Regulat Ctr, DK-1307 Copenhagen K, Denmark; Univ Copenhagen, Inst Mol Pathol, DK-1307 Copenhagen, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen O, Denmark	University of Copenhagen; University of Copenhagen; Rigshospitalet	Christiansen, J (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, RNA Regulat Ctr, Solvgade 83 H, DK-1307 Copenhagen K, Denmark.		Christiansen, Jan/L-3312-2014; Nielsen, Finn Cilius/AAA-4926-2020	Christiansen, Jan/0000-0001-8624-4601; Nielsen, Jacob/0000-0001-9842-2276; Lykke-Andersen, Jens/0000-0003-1821-0754; Nielsen, Finn Cilius/0000-0002-9829-1031				Adam GIR, 1996, DEVELOPMENT, V122, P839; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gautreau D, 1997, DEVELOPMENT, V124, P5013; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Jaenisch R, 1998, CIBA F SYMP, V214, P200; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; King ML, 1999, BIOESSAYS, V21, P546, DOI 10.1002/(SICI)1521-1878(199907)21:7<546::AID-BIES3>3.0.CO;2-Z; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Kobayashi S, 1998, CURR BIOL, V8, P1117, DOI 10.1016/S0960-9822(98)70466-X; KOBAYASHI S, 1993, SCIENCE, V260, P1521, DOI 10.1126/science.7684857; LEE JE, 1990, DEVELOPMENT, V110, P151; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; POIRIER F, 1991, DEVELOPMENT, V113, P1105; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schmidt JV, 1999, P NATL ACAD SCI USA, V96, P9733, DOI 10.1073/pnas.96.17.9733; SVENSSON K, 1995, MECH DEVELOP, V51, P31, DOI 10.1016/0925-4773(94)00345-N; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Wickham L, 1999, MOL CELL BIOL, V19, P2220	46	139	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29562	29569		10.1074/jbc.M001156200	http://dx.doi.org/10.1074/jbc.M001156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875929	hybrid			2022-12-25	WOS:000089439800052
J	Brembeck, FH; Rustgi, AK				Brembeck, FH; Rustgi, AK			The tissue-dependent keratin 19 gene transcription is regulated by GKLF/KLF4 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; AMINO-ACID-SEQUENCE; CARCINOMA CELL-LINE; INTERMEDIATE FILAMENTS; EPITHELIAL-CELLS; NUCLEAR PROTEINS; EXPRESSION; DIFFERENTIATION; GROWTH; IDENTIFICATION	Keratins play critical roles in cellular differentiation and cytoskeletal organization, Keratin 19 (K19) is unique because it has been implicated as a marker of stem cells in some tissues, such as the hair follicle in the skin. It is also associated with malignant transformation in esophageal and pancreatic cancers. Here, we show that the K19 promoter is active in a subset of gastrointestinal cancer cells derived from esophageal and pancreas but inactive in other contexts. This activity was mapped to a short region containing an overlapping binding site for gut-enriched Kruppel-like factor (GKLF/KLF4) and Sp1. GKLF has a higher binding affinity and is the predominant binding factor in cells with low Sp-1 protein levels. Pancreatic acinar cells normally do not express K19, but overexpression of GKLF and Spl in these cells leads to aberrant expression, similar to what is observed in pancreatic cancer. These results demonstrate the functional interaction of ubiquitous and tissue-restricted transcription factors in determining tissue- and neoplasm-specific patterns of gene expression.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 600A CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BARTEK J, 1986, HISTOCHEM J, V18, P565, DOI 10.1007/BF01675198; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; Bouwens L, 1998, J PATHOL, V184, P234; Brembeck FH, 1998, BRIT J CANCER, V78, P1288, DOI 10.1038/bjc.1998.673; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Ceratto N, 1997, CYTOGENET CELL GENET, V77, P169, DOI 10.1159/000134566; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; FILION M, 1994, GENOMICS, V24, P303, DOI 10.1006/geno.1994.1620; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON BW, 1980, DIFFERENTIATION, V17, P161, DOI 10.1111/j.1432-0436.1980.tb01093.x; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LUSSIER M, 1989, GENE, V85, P435, DOI 10.1016/0378-1119(89)90437-X; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Michel M, 1996, J CELL SCI, V109, P1017; Milisavljevic V, 1996, DNA CELL BIOL, V15, P65, DOI 10.1089/dna.1996.15.65; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; Opitz OG, 2000, CANCER RES, V60, P2825; PENDLETON JW, 1991, GENOMICS, V9, P369, DOI 10.1016/0888-7543(91)90267-I; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Prochasson P, 1999, EXP CELL RES, V248, P243, DOI 10.1006/excr.1999.4402; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; SCHRODER FH, 1989, PROSTATE, P17; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WU RL, 1994, J BIOL CHEM, V269, P28450; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	51	105	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28230	28239						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859317				2022-12-25	WOS:000089197100093
J	Finlay, GA; Thannickal, VJ; Fanburg, BL; Paulson, KE				Finlay, GA; Thannickal, VJ; Fanburg, BL; Paulson, KE			Transforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL KINASE SAPK/JNK; BETA SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; GENE-EXPRESSION; AP-1 COMPLEX; II RECEPTOR; PATHWAY; JUN; STRESS; RESPONSES	Transforming growth factor-beta (TGF-beta) is involved in multiple processes including cell growth and differentiation. In particular, TGF-beta has been implicated in the pathogenesis of fibrotic lung diseases. In this study, we examined regulation of the mitogen-activated protein kinase pathway by TGF-beta 1 in primary human lung fibroblasts. TGF-beta 1 treatment resulted in extracellular signal-regulated kinase (ERK) pathway activation in a delayed manner, with maximal activity at 16 h, ERK activation occurred concomitantly with the induction of activator protein-1 (AP-1) binding, a nuclear factor required for activation of multiple genes involved in fibrosis. AP-1 binding was dependent on ERK activation, since the MEK-1 (mitogen-activated protein kinase kinase) inhibitor PD98059 inhibited TGF-beta 1-induced binding. Induction of the receptor tyrosine kinase-linked growth factor, basic fibroblast growth factor (bFGF) protein expression temporally paralleled the activation of ERK/AP-1. Induction of AP-1 by TGF-beta 1-conditioned medium was observed at 2 h, similar to AP-1 induction in response to exogenous bFGF, Dependence of ERK/AP-1 activation on bFGF induction was demonstrated by inhibition of TGF-beta 1-induced ERK/AP-1 activation when conditioned medium from TGF-beta 1-treated cells was incubated with bFGF-neutralizing antibody. Together, these results demonstrate that TGF-beta 1 regulates the autocrine induction of bFGF, resulting in activation of the ERK mitogen-activated protein kinase pathway and induction of AP-1 binding.	Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; New England Med Ctr, Dept Med, Tupper Res Inst, Div Pulm & Crit Care, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center	Paulson, KE (corresponding author), Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.				NHLBI NIH HHS [1K08 HLO3552, R01 HL42376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003552, R01HL042376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1992, P MATR MET C, P156; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1994, J LAB CLIN MED, V124, P755; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Frey RS, 1997, CANCER RES, V57, P628; GEISER AG, 1992, J BIOL CHEM, V267, P2588; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Jones SG, 1999, KIDNEY INT, V56, P83, DOI 10.1046/j.1523-1755.1999.00517.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MUSCI I, 1996, J BIOL CHEM, V271, P16567; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VAN BT, 1995, NATURE, V376, P781; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	52	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27650	27656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862759				2022-12-25	WOS:000089197100018
J	Inohara, N; Koseki, T; Lin, JM; del Peso, L; Lucas, PC; Chen, FF; Ogura, Y; Nunez, G				Inohara, N; Koseki, T; Lin, JM; del Peso, L; Lucas, PC; Chen, FF; Ogura, Y; Nunez, G			An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CYTOCHROME-C; PROCASPASE-9 ACTIVATION; KINASE-ACTIVITY; DEATH DOMAIN; IKK-BETA; COMPLEX; RECEPTOR; PROTEIN; APOPTOSIS	Nod1 is an Apaf-1-like molecule composed of a caspase-recruitment domain (CARD), nucleotide-binding domain, and leucine-rich repeats that associates with the CARD-containing kinase RICK and activates nuclear factor kappa B (NF-kappa B). We show that self-association of Nod1 mediates proximity of RICK and the interaction of RICK with the gamma subunit of the I kappa B kinase (IKK gamma). Similarly, the RICK-related kinase RIP associated via its intermediate region with IKK gamma, A mutant form of IKK gamma deficient in binding to IKK alpha and IKK beta inhibited NF-kappa B activation induced by RICK or RIP. Enforced oligomerization of RICK or RIP as well as of IKK gamma, IKK alpha, or IKK beta was sufficient for induction of NF-kappa B activation. Thus, the proximity of RICK, RIP, and IKK complexes may play an important role for NF-kappa B activation during Nod1 oligomerization or trimerization of the tumor necrosis factor alpha receptor.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014; del Peso, Luis/K-9391-2014	del Peso, Luis/0000-0003-4014-5688	NCI NIH HHS [CA-64556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; INCHARA N, 1998, J BIOL CHEM, V273, P12296; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KOIKE T, 1994, BIOCHEM BIOPH RES CO, V202, P225, DOI 10.1006/bbrc.1994.1916; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	40	430	456	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27823	27831						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10880512				2022-12-25	WOS:000089197100042
J	Lokeshwar, VB; Selzer, MG				Lokeshwar, VB; Selzer, MG			Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; RECEPTOR RHAMM; ANGIOGENIC OLIGOSACCHARIDES; TUMOR ANGIOGENESIS; BINDING PROTEINS; BLADDER-CANCER; URINE MARKER; CD44; IDENTIFICATION; PROLIFERATION	Hyaluronic acid (HA), a nonsulfated glycosaminoglycan, regulates cell adhesion and migration. Small HA fragments (3-25 disaccharide units) induce neovascularization, We investigated the effect of HA and a HA fragment (10-15 disaccharide units, F1) on primary human endothelial cells (ECs). Human pulmonary ECs (HPAEC) and lung microvessel ECs (HMVEC-L) bound HA (K-d similar to 1 and 2.3 nM, respectively) and expressed 17,780 and 16,690 HA binding sites, respectively. Both ECs showed HA-mediated cell adhesion; however, HMVEC-L was 1.5-fold better. Human umbilical vein ECs neither bound HA nor showed HA-mediated adhesion. All three ECs expressed CD44 (similar to 110 kDa). The expression of receptor for HA-mediated motility (RHAMM) (similar to 80 kDa) was the highest in HMVEC-L, followed by HPAEC and human umbilical vein ECs, RHAMM, not CD44, bound HA in all three ECs. Fl was better than HA and stimulated a 2.5- and 1.8-fold mitogenic response in HMVEC-L and HPAEC, respectively. Both HA and F1 induced tyrosine phosphorylation of p125(FAK), paxillin, and p42/44 ERK in HMVEC-L and HPAEC, which was blocked by an anti-RHAMM antibody. These results demonstrate that RHARIM is the functional HA receptor in primary human ECs. Heterogeneity exists among primary human ECs of different vascular origins, with respect to functional HA receptor expression and function.	Univ Miami, Sch Med, Dept Urol M 800, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami; University of Miami	Lokeshwar, VB (corresponding author), Univ Miami, Sch Med, Dept Urol M 800, POB 016960, Miami, FL 33101 USA.							Abmann V., 1996, CLIN CANCER RES, V2, P1607; Assmann V, 1998, J CELL SCI, V111, P1685; BENERSON GS, 1988, ARCH PATHOL LAB MED, V112, P1002; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; English NM, 1998, CANCER RES, V58, P3736; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; ENTWISTLE J, 1995, GENE, V163, P233, DOI 10.1016/0378-1119(95)00398-P; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; Gross N, 1997, CANCER RES, V57, P1387; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEEGAN A, 1982, J CELL SCI, V55, P261; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson W, 1996, AM J PATHOL, V148, P1721; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEVESQUE H, 1994, ATHEROSCLEROSIS, V105, P51, DOI 10.1016/0021-9150(94)90007-8; LOEKSHWAR VB, 2000, J UROLOGY, V163, P348; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lokeshwar VB, 1996, CANCER RES, V56, P651; Lokeshwar VB, 1999, CANCER RES, V59, P4464; MARITA H, 1990, BIOCHEM J, V265, P61; MARTIN JF, 1990, ENDOTHELIUM INTRO CU, P95; MasellisSmith A, 1996, BLOOD, V87, P1891; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MONTESANO R, 1996, LAB INVEST, V75, P211; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; PAKU S, 1991, LAB INVEST, V65, P334; Pham HT, 1997, CANCER RES, V57, P778; Roden L, 1989, CIBA F SYMP, P76; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHEN JK, 1995, MICROVASC RES, V50, P360, DOI 10.1006/mvre.1995.1064; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Slevin M, 1998, LAB INVEST, V78, P987; TEDER P, 1995, CANCER RES, V55, P3908; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Tsifrina E, 1999, AM J PATHOL, V155, P1625, DOI 10.1016/S0002-9440(10)65478-8; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; UNDERHILL C, 1992, J CELL SCI, V103, P293; Wang C, 1996, AM J PATHOL, V148, P1861; West D. C., 1989, CIBA F SYMP, V143, P201; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; ZOLLER M, 1995, J MOL MED, V73, P425	58	170	180	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27641	27649						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882722				2022-12-25	WOS:000089197100017
J	Pederson, BA; Cheng, C; Wilson, WA; Roach, PJ				Pederson, BA; Cheng, C; Wilson, WA; Roach, PJ			Regulation of glycogen synthase - Identification of residues involved in regulation by the allosteric ligand glucose-6-P and by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLATING INITIATOR PROTEINS; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; CDNA CLONING; ACTIVE-SITE; YEAST; BIOSYNTHESIS; SUBUNIT; ACCUMULATION; METABOLISM	The major yeast glycogen synthase, Gsy2p, is inactivated by phosphorylation and activated by the allosteric ligand glucose-6-P. From studies of recombinant proteins, the control can be accommodated by a three-state model, in which unphosphorylated enzyme has intermediate activity (state II). Glucose-6-P increased V-max/K-m by about 2-fold (state III), whereas phosphorylation by the cyclin-dependent protein kinase Pcl10p/Pho85p decreased V-max/K-m by similar to 30-fold (state I). In the presence of glucose-6-P, state III is achieved regardless of phosphorylation state. The enzyme forms complexes in solution with the yeast glycogenin Glg2p, but this interaction appears not to affect control either by glucose-6-P binding or by phosphorylation, Scanning mutagenesis was applied to identify residues potentially involved in ligand binding. Of 22 mutant enzymes analyzed, seven were essentially inactive. Five mutant proteins were altered in their activation by glucose-6-P, and two were completely unaffected by the hexose phosphate, One of these, R586A/R588A/R591A (all three of the indicated Arg residues mutated to Ala), had wild-type activity and was normally inactivated by phosphorylation. A second mutant, R579A/R580A/R582A, had somewhat reduced V-max, but its activity was not greatly reduced by phosphorylation. The Arg residues in these two mutants are restricted to a highly conserved, 13-residue segment of Gsy2p that me propose to be important for glucose-6-P binding and/or the ability of the enzyme to undergo transitions between activity states.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.			Wilson, Wayne/0000-0003-2417-5756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542, R01DK042576] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20542, DK42576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRANATI ID, 1962, J BIOL CHEM, V237, P1007; BAI G, 1990, J BIOL CHEM, V265, P7843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHENG C, 1995, MOL CELL BIOL, V15, P6632; FARKAS I, 1991, J BIOL CHEM, V266, P15602; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; HUANG KP, 1974, J BIOL CHEM, V249, P3851; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lin A, 1999, ARCH BIOCHEM BIOPHYS, V363, P163, DOI 10.1006/abbi.1998.1073; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MAHRENHOLZ AM, 1988, J BIOL CHEM, V263, P10561; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Orho-Melander M, 1999, DIABETES, V48, P918, DOI 10.2337/diabetes.48.4.918; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Preiss J, 1987, Basic Life Sci, V41, P133; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; ROACH PJ, 1977, MOL CELL BIOCHEM, V15, P179, DOI 10.1007/BF01734108; ROACH PJ, 1981, CURR TOP CELL REGUL, V20, P45; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; ROTHMAN LB, 1967, BIOCHEMISTRY-US, V6, P2098, DOI 10.1021/bi00859a030; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; Schulz AR, 1998, ARCH BIOCHEM BIOPHYS, V353, P172, DOI 10.1006/abbi.1998.0643; Shimomura H, 1997, DIABETOLOGIA, V40, P947, DOI 10.1007/s001250050772; SKURAT AV, 1995, DIABETES MELLITUS FU, P213; TAGAYA M, 1985, J BIOL CHEM, V260, P6670; TAKEDA Y, 1975, J BIOL CHEM, V250, P8943; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THON VJ, 1992, J BIOL CHEM, V267, P15224; Williamson BD, 1996, DEV GENET, V19, P350, DOI 10.1002/(SICI)1520-6408(1996)19:4<350::AID-DVG8>3.0.CO;2-8; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Wilson WA, 1999, MOL CELL BIOL, V19, P7020; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	43	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27753	27761						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874034				2022-12-25	WOS:000089197100033
J	Yamashita, H; Tyska, MJ; Warshaw, DM; Lowey, S; Trybus, KM				Yamashita, H; Tyska, MJ; Warshaw, DM; Lowey, S; Trybus, KM			Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; BETA-CARDIAC MYOSIN; SKELETAL-MUSCLE; LASER TRAP; ACTIN-BINDING; MOTOR DOMAIN; ADP RELEASE; IN-VITRO; COMPLEX; GENE	Familial hypertrophic cardiomyopathy (FHC) is frequently associated with mutations in the beta-cardiac myosin heavy chain. Many of the implicated residues are located in highly conserved regions of the myosin II class, suggesting that these mutations may impair the basic functions of the molecular motor. To test this hypothesis, we have prepared recombinant smooth muscle heavy meromyosin with mutations at sites homologous to those associated with FHC by using a baculovirus/ insect cell expression system. Several of the heavy meromyosin mutants, in particular R403Q, showed an increase in actin filament velocity in a motility assay and an enhanced actin-activated ATPase activity. Single molecule mechanics, using a laser trap, gave unitary displacements and forces for the mutants that were similar to wild type, but the attachment times to actin following a unitary displacement were markedly reduced. These results suggest that the increases in activity are due to a change in kinetics and not due to a change in the intrinsic mechanical properties of the motor. In contrast to earlier reports, we find that mutations in residues implicated in FHC affect motor function by enhancing myosin activity rather than by a loss of function.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	University of Vermont; University of Tokyo; Brandeis University	Lowey, S (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Given E209, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL54568, HL51126] Funding Source: Medline; NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568, R01HL051126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350, R01AR017350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fujita H, 1997, J CLIN INVEST, V99, P1010, DOI 10.1172/JCI119228; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1985, J BIOL CHEM, V260, P3747; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Palmiter KA, 1999, CIRCULATION, V100, P193; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; PATLAK JB, 1993, BIOPHYS J, V65, P29, DOI 10.1016/S0006-3495(93)81041-5; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Roopnarine O, 1998, BIOPHYS J, V75, P3023, DOI 10.1016/S0006-3495(98)77743-4; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l	45	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28045	28052						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882745				2022-12-25	WOS:000089197100070
J	Hyyrylainen, HL; Vitikainen, M; Thwaite, J; Wu, HY; Sarvas, M; Harwood, CR; Kontinen, VP; Stephenson, K				Hyyrylainen, HL; Vitikainen, M; Thwaite, J; Wu, HY; Sarvas, M; Harwood, CR; Kontinen, VP; Stephenson, K			D-Alanine substitution of teichoic acids as a modulator of protein folding and stability at the cytoplasmic membrane/cell wall interface of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIPOTEICHOIC ACID; STAPHYLOCOCCUS-AUREUS; PERIPLASMIC PROTEIN; CELL-ENVELOPE; DLT OPERON; SECRETION; GENE; EXPRESSION; GROWTH	The extracytoplasmic folding of secreted proteins in Gram-positive bacteria is influenced by the microenvironment of the compartment into which they are translocated, namely the negatively charged matrix of the cell wall polymers. In this compartment, the PrsA lipoprotein facilitates correct post-translocational folding or prevents misfolding of secreted proteins. In this study, a secretion mutant of B, subtilis (prsA3) encoding a defective PrsA protein was mutagenized and screened for restored secretion of the AmyQ alpha-amylase, One mini-Tn10 insertion, which partially suppressed the secretion deficiency, was found to interrupt dht, the operon involved in the D-alanylation of teichoic acids. The inactivation of dlt rescued the mutant PrsA3 protein from degradation, and the increased amount of PrsA3 was shown to enhance the secretion of PrsA-dependent proteins. Heterologous or abnormal secreted proteins, which are prone to degradation after translocation, were also stabilized and secreted in increased quantities from a dlt prsA(+) strain, Furthermore, the dlt mutation partially suppressed the lethal effect of PrsA depletion, suggesting that the dlt deficiency also leads to stabilization of an essential cell wall protein(s), Our results suggest that main influence of the increased net negative charge of the wall caused by the absence of D-alanine is to increase the rate of post-translocational folding of exported proteins.	Natl Publ Hlth Inst, Vaccine Dev Lab, FI-00300 Helsinki, Finland; Newcastle Univ, Sch Med, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Finland National Institute for Health & Welfare; Newcastle University - UK	Kontinen, VP (corresponding author), Natl Publ Hlth Inst, Vaccine Dev Lab, FI-00300 Helsinki, Finland.	Vesa.Kontinen@ktl.fi	Kontinen, Vesa P/A-2260-2012; Harwood, Colin/AGF-0120-2022	Harwood, Colin/0000-0002-3624-0001				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Archibald A. R., 1993, P381; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BEVERIDGE TJ, 1980, J BACTERIOL, V141, P876, DOI 10.1128/JB.141.2.876-887.1980; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; CHAMBERT R, 1990, BIOCHEM J, V265, P375, DOI 10.1042/bj2650375; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; HUGHES AH, 1973, BIOCHEM J, V132, P83, DOI 10.1042/bj1320083; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KONTINEN VP, 1991, MOL MICROBIOL, V5, P1273, DOI 10.1111/j.1365-2958.1991.tb01901.x; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAMBERT PA, 1975, BIOCHEM J, V151, P671, DOI 10.1042/bj1510671; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; Leloup L, 1997, MICROBIOL-UK, V143, P3295, DOI 10.1099/00221287-143-10-3295; Leskela S, 1999, MOL MICROBIOL, V31, P533, DOI 10.1046/j.1365-2958.1999.01194.x; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; MACARTHUR AE, 1984, J BACTERIOL, V160, P792, DOI 10.1128/JB.160.2.792-793.1984; MEENS J, 1993, MOL MICROBIOL, V9, P847, DOI 10.1111/j.1365-2958.1993.tb01743.x; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Neuhaus FC, 1996, MICROB DRUG RESIST, V2, P77, DOI 10.1089/mdr.1996.2.77; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; PETITGLATRON MF, 1993, MOL MICROBIOL, V9, P1097, DOI 10.1111/j.1365-2958.1993.tb01239.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spatafora GA, 1999, J BACTERIOL, V181, P2363, DOI 10.1128/JB.181.8.2363-2372.1999; Stephenson K, 1998, FEBS LETT, V430, P385, DOI 10.1016/S0014-5793(98)00698-X; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; THOMAS M, 1975, J MOL BIOL, V91, P315, DOI 10.1016/0022-2836(75)90383-6; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Wecke J, 1996, MICROB DRUG RESIST, V2, P123, DOI 10.1089/mdr.1996.2.123	47	97	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26696	26703						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871614				2022-12-25	WOS:000089144800006
J	Shao, HP; Andres, DA				Shao, HP; Andres, DA			A novel RalGEF-like protein, RGL3, as a candidate effector for Rit and Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING PROTEINS; C-FOS PROMOTER; PUTATIVE EFFECTOR; CELLULAR-TRANSFORMATION; SIGNALING PATHWAY; EXCHANGE FACTORS; H-RAS; R-RAS; ACTIVATION	The small GTPase Rit is a close relative of Ras, and constitutively active Rit can induce oncogenic transformation. Although the effector loops of Rit and Ras are highly related, Rit fails to interact with the majority of the known Ras candidate effector proteins, suggesting that novel cellular targets may be responsible for Rit transforming activity. To gain insight into the cellular function of Rit, we searched for Rit-binding proteins by yeast two-hybrid screening. We identified the C-terminal Rit/Ras interaction domain of a protein we have designated RGL3 (Ral GEF-like 3) that shares 35% sequence identity with the known Ral guanine nucleotide exchange factors (RalGEFs). RGL3, through a C-terminal 99-amino acid domain, interacted in a GTP- and effector loop-dependent manner with Rit and Ras. Importantly, RGL3 exhibited guanine nucleotide exchange activity toward the small GTPase Ral that was stimulated in vivo by the expression of either activated Rit or Res. These data suggest that RGL3 functions as an exchange factor for Ral and may serve as a downstream effector for both Rit and Ras.	Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER; NEI NIH HHS [EY11231] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; James P, 1996, GENETICS, V144, P1425; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULIENFLORES V, 1995, J BIOL CHEM, V270, P22473; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lee T, 1996, DEVELOPMENT, V122, P409; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Murai H, 1997, J BIOL CHEM, V272, P10483; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; ORITA S, 1993, J BIOL CHEM, V268, P25542; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	62	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26914	26924						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869344				2022-12-25	WOS:000089144800035
J	Mao, Y; Desai, SD; Liu, LF				Mao, Y; Desai, SD; Liu, LF			SUMO-1 conjugation to human DNA topoisomerase II isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; ENZYME; RANGAP1; YEAST; DEGRADATION; ALPHA; GENE	Topoisomerase I-mediated DNA damage induced by camptothecin has been shown to induce rapid small ubiquitin-related modifier (SUMO)-1 conjugation to topoisomerase I. In the current study, we show that topoisomerase II-mediated DNA damage induced by teniposide (VM-26) results in the formation of high molecular weight conjugates of both topoisomerase II alpha and II beta isozymes in HeLa cells. Immunological characterization of these conjugates suggests that both topoisomerase II alpha and II beta isozymes are conjugated to SUMO-1, The involvement of SUMO-1/UBC9 in the modification of topoisomerase II isozymes is also supported by the demonstration of physical interaction between topoisomerase II and SUMO-1/UBC9. Surprisingly, ICRF-193, which does not induce topoisomerase II-mediated DNA damage but traps topoisomerase II into a circular clamp conformation, is also shown to induce similar SUMO-1 conjugation to topoisomerase II isozymes. In addition, we show that both oxidative and heat shock stresses, which can cause protein damage, rapidly increase nuclear SUMO-1 conjugates. These studies raise the question on whether SUMO-1 conjugation to topoisomerases is an indirect result of a DNA damage response or a direct result because of protein conformational changes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA 39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Boddy MN, 1996, ONCOGENE, V13, P971; Chen A, 1998, BIOCHEM MOL BIOL INT, V46, P1161; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Danks M K, 1989, Cancer Commun, V1, P101; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu LF, 1996, ANN NY ACAD SCI, V803, P44, DOI 10.1111/j.1749-6632.1996.tb26375.x; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 1999, J VIROL, V73, P5137; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Tyrrell R M, 1996, EXS, V77, P255; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WASSERMAN RA, 1993, CANCER RES, V53, P3591	46	124	127	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26066	26073		10.1074/jbc.M001831200	http://dx.doi.org/10.1074/jbc.M001831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862613	hybrid			2022-12-25	WOS:000088999700026
J	Biederbick, A; Kosan, C; Kunz, J; Elsasser, HP				Biederbick, A; Kosan, C; Kunz, J; Elsasser, HP			First apyrase splice variants have different enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; BRAIN ECTO-APYRASE; E-TYPE ATPASES; ENDOPLASMIC-RETICULUM; ATP-DIPHOSPHOHYDROLASE; TOXOPLASMA-GONDII; DIPHOSPHATASE; CLONING; GLYCOSYLATION; LOCALIZATION	LALP70 is a novel lysosomal membrane protein belonging to the apyrase protein family. The apyrase protein family comprises enzymes capable of cleaving nucleotidetri- and diphosphates in a calcium- or magnesium-dependent manner, not being altered by P-type, F-type, or V-type NTPase inhibitors. In this study we have cloned and sequenced the human LALP70 gene to deter mine the genomic structure. The gene is organized in 11 introns and 12 exons covering a genomic region of approximately 16 kilobase pairs. By fluorescence in, situ hybridization analysis, the hLALP70 gene was mapped to the human chromosome 8p21.1-p21.3. We further show that there is at least one alternatively spliced variant, hLALP70v, which can be generated via an alternative splice side at the 3'-end of exon 7, leading to a protein variant differing in 8 amino acids (VSFASSQQ). This is the first splice variant that has been described in the apyrase protein family. Reverse transcriptase polymerase chain reaction analysis showed an ubiquitous expression of both variants, with different relative mRNA expression levels in different tissues. Comparison of the enzymatic properties of the splice variants revealed a broader substrate specificity for hLALP70v with CTP, UDP, CDP, GTP, and GDP as preferred substrates, while hLALP70 utilized UTP and TTP preferentially. Furthermore, enzyme activity of hLALP70v was equally dependent on Ca2+ and Mg2+, being saturated already at 1 mM concentration. In contrast, hLALP70 enzymatic activity were unsaturated up to 10 mM Ca2+, while Mg2+ showed a saturation at already 1 mhz concentration with 2-3-fold lower enzymatic activity as observed with Ca2+. Our data suggest that the presence or absence of the 8-amino acid motif VSFASSQQ provoke differences in substrate specificity and divalent cation dependence of hLALP70/hLALP70v.	Univ Marburg, Inst Klin Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Marburg, Inst Allgemeine Humangenet, Zentrum Humangenet, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Elsasser, HP (corresponding author), Univ Marburg, Inst Klin Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.		Kosan, Christian/C-1213-2017	Kosan, Christian/0000-0002-8387-3653				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Biederbick A, 1999, J CELL SCI, V112, P2473; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nakaar V, 1998, MOL BIOCHEM PARASIT, V97, P209, DOI 10.1016/S0166-6851(98)00153-4; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PLESNER L, 1995, INT REV CYTOL, V158, P141; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Smith TM, 1999, BIOCHEMISTRY-US, V38, P5849, DOI 10.1021/bi990171k; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; VANSTAPEL F, 1988, J CLIN INVEST, V82, P1113, DOI 10.1172/JCI113668; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392	23	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19018	19024		10.1074/jbc.M001245200	http://dx.doi.org/10.1074/jbc.M001245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858452	hybrid			2022-12-25	WOS:000087815900054
J	Ginisty, H; Serin, G; Ghisolfi-Nieto, L; Roger, B; Libante, V; Amalric, F; Bouvet, P				Ginisty, H; Serin, G; Ghisolfi-Nieto, L; Roger, B; Libante, V; Amalric, F; Bouvet, P			Interaction of nucleolin with an evolutionarily conserved pre-ribosomal RNA sequence is required for the assembly of the primary processing complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL TRANSCRIBED SPACER; PRERIBOSOMAL RNA; NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SECONDARY STRUCTURE; BINDING DOMAINS; MOUSE; CLEAVAGE; SITE; U3	The first processing event of the precursor ribosomal RNA (pre-rRNA) takes place within the 5' external transcribed spacer. This primary processing requires conserved cia-acting RNA sequence downstream from the cleavage site and several nucleic acids (small nucleolar RNAs) and proteins trans-acting factors including nucleolin, a major nucleolar protein, The specific interaction of nucleolin with the pre-rRNA is required for processing in vitro. Xenopus laevis and hamster nucleolin interact with the same pre-rRNA site and stimulate the processing activity of a mouse cell extract. A highly conserved 11-nucleotide sequence located 5-6 nucleotides after the processing site is required for the interaction of nucleolin and processing. In vitro selection experiments with nucleolin have identified an RNA sequence that contains the UCGA motif present in the 11-nucleotide conserved sequence, The interaction of nucleolin with pre-rRNA is required for the formation of an active processing complex. Our findings demonstrate that nucleolin is a key factor for the assembly and maturation of pre-ribosomal ribonucleoparticles.	CNRS, UMR 5089, Lab Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bouvet, P (corresponding author), CNRS, UMR 5089, Lab Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	bouvet@ipbs.fr	Nieto, Laurence/AAJ-5703-2021; , Bouvet/AAC-8779-2020	Nieto, Laurence/0000-0002-1006-0168; Libante, Virginie/0000-0001-9728-8343; Bouvet, Philippe/0000-0003-4524-2233				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BACH R, 1981, NUCLEIC ACIDS RES, V9, P1559, DOI 10.1093/nar/9.7.1559; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BLUM B, 1986, NUCLEIC ACIDS RES, V14, P3153, DOI 10.1093/nar/14.8.3153; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; DELCASSOTREMOUSAYGUE D, 1988, EUR J BIOCHEM, V172, P767, DOI 10.1111/j.1432-1033.1988.tb13956.x; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Enright CA, 1996, RNA, V2, P1094; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Hadjiolov A.A., 1985, CELL BIOL MONOGRAPHS, V12; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MICHOT B, 1982, NUCLEIC ACIDS RES, V10, P5273, DOI 10.1093/nar/10.17.5273; MICHOT B, 1991, EUR J BIOCHEM, V195, P601, DOI 10.1111/j.1432-1033.1991.tb15743.x; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; SAVINO R, 1991, BIOCHIMIE, V73, P805, DOI 10.1016/0300-9084(91)90060-E; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; SHUMARD CM, 1988, J BIOL CHEM, V263, P19346; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; URANO Y, 1980, NUCLEIC ACIDS RES, V8, P6043, DOI 10.1093/nar/8.24.6043	39	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18845	18850		10.1074/jbc.M002350200	http://dx.doi.org/10.1074/jbc.M002350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858445	hybrid			2022-12-25	WOS:000087815900033
J	Janji, B; Melchior, C; Vallar, L; Kieffer, N				Janji, B; Melchior, C; Vallar, L; Kieffer, N			Cloning of an isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-beta 1 stimulation	ONCOGENE			English	Article						integrin-linked kinase; integrin; TGF-beta; cDNA sequence; melanoma phosphorylation	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE; REGULATED EXPRESSION; NEGATIVE REGULATION; ADHESION; GENE; IDENTIFICATION; SURVIVAL; MICE	We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-beta 1 stimulation, Using mRNA from TGF-beta 1 stimulated HT-144 cells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1, Expression of ILK2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma tell lines, but not in normal human tissues, Moreover, stimulation of HT-144 cells with TGF-beta 1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA, Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a retombinant GST/beta 3 integrin cytoplasmic tail peptide, Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar, Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-beta 1.	Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, L-1150 Luxembourg, Luxembourg	Luxembourg Institute of Health; University of Luxembourg	Kieffer, N (corresponding author), Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, 162A Ave de la Faiencerie, L-1150 Luxembourg, Luxembourg.			Vallar, Laurent/0000-0002-4404-1010; JANJI, Bassam/0000-0002-9763-0943				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Gouon V, 1996, INT J CANCER, V68, P650; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 1999, INT J MOL MED, V3, P563; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Li DM, 1997, CANCER RES, V57, P2124; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MATSUMOTO K, 1995, CANCER METAST REV, V14, P205, DOI 10.1007/BF00690292; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Robertson GP, 1999, CANCER RES, V59, P3596; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0	33	27	30	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3069	3077		10.1038/sj.onc.1203640	http://dx.doi.org/10.1038/sj.onc.1203640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871859				2022-12-25	WOS:000087903900004
J	Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S				Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S			Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCFp45Skp2 pathway	ONCOGENE			English	Article						B-Myb; ubiquitination; p45(Skp2); cyclin A	KINASE INHIBITOR P27; PROTEASOME-DEPENDENT DEGRADATION; F-BOX PROTEIN; CELL-CYCLE; C-MYB; MESSENGER-RNA; BETA-CATENIN; IN-VIVO; A-MYB; ACTIVATION	B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-specific DNA binding protein expressed in virtually all proliferating cells, B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic effects of cyclin Dt and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level, We provide evidence that in addition to triggering B-Myb activity an important effect of cyclin A is to facilitate multiple ubiquitination of B-Myb, The C-terminal domain of B-Myb is of key importance in mediating this effect of cyclin A, Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its half-life is not affected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45(Skp2), respectively the E2 and E3 components of a ubiquitination pathway that regulates the G1/S transition, accelerates degradation of B-Myb, We show that B-Myb physically and functionally interacts with components of the Cdc34-SCFp45Skp2 ubiquitin pathway and propose that B-Myb degradation may be required for controlling the correct alternation of events during progression through the cell division cycle.	Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland; Univ Munster, Inst Biochem, D-48149 Munster, Germany	Novartis; University of Munster	Ferrari, S (corresponding author), Novartis Pharma AG, Dept Oncol, Klybeckstr 141, CH-4057 Basel, Switzerland.		Brondani, Vincent/AAB-8394-2021; Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bartsch O, 1998, BIOLOGY OF TUMORS, P31; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; CURRAN T, 1984, CELL, V36, P259; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Esposito V, 1997, CANCER RES, V57, P3381; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	58	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2986	2995		10.1038/sj.onc.1203618	http://dx.doi.org/10.1038/sj.onc.1203618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871850				2022-12-25	WOS:000087581400005
J	Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD				Haik, S; Gauthier, LR; Granotier, C; Peyrin, JM; Lages, CS; Dormont, D; Boussin, FD			Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells	ONCOGENE			English	Article						telomerase; neural precursor cells; fibroblast growth factor 2	MOUSE TELOMERASE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; STEM-CELLS; NEURONAL DIFFERENTIATION; LYMPHOCYTE DEVELOPMENT; PROGENITOR CELLS; IMMORTAL CELLS; GLIOMA-CELLS; TUMOR-CELLS	During brain development, neuronal and glial cells are generated from neural precursors on a precise schedule involving steps of proliferation, fate commitment and differentiation. We report that telomerase activity is highly expressed during embryonic murine cortical neurogenesis and early steps of gliogenesis and progressively decreases thereafter during cortex maturation to be undetectable in the normal adult brain. We evidenced neural precursor cells (NPC) as the principal telomerase-expressing cells in primary cultures from E15 mouse embryo cortices, Their differentiation either in neurons or in glial cells lead to a down regulation of telomerase activity that was directly correlated to the decrease of telomerase core protein (mTERT) mRNA synthesis. Furthermore, we show that FGF2 (fibroblast growth factor 2), one of the main regulators of CNS development, induces a dose-dependant increase of both the proliferation of NPC and telomerase activity in primary cortical cultures without affecting the mTERT mRNA synthesis compared to that of glyceraldehyde-3-phosphate dehydrogenase (mGAPDH). Finally, we evidenced that AZT (3'-azido-2',3'-dideoxythymidine), known to inhibit telomerase activity, blocks in a dose dependant manner the FGF2-induced proliferation of NPC. Altogether, our results are in favor of an important role of telomerase activity during brain organogenesis.	CEA, Lab Radiopathol, DSV, DRR,IPSCI, F-92265 Fontenay Aux Roses, France; CEA, Serv Neurovirol, DSV, DRM,CRSSA,IPSC, F-92265 Fontenay Aux Roses, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boussin, FD (corresponding author), CEA, Lab Radiopathol, DSV, DRR,IPSCI, BP 6, F-92265 Fontenay Aux Roses, France.		Gauthier, Laurent/ABC-7614-2021; Haik, Stephane/M-7247-2018	Gauthier, Laurent/0000-0003-4644-7660; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Boussin, francois/0000-0003-3778-4403; Peyrin, Jean-Michel/0000-0002-8705-8672; Peyrin, Jean-Michel/0000-0002-0108-1266				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Engelhardt M, 1997, BLOOD, V90, P182; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; Gomez DE, 1998, BIOCHEM BIOPH RES CO, V246, P107, DOI 10.1006/bbrc.1998.8555; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Hiratochi M, 1998, DEV GROWTH DIFFER, V40, P59; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Ito H, 1998, CLIN CANCER RES, V4, P1603; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kruk PA, 1996, BIOCHEM BIOPH RES CO, V224, P487, DOI 10.1006/bbrc.1996.1054; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Melana SM, 1998, CLIN CANCER RES, V4, P693; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; Miyagi N, 1998, INT J ONCOL, V12, P1085; Multani AS, 1998, INT J ONCOL, V13, P923; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OLIVERO OA, 1993, MOL CARCINOGEN, V8, P81, DOI 10.1002/mc.2940080204; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Reichman TW, 1997, J CELL BIOCHEM, V67, P13, DOI 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strahl C, 1996, MOL CELL BIOL, V16, P53; Takakura M, 1998, CANCER RES, V58, P1558; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	70	54	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2957	2966		10.1038/sj.onc.1203596	http://dx.doi.org/10.1038/sj.onc.1203596			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871847				2022-12-25	WOS:000087581400002
J	Lu, W; Peterson, R; Dasgupta, A; Scovell, WM				Lu, W; Peterson, R; Dasgupta, A; Scovell, WM			Influence of HMG-1 and adenovirus oncoprotein E1A on early stages of transcriptional preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; MOBILITY GROUP PROTEIN-1; MAJOR LATE PROMOTER; DNA-BINDING; GENE-TRANSCRIPTION; FACTOR TFIIB; FUNCTIONAL INTERACTION; CRYSTAL-STRUCTURE; CORE DOMAIN	The TATA-binding protein (TBP) in the TFIID complex binds specifically to the TATA-box to initiate the stepwise assembly of the preinitiation complex (PIC) for RNA polymerase II transcription. Transcriptional activators and repressors compete with general transcription factors at each step to influence the course of the assembly. To investigate this process, the TBP.TATA complex was titrated with HMG-1 and the interaction monitored by electrophoretic mobility shift assays. The titration produced a ternary HMG-1.TBP.TATA complex, which exhibits increased mobility relative to the TBP.TATA complex. The addition of increasing levels of TFIIB to this complex results in the formation of the TFIIB.TBP.TATA complex. However, in the reverse titration, with very high mole ratios of HMG-1 present, TFIIB is not dissociated off and a complex is formed that contains all factors. The simultaneous addition of E1A to a mixture of TBP and TATA; or HMG-1, TBP, and TATA; or TFIIB, TBP, and TATA inhibits complex formation. On the other hand, E1A added to the pre-established complexes shows a significantly reduced capability to disrupt the complex. In add-back experiments with all complexes, increased levels of TBP re-established the complexes, indicating that the primary target for E1A in all complexes is TBP.	Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; Ohio No Univ, Dept Chem, Ada, OH 45810 USA	Bowling Green State University; Ohio Northern University	Scovell, WM (corresponding author), Bowling Green State Univ, Dept Chem, Overman Hall, Bowling Green, OH 43403 USA.			DASGUPTA, ATREYI/0000-0002-4734-9766	PHS HHS [R15] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BURTOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509; BURTOWSKI S, 1992, SCIENCE, V255, P1130; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; GE H, 1994, J BIOL CHEM, V269, P17136; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILJELUND P, 1993, MOL GEN GENET, V241, P694, DOI 10.1007/BF00279913; Marmillot P, 1998, BBA-GENE STRUCT EXPR, V1395, P228, DOI 10.1016/S0167-4781(97)00153-X; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Phillips AC, 1997, J GEN VIROL, V78, P905, DOI 10.1099/0022-1317-78-4-905; Pugh B F, 1995, Methods Mol Biol, V37, P359; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	61	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35006	35012		10.1074/jbc.M004735200	http://dx.doi.org/10.1074/jbc.M004735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10882737	hybrid			2022-12-25	WOS:000165422800026
J	Matsuura, I; Bondarenko, VA; Maeda, T; Kachi, S; Yamazaki, M; Usukura, J; Hayashi, F; Yamazaki, A				Matsuura, I; Bondarenko, VA; Maeda, T; Kachi, S; Yamazaki, M; Usukura, J; Hayashi, F; Yamazaki, A			Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit of retinal cGMP phosphodiesterase I. Identification of the kinase and its role in the turnoff of phosphodiesterase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATESBIANA ROD PHOTORECEPTORS; TRANSDUCIN ALPHA-SUBUNIT; BRAIN-SPECIFIC ACTIVATOR; GTP-BINDING PROTEIN; GAMMA-SUBUNIT; INHIBITORY SUBUNIT; GMP PHOSPHODIESTERASE; BOVINE BRAIN; ADP-RIBOSYLATION; OUTER SEGMENTS	Cyclic GMP phosphodiesterase (PDE) is an essential component in retinal phototransduction. PDE is regulated by P gamma, the regulatory subunit of PDE, and GTP/T alpha, the GTP-bound cu subunit of transducin. In previous studies (Tsuboi, S., Matsumoto, H., Jackson, K. W., Tsujimoto, K., Williamas, T., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15016-15023; Tsuboi, S., Matsumoto, H., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15024-15029), we showed that P gamma is phosphorylated by a previously unknown kinase (Py kinase) in a GTP-dependent manner in photoreceptor outer segment membranes. We also showed that phosphorylated P gamma loses its ability to interact with GTP/T alpha, but gains a 10-15 times higher ability to inhibit GTP/T alpha -activated PDE than that of nonphosphorylated P gamma. Thus, we propose that the P gamma phosphorylation is probably involved in the recovery phase of phototransduction through shut off of GTP/T alpha -activated PDE. Here we demonstrate that all known P gammas preserve a consensus motif for cyclin-dependent protein kinase 5 (Cdk5), a protein kinase believed to be involved in neuronal cell development, and that P gamma kinase is Cdk5 complexed with p35, a neuronal Cdk5 activator. Mutational analysis of P gamma indicates that all known P gammas contain a P-X-T-P-R sequence and that this sequence is required for the P gamma phosphorylation by P gamma kinase. In three different column chromatographies of a cytosolic fraction of frog photoreceptor outer segments, the P gamma kinase activity exactly coelutes with Cdk5 and p35. The P gamma kinase activity (similar to 85%) is also immunoprecipitated by a Cdk5-specific antibody, and the immunoprecipitate phosphorylates P gamma. Finally, recombinant Cdk5/p35, which were expressed using clones from a bovine retina cDNA library, phosphorylates P gamma in frog outer segment membranes in a GTP-dependent manner. These observations suggest that Cdk5 is probably involved in the recovery phase of phototransduction through phosphorylation of P gamma complexed with GTP/T alpha in mature vertebrate retinal photoreceptors.	Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan; Nagoya Univ, Sch Med, Dept Anat, Nagoya, Aichi 466, Japan	Wayne State University; Wayne State University; Wayne State University; Kobe University; Nagoya University	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA.	ayamazak@med.wayne.edu	Bondarenko, Vladimir/AFY-8370-2022	Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY09631, EY07546] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CLERC A, 1992, J BIOL CHEM, V267, P6620; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIN W, 1998, J BIOL CHEM, V273, P34284; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; TUTEJA N, 1990, GENE, V88, P227, DOI 10.1016/0378-1119(90)90035-P; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A., 1998, IOVS, V39, pS953; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495	58	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32950	32957		10.1074/jbc.M000702200	http://dx.doi.org/10.1074/jbc.M000702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884378	hybrid			2022-12-25	WOS:000090003800079
J	Kurys, G; Tagaya, Y; Bamford, R; Hanover, JA; Waldmann, TA				Kurys, G; Tagaya, Y; Bamford, R; Hanover, JA; Waldmann, TA			The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED KILLER-CELLS; IL-15 MESSENGER-RNA; GROWTH-FACTOR; BETA-CHAIN; TRANSLATIONAL EFFICIENCY; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; TRANSLOCATION; EXPRESSION; PROTEINS	Two isoforms of interleukin (IL)-15 exist: one with a short and another with a long signal peptide (LSP). Experiments using combinations of the LSP and mature proteins IL-2, IL-15, and green fluorescent protein revealed complex pathways of intracellular trafficking. In one pathway, the LSP was unprocessed, and IL-15 was not glycosylated, remained in the cytoplasm, and was degraded. The second trafficking pathway involved endoplasmic reticulum entry, N-linked glycosylation, and alternative partial LSP processing. The third pathway involved endoplasmic reticulum entry, followed by glycosylation, complete processing, and ultimately secretion. The complex intracellular trafficking patterns of LSP-IL-15 with its impediments to secretion as well as impediments to translation may be required due to the potency of IL-15 as an inflammatory cytokine. In terms of a more positive role, we propose that intracellular infection may relieve the burdens on translation and intracellular trafficking to yield effective IL-15 expression.	NCI, Metab Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Waldmann, TA (corresponding author), NCI, Metab Branch, NIH, Bldg 10,Rm 4N115,10 Ctr Dr,MSC 1374, Bethesda, MD 20892 USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; Bamford RN, 1998, J IMMUNOL, V160, P4418; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 1996, ONCOGENE, V12, P2187; Nishimura H, 1998, J IMMUNOL, V160, P936; Onu A, 1997, J IMMUNOL, V158, P255; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Perera LP, 1999, J IMMUNOL, V162, P2606; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; YANG H, 1995, MOL ENDOCRINOL, V9, P1380, DOI 10.1210/me.9.10.1380	29	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30653	30659		10.1074/jbc.M002373200	http://dx.doi.org/10.1074/jbc.M002373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869346	hybrid			2022-12-25	WOS:000089577900101
J	Kiyono, M; Kato, J; Kataoka, T; Kaziro, Y; Satoh, T				Kiyono, M; Kato, J; Kataoka, T; Kaziro, Y; Satoh, T			Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; MAP KINASE; DEPENDENT ACTIVATION; PROTEIN; BINDING; CLONING; CDC25; GRF	Ras-GRF1 is a brain-specific guanine nucleotide exchange factor (GEF) for Ras, whose activity is regulated in response to Ca2+ influx and G protein-coupled receptor signals. In addition, Ras-GRF1 acts as a GEF for Rac when tyrosine-phosphorylated following G protein-coupled receptor stimulation. However, the mechanisms underlying the regulation of Ras-GRF1 functions remain incompletely understood. We show here that activated ACK1, a nonreceptor tyrosine kinase that belongs to the focal adhesion kinase family, causes tyrosine phosphorylation of Ras-GRF1. On the other hand, kinase-deficient ACK1 exerted no effect. GEF activity of Ras-GRF1 toward Ha-Has, as defined by in vitro GDP binding and release assays, was augmented after tyrosine phosphorylation by ACK1. In contrast, GEF activity toward Rad remained latent, implying that ACK1 does not represent a tyrosine kinase that acts downstream of G protein-coupled receptors. Consistent with enhanced Ras-GEF activity, accumulation of the GTP-bound form of Ras within the cell was shown through the use of has-binding domain pull-down assays. Furthermore, Ras-dependent activation of ERK2 by Ras-GRF1 was enhanced following co-expression of activated ACK1. These results implicate ACK1 as an upstream modulator of Ras-GRF1 and suggest a signaling cascade consisting of Cdc42, ACK1, Ras-GRF1, and Has in neuronal cells.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Kobe University; Tokyo Institute of Technology	Satoh, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Satoh, Takaya/K-2628-2014					Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Hoehn GT, 1996, ONCOGENE, V12, P903; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tago K, 1998, J BIOCHEM-TOKYO, V123, P659; VAN BT, 1995, NATURE, V376, P781; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524	42	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29788	29793		10.1074/jbc.M001378200	http://dx.doi.org/10.1074/jbc.M001378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882715	hybrid			2022-12-25	WOS:000089439800083
J	Hutt, JA; O'Rourke, JP; DeWille, J				Hutt, JA; O'Rourke, JP; DeWille, J			Signal transducer and activator of transcription 3 activates CCAAT enhancer-binding protein delta gene transcription in G(0) growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; BREAST-CANCER CELLS; C/EBP-DELTA; CONSTITUTIVE ACTIVATION; STAT3 ACTIVATION; DOWN-REGULATION; EXPRESSION; INTERLEUKIN-6; DIFFERENTIATION; PROLIFERATION	The CCAAT enhancer-binding protein (C/EBP) family of transcription factors is implicated in the regulation of cell proliferation and differentiation in a variety of tissues. C/EBP delta is involved in regulating G(0) growth arrest and apoptosis of mouse mammary epithelial cells. This study shows that activation of signal transducer and activator of transcription 3 (Stat3), but not activation of Stat1 or Stat5, occurs concurrently with G(0) growth arrest of HC11 mouse mammary epithelial cells, but not NIH 3T3 fibroblasts. Promoter analysis demonstrates that the C/EBP delta promoter fragment involved in transcriptional activation during G(0) growth arrest contains a Stat3 binding site and that mutation of this site eliminates the G(0) growth arrest inducibility of the C/EBP delta promoter. Overexpression of Stat3 increases C/EBP delta promoter activity during G(0) growth arrest of HC11 cells, whereas dominant negative Stat3 decreases C/EBP delta promoter activity under the same conditions. Neither Stat3 overexpression nor dominant negative Stat3 expression influences C/EBP delta promoter activity in growing HC11 cells or G(0) growth-arrested NIH3T3 cells, demonstrating that the effect is specific to G(0) growth arrest of mammary epithelial cells. Band shift assays and antibody interference assays demonstrate specific binding of Stat3 to the acute phase response element in the C/EBP delta promoter in G(0) growth-arrested HC11 cell extracts and 24 h involuting mouse mammary gland extracts. These data indicate that Stat3 activates C/EBP delta transcription in G(0) growth-arrested mouse mammary epithelial cells and binds to the C/EBP delta promoter during involution, An autocrine mechanism of Stat3 activation is proposed.	Ohio State Univ, Dept Vet Biosci, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Div Mol Biol & Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Dept Vet Biosci, Ctr Comprehens Canc, 1900 Coffey Rd, Columbus, OH 43210 USA.				NCI NIH HHS [P30CA16058, CA 57607] Funding Source: Medline; NCRR NIH HHS [RR00136CA] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057607, R01CA057607, P30CA016058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALAM T, 1992, J BIOL CHEM, V267, P5021; Basolo F, 1996, CANCER RES, V56, P3118; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASELLA G, 1990, STAT INFERENCE, P328; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Ji CH, 1999, ENDOCRINOLOGY, V140, P4564, DOI 10.1210/en.140.10.4564; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; Mayol Xavier, 1998, Frontiers in Bioscience, V3, pD11; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256; Okada H, 1997, J VET MED SCI, V59, P503, DOI 10.1292/jvms.59.503; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; Sartor CI, 1997, CANCER RES, V57, P978; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Skov S, 1998, BLOOD, V91, P3566; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tone E, 1998, BIOCHEM BIOPH RES CO, V253, P147, DOI 10.1006/bbrc.1998.9767; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	52	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29123	29131		10.1074/jbc.M004476200	http://dx.doi.org/10.1074/jbc.M004476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867011	hybrid			2022-12-25	WOS:000089330700101
J	Sandberg, M; Hassett, C; Adman, ET; Meijer, J; Omiecinski, CJ				Sandberg, M; Hassett, C; Adman, ET; Meijer, J; Omiecinski, CJ			Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPOXYGENASE-DERIVED EICOSANOIDS; AMINO-ACID SUBSTITUTIONS; CATALYTIC MECHANISM; ARACHIDONIC-ACID; CYTOCHROME-P-450 METABOLISM; HUMAN-LYMPHOCYTES; DIMER INTERFACE; HUMAN-LIVER; RAT-LIVER; EXPRESSION	Human soluble epoxide hydrolase (sEH), an enzyme directing the functional disposition of a variety of endogenous and xenobiotic-derived chemical epoxides, was characterized at the genomic level for interindividual variation capable of impacting function. RNA was isolated from 25 human liver samples and used to generate full-length copies of soluble epoxide hydrolase cDNA. The resulting cDNAs were polymerase chain reaction amplified, sequenced, and eight variant loci were identified. The coding region contained five silent single nucleotide polymorphisms (SNPs) and two variant loci resulting in altered protein sequence. An amino acid substitution was identified at residue 287 in exon 8, where the more common arginine was replaced by glutamine. A second variant locus was identified in exon 13 where an arginine residue was inserted following serine 402 resulting in the sequence, arginine 403-404, instead of the more common, arginine 403. This amino acid insertion was confirmed by analyzing genomic DNA from individuals harboring the polymorphic allele. Slot blot hybridization analyses of the liver samples indicated that sEH mRNA steady-state expression varied approximately 10-fold. Transient transfection experiments with CHO and COS-7 cells were used to demonstrate that the two new alleles possess catalytic activity using trans-stilbene oxide as a model substrate. Although the activity of the glutamine 287 variant was similar to the sEH wild type allele, proteins containing the arginine insertion exhibited strikingly lower activity. Allelic forms of human sEH, with markedly different enzymatic profiles, may have important physiological implications with respect to the disposition of epoxides formed from the oxidation of fatty acids, such as arachidonic acid-derived intermediates, as well in the regulation of toxicity due to xenobiotic epoxide exposures.	Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98105 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA; Swedish Univ Agr Sci, Uppsala Genet Ctr, Dept Plant Biol, SE-75007 Uppsala, Sweden	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swedish University of Agricultural Sciences	Omiecinski, CJ (corresponding author), Univ Washington, Dept Environm Hlth, 4225 Roosevelt Way NE, Seattle, WA 98105 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004978, P30ES007033] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES07033, ES04978] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonarakis SE, 1998, HUM MUTAT, V11, P1; ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; FAHLSTADIUS P, 1988, LIPIDS, V23, P1015; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; Gandolfi A.J., 1997, COMPREHENSIVE TOXICO, P283; GILL SS, 1983, ANAL BIOCHEM, V131, P273, DOI 10.1016/0003-2697(83)90166-5; Gonzalez FJ, 1997, REPROD TOXICOL, V11, P397, DOI 10.1016/S0890-6238(96)00154-2; GRANT DF, 1993, J BIOL CHEM, V268, P17628; Hartsfield JK, 1998, CYTOGENET CELL GENET, V83, P44, DOI 10.1159/000015164; Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KOSAKA K, 1994, MOL CELL BIOCHEM, V139, P141, DOI 10.1007/BF01081737; KRAMER A, 1991, BIOCHEM PHARMACOL, V42, P2147, DOI 10.1016/0006-2952(91)90350-E; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001; LARSSON C, 1995, HUM GENET, V95, P356; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MEIJER J, 1985, EUR J BIOCHEM, V148, P421, DOI 10.1111/j.1432-1033.1985.tb08856.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERTES I, 1985, CARCINOGENESIS, V6, P219, DOI 10.1093/carcin/6.2.219; Misawa E, 1998, EUR J BIOCHEM, V253, P173, DOI 10.1046/j.1432-1327.1998.2530173.x; Moghaddam MF, 1997, NAT MED, V3, P562, DOI 10.1038/nm0597-562; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; Mueller MJ, 1998, J BIOL CHEM, V273, P11570, DOI 10.1074/jbc.273.19.11570; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; NORRIS KK, 1989, J CLIN INVEST, V84, P1749, DOI 10.1172/JCI114358; PACEASCIAK CR, 1989, J BIOL CHEM, V264, P9310; Parkinson A., 1996, BASIC SCI POISONS, P113; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; Prasanna V, 1999, PROTEINS, V34, P356; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Sandberg M, 1996, BIOCHEM BIOPH RES CO, V221, P333, DOI 10.1006/bbrc.1996.0596; Scopes DA, 1998, EUR J BIOCHEM, V251, P382, DOI 10.1046/j.1432-1327.1998.2510382.x; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; VanRollins M, 1996, J BIOL CHEM, V271, P14001, DOI 10.1074/jbc.271.24.14001; WATABE T, 1981, J BIOL CHEM, V256, P2900; Weintraub NL, 1999, AM J PHYSIOL-HEART C, V277, pH2098, DOI 10.1152/ajpheart.1999.277.5.H2098; WRENSCH MR, 1989, CANCER RES, V49, P2168; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059	52	68	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28873	28881		10.1074/jbc.M001153200	http://dx.doi.org/10.1074/jbc.M001153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862610	hybrid			2022-12-25	WOS:000089330700071
J	Wieland, T; Bahtijari, N; Zhou, XB; Kleuss, C; Simon, MI				Wieland, T; Bahtijari, N; Zhou, XB; Kleuss, C; Simon, MI			Polarity exchange at the interface of regulators of G protein signaling with G protein alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C; RGS PROTEINS; ADENYLYL-CYCLASE; BINDING; TRANSDUCIN; GAIP; SELECTIVITY; INHIBITION	RGS proteins are GTPase-activating proteins (GAPs) for G protein alpha-subunits. This GAP activity is mediated by the interaction of conserved residues on regulator of G protein signaling (RGS) proteins and G alpha-subunits. We mutated the important contact sites Glu-89, Asn-90, and Asn-130 in RGS16 to lysine, aspartate, and alanine, respectively. The interaction of RGS16 and its mutants with G alpha(t) and G alpha(i1) was studied. The GAP activities of RGS16N90D and RGS16N130A were strongly attenuated. RGS16E89K increased GTP hydrolysis of G alpha(i1) by a similar extent, but with an about 100-fold reduced affinity compared with non-mutated RGS16. As Glu-89 in RGS16 is interacting with Lys-210 in G alpha(i1), this lysine was changed to glutamate for compensation. G alpha(i1)K210E was insensitive to RGS16 but interacted with RGS16E89K. In rat uterine smooth muscle cells, wild type RGS16 abolished G(1)-mediated alpha(2)-adrenoreceptor signaling, whereas RGS16E89K was without effect. Both G alpha(i1) and G alpha(i1) K210E mimicked the effect of alpha(2)-adrenoreceptor stimulation. G alpha(i1)K210E was sensitive to RGS16E89K and 10-fold more potent than G alpha(i1). Analogous mutants of G alpha(q) (G alpha(q)K215E) and RGS4 (RGS4E87K) were created and studied in COS-7 cells. The activity of wild type G alpha(q) was counteracted by wild type RGS4 but not by RGS4E87K. The activity of G alpha(q)K215E was inhibited by RGS4E87K, whereas non-mutated RGS4 was ineffective. We conclude that mutation of a conserved lysine residue to glutamate in G alpha(i) and G alpha(q) family members renders these proteins insensitive to wild type RGS proteins. Nevertheless, they are sensitive to glutamate to lysine mutants of RGS proteins. Such mutant pairs will be helpful tools in analyzing G alpha-RGS specificities in living cells.	Univ Hamburg, Inst Expt & Klin Pharmakol & Toxikol, Krankenhaus Eppendorf, D-20246 Hamburg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Hamburg; Free University of Berlin; California Institute of Technology	Wieland, T (corresponding author), Univ Hamburg, Inst Expt & Klin Pharmakol & Toxikol, Krankenhaus Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Offermanns S, 1996, CANCER SURV, V27, P177; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P238; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; Wieland T, 1997, J BIOL CHEM, V272, P8853; WIELAND T, 1999, N-S ARCH PHARMACOL, V360, P99; WU DQ, 1992, J BIOL CHEM, V267, P1811; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	33	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28500	28506		10.1074/jbc.M004187200	http://dx.doi.org/10.1074/jbc.M004187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878019	Green Accepted, hybrid			2022-12-25	WOS:000089330700023
J	Zhou, YL; Lei, YP; Snead, ML				Zhou, YL; Lei, YP; Snead, ML			Functional antagonism between Msx2 and CCAAT/enhancer-binding protein alpha in regulating the mouse amelogenin gene expression is mediated by protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTICALLY ACTIVATE TRANSCRIPTION; FACTOR C/EBP-ALPHA; NF-KAPPA-B; HOMEOBOX GENE; TOOTH DEVELOPMENT; ADIPOCYTE DIFFERENTIATION; RECIPROCAL REGULATION; NEGATIVE INHIBITOR; CELL-PROLIFERATION; IMPERFECTA AIH1	Ameloblast-specific amelogenin gene expression is spatiotemporally regulated during tooth development. In a previous study, the CCAAT/enhancer-binding protein alpha (C/EBP alpha) was identified as a transcriptional activator of the mouse amelogenin gene in a cell type-specific manner. Here, Msx2 is shown to repress the promoter activity of amelogenin-promoter reporter constructs independent of its intrinsic DNA binding activity. In transient cotransfection assays, Msx2 and C/EBP alpha antagonize each other in regulating the expression of the mouse amelogenin gene. Electrophoresis mobility shift assays demonstrate that Msx2 interferes with the binding of C/EBP alpha to its cognate site in the mouse amelogenin minimal promoter, although Msx2 itself does not bind to the same promoter fragment. Protein-protein interaction between Msx2 and C/EBP alpha is identified with co-immunoprecipitation analyses. Functional antagonism between Msx2 and C/EBP alpha is also observed on the stably transfected a,a-kilobase mouse amelogenin promoter in ameloblast-like LS8 cells, Furthermore, the carboxyl-terminal residues 183-267 of Msx2 are required for protein-protein interaction, whereas the amino-terminal residues 2-97 of Msx2 play a less critical role. Among three family members tested (C/EBP alpha, -beta, and -gamma), Msx2 preferentially interacts with C/EBP alpha. Taken together, these data indicate that protein-protein interaction rather than competition for overlapping binding sites results in the functional antagonism between Msx2 and C/EBP alpha in regulating the mouse amelogenin gene expression.	Univ So Calif, CCMB, Los Angeles, CA 90033 USA	University of Southern California	Snead, ML (corresponding author), Univ So Calif, CCMB, CSA142,2250 Alcazar St, Los Angeles, CA 90033 USA.				NIDCR NIH HHS [DE06988] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALDRED MJ, 1992, HUM GENET, V90, P413; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; CHEN EH, 1994, DEV DYNAM, V199, P189, DOI 10.1002/aja.1001990304; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COUWENHOVEN RI, 1993, J CRAN GENET DEV BIO, V13, P259; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DAlessio M, 1996, MECH DEVELOP, V58, P217, DOI 10.1016/S0925-4773(96)00583-7; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Dhamija S, 1999, J BIOL CHEM, V274, P20738, DOI 10.1074/jbc.274.29.20738; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; Diekwisch TGH, 1997, J HISTOCHEM CYTOCHEM, V45, P859, DOI 10.1177/002215549704500610; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAGERSTROMFERMER M, 1995, GENOMICS, V26, P159, DOI 10.1016/0888-7543(95)80097-6; LANE MD, 1996, INT J OBESITY, V20, P91; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1991, DEVELOPMENT, V113, P601; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; METZGER S, 1993, J BIOL CHEM, V268, P16831; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mina M, 1996, CONNECT TISSUE RES, V35, P79, DOI 10.3109/03008209609029177; MINA M, 1995, DEV DYNAM, V202, P195, DOI 10.1002/aja.1002020211; Mink S, 1996, MOL CELL BIOL, V16, P1316; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; *QIAG INC, 1997, QIAEXPR, P38; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Shimeld SM, 1996, MECH DEVELOP, V55, P201, DOI 10.1016/0925-4773(96)00505-9; SNEAD ML, 1988, DEVELOPMENT, V104, P77; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; SNEAD ML, 1984, DEV BIOL, V104, P255, DOI 10.1016/0012-1606(84)90053-8; SNEAD ML, 1987, MOL APPROACHES DEV B, P641; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stocum DL, 1997, SCIENCE, V276, P15, DOI 10.1126/science.276.5309.15; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; WU KJ, 1994, J BIOL CHEM, V269, P1177; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZeichnerDavid M, 1997, INT J DEV BIOL, V41, P27; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273	77	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29066	29075		10.1074/jbc.M002031200	http://dx.doi.org/10.1074/jbc.M002031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10859305	hybrid			2022-12-25	WOS:000089330700094
J	Trainor, CD; Ghirlando, R; Simpson, MA				Trainor, CD; Ghirlando, R; Simpson, MA			GATA zinc finger interactions modulate DNA binding and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LOCUS-CONTROL REGION; EPSILON-GLOBIN GENE; REGULATORY GENE; COFACTOR FOG; MICE LACKING; PROTEIN; EXPRESSION; PROMOTER; FAMILY	GATA-1 and other vertebrate GATA factors contain a DNA binding domain composed of two adjacent homologous zinc fingers. Whereas only the C-terminal finger of GATA-1 is capable of independent binding to the GATA recognition sequence, double GATA sites that require both fingers for high affinity interaction are found in several genes. We propose a mechanism whereby adjacent zinc fingers interact to influence the binding and transactivation properties of GATA-1 at a subset of DNA-binding sites. By using two such double GATA sites we demonstrate that the N-terminal finger and adjacent linker region can alter the binding specificity of the C-terminal finger sufficiently to prevent it from recognizing some consensus GATA sequences. Therefore, the two zinc fingers form a composite binding domain having a different DNA binding specificity from that shown by the constituent single C-terminal finger. Furthermore, we compare two of these double sites and show that high affinity binding of GATA-1 to a reporter gene does not necessarily induce transactivation, namely the sequence of the DNA-binding site can alter the ability of GATA-1 to stimulate transcription.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Trainor, CD (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	cecelia@intra.niddk.nih.gov	Ghirlando, Rodolfo/A-8880-2009		NHLBI NIH HHS [HL03601] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUG H, 1982, J CELL PHYSIOL, P195; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KLUG A, 1995, ANN NY ACAD SCI, V758, P143, DOI 10.1111/j.1749-6632.1995.tb24814.x; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Onodera K, 1997, J BIOCHEM, V121, P251; ORKIN SH, 1992, BLOOD, V80, P575; Osada H., 1997, Leukemia (Basingstoke), V11, P307; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PETERS B, 1993, J BIOL CHEM, V268, P3430; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	55	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28157	28166						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862757				2022-12-25	WOS:000089197100083
J	Spady, DK; Willard, MN; Meidell, RS				Spady, DK; Willard, MN; Meidell, RS			Role of acyl-coenzyme A : cholesterol acyltransferase-1 in the control of hepatic very low density lipoprotein secretion and low density lipoprotein receptor expression in the mouse and hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; ADENOVIRUS-MEDIATED TRANSFER; ELEMENT-BINDING PROTEIN-1; MESSENGER-RNA LEVELS; APOLIPOPROTEIN-B; HEPG2 CELLS; FATTY-ACIDS; IN-VIVO; ABETALIPOPROTEINEMIA GENE	Cholesteryl esters present in nascent very low density lipoproteins are generated in a reaction catalyzed by acyl CoA:cholesterol acyltransferase (ACAT), To examine the effect of cholesteryl esters on the secretion of apoB-containing lipoproteins, we transiently overexpressed human (h) ACAT-1 in the livers of low density lipoprotein (LDL) receptor(-/-) mice using adenovirus-mediated gene transfer. Overexpression of hACAT-1 increased hepatic total and esterified cholesterol but did not reduce hepatic free cholesterol due to a compensatory increase in the rate of de novo cholesterol synthesis. Overexpression of hACAT-1 markedly increased the plasma concentration and hepatic secretion of apoB-containing lipoproteins but had no effect on the clearance of very low density lipoprotein-apoB from plasma indicating that cholesteryl esters play an important role in regulating the assembly and secretion of apoB-containing lipoproteins. ACAT activity has been implicated in the regulation of the LDL receptor pathway by dietary fatty acids. it has been hypothesized that unsaturated fatty acids, by enhancing ACAT activity, reduce the amount of free cholesterol in a putative regulatory pool that feeds back on LDL receptor expression. We directly tested this hypothesis in hamsters by transiently overexpressing hACAT-1 in the liver. Enhanced cholesterol esterification in the liver resulted in a compensatory increase in de novo cholesterol synthesis but no induction of LDL receptor expression suggesting that fatty acids regulate LDL receptor expression via a mechanism independent of ACAT.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Spady, DK (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	spady@utsw.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047551, R01HL038049] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38049, HL-47551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Burnett JR, 1999, J LIPID RES, V40, P1317; CARR TP, 1995, J LIPID RES, V36, P25; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; GERARD RD, 1995, DNA CLONING PRACTICA; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Graham A, 1996, BBA-LIPID LIPID MET, V1302, P46, DOI 10.1016/0005-2760(96)00030-6; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jamil H, 1998, J LIPID RES, V39, P1448; Joyce C, 1999, CURR OPIN LIPIDOL, V10, P89, DOI 10.1097/00041433-199904000-00002; Lee O, 1998, J LIPID RES, V39, P1722; Li XH, 1996, J LIPID RES, V37, P210; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Musanti R, 1996, J LIPID RES, V37, P1; Ooyen C, 1997, ATHEROSCLEROSIS, V130, P143, DOI 10.1016/S0021-9150(96)06060-1; PAPE ME, 1995, J LIPID RES, V36, P823; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rudel LL, 1998, PROG LIPID RES, V37, P353, DOI 10.1016/S0163-7827(98)00015-0; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; SPECTOR AA, 1980, J LIPID RES, V21, P169; TABAS I, 1986, J BIOL CHEM, V261, P3147; TANAKA M, 1993, J BIOL CHEM, V268, P12713; Tietge UJF, 1999, J LIPID RES, V40, P2134; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WETTERAU JR, 1992, SCIENCE, V258, P999; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Zhang ZJ, 1999, ARTERIOSCL THROM VAS, V19, P743, DOI 10.1161/01.ATV.19.3.743	52	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27005	27012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869364				2022-12-25	WOS:000089144800046
J	Forsee, WT; Cartee, RT; Yother, J				Forsee, WT; Cartee, RT; Yother, J			Biosynthesis of type 3 capsular polysaccharide in Streptococcus pneumoniae - Enzymatic chain release by an abortive translocation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASES; ARCHITECTURE; EQUISIMILIS; PYOGENES	The type 3 polysaccharide synthase from Streptococcus pneumoniae catalyzes sugar transfer from UDP-Glc and UDP-glucuronic acid (GlcUA) to a polymer with the repeating disaccharide unit of [3)-beta-D-GlcUA-(1-->4)-beta-D-Glc-(1-->]. Evidence is presented that release of the polysaccharide chains from S, pneumoniae membranes is time-, temperature, and pH-dependent and saturable with respect to specific catalytic metabolites. In these studies, the membrane-bound synthase was shown to catalyze a rapid release of enzyme-bound polysaccharide when either UDP-Glc or UDP-GlcUA alone was present in the reaction. Only a slow release of polysaccharide occurred when both UDP sugars were present or when both UDP sugars were absent. Chain size was not a specific determinant in polymer release. The release reaction was saturable with increasing concentrations of UDP-Glc or UDP-GlcUA, with respective apparent K-m, values of 880 and 0.004 mu M, The apparent V-max was 48-fold greater with UDP-Glc compared with UDP-GlcUA. The UDP-Glc-actuated reaction was inhibited by UDP-GlcUA with an approximate K-i of 2 mu m, and UDP-GlcUA-actuated release was inhibited by UDP-Glc with an approximate K-i of 5 mu m. In conjunction with kinetic data regarding the polymerization reaction, these data indicate that UDP-Glc and UDP-GlcUA bind to the same synthase sites in both the biosynthetic reaction and the chain release reaction and that polymer release is catalyzed when one binding site is filled and the concentration of the conjugate UDP-precursor is insufficient to fill the other binding site. The approximate energy of activation values of the biosynthetic and release reactions indicate that release of the polysaccharide occurs by an abortive translocation process. These results are the first to demonstrate a specific enzymatic mechanism for the termination and release of a polysaccharide.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama, Dept Microbiol, BBRB 661-12,845 19th St S, Birmingham, AL 35294 USA.				NHLBI NIH HHS [T32HL07553] Funding Source: Medline; NIGMS NIH HHS [GM53017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Hardy GG, 2000, J BACTERIOL, V182, P1854, DOI 10.1128/JB.182.7.1854-1863.2000; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; Reeves RE, 1941, J BIOL CHEM, V139, P511; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SMITH EEB, 1960, J BIOL CHEM, V235, P1876; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Sunthankar P, 1998, ANAL BIOCHEM, V258, P195, DOI 10.1006/abio.1998.2600; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; TORRIANI A, 1962, J BIOL CHEM, V237, P3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; ZWEIG G, 1967, PAPER CHROMATOGRAPHY	22	29	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25972	25978		10.1074/jbc.M002613200	http://dx.doi.org/10.1074/jbc.M002613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854426	hybrid			2022-12-25	WOS:000088999700014
J	Kuang, AA; Diehl, GE; Zhang, JK; Winoto, A				Kuang, AA; Diehl, GE; Zhang, JK; Winoto, A			FADD is required for DR4-and DR5-mediated apoptosis - Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC LIGAND TRAIL; NF-KAPPA-B; CELL-DEATH INDUCTION; SIGNALING COMPLEX; DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; MOLECULAR-CLONING; APO-2 LIGAND; RECEPTOR; FAMILY	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a member of the tumor necrosis factor family that can kill a wide variety of tumor cells but not normal cells. TRAIL-induced apoptosis in humans is mediated by its receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2). What constitutes the signaling molecules downstream of these receptors, however, remains highly controversial. Using the FADD dominant negative molecule, several groups have reached different conclusions with respect to the role of FADD in TRAIL-induced apoptosis. More recently, using FADD-deficient (-/-) mouse embryonic fibroblasts, Yeh ct at (Yeh, W. C., Pompa, J. L., McCurrach, M. E., Shu, H.-B., Elia, A. J,, Shahinian, A, Ng, M., Wakeham, A, Khoo, W., Mitchell, K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T,W. (1998) Science 279, 1954-1958) concluded that DR4 utilizes a FADD-independent apoptotic pathway. The latter experiment, however, involved transient overexpression, which often leads to nonspecific aggregation of death domain-containing receptors. To address this issue in a more physiological setting, we stably transfected mouse DR4/5, human DR4, or human DR5 into FADD(-/-) mouse embryonic fibroblast cells. We showed that FADD(-/-) MEF cells stably transfected with TRAIL receptors are resistant to TRAIL-mediated cell death. In contrast, TRAIL receptors stably transfected into heterozygous FADD(+/-) cells or FADD(-/-) cells reconstituted with a FADD retroviral construct are sensitive to the TRAIL cytotoxic effect. We conclude that FADD is required for DR4- and DR5-mediated apoptosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Canc Res Lab, 229 Stanley Hall, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226; Diehl, Gretchen/0000-0002-1841-2842	NCI NIH HHS [CA75162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	35	196	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25065	25068		10.1074/jbc.C000284200	http://dx.doi.org/10.1074/jbc.C000284200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10862756	hybrid			2022-12-25	WOS:000088849400004
J	Paz, Y; Elazar, Z; Fass, D				Paz, Y; Elazar, Z; Fass, D			Structure of GATE-16, membrane transport modulator and mammalian ortholog of autophagocytosis factor Aut7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; COMPLEX; INSIGHTS; MUTANTS; VACUOLE; MODELS; YEAST; NSF	The GATE-16 protein participates in intra-Golgi transport and can associate with the N-ethylmaleimide-sensitive fusion protein and with Golgi SNAREs, The yeast ortholog of GATE-16 is the autophagocytosis factor Aut7p, GATE-16 is also closely related to the GABA receptor-associated protein (GABARAP), which has been proposed to cluster neurotransmitter receptors by mediating interaction with the cytoskeleton, and to the light chain-3 subunit of the neuronal microtubule-associated protein complex. Here, we present the crystal structure of GATE-16 refined to 1.8 Angstrom resolution. GATE-16 contains a ubiquitin fold decorated by two additional N-terminal helices, Proteins with strong structural similarity but no detectable sequence homology to GATE-16 include Ras effectors that mediate diverse downstream functions, but each interacts with Ras by forming pseudo-continuous beta-sheets, The GATE-16 surface suggests that it binds its targets in a similar manner. Moreover, a second potential protein-protein interaction site on GATE-16 may explain the adapter activity observed for members of the GATE-16 family.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Fass, D (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	csfass@wis.weizmann.ac.il						Babor SM, 1999, P NATL ACAD SCI USA, V96, P14759, DOI 10.1073/pnas.96.26.14759; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DOERING D, 1992, THESIS MIT CAMBRIDGE; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LEGESSEMILLER A, 2000, IN PRESS J BIOL CHEM; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MANN SS, 1994, J BIOL CHEM, V269, P11492; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	44	131	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25445	25450		10.1074/jbc.C000307200	http://dx.doi.org/10.1074/jbc.C000307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10856287	hybrid			2022-12-25	WOS:000088849400053
J	Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T				Hori, T; Takaori-Kondo, A; Kamikubo, Y; Uchiyama, T			Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor	ONCOGENE			English	Article						protein kinase; tumor suppressor; cell cycle; mitosis; phosphorylation	MYOTONIC-DYSTROPHY KINASE; CELL-CYCLE; GENE DBF2; ENCODES; SEQUENCE	A novel human protein kinase, designated kpm, was identified and molecularly cloned. The isolated cDNA done had an open reading frame consisting of 1088 amino acid residues with a putative kinase domain located near the carboxy-terminus. Homology search revealed that kpm belongs to a subfamily of serine/threonine protein kinases including warts/lats, a Drosophila tumor suppressor. Among these, kpm is most homologous to, but distinct from, recently reported LATS1, a human homolog of DI Drosophila warts/lats. Northern blot analysis disclosed that kpm is expressed as a 6.0 kb transcript in most of the tissues examined and also as an additional shorter 4.0 kb transcript in testis, Western blotting using polyclonal rabbit anti-kpm antibody detected kpm protein as a band with an apparent M-r of 150 kD. Immune complex kinase assay of HA-tagged kpm showed that kpm had kinase activity and phosphorylated itself in vitro. Studies with synchronized HeLa cells indicated that kpm protein was expressed relatively constantly throughout the cell cycle and underwent significant phosphorylation at mitotic phase. These results suggest that kpm plays a role in cell cycle progression during mitosis and its deletion or dysfunction might be involved in certain types of human cancers.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hori, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Kawaracho, Kyoto 6068507, Japan.							HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KOEFFLER HP, 1980, BLOOD, V56, P265; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; VALLEJO AN, 1995, COLD SPRING HARBOR L; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU TA, 1995, DEVELOPMENT, V121, P1053; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	21	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3101	3109		10.1038/sj.onc.1203659	http://dx.doi.org/10.1038/sj.onc.1203659			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871863				2022-12-25	WOS:000087903900008
J	Nemoto, Y; Kearns, BG; Wenk, MR; Chen, H; Mori, K; Alb, JG; De Camilli, P; Bankaitis, VA				Nemoto, Y; Kearns, BG; Wenk, MR; Chen, H; Mori, K; Alb, JG; De Camilli, P; Bankaitis, VA			Functional characterization of a mammalian Sac1 and mutants exhibiting substrate-specific defects in phosphoinositide phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; RETINAL-DEGENERATION-B; YEAST GOLGI-COMPLEX; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GENE ENCODES; SIGNAL-TRANSDUCTION; IN-VIVO; TRANSPORT	The Saccharomyces cerevisiae SAC1 gene was identified via independent analyses of mutations that modulate yeast actin function and alleviate the essential requirement for phosphatidylinositol transfer protein (Sec14p) activity in Golgis secretory function. The SAC1 gene product (Sac1p) is an integral membrane protein of the endoplasmic reticulum and the Golgi complex, Sac1p shares primary sequence homology with a subfamily of cytosolic/peripheral membrane phosphoinositide phosphatases, the synaptojanins, and these Sad domains define novel phosphoinositide phosphatase modules. We now report the characterization of a rat counterpart of Sac1p, Rat Sad is a ubiquitously expressed 65-kDa integral membrane protein of the endoplasmic reticulum that is found at particularly high levels in cerebellar Purkinje cells. Like Sac1p, rat Sad exhibits intrinsic phosphoinositide phosphatase activity directed toward phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, and phosphatidylinositol 3,5-bisphosphate substrates, and we identify mutant rat sad alleles that evoke substrate-specific defects in this enzymatic activity. Finally, rat Sad expression in Delta sac1 yeast strains complements a wide phenotypes associated with Sac1p insufficiency. Biochemical and in vivo data indicate that rat Sad phosphatidylinositol-4-phosphate phosphatase activity, but not its phosphatidylinositol-3-phosphate or pho sphatidylinositol-3,5 bisphosphate phosphatase activities, is essential for the heterologous complementation of Sac1p defects in vivo. Thus, yeast Sac1p and rat Sad are integral membrane lipid phosphatases that play evolutionary conserved roles in eukaryotic cell physiology.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Inst Phys & Chem Res, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Howard Hughes Medical Institute; Yale University; Yale University; RIKEN; University of Alabama System; University of Alabama Birmingham	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.		Wenk, Markus Rene/D-1441-2014	Mori, Kensaku/0000-0001-7853-9370	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS037723, R01NS036251, R56NS037723] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44530] Funding Source: Medline; NINDS NIH HHS [NS37723, NS36251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINSON KD, 1984, J BACTERIOL, V160, P80, DOI 10.1128/JB.160.1.80-86.1984; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cockcroft S, 1999, CHEM PHYS LIPIDS, V98, P23, DOI 10.1016/S0009-3084(99)00015-8; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Fleischer S, 1974, Methods Enzymol, V31, P6; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Harlow E., 1988, ANTIBODIES LAB MANUA; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; HWANG PM, 1990, SCIENCE, V249, P802, DOI 10.1126/science.1975122; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1983, METHODS YEAST GENITC; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stock SD, 1999, J BIOL CHEM, V274, P12979, DOI 10.1074/jbc.274.19.12979; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TAKEI K, 1992, J NEUROSCI, V12, P489; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WEIMAR WR, 1982, BRAIN RES, V251, P357, DOI 10.1016/0006-8993(82)90754-5; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	67	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34293	34305		10.1074/jbc.M003923200	http://dx.doi.org/10.1074/jbc.M003923200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10887188	hybrid			2022-12-25	WOS:000165095300042
J	Grimme, S; Honing, S; von Figura, K; Schmidt, B				Grimme, S; Honing, S; von Figura, K; Schmidt, B			Endocytosis of insulin-like growth factor II by a mini-receptor based on repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; IGF-II; CYTOPLASMIC DOMAIN; LYSOSOMAL-ENZYMES; MANNOSE-6-PHOSPHATE RECEPTORS; MICROSATELLITE INSTABILITY; PERINATAL LETHALITY; OVERLAP EXTENSION; HUMAN-FIBROBLASTS	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) plays an important role in controlling the extracellular level of the insulin-like growth factor II (IGF-II) by mediating its binding at the cell surface and delivery to lysosomes. Loss of the receptor is associated with an accumulation of IGF-II, which can cause perinatal lethality if it is systemic, or local proliferation and tumorgenesis if it is spatially restricted. The extracytoplasmic domain of the receptor consists of 15 homologous repeats, of which repeat 11 carries the IGF-II-binding site of the multifunctional receptor. To investigate whether repeat 11 is sufficient to mediate binding and internalization of IGF-II, a construct consisting of repeat 11 fused to the transmembrane and cytoplasmic domain of the M6P/IGF-II receptor was transfected into mouse embryonic fibroblasts. The construct was expressed as a stable membrane protein which binds IGF-II with a 10-fold lower affinity as observed for the M6P/IGF-II receptor and is found at the cell surface and in endosomes. It mediates the internalization of IGF-II and its delivery to lysosomes, suggesting that it can function as a IGF-II mini-receptor controlling the extracellular IGF-II level.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	bschmidt@uni-bc2.gwdg.de						AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BALLARD FJ, 1988, BIOCHEM J, V249, P721, DOI 10.1042/bj2490721; Boker C, 1997, J CELL SCI, V110, P1023; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; CREEK KE, 1983, BIOCHEM J, V214, P353, DOI 10.1042/bj2140353; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; Hankins GR, 1996, ONCOGENE, V12, P2003; HEMER F, 1993, J BIOL CHEM, V268, P17108; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KIESS W, 1988, J BIOL CHEM, V263, P9339; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; Ouyang H, 1997, CANCER RES, V57, P1851; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; POHLMANN R, 1996, BIOMEMBR, V4, P223; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SCHULZEGARG C, 1993, J CELL BIOL, V122, P541, DOI 10.1083/jcb.122.3.541; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TONG PY, 1988, J BIOL CHEM, V263, P2585; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wang SN, 1997, CANCER RES, V57, P2543; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; YU KT, 1986, J BIOL CHEM, V261, P1341	52	17	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33697	33703		10.1074/jbc.M003789200	http://dx.doi.org/10.1074/jbc.M003789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10884392	hybrid			2022-12-25	WOS:000090104600072
J	Miller, T; Williams, K; Johnstone, RW; Shilatifard, A				Miller, T; Williams, K; Johnstone, RW; Shilatifard, A			Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION; MYELOID-LEUKEMIA; TIGHT JUNCTIONS; PURIFICATION; PROTEIN; DROSOPHILA; GENE; LOCALIZATION; OCCLUDIN; COMPLEX	The human ELL gene, which is a frequent target for translocation in acute myeloid leukemia, was initially isolated from rat liver nuclei and found to be an RNA polymerase II elongation factor. Based on homology to ELL, we later cloned ELL2 and demonstrated that it can also increase the catalytic rate of transcription elongation by RNA polymerase II. To better understand the role of ELL proteins in the regulation of transcription by RNA polymerase II, we have initiated a search for proteins related to ELLs. In this report, we describe the molecular cloning, expression, and characterization of ELL3, a novel RNA polymerase II elongation factor approximately 50% similar to both ELL and ELL2. Our transcriptional studies have demonstrated that ELLS can also increase the catalytic rate of transcription elongation by RNA polymerase II, The C-terminal domain of ELL, which we recently demonstrated to be required and sufficient for the immortalization of myeloid progenitor cells, shares strong similarities to the C-terminal domain of ELL3. ELL3 was localized by immunofluorescence to the nucleus of cells, and Northern analysis indicated that ELL3 is a testis-specific RNA polymerase II elongation factor.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA; Peter MacCallum Canc Inst, Canc Immunol Div, E Melbourne, Vic 3000, Australia	Saint Louis University; Peter Maccallum Cancer Center	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237				Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Shilatifard A, 1998, BIOL CHEM, V379, P27; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Weaver ZA, 1997, GENOMICS, V46, P516, DOI 10.1006/geno.1997.5073; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; [No title captured]	33	60	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32052	32056		10.1074/jbc.M005175200	http://dx.doi.org/10.1074/jbc.M005175200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882741	hybrid			2022-12-25	WOS:000089858900069
J	Ono, T; Kitaura, H; Ugai, H; Murata, T; Yokoyama, KK; Iguchi-Ariga, SMM; Ariga, H				Ono, T; Kitaura, H; Ugai, H; Murata, T; Yokoyama, KK; Iguchi-Ariga, SMM; Ariga, H			TOK-1, a novel p21(Cip1)-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING DOMAINS; E7 ONCOPROTEIN; P21; PCNA; IDENTIFICATION	A p21(Cip1/Waf1/Sdi1) is known to act as a negative cell-cycle regulator by inhibiting kinase activity of a variety of cyclin-dependent kinases. In addition to binding of the cyclin-dependent kinase to the N-terminal region of p21, p21 is also bound at its C-terminal region by proliferating cell nuclear antigen (PCNA), SET/TAF1, and calmodulin, indicating the versatile function of p21. In this study, we cloned cDNA encoding a novel protein named TOK-1 as a p21 C-terminal-binding protein by a two-hybrid system. Two splicing isoforms of TOK-1, TOK-1 alpha and TOK-1 beta, comprising 322 and 314 amino acids, respectively, were co-localized with p21 in nuclei and showed a similar expression profile to that of p21 in human tissues. TOK-1 alpha, but not TOK-1 beta, directly bound to the C-terminal proximal region of p21, and both were expressed at the G(1)/S boundary of the cell cycle. TOK-1 alpha also preferentially bound to an active form of cyclin-dependent kinase 2 (CDK2) via p21, and these made a ternary complex in human cells. Furthermore, the results of three different types of experiments showed that TOK-1 alpha enhanced the inhibitory activity of pal toward histone Ill kinase activity of CDK2. TOK-1 alpha is thus thought to be a new type of CDK2 modulator.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; RIKEN, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan; CREST, Japan Sci & Technol Corp, Kawaguchi, Saitama, Japan	Hokkaido University; Hokkaido University; RIKEN; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ugai, Hideyo/K-4920-2017; Ariga, Hiroyoshi/B-5895-2013	Ugai, Hideyo/0000-0002-9121-8480; Ariga, Hiroyoshi/0000-0001-7384-2143; Ono, Takashi/0000-0002-1820-8040				CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO J, 1999, FRONT BIOSCI, V4, P787; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NEGISHI Y, 1994, ONCOGENE, V9, P1133; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3	35	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31145	31154		10.1074/jbc.M003031200	http://dx.doi.org/10.1074/jbc.M003031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878006	hybrid			2022-12-25	WOS:000089762700057
J	Chatterjee, TK; Fisher, RA				Chatterjee, TK; Fisher, RA			Novel alternative splicing and nuclear localization of human RGS12 gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GTPASE-ACTIVATING PROTEINS; TRANSITION-STATE; PHOSPHOLIPASE-C; HEAVY-CHAIN; DNA-DAMAGE; PML-RAR; RNA; ALPHA; TRANSCRIPTION	RGS proteins are GTPase-activating proteins for certain Ga subunits, accelerating the shutoff mechanism of G protein signaling, and also may interact with receptors and effecters to modulate G protein signaling. Here, we report identification of 12 distinct transcripts of human RGS12 that arise by unusually complex splicing of the RGS12 gene, which spans 76 kilobase pairs of genomic DNA and contains 16 exons, These transcripts arise by both cis- and trans-splicing mechanisms, are expressed in a tissue-specific manner, and encode proteins ranging in size from 356 to 1447 amino acids. Both 5'- and 3'-splicing of two primary RGS12 transcripts occur to generate RGS12 mRNAs encoding proteins with four distinct N-terminal domains, three distinct C-terminal domains, and a common internal region where the semiconserved RGS domain is located. Confocal microscopy and subcellular fractionation of COS-7 cells expressing RGS12 proteins with three different N termini (brain (B), peripheral (P), and trans-spliced (TS)) and a shared short (S) C-terminal domain demonstrated exclusive nuclear localization of these proteins and an influence of the N-terminal region on the pattern of intranuclear distribution. Both native RGS12TS-S in HEK-293T cells and ectopically expressed RGS12TS-S localized to discrete nuclear foci (dots), a characteristic of various tumor suppressor proteins. Subnuclear localization of RGS12TS-S into nuclear dots was cell cycle-dependent. Native RGS12TS-S associated with the metaphase chromosome during mitosis, and ectopically expressed RGS12TS-S induced formation of abnormally shaped and multiple nuclei in COS-7 cells, Expression of RGS12 proteins with long and intermediate C-terminal domains was not observed in COS-7 cells, suggesting that 3'-splicing of RGS12 transcripts may influence the expression or stability of the encoded proteins. These results document extraordinary structural complexity in the RGS12 family and the role of alternative splicing and cell cycle-dependent mechanisms in expression and subnuclear targeting of RGS12 proteins.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.		Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fujieda S, 1996, J IMMUNOL, V157, P3450; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	38	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29660	29671		10.1074/jbc.M000330200	http://dx.doi.org/10.1074/jbc.M000330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10869340	hybrid			2022-12-25	WOS:000089439800066
J	Chung, L; Shimokawa, K; Dinakarpandian, D; Grams, F; Fields, GB; Nagase, H				Chung, L; Shimokawa, K; Dinakarpandian, D; Grams, F; Fields, GB; Nagase, H			Identification of the (RWTNNFREY191)-R-183 region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; ALANINE SCANNING MUTAGENESIS; HUMAN FIBROBLAST COLLAGENASE; HUMAN NEUTROPHIL COLLAGENASE; HEMOPEXIN-LIKE DOMAIN; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; GELATINASE-A; I COLLAGEN; CATALYTIC DOMAIN	Matrix metalloproteinase 1 (MMP-1) cleaves types I, II, and III collagen triple helices into 3/4 and 1/4 fragments. To understand the structural elements responsible for this activity, various lengths of MMP-1 segments have been introduced into MMP-3 (stromelysin 1) starting from the C-terminal end. MMP-3/MMP-1 chimeras and variants were overexpressed in Escherichia coli, folded from inclusion bodies, and isolated as zymogens, After activation, recombinant chimeras were tested for their ability to digest triple helical type I collagen at 25 degrees C. The results indicate that the nine residues (RWTNNFREY191)-R-183 located between the fifth beta-strand and the second alpha-helix in the catalytic domain of MMP-1 are critical for the expression of collagenolytic activity. Mutation of Tyr(191) of MMP-1 to Thr, the corresponding residue in MMP-3, reduced collagenolytic activity about 5-fold. Replacement of the nine residues with those of the MMP-3 sequence further decreased the activity 2-fold. Those variants exhibited significant changes in substrate specificity and activity against gelatin and synthetic substrates, further supporting the notion that this region plays a critical role in the expression of collagenolytic activity. However, introduction of this sequence into MMP-3 or a chimera consisting of the catalytic domain of MMP-3 with the hinge region and the C-terminal hemopexin domain of MMP-1 did not express any collagenolytic activity. It is therefore concluded that RWTNNFREY, together with the C-terminal hemopexin domain, is essential for collagenolytic activity but that additional structural elements in the catalytic domain are also required. These elements probably act in a concerted manner to cleave the collagen triple helix.	Imperial Coll Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; F Hoffmann La Roche & Co Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland; Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	Imperial College London; University of Oxford; University of Kansas; University of Kansas Medical Center; Roche Holding; State University System of Florida; Florida Atlantic University	Nagase, H (corresponding author), Imperial Coll Sch Med, Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.				NATIONAL CANCER INSTITUTE [R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NCI NIH HHS [CA77402] Funding Source: Medline; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; GLIMCHER MJ, 1964, BIOCHIM BIOPHYS ACTA, V93, P585, DOI 10.1016/0304-4165(64)90342-3; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nagase H, 1997, BIOL CHEM, V378, P151; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SAUS J, 1988, J BIOL CHEM, V263, P6742; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STARKEY PM, 1977, BIOCHIM BIOPHYS ACTA, V483, P386, DOI 10.1016/0005-2744(77)90066-3; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 2000, MATRIX METALLOPROTEI; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	44	115	118	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29610	29617		10.1074/jbc.M004039200	http://dx.doi.org/10.1074/jbc.M004039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871619	hybrid			2022-12-25	WOS:000089439800058
J	Liu, MQ; Spremulli, L				Liu, MQ; Spremulli, L			Interaction of mammalian mitochondrial ribosomes with the inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; SACCHAROMYCES-CEREVISIAE; DEHYDROGENASE SUBUNIT; YEAST; DNA; IDENTIFICATION; EXPRESSION; MUTATIONS; EXPORT; MATRIX	All of the products of mitochondrial protein biosynthesis in animals are hydrophobic proteins that are localized in the inner membrane. Hence, it is possible that the synthesis of these proteins could occur on ribosomes associated with the inner membrane. To examine this possibility, inner membrane and matrix fractions of bovine mitochondria were examined for the presence of ribosomes using probes for the rRNAs. Between 40 and 50% of the ribosomes were found to fractionate with the inner membrane. About half of the ribosomes associated with the inner membrane could be released by high salt treatment, indicating that they interact with the membrane largely through electrostatic forces. No release of the ribosome was observed upon treatment with puromycin, suggesting that the association observed is not due to insertion of a nascent polypeptide chain into the membrane. A fraction of the ribosomes remained with residual portions of the membranes that cannot be solubilized in the presence of Triton X-100. These ribosomes may be associated with large oligomeric complexes in the membrane.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Spremulli, L (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN M, 2000, J CELL BIOL, V56, P206; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P596; Crowley KS, 1998, J BIOL CHEM, V273, P17278, DOI 10.1074/jbc.273.27.17278; DAUM G, 1982, J BIOL CHEM, V257, P3028; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; FOX TD, 1996, TRANSLATIONAL CONTRO, P733; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GURTUBAY JIG, 1980, J BIOENERG BIOMEMBR, V12, P47, DOI 10.1007/BF00745012; He SC, 1999, MOL CELL BIOL, V19, P6598; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; LINNANE A, 1973, YEAST MOLD PLANT PRO, P344; Manthey GM, 1998, EUR J BIOCHEM, V255, P156, DOI 10.1046/j.1432-1327.1998.2550156.x; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MCCONKEY EH, 1979, MOL GEN GENET, V169, P1, DOI 10.1007/BF00267538; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; Obbink D J, 1977, Mol Gen Genet, V151, P127; PEL HJ, 1994, MOL BIOL REP, V19, P183, DOI 10.1007/BF00986960; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; RUSSELL DW, 1980, ARCH BIOCHEM BIOPHYS, V201, P518, DOI 10.1016/0003-9861(80)90540-8; Sambrook J., 2002, MOL CLONING LAB MANU; Scheffler IE, 1999, MITOCHONDRIA; Smith J.A., 2000, CURRENT PROTOCOLS MO; SPITHILL TW, 1978, MOL GEN GENET, V164, P155, DOI 10.1007/BF00267380; SPREMULLI L, 1987, BIOCHEM BIOPH RES CO, V147, P1077, DOI 10.1016/S0006-291X(87)80180-8; TREMBATH MK, 1973, MOL GEN GENET, V121, P35, DOI 10.1007/BF00353691; Warburg O., 1942, BIOCHEM Z, V310, P384; WITTMANNLIEBOLD B, 1980, RIBOSOMES STRUCTURE, P51; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Wolstenholme D. R., 1992, Mitochondrial genomes., P173	41	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29400	29406		10.1074/jbc.M002173200	http://dx.doi.org/10.1074/jbc.M002173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887179	hybrid, Green Published			2022-12-25	WOS:000089439800031
J	Dennler, S; Prunier, C; Ferrand, N; Gauthier, JM; Atfi, A				Dennler, S; Prunier, C; Ferrand, N; Gauthier, JM; Atfi, A			c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; SKI ONCOPROTEIN; DIRECT BINDING; PROMOTER; ACTIVATION; PROTEINS; AP-1; PATHWAY; EXPRESSION; ELEMENTS	Transforming growth factor beta (TGF-beta) is a pleiotropic cytokine that exerts its effects through a heteromeric complex of transmembrane serine/threonine kinase receptors, At least two intracellular pathways are activated by TGF-beta as follows: the SAPK/JNK, involving the MEKK1, MKK4, and JNK cascade, and the Smad pathway. Here, we report that the SAPK/JNK pathway inhibits the Smad3 pathway. Expression of dominant negative or constitutively active mutants of kinases of the SAPK/JNK pathway, respectively, activates or represses a TGF-beta-induced reporter containing Smad3-binding sites. This effect is not dependent on blocking of Smad3 nuclear translocation but involves a functional interaction between Smad3 and c-Jun, a transcription factor activated by the SAPK/JNK pathway. Overexpression of constitutively active MEKK1 or MKK4 mutants stabilizes the physical interaction between Smad3 and c-Jun, whereas dominant negative mutants inhibit this interaction. Moreover, overexpression of wild-type c-Jun inhibits Smad3-dependent transcription. However, c-Jun does not inhibit Smad3 binding to DNA in vitro. The repression obtained with a c-Jun mutant unable to activate transcription through AP-1 sites indicates that the inhibitory mechanism does not rely on the induction of a Smad3 repressor by c-Jun, suggesting that c-Jun could act as a Smad3 co-repressor. The inhibition of the Smad3 pathway by the SAPK/JNK pathway, both triggered by TGF-beta, could participate in a negative feedback loop to control TGF-beta responses.	Lab GlaxoWellcome, F-91951 Les Ulis, France; Hop St Antoine, INSERM U482, F-75571 Paris 12, France	GlaxoSmithKline; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Gauthier, JM (corresponding author), Lab GlaxoWellcome, 25 Ave Quebec, F-91951 Les Ulis, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	36	78	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28858	28865		10.1074/jbc.M910358199	http://dx.doi.org/10.1074/jbc.M910358199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871633	hybrid			2022-12-25	WOS:000089330700069
J	Jensen, SA; Vrhovski, B; Weiss, AS				Jensen, SA; Vrhovski, B; Weiss, AS			Domain 26 of tropoelastin plays a dominant role in association by coacervation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN ELASTIN; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; FIBER FORMATION; EXPRESSION; PEPTIDES; POLYMERS; CHAINS	The temperature-dependent association of tropoelastin molecules through coacervation is an essential step in their assembly leading to elastogenesis. The relative contributions of C-terminal hydrophobic domains in coacervation were assessed. Truncated tropoelastins were constructed with N termini positioned variably downstream of domain 25. The purified proteins were assessed for their ability to coacervate. Disruption to domain 26 had a substantial effect and abolished coacervation. Circular dichroism spectroscopy of an isolated peptide comprising domain 26 showed that it undergoes a structural transition to a state of increased order with increasing temperature. Protease mapping demonstrated that domain 26 is flanked by surface sites and is likely to be in an exposed position on the surface of the tropoelastin molecule. These results suggest that the hydrophobic domain 26 is positioned to play a dominant role in the intermolecular interactions that occur during coacervation.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/F-8103-2010; Jensen, Sacha A./AAB-4034-2019; Weiss, Anthony S/GYV-0157-2022	Weiss, Anthony S/0000-0002-8106-4836; Jensen, Sacha A./0000-0002-0560-9531; 				Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Bisaccia F, 1998, BIOCHEMISTRY-US, V37, P11128, DOI 10.1021/bi9802566; BOYD CD, 1991, MATRIX, V11, P235, DOI 10.1016/S0934-8832(11)80230-1; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; Broch H, 1998, J BIOMOL STRUCT DYN, V15, P1073, DOI 10.1080/07391102.1998.10509002; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; Debelle L, 1998, EUR J BIOCHEM, V258, P533, DOI 10.1046/j.1432-1327.1998.2580533.x; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOWDA DC, 1995, INT J PEPT PROT RES, V46, P453; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KONDO M, 1987, J BIOCHEM-TOKYO, V101, P89, DOI 10.1093/oxfordjournals.jbchem.a121911; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; NARAYANAN AS, 1978, BIOCHEM J, V173, P857, DOI 10.1042/bj1730857; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P97; Reiersen H, 1998, J MOL BIOL, V283, P255, DOI 10.1006/jmbi.1998.2067; ROMERO N, 1986, ARCH BIOCHEM BIOPHYS, V244, P161, DOI 10.1016/0003-9861(86)90105-0; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; Urry D W, 1977, Adv Exp Med Biol, V79, P685; URRY DW, 1978, PERSPECT BIOL MED, V21, P265; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1982, METHOD ENZYMOL, V82, P673; Urry DW, 1995, CIBA F SYMP, V192, P4; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	35	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28449	28454		10.1074/jbc.M004265200	http://dx.doi.org/10.1074/jbc.M004265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862774	hybrid			2022-12-25	WOS:000089330700017
J	Li, BM; Comai, L				Li, BM; Comai, L			Functional interaction between Ku and the Werner syndrome protein in DNA end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HELICASE ACTIVITY; SYNDROME GENE; EXONUCLEASE; REPAIR; SYSTEM; CELLS	Werner syndrome (WS) is an autosomal recessive disease characterized by premature aging. The gene responsible for the syndrome was recently cloned and shown to encode a protein, with strong homology to DNA/RNA helicases. In addition, the Werner syndrome protein (WRN) possesses an exonuclease activity. Eased on the homology to helicases it has been proposed that WRN functions in some aspects of DNA replication, recombination, or repair. However, there is currently no evidence of a role of WRN in any of these processes; therefore, its biological function remains unknown. Using a biochemical approach, we have identified two polypeptides that bind to the WRN protein. Peptide sequence analysis indicates that the two proteins are identical to Ku70 and Ku80, a heterodimer involved in double strand DNA break repair by non-homologous DNA end joining. Protein-protein interaction studies reveal that WRN binds directly to Ku80 and that this interaction is mediated by the amino terminus of WRN. In addition, we show that the binding of Ku alters the specificity of the WRN exonuclease. These results suggest a potential involvement of WRN in the repair of double strand DNA breaks.	Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Comai, L (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, 2011 Zonal Ave,HMR-509, Los Angeles, CA 90033 USA.		Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Cooper MP, 2000, GENE DEV, V14, P907; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dyer CAE, 1998, AGE AGEING, V27, P73, DOI 10.1093/ageing/27.1.73; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Fry M, 1998, NAT GENET, V19, P308, DOI 10.1038/1188; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tham WH, 2000, NATURE, V403, P34, DOI 10.1038/47385; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	28	151	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28349	28352		10.1074/jbc.C000289200	http://dx.doi.org/10.1074/jbc.C000289200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880505	hybrid			2022-12-25	WOS:000089330700003
J	McDonough, J; Francis, N; Miller, T; Deneris, ES				McDonough, J; Francis, N; Miller, T; Deneris, ES			Regulation of transcription in the neuronal nicotinic receptor subunit gene cluster by a neuron-selective enhancer and ETS domain factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; RAT-BRAIN; MESSENGER-RNAS; ALPHA-3 GENE; MICE LACKING; POU DOMAIN; EXPRESSION; ELEMENT; BETA-4; PROMOTER	Expression of neurotransmitter receptors encoded by the nicotinic acetylcholine receptor (nAchR) subunit gene cluster depends on coexpression of the beta 4, alpha 3, and alpha 5 subunits in certain kinds of neurons. One way in which coexpression might be achieved is through the regulation of promoters in the cluster by neuron-selective enhancers. The beta 43' enhancer is located between the beta 4 and alpha 3 promoters and it directs cell type-specific expression in cell lines. It is not known, however, whether beta 43' is active in neurons, Therefore, we assayed beta 43' in dissociated rat sympathetic ganglia cultures, which contain nAchR-positive neurons as well as nAchR-negative non-neuronal cells. Reporters controlled by the alpha 3 promoter and beta 43' were expressed in a neuron-selective manner; greater than 90% and up to 100% of luciferase expression was detected in neurons. Neuron selectivity was maintained when beta 43' was placed next to ubiquitously active viral promoters. In contrast, replacing beta 43' with the SV40 enhancer eliminated neuron selectivity. The enhancer is composed of at least two separate but functionally interdependent elements, each of which interacts with a different type of ETS domain factor. These findings support a model in which beta 43' controls neuronal expression of one or more genes in the cluster through interactions with a combination of ETS factors.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University	Deneris, ES (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, 2109 Adelbert Rd, Cleveland, OH 44106 USA.				NINDS NIH HHS [NS29123] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029123] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN AS, 1988, CURRENT PROTOCOLS MO, V2; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; Francis NJ, 1997, DEV BIOL, V182, P76, DOI 10.1006/dbio.1996.8464; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hawrot E, 1979, Methods Enzymol, V58, P574; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Hendricks T, 1999, J NEUROSCI, V19, P10348; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MATTER JM, 1995, J NEUROSCI, V15, P5919; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; McDonough J, 1997, J NEUROSCI, V17, P2273; Myers SJ, 1998, J NEUROSCI, V18, P6723; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weber JRM, 1997, J NEUROSCI, V17, P7583; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28962	28970		10.1074/jbc.M004181200	http://dx.doi.org/10.1074/jbc.M004181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878018	hybrid			2022-12-25	WOS:000089330700082
J	Yun, M; Park, CG; Kim, JY; Rock, CO; Jackowski, S; Park, HW				Yun, M; Park, CG; Kim, JY; Rock, CO; Jackowski, S; Park, HW			Structural basis for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR-AROMATIC INTERACTIONS; CRYSTAL-STRUCTURE; ADENYLATE KINASE; PROTEINS; PHOSPHORIBULOKINASE; REVEALS; COMPLEX; DOMAIN; BIOSYNTHESIS; RESOLUTION	Pantothenate kinase (PanK) is a key regulatory enzyme in the coenzyme A (CoA) biosynthetic pathway and catalyzes the phosphorylation of pantothenic acid to form phosphopantothenate, CoA is a feedback inhibitor of PanK activity by competitive binding to the ATP site. The structures of the Escherichia coli enzyme, in complex with a nonhydrolyzable analogue of ATP, 5'-adenylimido-diphosphate (AMPPNP), or with CoA, were determined at 2.6 and 2.5 Angstrom respectively. Both structures show that two dimers occupy an asymmetric unit; each subunit has a alpha/beta mononucleotide-binding fold with an extensive antiparallel coiled coil formed by two long helices along the dimerization interface. The two ligands, AMPPNP and CoA, associate with PanK in very different ways, but their phosphate binding sites overlap, explaining the kinetic competition between CoA and ATP, Residues Asp(127), His(177) and Arg(243) are proposed to be involved in catalysis, based on modeling of the pentacoordinate transition state. The more potent inhibition by CoA, compared with the CoA thioesters, is explained by a tight interaction of the CoA thiol group with the side chains of aromatic residues, which is predicted to discriminate against the CoA thioesters. The PanK structure provides the framework for a more detailed understanding of the mechanism of catalysis and feedback regulation of PanK.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737, GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CHARLIER HA, 1994, BIOCHEMISTRY-US, V33, P9343, DOI 10.1021/bi00197a039; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; FISHER MN, 1985, J BIOL CHEM, V260, P5745; FISHER MN, 1985, FEBS LETT, V190, P293, DOI 10.1016/0014-5793(85)81303-X; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; Harrison DHT, 1998, BIOCHEMISTRY-US, V37, P5074, DOI 10.1021/bi972805y; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARASAWA T, 1972, J BIOCHEM-TOKYO, V71, P1065, DOI 10.1093/oxfordjournals.jbchem.a129854; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; MCREE DE, 1998, XTALVIEW 3 2 1; MORGAN RS, 1978, INT J PEPT PROT RES, V11, P209; MORGAN RS, 1980, INT J PEPT PROT RES, V15, P177; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal D, 1998, J BIOMOL STRUCT DYN, V15, P1059, DOI 10.1080/07391102.1998.10509001; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; ROBISHAW JD, 1984, AM J PHYSIOL, V246, pH532, DOI 10.1152/ajpheart.1984.246.4.H532; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; Runquist JA, 1998, BIOCHEMISTRY-US, V37, P1221, DOI 10.1021/bi972052f; Schlauderer GJ, 1996, PROTEIN SCI, V5, P434; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; SUMMERS L, 1984, PEPTIDE PROTEIN REV, V3, P147; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	43	86	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28093	28099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862768				2022-12-25	WOS:000089197100075
J	Bae, KA; Longobardi, L; Karasawa, K; Malone, B; Inoue, T; Aoki, J; Arai, H; Inoue, K; Lee, TC				Bae, KA; Longobardi, L; Karasawa, K; Malone, B; Inoue, T; Aoki, J; Arai, H; Inoue, K; Lee, TC			Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-INDEPENDENT TRANSACETYLASE; BETA-SUBUNIT; HL-60 CELLS; PURIFICATION; BRAIN; ACYLTRANSFERASE; BIOSYNTHESIS; EXPRESSION; CLONING; ANALOGS	Platelet-activating factor (PAF)-dependent transacetylase (TA) is an enzyme that transfers an acetyl group from PAF to acceptor lipids such as lysophospholipids and sphingosine, This enzyme is distributed in membrane and cytosol of the cells. We previously revealed that TA purified from rat kidney membrane showed an amino acid sequence similarity to that of bovine PAF-acetylhydrolase (AH) (II), In the present study, we purified TA from the rat kidney cytosol and analyzed its amino acid sequence, The amino acid sequence of the cytosolic TA is similar to that of bovine PAF-AH (II) and membrane TA, To clarify the relationship between TA and PAF-AH (II), we isolated cDNA of rat PAF-AH (II), The predicted amino acid sequence of rat PAF-AH (II) from isolated cDNA included all the sequences found in TAs purified from the membrane and cytosolic TAs, In addition, monoclonal antibody to recombinant PAF-AH (II) cross-reacted with both cytosolic and membrane TAs, Consistent with sequence identity, recombinant PAF-AH (II) showed TA activity, whereas recombinant PAF-AH Ib, which is a different subtype of intracellular PAF-AHs, did not possess TA activity. Analysis of a series of site-directed mutant PAF-AH (II) proteins showed that TA activity was decreased, whereas PAF-AH activity was not affected in C120S and G2A mutant proteins. Thus, Cys(120) and Gly(2) are implicated in the catalysis of TA reaction in this enzyme. Furthermore, the transfer of acetate from PAF to endogenous acceptor lipids was significantly increased in a time-dependent manner in CHO-KI cells transfected with PAF-AH (II) gene. These results demonstrate that PAF-AH (II) can function, as a TA in intact cells, and PAF-AH (II) and TA are the same enzyme.	Oak Ridge Associated Univ, Basic & Appl Res Unit, Oak Ridge, TN 37831 USA; Univ Tokyo, Fac Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tokyo	Lee, TC (corresponding author), Oak Ridge Associated Univ, Basic & Appl Res Unit, Oak Ridge, TN 37831 USA.	leetc@orau.gov		Aoki, Junken/0000-0001-9435-1896	NHLBI NIH HHS [HL-52492] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURIN JA, 1997, CELL SIGNAL, V9, P15; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; Lee TC, 1996, ADV EXP MED BIOL, V416, P113; LEE TC, 1992, J BIOL CHEM, V267, P19992; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; LIU M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P144, DOI 10.1016/0005-2760(93)90118-S; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	24	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26704	26709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867005				2022-12-25	WOS:000089144800007
J	Ye, JP; Kohli, LL; Stone, MJ				Ye, JP; Kohli, LL; Stone, MJ			Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HIGH-AFFINITY BINDING; HUMAN INTERLEUKIN-8 RECEPTOR; AMINO-TERMINAL DOMAIN; MOLECULAR-CLONING; ALLERGIC INFLAMMATION; EXTRACELLULAR DOMAIN; COUPLED RECEPTORS; MCP-1 RECEPTOR; RESIDUES	The CC chemokine eotaxin plays a predominant role in eosinophil trafficking in vivo by specifically activating the chemokine receptor CCR3. We have screened a series of synthetic peptides corresponding to extracellular regions of CCR3 for their ability to bind eotaxin, A peptide corresponding to the N terminus of CCR3 (CCR3-(1-35)) bound to eotaxin with a dissociation constant of 80 +/- 38 mu M. However, linear or cyclic peptides derived from the first and third extracellular loops of CCR3 did not bind to eotaxin. Linear and cyclic peptides derived from the second extracellular loop precipitated upon addition of eotaxin, H-1-N-15 correlation NMR spectroscopy indicated that an extended groove in the eotaxin surface, whose edges are defined by the N-loop, 3(10)-helical turn, and beta(2)-beta(3) hairpin, is the most likely binding surface for CCR3-(1-35). NMR assignments for CCR3-(1-35) were obtained using two-dimensional and three-dimensional homonuclear NMR experiments, N-15-Filtered TOCSY spectra indicated that the central region of CCR3-(1-35), surrounding the DDYY sequence, is involved in the interaction with eotaxin, This was supported by the observation that a truncated N-terminal peptide (CCR3-(8-23)) binds to eotaxin with a dissociation constant of 136 +/- 23 mu M, only slightly weaker than the full-length N terminal peptide. Taken together with previous studies, these results suggest that interactions between the N-loop/beta(3), regions of chemokines and the N-terminal regions of their receptors may be a conserved feature of chemokine-receptor complexes across the CC, CXC, and C chemokine subfamilies. However, the low affinity of the interactions observed in these studies suggests the existence of additional binding regions in both the chemokines and the receptors.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Stone, MJ (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	mastone@indiana.edu	Stone, Martin/C-2492-2012	Stone, Martin/0000-0002-6468-4427	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055055, R29GM055055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Baggiolini M, 1996, J CLIN INVEST, V97, P587, DOI 10.1172/JCI118451; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; CIESLAR C, 1990, J MAGN RESON, V89, P184, DOI 10.1016/0022-2364(90)90174-8; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE KK, 1991, HPLC PEPTIDES PROTEI, P389; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MAYER KL, 2000, IN PRESS BIOCHEMISTR; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OSCHKINAT H, 1988, NATURE, V332, P374, DOI 10.1038/332374a0; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Stone MJ, 2000, CHEMOKINES IN ALLERGIC DISEASE, P67; VUISTER GW, 1988, J MAGN RESON, V80, P176, DOI 10.1016/0022-2364(88)90072-8; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	59	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27250	27257						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859315				2022-12-25	WOS:000089144800078
J	Manion, MK; Su, ZC; Villain, M; Blalock, JE				Manion, MK; Su, ZC; Villain, M; Blalock, JE			A new type of Ca2+ channel blocker that targets Ca2+ sensors and prevents Ca2+-mediated apoptosis	FASEB JOURNAL			English	Article						calmodulin; CALP; Fura-2; cation channel; complementary peptide; antisense peptide	METHYL-D-ASPARTATE; CALCIUM-DEPENDENT INACTIVATION; PROGRAMMED CELL-DEATH; HIV COAT PROTEIN; NMDA RECEPTORS; T-CELLS; NEURONAL INJURY; ALPHA-ACTININ; NR1 SUBUNIT; CALMODULIN	Calmodulin (CaM), as well as other Ca2+ binding motifs (i.e., EF hands), have been demonstrated to be Ca2+ sensors for several ion channel types, usually resulting in an inactivation in a negative feedback manner. This provides a novel target for the regulation of such channels. We have designed peptides that interact with EF hands of CaM in a specific and productive manner. Here we have examined whether these peptides block certain Ca2+-permeant channels and inhibit biological activity that is dependent on the influx of Ca2+. We found that these peptides are able to enter the cell and directly, as well as indirectly (through CaM), block the activity of glutamate receptor channels in cultured neocortical neurons and a nonselective cation channel in Jurkat T cells that is activated by HIV-1 gp120. As a consequence, apoptosis mediated by an influx of Ca2+ through these channels was also dose-dependently inhibited by these novel peptides, Thus, this new type of Ca2+ channel blocker may have utility in controlling apoptosis due to HIV infection or neuronal loss due to ischemia.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, McCallum Bldg,Rm 898,1918 Univ Blvd, Birmingham, AL 35294 USA.	blalock@uab.edu		Blalock, J. Edwin/0000-0001-5303-8123	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037670, R21AI037670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37670] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NINDS NIH HHS [NS 29719] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN SA, 1993, BIOTECHNOL PROGR, V9, P671, DOI 10.1021/bp00024a017; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BANSAL N, 1990, J CELL PHYSIOL, V143, P105, DOI 10.1002/jcp.1041430114; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; DIOP AG, 1994, NEUROSCI LETT, V165, P187, DOI 10.1016/0304-3940(94)90741-2; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Estacion M, 1999, BIOCHEM J, V341, P41, DOI 10.1042/0264-6021:3410041; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; FOSTER S, 1995, EUR J IMMUNOL, V25, P1778, DOI 10.1002/eji.1830250644; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757; KEILHOFF G, 1993, NEUROREPORT, V5, P129, DOI 10.1097/00001756-199311180-00008; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; McConkey David J., 1996, Scanning Microscopy, V10, P777; OYAIZU N, 1995, CELL ACTIVATION APOP; Peterson BZ, 1999, BIOPHYS J, V76, pA340; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303; SHERMAN A, 1990, BIOPHYS J, V58, P985, DOI 10.1016/S0006-3495(90)82443-7; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tuosto L, 1995, EUR J IMMUNOL, V25, P2907, DOI 10.1002/eji.1830251030; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; WOODRUFF GN, 1987, NEUROPHARMACOLOGY, V26, P903, DOI 10.1016/0028-3908(87)90068-2; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZUHKLE RD, 1998, P NATL ACAD SCI USA, V95, P3287	54	15	17	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1297	1306		10.1096/fj.14.10.1297	http://dx.doi.org/10.1096/fj.14.10.1297			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877822				2022-12-25	WOS:000087932200004
J	Sweeney, C; Lai, C; Riese, DJ; Diamonti, AJ; Cantley, LC; Carraway, KL				Sweeney, C; Lai, C; Riese, DJ; Diamonti, AJ; Cantley, LC; Carraway, KL			Ligand discrimination in signaling through an ErbB4 receptor homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; EGF-RECEPTOR; FACTOR-ALPHA; DIMERIZATION; NEUREGULIN-2; TRANSDUCTION; ONCOGENESIS; ACTIVATION; COMPLEXES	The epidermal growth factor (EGF)-like family of growth factors elicits cellular responses by stimulating the dimerization, autophosphorylation, and tyrosine kinase activities of the ErbB family of receptor tyrosine kinases, Although several different EGF-like ligands are capable of binding to a single ErbB family member, it is generally thought that the biological and biochemical responses of a single receptor dimer to different ligands are indistinguishable. To test whether an ErbB receptor dimer is capable of discriminating among ligands we have examined the effect of four EGF-like growth factors on signaling through the ErbB4 receptor homodimer in CEM/HER4 cells, a transfected human T cell line ectopically expressing ErbB4 in an ErbB-null background. Despite stimulating similar levels of gross receptor tyrosine phosphorylation, the EGF-like growth factors betacellulin, neuregulin-1 beta, neuregulin-2 beta, and neuregulin-3 exhibited different biological potencies in a cellular growth assay. Moreover, the different ligands induced different patterns of recruitment of intracellular signaling proteins to the activated receptor and induced differential usage of intracellular kinase signaling cascades. Finally, two-dimensional phosphopeptide mapping of ligand-stimulated ErbB4 revealed that the different growth factors induce different patterns of receptor tyrosine phosphorylation, These results indicate that ErbB4 activation by growth factors is not generic and suggest that individual ErbB receptors can discriminate between different EGF-like ligands within the context of a single receptor dimer. More generally, our observations significantly modify our understanding of signaling through receptor tyrosine kinases and point to a number of possible models for ligand-mediated signal diversification.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Scripps Res Inst, Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Scripps Research Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Sweeney, C (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.	ccrovell@caregroup.harvard.edu	Cantley, Lewis C/D-1800-2014; Riese, David/AAF-3581-2020	Cantley, Lewis C/0000-0002-1298-7653; Riese, David/0000-0002-8823-5802	NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	90	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19803	19807		10.1074/jbc.C901015199	http://dx.doi.org/10.1074/jbc.C901015199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867024	hybrid			2022-12-25	WOS:000087941300051
J	Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E				Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E			Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b	ONCOGENE			English	Article						Rho GTPases; Rac1; isoform; breast cancer; ductal carcinoma-in-situ; metastasis	GTP-BINDING PROTEIN; RAS TRANSFORMATION; NADPH OXIDASE; GROWTH-FACTOR; CELL-LINES; EXPRESSION; RHO; GTPASES; FAMILY; CDC42	Rac1 is a member of the Ras superfamily of small guanosine triphosphatases (GTPases) that act as molecular switches to control cytoskeletal rearrangements and cell growth. Analogous to Ras, constitutively activating point mutations of Rad cause tumorigenic transformation of cell lines. However, there is no information about whether Rad is also mutated in vivo, After RT-PCR of Rad, several clones of seven benign and 10 malignant breast cancer tissues as well as eight breast cancer cell lines were sequenced. Only single-nucleotide polymorphisms of Rad could be detected, and none of these corresponded to constitutively activating point mutations that have been used in cell lines for transformation. While sequencing Rad in breast tissues, a new Rad isoform with an insertion of 19 codons within the reading frame of Rad close to switch region II was identified and named Rac1b, The Rac1b protein acts like a fast cycling GTPase in GTP binding and hydrolysis assays, In Northern and Western blot experiments both Rad RNA and Rad protein had a significantly higher expression in breast cancer tissues compared to normal breast tissue samples. Immunohistochemical staining of Rad showed weak Rad expression in benign breast disease but high expression level in ductal carcinoma-in-situ, primary breast cancer, and lymph node metastases. In addition, breast tumor cells from patients with recurrent disease had Rad expression at the plasma membrane, suggesting activation of Rad, in patients with aggressive breast cancer.	Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-81675 Munich, Germany; Tech Univ Munich, Klinikum Rechts Isar, Dept Pathol, D-81675 Munich, Germany; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich; Scripps Research Institute; Technical University of Munich	Lengyel, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, Ismaninger Str 22, D-81675 Munich, Germany.		Gerhard, Markus/N-3387-2014; Gerhard, Markus/P-8996-2019; Lengyel, Ernst/D-9220-2014	Gerhard, Markus/0000-0001-9110-3950; Gerhard, Markus/0000-0001-9110-3950; Lengyel, Ernst/0000-0001-8624-1507; Schnelzer, Andreas/0000-0002-5410-3561				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BOS JL, 1989, CANCER RES, V49, P4682; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dickson R B, 1992, Cancer Treat Res, V61, P249; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Krizman DB, 1996, CANCER RES, V56, P5380; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Schiedt K., 1995, ISOLATION ANAL, V1A, P81; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	31	313	323	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3013	3020		10.1038/sj.onc.1203621	http://dx.doi.org/10.1038/sj.onc.1203621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871853	Green Published			2022-12-25	WOS:000087581400008
J	Liu, BR; Lee, HY; Weinzimer, SA; Powell, DR; Clifford, JL; Kurie, JM; Cohen, P				Liu, BR; Lee, HY; Weinzimer, SA; Powell, DR; Clifford, JL; Kurie, JM; Cohen, P			Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BREAST-CANCER CELLS; EPITHELIAL-CELLS; PROSTATE-CANCER; FACTOR-I; FACTOR BINDING-PROTEIN-3; NUCLEAR TRANSPORT; SURFACE BINDING; THYROID-HORMONE; ACID	Insulin-like growth factor-binding protein (IGFBP)-3 regulates apoptosis in an IGF-independent fashion and has been shown to localize to nuclei. We cloned the nuclear receptor retinoid X receptor-alpha>(*) over bar * (RXR-alpha) as an IGFBP-3 protein partner in a yeast two-hybrid screen. Multiple methodologies showed that IGFBP-3 and RXR-alpha bind each other within the nucleus. IGFBP-3-induced apoptosis was abolished in RXR-alpha -knockout cells. IGFBP-3 and RXR ligands mere additive in inducing apoptosis in prostate cancer cells. IGFBP-3 enhanced RXR response element and inhibited RARE signaling. Thus, RXR-alpha -IGFBP-3 interaction leads to modulation of the transcriptional activity of RXR-alpha and is essential for mediating the effects of IGFBP-3 on apoptosis.	Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Baylor College of Medicine	Cohen, P (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Pediat, Div Endocrinol, 10833 Le Conte Ave,MDCC 22-315, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu		Lee, Ho-Young/0000-0001-7556-9312	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047591] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1 AI40203] Funding Source: Medline; NIDDK NIH HHS [2R01 DK47591] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campbell PG, 1999, J BIOL CHEM, V274, P30215, DOI 10.1074/jbc.274.42.30215; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Clifford JL, 1999, CANCER RES, V59, P14; Collett-Solberg PF, 1998, J CLIN ENDOCR METAB, V83, P2843, DOI 10.1210/jc.83.8.2843; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; deVos S, 1997, PROSTATE, V32, P115; Feldser D, 1999, CANCER RES, V59, P3915; Ferry RJ, 1999, HORM RES, V51, P53; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hembree JR, 1996, CANCER RES, V56, P1794; Janosi JBM, 1999, J BIOL CHEM, V274, P23328, DOI 10.1074/jbc.274.33.23328; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Perez-Juste G, 1999, ONCOGENE, V18, P5393, DOI 10.1038/sj.onc.1202906; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wendling O, 1999, P NATL ACAD SCI USA, V96, P547, DOI 10.1073/pnas.96.2.547; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040	44	257	266	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33607	33613		10.1074/jbc.M002547200	http://dx.doi.org/10.1074/jbc.M002547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10874028	hybrid			2022-12-25	WOS:000090104600061
J	Yano, JK; Koo, LS; Schuller, DJ; Li, HY; de Montellano, PRO; Poulos, TL				Yano, JK; Koo, LS; Schuller, DJ; Li, HY; de Montellano, PRO; Poulos, TL			Crystal structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; PROGRAM PACKAGE; AMINO-ACID; PROTEIN; MACROMOLECULES; SUBSTRATE; EVOLUTION; STABILITY; SEQUENCE; SITES	The structure of the first P450 identified in Archaea, CYP119 from Sulfolobus solfataricus, has been solved in two different crystal forms that differ by the ligand (imidazole or 4-phenylimidazole) coordinated to the heme iron. A comparison of the two structures reveals an unprecedented rearrangement of the active site to adapt to the different size and shape of ligands bound to the heme iron. These changes involve unraveling of the F helix C-terminal segment to extend a loop structure connecting the F and G helices, allowing the longer loop to dip down into the active site and interact with the smaller imidazole ligand, A comparison of CYP119 with P450cam and P450eryF indicates an extensive clustering of aromatic residues may provide the structural basis for the enhanced thermal stability of CYP119. An additional feature of the 4-phenylimidazole-bound structure is a zinc ion tetrahedrally bound by symmetry-related His and Glu residues.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Francisco	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32668, GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang YT, 2000, BIOCHEMISTRY-US, V39, P2484, DOI 10.1021/bi991966u; Consonni R, 1999, BIOCHEMISTRY-US, V38, P12709, DOI 10.1021/bi9911280; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DiGleria K, 1996, FEBS LETT, V390, P142, DOI 10.1016/0014-5793(96)00648-5; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Georis J, 1999, GENE, V237, P123, DOI 10.1016/S0378-1119(99)00311-X; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Kellner DG, 1997, CURR OPIN BIOTECH, V8, P274, DOI 10.1016/S0958-1669(97)80003-1; Koo LS, 2000, J BIOL CHEM, V275, P14112, DOI 10.1074/jbc.275.19.14112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schuller DJ, 1996, ACTA CRYSTALLOGR D, V52, P425, DOI 10.1107/S0907444995013291; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Wright RL, 1996, FEBS LETT, V384, P235, DOI 10.1016/0014-5793(96)00322-5; Zeikus JG, 1998, EXTREMOPHILES, V2, P179, DOI 10.1007/s007920050058	39	176	178	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31086	31092		10.1074/jbc.M004281200	http://dx.doi.org/10.1074/jbc.M004281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859321	hybrid			2022-12-25	WOS:000089762700049
J	Fridman, M; Maruta, H; Gonez, J; Walker, F; Treutlein, H; Zeng, J; Burgess, A				Fridman, M; Maruta, H; Gonez, J; Walker, F; Treutlein, H; Zeng, J; Burgess, A			Point mutants of c-RAF-1 RBD with elevated binding to v-Ha-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN GAP; MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; RAS/RAF INTERACTION; DOWNSTREAM TARGETS; GTPASE ACTIVITY; P21 PROTEINS	A mutational analysis of the Ras-binding domain (RBD) of c-Raf-1 identified three amino acid positions (Asn(64), Ala(85), and Val(88)) where amino acid substitution with basic residues increases the binding of RBD to recombinant v-Ha-Ras. The greatest increase in binding (6-9-fold) was observed with the A85K-RBD mutant. The elevated binding for the A85K-RBD and V88R-RBD mutants was also detected with Ras expressed in cultured mammalian cells, namely NIH-3T3 and BAF cells. None of the wild type residues in RBD positions Asn64, Ala85, and Val(88) have been previously implicated in the interaction with Ras (Block, C., Janknecht, R., Herrmann, C., Nassar, N., and Wittinghofer, A. (1996) Nat. Struct. Biol. 3, 244-251; Nassar, N,, Horn, G., Herrmann, C., Scherer, A. McCormick, F., and Wittinghofer, A. (1995) Nature 375, 554-560). The discovery of elevated binding among the mutants in these positions implies that additional RBD residues can be used to generate the Ras.RBD complex. These findings are of particular significance in the design of Ras antagonists based on the RBD prototype. The A85K-RBD mutant can be used to develop an assay for measuring the level of activated Ras in cultured cells; Sepharose-linked A85K-RBD.GST fusion protein served as an activation-specific probe to precipitate Ras.GTP but not Ras.GDP from epidermal growth factor-stimulated cells. A85K-RBD precipitates up to 5-fold more Ras.GTP from mammalian cells than wild type RBD.	Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Burgess, A (corresponding author), Cooperat Res Ctr Cellular Growth Factors, POB 2008, Melbourne, Vic 3050, Australia.	tony.burgess@ludwig.edu.au	Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Zeng, Jun/0000-0002-2736-1928				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Barnard D, 1995, ONCOGENE, V10, P1283; BASU T, 1994, ONCOGENE, V9, P3483; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Dalley BK, 1996, ONCOGENE, V13, P1209; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1996, CANCER SURV, V27, P87; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Higuchi R., 1989, PCR TECHNOLOGY, P61; Horn IR, 1999, FEBS LETT, V463, P115, DOI 10.1016/S0014-5793(99)01617-8; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mangues R, 1992, Semin Cancer Biol, V3, P229; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORI S, 1995, J BIOL CHEM, V270, P28834, DOI 10.1074/jbc.270.48.28834; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Ohnishi M, 1998, J BIOL CHEM, V273, P10210, DOI 10.1074/jbc.273.17.10210; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SCHEFFZEK K, 1998, G PROTEINS CYTOSKELE; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEIN RB, 1984, J VIROL, V50, P343, DOI 10.1128/JVI.50.2.343-351.1984; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Terada T, 1999, J MOL BIOL, V286, P219, DOI 10.1006/jmbi.1998.2472; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wittinghofer A, 1997, FEBS LETT, V410, P63, DOI 10.1016/S0014-5793(97)00321-9; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zeng J, 1998, PROTEINS, V31, P186, DOI 10.1002/(SICI)1097-0134(19980501)31:2<186::AID-PROT8>3.0.CO;2-K; Zeng J, 1999, PROTEIN SCI, V8, P50; Zeng J, 1999, PROTEINS, V35, P89; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	76	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30363	30371		10.1074/jbc.M003193200	http://dx.doi.org/10.1074/jbc.M003193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887184	hybrid			2022-12-25	WOS:000089577900061
J	Gribble, FM; Loussouarn, G; Tucker, SJ; Zhao, C; Nichols, CG; Ashcroft, FM				Gribble, FM; Loussouarn, G; Tucker, SJ; Zhao, C; Nichols, CG; Ashcroft, FM			Novel method for measurement of submembrane ATP concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; ISLET BETA-CELLS; SULFONYLUREA RECEPTOR; RELEASE; RECONSTITUTION; STOICHIOMETRY; NA,K-ATPASE; ADP	There has been considerable debate as to whether adenosine triphosphate (ATP) is compartmentalized within cells and, in particular, whether the ATP concentration directly beneath the plasma membrane, experienced by membrane proteins, is the same as that of the bulk cytoplasm. This issue has been difficult to address because there is no indicator of cytosolic ATP, such as those available for Ca2+, capable of resolving the submembrane ATP concentration ([ATP](sm)) in real time within a single cell. We show here that mutant ATP-sensitive K+ channels can be used to measure [ATP](sm) by comparing the increase in current amplitude on patch excision with the ATP dose-response curve. In Xenopus oocytes, [ATP](sm) was 4.6 +/- 0.3 mM (n = 29) under resting conditions, slightly higher than that measured for the bulk cytoplasm (2.3 mM). In mammalian (COSm6) cells, [ATP](sm) was slightly lower and averaged 1.4 +/- 0.1 mM (n = 66). Metabolic poisoning (10 min of 3 mM azide) produced a significant fall in [ATP](sm) in both types of cells: to 1.2 +/- 0.1 mM (n = 24) in oocytes and 0.8 +/- 0.11 mM for COSm6 cells. We conclude that [ATP](sm) lies in the low millimolar range and that there is no gradient between bulk cytosolic and submembrane [ATP].	Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Oxford; Washington University (WUSTL)	Ashcroft, FM (corresponding author), Univ Oxford, Univ Lab Physiol, Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@physiol.ox.ac.uk	Nichols, Colin/D-6336-2012; Loussouarn, Gildas/D-3590-2015; Tucker, Stephen J./ABE-7468-2020; Loussouarn, Gildas/ABH-6043-2020; Tucker, Stephen J./ABE-6741-2020	Loussouarn, Gildas/0000-0001-8007-5931; Tucker, Stephen J./0000-0001-8996-2000; Loussouarn, Gildas/0000-0001-8007-5931; Tucker, Stephen J./0000-0001-8996-2000; Gribble, Fiona/0000-0002-4232-2898	NHLBI NIH HHS [HL45742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AW TY, 1985, AM J PHYSIOL, V249, pC385, DOI 10.1152/ajpcell.1985.249.5.C385; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; GHOSH A, 1991, J BIOL CHEM, V266, P22887; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; MILLER DS, 1986, J BIOL CHEM, V261, P13911; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NIKI I, 1989, FEBS LETT, V257, P361, DOI 10.1016/0014-5793(89)81572-8; Prakriya M, 1996, J NEUROSCI, V16, P4344; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405	28	227	232	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30046	30049		10.1074/jbc.M001010200	http://dx.doi.org/10.1074/jbc.M001010200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10866996	hybrid			2022-12-25	WOS:000089577900018
J	Herget, T; Esdar, C; Oehrlein, SA; Heinrich, M; Schutze, S; Maelicke, A; van Echten-Deckert, G				Herget, T; Esdar, C; Oehrlein, SA; Heinrich, M; Schutze, S; Maelicke, A; van Echten-Deckert, G			Production of ceramides causes apoptosis during early neural differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RETINOIC ACID; SPHINGOLIPID BIOSYNTHESIS; SPHINGOMYELIN PATHWAY; GENE-PRODUCT; CHICK-EMBRYO; SPINAL-CORD; DNA-DAMAGE; IN-VITRO; GROWTH	To investigate signal transduction pathways leading to apoptosis during the early phase of neurogenesis, we employed PCC7-Mz1 cells, which cease to proliferate and begin to differentiate into a stable pattern of neurons, astroglial cells, and fibroblasts upon incubation with retinoic acid (RA). As part of lineage determination, a sizable fraction of RA-treated cultures die by apoptosis. Applying natural long-chain C-16-ceramides as well as membrane-permeable C-2/C-6-ceramide analogs caused apoptosis, whereas the biologically nonactive C-2-dihydroceramide did not. Treating PCC7-Mz1 stem cells with a neutral sphingomyelinase or with the ceramidase inhibitor N-oleoylethanolamine elevated the endogenous ceramide levels and concomitantly induced apoptosis. Addition of RA caused an increase in ceramide levels within 3-5 h, which reached a maximum (up to 3.5-fold of control) between days 1 and 3 of differentiation. Differentiated PCC7-Mz1 cells did not respond with ceramide formation and apoptosis to RA treatment. The acidic sphingomyelinase contributed only weakly and the neutral Mg2+-dependent and Mg2+-independent sphingomyelinases not at all to the RA-mediated production of ceramides. However, ceramide increase was sensitive to the ceramide synthase inhibitor fumonisin B-1, suggesting a crucial role for the de novo synthesis pathway. Enzymatic assays revealed that ceramide synthase activity remained unaltered, whereas serine palmitoyltransferase (SPT), a key enzyme in ceramide synthesis, was activated similar to 2.5-fold by RA treatment. Activation of SPT seemed to be mediated via a post-translational mechanism because levels of the mRNAs coding for the two SPT subunits were unaffected. Expression of marker proteins shows that ceramide regulates apoptosis, rather than differentiation, during early neural differentiation.	Univ Mainz, Mol Neurobiol Lab, D-55099 Mainz, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Johannes Gutenberg University of Mainz; University of Kiel; University of Bonn	Herget, T (corresponding author), Axxima Pharmaceut AG, Klopferspitz 19, D-82152 Martinsried, Germany.		Schütze, Stefan/C-8596-2011					Berger C, 1997, EUR J CELL BIOL, V74, P230; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; BUREK MJ, 1998, CELL DEATH DIS NERVO; CARR VM, 1993, EXP NEUROL, V124, P308, DOI 10.1006/exnr.1993.1201; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Esdar C, 1999, EUR J NEUROSCI, V11, P503, DOI 10.1046/j.1460-9568.1999.00455.x; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Gallinat S, 1999, FEBS LETT, V443, P75, DOI 10.1016/S0014-5793(98)01675-5; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Herget T, 1998, J NEUROCHEM, V70, P47; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Jostock R, 1998, EUR J CELL BIOL, V76, P63, DOI 10.1016/S0171-9335(98)80018-6; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LANG E, 1989, J CELL BIOL, V109, P2481, DOI 10.1083/jcb.109.5.2481; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NELSON PE, 1993, ANNU REV PHYTOPATHOL, V31, P233, DOI 10.1146/annurev.py.31.090193.001313; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Oehrlein SA, 1998, EUR J CELL BIOL, V77, P323, DOI 10.1016/S0171-9335(98)80091-5; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P435; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUTZE S, 1995, CYTOKINES PRACTICAL, P93; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Yaginuma H, 1996, J NEUROSCI, V16, P3685; ZAKERI Z, 1988, CELLS DIE, P97; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	54	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30344	30354		10.1074/jbc.M000714200	http://dx.doi.org/10.1074/jbc.M000714200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862608	hybrid			2022-12-25	WOS:000089577900059
J	Mattagajasingh, SN; Huang, SC; Hartenstein, JS; Benz, EJ				Mattagajasingh, SN; Huang, SC; Hartenstein, JS; Benz, EJ			Characterization of the interaction between protein 4.1R and ZO-2 - A possible link between the tight junction and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MEMBRANE SKELETAL PROTEIN-4.1; EPITHELIAL-CELLS; ERYTHROCYTE PROTEIN-4.1; STRUCTURAL PROTEIN-4.1; POSSIBLE INVOLVEMENT; NONEPITHELIAL CELLS; FUNCTIONAL DOMAINS; MULTIPLE ISOFORMS; SEPTATE JUNCTIONS	Multiple isoforms of the red cell protein 4.1R are expressed in nonerythroid cells, including novel 135-kDa isoforms. Using a yeast two-hybrid system, immunocolocalization, immunoprecipitation, and in vitro binding studies, we found that two 4.1R isoforms of 135 and 150 kDa specifically interact with the protein ZO-2 (zonula occludens-2). 4.1R is colocalized with ZO-2 and occludin at Madin-Darby canine kidney (MDCK) cell tight junctions. Both isoforms of 4.1R coprecipitated with proteins that organize tight junctions such as ZO-2, ZO-1, and occludin. Western blot analysis also revealed the presence of actin and cu-spectrin in these immunoprecipitates. Association of 4.1R isoforms with these tight junction and cytoskeletal proteins was found to be specific for the tight junction and was not seen in nonconfluent MDCK cells. The amino acid residues that sustain the interaction between 4.1R and ZO-2 reside within the amino acids encoded by exons 19-21 of 4.1R and residues 1054-1118 of ZO-2. Exogenously expressed 4.1R containing the spectrin/actin- and ZO-2-binding domains was recruited to tight junctions in confluent MDCK cells. Taken together, our results suggest that 4.1R might play an important role in organization and function of the tight junction by establishing a link between the tight junction and the actin cytoskeleton.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Huang, SC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1033 Ross Res Bldg, Baltimore, MD 21205 USA.	schuang@welch.jhu.edu			NHLBI NIH HHS [HL44985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BENTZEL CJ, 1976, NATURE, V264, P666, DOI 10.1038/264666a0; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Chasis JA, 1996, BLOOD, V87, P5324, DOI 10.1182/blood.V87.12.5324.bloodjournal87125324; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; COHEN CM, 1982, NATURE, V299, P648, DOI 10.1038/299648a0; COLLINS JR, 1992, BIOCHEM BIOPH RES CO, V252, P617; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CORREAS I, 1988, BIOCHEM J, V255, P217; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FEHON RG, 1994, DEVELOPMENT, V120, P545; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gonzalez-Mariscal L, 1999, MOL BIOL CELL, V10, p407A; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORNE WC, 1993, BLOOD, V82, P2558; HOWARTH AG, 1992, AM J PHYSIOL, V262, pC461, DOI 10.1152/ajpcell.1992.262.2.C461; HOWARTH AG, 1995, CELL MOTIL CYTOSKEL, V31, P323, DOI 10.1002/cm.970310408; HUANG SC, 1992, T ASSOC AM PHYSICIAN, V105, P165; Huang SC, 1999, BLOOD, V94, p194A; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Leclerc E, 1998, EUR J BIOCHEM, V258, P567, DOI 10.1046/j.1432-1327.1998.2580567.x; LETO TL, 1986, J CELL PHYSIOL, V127, P423, DOI 10.1002/jcp.1041270311; LETO TL, 1984, J BIOL CHEM, V259, P4603; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; MONTERMINI L, 1995, AM J HUM GENET, V57, P1520; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; PANDOLFO M, 1994, BIOCHEM MED METAB B, V52, P115, DOI 10.1006/bmmb.1994.1041; Saitou M, 1997, EUR J CELL BIOL, V73, P222; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANG UH, 1979, EXP CELL RES, V122, P384, DOI 10.1016/0014-4827(79)90315-X; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1994, J CELL SCI, V107, P367; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TANAKA T, 1991, J BIOL CHEM, V266, P1134; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469	77	119	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30573	30585		10.1074/jbc.M004578200	http://dx.doi.org/10.1074/jbc.M004578200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10874042	hybrid			2022-12-25	WOS:000089577900091
J	Wastl, J; Duin, EC; Iuzzolino, L; Dorner, W; Link, T; Hoffmann, S; Sticht, H; Dau, H; Lingelbach, K; Maier, UG				Wastl, J; Duin, EC; Iuzzolino, L; Dorner, W; Link, T; Hoffmann, S; Sticht, H; Dau, H; Lingelbach, K; Maier, UG			Eukaryotically encoded and chloroplast-located rubredoxin is associated with photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MEMBRANES; SPECTROSCOPY; FERREDOXIN; TRANSPORT; SPINACH; COMPLEX; ORIGIN	We analyzed a eukaryotically encoded rubredoxin from the cryptomonad Guillardia theta and identified additional domains at the N- and C-termini in comparison to known prokaryotic paralogous molecules. The cryptophytic N-terminal extension was shown to be a transit peptide for intracellular targeting of the protein to the plastid, whereas a C-terminal domain represents a membrane anchor. Rubredoxin was identified in all tested phototrophic eukaryotes. Presumably facilitated by its C-terminal extension, nucleomorph-encoded rubredoxin (nmRub) is associated with the thylakoid membrane. Association with photosystem II (PSII) was demonstrated by co-localization of nmRub and PSII membrane particles and PSII core complexes and confirmed by comparative electron paramagnetic resonance measurements. The midpoint potential of nmRub was determined as +125 mV, which is the highest redox potential of all known rubredoxins. Therefore, nmRub provides a striking example of the ability of the protein environment to tune the redox potentials of metal sites, allowing for evolutionary adaption in specific electron transport systems, as for example that coupled to the PSII pathway.	Univ Marburg, Fachbereich Biol, D-35032 Marburg, Germany; Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany; Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Free Univ Berlin, Fachbereich Phys, Inst Expt Phys, D-14195 Berlin, Germany	Philipps University Marburg; Max Planck Society; Goethe University Frankfurt; University of Bayreuth; Free University of Berlin	Maier, UG (corresponding author), Univ Marburg, Fachbereich Biol, Karl-von-Frisch-Str, D-35032 Marburg, Germany.	maier@mailer.uni-marburg.de	Hoffmann, Silke/H-5059-2013; Wastl, Juergen/C-6876-2016	Hoffmann, Silke/0000-0003-1414-8957; Wastl, Juergen/0000-0001-7757-8001; Sticht, Heinrich/0000-0001-5644-045X; Dau, Holger/0000-0001-6482-7494				BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Catucci L, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P973; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; Dorner W, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1343; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; Fraunholz MJ, 1998, MOL GEN GENET, V260, P207, DOI 10.1007/s004380050887; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; Gilson PR, 1997, CURR OPIN GENET DEV, V7, P800, DOI 10.1016/S0959-437X(97)80043-3; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MEYER J, 1995, BIOCHEM BIOPH RES CO, V212, P827, DOI 10.1006/bbrc.1995.2043; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; STAEHELIN LA, 1984, J CELL BIOCHEM, V24, P261, DOI 10.1002/jcb.240240307; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; Wastl J, 2000, J BIOL CHEM, V275, P23194, DOI 10.1074/jbc.M003125200; Xiao ZG, 2000, J BIOL INORG CHEM, V5, P75, DOI 10.1007/PL00010656; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Zauner S, 2000, P NATL ACAD SCI USA, V97, P200, DOI 10.1073/pnas.97.1.200	26	18	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30058	30063		10.1074/jbc.M004629200	http://dx.doi.org/10.1074/jbc.M004629200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10878021	hybrid			2022-12-25	WOS:000089577900020
J	Delacoux, F; Fichard, A; Cogne, S; Garrone, R; Ruggiero, F				Delacoux, F; Fichard, A; Cogne, S; Garrone, R; Ruggiero, F			Unraveling the amino acid sequence crucial for heparin binding to collagen V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; FIBROBLAST GROWTH-FACTOR; ALPHA-1(V) CHAIN; COL5A1 GENE; SITE; DOMAIN; XI; IDENTIFICATION; MUTAGENESIS; MUTATIONS	We have previously shown that a recombinant 18-kDa fragment of the collagen alpha 1(V) chain (Ile(824)-Pro(950)), referred to as HepV, binds to heparin and heparan sulfate (Delacoux, F., Fichard, A, Geourjon, C., Garrone, R., and Ruggiero, F, (1998) J, Biol, Chem. 273, 15069-15076), No consensus sequence was found in the alpha 1(V) primary sequence, but a cluster of 7 basic amino acids tin the Arg(900)-Arg(924) region) was postulated to contain the heparin-binding site, The contribution of individual basic amino acids within this sequence was examined by site-directed mutagenesis, Further evidence for the precise localization of the heparin-binding site was provided by experiments based on the fact that heparin can protect the alpha 1(V) chain heparin-binding site from trypsin digestion. The results parallel the alanine scanning mutagenesis data, i.e. heparin binding to the alpha 1(V) chain involved Arg(912), Arg(918), and Arg(921) and two additional neighboring basic residues, Lys(905) and Arg(909), Our data suggest that this extended sequence functions as a heparin-binding site in both collagens V and XI, indicating that these collagens use a novel sequence motif to interact with heparin.	Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UPR 412, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ruggiero, F (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UPR 412, 7 Passage Vercors, F-69367 Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359				ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DePaepe A, 1997, AM J HUM GENET, V60, P547; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Giry-Lozinguez C, 1998, MATRIX BIOL, V17, P145, DOI 10.1016/S0945-053X(98)90027-0; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Tillet E, 1997, J BIOL CHEM, V272, P10769; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	31	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29377	29382		10.1074/jbc.M004724200	http://dx.doi.org/10.1074/jbc.M004724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10862775	hybrid			2022-12-25	WOS:000089439800028
J	Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Kubo, M; LaRochelle, WJ; Yoshikai, Y				Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Kubo, M; LaRochelle, WJ; Yoshikai, Y			Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; BETA-CHAIN; IL-4 PRODUCTION; GROWTH-FACTOR; GM-CSF; RECEPTOR; CYTOKINE; LYMPHOKINE; DIFFERENTIATION; ACTIVATION	Interleukin (IL)-4 plays an important role in the differentiation of naive T helper (Th) cells into Th2. Mast cells can produce a significant amount of IL-4 and have been proposed to play a major role in the induction of Th2 responses. Recently, it has been reported that mast cells have a distinct IL-15 receptor system different from that of T or natural killer cells. In the present study, we demonstrated that IL-15 induced IL-4 production from a mouse mast cell line, MC/9, and bone marrow-derived mast cells. IL-4 mRNA expression was increased by IL-15, suggesting that IL-15 promotes IL-4 expression at the transcriptional Level. In these mast cells, signal transducer and activator of transcription (STAT) 6 were rapidly tyrosine-phosphorylated in response to IL-15. In MC/9 cells, the expression of a C-terminally truncated dominant negative form of STAT6 significantly suppressed the IL-4 mRNA up-regulation by IL-15, suggesting that STAT6 activation is essential for the IL-15-mediated IL-4 production. Additionally, tyrosine phosphorylation of Tyk2 was rapidly increased by IL-15 treatment in this cell line. Altogether, our results suggest that IL-15 plays an important role in stimulating early IL-4 production in mast cells that may be responsible for the initiation of Th2 response.	Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Dept Internal Med 2,Showa Ku, Nagoya, Aichi 4668550, Japan; Sci Univ Tokyo, Res Inst Biol Sci, Div Immunobiol, Tokyo 2780022, Japan; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Nagoya University; Nagoya University; Tokyo University of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Matsuguchi, T (corresponding author), Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Masuda, Akio/H-6323-2012					BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Coffman RL, 1997, J EXP MED, V185, P373, DOI 10.1084/jem.185.3.373; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Doherty TM, 1996, J IMMUNOL, V156, P735; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Georas SN, 1998, BLOOD, V92, P4529, DOI 10.1182/blood.V92.12.4529.424k39_4529_4538; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hirose K, 1998, INFECT IMMUN, V66, P5677, DOI 10.1128/IAI.66.12.5677-5683.1998; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Huang H, 1997, J IMMUNOL, V159, P3731; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nishimura H, 1996, J IMMUNOL, V156, P663; PAUL WE, 1991, BLOOD, V77, P1859; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Ruckert R, 1998, EUR J IMMUNOL, V28, P3312; Sakai T, 1998, GASTROENTEROLOGY, V114, P1237, DOI 10.1016/S0016-5085(98)70430-5; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Sherman MA, 1999, J IMMUNOL, V163, P1733; Sherman MA, 1999, EUR J IMMUNOL, V29, P1235, DOI 10.1002/(SICI)1521-4141(199904)29:04<1235::AID-IMMU1235>3.3.CO;2-S; Sherman MA, 1999, J IMMUNOL, V162, P2703; SWAIN SL, 1990, J IMMUNOL, V144, P1788; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Yoshikawa H, 1999, J IMMUNOL, V162, P6162; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	43	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29331	29337		10.1074/jbc.M910290199	http://dx.doi.org/10.1074/jbc.M910290199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882748	hybrid			2022-12-25	WOS:000089439800022
J	Mitton, KP; Swain, PK; Chen, SM; Xu, SQ; Zack, DJ; Swaroop, A				Mitton, KP; Swain, PK; Chen, SM; Xu, SQ; Zack, DJ; Swaroop, A			The leucine zipper of NRL interacts with the CRX homeodomain - A possible mechanism of transcriptional synergy in rhodopsin regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEBER CONGENITAL AMAUROSIS; CONE-ROD DYSTROPHY; RAT OPSIN GENE; HOMEOBOX GENE; DNA-BINDING; PHOTORECEPTOR DIFFERENTIATION; BETA ENHANCEOSOME; CRYSTAL-STRUCTURE; UPSTREAM REGION; C-JUN	Photoreceptor-specific expression of rhodopsin is mediated by multiple cis-acting elements in the proximal promoter region. NRL (neural retina leucine zipper) and CRX (cone rod homeobox) proteins bind to the adjacent NRE and Ret-4 sites, respectively, within this region. Although NRL and CRX are each individually able to induce rhodopsin promoter activity, when expressed together they exhibit transcriptional synergy in rhodopsin promoter activation. Using the yeast two-hybrid method and glutathione S-transferase pull-down assays, we demonstrate that the leucine zipper of NRL can physically interact with CRX Deletion analysis revealed that the CRX homeodomain (CRX-HD) plays an important role in the interaction with the NRL leucine zipper. Although binding with the CRX-HD alone was weak, a strong interaction was detected when flanking regions including the glutamine-rich and the basic regions that follow the HD were included. A reciprocal deletion analysis showed that the leucine zipper of NRL is required for interaction with CRX-HD, Two disease-causing mutations in CRX-HD (R41W and R90W) that exhibit reduced DNA binding and transcriptional synergy also decrease its interaction with NRL, These studies suggest novel possibilities for protein-protein interaction between two conserved DNA-binding motifs and imply that cross-talk among distinct regulatory pathways contributes to the establishment and maintenance of photoreceptor function.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Human Genet, Ann Arbor, MI 48105 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	mitton, kenneth/Y-1974-2019	mitton, kenneth/0000-0002-4751-7440; Swaroop, Anand/0000-0002-1975-1141; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY011115, R01EY012543, R01EY009769] Funding Source: NIH RePORTER; NEI NIH HHS [EY11115, EY09769, EY07003, R01 EY012543] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEFTSIN J, 1998, NATURE, V392, P885; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Liu Q, 1996, ONCOGENE, V12, P207; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Moore DD, 1995, GLOB MOB SURV; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SCHNARR M, 1991, BIOCHIMIE, V73, P423, DOI 10.1016/0300-9084(91)90109-E; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	60	167	171	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29794	29799		10.1074/jbc.M003658200	http://dx.doi.org/10.1074/jbc.M003658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887186	hybrid			2022-12-25	WOS:000089439800084
J	Tzivion, G; Luo, ZJ; Avruch, J				Tzivion, G; Luo, ZJ; Avruch, J			Calyculin A-induced vimentin phosphorylation sequesters 14-3-3 and displaces other 14-3-3 partners in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT REORGANIZATION; KINASE-ACTIVITY; DNA-DAMAGE; 14-3-3-PROTEINS; BINDING; RAF; CHECKPOINT; CELLS; ASSOCIATION; INHIBITION	14-3-3 proteins bind their targets through a specific serine/threonine-phosphorylated motif present on the target protein. This binding is a crucial step in the phosphorylation-dependent regulation of various key proteins involved in signal transduction and cell cycle control, We report that treatment of COS-7 cells with the phosphatase inhibitor calyculin A induces association of 14-3-3 with a 55-kDa protein, identified as the intermediate filament protein vimentin, Association of vimentin with 14-3-3 depends on vimentin phosphorylation and requires the phosphopeptide-binding domain of 14-3-3, The region necessary for binding to 14-3-3 is confined to the vimentin amino-terminal head domain (amino acids 1-96). Monomeric forms of 14-3-3 do not bind vimentin in vivo or in vitro, indicating that a stable complex requires the binding of a 14-3-3 dimer to two sites on a single vimentin polypeptide. The calyculin A-induced association of vimentin with 14-3-3 in vivo results in the displacement of most other 14-3-3 partners, including the protooncogene Raf, which nevertheless remain capable of binding 14-3-3 in vitro, Concomitant with 14-3-3 displacement, calyculin A treatment blocks Raf activation by EGF; however, this inhibition is completely overcome by 14-3-3 overexpression in vivo or by the addition of prokaryotic recombinant 14-3-3 in vitro, Thus, phosphovimentin, by sequestering 14-3-3 and limiting its availability to other target proteins can affect intracellular signaling processes that require 14-3-3.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Boston Univ, Med Ctr, Diabet & Metab Unit, Boston, MA 02118 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Tzivion, G (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, 1901 S 1st St,Bldg 162, Temple, TX 76504 USA.		Tzivion, Guri/D-8954-2011; Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rommel C, 1996, ONCOGENE, V12, P609; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	32	123	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29772	29778		10.1074/jbc.M001207200	http://dx.doi.org/10.1074/jbc.M001207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887173	hybrid, Green Published			2022-12-25	WOS:000089439800081
J	Hunt, MC; Yang, YZ; Eggertsen, G; Carneheim, CM; Gafvels, M; Einarsson, C; Alexson, SEH				Hunt, MC; Yang, YZ; Eggertsen, G; Carneheim, CM; Gafvels, M; Einarsson, C; Alexson, SEH			The peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates bile acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL 12-ALPHA-HYDROXYLASE; FATTY-ACIDS; CHOLESTEROL-METABOLISM; RESPONSIVE ELEMENT; ADAPTIVE RESPONSE; GENE-EXPRESSION; IDENTIFICATION; MOUSE; MICE; EICOSANOIDS	Fibrates are a group of hypolipidemic agents that efficiently lower serum triglyceride levels by affecting the expression of many genes involved in lipid metabolism. These effects are exerted via the peroxisome proliferator-activated receptor alpha (PPAR alpha). In addition, fibrates also lower serum cholesterol levels, suggesting a possible link between the PPAR alpha and cholesterol metabolism. Bile acid formation represents an important pathway for elimination of cholesterol, and the sterol 12 alpha-hydroxylase is a branch-point enzyme in the bile acid biosynthetic pathway, which determines the ratio of cholic acid to chenodeoxycholic acid. Treatment of mice for 1 week with the peroxisome proliferator WY-14,643 or fasting for 24 h both induced the sterol 12 alpha-hydroxylase mRNA in liver. Using the PPAR alpha knockout mouse model, we show that the induction by both treatments was dependent on the PPAR alpha. A reporter plasmid containing a putative peroxisome proliferator-response element (PPRE) identified in the rat sterol 12 alpha-hydroxylase promoter region was activated by treatment with WY-14,643 in HepG2 cells, being dependent on co-transfection with a PPAR alpha expression plasmid, The rat 12 alpha-hydroxylase PPRE bound in vitro translated PPAR alpha and retinoid X receptor alpha, albeit weakly, in electrophoretic mobility shift assay, Treatment of wild-type mice with WY-14,643 for 1 week resulted in an increased relative amount of cholic acid, an effect that was abolished in the PPAR alpha null mice, verifying the functionality of the PPRE in vivo.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, S-14186 Huddinge, Sweden; Pharmacia & Upjohn AB, Plasma Prod R&D, S-11287 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med, Div Gastroenterol & Hepatol, S-14186 Huddinge, Sweden	Karolinska Institutet; Pfizer; Pharmacia Corporation; Karolinska Institutet	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, S-14186 Huddinge, Sweden.	stefan.alexson@chemlab.hs.sll.se						Andersson U, 1999, BBA-MOL CELL BIOL L, V1438, P167, DOI 10.1016/S1388-1981(99)00036-0; ANGELIN B, 1976, BIOCHEM J, V156, P445, DOI 10.1042/bj1560445; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gafvels M, 1999, GENOMICS, V56, P184, DOI 10.1006/geno.1998.5606; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GRUNDY SM, 1972, J LIPID RES, V13, P531; Hunt MC, 2000, J LIPID RES, V41, P814; ISHIDA H, 1992, J BIOL CHEM, V267, P21319; Ishida H, 1999, J BIOCHEM-TOKYO, V126, P19, DOI 10.1093/oxfordjournals.jbchem.a022422; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KESANIEMI YA, 1984, JAMA-J AM MED ASSOC, V251, P2241, DOI 10.1001/jama.251.17.2241; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Princen HMG, 1997, CURR PHARM DESIGN, V3, P59; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Schoonjans K, 1996, J LIPID RES, V37, P907; STAHLBERG D, 1995, HEPATOLOGY, V21, P1025, DOI 10.1016/0270-9139(95)90250-3; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Wang DQH, 1999, J LIPID RES, V40, P2066; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	31	128	132	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28947	28953		10.1074/jbc.M002782200	http://dx.doi.org/10.1074/jbc.M002782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867000	hybrid			2022-12-25	WOS:000089330700080
J	Priel-Halachmi, S; Ben-Dor, I; Shpungin, S; Tennenbaum, T; Molavani, H; Bachrach, M; Salzberg, S; Nir, U				Priel-Halachmi, S; Ben-Dor, I; Shpungin, S; Tennenbaum, T; Molavani, H; Bachrach, M; Salzberg, S; Nir, U			FER kinase activation of Stat3 is determined by the N-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-FES; CONSTITUTIVE ACTIVATION; TRANSCRIPT FERT; SRC-FAMILY; CELLS; GENE; NUCLEAR	p94(fer) and p51(ferT) are two tyrosine kinases that share identical SH2 and kinase domains but differ in their N-terminal regions. To further explore the cellular functions of these two highly related tyrosine kinases, their subcellular distribution profiles and in vivo phosphorylation activity were followed using double immunofluorescence assay. When combined with immunoprecipitation analysis, this assay showed that p94(fer) can lead to the tyrosine phosphorylation and activation of Stat3 but not of Stat1 or Stat2. Native p94fer exerted this activity when residing in the cytoplasm, However, modified forms of p94(fer), which are constitutively nuclear, could also lead to the phosphorylation of Stat3. Endogenous Stat3 and p94(fer) co-immunoprecipitated with each other, thus proving the interaction of these two proteins in vivo. Unlike p94(fer), p51(ferT) did not induce the phosphorylation of Stat3 but led to the phosphorylation of other nuclear proteins. Replacing the unique 43-amino acid-long N-terminal tail of p51(ferT) with a parallel segment from the N-terminal tail of p94fer did not change the subcellular localization of p51(ferT) but enabled it to activate Stat3. Thus the different N-terminal sequences of p94(fer) and p51(ferT) can affect their ability to induce phosphorylation of Stat3 and most probably direct their different cellular functions.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Salzberg, Steven/Q-6514-2019	Salzberg, Steven/0000-0002-8859-7432				Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bern O, 1997, FEBS LETT, V403, P45, DOI 10.1016/S0014-5793(97)00028-8; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; DAMELL JE, 1997, SCIENCE, V277, P1630; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Karras JG, 1997, J EXP MED, V185, P1035, DOI 10.1084/jem.185.6.1035; KATCOFF DJ, 1993, NUCLEIC ACIDS RES, V21, P5101, DOI 10.1093/nar/21.22.5101; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LETWIN K, 1988, ONCOGENE, V3, P621; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Sartor CI, 1997, CANCER RES, V57, P978; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WeberNordt RM, 1996, BLOOD, V88, P809; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS AF, 1988, ONCOGENE, V3, P289; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YATES KE, 1995, ONCOGENE, V10, P1239; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	48	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28902	28910		10.1074/jbc.M003402200	http://dx.doi.org/10.1074/jbc.M003402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878010	hybrid			2022-12-25	WOS:000089330700075
J	Zharkov, DO; Rosenquist, TA; Gerchman, SE; Grollman, AP				Zharkov, DO; Rosenquist, TA; Gerchman, SE; Grollman, AP			Substrate specificity and reaction mechanism of murine 8-oxoguanine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; 7,8-DIHYDRO-8-OXOGUANINE DNA GLYCOSYLASE; OXIDATIVELY DAMAGED DNA; ESCHERICHIA-COLI MUTY; DEOXYRIBOPHOSPHODIESTERASE DRPASE ACTIVITY; NUCLEIC-ACID ADDUCTS; SACCHAROMYCES-CEREVISIAE; FPG PROTEIN; CATALYTIC MECHANISM; HUMAN HOMOLOG	Genomic DNA is prone to oxidation by reactive oxygen species. A major product of DNA oxidation is the miscoding base 8-oxoguanine (8-oxoG). The mutagenic effects of 8-oxoG in mammalian cells are prevented by a DNA repair system consisting of 8-oxoguanine-DNA glycosylase (Ogg1), adenine-DNA glycosylase, and 8-oxo-dGTPase. We have cloned, overexpressed, and characterized mOgg1, the product of the murine ogg1 gene. mOgg1 is a DNA glycosylase/AP lyase belonging to the endonuclease III family of DNA repair enzymes. The AP lyase activity of mOgg1 is significantly lower than its glycosylase activity. mOgg1 releases 8-oxoG from DNA when paired with C, T, or G, but efficient DNA strand nicking is observed only with 8-oxoG:C. Binding of mOgg1 to oligonucleotides containing 8-oxoG:C is strong (K-D = 51.5 nM), unlike other mispairs. The average residence time for mOgg1 bound to substrate containing 8-oxoG:C is 18.3 min; the time course for accumulation of the NaBH4-sensitive intermediate suggests a two-step reaction mechanism. Various analogs of 8-oxoG were tested as substrates for mOgg1. An electron-withdrawing or hydrogen bond acceptor moiety at CS is required for efficient binding of mOgg1. A substituent at C6 and a keto group at C8 are required for cleavage. The proposed mechanism of 8-oxoG excision involves protonation of O-8 Or the deoxyribose oxygen moiety.	SUNY Stony Brook, Biol Chem Lab, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Russian Acad Sci, Novosibirsk Bioorgan Chem Inst, Siberian Div, Novosibirsk 630090, Russia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; United States Department of Energy (DOE); Brookhaven National Laboratory	Zharkov, DO (corresponding author), SUNY Stony Brook, Biol Chem Lab, Stony Brook, NY 11794 USA.		Zharkov, Dmitry/K-2158-2012	Zharkov, Dmitry/0000-0001-5013-0194	NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aburatani H, 1997, CANCER RES, V57, P2151; AIDA M, 1987, MUTAT RES, V192, P83, DOI 10.1016/0165-7992(87)90101-1; Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CHEN H, 1996, MAGN RESON CHEM, V0034; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHO BP, 1993, MAGN RESON CHEM, V31, P1048, DOI 10.1002/mrc.1260311204; CHO BP, 1991, NUCLEIC ACIDS RES, V19, P1041, DOI 10.1093/nar/19.5.1041; CHO BP, 1990, CHEM RES TOXICOL, V3, P445, DOI 10.1021/tx00017a010; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; CYSEWSKI P, 1997, THEOCHEM-J MOL STRUC, V397, P167; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1995, CURR BIOL, V5, P719, DOI 10.1016/S0960-9822(95)00143-6; Deng L, 1997, J AM CHEM SOC, V119, P7865, DOI 10.1021/ja970828u; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Fersht A., 1985, ENZYME STRUCTURE MEC; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Grollman AP, 1999, NATO ADV SCI I A-LIF, V302, P135; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Johnson F, 1998, CHEM RES TOXICOL, V11, P193, DOI 10.1021/tx9701539; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kennedy LJ, 1997, CHEM RES TOXICOL, V10, P386, DOI 10.1021/tx960102w; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; LIN TS, 1985, J MED CHEM, V28, P1194, DOI 10.1021/jm00147a012; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; ODA Y, 1992, NUCLEOS NUCLEOT, V11, P261, DOI 10.1080/07328319208021701; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Ohtsubo T, 1998, MOL GEN GENET, V259, P577, DOI 10.1007/s004380050851; PLUM GE, 1995, BIOCHEMISTRY-US, V34, P16418; Purmal AA, 1996, MUTAT RES-DNA REPAIR, V364, P193, DOI 10.1016/S0921-8777(96)00032-8; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rieger RA, 1999, NUCLEOS NUCLEOT, V18, P73, DOI 10.1080/07328319908045595; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; Sandigursky M, 1997, NUCLEIC ACIDS RES, V25, P4557, DOI 10.1093/nar/25.22.4557; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SODUM RS, 1993, CHEM RES TOXICOL, V6, P269, DOI 10.1021/tx00033a004; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Varaprasad CV, 1996, TETRAHEDRON LETT, V37, P9, DOI 10.1016/0040-4039(95)02069-1; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	85	168	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28607	28617		10.1074/jbc.M002441200	http://dx.doi.org/10.1074/jbc.M002441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10884383	hybrid			2022-12-25	WOS:000089330700038
J	Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS				Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS			Activation of the pro-drug ethionamide is regulated in mycobaeteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID RESISTANCE; CATALASE PEROXIDASE; GENE; BIOACTIVATION; OXIDATION; TARGET	The anti-tuberculosis drug ethionamide (ETH), which is a structural analog of isoniazid (INH), is known to strongly inhibit mycolic acid synthesis in Mycobacterium tuberculosis. Although several targets have been identified for INH, only speculative information is available concerning ETH, Mutations within the promoter and the coding region of enoyl-acyl carrier protein reductase (InhA) were found to confer resistance to both drugs, thus leading to the impression that INR and ETH may: share a common mode of action. However, a notable distinction between the two drugs Lies in the lack of cross-resistance in clinical isolates. This may be attributed in part to the fact that the pro-drug INH must be activated via KatG, and no activation step for ETH has yet been described. Here we report the identification of an activator for ETH, The ETH activator (Rv3854c), which we have termed EthA, was found to be homologous to various monooxygenases and induced ETR sensitivity when overexpressed in mycobacteria, Interestingly, the neighboring open reading frame (Rv3855), which was found homologous to transcriptional repressors of the tetR family, led to ETH resistance when overexpressed. In addition, chromosomal inactivation of this gene by transposition led to ETH hypersensitivity. These data strongly suggest that Rv3855, which me have termed EthR, regulates the production of EthA, which subsequently activates the pro-drug ETH, This study opens up new avenues of research relating to ETR activation in mycobacteria, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.	Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Inst Pasteur, Inst Biol, INSERM, U447, F-59019 Lille, France	Newcastle University - UK; Colorado State University; GlaxoSmithKline; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Besra, GS (corresponding author), Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.s.besra@newcastle.ac.uk	Locht, Camille/L-3516-2018; Baulard, Alain R/E-6830-2017	Baulard, Alain R/0000-0002-0150-5241; Betts, Joanna/0000-0003-1729-1839; Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI-18357, AI-38087, AI-33706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI033706, U19AI038087, R01AI018357, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Barry CE, 1998, DRUG RESIST UPDATE, V1, P128, DOI 10.1016/S1368-7646(98)80028-9; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; CHIELI E, 1985, BIOCHEM PHARMACOL, V34, P395, DOI 10.1016/0006-2952(85)90056-5; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; DELENCASTRE H, 1983, J GEN MICROBIOL, V129, P3203; ESPINAL M, 1999, 260 WHO; Fattorini L, 1999, MICROB DRUG RESIST, V5, P265, DOI 10.1089/mdr.1999.5.265; GUYER MS, 1978, J MOL BIOL, V126, P347, DOI 10.1016/0022-2836(78)90045-1; Heym B., 1999, Tubercle and Lung Disease, V79, P267, DOI 10.1054/tuld.1998.0208; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; LIU J, 1999, MYCOBACTERIA MOL BIO; Loewen PC, 2000, ASM NEWS, V66, P76; QUEMARD A, 1992, ANTIMICROB AGENTS CH, V36, P1316, DOI 10.1128/AAC.36.6.1316; RIST NOEL, 1960, ADVANCES TUBERC RES, V10, P69; Rollier R, 1972, Maroc Med, V52, P148; RUSE MJ, 1991, BIOCHEM SOC T, V19, pS233, DOI 10.1042/bst019233s; RUSE MJ, 1991, TOXICOL LETT, V58, P37, DOI 10.1016/0378-4274(91)90188-C; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAYAMA K, 1974, ANN NY ACAD SCI, V235, P426, DOI 10.1111/j.1749-6632.1974.tb43281.x; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WANG L, 1972, ANTIMICROB AGENTS CH, V2, P438, DOI 10.1128/AAC.2.6.438; Wards BJ, 1996, FEMS MICROBIOL LETT, V145, P101, DOI 10.1016/0378-1097(96)00394-1; WATERS MFR, 1989, BIOL MYCOBACTERIA, V3, P405; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	244	266	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28326	28331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869356				2022-12-25	WOS:000089197100105
J	Dong, AC; Randolph, TW; Carpenter, JF				Dong, AC; Randolph, TW; Carpenter, JF			Entrapping intermediates of thermal aggregation in alpha-helical proteins with low concentration of guanidine hydrochloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; DENATURED STATE; BETA-SHEET; STABILITY; PEPTIDES; SPECTRA; CHYMOTRYPSINOGEN; CONFORMATION; TEMPERATURE	Aggregation of proteins is a problem with serious medical implications and economic importance. To develop strategies for preventing aggregation, the mechanism(s) and pathways by which proteins aggregate must be characterized. In this study, the thermally induced aggregation processes of three alpha-helix proteins (myoglobin, cytochrome c, and lysozyme) in the presence and absence of 1.0 M guanidine hydrochloride (GdnHCl) were investigated by means of infrared spectroscopy. In the absence of GdnHCl, intensities of the alpha-helix bands (similar to 1656 cm(-1)) decrease as a function of temperature at above 50 degrees C. With myoglobin and cytochrome c, the loss of helix bands was accompanied by the appearance of two new bands at 1694 and 1623 cm(-1), indicative of the formation of intermolecular beta-sheet aggregates. For lysozyme, bands indicative of intermolecular beta-sheet aggregates did not appear in any significant intensity. In the presence of 1.0 M GdnHCl, two major intermediate states rich in 3(10)-helix (represented by the band at 1663 cm(-1)) and beta-turn structure (represented by the band at cm 1667 cm(-1)), respectively, were observed. These findings demonstrated that IR spectroscopic studies of protein aggregation using a combination of thermal and chemical denaturing factors could provide a means to populate and characterize aggregation intermediates.	Univ No Colorado, Dept Chem & Biochem, Greeley, CO 80639 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Northern Colorado; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dong, AC (corresponding author), Univ No Colorado, Dept Chem & Biochem, Greeley, CO 80639 USA.	adong@unco.edu	randolph, theodore/A-3301-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055889] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R15GM5588901] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD Z, 1994, BBA-PROTEIN STRUCT M, V1207, P223, DOI 10.1016/0167-4838(94)00045-X; Allison SD, 1996, BIOPHYS J, V71, P2022, DOI 10.1016/S0006-3495(96)79400-6; ARCHARYA KR, 1989, J MOL BIOL, V208, P99; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BOSCH R, 1983, ACTA CRYSTALLOGR C, V39, P776, DOI 10.1107/S0108270183006289; BOWLER BE, 1994, BIOCHEMISTRY-US, V33, P2402, DOI 10.1021/bi00175a008; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CLARK AH, 1980, INT J PEPT PROT RES, V16, P339; CLARK AH, 1981, INT J PEPT PROT RES, V17, P353; Damaschun G, 2000, PROTEINS, V39, P204, DOI 10.1002/(SICI)1097-0134(20000515)39:3<204::AID-PROT20>3.0.CO;2-8; Dhodapkar MV, 1997, HEMATOL ONCOL CLIN N, V11, P89, DOI 10.1016/S0889-8588(05)70417-2; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 1997, ARCH BIOCHEM BIOPHYS, V347, P213, DOI 10.1006/abbi.1997.0349; DONG AC, 1995, ARCH BIOCHEM BIOPHYS, V320, P59, DOI 10.1006/abbi.1995.1342; Dornberger U, 1996, BBA-PROTEIN STRUCT M, V1294, P168, DOI 10.1016/0167-4838(96)00018-0; EPAND RM, 1974, BIOPOLYMERS, V13, P359, DOI 10.1002/bip.1974.360130211; FABIAN H, 1995, BIOCHEMISTRY-US, V34, P13651, DOI 10.1021/bi00041a046; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Gupta R, 1996, BIOCHEMISTRY-US, V35, P11925, DOI 10.1021/bi961079g; ISMAIL AA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P183, DOI 10.1016/0167-4838(92)90353-F; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MANNING MC, 1999, IN PRESS PEPTIDE PRO; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; Nozaki Y, 1972, Methods Enzymol, V26, P43; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; PRESTRELSKI SJ, 1993, BIOPHYS J, V65, P661, DOI 10.1016/S0006-3495(93)81120-2; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; SHAMALA N, 1977, BIOCHEM BIOPH RES CO, V79, P292, DOI 10.1016/0006-291X(77)90094-8; SHIBATA A, 1992, BIOCHEMISTRY-US, V31, P5728, DOI 10.1021/bi00140a006; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; SOMAN KV, 1991, BIOPOLYMERS, V31, P1351, DOI 10.1002/bip.360311202; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TIFFANY ML, 1969, BIOPOLYMERS, V8, P347, DOI 10.1002/bip.1969.360080306; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006	48	87	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27689	27693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871628				2022-12-25	WOS:000089197100023
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Distinct self-oligomerization activities of synaptotagmin family - Unique calcium-dependent oligomerization properties of synaptotagmin VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; PHOSPHOLIPID-BINDING; SYNAPTIC-VESICLE; PROTEINS; ISOFORMS; CELLS	Synaptotagmins constitute a large protein family, characterized by one transmembrane region and two C2 domains, and can be classified into several subclasses based on phylogenetic relationships and biochemical activities (Fukuda, M., Kanno, E., and Mikoshiba, K. (1999) J, Biol. Chem. 274, 31421-31427). Synaptotagmin I (Syt I), a possible Ca2+ sensor for neurotransmitter release, showed both Ca2+-dependent (via the C2 domain) and -independent (via the NH2-terminal domain) self-oligomerization, which are thought to be important for synaptic vesicle exocytosis. However, little is known about the relationship between these two interactions and the Ca2+-dependent oligomerization properties of other synaptotagmin isoforms, In this study, we first examined the Ca2+-dependent self-oligomerization properties of synaptotagmin family by co-expression of T7- and FLAG-tagged Syts (full-length or cytoplasmic domain) in COS-7 cells. We found that Syt VII is a unique class of synaptotagmins that only showed robust Ca2+-dependent self-oligomerization at the cytoplasmic domain with EC50 values of about 150 mu M Ca2+. In addition, Syt VII preferentially interacted with the previously described subclass of Syts (V, VI, and X) in a Ca2+-dependent manner. Co-expression of full-length and cytoplasmic portion of Syts VII (or II) indicate that Syt VII cytoplasmic domain oligomerizes in a Ca2+-dependent manner without being tethered at the NH2-terminal domain, whereas Ca2+-dependent self-oligomerization at the cytoplasmic domain of other isoforms (e,g. Syt II) occurs only when the two molecules are tethered at the NH2-terminal domain.	RIKEN, Inst Phys & Chem Res, Inst Basic Sci, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Inst Basic Sci, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Damer CK, 1996, J NEUROCHEM, V67, P1661; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Linial M, 1997, J NEUROCHEM, V69, P1781; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	33	69	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28180	28185						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871604				2022-12-25	WOS:000089197100086
J	Kalinec, F; Zhang, M; Urrutia, R; Kalinec, G				Kalinec, F; Zhang, M; Urrutia, R; Kalinec, G			Rho GTPases mediate the regulation of cochlear outer hair cell motility by acetylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROKINETIC SHAPE CHANGES; GUINEA-PIG; SUBSURFACE CISTERNAE; PLASMA-MEMBRANE; FAMILY GTPASES; LATERAL WALL; PROTEIN; ACTIN; CYTOSKELETON; MECHANISM	Outer hair cells are the mechanical effecters of the cochlear amplifier, an active process that improves the sensitivity and frequency discrimination of the mammalian ear. In vivo the gain of the cochlear amplifier is regulated by the efferent neurotransmitter acetylcholine through the modulation of outer hair cell mobility. Little is known, however, regarding the molecular mechanisms activated by acetylcholine. In this study, intracellular signaling pathways involving the small GTPases RhoA, Rac1, and Cdc42 have been identified as regulators of outer hair cell motility, Changes in cell length (slow motility) and in the amplitude of electrically induced movement (fast motility) were measured in isolated outer hair cells patch clamped in whole-cell mode, internally perfused through the patch pipette with different inhibitors and activators of these small GTPases while being externally stimulated with acetylcholine. me found that acetylcholine induces outer hair cell shortening and a simultaneous increase in the amplitude of fast motility through Rad and Cdc42 activation. In contrast, a RhoA- and Rac1-mediated signaling pathway induces outer hair cell elongation and decreases fast motility amplitude. These two opposing processes preside the basis for a regulatory mechanism of outer hair cell mobility.	House Ear Res Inst, Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Mayo Clin, GI Res Inst, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Neurosci, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Tumor Biol, Rochester, MN 55905 USA	House Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kalinec, F (corresponding author), House Ear Res Inst, Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	fkalinec@hei.org						ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1992, J NEUROSCI, V12, P4575; DRENCKHAHN D, 1991, J CELL BIOL, V112, P641, DOI 10.1083/jcb.112.4.641; DULON D, 1992, AM J OTOL, V13, P108; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FLOCK A, 1986, ARCH OTO-RHINO-LARYN, V243, P83, DOI 10.1007/BF00453755; FORGE A, 1993, HEARING RES, V64, P175, DOI 10.1016/0378-5955(93)90003-J; Frolenkov GI, 1997, BIOPHYS J, V73, P1665, DOI 10.1016/S0006-3495(97)78198-0; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Guinan J.J., 1996, COCHLEA EDITED, P435; GULLEY RL, 1977, ANAT RECORD, V189, P109, DOI 10.1002/ar.1091890108; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; HOLLEY MC, 1992, J CELL SCI, V102, P569; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; IWASA KH, 1991, NEUROSCI LETT, V133, P171, DOI 10.1016/0304-3940(91)90562-8; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; Kalinec F, 1997, HEARING RES, V110, P141, DOI 10.1016/S0378-5955(97)00076-2; Kalinec F, 1993, BIOPHYSICS HAIR CELL, P175; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lim DJ, 1998, KIDNEY INT, pS104; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; POLLICE PA, 1993, HEARING RES, V70, P187, DOI 10.1016/0378-5955(93)90157-V; RAPHAEL Y, 1986, J SUBMICR CYTOL PATH, V18, P731; RAPHAEL Y, 1994, HEARING RES, V76, P173, DOI 10.1016/0378-5955(94)90098-1; SAITO K, 1983, CELL TISSUE RES, V229, P467; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wiederhold M. L., 1986, NEUROBIOLOGY HEARING, P349; ZAJIC G, 1987, HEARING RES, V26, P249, DOI 10.1016/0378-5955(87)90061-X; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	49	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28000	28005						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862776				2022-12-25	WOS:000089197100064
J	Kustedjo, K; Bracey, MH; Cravatt, BF				Kustedjo, K; Bracey, MH; Cravatt, BF			Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; ASHKENAZI JEWS; PROTEIN; DYT1; HSP104; CHAPERONES; MUTATION; MEMBRANE; CLPAP	Early-onset torsion dystonia is an autosomal dominant hyperkinetic movement disorder that has recently been linked to a 3-base pair deletion in the DYT1 gene. The DYT1 gene encodes a 332-amino acid protein, torsin Ih, that bears low but significant homology to the Hsp100/Clp family of ATPase chaperones. The deletion in DYT1 associated with torsion dystonia results in the loss of one of a pair of glutamic acid residues residing near the C terminus of torsin A (Delta E-torsin A). At present, Little is known about the expression, subcellular distribution, and/or function of either the torsin A or Delta E-torsin A protein. When transfected into mammalian cells, both torsin A and Delta E-torsin A were found to behave as lumenally oriented glycoproteins. Immunofluorescence studies revealed that torsin A localized to a diffuse network of intracellular membranes displaying significant co-immunoreactivity for the endoplasmic reticulum resident protein BiP, whereas Delta E-torsin A resided in large spheroid intracellular structures exclusive of BiP immunoreactivity. These results initially suggested that Delta E-torsin A might exist as insoluble aggregates. However, both torsin A and Delta E-torsin A were readily solubilized by nonionic detergents, were similarly accessible to proteases, and displayed equivalent migration patterns on sucrose gradients. Collectively, these data support that both the wild type and torsion dystonia-associated forms of torsin A are properly folded, lumenal proteins of similar oligomeric states. The potential relationship between the altered subcellular distribution of Delta E-torsin A and the disease-inducing phenotype of the protein is discussed.	Scripps Res Inst, Skaggs Inst Chem Res, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Res, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BRESSMAN SB, 1994, ANN NEUROL, V36, P771, DOI 10.1002/ana.410360514; COLEMAN RA, 1980, BIOCHIM BIOPHYS ACTA, V595, P184, DOI 10.1016/0005-2736(80)90082-6; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; Eidelberg D, 1998, ANN NEUROL, V44, P303, DOI 10.1002/ana.410440304; Fahn S, 1998, Adv Neurol, V78, P1; Fahn S, 1988, Adv Neurol, V50, P1; Feng HP, 1998, CURR BIOL, V8, pR464, DOI 10.1016/S0960-9822(98)70294-5; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GREENE P, 1995, MOVEMENT DISORD, V10, P143, DOI 10.1002/mds.870100204; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hedreen J C, 1988, Adv Neurol, V50, P123; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Lebre AS, 1999, BRAIN, V122, P41, DOI 10.1093/brain/122.1.41; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Ozelius L J, 1998, Adv Neurol, V78, P93; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; RISCH NJ, 1990, AM J HUM GENET, V46, P533; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Valente EM, 1998, BRAIN, V121, P2335, DOI 10.1093/brain/121.12.2335; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x	26	141	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27933	27939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871631				2022-12-25	WOS:000089197100056
J	Taylor, MK; Uhler, MD				Taylor, MK; Uhler, MD			The amino-terminal cyclic nucleotide binding site of the type II cGMP-dependent protein kinase is essential for full cyclic nucleotide-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; CAMP BINDING; CATALYTIC SUBUNIT; GMP; AMP; EXPRESSION; ALPHA; MUTATIONS; DISTINCT; DOMAINS	For the type I cGMP-dependent protein kinases (cGKI alpha and cGKI beta), a high affinity interaction exists between the C2 amino group of cGMP and the hydroxyl side chain of a threonine conserved in most cGMP binding sites. To examine the effect of this interaction on ligand binding and kinase activation in the type II isozyme of cGMP-dependent protein kinase (cGKII), alanine was substituted for the conserved threonine or serine. cGKII was found to require the C2 amino group of cGMP and its cognate serine or threonine hydroxyl for efficient cGMP activation. Of the two binding sites, disruption of cGMP-specific binding in the NH2-terminal binding site had the greatest effect on cGMP-dependent kinase activation, like cGKI. However, ligand dissociation studies showed that the location of the rapid and slow dissociation sites of cGKII was reversed relative to cGKI, Another set of mutations that prevented cyclic nucleotide binding demonstrated the necessity of the NH2-terminal, rapid dissociation binding site for cyclic nucleotide-dependent activation of cGKII. These findings suggest distinct mechanisms of activation for cGKII and cGKI isoforms, Because cGKII mediates the effects of heat-stable enterotoxins via the cystic fibrosis transmembrane regulator Cl- channel, these findings define a structural target for drug design.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA; Univ Michigan, Grad Program Neurosci, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Uhler, MD (corresponding author), Univ Michigan, Dept Biol Chem, Neurosci Labs Bldg,1103 E Huron St, Ann Arbor, MI 48104 USA.	muhler@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050791] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50791] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DMACKENZIE CW, 1981, INT J BIOCHEM, V13, P273; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOUGE G, 1990, J BIOL CHEM, V265, P19507; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1988, J BIOL CHEM, V263, P17397; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RANNELS SR, 1981, J BIOL CHEM, V256, P7871; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; Reed RB, 1997, ADV SEC MESS PHOSPH, V31, P205; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816; Wagner C, 1998, J CLIN INVEST, V102, P1576, DOI 10.1172/JCI4044; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	58	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28053	28062						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864932				2022-12-25	WOS:000089197100071
J	Hoare, SRJ; Clark, JA; Usdin, TB				Hoare, SRJ; Clark, JA; Usdin, TB			Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor - N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; TRANSMEMBRANE RESIDUES; EXTRACELLULAR LOOP; CHIMERIC RECEPTORS; AMINO-TERMINUS; AGONIST; LIGAND; ACTIVATION; CALCITONIN; EXPRESSION	Tuberoinfundibular peptide of 39 residues (TIP39) and the parathyroid hormone-a (PTH2) receptor form part of an extended family of related signaling molecules that includes the PTH1 receptor, which responds to PTH and PTH-related protein. TIP39 does not appreciably activate the PTH1 receptor, but in this study it is shown to bind the receptor with moderate affinity (59 nM), In this study, we investigated the molecular determinants of both ligand and receptor for the PTH2 receptor selectivity of TIP39 and quantitatively evaluated the role of molecular elements in the binding of TIP39 to the PTH2 and PTH1 receptors, A chimeric receptor composed of the N-terminal extracellular domain of the PTH1 receptor and the remainder (juxtamembrane domain) of the PTH2 receptor (P2-NP1) was fully activated by TIP39 (E-max = 98% of the rPTH-(1-34), E-max, EC50 = 2.0 nnr). This receptor chimera bound TIP39 with an equivalent affinity to the wild-type PTH2 receptor (2.3 and 2.0 nM, respectively). The reciprocal chimeric receptor (P1-NP2) was not activated by TIP39 and bound the ligand with an affinity equivalent to that of the PTH1 receptor. Thus, the juxtamembrane receptor domain specifies the signaling and binding selectivity of TIP39 for the PTH2 receptor over the PTH1 receptor. Removing six N-terminal residues of TIP39 eliminated activation of the PTH2 receptor and reduced binding affinity 70-fold. In contrast, this truncation increased affinity for the PTH1 receptor 10-fold, reversing the PTH2/PTH1 receptor binding selectivity and resulting in a high affinity interaction of TIP-(7-39) with the PTH1 receptor (6 mM), These findings can be explained by a strong interaction between the N-terminal region of TIP39 and the juxtamembrane domain of the PTH2 receptor, with the corresponding domain of the PTH1 receptor acting as a selectivity barrier against high affinity binding of TIP39, As a result, TIP-(7-39) is a highly potent, selective antagonist for the PTH1 receptor.	NIMH, Cell Biol Unit, Genet Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Usdin, TB (corresponding author), NIH, Rm 3D06,Bldg 36,36 Convent Dr MSC4094, Bethesda, MD 20892 USA.		Hoare, Sam/J-9018-2019; Clark, Janet/P-4896-2018		NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002685, ZIAMH002685] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; DELEAN A, 1979, MOL PHARMACOL, V15, P60; ENGLAND RD, 1983, BIOCHEMISTRY-US, V22, P1722, DOI 10.1021/bi00276a031; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hoare SRJ, 1999, ENDOCRINOLOGY, V140, P4419, DOI 10.1210/en.140.10.4419; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; Hoare SRJ, 1999, J PHARMACOL TOXICOL, V41, P83, DOI 10.1016/S1056-8719(99)00024-6; Hoare SRJ, 2000, J BONE MINER RES, V15, P605, DOI 10.1359/jbmr.2000.15.3.605; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KUKREJA SC, 1994, ENDOCRINOLOGY, V134, P2184, DOI 10.1210/en.134.5.2184; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARTIN TJ, 1995, WILLIAMS TXB ENDOCRI, P967; Piserchio A, 2000, J BIOL CHEM, V275, P27284; POTTS JT, 1995, WILLIAMS TXB ENDOCRI, P920; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Rosen HN, 1997, CALCIFIED TISSUE INT, V61, P455, DOI 10.1007/s002239900367; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724; Usdin TB, 1999, ENDOCRINOLOGY, V140, P3363, DOI 10.1210/en.140.7.3363; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455	41	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27274	27283						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854439				2022-12-25	WOS:000089144800081
J	Huang, HK; Joazeiro, CAP; Bonfoco, E; Kamada, S; Leverson, JD; Hunter, T				Huang, HK; Joazeiro, CAP; Bonfoco, E; Kamada, S; Leverson, JD; Hunter, T			The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIAP; SYSTEM; DOMAIN; MOTIF	The inhibitor of apoptosis, cIAP2, contains a putative Ring finger motif at the C terminus. Using in vitro ubiquitination assays, we found that the Ring finger of cIAP2 alone possesses intrinsic ubiquitin ligase activity and promotes substrate-independent ubiquitination. It also promotes ubiquitination of caspases 3 and 7 but not caspase-1. The Ring fingers of c-Cbl and Apc11 failed to promote caspase-7 ubiquitination, suggesting that the Ring finger of cIAP2 itself is involved in substrate recognition.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu			NATIONAL CANCER INSTITUTE [R01CA082683, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA82683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DEVERAUX QL, 1998, EMBO J, V17, P2215, DOI DOI 10.1093/EMBOJ/17.8.2215; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Ravi R, 2000, GENE DEV, V14, P34; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	37	289	295	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26661	26664						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862606				2022-12-25	WOS:000089144800001
J	Legate, KR; Falcone, D; Andrews, DW				Legate, KR; Falcone, D; Andrews, DW			Nucleotide-dependent binding of the GTPase domain of the signal recognition particle receptor beta-subunit to the alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ELONGATION-FACTOR-TU; H-RAS P21; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; MECHANISM; FTSY; SEQUENCES; INTEGRATION	The signal recognition particle (SRP) receptor (SR) is a heterodimer of two polypeptides (SR alpha and SR beta) that each contain a GTP-binding. domain. The GTP-binding domain in the peripheral membrane SR alpha subunit has a well defined role in regulating targeting of SRP-ribosome-nascent chain complexes to the translocon. The only well established function for the transmembrane SRP subunit is anchoring SR alpha On the endoplasmic reticulum membrane. Deletion of the amino-terminal transmembrane domain of SRP did not affect receptor dimerization, but revealed a cryptic translocation signal that overlaps the GTPase domain. We demonstrate that the domain of SRa that binds SRP does so by binding directly to the nucleotide-bound form of the GTPase domain of SR beta. An SR beta mutant containing an amino acid substitution that allows the GTPase domain to bind XTP dimerized with SRa most efficiently in the presence of XTP or XDP, but not ATP. Our results suggest an additional level of regulation of SRP receptor function based on regulated dissociation of the receptor subunits.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Legate, Kyle/0000-0003-3243-579X; Andrews, David/0000-0002-9266-7157				ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; Falcone D, 1999, J BIOL CHEM, V274, P33661, DOI 10.1074/jbc.274.47.33661; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; Hughes MJG, 1996, BIOTECHNIQUES, V20, P188; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Millman JS, 1999, J BIOL CHEM, V274, P33227, DOI 10.1074/jbc.274.47.33227; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; Young JC, 1996, EMBO J, V15, P172, DOI 10.1002/j.1460-2075.1996.tb00345.x; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	36	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27439	27446						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859309				2022-12-25	WOS:000089144800102
J	Lemaire, M; Collart, MA				Lemaire, M; Collart, MA			The TATA-binding protein-associated factor yTaf(II)19p functionally interacts with components of the global transcriptional regulator Ccr4-not complex and physically interacts with the NOT5 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TAF(II)-CONTAINING COMPLEX; NUCLEOSOME ACETYLATION; DIFFERENTIALLY AFFECTS; HISTONE ACETYLASE; YEAST; GENE; ELEMENT; TAFS	The Saccharomyces cerevisiae HIS3 gene is a model system to characterize transcription initiation from different types of core promoters. The NOT genes were identified by mutations that preferentially increased transcription of the HIS3 promoter lacking a canonical TATA sequence. They encode proteins associated in a complex that also contains the Caf1 and Ccr4 proteins. It has been suggested that the Ccr4-Not complex represses transcription by inhibiting factors more specifically required for promoters lacking a TATA sequence. A potential target is the yTaf(11)19 subunit of TFIID, which, when depleted, leads to a preferential decrease of HIS3 TATA-less transcription. We isolated conditional taf19 alleles that display synthetic growth phenotypes when combined with not4 or specific not5 alleles. Inactivation of yTaf(11)19p by shifting these mutants to the restrictive temperature led to a more rapid and striking decrease in transcription from promoters that do not contain a canonical TATA sequence. We demonstrated by the two-hybrid assay and directly in vitro that yTaf(11)19p and Not5p could interact. Finally, we found by the two-hybrid assay that yTaf(11)19p also interacted with many components of the Ccr4 Not complex, Taken together, our results provide evidence that interactions between Not5p and yTaf(11)19p may be involved in transcriptional regulation by the Ccr4-Not complex.	Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Collart, MA (corresponding author), Ctr Med Univ Geneva, Dept Biochim Med, 1 Rue Michel St, CH-1211 Geneva 4, Switzerland.							Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; Collart MA, 1996, MOL CELL BIOL, V16, P6668; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; POON D, 1994, J BIOL CHEM, V269, P23135; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26925	26934						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864925				2022-12-25	WOS:000089144800036
J	Taggart, C; Cervantes-Laurean, D; Kim, G; McElvaney, NG; Wehr, N; Moss, J; Levine, RL				Taggart, C; Cervantes-Laurean, D; Kim, G; McElvaney, NG; Wehr, N; Moss, J; Levine, RL			Oxidation of either methionine 351 or methionine 358 in alpha(1)-antitrypsin causes loss of anti-neutrophil elastase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CYSTIC-FIBROSIS; SERINE PROTEINASES; ESCHERICHIA-COLI; REACTIVE-CENTER; ALPHA-1-ANTITRYPSIN; EMPHYSEMA; RESIDUES; DEFICIENCY; INACTIVATION	Hydrogen peroxide is a component of cigarette smoke known to be essential for inactivation of alpha(1)-antitrypsin, the primary inhibitor of neutrophil elastase, To establish the molecular basis of the inactivation of alpha(1)-antitrypsin, we determined the sites oxidized by hydrogen peroxide, Two of the nine methionines were particularly susceptible to oxidation, One was methionine 358, whose oxidation was known to cause loss of antielastase activity. The other, methionine 351, was as susceptible to oxidation as methionine 358, Its oxidation also resulted in loss of anti-elastase activity, an effect not previously recognized, The equal susceptibility of methionine 358 and methionine 351 to oxidation was confirmed by mass spectrometry. To verify this finding, we produced recombinant alpha(1)-antitrypsins in which one or both of the susceptible methionines were mutated to valine, M351V and M358V were not as rapidly inactivated as wild-type alpha 1-antitrypsin, but only the double mutant M351V/M358V was markedly resistant to oxidative inactivation. We suggest that inactivation of alpha(1)-antitrypsin by oxidation of either methionine 351 or 358 provides a mechanism for regulation of its activity at sites of inflammation.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Royal Coll Surgeons Ireland, Div Pulm, Dublin 9, Ireland; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 106,MSC 0320, Bethesda, MD 20892 USA.	rlevine@nih.gov	Taggart, Clifford C/G-4492-2014; McElvaney, Noel/A-6809-2010; Levine, Rodney L/D-9885-2011	mcelvaney, Noel/0000-0002-0152-4370; Taggart, Clifford/0000-0002-9930-2978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225, Z01HL000225] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPER CA, 1980, CLIN IMMUNOL IMMUNOP, V16, P84, DOI 10.1016/0090-1229(80)90169-5; APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; APFFEL A, 1994, PROTEIN SCI, V3, P99; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTLY ML, 1991, CHEST, V100, P703, DOI 10.1378/chest.100.3.703; BRAUN J, 1994, EUR RESPIR J, V7, P127, DOI 10.1183/09031936.94.07010127; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CARP H, 1983, AM REV RESPIR DIS, V127, P301; COURTNEY M, 1985, NATURE, V313, P149, DOI 10.1038/313149a0; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; EVANS MD, 1991, CHEM-BIOL INTERACT, V79, P151, DOI 10.1016/0009-2797(91)90079-M; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GADEK JE, 1983, METABOLIC BASIS INHE, P1450; GONIAS SL, 1988, J BIOL CHEM, V263, P393; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALL PK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P325, DOI 10.1016/0167-4838(92)90164-9; JANOFF A, 1977, AM REV RESPIR DIS, V116, P65; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; Luisetti M, 1996, CHEST, V110, pS278, DOI 10.1378/chest.110.6_Supplement.278S; MAIER KL, 1989, FEBS LETT, V250, P221, DOI 10.1016/0014-5793(89)80725-2; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P331, DOI 10.1021/bi00505a016; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; McElvaney NG, 1997, LUNG SCI FDN, P2205; MCELVANEY NG, 1996, AM J RESP CRIT CARE, V153, P737; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; REDDY VY, 1994, J BIOL CHEM, V269, P4683; ROSENBERG S, 1984, NATURE, V312, P77, DOI 10.1038/312077a0; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; STONE PJ, 1983, CLIN CHEST MED, V4, P405; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	53	253	265	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27258	27265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867014				2022-12-25	WOS:000089144800079
J	Antes, TJ; Goodart, SA; Huynh, C; Sullivan, M; Young, SG; Levy-Wilson, B				Antes, TJ; Goodart, SA; Huynh, C; Sullivan, M; Young, SG; Levy-Wilson, B			Identification and characterization of a 315-base pair enhancer, located more than 55 kilobases 5 ' of the apolipoprotein B gene, that confers expression in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ARTIFICIAL CHROMOSOMES; NUCLEASE-HYPERSENSITIVE SITES; HORMONE FUSION GENES; TRANSGENIC MICE; TRANSCRIPTION FACTORS; 2ND-INTRON ENHANCER; PROMOTER; ELEMENTS; PROTEINS; FAMILY	We recently reported that an 8-kilobase (kb) region, spanning from -54 to -62 kb 5' of the human apolipoprotein B (apoB) gene, contains intestine-specific regulatory elements that control apoB expression in the intestines of transgenic mice. In this study, we further localized the apoB intestinal control region to a 3-kb segment (-54 to -57 kb). DNaseI hypersensitivity studies uncovered a prominent DNaseI hypersensitivity site, located within a 315-base pair (bp) fragment at the 5'-end of the 3-kb segment, in transcriptionally active CaCo-2 cells but not in transcriptionally inactive HeLa cells. Transient transfection experiments with CaCo-2 and HepG2 cells indicated that the 315-bp fragment contained an intestine-specific enhancer, and analysis of the DNA sequence revealed putative binding sites for the tissue-specific transcription factors hepatocyte nuclear factor 3 beta, hepatocyte nuclear factor 4, and CAAT enhancer-binding protein beta. Binding of these factors to the 315-bp enhancer was demonstrated in gel retardation experiments. Transfection of deletion mutants of the 315-bp enhancer revealed the relative contributions of these transcription factors in the activity of the apoB intestinal enhancer. The corresponding segment of the mouse apoB gene (located -40 to -83 kb 5' of the structural gene) exhibited a high degree of sequence conservation in the binding sites for the key transcriptional activators and also exhibited enhancer activity in transient transfection assays with CaCo-2 cells. In transgenic mouse expression studies, the 315-bp enhancer conferred intestinal expression to human apoB transgenes.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Stanford Univ, Dept Med, Div Gastroenterol, Stanford, CA 94303 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Palo Alto Medical Foundation Research Institute; Stanford University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Young, SG (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.			Young, Stephen/0000-0001-7270-3176; Antes, Travis/0000-0002-2294-8797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHEN SH, 1990, J BIOL CHEM, V265, P6811; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fraser P, 1998, Curr Opin Hematol, V5, P139; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LEVYWILSON B, 1992, J BIOL CHEM, V267, P18735; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; MCCORMICK SPA, 1997, TRANSGENIC ANIMALS G, P273; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Namciu SJ, 1998, MOL CELL BIOL, V18, P2382, DOI 10.1128/MCB.18.4.2382; Nielsen LB, 1998, J BIOL CHEM, V273, P21800, DOI 10.1074/jbc.273.34.21800; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; Oesterreicher TJ, 1998, BIOCHEM J, V330, P1165; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU GD, 1994, J BIOL CHEM, V269, P17080; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	49	20	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26637	26648		10.1074/jbc.M003025200	http://dx.doi.org/10.1074/jbc.M003025200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859308	hybrid			2022-12-25	WOS:000088999700103
J	Guo, YJ; Higazi, AA; Arakelian, A; Sachais, BS; Cines, D; Goldfarb, RH; Jones, TR; Kwaan, H; Mazar, AP; Rabbani, SA				Guo, YJ; Higazi, AA; Arakelian, A; Sachais, BS; Cines, D; Goldfarb, RH; Jones, TR; Kwaan, H; Mazar, AP; Rabbani, SA			A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo	FASEB JOURNAL			English	Article						apoptosis; breast cancer; endothelial cell; tumor necrosis	BOUND REACTANTS; GROWTH-FACTOR; RECEPTOR; SYSTEM; METASTASIS; EXPRESSION; INVASION; CANCER; CARCINOMA; COMPLEXES	Urokinase plasminogen activator (uPA) plays an important role in the progression of several malignancies including breast cancer. We have identified a noncompetitive antagonist of the uPA-uPAR interaction derived from a nonreceptor binding region of uPA (amino acids 136-143). This 8-mer capped peptide (Angstrom 6) inhibited breast cancer cell invasion and endothelial cell migration in a dose-dependent manner in vitro without altering cell doubling time. Intraperitoneal administration of Angstrom 6 resulted in a significant inhibition of tumor growth and suppressed the development of lymph node metastases in several models of breast cancer cell growth and metastasis, Large areas of tumor necrosis and extensive positive staining by TUNEL were observed on histological and inmunohistochemical analysis of experimental tumor sections from Angstrom 6-treated animals.;is treatment also resulted in a decrease in factor VIII-positive tumor microvessel hot-spots. These results identify a new epitope in uPA that is involved in the uPA-uPAR interaction and indicate that an antagonist based on this epitope is able to inhibit tumor progression by modulating the tumor microenvironment in the absence of direct cytotoxic effects in vivo.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Hadassah Med Sch, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Angstrom Pharmaceut Inst, Dept Biol, San Diego, CA 92121 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Univ N Texas, Inst Canc Res, Ft Worth, TX 76107 USA	McGill University; McGill University; McGill University; Royal Victoria Hospital; University of Pennsylvania; Hebrew University of Jerusalem; University of North Texas System; University of North Texas Health Science Center; Northwestern University; University of North Texas System; University of North Texas Health Science Center	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Room H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Sachais, Bruce/D-1236-2009	rabbani, shafaat/0000-0001-5594-3899	NHLBI NIH HHS [T32 HL007775, HL60169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169, T32HL007775] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Choi HJ, 1998, ONCOLOGY-BASEL, V55, P575, DOI 10.1159/000011915; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Franco P, 1998, J BIOL CHEM, V273, P27734, DOI 10.1074/jbc.273.42.27734; FRANCO P, 1997, J CELL BIOL, V137, P777; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; LIU DF, 1995, PROSTATE, V27, P269, DOI 10.1002/pros.2990270506; Mandriota SJ, 1997, J CELL SCI, V110, P2293; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Min HY, 1996, CANCER RES, V56, P2428; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PYKE C, 1993, CANCER RES, V53, P1911; QUATTRONE A, 1995, CANCER RES, V55, P90; Rabbani SA, 1997, J CELL PHYSIOL, V172, P137, DOI 10.1002/(SICI)1097-4652(199708)172:2<137::AID-JCP1>3.0.CO;2-P; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tozer GM, 1999, CANCER RES, V59, P1626; YAMAMOTO M, 1994, CANCER RES, V54, P5016	33	127	143	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1400	1410		10.1096/fj.14.10.1400	http://dx.doi.org/10.1096/fj.14.10.1400			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877833				2022-12-25	WOS:000087932200015
J	Krebitz, M; Wiedermann, U; Essl, D; Steinkellner, H; Wagner, B; Turpen, TH; Ebner, C; Scheiner, O; Breiteneder, H				Krebitz, M; Wiedermann, U; Essl, D; Steinkellner, H; Wagner, B; Turpen, TH; Ebner, C; Scheiner, O; Breiteneder, H			Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization	FASEB JOURNAL			English	Article						plant expression system; tobacco mosaic virus; recombinant allergen; BALB/c; Th2 response	YEAST PICHIA-PASTORIS; HIGH-LEVEL EXPRESSION; TOBACCO MOSAIC-VIRUS; T-CELL EPITOPES; MURINE MODEL; RECOMBINANT ALLERGENS; OVERLAPPING PEPTIDES; TRANSGENIC PLANTS; IMMUNE-RESPONSE; CDNA CLONING	Type I allergies are immunological disorders that afflict a quarter of the world's population. Improved diagnosis of allergic diseases and the formulation of new therapeutic approaches are based on the use of recombinant allergens. We describe here for the first time the application of a rapid plant-based expression system for a plant-derived allergen and its immunological characterization. We expressed our model allergen Bet v 1, the major birch pollen allergen, in the tobacco-related species Nicotiana benthamiana using a tobacco mosaic virus vector. Two weeks postinoculation, plants infected with recombinant viral RNA containing the Bet v 1 coding sequence accumulated the allergen to levels of 200 mu g/g leaf material. Total nonpurified protein extracts from plants were used for immunological characterizations. IgE immunoblots and ELISA (enzyme-linked immunoassay) inhibition assays showed comparable IgE binding properties for tobacco recombinant (r) Bet v 1 and natural (n) Bet v 1, suggesting that the B cell epitopes were preserved when the allergen was expressed in N. benthamiana plants. Using a murine model of type I allergy, mice immunized with crude leaf extracts containing Bet v 1 with purified rBet v 1 produced in Il: coli or with birch pollen extract generated comparable allergen-specific IgE and IgG1 antibody responses and positive type I skin test reactions. These results demonstrate that nonpurified Bet v 1 overexpressed in N. benthamina has the same immunogenicity as purified Bet v 1 produced in E. coli or nBet v 1. We therefore conclude that this plant expression system offers a viable alternative to fermentation-based production of allergens in bacteria or yeasts. In addition, there may be a broad utility of this system for the development of new and low-cost vaccination strategies against allergy.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Large Scale Biol Corp, Vacaville, CA 95699 USA; Univ Agr Sci, Ctr Appl Genet, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Breiteneder, H (corresponding author), Univ Vienna, Dept Pathophysiol, AKH EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Steinkellner, Herta/N-4267-2016	Steinkellner, Herta/0000-0003-4823-1505; Wiedermann, Ursula/0000-0002-1302-3223				Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Casper SJ, 1996, GENE, V173, P69, DOI 10.1016/0378-1119(95)00782-2; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P45, DOI 10.1046/j.1365-2222.1998.00164.x; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; HoffmannSommergruber K, 1997, GENE, V197, P91, DOI 10.1016/S0378-1119(97)00246-1; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Koo M, 1999, P NATL ACAD SCI USA, V96, P7774, DOI 10.1073/pnas.96.14.7774; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; Kraft D, 1998, ALLERGY, V53, P62, DOI 10.1111/j.1398-9995.1998.tb04942.x; KUMAGAI MH, 1993, P NATL ACAD SCI USA, V90, P427, DOI 10.1073/pnas.90.2.427; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; McCormick AA, 1999, P NATL ACAD SCI USA, V96, P703, DOI 10.1073/pnas.96.2.703; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Wiedermann U, 1999, INT IMMUNOL, V11, P1131, DOI 10.1093/intimm/11.7.1131; Yasue M, 1997, CELL IMMUNOL, V181, P30, DOI 10.1006/cimm.1997.1184	41	40	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1279	1288		10.1096/fj.14.10.1279	http://dx.doi.org/10.1096/fj.14.10.1279			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877820				2022-12-25	WOS:000087932200002
J	de Chaves, EIP; Vance, DE; Campenot, RB; Kiss, RS; Vance, JE				de Chaves, EIP; Vance, DE; Campenot, RB; Kiss, RS; Vance, JE			Uptake of lipoproteins for axonal growth of sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RECEPTOR-RELATED PROTEIN; RAT SCIATIC-NERVE; SCAVENGER RECEPTOR; PERIPHERAL-NERVE; CHOLESTEROL TRANSPORT; CEREBROSPINAL-FLUID; CELLULAR CHOLESTEROL; MEDIATED ENDOCYTOSIS	Lipoproteins originating from axon and myelin breakdown in injured peripheral nerves are believed to supply cholesterol to regenerating axons. We have used compartmented cultures of rat sympathetic neurons to investigate the utilization of lipids from lipoproteins for axon elongation. Lipids and proteins from human low density lipoproteins (LDL) and high density lipoproteins (HDL) were taken up by distal axons and transported to cell bodies, whereas cell bodies/proximal axons internalized these components from only LDL, not HDL. Consistent with these observations, the impairment of axonal growth, induced by inhibition of cholesterol synthesis, was reversed when LDL or HDL were added to distal axons or when LDL, but not HDL, were added to cell bodies. LDL receptors (LDLRs) and LR7/8B (apoER2) were present in cell bodies/proximal axons and distal axons, with LDLRs being more abundant in the former. Inhibition of cholesterol biosynthesis increased LDLR expression in cell bodies/proximal axons but not distal axons. LR11 (SorLA) was restricted to cell bodies/proximal axons and was undetectable in distal axons, Neither the LDL receptor-related protein nor the HDL receptor, SR-B1, was detected in sympathetic neurons. These studies demonstrate for the first time that lipids are taken up from lipoproteins by sympathetic neurons for use in axonal regeneration.	Univ Alberta, Fac Med, Dept Med, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Fac Med, Dept Med, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BLUE ML, 1982, J BIOL CHEM, V257, P1151; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BU GJ, 1994, J BIOL CHEM, V269, P18521; Campenot R B, 1979, Methods Enzymol, V58, P302; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; Charest MC, 1999, EUR J BIOCHEM, V263, P402, DOI 10.1046/j.1432-1327.1999.00527.x; CHIBA H, 1991, NEUROSCI LETT, V133, P207, DOI 10.1016/0304-3940(91)90571-A; CIDARREGUI A, 1995, J NEUROSCI, V15, P4259; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Garcia A, 1996, BIOCHEMISTRY-US, V35, P13064, DOI 10.1021/bi952223l; GOODRUM JF, 1993, J NEUROCHEM, V60, P1564, DOI 10.1111/j.1471-4159.1993.tb03322.x; GOODRUM JF, 1991, J NEUROCHEM, V56, P2082, DOI 10.1111/j.1471-4159.1991.tb03469.x; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; GREEN SR, 1991, J LIPID RES, V32, P667; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HARA H, 1991, J BIOL CHEM, V266, P3080; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hermo L, 1999, MOL REPROD DEV, V53, P282, DOI 10.1002/(SICI)1098-2795(199907)53:3&lt;282::AID-MRD4&gt;3.0.CO;2-A; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; Jareb M, 1997, J NEUROSCI, V17, P8955; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics H, 1998, NEUROCHEM RES, V23, P401, DOI 10.1023/A:1022469803426; JUREVICS HA, 1994, J LIPID RES, V35, P112; Jurevics HA, 1997, J LIPID RES, V38, P723; Kanaki T, 1998, DNA CELL BIOL, V17, P647, DOI 10.1089/dna.1998.17.647; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Klinger A, 1997, BBA-LIPID LIPID MET, V1345, P65, DOI 10.1016/S0005-2760(96)00164-6; Kounnas M Z, 1994, In Vivo, V8, P343; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; LAMONFAVA S, 1992, J LIPID RES, V33, P831; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; LEBLANC AC, 1989, J CELL BIOL, V109, P1245, DOI 10.1083/jcb.109.3.1245; Lemieux MJ, 1995, NEUROCHEM RES, V20, P1239; LI CX, 1991, J BIOL CHEM, V266, P9263; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Morwald S, 1997, ARTERIOSCL THROM VAS, V17, P996, DOI 10.1161/01.ATV.17.5.996; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; Narita M, 1997, J NEUROCHEM, V68, P587; Ness GC, 1997, AM J MED GENET, V68, P294, DOI 10.1002/(SICI)1096-8628(19970131)68:3<294::AID-AJMG9>3.0.CO;2-M; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITTMAN RC, 1984, J LIPID RES, V25, P1577; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; REYNOLDS GD, 1985, AM J PATHOL, V121, P200; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROTHE T, 1991, J NEUROCHEM, V57, P2016, DOI 10.1111/j.1471-4159.1991.tb06417.x; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turley SD, 1996, J LIPID RES, V37, P1953; VANCE JE, 1994, J NEUROCHEM, V62, P329; WOLF BB, 1992, AM J PATHOL, V141, P37; Xu SZ, 1997, J LIPID RES, V38, P1289; Yamamoto M, 1998, Brain Tumor Pathol, V15, P23, DOI 10.1007/BF02482097; Yamauchi K, 1999, CLIN CHEM, V45, P1431; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	87	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19883	19890		10.1074/jbc.275.26.19883	http://dx.doi.org/10.1074/jbc.275.26.19883			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867025				2022-12-25	WOS:000087941300062
J	Cunningham, O; Dunne, A; Sabido, P; Lightner, D; Mantle, TJ				Cunningham, O; Dunne, A; Sabido, P; Lightner, D; Mantle, TJ			Studies on the specificity of the tetrapyrrole substrate for human biliverdin-IX alpha reductase and biliverdin-IX beta reductase - Structure-activity relationships define models for both active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESOBILIRUBIN-XIII-ALPHA; FLAVIN REDUCTASE; BILIRUBIN ANALOGS; LEISHMANIA-MAJOR; HEME OXYGENASE; BILE-PIGMENTS; C57BL/6 MICE; IFN-GAMMA; CELLS; STEREOCHEMISTRY	comparison of the initial rate kinetics for human biliverdin-IX alpha reductase and biliverdin-IX beta reductase with a series of synthetic biliverdins with propionate side chains "moving" from a bridging position across the central methene bridge (alpha isomers) to a "gamma-configuration" reveals characteristic behavior that allows us to propose distinct models for the two active sites. For human biliverdin-IX alpha reductase, as previously discussed for the rat and ox enzymes, it appears that at least one "bridging propionate" is necessary for optimal binding and catalytic activity, whereas two are preferred. All other configurations studied were substrates for human biliverdin-IX alpha reductase, albeit poor ones. In the case of mesobiliverdin-XIIII alpha, extending the propionate side chains to hexanoate resulted in a significant loss of activity, whereas the butyrate derivative retained high activity. For human biliverdin-IX alpha reductase, we suggest that a pair of positively charged side chains play a key role in optimally binding the IX alpha isomers. In the case of human biliverdin-IX beta reductase, the enzyme cannot tolerate even one propionate in the bridging position, suggesting that two negatively charged residues on the enzyme surface may preclude productive binding in this case. The flavin reductase activity of biliverdin-IX beta reductase is potently inhibited by mesobiliverdin-XIII alpha and protohemin, which is consistent with the hypothesis that the tetrapyrrole and flavin substrate bind at a common site.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Nevada, Dept Chem, Reno, NV 89557 USA; Univ Nevada, Dept Biochem, Reno, NV 89557 USA	Trinity College Dublin; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Dunne, A (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.			dunne, aisling/0000-0002-2342-9518				Boiadjiev SE, 1998, J ORG CHEM, V63, P6220, DOI 10.1021/jo980740e; Boiadjiev SE, 1997, TETRAHEDRON, V53, P14547, DOI 10.1016/S0040-4020(97)01066-1; BOIADJIEV SE, 1995, TETRAHEDRON, V51, P10663, DOI 10.1016/0040-4020(95)00658-U; Chuniaud L, 1996, CLIN CHIM ACTA, V256, P103, DOI 10.1016/S0009-8981(96)06407-8; COLLERAN E, 1977, DEP HLTH ED WELFARE; Cunningham O, 2000, BIOCHEM J, V345, P393, DOI 10.1042/0264-6021:3450393; CUNNINGHAM O, 1997, BIOCH SOC T S, V25, P613; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Ennis O, 1997, BIOCHEM J, V328, P33, DOI 10.1042/bj3280033; HEALTPAGLIUSO S, 1998, BIOCHEMISTRY-US, V37, P11508; HOLMES DL, 1995, J HETEROCYCLIC CHEM, V32, P113, DOI 10.1002/jhet.5570320120; Hunt SC, 1996, ARTERIOSCL THROM VAS, V16, P912, DOI 10.1161/01.ATV.16.8.912; IGARASHI T, 1991, J BIOCHEM-TOKYO, V109, P3, DOI 10.1093/oxfordjournals.jbchem.a123346; Kar AK, 1998, TETRAHEDRON-ASYMMETR, V9, P3863, DOI 10.1016/S0957-4166(98)00400-5; KAR AK, 1998, THESIS U NEVADA RENO; Krishnan L, 1996, J IMMUNOL, V156, P644; Krishnan L, 1996, J IMMUNOL, V156, P653; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MORI H, 1991, JPN J CANCER RES, V82, P755, DOI 10.1111/j.1349-7006.1991.tb02698.x; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; Ocarra P., 1970, BIOCHEM J, V119, p42P; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; PHILLIPS O, 1981, Biochemical Society Transactions, V9, P275; PHILLIPS O, 1981, THESIS U DUBLIN TRIN; Pitkanen OM, 1998, ANN MED, V30, P134, DOI 10.3109/07853899808999396; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; RIGNEY E, 1988, BIOCHIM BIOPHYS ACTA, V957, P237, DOI 10.1016/0167-4838(88)90278-6; RIGNEY EM, 1988, BIOCHEM J, V255, P431, DOI 10.1042/bj2550431; SABIDO PM, 1997, THESIS U NEVADA RENO; Sambrook J., 1989, MOL CLONING, pA1; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Shalloe F, 1996, BIOCHEM J, V316, P385, DOI 10.1042/bj3160385; SHROUT DP, 1992, SYNTHESIS-STUTTGART, P328; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; STOKER R, 1987, SCIENCE, V235, P1043; STOKER R, 1987, P NATL ACAD SCI USA, V84, P5918; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; TRULL FR, 1987, J HETEROCYCLIC CHEM, V24, P1573, DOI 10.1002/jhet.5570240614; WALKER PC, 1987, CLIN PHARMACOKINET, V13, P26, DOI 10.2165/00003088-198713010-00002; XU F, 1992, P NATL ACAD SCI USA, V89, P2130, DOI 10.1073/pnas.89.6.2130; XU F, 1993, BIOCHEM BIOPH RES CO, V193, P434, DOI 10.1006/bbrc.1993.1642; YAMAGUCHI T, 1994, J BIOL CHEM, V269, P24343; YAMAGUCHI T, 1995, EUR J BIOCHEM, V233, P467, DOI 10.1111/j.1432-1033.1995.467_2.x; YUBISUI T, 1979, J BIOCHEM, V85, P719	48	25	26	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19009	19017		10.1074/jbc.275.25.19009	http://dx.doi.org/10.1074/jbc.275.25.19009			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858451	hybrid			2022-12-25	WOS:000087815900053
J	MacLachlan, TK; Dash, BC; Dicker, DT; El Deiry, WS				MacLachlan, TK; Dash, BC; Dicker, DT; El Deiry, WS			Repression of BRCA1 through a feedback loop involving p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	91st Annual Meeting of the American-Association-for-Cancer-Research	APR 01-05, 2000	SAN FRANCISCO, CA	Amer Assoc Canc Res			DNA-DAMAGE RESPONSE; WILD-TYPE P53; CELL-CYCLE; CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; EXPRESSION; GENE; PHOSPHORYLATION; ASSOCIATION; RADIATION	The BRCA1 and p53 tumor suppressors have been shown to interact and cooperate to activate transcription of p53-responsive genes. In this study, we show that BRCA1 is initially up-regulated, followed by a reduction to below basal levels in response to treatment with the DNA-damaging agents adriamycin and mitomycin C, and that the reduction of BRCA1 expression is dependent on the presence of wild-type p53. Elimination of p53 by expression of human papilloma virus E6 resulted in an inability to down-regulate BRCA1 in response to adriamycin. Ectopic expression of p53 resulted in a rapid decrease in BRCA1 protein and RNA levels and BRCA1 promoter-driven luciferase activity even in null p21 cells deficient in p53-dependent G(1) arrest. ATM(-/-) lymphoblastoid cells were deficient in their ability to reduce BRCA1 protein in response to DNA damage, whereas the wild-type counterparts reduced BRCA1 protein levels after exposure to adriamycin. These results, in conjunction with others, suggest a loop wherein BRCA1 initially participates in accumulation of p53 protein, whereas later p53 acts to reduce BRCA1 expression.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	El Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med, CRB 437A,415 Curie Blvd, Philadelphia, PA 19104 USA.	weldeir@hhmi.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1996, CLIN CANCER RES, V2, P623; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31869	31875		10.1074/jbc.M003338200	http://dx.doi.org/10.1074/jbc.M003338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	363VT	10884389	hybrid			2022-12-25	WOS:000089858900046
J	Dubuisson, J; Duvet, S; Meunier, JC; De Beeck, AO; Cacan, R; Wychowski, C; Cocquerel, L				Dubuisson, J; Duvet, S; Meunier, JC; De Beeck, AO; Cacan, R; Wychowski, C; Cocquerel, L			Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; PRIMARY STRUCTURAL REQUIREMENTS; RECOMBINANT VACCINIA VIRUS; DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; CORE-GLYCOSYLATION; PLASMINOGEN-ACTIVATOR; IMPORTANT DETERMINANT; GLYCOPROTEIN E1; INSECT CELLS	The addition of N-linked oligosaccharides to Asn-X-(Ser/Thr) sites is catalyzed by the oligosaccharyltransferase, an enzyme closely associated with the translocon and generally thought to have access only to nascent chains as they emerge from the ribosome. However, the presence of the sequon does not automatically ensure core glycosylation because many proteins contain sequons that remain either nonglycosylated or glycosylated to a variable extent. In this study, hepatitis C virus (HCV) envelope protein E1 was used as a model to study the efficiency of N-glycosylation. HCV envelope proteins, E1 and E2, were released from a polyprotein precursor after cleavage by host signal peptidase(s). When expressed alone, E1 was not efficiently glycosylated. However, E1 glycosylation was improved when expressed as a polyprotein including full-length or truncated forms of E2. These data indicate that glycosylation of E1 is dependent on the presence of polypeptide sequences located downstream of E1 on HCV polyprotein.	Inst Pasteur, Inst Biol Lille, CNRS, Unite Mixte Rech 8526, F-59021 Lille, France; Univ Sci & Tech Lille Flandres Artois, CNRS, UMR8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UMR8526, Equipe Hepatitis C, 1 Rue Calmette,BP447, F-59021 Lille, France.		Cocquerel, Laurence/P-1951-2016; Dubuisson, Jean/E-6813-2016	Cocquerel, Laurence/0000-0002-2136-5178; Dubuisson, Jean/0000-0003-1626-7693				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BAUSE E, 1982, BIOCHEM J, V203, P761, DOI 10.1042/bj2030761; BAUSE E, 1979, FEBS LETT, V108, P341, DOI 10.1016/0014-5793(79)80559-1; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7042; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; LIVI GP, 1991, J BIOL CHEM, V266, P15348; Marshall R D, 1974, Biochem Soc Symp, P17; MATSUURA Y, 1992, J VIROL, V66, P1425, DOI 10.1128/JVI.66.3.1425-1431.1992; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RICE CM, 1996, FIELDS VIROLOGY, P931; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; [No title captured]	45	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30605	30609		10.1074/jbc.M004326200	http://dx.doi.org/10.1074/jbc.M004326200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882734	hybrid			2022-12-25	WOS:000089577900094
J	Becker, MN; Diamond, G; Verghese, MW; Randell, SH				Becker, MN; Diamond, G; Verghese, MW; Randell, SH			CD14-dependent lipopolysaccharide-induced ss-defensin-2 expression in human tracheobronchial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; HUMAN AIRWAY EPITHELIA; FACTOR-KAPPA-B; BETA-DEFENSIN; GENE-EXPRESSION; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-2; CELL ACTIVATION; FAMILY; HBD-1	The induction of host antimicrobial molecules following binding of pathogen components to pattern recognition receptors such as CD14 and the Toll-like receptors (TLRs) is a key feature of innate immunity. The human airway epithelium is an important environmental interface, but LPS recognition pathways have not been determined. We hypothesized that LPS would trigger beta-defensin (hBD2) mRNA in human tracheobronchial epithelial (hTBE) cells through a CD14-dependent mechanism, ultimately activating NF-kappa B. An average 3-fold increase in hBD2 mRNA occurs 24 h after LPS challenge of hTBE cells. For the first time, we demonstrate the presence of CD14 mRNA and cell surface protein in hTBE cells and show that CD14 neutralization abolishes LPS induction of hBD2 mRNA. Furthermore, we demonstrate TLR mRNA in hTBE cells and NF-kappa B activation following LPS. Thus, LPS induction of hBD2 in hTBE cells requires CD14, which may complex with a TLR to ultimately activate NF-kappa B.	Univ N Carolina, Sch Med, Dept Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anat Cell Biol & Injury Sci, Newark, NJ 07103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Randell, SH (corresponding author), Univ N Carolina, Cyst Fibrosis Ctr, 4006 Thurston Bowles,CB 7248, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL53400] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEARNS C, 1995, J EXP MED, V181, P857, DOI 10.1084/jem.181.3.857; Fraser IP, 1998, SEMIN IMMUNOL, V10, P363, DOI 10.1006/smim.1998.0141; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heine H, 1999, J IMMUNOL, V162, P6971; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; MARCHANT A, 1992, EUR J IMMUNOL, V22, P1663, DOI 10.1002/eji.1830220650; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McNamara NA, 1999, EXP EYE RES, V69, P483, DOI 10.1006/exer.1999.0722; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MEDZHITOV R, 1997, NATURE, V388, P397; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Young RS, 1998, J PHARM PHARMACOL, V50, P11, DOI 10.1111/j.2042-7158.1998.tb03299.x; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	48	259	278	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29731	29736		10.1074/jbc.M000184200	http://dx.doi.org/10.1074/jbc.M000184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882713	Green Published, hybrid			2022-12-25	WOS:000089439800074
J	Arrizubieta, MJ; Polaina, J				Arrizubieta, MJ; Polaina, J			Increased thermal resistance and modification of the catalytic properties of a beta-glucosidase by random mutagenesis and in vitro recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; SITE-DIRECTED MUTAGENESIS; BINDING PROTEIN HU; BACILLUS-POLYMYXA; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; T4 LYSOZYME; ESCHERICHIA-COLI; SULFOLOBUS-SOLFATARICUS; SWISS-MODEL	The bglB gene from Paenibacillus polymyxa was subjected to random mutagenesis mediated by error prone polymerase chain reaction amplification and DNA shuffling. After this treatment, mutant variants of the encoded p-glucosidase with enhanced thermal resistance were selected. We identified five amino acid substitutions at four different positions of the sequence that increased the resistance of the enzyme to heat denaturation, Four of the mutations, H62R, M319V, M319I, and M361I, did not change the kinetic parameters of the enzyme. However, mutant N223Y, which caused only a marginal increase in thermoresistance, showed an 8-fold decrease in K-m. Copies of the bglB gene carrying each one of the individual mutations were recombined in vitro by DNA shuffling. As a result, we obtained an enzyme that simultaneously exhibited a 20-fold increase in heat resistance and an 8-fold increase in the catalytic efficiency. The structural basis of the properties conferred by the mutations was analyzed using homology-based structural models. The four mutations causing a more pronounced effect on thermoresistance were located in loops, on the periphery of the (alpha/beta)(8) barrel that conforms the structure of the protein. Mutation N223Y, which modifies the catalytic properties of the enzyme, was on one of the barrel beta-strands that shape the active center.	CSIC, Inst Agroquim & Tecnol Alimentos, E-46100 Burjassot, Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Polaina, J (corresponding author), CSIC, Inst Agroquim & Tecnol Alimentos, Apdo 73, E-46100 Burjassot, Valencia, Spain.		Polaina, Julio/H-4498-2012	Polaina, Julio/0000-0001-9912-0640				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Akanuma S, 1998, PROTEIN SCI, V7, P698, DOI 10.1002/pro.5560070319; AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; Auerbach G, 1998, STRUCTURE, V6, P769, DOI 10.1016/S0969-2126(98)00078-1; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; ESTELL DA, 1985, J BIOL CHEM, V260, P6518; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Giordano A, 1999, BIOCHEMISTRY-US, V38, P3043, DOI 10.1021/bi982326e; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Gonzalez-Blasco G, 2000, J BIOL CHEM, V275, P13708, DOI 10.1074/jbc.275.18.13708; GONZALEZCANDELAS L, 1989, APPL ENVIRON MICROB, V55, P3173; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gunata Z, 1996, ENZYME MICROB TECH, V18, P286, DOI 10.1016/0141-0229(95)00124-7; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; Kawamura S, 1997, J BIOCHEM-TOKYO, V121, P448; Kawamura S, 1998, J BIOL CHEM, V273, P19982, DOI 10.1074/jbc.273.32.19982; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; LIAO XB, 1990, GENE, V88, P107, DOI 10.1016/0378-1119(90)90066-Z; LOPEZCAMACHO C, 1993, MUTAT RES, V301, P73, DOI 10.1016/0165-7992(93)90027-S; LopezCamacho C, 1996, BIOCHEM J, V314, P833, DOI 10.1042/bj3140833; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Peterson RW, 1999, J MOL BIOL, V286, P1609, DOI 10.1006/jmbi.1999.2574; Sanz-Aparicio J, 1998, PROTEINS, V33, P567, DOI 10.1002/(SICI)1097-0134(19981201)33:4<567::AID-PROT9>3.0.CO;2-U; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; SANZAPARICIO J, 1994, J MOL BIOL, V240, P267, DOI 10.1006/jmbi.1994.1441; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Vieille C, 1996, Biotechnol Annu Rev, V2, P1, DOI 10.1016/S1387-2656(08)70006-1; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511; Yip KSP, 1998, EUR J BIOCHEM, V255, P336, DOI 10.1046/j.1432-1327.1998.2550336.x; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; Zhang XJ, 1995, PROTEIN ENG, V8, P1017, DOI 10.1093/protein/8.10.1017	55	51	62	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28843	28848		10.1074/jbc.M003036200	http://dx.doi.org/10.1074/jbc.M003036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871610	hybrid			2022-12-25	WOS:000089330700067
J	Bertram, JG; Bloom, LB; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF				Bertram, JG; Bloom, LB; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF			Molecular mechanism and energetics of clamp assembly in Escherichia coli - The role of ATP hydrolysis when gamma complex loads beta on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; CHROMOSOMAL REPLICATION MACHINE; ACCESSORY PROTEINS; SLIDING CLAMPS; SUBUNIT; PURIFICATION; PARTICLE; DELTA	Escherichia coli DNA polymerase III holoenzyme is a multisubunit composite containing the beta sliding clamp and clamp loading gamma complex. The gamma complex requires ATP to load beta onto DNA. A two-color fluorescence spectroscopic approach was utilized to study this system, wherein both assembly (red fluorescence; X-rhodamine labeled DNA anisotropy assay) and ATP hydrolysis (green fluorescence; phosphate binding protein assay) were simultaneously measured with millisecond timing resolution. The two temporally correlated stopped-flow signals revealed that a preassembled beta.gamma complex composite rapidly binds primer/template DNA in an ATP hydrolysis independent step. Once bound, two molecules of ATP are rapidly hydrolyzed (similar to 34 s(-1)). Following hydrolysis, gamma complex dissociates from the DNA (similar to 22 s(-1)). Once dissociated, the next cycle of loading is severely compromised, resulting in steady-state ATP hydrolysis rates with a maximum of only similar to 3 s(-1). Two single-site beta dimer interface mutants were examined which had impaired steady-state rates of ATP hydrolysis. The pre-steady-state correlated kinetics of these mutants revealed a pattern essentially identical to wild type. The anisotropy data showed that these mutants decrease the steady-state rates of ATP hydrolysis by causing a buildup of "stuck" binary-ternary complexes on the primer/template DNA.	Univ So Calif, Hedco Mol Biol Lab, Dept Biol Sci & Chem, Los Angeles, CA 90089 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	University of Southern California; State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute; Vanderbilt University	Goodman, MF (corresponding author), Univ So Calif, Dept Sci Biol, Los Angeles, CA 90089 USA.		Bloom, Linda B/F-3684-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839, GM21422, GM55596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; BULT CJ, 1996, SCIENCE, V273, P1017; DONG ZM, 1993, J BIOL CHEM, V268, P11758; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FAY PJ, 1981, J BIOL CHEM, V256, P976; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	29	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28413	28420		10.1074/jbc.M910441199	http://dx.doi.org/10.1074/jbc.M910441199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874049	hybrid			2022-12-25	WOS:000089330700012
J	Segev, DL; Ha, TU; Tran, TT; Kenneally, M; Harkin, P; Jung, M; MacLaughlin, DT; Donahoe, PK; Maheswaran, S				Segev, DL; Ha, TU; Tran, TT; Kenneally, M; Harkin, P; Jung, M; MacLaughlin, DT; Donahoe, PK; Maheswaran, S			Mullerian inhibiting substance inhibits breast cancer cell growth through an NF kappa B-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN OVARIAN-CANCER; FETAL-RAT LUNG; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; SEXUAL DEVELOPMENT; B/REL EXPRESSION; RESPONSE GENE; TUMOR-GROWTH; II RECEPTOR	Mullerian inhibiting substance (MIS), a member of the transforming growth factor-beta superfamily, induces regression of the Mullerian duct in male embryos. In this report, we demonstrate MMS type II receptor expression in normal breast tissue and in human breast cancer cell lines, breast fibroadenoma, and ductal adenocarcinomas. MIS inhibited the growth of both estrogen receptor (ER)-positive T47D and ER-negative MDA-MB-231 breast cancer cell lines, suggesting a broader range of target tissues for MIS action. Inhibition of growth was manifested by an increase in the fraction of cells in the G(1) phase of the cell cycle and induction of apoptosis, Treatment of breast cancer cells with MIS activated the NF kappa B pathway and selectively up-regulated the immediate early gene IEX-1S, which, when overexpressed, inhibited breast cancer cell growth. Dominant negative I kappa B alpha expression ablated both MIS-mediated induction of IEX-1S and inhibition of growth, indicating that activation of the NF kappa B signaling pathway was required for these processes. These results identify the NF kappa B-mediated signaling pathway and a target gene for MIS action and suggest a putative role for the MIS ligand and its downstream interactors in the treatment of ER-positive as well as negative breast cancers.	Massachusetts Gen Hosp, Pediat Surg Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Queens Univ, Dept Oncol, Belfast BT9 7AB, Antrim, North Ireland; Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20057 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Queens University Belfast; Georgetown University	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Lab, WRN1024,55 Fruit St, Boston, MA 02114 USA.				NCI NIH HHS [CA17393] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold SF, 1999, CYTOKINE, V11, P1031, DOI 10.1006/cyto.1999.0508; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; BOVERI JF, 1993, INT J ONCOL, V2, P135; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Catlin EA, 1997, ENDOCRINOLOGY, V138, P790, DOI 10.1210/en.138.2.790; CATLIN EA, 1988, AM J OBSTET GYNECOL, V159, P1299, DOI 10.1016/0002-9378(88)90467-X; CATLIN EA, 1990, AM REV RESPIR DIS, V141, P466, DOI 10.1164/ajrccm/141.2.466; Chen TP, 1998, CANCER RES, V58, P4805; CHIN TW, 1991, CANCER RES, V51, P2101; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11; Di Loreto C, 1999, EUR J ENDOCRINOL, V141, P190, DOI 10.1530/eje.0.1410190; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DONAHOE PK, 1981, ANN SURG, V194, P472, DOI 10.1097/00000658-198110000-00010; DONAHOE PK, 1992, MOL REPROD DEV, V32, P168, DOI 10.1002/mrd.1080320213; FULLER AF, 1985, GYNECOL ONCOL, V22, P135, DOI 10.1016/0090-8258(85)90019-8; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kondratyev AD, 1996, CANCER RES, V56, P1498; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KURIAN MS, 1995, CLIN CANCER RES, V1, P343; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu QY, 1996, CANCER RES, V56, P1155; Loser P, 1998, J VIROL, V72, P180; Masiakos PT, 1999, CLIN CANCER RES, V5, P3488; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; PARRY RL, 1992, CANCER RES, V52, P1182; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1999, ENDOCRINOLOGY, V140, P4732, DOI 10.1210/en.140.10.4732; Teixeira J, 1996, J ANDROL, V17, P336; UENO S, 1988, ENDOCRINOLOGY, V123, P1652, DOI 10.1210/endo-123-3-1652; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217; ZUGMAIER G, 1990, ANN NY ACAD SCI, V593, P272, DOI 10.1111/j.1749-6632.1990.tb16118.x	65	116	127	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28371	28379		10.1074/jbc.M004554200	http://dx.doi.org/10.1074/jbc.M004554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874041	hybrid			2022-12-25	WOS:000089330700007
J	Cozier, GE; Lockyer, PJ; Reynolds, JS; Kupzig, S; Bottomley, JR; Millard, TH; Banting, G; Cullen, PJ				Cozier, GE; Lockyer, PJ; Reynolds, JS; Kupzig, S; Bottomley, JR; Millard, TH; Banting, G; Cullen, PJ			GAP1(IP4BP) contains a novel group I pleckstrin homology domain that directs constitutive plasma membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; 1,3,4,5-TETRAKISPHOSPHATE RECEPTORS GAP1(IP4BP); INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE BINDING; STIMULATED TRANSLOCATION; FUNCTIONAL-ANALYSIS; CA2+ MOBILIZATION; PHOSPHOLIPASE-C	The group I family of pleckstrin homology (PH) domains are characterized by their inherent ability to specifically bind phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and its corresponding inositol headgroup inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4). In vivo this interaction results in the regulated plasma membrane recruitment of cytosolic group I PH domain-containing proteins following agonist-stimulated PtdIns(3,4,5)P-3 production. Among group I PH domain-containing proteins, the Pas GTPase-activating protein GAP1(IP4BP) is unique in being constitutively associated with the plasma membrane. Here we show that, although the GAP1(IP4BP) PH domain interacts with PtdIns(3,4,5)P-3, it also binds, with a comparable affinity, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) (K-d values of 0.5 +/- 0.2 and 0.8 +/- 0.5 mu M, respectively). Intriguingly, whereas this binding site overlaps with that for Ins(1,3,4,5)P-4, consistent with the constitutive plasma membrane association of GAP1(IP4BP) resulting from its PH domain-binding PtdIns(4,5)P-2, we show that in vivo depletion of PtdIns(4,5)P-2, but not PtdIns(3,4,5)P-3, results in dissociation of GAP1(IP4BP) from this membrane. Thus, the Ins(1,3,4,5)P-4-binding PH domain from GAP1(IP4BP) defines a novel class of group I PH domains that constitutively targets the protein to the plasma membrane and may allow GAP1(IP4BP) to be regulated in vivo by Ins(1,3,4,5)P-4 rather than PtdIns(3,4,5)P-3.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	pete.cullen@bristol.ac.uk	Cozier, Gyles/A-5891-2009	Cullen, Peter/0000-0002-9070-8349; Banting, George/0000-0001-8249-1621; Cozier, Gyles/0000-0003-2851-0902				BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, BIOCHEM BIOPH RES CO, V255, P421, DOI 10.1006/bbrc.1999.0217; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; ORourke F, 1996, BIOCHEM J, V315, P1027, DOI 10.1042/bj3151027; Powe AC, 1999, MECH DEVELOP, V81, P89, DOI 10.1016/S0925-4773(98)00230-5; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	45	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28261	28268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869341				2022-12-25	WOS:000089197100097
J	Wei, G; Bai, XM; Gabb, MMG; Bame, KJ; Koshy, TI; Spear, PG; Esko, JD				Wei, G; Bai, XM; Gabb, MMG; Bame, KJ; Koshy, TI; Spear, PG; Esko, JD			Location of the glucuronosyltransferase domain in the heparan sulfate copolymerase EXT1 by analysis of Chinese hamster ovary cell mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; HERPES-SIMPLEX VIRUS; D-GLUCOSAMINYLTRANSFERASE REACTIONS; TUMOR-SUPPRESSOR GENE; N-ACETYLGLUCOSAMINYLTRANSFERASE; CAPSULAR POLYSACCHARIDE; POLYMER-MODIFICATION; LINKAGE REGION; TOUT-VELU; BIOSYNTHESIS	Heparan sulfate formation occurs by the copolymerization of glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) residues. Recent studies have shown that these reactions are catalyzed by a copolymerase encoded by EXT1 and EXT2, members of the exostosin family of putative tumor suppressors linked to hereditary multiple exostoses. Previously, we identified a collection of Chinese hamster ovary cell mutants (pgsD) that failed to make heparan sulfate (Lidholt, K,, Weinke, J. L., Riser, C. S., Lugemwa, F. N., Bame, K. J., Cheifetz, S., Massague, J,, Lindahl, U., and Esko, J. D. (1992) Proc. Natl. Acad, Sci. U.S.A. 89, 2267-2271). Here, we show that pgsD mutants contain mutations that either alter GlcA transferase activity selectively or that affect both GlcNAc and GlcA transferase activities. Expression of EXT1 corrects the deficiencies in the mutants, whereas EXT2 and the related EXT-like cDNAs do not. Analysis of the EXT1 mutant alleles revealed clustered missense mutations in a domain that included a (D/E)X(D/E) motif thought to bind the nucleotide sugar from studies of other transferases. These findings provide insight into the location of the GlcA transferase subdomain of the enzyme and indicate that loss of the GlcA transferase domain may be sufficient to cause hereditary multiple exostoses.	Univ Calif San Diego, Glycobiol Res & Training Program, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	University of California System; University of California San Diego; University of Missouri System; University of Missouri Kansas City; Northwestern University	Esko, JD (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Program, Dept Cellular & Mol Biol, CMM E Rm 1054,9500 Gilman Dr, La Jolla, CA 92093 USA.	jesko@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293, R37AI036293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36293] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BANFIELD BW, 1995, VIROLOGY, V208, P531, DOI 10.1006/viro.1995.1184; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Blanton SH, 1996, AM J MED GENET, V62, P150; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Fritz TA, 1997, GLYCOBIOLOGY, V7, P587, DOI 10.1093/glycob/7.5.587-c; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hecht JT, 1997, AM J HUM GENET, V60, P80; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LANDER A, 1999, CELL SURFACE PROTEOG; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LegeaiMallet L, 1997, CLIN GENET, V52, P12; LegeaiMallet L, 1997, HUM GENET, V99, P298, DOI 10.1007/s004390050361; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIN X, 2000, IN PRESS DEVELOPMENT; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Manez S, 1999, J NAT PROD, V62, P601, DOI 10.1021/np980132u; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Michaelis L, 1913, BIOCHEM Z, V49, P333; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; SHIEH MT, 1994, J VIROL, V68, P1224, DOI 10.1128/JVI.68.2.1224-1228.1994; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wells DE, 1997, HUM GENET, V99, P612, DOI 10.1007/s004390050415; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547; Wuyts W, 1998, AM J HUM GENET, V62, P346, DOI 10.1086/301726; WUYTS W, 1995, AM J HUM GENET, V57, P382	63	67	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27733	27740						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864928				2022-12-25	WOS:000089197100030
J	Kotani, K; Ogawa, W; Hashiramoto, M; Onishi, T; Ohno, S; Kasuga, M				Kotani, K; Ogawa, W; Hashiramoto, M; Onishi, T; Ohno, S; Kasuga, M			Inhibition of insulin-induced glucose uptake by atypical protein kinase C isotype-specific interacting protein in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; CAENORHABDITIS-ELEGANS; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED TRANSLOCATION; DROSOPHILA NEUROBLASTS; MAMMALIAN HOMOLOG; GROWTH-HORMONE; IN-VITRO; ZETA	Atypical protein kinase C (PKC) isotype-specific interacting protein (ASIP) specifically interacts with the atypical protein kinase C isozymes PKC lambda and PKC zeta. ASIP and atypical PKC, as well as their Caenorhabditis elegans counterparts (PAR-3 and PKC-3, respectively), are thought to coordinately participate in intracellular signaling that contributes to the maintenance of cellular polarity and to the formation of junctional complexes. The potential role of ASIP in other cellular functions of atypical PKC was investigated by examining the effect of overexpression of ASIP on insulin-induced glucose uptake, previously shown to be mediated through PKC lambda, in 3T3-L1 adipocytes. When overexpressed in these cells, which contain PKC lambda but not PKC zeta, ASIP was co-immunoprecipitated with endogenous PKC lambda but not with PKC epsilon or with Akt, The subcellular localization of PKC lambda was also altered in cells overexpressing ASIP. Overexpression of ASIP inhibited insulin stimulation of both glucose uptake and translocation of the glucose transporter GLUT4 to the plasma membrane, but it did not inhibit glucose uptake induced by either growth hormone or hyperosmolarity both of which promote glucose uptake in a PKC lambda-independent manner. Moreover, glucose uptake stimulated by a constitutively active mutant of PKC lambda, but not that induced by an active form of Akt, was inhibited by ASIP. Insulin-induced activation of PKC lambda, but not that of phosphoinositide 3-kinase or Akt, was also inhibited by overexpression of ASIP. These data suggest that overexpression of ASIP inhibits insulin-induced glucose uptake by specifically interfering with signals transmitted through PKC lambda.	Kobe Univ, Sch Med, Dept Internal Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 232, Japan	Kobe University; Yokohama City University	Ogawa, W (corresponding author), Kobe Univ, Sch Med, Dept Internal Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Ohnishi, Tetsuo/AAC-2767-2022; OGAWA, Wataru/AAQ-9586-2020; Ohnishi, Tetsuo/AAC-5694-2019; Ohnishi, Tetsuo/D-3791-2018; Ohno, Shigeo/B-1768-2010	Ohnishi, Tetsuo/0000-0002-6696-9725; Ohnishi, Tetsuo/0000-0002-6696-9725; Ohno, Shigeo/0000-0002-1294-5269				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOYODA N, 1986, J BIOL CHEM, V261, P2117; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	39	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26390	26395		10.1074/jbc.M002537200	http://dx.doi.org/10.1074/jbc.M002537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10869347	hybrid			2022-12-25	WOS:000088999700070
J	Krijgsveld, J; Zaat, SAJ; Meeldijk, J; van Veelen, PA; Fang, G; Poolman, B; Brandt, E; Ehlert, JE; Kuijpers, AJ; Engbers, GHM; Feijen, J; Dankert, J				Krijgsveld, J; Zaat, SAJ; Meeldijk, J; van Veelen, PA; Fang, G; Poolman, B; Brandt, E; Ehlert, JE; Kuijpers, AJ; Engbers, GHM; Feijen, J; Dankert, J			Thrombocidins, microbicidal proteins from human flood platelets, are C-terminal deletion products of CXC chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; ANTIMICROBIAL PEPTIDE; INFECTIVE ENDOCARDITIS; BETA-DEFENSINS; HOST-DEFENSE; VIRIDANS STREPTOCOCCI; HUMAN BETA-DEFENSIN-1; INNATE IMMUNITY; SMALL-INTESTINE; PANETH CELLS	Antibacterial proteins are components of the innate immune system found in many organisms and produced by a variety of cell types. Human blood platelets contain a number of antibacterial proteins in their cu-granules that are released upon thrombin activation. The present study was designed to purify these proteins obtained from human platelets and to characterize them chemically and biologically. Two antibacterial proteins were purified from platelet granules in a two-step protocol using cation exchange chromatography and continuous acid urea polyacrylamide gel electrophoresis and were designated thrombocidin (TC)-1 and TC-2, Characterization of these proteins using mass spectrometry and N-terminal sequencing revealed that TC-1 and TC-2 are variants of the CXC chemokines neutrophil-activating peptide-2 and connective tissue-activating peptide-III, respectively. TC-1 and TC-2 differ from these chemokines by a C-terminal truncation of 2 amino acids. Both TCs, but not neutrophil-activating peptide-2 and connective tissue-activating peptide-III, were bactericidal for Bacillus subtilis, Escherichia coli, Staphylococcus aureus, and Lactococcus lactis and fungicidal for Cryptococcus neoformans. Killing of B. subtilis by either TC appeared to be very rapid. Because TCs were unable to dissipate the membrane potential of L. lactis, the mechanism of TC-mediated killing most probably does not involve pore formation.	Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; Leiden State Univ, Ctr Med, Dept Immunohaematol, NL-2333 AA Leiden, Netherlands; Leiden State Univ, Ctr Med, Blood Bank, NL-2333 AA Leiden, Netherlands; Univ Groningen, Dept Microbiol, NL-9751 AA Haren, Netherlands; Forschungszentrum Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Univ Twente, Inst Biomed Technol, Dept Chem Technol, NL-8500 AE Enschede, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Groningen; Forschungszentrum Borstel; University of Twente	Zaat, SAJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Rm L1-163,Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Poolman, Bert/D-1882-2012; Krijgsveld, Jeroen/F-5974-2011	van Veelen, Peter/0000-0002-7898-9408; Kuijpers, Alma/0000-0002-6191-1815	NHLBI NIH HHS [HL-18574, HL-50590] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050590, P01HL018574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; BRANDT E, 1992, J IMMUNOL, V149, P1356; BRANDT E, 1993, MOL IMMUNOL, V30, P979, DOI 10.1016/0161-5890(93)90123-S; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; CASTOR CW, 1989, BIOCHEM BIOPH RES CO, V163, P1071, DOI 10.1016/0006-291X(89)92330-9; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COHEN AB, 1992, AM J PHYSIOL, V263, pL249, DOI 10.1152/ajplung.1992.263.2.L249; DANKERT J, 1995, INFECT IMMUN, V63, P663, DOI 10.1128/IAI.63.2.663-671.1995; Dankert J., 1988, THESIS U GRONINGEN G; Dhawan VK, 1998, INFECT IMMUN, V66, P3476, DOI 10.1128/IAI.66.7.3476-3479.1998; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DONALDSON DM, 1977, BACTERIOL REV, V41, P501, DOI 10.1128/MMBR.41.2.501-513.1977; FIJNHEER R, 1990, TRANSFUSION, V30, P634, DOI 10.1046/j.1537-2995.1990.30790385523.x; FONTANA R, 1990, ANTIMICROB AGENTS CH, V34, P314, DOI 10.1128/AAC.34.2.314; FORD I, 1993, BRIT J HAEMATOL, V84, P95, DOI 10.1111/j.1365-2141.1993.tb03030.x; FUKAMI MH, 1992, METHOD ENZYMOL, V215, P36; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GOODE J, 1994, CIBA F S, V186, P1; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARTER L, 1994, J IMMUNOL, V153, P5698; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; HERZBERG MC, 1983, INFECT IMMUN, V39, P1457, DOI 10.1128/IAI.39.3.1457-1469.1983; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JOHNSON FB, 1968, J BACTERIOL, V96, P589, DOI 10.1128/JB.96.3.589-595.1968; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAPLAN KL, 1979, BLOOD, V53, P604; Koo SP, 1999, INFECT IMMUN, V67, P2475, DOI 10.1128/IAI.67.5.2475-2481.1999; KRIJGSVELD J, 1998, C MICR HAEM VASC BIO; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LOLKEMA JS, 1996, TRANSPORT PROCESSES, P229; LUDWIG A, 1997, BLOOD, V90, P3488; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; Marciset O, 1997, J BIOL CHEM, V272, P14277, DOI 10.1074/jbc.272.22.14277; MEYLAN PR, 1986, ANTIMICROB AGENTS CH, V29, P418, DOI 10.1128/AAC.29.3.418; Moore AJ, 1996, J ANTIMICROB CHEMOTH, V37, P1077, DOI 10.1093/jac/37.6.1077; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; O'Neil DA, 1999, J IMMUNOL, V163, P6718; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Petersen F, 1996, J IMMUNOL, V156, P1954; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; SULLAM PM, 1993, J INFECT DIS, V168, P910, DOI 10.1093/infdis/168.4.910; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WALTZ A, 1990, J EXP MED, V171, P449; WEKSLER BB, 1971, J EXP MED, V134, P1114, DOI 10.1084/jem.134.5.1114; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P12869, DOI 10.1021/bi971398n; Yeaman MR, 1997, INFECT IMMUN, V65, P1023, DOI 10.1128/IAI.65.3.1023-1031.1997; YEAMAN MR, 1993, ANTIMICROB AGENTS CH, V37, P546, DOI 10.1128/AAC.37.3.546; Yeaman MR, 1996, INFECT IMMUN, V64, P1379, DOI 10.1128/IAI.64.4.1379-1384.1996; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; YEAMAN MR, 1992, INFECT IMMUN, V60, P1202, DOI 10.1128/IAI.60.3.1202-1209.1992; Yeaman MR, 1997, CLIN INFECT DIS, V25, P951, DOI 10.1086/516120; Zaat SAJ, 1997, ADV EXP MED BIOL, V418, P709; ZAAT SAJ, 1994, PATHOGENIC STREPTOCO, P473	70	238	250	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20374	20381		10.1074/jbc.275.27.20374	http://dx.doi.org/10.1074/jbc.275.27.20374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877842	hybrid, Green Published			2022-12-25	WOS:000088084500023
J	Akaike, T; Fujii, S; Kato, A; Yoshitake, J; Miyamoto, Y; Sawa, T; Okamoto, S; Suga, M; Asakawa, M; Nagai, Y; Maeda, H				Akaike, T; Fujii, S; Kato, A; Yoshitake, J; Miyamoto, Y; Sawa, T; Okamoto, S; Suga, M; Asakawa, M; Nagai, Y; Maeda, H			Viral mutation accelerated by nitric oxide production during infection in vivo	FASEB JOURNAL			English	Article						NO; peroxynitrite; oxidative stress	SENDAI VIRUS; VESICULAR STOMATITIS; OXYGEN RADICALS; PEROXYNITRITE; MICE; PATHOGENESIS; MUTAGENESIS; SUPEROXIDE; CARCINOGENESIS; FREQUENCIES	Nitric oxide (NO), superoxide (O-2(-)), and their reaction product peroxynitrite (ONOO-) are generated in excess during a host's response against viral infection, and contribute to viral pathogenesis by promoting oxidative stress and tissue injury. Here we demonstrate that NO and peroxynitrite greatly accelerates the mutation of Sendai virus (SeV), a nonsegmented negative-strand RNA virus, by using green fluorescent protein (GFP) inserted into and expressed by a recombinant SeV (GFP-SeV) as an indicator for mutation. GFP-SeV mutation frequencies were much higher in the wild-type mice than in those lacking inducible NO synthase, suggesting that mutation of the virus in vivo is NO dependent. High levels of NO and NO-mediated oxidative stress were induced by GFP-SeV infection in the lung of the wild-type mice, but not in the iNOS-deficient mice, as evidenced by electron spin resonance spectroscopy and immunohistochemical analysis for nitrotyrosine formation as well as histopathological examination. Furthermore, peroxynitrite, an NO-derived reactive nitrogen intermediate, enhanced viral mutation in vitro. These results indicate that the oxidative stress induced by NO produced during the natural course of viral infection increases mutation, expands the quasispecies spectrum, and facilitates evolution of RNA viruses.	Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Med 1, Kumamoto 8600811, Japan; Univ Tokyo, Inst Ind Sci, Dept Viral Infect, Tokyo 1080071, Japan; DNAVEC Res Inst, Tsukuba, Ibaraki, Japan	Kumamoto University; Kumamoto University; University of Tokyo; DNAVEC Corporation	Akaike, T (corresponding author), Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan.							AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Akaike T, 1998, P SOC EXP BIOL MED, V217, P64; Beck MA, 1998, FASEB J, V12, P1143, DOI 10.1096/fasebj.12.12.1143; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CARP RI, 1962, VIROLOGY, V17, P99, DOI 10.1016/0042-6822(62)90086-7; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Domingo E, 1997, REV MED VIROL, V7, P87, DOI 10.1002/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0; Fujii S, 1999, VIROLOGY, V256, P203, DOI 10.1006/viro.1999.9610; Gal A, 1996, P NATL ACAD SCI USA, V93, P15102, DOI 10.1073/pnas.93.26.15102; GRANOFF A, 1961, VIROLOGY, V13, P402, DOI 10.1016/0042-6822(61)90270-7; HARRIS CC, 1991, CANCER RES, V51, pS5023; HASSAN MK, 1997, J GEN VIROL, V78, P2813; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; NISHIKAWA K, 1983, VIROLOGY, V130, P318, DOI 10.1016/0042-6822(83)90086-7; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; PORTNER A, 1980, VIROLOGY, V104, P235, DOI 10.1016/0042-6822(80)90382-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SINGER B, 1969, VIROLOGY, V39, P395, DOI 10.1016/0042-6822(69)90087-7; SMITH DB, 1987, J GEN VIROL, V68, P2729, DOI 10.1099/0022-1317-68-11-2729; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TSUGITA A, 1962, J MOL BIOL, V4, P73, DOI 10.1016/S0022-2836(62)80039-4; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; WEITZMAN SA, 1981, SCIENCE, V212, P546, DOI 10.1126/science.6259738; Zhuang JC, 1998, P NATL ACAD SCI USA, V95, P8286, DOI 10.1073/pnas.95.14.8286	40	80	82	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1447	1454		10.1096/fj.14.10.1447	http://dx.doi.org/10.1096/fj.14.10.1447			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877838				2022-12-25	WOS:000087932200020
J	Forsberg, LS; Bhat, UR; Carlson, RW				Forsberg, LS; Bhat, UR; Carlson, RW			Structural characterization of the O-antigenic polysaccharide of the lipopolysaccharide from Rhizobium etli strain CE3 - A unique O-acetylated glycan of discrete size, containing 3-O-methyl-6-deoxy-L-talose and 2,3,4-tri-O-methyl-L-fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEGUMINOSARUM BIOVAR PHASEOLI; PEA ROOT-NODULES; MONOCLONAL-ANTIBODIES; CHEMICAL CHARACTERIZATION; BRADYRHIZOBIUM-JAPONICUM; LIPID-A; CORE; MUTANT; PLANT; CELL	The O-antigenic polysaccharide of the Rhizobium etli CE3 lipopolysaccharide (LPS) was structurally characterized using chemical degradations (Smith degradation and beta-elimination of uronosyl residues) in combination with alkylation analysis, electrospray, and matrix-assisted laser desorption ionization-time of flight mass spectrometry, tandem mass spectrometry, and H-1 COSY and TOCSY nuclear magnetic resonance spectroscopy analyses of the native polysaccharide and the derived oligosaccharides. The polysaccharide was found to be a unique, relatively low molecular weight glycan having a fairly discrete size, with surprisingly little variation in the number of repeating units (degree of polymerization = 5). The polysaccharide is O-acetylated and contains a variety of O-methylated glycosyl residues, rendering the native glycan somewhat hydrophobic. The molecular mass of the major de-O-acetylated species, including the reducing end 3-deoxy-D-manno-2-octulosonic acid (Kdo) residue, is 3330 Da. The polysaccharide is comprised of a trisaccharide repeating unit having the structure -->4)-alpha-D-GlcpA-(1-->4)-[alpha-3-O-Me-6-deoxy-Talp-(1-->3)]-alpha-L-Fucp-(1-->. The nonreducing end of the glycan is terminated with the capping sequence alpha-2,3,4-tri-O-Me-Fucp-(1-->4)-alpha-D-GlcpA-(1-->, and the reducing end of the molecule consists of the non-repeating sequence -->3)-alpha-L-Fucp-(1-->3)-beta-D-Manp-(1-->3)-beta-QuiNAcp-(1-->4)-alpha-Kdop-(2-->, where QuiNAc is N-acetylquinovosamine (2-N-acetamido-2,6-dideoxyglucose). The reducing end Kdo residue links the O-chain polysaccharide to the core region oligosaccharide, resulting in a unique location for a Kdo residue in LPS, removed four residues distally from the lipid A moiety, Structural heterogeneity in the O-chain arises mainly from the O-acetyl and O-methyl substitution. Methylation analysis using trideuteriomethyl iodide indicates that a portion of the 2,3,4-tri-O-methylfucosyl capping residues, typically 15%, are replaced with 2-O-methyl- and/or 2,3-di-O-methylfucosyl residues. In addition, approximately 25% of the 3,4-linked branching fucosyl residues and 10% of the 3-linked fucosyl residues are 2-O-methylated, A majority of the glucuronosyl residues are methyl-esterified at C-6, These unique structural features may be significant in the infection process.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Miles Cutter Labs, Berkeley, CA 94701 USA	University System of Georgia; University of Georgia	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.				NIGMS NIH HHS [GM39583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allaway D, 1996, J BACTERIOL, V178, P6403, DOI 10.1128/jb.178.21.6403-6406.1996; ASPINALL GO, 1993, J BIOL CHEM, V268, P6263; Banaszek A, 1998, CARBOHYD RES, V306, P379, DOI 10.1016/S0008-6215(97)10073-8; BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BRADE H, 1984, CARBOHYD RES, V134, P157, DOI 10.1016/0008-6215(84)85030-2; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CARLSON RW, 1992, CARBOHYD RES, V231, P205, DOI 10.1016/0008-6215(92)84020-S; CARLSON RW, 1987, PLANT PHYSIOL, V84, P421, DOI 10.1104/pp.84.2.421; CARLSON RW, IN PRESS P 12 INT C; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHAPMAN K, 1990, NITROGEN FIXATION AC, P254; DEMAAGD RA, 1989, J BACTERIOL, V171, P1136, DOI 10.1128/jb.171.2.1136-1142.1989; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; Duelli DM, 1997, MOL PLANT MICROBE IN, V10, P903, DOI 10.1094/MPMI.1997.10.7.903; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GILSERRANO AM, 1995, CARBOHYD RES, V275, P285, DOI 10.1016/0008-6215(95)00178-V; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; Jabbouri S, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P319; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KONDO S, 1990, CARBOHYD RES, V196, P191, DOI 10.1016/0008-6215(90)84119-F; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; LINDBERG B, 1972, ACTA CHEM SCAND, V26, P2231, DOI 10.3891/acta.chem.scand.26-2231; Martinez E., 1993, V17, P171; MAYER H, 1989, PURE APPL CHEM, V61, P1271, DOI 10.1351/pac198961071271; MCNEIL M, 1986, CARBOHYD RES, V146, P307, DOI 10.1016/0008-6215(86)85048-0; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; Noel KD, 1996, MOL PLANT MICROBE IN, V9, P180, DOI 10.1094/MPMI-9-0180; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; OLSEN P, 1994, APPL ENVIRON MICROB, V60, P654, DOI 10.1128/AEM.60.2.654-661.1994; PAZUR JH, 1980, METHODS CARBOHYDR CH, V8, P107; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PERRY MB, 1995, INFECT IMMUN, V63, P3348, DOI 10.1128/IAI.63.9.3348-3352.1995; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; RICHTER WJ, 1990, METHOD ENZYMOL, V193, P607, DOI 10.1016/0076-6879(90)93441-M; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; STEVENSON TT, 1991, CARBOHYD RES, V210, P277, DOI 10.1016/0008-6215(91)80129-B; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; VANDENBOSCH KA, 1989, J BACTERIOL, V171, P4537, DOI 10.1128/jb.171.9.4537-4542.1989; VANRHIJN P, 1995, MICROBIOL REV, V59, P124, DOI 10.1128/MMBR.59.1.124-142.1995; WECKESSER J, 1979, ANNU REV MICROBIOL, V33, P215, DOI 10.1146/annurev.mi.33.100179.001243; WEIBGEN U, 1993, SYST APPL MICROBIOL, V16, P177, DOI 10.1016/S0723-2020(11)80465-0; WILKINSON SG, 1983, CARBOHYD RES, V112, P241, DOI 10.1016/0008-6215(83)88289-5; WRIGHT SF, 1990, APPL ENVIRON MICROB, V56, P2262, DOI 10.1128/AEM.56.7.2262-2264.1990; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZAHRINGER U, 1995, BACTERIAL ENDOTOXINS, P113; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191; [No title captured]	66	73	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18851	18863		10.1074/jbc.M001090200	http://dx.doi.org/10.1074/jbc.M001090200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858446	hybrid			2022-12-25	WOS:000087815900034
J	Fosang, AJ; Last, K; Stanton, H; Weeks, DB; Campbell, IK; Hardingham, TE; Hembry, RM				Fosang, AJ; Last, K; Stanton, H; Weeks, DB; Campbell, IK; Hardingham, TE; Hembry, RM			Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; HYALURONAN-BINDING REGION; ANTIGEN-INDUCED ARTHRITIS; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; BOVINE CARTILAGE; KERATAN SULFATE; ADAMTS FAMILY; CLEAVAGE-SITE; LINK-PROTEIN	We have studied aggrecan catabolism mediated by matrix metalloproteinases (MMPs) in a porcine cartilage culture system. Using antibodies specific for DIPEN341 and (342)FFGVG neoepitopes, we have detected MMP-derived fragments in conditioned medium and cultured cartilage, by radioimmunoassay, Western blotting, and immunolocalization. Radioimmunoassay revealed that the amount (pmol of epitope/mg of total glycosaminoglycan) of (342)FFGVG epitope released from cartilage remained constant over a 5-day culture period and was not increased by IL-1 alpha or retinoate. However, the proportion (pmol of epitope/mg of released glycosaminoglycan) of (342)FFGVG epitope released was decreased upon stimulation, consistent with the involvement of a non-MMP proteinase, such as aggrecanase. The data suggest that in vitro MMPs may be involved in the base-line catabolism of aggrecan, Immunolocalization experiments showed that DIPEN341 and ITEGE(373) epitopes were increased by treatment with IL-1 alpha and retinoate. Confocal microscopy revealed that ITEGE(373) epitope was largely intracellular but with matrix staining in the superficial zone, whereas DIPEN341 epitope was cell-associated and widely distributed in the matrix. Surprisingly, the majority of (342)FFGVG epitope, determined by radioimmunoassay and Western blotting, was retained in the tissue despite the absence of a G1 domain anchor. Interleukin-1 alpha stimulation caused a marked increase in tissue DIPEN341 and (342)FFGVG epitope, and the (342)FFGVG fragments retained in the tissue were larger than those released into the medium. Active porcine aggrecanase was unable to cleave (342)FFGVG fragments at the down arrow Glu(373) down arrow Ala(374) bond but cleaved intact aggrecan at this site, suggesting that (342)FFGVG fragments are not substrates for aggrecanase, The apparent retention of large (342)FFGVG fragments within cartilage, and their resistance to N-terminal cleavage by aggrecanase suggests that (342)FF6V6 fragments may have a role in cartilage homeostasis.	Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdock Childrens Res Inst, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Walter & Eliza Hall Institute; University of Manchester; University of East Anglia	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.	fosang@cryptic.rch.unimelb.edu.au		Last, Karena/0000-0002-4396-8404; Hardingham, Timothy/0000-0001-8271-6763; Fosang, Amanda/0000-0002-5523-5427; STANTON, HEATHER/0000-0002-3427-5614				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BOLIS S, 1989, BIOCHIM BIOPHYS ACTA, V993, P157, DOI 10.1016/0304-4165(89)90158-X; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; COMPER WD, 1987, J BIOL CHEM, V262, P13464; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; FOSANG AJ, 1998, T ORTHOP RES SOC, V23, P83; FOSANG AJ, 1999, PROG INFLAM RES, P117; FRANZEN A, 1981, BIOCHEM J, V195, P535, DOI 10.1042/bj1950535; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HASCALL VC, 1999, BIOL SYNOVIAL JOINT; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Ilic MZ, 1995, ACTA ORTHOP SCAND, V66, P33, DOI 10.3109/17453679509157644; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOHMANDER S, 1977, ARCH BIOCHEM BIOPHYS, V180, P93, DOI 10.1016/0003-9861(77)90012-1; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; MOK SS, 1994, J BIOL CHEM, V269, P33021; Mort JS, 1998, BIOCHEM J, V335, P491, DOI 10.1042/bj3350491; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; PLAAS AHK, 1983, BIOCHEM J, V214, P855, DOI 10.1042/bj2140855; SAH RLY, 1990, BIOCHEM J, V267, P803, DOI 10.1042/bj2670803; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P21; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; WITT M, 1995, T ORTHOP RES SOC, V20, P122	55	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33027	33037		10.1074/jbc.M910207199	http://dx.doi.org/10.1074/jbc.M910207199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10882746	hybrid			2022-12-25	WOS:000090003800089
J	Hayashi, F; Matsuura, I; Kachi, S; Maeda, T; Yamamoto, M; Fujii, Y; Liu, H; Yamazaki, M; Usukura, J; Yamazaki, A				Hayashi, F; Matsuura, I; Kachi, S; Maeda, T; Yamamoto, M; Fujii, Y; Liu, H; Yamazaki, M; Usukura, J; Yamazaki, A			Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit of retinal cGMP phosphodiesterase II. Its role in the turnoff of phosphodiesterase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GTP-BINDING PROTEIN; GMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; GAMMA-SUBUNIT; ADP-RIBOSYLATION; IN-VIVO; PHOTORECEPTORS; ACTIVATION; TRANSDUCIN	Retinal cGMP phosphodiesterase (PDE) is regulated by P gamma, the regulatory subunit of PDE, and GTP/T alpha, the GTP-bound cu subunit of transducin. In the accompanying paper (Matsuura, I., Bondarenko, V. A., Maeda, T., Kachi, S., Yamazahi, M., Usukura, J., Hayashi, F., and Yamazaki, A. (2000) J. Biol. Chem. 275, 32950-32957), we have shown that all known P gammas contain a specific phosphorylation motif for cyclin-dependent protein kinase 5 (Cdk5) and that the unknown kinase is Cdk5 complexed with its activator. Here, using frog rod photoreceptor outer segments (ROS) isolated by a new method, we show that Cdk5 is involved in light-dependent P gamma phosphorylation in vivo. Under dark conditions only negligible amounts of P gamma were phosphorylated. However, under illumination that bleached less than 0.3% of the rhodopsin, similar to4% of the total P gamma was phosphorylated in less than 10 s. P gamma dephosphorylation occurred in less than 1 s after the light was turned off. Analysis of the phosphorylated amino acid, inhibition of P gamma phosphorylation by Cdk inhibitors in vivo and in vitro, and two-dimensional peptide map analysis of P gamma phosphorylated in vivo and in vitro indicate that Cdk5 phosphorylates a P gamma threonine in the same manner in vivo and in vitro. These observations, together with immunological data showing the presence of Cdk5 in ROS, suggest that Cdk5 is involved in light-dependent P gamma phosphorylation in ROS and that the phosphorylation is significant and reversible. In an homogenate of frog ROS, PDE activated by light/guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS) was inhibited by P gamma alone, but not by P gamma complexed with GDP/T alpha or GTP gammaS/T alpha. Under these conditions, Py phosphorylated by Cdk5 inhibited the light/GTP gammaS-activated PDE even in the presence of GTP gammaS/T alpha. These observations suggest that phosphorylated P gamma interacts with and inhibits light/GTP gammaS-activated PDE, but does not interact with GTP gammaS/T alpha in the homogenate. Together, our results strongly suggest that after activation of PDE by light/GTP, P gamma is phosphorylated by Cdk5 and the phosphorylated P gamma inhibits GTP/T alpha -activated PDE, even in the presence of GTP/T alpha in ROS.	Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Pharmacol, Detroit, MI 48201 USA; Nagoya Univ, Sch Med, Dept Anat, Nagoya, Aichi 466, Japan	Kobe University; Wayne State University; Wayne State University; Nagoya University	Hayashi, F (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan.	fhayashi@kobe-u.ac.jp		Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY07546, EY09631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GEER PD, 1905, PROTEIN PHOSPHORYLAT, P31; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1994, FEBS LETT, V338, P203, DOI 10.1016/0014-5793(94)80365-X; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIKI N, 1975, J BIOL CHEM, V250, P6320; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; Nishizawa Y, 1999, EXP EYE RES, V69, P195, DOI 10.1006/exer.1999.0693; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	42	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32958	32965		10.1074/jbc.M000703200	http://dx.doi.org/10.1074/jbc.M000703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884379	hybrid			2022-12-25	WOS:000090003800080
J	Miyagi, T; Chuang, LF; Doi, RH; Carlos, MP; Torres, JV; Chuang, RY				Miyagi, T; Chuang, LF; Doi, RH; Carlos, MP; Torres, JV; Chuang, RY			Morphine induces gene expression of CCR5 in human CEM x174 lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ENVELOPE GLYCOPROTEIN; CHEMOKINE RECEPTORS; OPIOID RECEPTORS; CELL-LINE; T-CELL; ACTIVATION; INFECTION; SULFATE; TYPE-1	All HIV-1 strains studied to date use CCR5, CXCR4, or both receptors to enter cells, Simian immunodeficiency virus (SIV) infection of non-human primates has served as a useful model for understanding AIDS pathogenesis in humans. Research on several genetically divergent SIV isolates has revealed that SIV uses CCR5, and not CXCR4, for entry. CEMx174, a human lymphoid cell line, has been routinely used to cultivate and maintain various SIV strains, However, questions have arisen about how CEMx174, which reportedly was unable to express detectable amounts of CCR5 transcripts, efficiently supports the growth of SIV. In searching for an answer, we resorted to a sensitive competitive reverse transcriptase-polymerase chain reaction procedure in an attempt to detect as well as quantify the amount of CCR5 expression. Here we present our findings, which indicate that CEMx174 indeed expresses CCR5 and that the amount of CCR5 is increased in cells pretreated with morphine. These results correlate well with our previous observations that morphine treatment causes CEMx174 cells to be more susceptible to SIV infection, Similar morphine effect was not observed on CEMx174 cells infected with simian retroviruses, which do not depend on CCR5 for entry. These findings suggest a plausible mechanism whereby opiate drug users render themselves more susceptible to HIV infection, thereby explaining the vast prevalence of HIV infection among endemic drug use populations.	Univ Calif Davis, Dept Med Pharmacol & Toxicol, Sch Med, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Chuang, RY (corresponding author), Univ Calif Davis, Dept Med Pharmacol & Toxicol, Sch Med, Davis, CA 95616 USA.				NIDA NIH HHS [DA 05901, DA 10433] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005901, R01DA010433] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anderson DE, 1999, VIRAL IMMUNOL, V12, P47, DOI 10.1089/vim.1999.12.47; CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choi Y, 1999, IN VIVO, V13, P389; Chuang L F, 1993, In Vivo, V7, P159; CHUANG LF, 1993, BIOCHEM BIOPH RES CO, V195, P1165, DOI 10.1006/bbrc.1993.2167; Chuang LF, 1997, ADDICT BIOL, V2, P421, DOI 10.1080/13556219772471; CHUANG LF, 1995, BIOCHEM BIOPH RES CO, V209, P1003, DOI 10.1006/bbrc.1995.1597; CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071; Chuang LF, 1997, J BIOL CHEM, V272, P26815, DOI 10.1074/jbc.272.43.26815; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Davey RA, 1997, J VIROL, V71, P8096, DOI 10.1128/JVI.71.11.8096-8102.1997; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Franchin G, 2000, J IMMUNOL, V164, P2592, DOI 10.4049/jimmunol.164.5.2592; Fraziano M, 1999, AIDS RES HUM RETROV, V15, P869, DOI 10.1089/088922299310575; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Kirchhoff F, 1997, J VIROL, V71, P6509, DOI 10.1128/JVI.71.9.6509-6516.1997; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Lee B, 1999, J LEUKOCYTE BIOL, V65, P552; LIU Y, 1992, J PHARMACOL EXP THER, V263, P533; MAZZONE A, 1994, INT J IMMUNOPHARMACO, V16, P959, DOI 10.1016/0192-0561(94)90049-3; Miyagi T, 2000, IMMUNOPHARMACOLOGY, V47, P53, DOI 10.1016/S0162-3109(99)00188-5; Morgan EL, 1996, J NEUROIMMUNOL, V65, P21, DOI 10.1016/0165-5728(95)00171-9; PARK IW, 1991, J VIROL, V65, P2987, DOI 10.1128/JVI.65.6.2987-2992.1991; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rosenblum LL, 2000, J VIROL, V74, P3449, DOI 10.1128/JVI.74.8.3449-3454.2000; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; TORRES JV, 1991, J MED PRIMATOL, V20, P218; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; VEYRIES ML, 1995, J PHARMACOL EXP THER, V272, P498; Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606	36	59	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31305	31310		10.1074/jbc.M001269200	http://dx.doi.org/10.1074/jbc.M001269200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887175	hybrid			2022-12-25	WOS:000089762700079
J	Ackmann, M; Wiech, H; Mandelkow, E				Ackmann, M; Wiech, H; Mandelkow, E			Nonsaturable binding indicates clustering of Tau on the microtubule surface in a paired helical filament-like conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TAU; ALZHEIMERS-DISEASE; BETA-TUBULIN; NEURODEGENERATIVE DISEASES; NERVOUS-SYSTEM; ALPHA-TUBULIN; LIVING CELLS; C-TERMINUS; PHOSPHORYLATION; DOMAIN	Tau protein modulates microtubule dynamics and forms insoluble aggregates in Alzheimer's disease. Because there is a discrepancy between reported affinities of Tau to microtubules, we determined the interaction over a wide concentration range using a sensitive enzyme -linked immunosorbent assay. We found that the interaction is biphasic and not monophasic as assumed earlier. The first binding phase is typical for identical and noninteracting binding sites, with dissociation constants around 0.1 mu M and stoichiometries around 0.2 Tau/tubulin dimer. Surprisingly, the second phase is nonsaturable and shows a nearly linear increase in bound Tau versus free Tau for free Tau concentrations higher than 2 mu M. The slope is proportional to the microtubule concentration. From this we define an overloading parameter with values around 50 mu M. The influence of Tau isoform, phosphorylation, and dimerization on both phases was investigated. Remarkably the overloading of Tau on microtubules leads to a thioflavin S fluorescence increase reminiscent of that seen with Tau aggregated into Alzheimer paired helical filaments. Because polyanions stimulate Tau aggregation and because the C-terminal domain of tubulin is polyanionic, we suggest that an early conformational change in Tau leading to paired helical filament aggregation occurs right on the microtubule surface.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Mandelkow, E (corresponding author), DESY, Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.							Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; AMOS LA, 1977, J CELL BIOL, V72, P642, DOI 10.1083/jcb.72.3.642; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chau MF, 1998, BIOCHEMISTRY-US, V37, P17692, DOI 10.1021/bi9812118; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1985, J MOL BIOL, V185, P911; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Perez M, 1996, J NEUROCHEM, V67, P1183; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; Westermann S, 1999, J CELL SCI, V112, P2185; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	61	111	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30335	30343		10.1074/jbc.M002590200	http://dx.doi.org/10.1074/jbc.M002590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869348	hybrid			2022-12-25	WOS:000089577900058
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Heterologous desensitization mediated by G protein-specific binding to caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; PLASMA-MEMBRANE; TYROSINE KINASE; SOMATOSTATIN RECEPTOR; SIGNAL-TRANSDUCTION; SCAFFOLDING DOMAIN; COUPLED RECEPTOR; CARDIAC MYOCYTES; ALPHA-SUBUNITS	We examined the notion that sequestration of G protein subunits by binding to caveolin impedes G protein reassociation and leads to transient, G protein-specific desensitization of response in dispersed smooth muscle cells. Cholecystokinin octapeptide (CCK-8) and substance P (SP) were used to activate G(q/11) cyclopentyl adenosine (CPA) was used to activate G(i3), and acetylcholine (ACh) was used to activate both G(q/11) and G(i3) via m3 and m2 receptors, respectively. CCK-8 and SP increased only G alpha(q/11), and CPA increased only G alpha(i3) in caveolin immunoprecipitates; caveolin and other G proteins were not increased. ACh increased both G alpha(q/11) and G alpha(i3) in a time- and concentration-dependent fashion: only G alpha(q/11) was increased in the presence of an m2 antagonist, and only G alpha(i3) was increased in the presence of an m3 antagonist. To determine whether transient G protein binding to caveolin affected subsequent responses mediated by the same G protein, PLC-beta activity was measured in cells stimulated sequentially with two different agonists that activate either the same or a different G;protein. After treatment of the cells with ACh and an m2 antagonist, the phospholipase C-beta (PLC-beta) response to CCK-8 and SP, but not CPG was decreased; conversely, after treatment of the cells with ACh and an m3 antagonist, the PLC-beta response to CPA, but not CCK-8 or SP, was decreased. Similarly, after treatment with CCK-8 or SP, the PLC-beta response mediated by G(q/11) only was decreased, whereas after treatment with CPA, the PLC-beta response mediated by G(i3) only was decreased. A caveolin-binding G alpha(q/11) fragment blocked the binding of activated G alpha(q/11) but not G alpha(i3) to caveolin-3 and prevented desensitization of the PLC-beta response mediated only by other G(q/11)-coupled receptors. A caveolin-binding G alpha(i3) fragment had the reverse effect. Thus, transient binding of receptor-activated G protein subunits to caveolin impedes reassociation of the heterotrimeric species and leads to desensitization of response mediated by other receptors coupled to the same G protein.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Murthy, KS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, POB 980711, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; KOSAZA T, 1996, J BIOL CHEM, V271, P12562; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1999, J BIOL CHEM, V274, P17587, DOI 10.1074/jbc.274.25.17587; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; Murthy KS, 2000, AM J PHYSIOL-CELL PH, V279, pC925, DOI 10.1152/ajpcell.2000.279.4.C925; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1996, MOL PHARMACOL, V50, P770; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRMONT RT, 1995, FASEB J, V9, P175; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SOHN UD, 1995, J PHARMACOL EXP THER, V273, P482; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	54	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30211	30219		10.1074/jbc.M002194200	http://dx.doi.org/10.1074/jbc.M002194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862762	hybrid			2022-12-25	WOS:000089577900042
J	Srinivasan, C; Liba, A; Imlay, JA; Valentine, JS; Gralla, EB				Srinivasan, C; Liba, A; Imlay, JA; Valentine, JS; Gralla, EB			Yeast lacking superoxide dismutase(s) show elevated levels of "free iron" as measured by whole cell electron paramagnetic resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; IN-VIVO; STATIONARY-PHASE; DNA-DAMAGE; MITOCHONDRIAL; ACONITASE; INACTIVATION; DEHYDRATASE	A current hypothesis explaining the toxicity of superoxide anion in vivo is that it oxidizes exposed [4Fe-4S] clusters in certain vulnerable enzymes causing release of iron and enzyme inactivation. The resulting increased levels of "free iron" catalyze deleterious oxidative reactions in the cell. In this study, we used low temperature Fe(III) electron paramagnetic resonance (EPR) spectroscopy to monitor iron status in whole cells of the unicellular eukaryote, Saccharomyces cerevisiae. The experimental protocol involved treatment of the cells with desferrioxamine, a cell-permeant, Fe(III)-specific chelator, to promote oxidation of all of the "free iron" to the Fe(III) state wherein it is EPR-detectable. Using this method, a small amount of EPR-detectable iron was detected in the wild-type strain, whereas significantly elevated levels were found in strains lacking CuZn-superoxide dismutase (CuZn-SOD) (sod1 Delta), Mn-SOD (sod2 Delta), or both SODs, throughout their growth but particularly in stationary phase, The accumulation was suppressed by expression of wild-type human CuZn-SOD (in the sod1 Delta mutant), by pmr1, a genetic suppressor of the sod Delta mutant phenotype (in the sod1 Delta sod2 Delta double knockout strain), and by anaerobic growth. In wild-type cells, an increase in the EPR-detectable iron pool could be induced by treatment with paraquat, a redox-cycling drug that generates superoxide. Cells that were not pretreated with desferrioxamine had Fe(III) EPR signals that were equally as strong as those from treated cells, indicating that "free iron" accumulated in the ferric form in our strains in vivo. Our results indicate a relationship between superoxide stress and iron handling and support the above hypothesis for superoxide-related oxidative damage.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; University of Illinois System; University of Illinois Urbana-Champaign	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	egralla@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM59030] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bencini A, 1999, INORGANIC ELECTRONIC STRUCTURE AND SPECTROSCOPY, VOL I, P93; Benov L, 1998, J BIOL CHEM, V273, P10313, DOI 10.1074/jbc.273.17.10313; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; FLINT DH, 1993, J BIOL CHEM, V268, P25547; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, COLD SPRING HARBOR M, V34, P495; Guthrie C, 1991, METHODS ENZYMOL, V194; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Kaiser C., 1994, METHODS YEAST GENETI; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kozlov AV, 1996, BIOMETALS, V9, P98, DOI 10.1007/BF00188097; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Liochev SI, 1996, FREE RADICAL RES, V25, P369, DOI 10.3109/10715769609149059; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Maringanti S, 1999, J BACTERIOL, V181, P3792, DOI 10.1128/JB.181.12.3792-3802.1999; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064	53	107	109	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29187	29192		10.1074/jbc.M004239200	http://dx.doi.org/10.1074/jbc.M004239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882731	hybrid			2022-12-25	WOS:000089439800003
J	Strano, S; Munarriz, E; Rossi, M; Cristofanelli, B; Shaul, Y; Castagnoli, L; Levine, AJ; Sacchi, A; Cesareni, G; Oren, M; Blandino, G				Strano, S; Munarriz, E; Rossi, M; Cristofanelli, B; Shaul, Y; Castagnoli, L; Levine, AJ; Sacchi, A; Cesareni, G; Oren, M; Blandino, G			Physical and functional interaction between p53 mutants and different isoforms of p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING DOMAIN; KINASE C-ABL; LUNG-CANCER; SV40-TRANSFORMED CELLS; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; DNA-DAMAGE; T-ANTIGEN; GENE	p53 is the most frequently inactivated tumor suppressor gene in human cancer, whereas its homologue, p73, is rarely mutated. Similarly to p53, p73 can promote growth arrest or apoptosis when overexpressed in certain p53-null tumor cells. It has previously been shown that some human tumor-derived p53 mutants can exert gain of function activity. The molecular mechanism underlying this activity remains to be elucidated. We show here that human tumor-derived p53 mutants (p53His175 and p53Gly281) associate in vitro and in vivo with p73 alpha, beta, gamma, and delta. This association occurs under physiological conditions, as verified in T47D and SKBR3 breast cancer cell lines. The core domain of mutant p53 is sufficient for the association with p73, whereas both the specific DNA binding and the oligomerization domains of p73 are required for the association with mutant p53. Furthermore, p53His175 and p53Gly281 mutants markedly reduce the transcriptional activity of the various isoforms of p73. Thus, human tumor-derived p53 mutants can associate with p73 not only physically but also functionally. These findings define a network involving mutant p53 and the various spliced isoforms of p73 that may confer upon tumor cells a selective survival advantage.	Regina Elena Canc Ctr, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00100 Rome, Italy; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Rockefeller Univ, New York, NY 10021 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	University of Rome Tor Vergata; Weizmann Institute of Science; Rockefeller University; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Canc Ctr, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.	blandino@ifo.it	Strano, Sabrina/K-9654-2016; strano, sabrina/B-6743-2013; Cesareni, Gianni/AAW-1382-2020; Blandino, Giovanni/B-1137-2013; Rossi, Mario/E-7666-2012	strano, sabrina/0000-0002-6341-4230; Blandino, Giovanni/0000-0002-6970-2241; Rossi, Mario/0000-0001-6349-8895; Munarriz, Eliana/0000-0002-3556-117X; Castagnoli, Luisa/0000-0001-5283-8671; Oren, Moshe/0000-0003-4311-7172	Telethon [369/BI] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gong JG, 1999, NATURE, V399, P806; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matoskova B, 1996, ONCOGENE, V12, P2679; Matoskova B, 1996, ONCOGENE, V12, P2563; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nomoto S, 1998, CANCER RES, V58, P1380; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prabhu NS, 1998, INT J ONCOL, V13, P5; Prives C, 1999, J PATHOL, V187, P112; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Takahashi H, 1998, CANCER RES, V58, P2076; Tsao H, 1999, CANCER RES, V59, P172; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	55	205	212	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29503	29512		10.1074/jbc.M003360200	http://dx.doi.org/10.1074/jbc.M003360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884390	hybrid			2022-12-25	WOS:000089439800044
J	Hasler, U; Greasley, PJ; von Heijne, G; Geering, K				Hasler, U; Greasley, PJ; von Heijne, G; Geering, K			Determinants of topogenesis and glycosylation of type II membrane proteins - Analysis of Na,K-ATPase beta(1) and beta(3) subunits by glycosylation mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; TRANSMEMBRANE ORIENTATION; INTRACELLULAR-TRANSPORT; STRUCTURE PREDICTION; CHARGED RESIDUES; PRIMARY SEQUENCE; INVARIANT CHAIN; SIGNAL SEQUENCE	The structural and molecular determinants that govern the correct membrane insertion and folding of membrane proteins are still ill-defined. By following the addition of sugar chains to engineered glycosylation sites (glycosylation mapping) in Na,R-ATPase beta isoforms expressed in vitro and in Xenopus oocytes, in combination with biochemical techniques, we have defined the C-terminal end of the transmembrane domain of these type II proteins. N-terminal truncation and the removal of a single charged residue at the N-terminal start of the putative transmembrane domain influence the proper positioning of the transmembrane domain in the membrane as reflected by a repositioning of the transmembrane domain, the exposure of a putative cryptic signal peptidase cleavage site, and the production of protein species unable to insert into the membrane. Glycosylation mapping in vivo revealed that the degree of glycosylation at acceptor sites located close to the membrane increases with the time proteins spend in the endoplasmic reticulum. Furthermore, core sugars added to such acceptor sites cannot be processed to fully glycosylated species even when the protein is transported to the cell surface. Thus, the glycosylation mapping strategy applied in intact cells is a useful tool for the study of determinants for the correct membrane insertion of type II and probably other membrane proteins, as well as for the processing of sugar chains in glycoproteins.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Stockholm Univ, Dept Biochem, S-10691 Stockholm, Sweden	University of Lausanne; Stockholm University	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				ACKERMANN U, 1992, J BIOL CHEM, V267, P12911; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; Beggah AT, 1997, J BIOL CHEM, V272, P10318; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1997, MOL B INT U, P173; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; ROST B, 1996, ISMB, V4, P192; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang XY, 1996, MOL PHARMACOL, V50, P687; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	54	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29011	29022		10.1074/jbc.M002867200	http://dx.doi.org/10.1074/jbc.M002867200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887183	hybrid			2022-12-25	WOS:000089330700088
J	Pearce, MC; Rubin, H; Bottomley, SP				Pearce, MC; Rubin, H; Bottomley, SP			Conformational change and intermediates in the unfolding of alpha(1)-antichymotrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; TUMOR-SUPPRESSING SERPIN; GUANIDINIUM CHLORIDE; HUMAN ALPHA(1)-ANTITRYPSIN; MECHANISM; DISEASE; COMPLEX; ALPHA-1-ANTITRYPSIN; ASSOCIATION; RECOMBINANT	Serpins are the prototypical members of the conformational disease family, a group of proteins that undergoes a change in shape that subsequently leads to tissue deposition. One specific example is alpha(1)-antichymotrypsin (ACT), which undergoes misfolding and aggregation that has been implicated in emphysema and Alzheimer's disease. In this study we have used guanidine hydrochloride (GdnHCl)-induced denaturation to investigate the conformational changes involved in the folding and unfolding of ACT. When the reaction was followed by circular dichroism spectroscopy, one stable intermediate was observed in 1.5 M GdnHCl. The same experiment monitored by fluorescence revealed a second intermediate formed in 2.5 M GdnHCl. Both these intermediates bound the hydrophobic dye ANS. These data suggest a four-state model for ACT folding N <----> I-1 <----> I-2 <----> U. I-1 and I-2 both have a similar loss of secondary structure (20%) compared with the native state. In I-2 however, there is a significant loss of tertiary interactions as revealed by changes in fluorescence emission maximum and intensity. Kinetic analysis of the unfolding reaction indicated that the native state is unstable with a fast rate of unfolding in water of 0.4 s(-1). The implications of these data for both ACT function and associated diseases are discussed.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Monash University; University of Pennsylvania	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.							BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Pace C N, 1986, Methods Enzymol, V131, P266; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sager R, 1997, ADV EXP MED BIOL, V425, P77; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILEZYNSKA M, 1997, NAT STRUCT BIOL, V4, P354; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28513	28518		10.1074/jbc.M004310200	http://dx.doi.org/10.1074/jbc.M004310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878020	hybrid			2022-12-25	WOS:000089330700025
J	Xavier, IJ; Mercier, PA; McLoughlin, CM; Ali, A; Woodgett, JR; Ovsenek, N				Xavier, IJ; Mercier, PA; McLoughlin, CM; Ali, A; Woodgett, JR; Ovsenek, N			Glycogen synthase kinase 3 beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED STRESS-RESPONSE; XENOPUS OOCYTES; FACTOR HSF1; IN-VIVO; SODIUM-SALICYLATE; NUCLEAR-PROTEIN; HSP70 GENE; PHOSPHORYLATION; CELLS	Stress activation of heat shock factor (HSF1) involves the conversion of repressed monomers to DNA-binding homotrimers with increased transcriptional capacity and results in transcriptional up-regulation of the heat shock protein (hsp) gene family. Cells tightly control the activity of HSF1 through interactions with hsp90 chaperone complexes and through integration into a number of different signaling cascades. A number of studies have shown that HSF1 transcriptional activity is negatively regulated by constitutive phosphorylation in the regulatory domain by glycogen synthase kinase (GSK3) isoforms alpha/beta. However, previous studies have not examined the ability of GSK3 to regulate the DNA-binding activity of native HSF1 in vivo under heat shock conditions. Here we show that GSK3 beta inhibits both DNA-binding and transcriptional activities of HSF1 in heat-shocked cells. Specific inhibition of GSK3 increased the levels of DNA binding and transcription after heat shock and delayed the attenuation of HSF1 during recovery. In contrast, the overexpression of GSK3 beta resulted in significant reduction in heat-induced HSF1 activities. These results confirm the role of GSK3 beta as a negative regulator of HSF1 transcription in cells during heat shock and demonstrate for the first time that GSK3 beta functions to repress DNA binding.	Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	University of Saskatchewan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Ovsenek, N (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ovsenekn@duke.usask.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Bharadwaj S, 1998, BBA-MOL CELL RES, V1402, P79, DOI 10.1016/S0167-4889(97)00146-8; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHANG NT, 1993, J BIOL CHEM, V268, P1436; Cheng TJ, 1998, J CELL BIOCHEM, V69, P221, DOI 10.1002/(SICI)1097-4644(19980501)69:2<221::AID-JCB12>3.0.CO;2-H; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Fritsch N, 1999, CELL STRESS CHAPERON, V4, P102; GOODE N, 1992, J BIOL CHEM, V267, P16878; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOJ A, 1994, EMBO J, V13, P2617; Holmberg CI, 1998, J CELL SCI, V111, P3357; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LANDSBERGER N, 1995, DEV BIOL, V170, P62, DOI 10.1006/dbio.1995.1195; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; Mercier PA, 1997, J BIOL CHEM, V272, P14147, DOI 10.1074/jbc.272.22.14147; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PULVERER BJ, 1994, ONCOGENE, V9, P59; RITZ MF, 1993, RECEPTOR, V3, P311; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Winegarden NA, 1996, J BIOL CHEM, V271, P26971, DOI 10.1074/jbc.271.43.26971; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P564; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	53	124	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29147	29152		10.1074/jbc.M002169200	http://dx.doi.org/10.1074/jbc.M002169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10856293	hybrid			2022-12-25	WOS:000089330700104
J	Herzig, S; Fuzesi, L; Knepel, W				Herzig, S; Fuzesi, L; Knepel, W			Heterodimeric Pbx-Prep1 homeodomain protein binding to the glucagon gene restricting transcription in a cell type-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN PROTOONCOGENE PBX1; COOPERATIVE INTERACTIONS; PANCREAS DEVELOPMENT; PROGLUCAGON GENE; HOMEOBOX GENES; HOX PROTEINS; ISLET CELLS; SOMATOSTATIN PROMOTER; FUNCTIONAL COMPLEX; REGULATORY ELEMENT	Homeodomain proteins specify developmental pathways and cell-specific gene transcription whereby proteins of the PBC subclass can direct target gene specificity of Hox proteins. Proteins encoded by nonclustered homeobox genes have been shown to be essential for cell lineage differentiation and gene expression in pancreatic islets. Using specific antiserum in an electrophoretic mobility shift assay and in vitro transcribed/ translated proteins, the nuclear proteins binding domain B of the G3 enhancer-like element of the glucagon gene were identified in the present study as heterodimers consisting of the ubiquitously expressed homeodomain protein Prep1 and the also widely expressed PBC homeoprotein Pbx (isoform 1a, 1b, or 2), These heterodimeric complexes were found to bind also to the glucagon cAMP response element and to a newly identified element termed G5 (from -169 to -140). Whereas the expression of Prep1 or Pbx forms alone had no effect, coexpression of Pbx1a/1b-Prep1 inhibited the glucagon promoter when activated by cotransfected Pax6 or another transcription factor in non-glucagon-producing cells. In contrast, in glucagon-producing pancreatic islet cells, Pbx-Prep1 had no effect on GAL4-Pax6-induced mutant glucagon promoter activity or on Pax6-dependent wild-type glucagon promoter activity. Furthermore, 5'-deletion of G5 enhanced glucagon promoter activity in a non-glucagon producing cell line but not in glucagon-producing islet cells. This study thus identifies a novel target and Hox-independent function of Pbx-Prep1 heterodimers that, through repression of glucagon gene transcription in non-glucagon-producing cells, may help to establish islet cell-specific expression of the glucagon gene.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany; Univ Gottingen, Dept Gastroenteropathol, D-37070 Gottingen, Germany	University of Gottingen; University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40,Postfach 3742, D-37070 Gottingen, Germany.			Herzig, Stephan/0000-0003-3950-3652				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DeCesare D, 1996, ONCOGENE, V13, P2551; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIEDRICH T, 1996, THESIS U GOTTINGEN G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jun S, 1996, DEVELOPMENT, V122, P2639; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1993, EXP CLIN ENDOCRINOL, V101, P39, DOI 10.1055/s-0029-1211206; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 2000, MOL BASIS ENDOCRINE; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEFEBVRE PJ, 1996, HDB EXPT PHARM, V30, P115; Li H, 1999, NAT GENET, V23, P67; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Offield MF, 1996, DEVELOPMENT, V122, P983; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANDER M, 1997, MOL MED, V75, P327; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Scott MP, 2000, CELL, V100, P27, DOI 10.1016/S0092-8674(00)81681-5; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; SUH E, 1994, MOL CELL BIOL, V14, P7430; Sussel L, 1998, DEVELOPMENT, V125, P2213; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wrege Antje, 1995, Gene Expression, V4, P205	102	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27989	27999						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869353				2022-12-25	WOS:000089197100063
J	Balendiran, GK; Schnutgen, F; Scapin, G; Borchers, T; Xhong, N; Lim, K; Godbout, R; Spener, F; Sacchettini, JC				Balendiran, GK; Schnutgen, F; Scapin, G; Borchers, T; Xhong, N; Lim, K; Godbout, R; Spener, F; Sacchettini, JC			Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCOSAHEXAENOIC ACID; 3-DIMENSIONAL STRUCTURE; ARACHIDONIC-ACID; LINOLENIC ACID; ANGSTROM RESOLUTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; FREE-RADICALS; RAT-BRAIN; SYSTEM	Expression of brain fatty acid-binding protein (B-FABP) is spatially and temporally correlated with neuronal differentiation during brain development. Isothermal titration calorimetry demonstrates that recombinant human B-FABP clearly exhibits high affinity for the polyunsaturated n-3 fatty acids cy-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and for monounsaturated n-9 oleic acid (K-d from 28 to 53 nM) over polyunsaturated n-6 fatty acids, linoleic acid, and arachidonic acid (K-d from 115 to 206 nhl), B-FABP has low binding affinity for saturated long chain fatty acids. The three-dimensional structure of recombinant human B-FABP in complex with oleic acid shows that the oleic acid hydrocarbon tail assumes a "U-shaped" conformation, whereas in the complex with docosahexaenoic acid the hydrocarbon tail adopts a helical conformation. A comparison of the three dimensional structures and binding properties of human B-FABP with other homologous FABPs, indicates that the binding specificity is in part the result of nonconserved amino acid Phe(104), which interacts with double bonds present in the lipid; hydrocarbon tail. In this context, analysis of the primary and tertiary structures of human B-FABP provides a rationale for its high affinity and specificity for polyunsaturated fatty acids. The expression of B-FABP in glial cells and its high affinity for docosahexaenoic acid, which is known to be an important component of neuronal membranes, points toward a role for B-FABP in sup plying brain abundant fatty acids to the developing neuron.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Munster, Dept Biochem, D-48149 Munster, Germany; Merck & Co Inc, Merck Res Lab, Rahway, NJ 07065 USA; Inst Chem & Biochem Sensor Res, D-48149 Munster, Germany; CUNY Queens Coll, Dept Chem, Flushing, NY 11367 USA; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	Texas A&M University System; Texas A&M University College Station; University of Munster; Merck & Company; City University of New York (CUNY) System; Queens College NY (CUNY); University of Alberta	Balendiran, GK (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	balendra@reddrum.tamu.edu	Godbout, Roseline/I-4639-2016; Schnütgen, Frank/ABD-8637-2020	Godbout, Roseline/0000-0002-4779-9265; Schnütgen, Frank/0000-0002-2426-6685	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT E, 1994, J NEUROCHEM, V63, P1616; BENNING MM, 1992, J MOL BIOL, V228, P208; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; BURTON L, 1989, P NATL ACAD SCI USA, V86, P2903; CHAM BE, 1976, J LIPID RES, V17, P176; CONNOR WE, 1984, T ASSOC AM PHYSICIAN, V97, P1; EADS J, 1993, J BIOL CHEM, V268, P26375; Ek BA, 1997, BBA-LIPID LIPID MET, V1346, P75, DOI 10.1016/S0005-2760(97)00021-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GODBOUT R, 1993, EXP EYE RES, V56, P95, DOI 10.1006/exer.1993.1014; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HASSAM AG, 1975, LIPIDS, V10, P417, DOI 10.1007/BF02532447; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; Hohoff C, 1998, FETT-LIPID, V100, P252; HOWARD AJ, 1986, GUIDE DATA REDUCTION; Innis SM, 1999, LIPIDS, V34, P139, DOI 10.1007/s11745-999-0348-x; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; MAATMAN RGHJ, 1994, EUR J BIOCHEM, V221, P801, DOI 10.1111/j.1432-1033.1994.tb18794.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Nourooz-Zadeh J, 1998, BIOCHEM BIOPH RES CO, V242, P338, DOI 10.1006/bbrc.1997.7883; Nourooz-Zadeh J, 1999, J NEUROCHEM, V72, P734, DOI 10.1046/j.1471-4159.1999.0720734.x; Nouvelot A., 1985, Cahiers de Nutrition et de Dietetique, V20, P123; OBRIEN JS, 1965, J LIPID RES, V6, P545; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILBRICK DJ, 1987, J NUTR, V117, P1663, DOI 10.1093/jn/117.10.1663; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SALEM N, 1980, CHEM PHYS LIPIDS, V27, P289, DOI 10.1016/0009-3084(80)90024-9; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; Schnutgen F, 1996, BIOL CHEM H-S, V377, P211; Schreiber A, 1998, CLIN CHEM LAB MED, V36, P283, DOI 10.1515/CCLM.1998.048; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wolfrum C, 1999, J LIPID RES, V40, P708; Xu LZ, 1996, J BIOL CHEM, V271, P24711; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; YAMAMOTO N, 1987, J LIPID RES, V28, P144; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; [No title captured]	65	151	157	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27045	27054						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854433				2022-12-25	WOS:000089144800052
J	Berrada, K; Plesnicher, CL; Luo, X; Thibonnier, M				Berrada, K; Plesnicher, CL; Luo, X; Thibonnier, M			Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; OXYTOCIN RECEPTOR; OPIOID RECEPTOR; V-2 RECEPTOR; INTERNALIZATION; IDENTIFICATION; EXPRESSION; TERMINUS	Examination of the structure of [Arg(8)]-vasopressin receptors (AVPRs) and oxytocin receptors (OTRs) suggests that G protein-coupled receptor kinases (GBKs) and protein kinase C (PKC) are involved in their signal transduction. To explore the physical association of AVPRs and OTRs with GRKs and PKC, wild types and mutated forms of these receptor subtypes were stably expressed as green fluorescent protein fusion proteins and analyzed by fluorescence, immunoprecipitation, and immunoblotting. Addition of a C-terminal GFP tag did not interfere with ligand binding, internalization, and signal transduction, After agonist stimulation, PKC dissociated from the V1R, did not associate with the V2R, but associated with the V3R and the OTR. After AVP stimulation, only GRK5 briefly associated with AVPRs following a time course that varied with the receptor subtype. No GRK associated with the OTR, Exchanging the V1R and V2R. C termini altered the time course of PKC and GRK5 association. Deletion of the V1R C terminus resulted in no PKC association and a ligand-independent sustained association of GRK5 with the receptor. Deletion of the GRK motif prevented association and reduced receptor phosphorylation, Thus, agonist stimulation of AVP/OT receptors leads to receptor subtype-specific interactions with GRK and PKC through specific motifs present in the C termini of the receptors.	Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Thibonnier, M (corresponding author), Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Sch Med, Rm BRB431,10900 Euclid Ave, Cleveland, OH 44106 USA.	mxt10@po.cwru.edu		, Marc/0000-0002-4546-180X	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039757, P01HL041618] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703] Funding Source: Medline; NHLBI NIH HHS [R01 HL39757, P01 HL41618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Conway BR, 1999, J BIOMOL SCREEN, V4, P75, DOI 10.1177/108705719900400207; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Iacovelli L, 1999, FASEB J, V13, P1; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; KIMURA T, 1995, ENDOCR J, V42, P607, DOI 10.1507/endocrj.42.607; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Milligan G, 1999, BRIT J PHARMACOL, V128, P501, DOI 10.1038/sj.bjp.0702824; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; Thibonnier M, 1998, ADV EXP MED BIOL, V449, P251; THIBONNIER M, IN PRESS AM J PHYSL; THIBONNIER M, 1992, NEUROENDOCRINOLOGY C, V5, P19	37	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27229	27237						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858434				2022-12-25	WOS:000089144800075
J	Hodson, N; Griffiths, G; Cook, N; Pourhossein, M; Gottfridson, E; Lind, T; Lidholt, K; Roberts, IS				Hodson, N; Griffiths, G; Cook, N; Pourhossein, M; Gottfridson, E; Lind, T; Lidholt, K; Roberts, IS			Identification that KfiA, a protein essential for the biosynthesis of the Escherichia coli K5 capsular polysaccharide, is an alpha-UDP-GlcNAc glycosyltransferase - The formation of a membrane-associated K5 biosynthetic complex requires KfiA, KfiB, and KfiC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; ENCODING PROTEINS; EXPRESSION; REGION-1; HEPARIN; ANTIGEN; ENZYME; MOTIF	The Escherichia coli K5 capsular polysaccharide consists of the repeat structure -4)GlcA-beta(1,4)-GlcNAc-alpha(1-and requires the KfiA, KfiB, KfiC, and KfiD proteins for its synthesis, Previously, the KfiC protein was shown to be a beta-UDP-GlcA glycosyltransferase, and KfiD was shown to be a UDP-Glc dehydrogenase. Here, we demonstrate that KfiA is an alpha-UDP-GlcNAc glycosyltransferase and that biosynthesis of the K5 polysaccharide involves the concerted action of the KfiA and KfiC proteins. By site-directed mutagenesis, we determined that the acidic motif of DDD, which is conserved between the C family of glycosyltransferases, is essential for the enzymatic activity of KfiA III addition, by Western blot analysis, we determined that association of KfiA with the cytoplasmic membrane requires KfiC but not KfiB, whereas the interaction of KfiC with the cytoplasmic membrane was dependent on both KfiA and KfiB. Likewise, KfiB was only detectable in cytoplasmic membrane fractions when both KfiA and KfiC were present. These data suggest that the interaction between the KfiA, KfiB, and KfiC proteins is essential for the stable association of these proteins with the cytoplasmic membrane and the biosynthesis of the K5 polysaccharide.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Manchester; Uppsala University	Roberts, IS (corresponding author), Univ Manchester, Sch Biol Sci, 1-800 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Pourhossein, Meraj/W-3666-2017	pourhossein, meraj/0000-0002-9627-8589; Hodson, Nigel/0000-0002-7486-1976; Lind, Thomas/0000-0003-2791-688X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Breton C, 1998, J BIOCHEM, V123, P1000; BRONNER D, 1993, FEMS MICROBIOL LETT, V113, P279, DOI 10.1016/0378-1097(93)90218-Q; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chung JY, 1998, FEMS MICROBIOL LETT, V166, P289, DOI 10.1111/j.1574-6968.1998.tb13903.x; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DURAND P, 1998, THESIS U P M CURIE P; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIND T, 1993, J BIOL CHEM, V268, P20705; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; ROBERSON EB, 1992, APPL ENVIRON MICROB, V58, P1284, DOI 10.1128/AEM.58.4.1284-1291.1992; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; ROBERTS IS, 1995, MICROBIOL-SGM, V141, P2023, DOI 10.1099/13500872-141-9-2023; SIEBERTH V, 1995, J BACTERIOL, V177, P4562, DOI 10.1128/jb.177.15.4562-4565.1995; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	22	61	70	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27311	27315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859322				2022-12-25	WOS:000089144800086
J	Lombard, M; Touati, D; Fontecave, M; Niviere, V				Lombard, M; Touati, D; Fontecave, M; Niviere, V			Superoxide reductase as a unique defense system against superoxide stress in the microaerophile Treponema pallidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; COMPLETE GENOME SEQUENCE; VULGARIS HILDENBOROUGH; ESCHERICHIA-COLI; DISMUTASE; DESULFOFERRODOXIN; OXYGEN; IRON; PROTEIN; RBO	Aerobic life requires the presence of antioxidant enzymes, such as superoxide dismutase, catalase, and per oxidase to eliminate deleterious oxygen derivatives, Treponema pallidum, a microaerophilic bacterium responsible for venereal syphilis, is an interesting organism because it lacks all of the above-mentioned enzymes, as deduced from its recently sequenced genome. In this paper, we describe a gene in T. pallidum with sequence homologies to a new class of antioxidant systems, named superoxide reductases, recently isolated from sulfate-reducing bacteria (Lombard, M., Fontecave, M., Touati, D., and Niviere, V. (2000) J. Biol. Chem. 275, 115-121). We report that (i) expression of the T. pallidum gene fully restored to a superoxide dismutase-deficient Escherichia coli mutant the ability to grow under aerobic conditions; (ii) the corresponding protein displays a strong superoxide reductase activity; and (iii) the T. pallidum protein contains only one mononuclear nonheme ferrous center, able to reduce superoxide selectively and efficiently, whereas previously characterized superoxide reductase from Desulfoarculus baarsii contains an additional rubredoxin-like ferric center. These results suggest that T, pallidum antioxidant defenses rely on a new class of superoxide reductase and raise the question of the importance of superoxide reductases in mechanisms for detoxifying superoxide radicals.	Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Niviere, V (corresponding author), Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.	vniviere@cea.fr	Lombard, Murielle/E-4974-2019	Lombard, Murielle/0000-0002-4775-3494; Niviere, Vincent/0000-0002-5132-457X				ARCHIBALD FS, 1981, J BACTERIOL, V146, P928, DOI 10.1128/JB.146.3.928-936.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; Dos Santos WG, 2000, J BACTERIOL, V182, P796, DOI 10.1128/JB.182.3.796-804.2000; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HALLIWELL B, 1989, FREE RADICAL BIO MED, P71; HATCHIKIAN EC, 1977, BIOCHIMIE, V59, P153, DOI 10.1016/S0300-9084(77)80286-1; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; KLUG D, 1972, J BIOL CHEM, V247, P4839; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MOURA I, 1990, J BIOL CHEM, V265, P21596; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; TAVARES P, 1994, J BIOL CHEM, V269, P10504; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; VERHAGEN MFJM, 1993, FEBS LETT, V336, P13, DOI 10.1016/0014-5793(93)81599-U; Voordouw JK, 1998, APPL ENVIRON MICROB, V64, P2882; [No title captured]	24	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27021	27026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867007				2022-12-25	WOS:000089144800048
J	Murasawa, S; Matsubara, H; Mori, Y; Masaki, H; Tsutsumi, Y; Shibasaki, Y; Kitabayashi, I; Tanaka, Y; Fujiyama, S; Koyama, Y; Fujiyama, A; Iba, S; Iwasaka, T				Murasawa, S; Matsubara, H; Mori, Y; Masaki, H; Tsutsumi, Y; Shibasaki, Y; Kitabayashi, I; Tanaka, Y; Fujiyama, S; Koyama, Y; Fujiyama, A; Iba, S; Iwasaka, T			Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; N-TERMINAL KINASE; GROWTH-FACTOR RECEPTOR; RAT CARDIAC FIBROBLASTS; PROTEIN-KINASES; DIFFERENTIAL ACTIVATION; EPITHELIAL-CELLS; TYPE-2 RECEPTORS; JNK; CALCIUM	Ca2+-sensitive tyrosine kinase Pyk2 was shown to be involved in angiotensin (Ang) II-mediated activation of extracellular signal-regulated kinase (ERK) via transactivation of epidermal growth factor receptor (EGF-R), In this study, we tested the involvement of Pyk2 and EGF-R in Ang II-induced activation of JNK and c-Jun in cardiac fibroblasts, Ang II markedly stimulated JNK activities, which were abolished by genistein and intracellular Ca2+ chelators but partially by protein kinase C depletion. Inhibition of EGF-R did not affect Pyk2 and JNK activation by Ang II. Stable transfection with a dominant negative (DN) mutant for Pyk2 (PKM) completely blocked JNK activation by Ang II. DN mutants of Rad (DN-Rac1) and MEK kinase (DN-MEKK1) also abolished it, whereas those of Cdc42, RhoA, and Ha-Ras had no effect, Induction of c-Jun gene transcription by Ang II was abolished in PKM, DN-Rac1, and DN-MEKK1, in which Ang II-induced binding of ATF2/c-Jun heterodimer to the activator protein-1 sequence at -190 played a key role. These results suggest that 1) in cardiac fibroblasts activation of JNK and c-Jun by Ang II is initiated by Pyk2-dependent signalings but not by downstream signals of EGF-R or Ras, 2) Rad but not Cdc42 is required for JNK activation by Ang II upstream of NEKK1, and 3) ATF-2/c-Jun binding to the activator protein-1 sequence at -190 plays a key role for induction of c-Jun gene by Ang II.	Kansai Med Univ, Dept Med 2, Moriguchi, Osaka 5708507, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan	Kansai Medical University; National Cancer Center - Japan	Matsubara, H (corresponding author), Kansai Med Univ, Dept Med 2, Fumizonocho 10-15, Moriguchi, Osaka 5708507, Japan.		Kitabayashi, Issay/G-2204-2017	Kitabayashi, Issay/0000-0002-8409-0407				BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Dam H., 1995, EMBO J, V14, P1798; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; INAGAMI T, 1994, HYPERTENS RES, V17, P87; Ishida M, 1998, CIRC RES, V82, P7; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsubara H, 1998, ENDOCR J, V45, P137, DOI 10.1507/endocrj.45.137; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; Murasawa S, 1996, Hypertens Res, V19, P271, DOI 10.1291/hypres.19.271; MURASAWA S, 1995, J BIOL CHEM, V270, P24282, DOI 10.1074/jbc.270.41.24282; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Ohkubo N, 1997, CIRCULATION, V96, P3954; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Yano P, 1998, CIRC RES, V83, P752, DOI 10.1161/01.RES.83.7.752; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOHN I, 1995, MOL CELL BIOL, V15, P6160; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	48	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26856	26863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856308				2022-12-25	WOS:000089144800027
J	Chung, SH; Polgar, J; Reed, GL				Chung, SH; Polgar, J; Reed, GL			Protein kinase C phosphorylation of syntaxin 4 in thrombin-activated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOME-ASSOCIATED PROTEIN; SYNAPTIC VESICLE FUSION; MEMBRANE-FUSION; SNARE PROTEINS; GRANULE SECRETION; COMPLEX-FORMATION; CORE COMPLEX; EXOCYTOSIS; MACHINERY; SYNAPTOTAGMIN	We postulated that the syntaxins, because of their key role in SNARE complex formation and exocytosis, could be important targets for signaling by intracellular kinases involved in secretion. We found that syntaxin 4 was phosphorylated in human platelets treated with a physiologic agent that induces secretion (thrombin) but not when they were treated with an agent that prevents secretion (prostacyclin). Syntaxin 4 phosphorylation was blocked by inhibitors of activated protein kinase C (PKC), and, in parallel assays, PKC inhibitors also blocked secretion from thrombin-activated platelets. In platelets, cellular activation by thrombin or phorbol 12-myristate 13-acetate decreased the binding of syntaxin 4 with SNAP-23, another platelet t-SNARE. Phosphatase inhibitors increased syntaxin 4 phosphorylation and further decreased syntaxin 4-SNAP-23 binding induced by cell activation. Conversely, a PKC inhibitor blocked syntaxin 4 phosphorylation and returned binding of syntaxin 4-SNAP-23 to that seen in nonstimulated platelets. In vitro, PKC directly phosphorylated platelet syntaxin 4 and recombinant syntaxin 4. PKC phosphorylation in vitro inhibited (71 +/- 8%) the binding of syntaxin 4 to SNAP-23, These results provide evidence that extracellular activation can be coupled through intracellular PKC signaling so as to modulate SNARE protein interactions involved in platelet exocytosis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave,2-127, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-64057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Hilfiker S, 1999, J PHYSIOL-LONDON, V515, P1, DOI 10.1111/j.1469-7793.1999.001ad.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Richards-Smith B, 1999, MOL GENET METAB, V68, P14, DOI 10.1006/mgme.1999.2891; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Sloan DC, 1997, BIOCHEM J, V328, P13; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Ware JA, 1997, HANDB EXP PHARM, V126, P247; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	41	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25286	25291		10.1074/jbc.M004204200	http://dx.doi.org/10.1074/jbc.M004204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10856305	hybrid			2022-12-25	WOS:000088849400033
J	Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU				Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU			Expression cloning of a new member of the ABO blood group glycosyltransferases, iGb(3) synthase, that directs the synthesis of isoglobo-glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SMALL-INTESTINE; ANTI-GAL; GENE; SERIES; ISOGLOBOTETRAOSYLCERAMIDE; CHROMATOGRAPHY; SYNTHETASE; ANTIBODIES; MICE	The large array of different glycolipids described in mammalian tissues is a reflection, in part, of diverse glycosyltransferase expression. Herein, we describe the cloning of a UDP-galactose: beta-D-galactosyl-1,4-glucosyl-ceramide alpha-1,3-galactosyltransferase (iGb(3) synthase) from a rat placental cDNA expression library. iGb(3) synthase acts on lactosylceramide, LacCer (Ga1 beta 1,4Glc-beta 1Cer) to form iGb(3) (Ga1 alpha 1,3Gal beta 1,4Glc beta 1Cer) initiating the synthesis of the isoglobo-series of glycosphingolipids. The isolated cDNA encoded a predicted protein of 339 amino acids, which shows extensive homology (40-50% identity) to members of the ABO gene family that includes: murine alpha 1,3-galactosyltransferase, Forssman (Gb,) synthase, and the ABO glycosyltransferases. In contrast to the murine alpha 1,3-galactosyltransferase, iGb(3) synthase preferentially modifies glycolipids over glycoprotein substrates, Reverse transcriptase-polymerase chain reaction revealed a widespread tissue distribution of iGb(3) synthase RNA expression, with high levels observed in spleen, thymus, and skeletal muscle. As an indirect consequence of the expression cloning strategy used, we have been able to identify several potential glycolipid biosynthetic pathways where iGb(3) functions, including the globo- and isoglobo-series of glycolipids.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center	Keusch, JJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	jkeusch@pathbox.wustl.edu	Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK 41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1995, J LIPID RES, V36, P611; ANGSTROM J, 1982, ARCH BIOCHEM BIOPHYS, V213, P708, DOI 10.1016/0003-9861(82)90601-4; ARIGA T, 1995, BBA-LIPID LIPID MET, V1254, P257, DOI 10.1016/0005-2760(94)00186-3; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREIMER ME, 1982, J BIOL CHEM, V257, P557; CARLSEN SA, 1993, CANCER RES, V53, P2906; FALK P, 1986, BIOCHIM BIOPHYS ACTA, V878, P296, DOI 10.1016/0005-2760(86)90161-X; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; Galili U, 1989, Prog Clin Biol Res, V319, P225; GLASGOW J, 1998, P 6 INT C INT SYST M, P175; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LaTemple DC, 1999, CANCER RES, V59, P3417; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; OSTRANDER GK, 1988, J BIOL CHEM, V263, P18716; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; SLOMIANY BL, 1974, EUR J BIOCHEM, V43, P161, DOI 10.1111/j.1432-1033.1974.tb03396.x; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SUNG SSJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P295, DOI 10.1016/0005-2760(79)90031-6; THURIN J, 1989, BIOCHIM BIOPHYS ACTA, V1002, P267, DOI 10.1016/0005-2760(89)90339-1; Wiegandt H, 1985, GLYCOLIPIDS, P1; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WINAND RJ, 1994, J IMMUNOL, V153, P1386; Xu HJ, 1999, J BIOL CHEM, V274, P29390, DOI 10.1074/jbc.274.41.29390; Yamamoto H, 1999, J BIOCHEM-TOKYO, V125, P923, DOI 10.1093/oxfordjournals.jbchem.a022370; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	35	92	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25308	25314		10.1074/jbc.M002629200	http://dx.doi.org/10.1074/jbc.M002629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854427	hybrid			2022-12-25	WOS:000088849400036
J	Fouassier, L; Yun, CC; Fitz, JG; Doctor, RB				Fouassier, L; Yun, CC; Fitz, JG; Doctor, RB			Evidence for ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) self-association through PDZ-PDZ interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA(2)-ADRENERGIC RECEPTOR; DOMAINS; PROTEINS; FAMILY; MEMBRANE; PSD-95	Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 (EBP50) is a versatile membrane-cytoskeleton linking protein that binds to the COOH-tail of specific integral membrane proteins through its two PDZ domains. These EBP50 binding interactions have been implicated in sequestering interactive sets of proteins into common microdomains, regulating the activity of interacting proteins, and modulating membrane protein trafficking. With only two PDZ domains, it is unclear how EBP50 forms multiprotein complexes. Other PDZ proteins increase their breadth and diversity of protein interactions through oligomerization. Hypothesizing that EBP50 self-associates to amplify its functional capacity, far-Western blotting of cholangiocyte epithelial cell proteins with EBP50 fusion protein revealed that EBP50 binds to a 50-kDa protein. Far-Western blotting of EBP50 isolated by two-dimensional gel electrophoresis or immunoprecipitation demonstrates that the 50-kDa binding partner is itself EBP50, Further, co-transfection/co-precipitation studies show the self-association can occur in an intracellular environment, In vitro analysis of the EBP50-EBP50 binding interaction indicates it is both saturable and of relatively high affinity. Analysis of truncated EBP50 proteins indicates EBP50 self-association is mediated through its PDZ domains. The ability to self-associate provides a mechanism for EBP50 to expand its capacity to form multiprotein complexes and regulate membrane transport events.	Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Denver, CO 80262 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21205 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University	Doctor, RB (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, 4200 E 9th Ave,Box B158, Denver, CO 80262 USA.		Fouassier, Laura/M-7556-2017	Fouassier, Laura/0000-0001-6377-5610	NIDDK NIH HHS [DK 44484, DK 43278, R01 DK 46082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046082, R01DK043278, P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	13	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25039	25045		10.1074/jbc.C000092200	http://dx.doi.org/10.1074/jbc.C000092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10859298	hybrid			2022-12-25	WOS:000088683300107
J	Yang, H; Young, DW; Gusovsky, F; Chow, JC				Yang, H; Young, DW; Gusovsky, F; Chow, JC			Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4 - MD-2 is required for activation of mitogen-activated protein kinases and Elk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; INTERLEUKIN-8 PRODUCTION; GENE; ENDOTOXIN; CELLS; TLR4; TRANSCRIPTION; EXPRESSION; MECHANISMS	Lipopolysaccharide (LPS) stimulates multiple signaling events, including nuclear factor-kappa B (NF-kappa B) activity and the mitogen-activated protein (MAP) kinases, ERK, JNK, and p38 in LPS-responsive cells, resulting in transcriptional activation and cytokine generation. LPS-induced signaling via toll-like receptor 4 (TLR4) results in the activation of the transcription factor NF-kappa B. Since LPS activates other signaling cascades in responsive cells, the objective of this study was to determine whether such events are mediated by TLR4 in response to LPS, me generated human embryonic kidney cells (HEK293) that stably express TLR4 (HEK-TLR4) and examined their responsiveness to LPS by measuring NF-kappa B activity and production of interleukin-8 (IL-8). A trans-reporting system was used to measure the activity of Elk-1, an ETS-domain transcription factor targeted by MAP kinase pathways. LPS stimulated NF-kappa B reporter activity and IL-8 production but not Elk-1 activity in HEK-TLR4 cells. When MD-2, a protein associated with the extracellular domain of TLR4, was expressed in these cells, there was a marked increase in Elk-1 activity as well as ERK, JNK, and p38 MAP kinase phosphorylation in response to LPS. TLR4-mediated NF-kappa B reporter activity and IL-8 production was enhanced by the expression of MD-2. This study demonstrates that expression of both TLR4 and MD-2 is required for LPS to activate or augment the MAP kinase pathways, Elk-1 stimulation, and IL-8 generation.	Eisai Res Inst, Div Infect Dis, Andover, MA 01810 USA	Eisai Co Ltd	Chow, JC (corresponding author), Eisai Res Inst, 100 Res Dr, Wilmington, MA 01887 USA.							Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DIBB CR, 1992, INFECT IMMUN, V60, P3052, DOI 10.1128/IAI.60.8.3052-3058.1992; Feoktistov I, 1999, MOL PHARMACOL, V55, P726; GEPPERT TD, 1994, MOL MED, V1, P93; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hoshino K, 1999, J IMMUNOL, V162, P3749; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	29	230	256	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20861	20866		10.1074/jbc.M002896200	http://dx.doi.org/10.1074/jbc.M002896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877845	hybrid			2022-12-25	WOS:000088084500090
J	Katagiri, T; Takahashi, T; Sasaki, T; Nakamura, S; Hattori, S				Katagiri, T; Takahashi, T; Sasaki, T; Nakamura, S; Hattori, S			Protein-tyrosine kinase Pyk2 is involved in interleukin-2 production by Jurkat T cells via its tyrosine 402	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNALING PATHWAY; CO-STIMULATION; ACTIVATION; LYMPHOCYTES; PHOSPHORYLATION; IDENTIFICATION; JNK; INTEGRIN; FAK	We established Jurkat transfectants that overexpress Pyk2 or its mutants, K457A (lysine 457 was mutated to alanine), Pyk2-Y402F (tyrosine 402 to phenylalanine), and Pyk2-Y881F to investigate the role of Pyk2 in T cell activation. Pyk2 as well as kinase-inactive Pyk2-K457A, was phosphorylated at tyrosine residues 402, 580, and 881 upon T cell antigen receptor cross-linking, indicating that these residues are phosphorylated by other tyrosine kinase(s), However, no tyrosine phosphorylation of Pyk2-Y402F was detected while more than 60% of the tyrosine phosphorylation was observed in Pyk2-Y881F. Pyk2-Y402F inhibited the activation of endogenous Pyk2. The degree of activation of both c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase but not extracellular signal-regulated protein kinase after concurrent ligation of T cell antigen receptor and CD28 was reduced by more than 50% in the clones expressing Pyk2-Y402F. Consistent with this inhibition, IL-2 production was significantly diminished in the Pyk2-Y402F-expressing clones. Furthermore, we found that Pyk2, when overexpressed, associates with Zap70 and Vav. Taken together, these findings suggest that Pyk2 is involved in the activation of T cells through its tyrosine 402.	Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan; Olympus Opt Co Ltd, Life Sci Technol Res Ctr, Tokyo 1928512, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	National Center for Neurology & Psychiatry - Japan; Olympus Corporation; Sapporo Medical University	Katagiri, T (corresponding author), Natl Inst Neurosci, Div Biochem & Cell Biol, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	katagiri@ncnp.go.jp						Andreev J, 1999, MOL CELL BIOL, V19, P2338; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Berg NN, 1997, J IMMUNOL, V159, P1753; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISHER MJ, 1995, NATURE, V376, P473, DOI 10.1038/376473a0; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Powell JD, 1998, IMMUNOL REV, V165, P287, DOI 10.1111/j.1600-065X.1998.tb01246.x; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sunder-Plassmann R, 1998, J BIOL CHEM, V273, P24249, DOI 10.1074/jbc.273.37.24249; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; van Seventer GA, 1998, EUR J IMMUNOL, V28, P3867, DOI 10.1002/(SICI)1521-4141(199811)28:11<3867::AID-IMMU3867>3.3.CO;2-B; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Xiong WC, 1998, J CELL SCI, V111, P1981; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	42	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19645	19652		10.1074/jbc.M909828199	http://dx.doi.org/10.1074/jbc.M909828199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867021	hybrid			2022-12-25	WOS:000087941300029
J	Jeoung, MK; Phang, T; Song, YS; Ji, I; Tae, TH				Jeoung, MK; Phang, T; Song, YS; Ji, I; Tae, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - III. Photoaffinity labeling of human chorionic gonadotropin with receptor Leu-rich repeat 4 peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HIGH-AFFINITY; EXTRACELLULAR DOMAIN; BINDING-SITE; LH RECEPTOR; PROTEIN; HCG; SUBUNIT; IDENTIFICATION; MUTAGENESIS	Human chorionic gonadotropin (hCG) binds to the extracellular N-terminal domain, exodomain, of its receptor, and the resulting hCG-exodomain complex is thought to modulate the membrane associated domain, endodomain, of the receptor to generate hormone signal. The bulk of the exodomain is speculated to assume a crescent structure consisting of eight to nine Leu-rich repeats (LRRs), which may provide the hormone contact sites. Unfortunately, little experimental evidence is available for the precise hormone contact points in the exodomain and the endodomain. The two preceding articles (Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T. (2001) J. Biol. Chem. 276, 3426-3435; Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T. (2001) J. Biol. Chem. 276, 3436-3442) show that putative LRR2 and LRR4 are crucial for hormone binding. In particular; the N-terminal region of LRR4 assumes the hydrophobic core of the LRR4 loop, whereas the C-terminal region is crucial for signal generation. However, it is unclear whether LRR4 interacts hCG and the endodomain and how it might be involved in signal generation. In this article, our affinity labeling results present the first evidence that the N-terminal region of LRR4 interacts with hCG, preferentially the hCG alpha subunit and that the hCG/LRR4 complex interacts with exoloop 2 of the endodomain. This interaction offers a mechanism to generate hormone signal.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea	University of Kentucky; Seoul National University (SNU)	Tae, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; JI TH, 1983, METHOD ENZYMOL, V91, P580; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEVITZKI A, 1984, RECEPTORS QUANTITATI; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MORBECK DE, 1993, MOL CELL ENDOCRINOL, V97, P173, DOI 10.1016/0303-7207(93)90225-9; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Puett D, 1996, MOL CELL ENDOCRINOL, V125, P55, DOI 10.1016/S0303-7207(96)03954-8; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411	34	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3443	3450		10.1074/jbc.M003774200	http://dx.doi.org/10.1074/jbc.M003774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10880517	hybrid			2022-12-25	WOS:000166784900060
J	Horibata, Y; Okino, N; Ichinose, S; Omori, A; Ito, M				Horibata, Y; Okino, N; Ichinose, S; Omori, A; Ito, M			Purification, characterization, and cDNA cloning of a novel acidic endoglycoceramidase from the jellyfish, Cyanea nozakii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-GLYCANASE; SEQUENCE; GLYCOSPHINGOLIPIDS; ELECTROPHORESIS; SPHINGOMYELIN; SUBSTRATE; PROTEINS; CLEAVES; LINKAGE; STRAIN	Endoglycoceramidase (EC 3.2.1.123) is an enzyme capable of cleaving the glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids, We report here the purification, characterization, and cDNA cloning of a novel endoglycoceramidase from the jellyfish, Cyanea nozakii. The purified enzyme showed a single protein band estimated to be 51 kDa on SDS-polyacrylamide gel electrophoresis. The enzyme showed a pH optimum of 3.0 and was activated by Triton X-100 and Lubrol PX but not by sodium taurodeoxycholate. This enzyme preferentially hydrolyzed gangliosides, especially GT1b and GQ1b, whereas neutral glycosphingolipids were somewhat resistant to hydrolysis by the enzyme. A full-length cDNA encoding the enzyme was cloned by 5'- and 3'-rapid amplification of cDNA ends using a partial amino acid sequence of the purified enzyme. The open reading frame of 1509 nucleotides encoded a polypeptide of 503 amino acids including a signal sequence of 25 residues and six potential N-glycosylation sites. Interestingly, the Asn-Glu-Pro sequence, which is the putative active site of Rhodococcus endoglycoceramidase, was conserved in the deduced amino acid sequences. This is the first report of the cloning of an endoglycoceramidase from a eukaryote.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818				ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; DAINESE HP, 1997, EUR J BIOCHEM, V264, P336; Fukano Y, 1997, APPL ENVIRON MICROB, V63, P1861, DOI 10.1128/AEM.63.5.1861-1865.1997; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; ISHIZUKA I, 1972, BIOCHIM BIOPHYS ACTA, V260, P279, DOI 10.1016/0005-2760(72)90039-2; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Miura Y, 1999, GLYCOBIOLOGY, V9, P957, DOI 10.1093/glycob/9.9.957; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; Nakagawa T, 1999, J BIOCHEM, V126, P604, DOI 10.1093/oxfordjournals.jbchem.a022492; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; PAUL LM, 1981, J CELL SCI, V49, P311; Sakaguchi K, 1999, BIOCHEM BIOPH RES CO, V260, P89, DOI 10.1006/bbrc.1999.0855; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZHOU B, 1989, J BIOL CHEM, V264, P12272	27	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31297	31304		10.1074/jbc.M003575200	http://dx.doi.org/10.1074/jbc.M003575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882727	hybrid			2022-12-25	WOS:000089762700078
J	Funakoshi, T; Yasuda, S; Fukasawa, M; Nishijima, M; Hanada, K				Funakoshi, T; Yasuda, S; Fukasawa, M; Nishijima, M; Hanada, K			Reconstitution of ATP- and cytosol-dependent transport of de Novo synthesized ceramide to the site of sphingomyelin synthesis in semi-intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-TRANSFER PROTEIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; RAT-LIVER; SERINE PALMITOYLTRANSFERASE; GLUCOSYLCERAMIDE SYNTHESIS; INTRACELLULAR-TRANSPORT; GLYCOPROTEIN TRANSPORT; PLASMA-MEMBRANE	Transport of ceramide synthesized at the endoplasmic reticulum to the Golgi compartment, where sphingomyelin (SM) synthase exists, was reconstituted within semi-intact Chinese hamster ovary cells. When [H-3]ceramide that had been produced from [H-3]sphingosine at 15 degrees C in perforated cells was chased at 37 degrees C, [H-3]ceramide-to-[H-3]SM conversion occurred in a cytosol-dependent manner. In various aspects (i.e. kinetics, ATP dependence, and temperature dependence), [H-3]ceramide-to-[H-3]SM conversion in perforated cells was consistent with that in intact cells. The cytosol from LY-A strain, a Chinese hamster ovary cell mutant defective in endoplasmic reticulum-to-Golgi transport of ceramide, did not support [H-3]ceramide-to-[H-3] SM conversion in perforated wild-type cells, whereas the wild-type cytosol rescued the conversion in perforated LY-A cells. Brefeldin A-treated cells, in which the endoplasmic reticulum and the Golgis apparatus were merged, no longer required cytosol for conversion of [H-3]ceramide to [H-3]SM. These results indicated that the assay of [H-3]ceramide-to-[H-3]SM conversion in semi-intact cells is a faithful in vitro assay for the activity of cytosol-dependent transport of ceramide and that LY-A cells are defective in a cytosolic factor involved in ceramide transport. In addition, conversion of [H-3]ceramide to [H-3]glucosylceramide in semi-intact cells was little dependent on cytosol, suggesting that ceramide reached the site of glucosylceramide synthesis by a cytosol-independent (or less dependent) pathway.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Japan Sci & Technol Corp, CREST, Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.			YASUDA, Satoshi/0000-0002-1011-0815; Hanada, Kentaro/0000-0003-1383-2781				Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Fukasawa M, 1997, EXP CELL RES, V230, P154, DOI 10.1006/excr.1996.3403; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; Hong WJ, 1998, J CELL SCI, V111, P2831; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; MORELL P, 1970, J BIOL CHEM, V245, P342; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; SLOMIANY A, 1992, ARCH BIOCHEM BIOPHYS, V298, P167, DOI 10.1016/0003-9861(92)90108-9; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; URBANI L, 1990, J BIOL CHEM, V265, P1919; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; van Tiel CM, 2000, BIOCHEM J, V346, P537, DOI 10.1042/0264-6021:3460537; VANHELVOOT A, 1997, J CELL SCI, V11, P75; WANG E, 1991, J BIOL CHEM, V266, P14486; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421	35	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29938	29945		10.1074/jbc.M004470200	http://dx.doi.org/10.1074/jbc.M004470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882735	hybrid			2022-12-25	WOS:000089577900005
J	Diverse-Pierluissi, M; McIntire, WE; Myung, CS; Lindorfer, MA; Garrison, JC; Goy, MF; Dunlap, K				Diverse-Pierluissi, M; McIntire, WE; Myung, CS; Lindorfer, MA; Garrison, JC; Goy, MF; Dunlap, K			Selective coupling of G protein beta gamma complexes to inhibition of Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATE CALCIUM CHANNELS; ATRIAL POTASSIUM CHANNEL; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; N-TYPE; MOLECULAR-CLONING; SENSORY NEURONS; BOVINE BRAIN; KINASE-C; ACTIVATION	Several mechanisms couple heterotrimeric guanine nucleotide-binding proteins (G proteins) to cellular effecters. Although alpha subunits of G proteins (G alpha) were the first recognized mediators of receptor-effector coupling, G beta gamma regulation of effecters is now well known. Five G beta and 12 G gamma subunit genes have been identified, suggesting through their diversity that specific subunits couple selectively to effecters. The molecular determinants of G beta gamma-effector coupling, however, are not well understood, and most studies of G protein-effector coupling do not support selectivity of G beta gamma action. To explore this issue further, we have introduced recombinant G beta gamma complexes into avian sensory neurons and measured the inhibition of Ca2+ currents mediated by an endogenous phospholipase C beta- (PLC beta) and protein kinase C-dependent pathway. Activities of G beta gamma in the native cells were compared with enzyme assays performed in vitro. We report a surprising selective activation of the PLC beta pathway by G beta gamma complexes containing beta(1) subunits, whereas beta(2)-containing complexes produced no activation. In contrast, when assayed in vitro, PLC beta and type II adenylyl cyclase did not discriminate among these same G beta gamma complexes, suggesting the possibility that additional cellular determinants confer specificity in vivo.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Tufts University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill	Dunlap, K (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.			Myung, Chang-Seon/0000-0002-6292-2911	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037443, R01NS016483] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19952] Funding Source: Medline; NINDS NIH HHS [NS16483, NS37443] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYER JL, 1994, J BIOL CHEM, V269, P2814; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COX DH, 1992, J NEUROSCI, V12, P906; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HARISH OE, 1992, INT J DEV NEUROSCI, V10, P421, DOI 10.1016/0736-5748(92)90032-U; HSU WH, 1990, J BIOL CHEM, V265, P11220; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lu Q, 2000, BIOPHYS J, V78, p265A; McIntire WE, 1998, BIOCHEMISTRY-US, V37, P14651, DOI 10.1021/bi981642q; Myung CS, 1999, ANAL BIOCHEM, V270, P303, DOI 10.1006/abio.1999.4086; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALDO GL, 1991, MOL PHARMACOL, V40, P480; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28380	28385		10.1074/jbc.M003571200	http://dx.doi.org/10.1074/jbc.M003571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880514	hybrid			2022-12-25	WOS:000089330700008
J	Moreno, B; Urbina, JA; Oldfield, E; Bailey, BN; Rodrigues, CO; Docampo, R				Moreno, B; Urbina, JA; Oldfield, E; Bailey, BN; Rodrigues, CO; Docampo, R			P-31 NMR spectroscopy of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major - Evidence for high levels of condensed inorganic phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; VACUOLAR H+-PYROPHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOSE-METABOLISM; CO2 FIXATION; ACIDOCALCISOMES; POLYPHOSPHATE; GLYCOLYSIS; INVIVO; PLANT	High resolution P-31 nuclear magnetic resonance spectra at 303.6 MHz (corresponding to a H-1 resonance frequency of 750 MHz) have been obtained of perchloric acid extracts of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major, the causative agents of African sleeping sickness, Chagas' disease, and leishmaniasis, Essentially complete assignments have been made based on chemical shifts and by direct addition of authentic reference compounds. The results indicate the presence of high levels of short chain condensed polyphosphates: di-, tri-, tetra-, and pentapolyphosphate. P-31 NMR spectra of purified T. brucei, T. cruzi, and L. major acidocalcisomes, calcium and phosphorus storage organelles, indicate that polyphosphates are abundant in these organelles and have an average chain length of 3.11-3.39 phosphates, In the context of the recent discovery of several pyrophosphate-utilizing enzymes in trypanosomatids, the presence of these inorganic polyphosphates implies a critical role for these molecules in these parasites and a potential new route to chemotherapy.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Biophys, Urbana, IL 61801 USA; Inst Venezolano Invest Cient, Caracas 1020A, Venezuela; Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Venezuelan Institute Science Research; University of Illinois System; University of Illinois Urbana-Champaign	Oldfield, E (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.	eo@chad.scs.uiuc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline; NIGMS NIH HHS [GM-50694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BOWES AE, 1993, J BIOL CHEM, V268, P13885; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CRUTCHFI.MM, 1965, J AM CHEM SOC, V87, P2815, DOI 10.1021/ja01091a007; CRUTCHFIELD MM, 1962, INORG CHEM, V1, P813, DOI 10.1021/ic50004a020; DELOSSANTOS C, 1985, EUR J BIOCHEM, V149, P421, DOI 10.1111/j.1432-1033.1985.tb08942.x; DESLAURIERS R, 1982, BIOCHIM BIOPHYS ACTA, V720, P329, DOI 10.1016/0167-4889(82)90109-4; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Eisenthal R, 1998, J BIOL CHEM, V273, P5500, DOI 10.1074/jbc.273.10.5500; FAN TWM, 1991, BIOCHIM BIOPHYS ACTA, V1092, P39, DOI 10.1016/0167-4889(91)90176-X; FRYDMAN B, 1990, EUR J BIOCHEM, V192, P363, DOI 10.1111/j.1432-1033.1990.tb19235.x; GLONEK T, 1972, INORG CHEM, V11, P567, DOI 10.1021/ic50109a029; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P63, DOI 10.1016/0166-6851(80)90032-8; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HART DT, 1984, MOL BIOCHEM PARASIT, V12, P25, DOI 10.1016/0166-6851(84)90041-0; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG SR, 1956, J BIOL CHEM, V218, P23; Kulaev I S, 1999, Prog Mol Subcell Biol, V23, P27; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; Kumble KD, 1996, J BIOL CHEM, V271, P27146, DOI 10.1074/jbc.271.43.27146; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; MACKENZIE NE, 1982, EUR J BIOCHEM, V121, P657, DOI 10.1111/j.1432-1033.1982.tb05836.x; MACKENZIE NE, 1983, BIOSCIENCE REP, V3, P141, DOI 10.1007/BF01121945; MACKENZIE NE, 1984, MOL BIOCHEM PARASIT, V13, P13, DOI 10.1016/0166-6851(84)90097-5; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; MARTIN JB, 1993, EUR J BIOCHEM, V214, P711, DOI 10.1111/j.1432-1033.1993.tb17972.x; MERTENS E, 1993, PARASITOL TODAY, V9, P122, DOI 10.1016/0169-4758(93)90169-G; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495; Platzer EG, 1999, J PARASITOL, V85, P603, DOI 10.2307/3285730; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; REEVES RE, 1974, J BIOL CHEM, V249, P7737; REEVES RE, 1968, J BIOL CHEM, V243, P3202; REEVES RE, 1975, BIOCHEM BIOPH RES CO, V66, P1389, DOI 10.1016/0006-291X(75)90513-6; REEVES RE, 1970, BIOCHIM BIOPHYS ACTA, V220, P346, DOI 10.1016/0005-2744(70)90021-5; ROBERTS MF, 1987, PHOSPHORUS NMR BIOL, P85; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; THOMPSON SN, 1992, MAGNET RESON MED, V28, P311, DOI 10.1002/mrm.1910280213; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; URBINA JA, 1990, ARCH BIOCHEM BIOPHYS, V282, P91, DOI 10.1016/0003-9861(90)90091-C; Van Wazer J. R., 1987, PHOSPHORUS NMR BIOL, P1; Vanderheyden N, 2000, BIOCHEM J, V346, P53, DOI 10.1042/0264-6021:3460053; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VIEIRA L, 1995, J BIOL CHEM, V270, P5299, DOI 10.1074/jbc.270.10.5299; WAKI H, 1982, POLYHEDRON, V1, P69, DOI 10.1016/S0277-5387(00)81071-2; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153	56	77	78	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28356	28362		10.1074/jbc.M003893200	http://dx.doi.org/10.1074/jbc.M003893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871617	hybrid			2022-12-25	WOS:000089330700005
J	Tobacman, LS; Butters, CA				Tobacman, LS; Butters, CA			A new model of cooperative myosin-thin filament binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN COMPLEX; F-ACTIN; SUBFRAGMENT-1; CONTRACTION; DYNAMICS	Cooperative myosin binding to the thin filament is critical to regulation of cardiac and skeletal muscle contraction. This report delineates and fits to experimental data a new model of this process, in which specific tropomyosin-actin interactions are important, the tropomyosin-tropomyosin polymer is continuous rather than disjointed, and tropomyosin affects myosin-actin binding by shifting among three positions as in recent structural studies. A myosin- and tropomyosin-induced conformational change in actin is proposed, rationalizing the similar to 10,000-fold strengthening effect of myosin on tropomyosin-actin binding. Also, myosin S1 binding to regulated filaments containing mutant tropomyosins with internal deletions exhibited exaggerated cooperativity, implying an allosteric effect of tropomyosin on actin and allowing the effect's measurement. Comparisons among the mutants suggest the change in actin is promoted much more strongly by the middle of tropomyosin than by its ends. Regardless of calcium binding to troponin, this change in actin facilitates the shift in tropomyosin position to the actin inner domain, which is required for tight myosin-actin association. It also increases myosin-actin affinity 7-fold compared with the absence of troponin-tropomyosin, Finally, initiation of a shift in tropomyosin position is 100-fold more difficult than is its extension from one actin to the next, producing the myosin binding cooperativity that underlies cooperative activation of muscle contraction.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Dr SE 610,GH, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu			NHLBI NIH HHS [HL-38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; Chen Y, 2000, BIOPHYS J, V78, p236A; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1985, COOPERATIVITY THEORY, P321; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1995, BIOPHYS J, V68, pS2; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; Orlova A, 1997, J MOL BIOL, V265, P469, DOI 10.1006/jmbi.1996.0761; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Prochniewicz E, 1999, BIOCHEMISTRY-US, V38, P14860, DOI 10.1021/bi991343g; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	36	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27587	27593						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864931				2022-12-25	WOS:000089197100011
J	Welm, AL; Mackey, SL; Timchenko, LT; Darlington, GJ; Timchenko, NA				Welm, AL; Mackey, SL; Timchenko, LT; Darlington, GJ; Timchenko, NA			Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA ISOFORMS; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; HEPATOCYTE PROLIFERATION; PARTIAL-HEPATECTOMY; GENE PROMOTER; CELL-CYCLE; EXPRESSION; MICE	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP), In this paper, we investigate the pathway for LIP induction during APR and the role of LIP in regulation of the C/EBP alpha promoter. The 5' region of C/EBP beta mRNA has been shown to be involved in the regulation of LIP translation. Our data demonstrate that binding of cytoplasmic proteins to the 5' region of C/EBP beta mRNA is altered in response to LPS administration, One of the major changes is induced binding of a cytoplasmic protein that is immunologically identical to the previously characterized RNA-binding protein CUGBP1. Induction of CUGBP1 binding activity in liver cytoplasm during APR is accompanied by the elevation of CUGBP1 binding activity on polysomes, CUGBP1 immunoprecipitated from livers of LPS-treated mice, but not from normal animals, is capable of inducing LIP translation in a cell-free translation system. The ability of CUGBP1 to induce LIP translation during APR depends on phosphorylation of CUGBP1, We show that elevation of LIP during APR and after partial hepatectomy leads to increased binding of LIP to the C/EBP consensus site found within the mouse C/EBPa promoter. This binding correlates with reduction of C/EBP alpha mRNA levels in both biological situations. Co-transfection experiments showed that full-length C/EBP alpha activates the C/EBP alpha promoter, while LIP blocks this activation. Our data suggest that the dominant negative isoform of C/EBP beta, LIP, down-regulates the C/EBP alpha promoter in liver and in cultured hepatocytes, Because full-length C/EBP alpha and C/EBP beta proteins regulate liver proliferation, this function of LIP may be important in liver growth and differentiation.	Baylor Coll Med, Huffington Ctr Aging, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Timchenko, NA (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Dept Pathol, N803,1 Baylor Pl, Houston, TX 77030 USA.				NIAMS NIH HHS [AR10D44387-01] Funding Source: Medline; NIA NIH HHS [AG00756] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044387] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; An MR, 1996, MOL CELL BIOL, V16, P2295; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Welm AL, 1999, MOL CELL BIOL, V19, P1695; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	34	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27406	27413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854425				2022-12-25	WOS:000089144800099
J	Sabroe, I; Peck, MJ; Van Keulen, BJ; Jorritsma, A; Simmons, G; Clapham, PR; Williams, TJ; Pease, JE				Sabroe, I; Peck, MJ; Van Keulen, BJ; Jorritsma, A; Simmons, G; Clapham, PR; Williams, TJ; Pease, JE			A small molecule antagonist of chemokine receptors CCR1 and CCR3 - Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG MODEL; ENDOTHELIAL-CELLS; EOTAXIN RECEPTOR; IN-VIVO; CHEMOATTRACTANT CYTOKINE; CROSS-DESENSITIZATION; CHEMOTACTIC CYTOKINES; MONOCLONAL-ANTIBODY; MESSENGER-RNA; BONE-MARROW	We describe a small molecule chemokine receptor antagonist, UCB35625 (the trans-isomer J113863 published by Banyu Pharmaceutical Co., patent WO98/04554), which is a potent, selective inhibitor of CCR1 and CCR3. Nanomolar concentrations of UCB35625 were sufficient to inhibit eosinophil shape change responses to MIP-1 alpha; MCP-4, and eotaxin, while greater concentrations could inhibit the chemokine induced internalization of both CCR1 and CCR3. UCB35625 also inhibited the CCR3-mediated entry of the human immunodeficiency virus-1 primary isolate 89.6 into the glial cell line, NP-2 (IC50 = 57 nM). Chemotaxis of transfected cells expressing either CCR1 or CCR3 was inhibited by nanomolar concentrations of the compound (IC50 values of CCR1-MIP-1 alpha = 9.6 nM, CCR3-eotaxin = 93.7 nM). However, competitive ligand binding assays on the same transfectants revealed that considerably larger concentrations of UCB35625 were needed for effective ligand displacement than were needed far the inhibition of receptor function. Thus, it appears that the compound may interact with a region present in both receptors that inhibits the conformational change necessary to initiate intracellular signaling. By virtue of its potency at the two major eosinophil chemokine receptors, UCB35625 is a prototypic therapy for the treatment of eosinophil-mediated inflammatory disorders, such as asthma and as an inhibitor of CCR3-mediated human immunodeficiency virus-1 entry.	Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, London SW7 2AZ, England; UCB, Pharma Res & Dev, B-1420 Braine Lalleud, Belgium; UCL, Sch Med, Wohl Vir Ctr, Dept Mol Pathol & Clin Biochem, London W1P 6DB, England	Imperial College London; UCB Pharma SA; University of London; University College London; UCL Medical School	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	j.pease@ic.ac.uk	Sabroe, Ian/I-5981-2013; Pease, James/X-4521-2018; Sabroe, Ian/AAE-5858-2019; Simmons, Graham/G-3523-2012	Sabroe, Ian/0000-0001-9750-8975; Pease, James/0000-0003-3749-0341; Simmons, Graham/0000-0002-9615-7023				Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955; Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954; HASLETT C, 1985, AM J PATHOL, V119, P101; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946; Li L, 1999, J IMMUNOL, V162, P2477; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; NAYA A, 1998, Patent No. 9804554; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; Reeves JD, 2000, METH MOL B, V138, P209; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Shinkai A, 1999, J IMMUNOL, V163, P1602; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Soda Y, 1999, BIOCHEM BIOPH RES CO, V258, P313, DOI 10.1006/bbrc.1999.0633; SPRY CJF, 1992, IMMUNOL TODAY, V13, P384, DOI 10.1016/0167-5699(92)90085-L; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; Wang ZX, 1999, J BIOL CHEM, V274, P28413, DOI 10.1074/jbc.274.40.28413; Williams CMM, 1998, IMMUNOGENETICS, V47, P178, DOI 10.1007/s002510050345; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	58	187	199	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25985	25992		10.1074/jbc.M908864199	http://dx.doi.org/10.1074/jbc.M908864199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854442	hybrid			2022-12-25	WOS:000088999700016
J	Puskas, F; Gergely, P; Banki, K; Perl, A				Puskas, F; Gergely, P; Banki, K; Perl, A			Stimulation of the pentose phosphate pathway and glutathione levels by dehydroascorbate, the oxidized form of vitamin C	FASEB JOURNAL			English	Article						DHA; transaldolase; glucose 6-phosphate dehydrogenase; GSH; apoptosis	NECROSIS-FACTOR-ALPHA; ASCORBIC-ACID; INDUCED APOPTOSIS; CELL-DEATH; ENDOTHELIAL-CELLS; RAT-LIVER; EXPRESSION; MITOCHONDRIA; ACTIVATION; PHOSPHATIDYLSERINE	Ascorbic acid, or vitamin C, generally functions as an antioxidant by directly reacting with reactive oxygen intermediates and has a vital role in defenses against oxidative stress. However, ascorbic acid also has pro-oxidant properties and may cause apoptosis of lymphoid and myeloid cells. The present study shows that dehydroascorbate, the oxidized form of vitamin C, stimulates the antioxidant defenses of cells,preferentially importing dehydroascorbate over ascorbate. While 200-800 mu M vitamin C caused apoptosis of Jurkat and H9 human T lymphocytes, pretreatment with 200-1000 mu M dehydroascorbate stimulated activity of pentose phosphate pathway enzymes glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and transaldolase, elevated intracellular glutathione levels, and inhibited H2O2-induced changes in mitochondrial transmembrane potential and cell death. A 3.3-fold maximal glutathione elevation was observed after 48 h stimulation with 800 mu M dehydroascorbate. In itself, dehydroascorbate did not affect cytosolic or mitochondrial reactive oxygen intermediate levels as monitored by flow cytometry using oxidation-sensitive fluorescent probes. The data reveal a novel mechanism for increasing glutathione levels through stimulation of the pentose phosphate pathway and identify dehydroascorbate as an antioxidant for cells susceptible to the pro-oxidant and proapoptotic properties of vitamin C.	SUNY Hlth Sci Ctr, Coll Med, Dept Med, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Microbiol & Immunol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.			Perl, Andras/0000-0002-5017-1348	FIC NIH HHS [1FO5TW05421] Funding Source: Medline; NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano Y, 1998, ANTICANCER RES, V18, P2503; Banhegyi G, 1997, FREE RADICAL BIO MED, V23, P793, DOI 10.1016/S0891-5849(97)00062-2; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Banki K, 1999, J IMMUNOL, V162, P1466; BARBIERI D, 1994, BIOCHEM BIOPH RES CO, V201, P1109, DOI 10.1006/bbrc.1994.1820; Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Braun L, 1996, FEBS LETT, V390, P183, DOI 10.1016/0014-5793(96)00654-0; BUROW S, 1987, EUR J CELL BIOL, V43, P128; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Constantini P., 1996, J BIOL CHEM, V271, P6746; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; Devamanoharan PS, 1996, MOL CELL BIOCHEM, V156, P131, DOI 10.1007/BF00426335; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HARAPANHALLI RS, 1993, J CHROMATOGR-BIOMED, V614, P233, DOI 10.1016/0378-4347(93)80314-T; HEINRICH PC, 1976, CANCER RES, V36, P3189; INGEBRETSEN OC, 1982, BIOCHIM BIOPHYS ACTA, V684, P21, DOI 10.1016/0005-2736(82)90044-X; KANFER J, 1960, J BIOL CHEM, V235, P2518; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Mayes P., 1993, HARPERS BIOCH, P201; MEISTER A, 1994, J BIOL CHEM, V269, P9397; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; Parker J.E., 1979, NATURE, V278, P737; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; PONTREMOLI S, 1961, P NATL ACAD SCI USA, V47, P1942, DOI 10.1073/pnas.47.12.1942; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUDACK D, 1971, J BIOL CHEM, V246, P1249; Sakagami H, 1997, ANTICANCER RES, V17, P3513; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TANNER MK, 1993, CYTOMETRY, V14, P59, DOI 10.1002/cyto.990140111; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UDENFRIEND S, 1954, J BIOL CHEM, V208, P731; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	53	90	96	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1352	1361		10.1096/fj.14.10.1352	http://dx.doi.org/10.1096/fj.14.10.1352			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877828				2022-12-25	WOS:000087932200010
J	Touriol, C; Roussigne, M; Gensac, MC; Prats, H; Prats, AC				Touriol, C; Roussigne, M; Gensac, MC; Prats, H; Prats, AC			Alternative translation initiation of human fibroblast growth factor 2 mRNA controlled by its 3 '-untranslated region involves a poly(A) switch and a translational enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCAPPED MESSENGER-RNA; HUMAN FIBROBLAST-GROWTH-FACTOR-2; REGULATES TRANSLATION; EXPRESSION; PROTEIN; FORMS; CELLS; SEQUENCE; CUG; POLYADENYLATION	Five fibroblast growth factor 2 (FGF-2) isoforms are synthesized from human FGF-2 mRNA by a process of alternative initiation of translation. The regulation of FGF-2 isoform expression by the mRNA 5823-nucleotide-long 3'-untranslated region containing eight alternative polyadenylation sites was examined. Because previous studies had shown that FGF-2 expression was regulated in primary cells but not in transformed cells, primary human skin fibroblasts were used in this study. Using an approach of cell transfection with synthetic reporter mRNAs, a novel translational enhancer (3'-TE) was identified in the 1370-nucleotide mRNA segment located upstream from the eighth poly(A) site, Deletion mutagenesis showed that the 3'-TE was composed of two domains with additive effects. The 3'-TE exhibited the unique feature of modulating the use of FGF-2 alternative initiation codons, which favored the relative expression of CUG-initiated isoforms. Interestingly, the use of an alternative polydenylation site removing the 3'-TE was detected in skin fibroblasts in response to heat shock and cell density variations. At high cell densities, 3'-TE removal was correlated with a loss of CUG-initiated FGF-2 expression. These data show that the FGF-2 mRNA 3'-untranslated region is able to modulate FGF-2 isoform expression by the coupled processes of translation activation and alternative polyadenylation.	CHU Rangueil, Inst Louis Bugnard, INSERM, U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U397, Ave Jean Poulhes, F-31403 Toulouse 04, France.		Prats, Anne-Catherine/E-5051-2016; TOURIOL, Christian/O-8949-2014	Prats, Anne-Catherine/0000-0002-5282-3776; TOURIOL, Christian/0000-0003-1219-4693; Roussigne, Myriam/0000-0002-4240-4105; Prats, Herve/0000-0002-4861-2167				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BENSAID M, 1989, EXP EYE RES, V45, P801; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BOST LM, 1993, GROWTH FACTORS, V9, P195, DOI 10.3109/08977199309010832; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Davis MG, 1997, J MOL CELL CARDIOL, V29, P1061, DOI 10.1006/jmcc.1997.0383; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gallie DR, 1996, NUCLEIC ACIDS RES, V24, P1954, DOI 10.1093/nar/24.10.1954; Galy B, 1999, CANCER RES, V59, P165; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; KNEE RS, 1994, BIOCHEM BIOPH RES CO, V205, P577, DOI 10.1006/bbrc.1994.2704; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEATHERS V, 1993, MOL CELL BIOL, V13, P5331, DOI 10.1128/MCB.13.9.5331; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	39	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19361	19367		10.1074/jbc.M908431199	http://dx.doi.org/10.1074/jbc.M908431199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858460	Green Published, hybrid			2022-12-25	WOS:000087815900096
J	Sangan, P; Brill, SR; Sangan, S; Forbush, B; Binder, HJ				Sangan, P; Brill, SR; Sangan, S; Forbush, B; Binder, HJ			Basolateral K-Cl cotransporter regulates colonic potassium absorption in potassium depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT DISTAL COLON; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VOLUME REGULATION; ALPHA-SUBUNIT; TRANSPORT; MEMBRANE; CELLS; H+,K+-ATPASE; ALDOSTERONE	Active potassium absorption in the rat distal colon is electroneutral, Na+-independent, partially chloride-dependent, and energized by an apical membrane H,K-ATPase, Both dietary sodium and dietary potassium depletion substantially increase active potassium absorption. We have recently reported that sodium depletion up regulates H,K-ATPase alpha-subunit mRNA and protein expression, whereas potassium depletion upregulates H,K-ATPase beta-subunit mRNA and protein expression. Because overall potassium absorption is non-conductive, H-CL cotransport (KCC) at the basolateral membrane may also be involved in potassium absorption. Although KCC1 has not been cloned from the colon, we established, in Northern blot analysis with mRNA from the rat distal colon using rabbit kidney KCC1 cDNA as a probe, the presence of an expected size mRNA in the rat colon, This KCC1 mRNA is substantially increased by potassium depletion but only minimally by sodium depletion. KCC1-specific antibody identified a 155-kDa protein in rat colonic basolateral membrane. Potassium depletion but not sodium depletion resulted in an increase in KCC1 protein expression in basolateral membrane. The increase of colonic KCC1 mRNA abundance and KCC1 protein expression in potassium depletion of the rat colonic basolateral membrane suggests that K-CI cotransporter: 1) is involved in transepithelial potassium absorption and 2) regulates the increase in potassium absorption induced by dietary potassium depletion, We conclude that active potassium absorption in the rat distal colon involves the coordinated regulation of both apical membrane II,K-ATPase and basolateral membrane KCC1 protein.	Yale Univ, Sch Med, Sect Digest Dis, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Binder, HJ (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, Dept Internal Med, 333 Cedar St,89 LMP, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK 18877, DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHINI L, 1988, J EXP BIOL, V137, P303; BINDER HJ, 1994, PHYSL GASTROINTESTIN, V2, P2133; BRUGNARA C, 1989, AM J PHYSIOL, V256, pC994, DOI 10.1152/ajpcell.1989.256.5.C994; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELGASILLO JR, 1991, AM J PHYSIOL, V261, pG1005; FOSTER ES, 1984, AM J PHYSIOL, V246, pG611, DOI 10.1152/ajpgi.1984.246.5.G611; FOSTER ES, 1986, AM J PHYSIOL, V251, pG619, DOI 10.1152/ajpgi.1986.251.5.G619; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; JAISSER F, 1993, AM J PHYSIOL, V265, pC1080, DOI 10.1152/ajpcell.1993.265.4.C1080; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; KRAMHOFT B, 1986, AM J PHYSIOL, V251, pC369, DOI 10.1152/ajpcell.1986.251.3.C369; LARSON M, 1984, J MEMBRANE BIOL, V81, P219, DOI 10.1007/BF01868715; Lauf P K, 1981, Prog Clin Biol Res, V56, P13; LEE J, 1995, J CLIN INVEST, V96, P2001; Liapis H, 1998, AM J PHYSIOL-CELL PH, V275, pC1432, DOI 10.1152/ajpcell.1998.275.6.C1432; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PERRY PB, 1993, AM J PHYSIOL, V265, pC763, DOI 10.1152/ajpcell.1993.265.3.C763; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rajendran VM, 2000, J BIOL CHEM, V275, P13035, DOI 10.1074/jbc.275.17.13035; Rajendran VM, 1998, AM J PHYSIOL-GASTR L, V274, pG424, DOI 10.1152/ajpgi.1998.274.2.G424; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; RAJENDRAN VM, 1989, J BIOL CHEM, V264, P18638; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Sangan P, 2000, AM J PHYSIOL-CELL PH, V278, pC182, DOI 10.1152/ajpcell.2000.278.1.C182; Sangan P, 1999, AM J PHYSIOL-CELL PH, V276, pC350, DOI 10.1152/ajpcell.1999.276.2.C350; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; SWEIRY JH, 1989, J CLIN INVEST, V83, P844, DOI 10.1172/JCI113967; TURNAMIAN SG, 1989, J CLIN INVEST, V84, P1924, DOI 10.1172/JCI114380	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30813	30816		10.1074/jbc.M003931200	http://dx.doi.org/10.1074/jbc.M003931200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878016	hybrid			2022-12-25	WOS:000089762700013
J	Rangasamy, D; Wilson, VG				Rangasamy, D; Wilson, VG			Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; GTPASE-ACTIVATING PROTEIN; DNA-POLYMERASE-ALPHA; LARGE T-ANTIGEN; REPLICATION PROTEIN; SUMO-1 MODIFICATION; COVALENT MODIFICATION; TYPE-1 E1; IN-VITRO; PML	Papillomavirus E1 protein is the replication initiator that recognizes and binds to the viral origin and initiates DNA strand separation through its ATP-dependent helicase activity. The E1 protein also functions in viral DNA replication by recruiting several cellular proteins to the origin, including host DNA polymerase alpha and replication protein A To identify other cellular proteins that interact with bovine papillomavirus E1, an HeLa cDNA library was screened using a yeast two hybrid assay. The host cell sumoylating enzyme, Ubc9, was found to interact specifically with E1 both in vitro and in vivo. Mapping studies localized critical E1 sequences for interaction to amino acids 315-459 and strongly implicated leucine 420 as critical for E1.Ubc9 complex formation. In addition to binding E1, Ubc9 catalyzed the covalent linkage of the ubiquitin-like protein, SUMO-1, to E1, An E1 mutant unable to bind Ubc9 showed normal intracellular stability, but was impaired for intranuclear distribution. Failure to accumulate in appropriate nuclear subdomains may account for the previously demonstrated replication defect of a human papillomavirus 16 E1 protein that was also unable to bind Ubc9 and suggests that sumoylation is a functionally important modification with regulatory implications for papillomavirus replication.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wilson, VG (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA.	v-wilson@tamu.edu	, Van G Wilson/B-1868-2009					BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gonzalez A, 2000, J VIROL, V74, P245, DOI 10.1128/JVI.74.1.245-253.2000; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Ma TL, 1999, P NATL ACAD SCI USA, V96, P382, DOI 10.1073/pnas.96.2.382; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; McShan GD, 2000, J GEN VIROL, V81, P1995, DOI 10.1099/0022-1317-81-8-1995; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; SANTUCCI S, 1990, J VIROL, V64, P6027, DOI 10.1128/JVI.64.12.6027-6039.1990; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Swindle CS, 1998, J VIROL, V72, P1994, DOI 10.1128/JVI.72.3.1994-2001.1998; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; XIAO XL, 1994, J GEN VIROL, V75, P2463, DOI 10.1099/0022-1317-75-9-2463; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yasugi T, 1997, J VIROL, V71, P5942, DOI 10.1128/JVI.71.8.5942-5951.1997	54	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30487	30495		10.1074/jbc.M003898200	http://dx.doi.org/10.1074/jbc.M003898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10871618	hybrid			2022-12-25	WOS:000089577900078
J	Poppers, DM; Schwenger, P; Vilcek, J				Poppers, DM; Schwenger, P; Vilcek, J			Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of I kappa B-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAF-INTERACTING PROTEIN; FACTOR-RECEPTOR; KINASE ACTIVATION; SODIUM-SALICYLATE; TNF; PHOSPHORYLATION; EXPRESSION; CELLS; INTERNALIZATION; INHIBITION	Transcription factor NF-kappa B is normally sequestered in the cytoplasm, complexed with I kappa B inhibitory proteins. Tumor necrosis factor (TNF) and interleukin-1 induce I kappa B-alpha phosphorylation, leading to I kappa B-alpha degradation and translocation of NF-kappa B to the nucleus where it activates genes important in inflammatory and immune responses. TNF and interleukin-1 actions are typically terminated by desensitization, and I kappa B-alpha reappearance normally occurs within 30-60 min. We found that in normal human FS-4 fibroblasts maintained in the presence of TNF, I kappa B-alpha protein failed to return to base-line levels for up to 15 h. Removal of TNF at any time during the 15-h period resulted in complete I kappa B-alpha resynthesis, suggesting that I kappa B-alpha reappearance was prevented by continued TNF signaling. Long term exposure of FS-4 fibroblasts to TNF led to a persistent presence of I kappa B-alpha mRNA, sustained I kappa B kinase activation, continuous proteasome-mediated degradation of I kappa B-alpha, and sustained nuclear localization of NF-kappa B. Continuous exposure of FS-4 cells to TNF did not bad to a sustained activation of p38 or ERK mitogen-activated protein kinases, suggesting that not all TNF-induced signaling pathways are persistently activated. These findings challenge the notion that all cytokine-mediated signals are rapidly terminated by desensitization and illustrate the need to elucidate the process of deactivation of TNF-induced signaling.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Schwenger, P (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R35CA049731, R01CA075071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA49731, R01-CA75071] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Decoster E, 1998, J BIOL CHEM, V273, P3271, DOI 10.1074/jbc.273.6.3271; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Feldmann M, 1998, Int Rev Immunol, V17, P217, DOI 10.3109/08830189809084493; Gerecitano J, 1999, J INTERF CYTOK RES, V19, P393, DOI 10.1089/107999099314108; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; IMAMURA K, 1987, J IMMUNOL, V139, P2989; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kollias G, 1999, IMMUNOL REV, V169, P175, DOI 10.1111/j.1600-065X.1999.tb01315.x; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pinckard JK, 1997, J IMMUNOL, V158, P3869; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VANOSTADE X, 1993, NATURE, V361, P266; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	45	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29587	29593		10.1074/jbc.M002806200	http://dx.doi.org/10.1074/jbc.M002806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10869349	hybrid			2022-12-25	WOS:000089439800055
J	Bai, Y; Fox, DT; Lacy, JA; Van Lanen, SG; Iwata-Reuyl, D				Bai, Y; Fox, DT; Lacy, JA; Van Lanen, SG; Iwata-Reuyl, D			Hypermodification of tRNA in thermophilic archaea - Cloning, overexpression, and characterization of tRNA-guanine transglycosylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSCRIPTIONAL MODIFICATION; TRANSFER RIBONUCLEIC-ACID; ACTIVE-SITE NUCLEOPHILE; MODIFIED NUCLEOSIDE-Q; TRANSFER-RNA; ESCHERICHIA-COLI; SEQUENCE; PRECURSOR; QUEUINE; IDENTIFICATION	tRNA is structurally unique among nucleic acids in harboring an astonishing diversity of modified nucleosides. Two structural variants of the hypermodified nucleoside 7-deazaguanosine have been identified in tRNA: queuosine, which is found at the wobble position of the anticodon in bacterial and eukaryotic tRNA, and archaeosine, which is found at position 15 of the D-loop in archaeal tRNA. From homology searching of the Methanococcus jannaschii genome, a gene coding for an enzyme in the biosynthesis of archaeosine (tgt) was identified and cloned. The tgt gene was overexpressed in an Escherichia coli expression system, and the recombinant tRNA-guanine transglycosylase enzyme was purified and characterized. The enzyme catalyzes a transglycosylation reaction in which guanine is eliminated from position 15 of the tRNA and an archaeosine precursor (preQ(0)) is inserted. The enzyme is able to utilize both guanine and the 7-deazaguanine base pre/Q(0) as substrates, but not other 7-deazaguanine bases, and is able to modify tRNA from all three phylogenetic domains. The enzyme shows optimal activity at high temperature and acidic pH, consistent with the optimal growth conditions of M. jannaschii. The nature of the temperature dependence is consistent with a requirement for some degree of tRNA tertiary structure in order for recognition by the enzyme to occur.	Portland State Univ, Dept Chem, Portland, OR 97201 USA	Portland State University	Iwata-Reuyl, D (corresponding author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.		Fox, David/B-3222-2011					AKIMOTO H, 1988, J CHEM SOC PERK T 1, P1637, DOI 10.1039/p19880001637; Bjork G. R., 1990, CHOMATOGRAPHY MODIFI, P13; Bjork Glenn R., 1995, P165; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GUPTA R, 1984, J BIOL CHEM, V259, P9461; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KERSTEN H, 1988, Biofactors, V1, P27; KERSTEN H, 1990, CHROMATOGRAPHY MODIF, P69; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; Maniatis T., 1982, MOL CLONING LAB MANU; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; Migawa MT, 1996, SYNTHETIC COMMUN, V26, P3317, DOI 10.1080/00397919608004641; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; ROBB FT, 1995, ARCHAEA LAB MANUAL, P4; Romier C, 1997, FEBS LETT, V416, P93, DOI 10.1016/S0014-5793(97)01175-7; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146	37	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28731	28738		10.1074/jbc.M002174200	http://dx.doi.org/10.1074/jbc.M002174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862614	hybrid			2022-12-25	WOS:000089330700054
J	Baumeister, H; Meyerhof, W				Baumeister, H; Meyerhof, W			The POU domain transcription factor Tst-1 activates somatostatin receptor 1 gene expression in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; DIFFERENTIAL EXPRESSION; INSULIN-SECRETION; SUBTYPES SSTR1; GLIAL-CELLS; RAT; PROMOTER; IDENTIFICATION; FAMILY; ACID	The peptide hormone somatostatin inhibits the release of insulin. The gene encoding somatostatin receptor 1 is expressed in pancreatic p-cells and insulinoma RIN 1046-38 cells. In the present study the mechanisms underlying the regulation of the somatostatin receptor 1 gene in pancreatic p-cells were investigated. Transient transfections of RIN 1046-38 cells with promoter/reporter gene constructs and footprint analysis revealed two regions, fp1 and fp2, that were necessary for the observed promoter activity. Mutagenesis of the fp2 region delineated the cis-acting element to the motif 5'-TTAATCATT-3'. The POU domain transcription factor Tst-1 was identified as trans-activator mediating the 5'-TTAATCATT-3' motif-dependent transcription in RIN 1046-38 cells and heterologous CV1 cells. Tst-1, known as a transcriptional regulator in keratinocytes, glial cells, and neurons, has been detected by immunohistochemistry in pancreatic islets. Altogether, we demonstrate Tst-1 as transcriptional regulator in pancreatic neuroendocrine cells.	Deutsch Inst Ernahruungsforsch, Abt Mol Genet, D-14558 Potsdam, Germany; Univ Potsdam, D-14558 Potsdam, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Potsdam	Meyerhof, W (corresponding author), Deutsch Inst Ernahruungsforsch, Abt Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Potsdam, Germany.	meyerhof@www.dife.de						Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Baumeister H, 2000, MOL ENDOCRINOL, V14, P255, DOI 10.1210/me.14.2.255; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; Chen LC, 1997, J BIOL CHEM, V272, P18666, DOI 10.1074/jbc.272.30.18666; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fagan SP, 1998, SURGERY, V124, P254, DOI 10.1016/S0039-6060(98)70128-X; FULLER PJ, 1995, J CELL BIOCHEM, V58, P260, DOI 10.1002/jcb.240580214; Genuth SM., 1993, PHYSIOLOGY, P851; GHERZI R, 1995, EXP CELL RES, V218, P460, DOI 10.1006/excr.1995.1179; GROMADA J, 1998, PFLUEGERS ARCH, V5, P583; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HSU WH, 1991, J BIOL CHEM, V266, P837; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Jaegle M, 1998, MICROSC RES TECHNIQ, V41, P372; KONG H, 1994, NEUROSCIENCE, V59, P175, DOI 10.1016/0306-4522(94)90108-2; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; Liapakis G, 1996, J BIOL CHEM, V271, P20331, DOI 10.1074/jbc.271.34.20331; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; McEvilly RJ, 2000, PROG NUCLEIC ACID RE, V63, P223, DOI 10.1016/S0079-6603(08)60724-2; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Mitra SW, 1999, ENDOCRINOLOGY, V140, P3790, DOI 10.1210/en.140.8.3790; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Poitout V, 1996, DIABETES METAB, V22, P7; Portois L, 1999, J BIOL CHEM, V274, P8181, DOI 10.1074/jbc.274.12.8181; RAULF F, 1994, DIGESTION, V55, P46, DOI 10.1159/000201201; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSSOWSKI WJ, 1994, PEPTIDES, V15, P1421, DOI 10.1016/0196-9781(94)90118-X; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schafer J, 1999, NEUROPEPTIDES, V33, P457, DOI 10.1054/npep.1999.0762; Schonemann MD, 1998, ADV EXP MED BIOL, V449, P39; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; WILSON CM, 1979, ANAL BIOCHEM, V96, P263, DOI 10.1016/0003-2697(79)90581-5; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	56	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28882	28887		10.1074/jbc.M002175200	http://dx.doi.org/10.1074/jbc.M002175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10866997	hybrid			2022-12-25	WOS:000089330700072
J	Bdeir, K; Kuo, A; Mazar, A; Sachais, BS; Xiao, WZ; Gawlak, S; Harris, S; Higazi, A; Cines, DB				Bdeir, K; Kuo, A; Mazar, A; Sachais, BS; Xiao, WZ; Gawlak, S; Harris, S; Higazi, A; Cines, DB			A region in domain II of the urokinase receptor required for urokinase binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR; LIGAND-BINDING; RECOGNITION; AFFINITY; PATHWAY; COMPLEX; SITES; CELLS	The urokinase receptor is composed of three homologous domains based on disulfide spacing. The contribution of each domain to the binding and activation of single chain urokinase (scuPA) remains poorly understood. In the present paper we examined the role of domain II (DII) in these processes. Repositioning DII to the amino or carboxyl terminus of the molecule abolished binding of scuPA as did deleting the domain entirely. By using alanine-scanning mutagenesis, we identified a g-amino acid continuous sequence in DII (Arg(137)-Arg(145)) required for both activities. Competition-inhibition and surface plasmon resonance studies demonstrated that mutation of Lys(139) and His(143) to alanine in soluble receptor (suPAR) reduced the affinity for scuPA similar to 5-fold due to an increase in the "off rate." Mutation of Arg(137), Arg(142), and Arg(145), each to alanine, leads to an similar to 100-fold decrease in affinity attributable to a 10-fold decrease in the apparent "on rate" and a 6-fold increase in off rate. These differences were confirmed on cells expressing variant urokinase receptor. suPAR-K139A/H143A displayed a 50% reduction in scuPA-mediated plasminogen activation activity, whereas the 3-arginine variant was unable to stimulate scuPA activity at all. Mutation of the three arginines did not affect binding of a decamer peptide antagonist of scuPA known to interact with DI and DIII. However, this mutation abolished both the binding of soluble DI to DII-III in the presence of scuPA and the synergistic activation of scuPA mediated by DI and wild type DII-DIII. These data show that DII is required for high affinity binding of scuPA and its activation. DII does not serve merely as a spacer function but appears to be required for interdomain cooperativity.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Angstrom Pharmaceut, San Diego, CA 92121 USA; Hadassah Med Org, Dept Clin Biochem, IL-91120 Jerusalem, Israel	University of Pennsylvania; University of Pennsylvania; Hebrew University of Jerusalem; Hadassah University Medical Center	Cines, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellat Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	dcines@mail.med.upenn.edu	Sachais, Bruce/D-1236-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775, R01HL060169, R01HL058107] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58107, T32 HL007775, HL60169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aceto J, 1999, BIOCHEMISTRY-US, V38, P992, DOI 10.1021/bi9810914; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LANDT O, 1990, GENE AMST, P125; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Newman PM, 1999, BRIT J HAEMATOL, V107, P303, DOI 10.1046/j.1365-2141.1999.01717.x; Oda M, 1998, EUR J BIOCHEM, V256, P411, DOI 10.1046/j.1432-1327.1998.2560411.x; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; POLLANEN JJ, 1993, BLOOD, V82, P2719; Preissner KT, 1999, BASIC RES CARDIOL, V94, P315, DOI 10.1007/s003950050157; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; Schwartz BS, 1999, J BIOL CHEM, V274, P15278, DOI 10.1074/jbc.274.21.15278; Sitrin RG, 1999, J IMMUNOL, V163, P6193; Wang JY, 1997, EUR J BIOCHEM, V247, P256, DOI 10.1111/j.1432-1033.1997.00256.x; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	33	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28532	28538		10.1074/jbc.M001595200	http://dx.doi.org/10.1074/jbc.M001595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864923	hybrid			2022-12-25	WOS:000089330700028
J	Ceponis, PJM; Botelho, F; Richards, CD; McKay, DM				Ceponis, PJM; Botelho, F; Richards, CD; McKay, DM			Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway - Lack of evidence for STAT 6 involvement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; BARRIER FUNCTION; CROHNS-DISEASE; ION-TRANSPORT; CELLS; EXPRESSION; IL-4	Interleukins 4 and 13 can affect their target cells by activation of signal transducer and activator of transcription 6 (STAT 6) or phosphatidylinositol 3-kinase (PI3K). We examined the signal transduction events involved in IL-4 and IL-13 regulation of epithelial paracellular permeability using T84 cells, a model human colonic epithelium. T84 cells treated with IL-4 or IL-13 displayed virtually identical dose- and time-dependent STAT 6 activation as assessed by electrophoretic mobility shift assay (EMSA) and decreases in transepithelial resistance (TER), STAT 6 DNA binding activity was maximal in nuclear extracts 30 min after exposure to IL-4 or IL-13, and TER was maximally reduced by 24 h posttreatment. Pretreatment of epithelia with transcription factor decoys (phosphorothioated DNA oligonucleotides containing the STAT 6 binding site) dramatically reduced STAT 6 activation as detected by EMSA, but did not attenuate the TER reduction by IL-4 or IL-13. In contrast, although the PI3K inhibitors wortmannin and LY294002 did not affect IL-4 or IL-13 STAT 6 activation, they significantly inhibited the ability of either cytokine to lower TER. Thus, we provide evidence for PI3K as the major proximal signaling event in IL-4 and IL-13 regulation of TER and speculate that pharmacological targeting of enterocytic PI3K activity may represent a means to manipulate epithelial permeability.	McMaster Univ, Intestinal Dis Res Programme, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Infect & Immun Programme, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	McKay, DM (corresponding author), McMaster Univ, Intestinal Dis Res Programme, HSC-3N5,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		McKay, Derek/HCH-3240-2022	Richards, Carl/0000-0002-0081-2231				Ahmad F, 1999, J IMMUNOL, V162, P4864; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERNARD A, 1996, J ALLERGY CLIN IMMUN, V97, P1173; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; COLGAN SP, 1994, J IMMUNOL, V153, P2122; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Desreumaux P, 1997, GASTROENTEROLOGY, V113, P118, DOI 10.1016/S0016-5085(97)70116-1; Donnelly GAE, 1999, J INFECT DIS, V180, P1590, DOI 10.1086/315075; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3; Ikizawa K, 1996, CELL IMMUNOL, V170, P134, DOI 10.1006/cimm.1996.0143; Jobin C, 1998, J IMMUNOL, V160, P410; Khaled AR, 1998, CLIN IMMUNOL IMMUNOP, V86, P170, DOI 10.1006/clin.1997.4486; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Lu J, 1998, J PHARMACOL EXP THER, V287, P128; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; McKay DM, 1999, GUT, V44, P283, DOI 10.1136/gut.44.2.283; Mizoguchi A, 1999, GASTROENTEROLOGY, V116, P320, DOI 10.1016/S0016-5085(99)70128-9; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ohmori Y, 1996, J IMMUNOL, V157, P2058; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Pfeffer LM, 2000, AM J PHYSIOL-CELL PH, V278, pC331, DOI 10.1152/ajpcell.2000.278.2.C331; Philpott DJ, 1998, INFECT IMMUN, V66, P1680, DOI 10.1128/IAI.66.4.1680-1687.1998; Reinecker HC, 1996, GASTROENTEROLOGY, V111, P1706, DOI 10.1016/S0016-5085(96)70036-7; Schmitz H, 1999, GASTROENTEROLOGY, V116, P301, DOI 10.1016/S0016-5085(99)70126-5; Sherman MA, 1999, J IMMUNOL, V162, P2703; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Siemasko K, 1998, J IMMUNOL, V160, P1581; Soderholm JD, 1999, GASTROENTEROLOGY, V117, P65, DOI 10.1016/S0016-5085(99)70551-2; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Turner JR, 1999, AM J PHYSIOL-CELL PH, V277, pC554, DOI 10.1152/ajpcell.1999.277.3.C554; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yu CR, 1998, J IMMUNOL, V161, P218; Zund G, 1996, J BIOL CHEM, V271, P7460	46	103	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29132	29137		10.1074/jbc.M003516200	http://dx.doi.org/10.1074/jbc.M003516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871612	hybrid			2022-12-25	WOS:000089330700102
J	Lame, MW; Jones, AD; Wilson, DW; Dunston, SK; Segall, HJ				Lame, MW; Jones, AD; Wilson, DW; Dunston, SK; Segall, HJ			Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLIZIDINE ALKALOID MONOCROTALINE; IMMOBILIZED PH GRADIENTS; CHAPERONE-LIKE ACTIVITY; RED-BLOOD-CELLS; DISULFIDE-ISOMERASE; GLUTATHIONE CONJUGATE; REACTIVE METABOLITES; C-14 MONOCROTALINE; SAMPLE APPLICATION; ESCHERICHIA-COLI	A single administration of monocrotaline to rats results in pathologic alterations in the lung and heart similar to human pulmonary hypertension. In order to produce these lesions, monocrotaline is oxidized to monocrotaline pyrrole in the liver followed by hematogenous transport to the lung where it injures pulmonary endothelium. In this study, we determined specific endothelial targets for C-14-monocrotaline pyrrole using two-dimensional gel electrophoresis and autoradiographic detection of protein metabolite adducts, Selective labeling of specific proteins was observed. Labeled proteins were digested with trypsin, and the resulting peptides were analyzed using matrix-assisted laser desorption ionization mass spectrometry, The results were searched against sequence data bases to identify the adducted proteins, Five abundant adducted proteins were identified as galectin-1, protein-disulfide isomerase, probable protein-disulfide isomerase (ER60), beta- or gamma-cytoplasmic actin, and cytoskeletal tropomyosin (TM30-NM). With the exception of actin, the proteins identified in this study have never been identified as potential targets for pyrroles, and the majority of these proteins have either received no or minimal attention as targets for other electrophilic compounds. The known functions of these proteins are discussed in terms of their potential for explaining the pulmonary toxicity of monocrotaline.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Penn State Univ, Davey Lab 152, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Davey Lab 152, Intercoll Mass Spectrometry Ctr, University Pk, PA 16802 USA	University of California System; University of California Davis; University of California System; University of California Davis; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Segall, HJ (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.	HJSegall@ucdavis.edu	Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NCRR NIH HHS [RR11318] Funding Source: Medline; NHLBI NIH HHS [HL48411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011318] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BOELSTERLI UA, 1993, DRUG METAB REV, V25, P395, DOI 10.3109/03602539308993981; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CAI H, 1994, J BIOL CHEM, V269, P24550; CERRA RF, 1984, J CELL BIOL, V98, P1580, DOI 10.1083/jcb.98.4.1580; CHESNEY CF, 1973, AM J PATHOL, V70, P489; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; CLAUSER KR, 1996, P 44 ASMS C MASS SPE, P365; Cohen SD, 1997, DRUG METAB REV, V29, P59, DOI 10.3109/03602539709037573; COLES B, 1985, DRUG METAB REV, V15, P1307, DOI 10.3109/03602538409029962; Cotran R.S., 1994, ROBBINS PATHOLOGIC B, V5th ed., P51; Coulombe RA, 1999, TOXICOL APPL PHARM, V154, P198, DOI 10.1006/taap.1998.8552; CULVENOR CC, 1970, AUST J CHEM, V23, P1853, DOI 10.1071/CH9701853; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; HOORN CM, 1993, TOXICOL APPL PHARM, V120, P281, DOI 10.1006/taap.1993.1113; HOORN CM, 1992, AM J PHYSIOL, V262, pL740, DOI 10.1152/ajplung.1992.262.6.L740; HUXTABLE RJ, 1979, GEN PHARMACOL, V10, P159, DOI 10.1016/0306-3623(79)90082-X; Jones PL, 1996, CIRC RES, V79, P1131, DOI 10.1161/01.RES.79.6.1131; KAJIKAWA T, 1986, LIFE SCI, V39, P1177, DOI 10.1016/0024-3205(86)90349-8; Kay JM, 1969, CROTALARIA SPECTABIL, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAME MW, 1995, DRUG METAB DISPOS, V23, P422; Lame MW, 1996, J LABELLED COMPD RAD, V38, P1053, DOI 10.1002/(SICI)1099-1344(199612)38:12<1053::AID-JLCR927>3.0.CO;2-Q; LAME MW, 1990, TOXICOL LETT, V51, P321, DOI 10.1016/0378-4274(90)90075-W; LAME MW, 1991, DRUG METAB DISPOS, V19, P516; Lame MW, 1997, CHEM RES TOXICOL, V10, P694, DOI 10.1021/tx960173v; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LOPES AA, 1993, ANGIOLOGY, V44, P701, DOI 10.1177/000331979304400905; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MATTOCKS AR, 1990, CHEM-BIOL INTERACT, V76, P19; MATTOCKS AR, 1983, TOXICOL LETT, V16, P1, DOI 10.1016/0378-4274(83)90002-4; MATTOCKS AR, 1989, TOXICON, V27, P561, DOI 10.1016/0041-0101(89)90117-7; MATTOCKS AR, 1990, CHEM-BIOL INTERACT, V75, P225; MATTOCKS AR, 1968, NATURE, V217, P723, DOI 10.1038/217723a0; MEYRICK BO, 1982, AM J PATHOL, V106, P84; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Nagayama Sekio, 1994, Journal of Toxicological Sciences, V19, P155; NOMURA M, 1987, EUR J BIOCHEM, V163, P467, DOI 10.1111/j.1432-1033.1987.tb10892.x; PAN LC, 1993, TOXICOLOGY, V79, P21, DOI 10.1016/0300-483X(93)90203-5; PAN LC, 1993, TOXICOL APPL PHARM, V118, P87, DOI 10.1006/taap.1993.1013; PAN LC, 1991, TOXICOL APPL PHARM, V110, P336, DOI 10.1016/S0041-008X(05)80016-X; Pappin Darryl J. C., 1997, V64, P165; PEARSON RG, 1967, J AM CHEM SOC, V89, P1827, DOI 10.1021/ja00984a014; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; POHL LR, 1989, DRUG METAB REV, V20, P203, DOI 10.3109/03602538909103537; Pohl LR, 1990, BIOL REACT INTERMED, VIV, P111; Qiu YC, 1998, J BIOL CHEM, V273, P17940, DOI 10.1074/jbc.273.28.17940; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; REED RL, 1992, XENOBIOTICA, V22, P1321, DOI 10.3109/00498259209053160; Reid MJ, 1998, J BIOCHEM MOL TOXIC, V12, P157; ROBERTSON KA, 1977, CANCER RES, V37, P3141; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SEAWRIGHT AA, 1991, VET HUM TOXICOL, V33, P286; SEGALL HJ, 1991, HDB NATURAL TOXINS, V6, P3; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Taylor DW, 1997, TOXICOL APPL PHARM, V143, P196, DOI 10.1006/taap.1996.8083; Thomas HC, 1998, TOXICOL APPL PHARM, V151, P236, DOI 10.1006/taap.1998.8458; Thomas HC, 1998, AM J RESP CELL MOL, V19, P129, DOI 10.1165/ajrcmb.19.1.2895; Thomas HC, 1996, TOXICOL APPL PHARM, V141, P319; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; VUORI K, 1992, J BIOL CHEM, V267, P7211; WAGENVOORT CA, 1993, CHEST, V103, P844, DOI 10.1378/chest.103.3.844; WAGNER JG, 1993, AM J PHYSIOL, V264, pL517, DOI 10.1152/ajplung.1993.264.5.L517; Walker KW, 1997, J BIOL CHEM, V272, P8845; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON DW, 1989, MICROVASC RES, V38, P57; WILSON DW, 1992, CRIT REV TOXICOL, V22, P307, DOI 10.3109/10408449209146311; Wilson DW, 1998, TOXICOL APPL PHARM, V152, P138, DOI 10.1006/taap.1998.8488; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yamaoka K, 1996, J BIOCHEM-TOKYO, V119, P878; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZEECE MG, 1979, BIOCHIM BIOPHYS ACTA, V581, P365, DOI 10.1016/0005-2795(79)90258-7	90	64	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29091	29099		10.1074/jbc.M001372200	http://dx.doi.org/10.1074/jbc.M001372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10875930	hybrid			2022-12-25	WOS:000089330700097
J	Patel, AJ; Maingret, F; Magnone, V; Fosset, M; Lazdunski, M; Honore, E				Patel, AJ; Maingret, F; Magnone, V; Fosset, M; Lazdunski, M; Honore, E			TWIK-2, an inactivating 2P domain K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; CLONING; PORE; SUBUNIT; ACID; PH	We cloned human and rat TWIK-2 and expressed this novel 2P domain K+ channel in transiently transfected COS cells. TWIK-2 is highly expressed in the gastrointestinal tract, the vasculature, and the immune system. Rat TWIK-2 currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological K+ gradient and mild inward rectification in symmetrical K+ conditions. TWIK-2 currents are inactivating at depolarized potentials, and the kinetic of inactivation is highly temperature-sensitive. TWIK-2 shows an extremely low conductance, which prevents the visualization of discrete single channel events. The inactivation and rectification are intrinsic properties of TWIK-2 channels. In a physiological K+ gradient, TWIK-2 is half inhibited by 0.1 mM Ba2+, quinine, and quinidine, Finally, cysteine 53 in the M1P1 external loop is required for functional expression of TWIK-2 but is not critical for subunit self-assembly. TWIK-2 is the first reported 2P domain K+ channel that inactivates. The base-line, transient, and delayed activities of TWIK-2 suggest that this novel 2P domain K+ channel may play an important functional role in cell electrogenesis.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route des Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr		HONORE, Eric/0000-0002-8007-0919				Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Immke D, 1999, J GEN PHYSIOL, V113, P819, DOI 10.1085/jgp.113.6.819; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1999, CURR TOP MEMBR, V46, P199; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Nobile M, 1997, EXP BRAIN RES, V114, P138, DOI 10.1007/PL00005613; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975	31	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28722	28730		10.1074/jbc.M003755200	http://dx.doi.org/10.1074/jbc.M003755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887187	hybrid			2022-12-25	WOS:000089330700053
J	Puig-Kroger, A; Lopez-Rodriguez, C; Relloso, M; Sanchez-Elsner, T; Nueda, A; Munoz, E; Bernabeu, C; Corbi, AL				Puig-Kroger, A; Lopez-Rodriguez, C; Relloso, M; Sanchez-Elsner, T; Nueda, A; Munoz, E; Bernabeu, C; Corbi, AL			Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; NUCLEAR FACTOR-I; TRANSCRIPTION FACTOR; MURINE MYELOPEROXIDASE; ADHESION MOLECULES; EXPRESSION; IDENTIFICATION; CLONING; LFA-1; LEUKEMOGENESIS	The CD11a/CD18 leukocyte integrin (LFA-1; also known as alpha L/beta 2) mediates leukocyte transendothelial migration during immune and inflammatory responses and participates in lymphoma metastasis. CD11a/CD18 leukocyte-restricted expression is controlled by the CD11a gene promoter, which confers tissue-specific expression to reporter genes in vitro and in vivo. DNase I protection analysis of the CD11a proximal gene promoter revealed DNA-protein interactions centered at position -110 (CD11a-110). Disruption of CD11a-110 reduced CD11a promoter activity in a cell type-specific manner, as it reduced its activity by 70% in Jurkat lymphoid cells, whereas the effect was considerably lower in K562 and HepG2 cells. Electrophoretic mobility shift assays showed evidence of cell type-specific differences in CD11a-110 binding and indicated its specific recognition by members of the polyomavirus enhancer-binding protein 2/core binding factor (CBF)/acute myeloid leukemia (AML) family of transcription factors. AML1B/CBF beta transactivated the CD11a promoter, with AML1B/CBF beta-mediated transactivation being completely dependent on the integrity of the CD11a-110 element. Therefore, CBF/AML factors play a role in the cell type-restricted transcription of the CD11a integrin gene through recognition of CD11a-110, The involvement of CBF/AML factors in CD11a expression raises the possibility that CD11a/CD18 expression might be deregulated in acute myeloid and B-lineage acute lymphoblastic leukemias, thus contributing to their altered adhesion and metastatic potential.	CSIC, Ctr Invest Biol, Madrid 28006, Spain; Univ Cordoba, Fac Med, Dept Inmunol, Cordoba 14071, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cordoba	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Madrid 28006, Spain.	acorbi@cib.csic.es	Lopez-Rodriguez, C/G-4482-2014; Corbi, Angel/B-7194-2011; Relloso, Miguel/K-2238-2014; Munoz, Eduardo/I-5225-2012; Bernabeu, Carmelo/L-3226-2014; Corbí, Angel L./ABC-8146-2020; Puig, Amaya/B-6164-2015; Bernabeu, Carmelo/P-4662-2019	Lopez-Rodriguez, C/0000-0002-2311-2406; Corbi, Angel/0000-0003-1980-5733; Relloso, Miguel/0000-0002-9181-2244; Munoz, Eduardo/0000-0001-8478-5842; Bernabeu, Carmelo/0000-0002-1563-6162; Corbí, Angel L./0000-0003-1980-5733; Puig, Amaya/0000-0003-2943-9757; Bernabeu, Carmelo/0000-0002-1563-6162; Nueda, Arsenio/0000-0001-8373-500X; Sanchez-Elsner, Tilman/0000-0003-1915-2410				AGURA ED, 1992, BLOOD, V79, P602; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CORBI AL, 1996, LEUKOCYTE INTEGRINS; CORNWELL RD, 1993, P NATL ACAD SCI USA, V90, P4221, DOI 10.1073/pnas.90.9.4221; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Kawada H, 1996, LEUKEMIA RES, V20, P327, DOI 10.1016/0145-2126(95)00113-1; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUEDA A, 1993, J BIOL CHEM, V268, P19305; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; RITCHIE KA, 1995, BLOOD, V86, P147, DOI 10.1182/blood.V86.1.147.bloodjournal861147; ROOS E, 1991, CANCER METAST REV, V10, P33, DOI 10.1007/BF00046842; ROSMARIN AG, 1992, BLOOD, V79, P2598; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; Speck NA, 1999, CANCER RES, V59, p1789S; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; Westendorf JJ, 1999, J CELL BIOCHEM, P51	42	26	26	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28507	28512		10.1074/jbc.M004323200	http://dx.doi.org/10.1074/jbc.M004323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10882733	hybrid, Green Published			2022-12-25	WOS:000089330700024
J	Bambai, B; Kulmacz, RJ				Bambai, B; Kulmacz, RJ			Prostaglandin H synthase - Effects of peroxidase cosubstrates on cyclooxygenase velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; VESICULAR GLAND; CIS,CIS-EICOSA-11,14-DIENOIC ACID; PROTOPORPHYRIN-IX; REACTION-KINETICS; BIOSYNTHESIS; PURIFICATION; OXYGENATION	Many cosubstrates for the peroxidase activity of prostaglandin H synthase-1 (PGHS-1) have been reported to produce a large (2-7-fold) increase in the cyclooxygenase velocity in addition to a substantial increase in the number of cyclooxygenase catalytic turnovers. The large stimulation of cyclooxygenase velocity has become an important criterion for evaluation of putative PGHS reaction mechanisms. This criterion has been a major weakness of branched-chain tyrosyl radical mechanisms, which correctly predict many other cyclooxygenase characteristics. Our computer simulations based on a branched-chain mechanism indicated that the uncorrected oxygen electrode signals commonly used to monitor activity can seriously overestimate the effects of cosubstrate on cyclooxygenase velocity, The simulation results prompted re-examination of the effect of several cosubstrates (phenol, acetaminophen, N,N,N',N'-tetramethylphenylenediamine, and Trolox) on PGHS-1 cyclooxygenase velocity, Cyclooxygenase kinetics were examined at reduced temperature or elevated pH, where the oxygen electrode signal can be corrected to provide reliable oxygen consumption trajectories. The cosubstrates produced only a slight (10-60%) stimulation of the cyclooxygenase velocity. Peroxidase cosubstrates thus have a much smaller stimulatory effect on cyclooxygenase velocity than previously reported. This corrects a longstanding misperception of cosubstrate effects, provides more realistic kinetic constraints on PGHS mechanisms, and removes what was a major deficiency of branched-chain tyrosyl radical mechanisms.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, MSB 5 284,6431 Fannin St, Houston, TX 77030 USA.			Bambai, Bijan/0000-0002-9947-1691	NIGMS NIH HHS [GM 52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, PROSTAG LEUKOTR ESS, V54, P341, DOI 10.1016/S0952-3278(96)90048-4; BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; COOK HW, 1979, ANAL BIOCHEM, V96, P341, DOI 10.1016/0003-2697(79)90591-8; DEWHIRST FE, 1980, PROSTAGLANDINS, V20, P209, DOI 10.1016/S0090-6980(80)80040-2; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1976, J BIOL CHEM, V251, P7329; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; HARVISON PJ, 1988, CHEM-BIOL INTERACT, V64, P251, DOI 10.1016/0009-2797(88)90101-9; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; Koshkin V, 1998, J BIOL CHEM, V273, P6046, DOI 10.1074/jbc.273.11.6046; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1983, PROSTAGLANDINS RELAT, P203; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1966, RECL TRAV CHIM PAY-B, V85, P405; O'BRIEN P J, 1981, Progress in Lipid Research, V20, P295, DOI 10.1016/0163-7827(81)90059-X; OGINO N, 1979, BIOCHEM BIOPH RES CO, V87, P184, DOI 10.1016/0006-291X(79)91664-4; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SAMUELSSON B., 1967, PROGR BIOCHEM PHARMACOL, V3, P59; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231	43	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27608	27614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862771				2022-12-25	WOS:000089197100013
J	Jang, GF; McNee, JK; Alekseev, AM; Haeseleer, F; Palczewski, K				Jang, GF; McNee, JK; Alekseev, AM; Haeseleer, F; Palczewski, K			Stereoisomeric specificity of the retinoid cycle in the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; SHORT-CHAIN DEHYDROGENASE/REDUCTASE; RETINALDEHYDE-BINDING PROTEIN; LIVER ALCOHOL-DEHYDROGENASE; PIGMENT EPITHELIUM; VISUAL CYCLE; CDNA CLONING; CONGENITAL AMAUROSIS; RIM PROTEIN; PHOTORECEPTORS	Understanding of the stereospecificity of enzymatic reactions that regenerate the universal chromophore required to sustain vision in vertebrates, 11-cis-retinal, is needed for an accurate molecular model of retinoid transformations. Ln rod outer segments (ROS), the redox reaction involves all-trans-retinal and pro-S-NADPH that results in the production of pro-R-all-trans-retinol. A recently identified all-trans-retinol dehydrogenase (photoreceptor retinol dehydrogenase) displays identical stereospecificity to that of the ROS enzyme(s), This result is unusual, because photoreceptor retinol dehydrogenase is a member of a short chain alcohol dehydrogenase family, which is often pro-S-specific toward their hydrophobic alcohol substrates. The second redox reaction occurring in retinal pigment epithelium, oxidation of 11-cis-retinol, which is largely catalyzed by abundantly expressed 11-cis-retinol dehydrogenase, is pro-S-specific to both 11-cis-retinol and NADH, However, there is notable presence of pro-R-specific activities. Therefore, multiple retinol dehydrogenases are involved in regeneration of 11-cis-retinal. Finally, the cellular retinaldehyde-binding protein-induced isomerization of all-trans-retinol to 11-cis-retinol proceeds with inversion of configuration at the C-15 carbon of retinol, Together, these results provide important additions to our understanding of retinoid transformations in the eye and a prelude for in vivo studies that ultimately may result in efficient pharmacological intervention to restore and prevent deterioration of vision in several inherited eye diseases.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu			NEI NIH HHS [EY08061, R01 EY008061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; CIDECIYAN AV, 2000, IN PRESS VISUAL NEUR; Crabb JW, 1998, METH MOL B, V89, P91; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DONNINGER C, 1964, BIOCHEM J, V91, pP11; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 1998, FEBS LETT, V428, P135, DOI 10.1016/S0014-5793(98)00473-6; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; EKLUND H, 1982, J BIOL CHEM, V257, P4349; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; Gamble MV, 1999, J LIPID RES, V40, P2279; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; JONES JB, 1982, CAN J CHEM, V60, P19, DOI 10.1139/v82-005; JONES JB, 1976, TECHNIQUES CHEM 1, V10, P260; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAW WC, 1989, J AM CHEM SOC, V111, P793, DOI 10.1021/ja00184a090; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; LEVY HR, 1983, BIOCHEMISTRY-US, V22, P2792, DOI 10.1021/bi00281a004; LEVY HR, 1957, J BIOL CHEM, V228, P85; Ma HC, 1999, P NATL ACAD SCI USA, V96, P11161, DOI 10.1073/pnas.96.20.11161; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Mata NL, 1998, BBA-LIPID LIPID MET, V1394, P16, DOI 10.1016/S0005-2760(98)00078-2; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; MERCER EI, 1997, CONCISE ENCY BIOCH M; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Nakajima K, 1999, J BIOL CHEM, V274, P16563, DOI 10.1074/jbc.274.23.16563; NAKAJIMA N, 1989, J BIOCHEM-TOKYO, V106, P515, DOI 10.1093/oxfordjournals.jbchem.a122884; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2000, METHOD ENZYMOL, V316, P359; Simon A, 2000, METHOD ENZYMOL, V316, P344; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Stecher H, 2000, METHOD ENZYMOL, V316, P330; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; SUZUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P201, DOI 10.1016/0167-4838(93)90182-Q; van der Werf MJ, 1999, J BIOL CHEM, V274, P26296, DOI 10.1074/jbc.274.37.26296; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; WONG SS, 1983, INT J BIOCHEM, V15, P147, DOI 10.1016/0020-711X(83)90057-5; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	68	49	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28128	28138						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871622				2022-12-25	WOS:000089197100079
J	Lintschinger, B; Balzer-Geldsetzer, M; Baskaran, T; Graier, WF; Romanin, C; Zhu, MX; Groschner, K				Lintschinger, B; Balzer-Geldsetzer, M; Baskaran, T; Graier, WF; Romanin, C; Zhu, MX; Groschner, K			Coassembly of Trp1 and Trp3 proteins generates diacylglycerol- and Ca2+-sensitive cation channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ENDOTHELIAL-CELLS; DROSOPHILA TRP; FUNCTIONAL EXPRESSION; STORE DEPLETION; HTRP3 CHANNELS; CA2+ ENTRY; RECEPTOR; PHOTOTRANSDUCTION; ACTIVATION	To analyze the functional consequences of coassembly of transient receptor potential 1 (Trp1) and Trp3 channel proteins, we characterized membrane conductances and divalent cation entry derived by separate overexpression and by coexpression of both Trp isoforms, Trp1 expression generated a 1-oleoyl-2-acetyl-sn-glycerol (OAG)-activated conductance that was detectable only in Ca2+-free extracellular solution. Trp3 expression gave rise to an OAG-activated conductance that was suppressed but clearly detectable at physiological Ca2+ concentrations. Coexpression of both species resulted in a constitutively active, OAG-sensitive conductance, which exhibited distinctive cation selectivity and high sensitivity to inhibition by intracellular Ca2+. Trp1-expressing cells displayed only modest carbachol-induced Ca2+ entry and lacked OAG-induced Sr2+ entry, whereas Trp3-expressing cells responded to both agents with a substantial divalent cation entry, Coexpression of Trp1 plus Trp3 suppressed carbachol-induced Ca2+ entry compared with Trp3 expression and abolished OAG-induced Sr2+ entry signals, We concluded that coassembly of Trp1 and Trp3 resulted in the formation of oligomeric Trp channels that are subject to regulation by phospholipase C and Ca2+. The distinguished Ca2+ sensitivity of these Trp1/Trp3 hetero-oligomers appeared to limit Trp-mediated Ca2+ signals and may be of importance for negative feedback control of Trp function in mammalian cells.	Graz Univ, Dept Pharmakol & Toxicol, A-8010 Graz, Austria; Graz Univ, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Linz, Dept Biophys, A-4040 Linz, Austria; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	University of Graz; University of Graz; Johannes Kepler University Linz; University System of Ohio; Ohio State University	Groschner, K (corresponding author), Graz Univ, Dept Pharmakol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.		Groschner, Klaus/A-2550-2010; Graier, Wolfgang F./B-7052-2008; Romanin, Christoph/D-5399-2009	Groschner, Klaus/0000-0002-8659-377X; Graier, Wolfgang F./0000-0003-1871-3298; Romanin, Christoph/0000-0003-3756-4136				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Chang AS, 1997, FEBS LETT, V415, P335, DOI 10.1016/S0014-5793(97)01155-1; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Putney JW, 1999, BIOESSAYS, V21, P38; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	25	237	248	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27799	27805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882720				2022-12-25	WOS:000089197100039
J	Antes, TJ; Chen, J; Cooper, AD; Levy-Wilson, B				Antes, TJ; Chen, J; Cooper, AD; Levy-Wilson, B			The nuclear matrix protein CDP represses hepatic transcription of the human cholesterol-7 alpha hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; CCAAT DISPLACEMENT PROTEIN; CHROMOSOMAL LOOP ANCHORAGE; BILE-ACID BIOSYNTHESIS; RECEPTOR LXR-ALPHA; 7-ALPHA-HYDROXYLASE GENE; ATTACHMENT REGIONS; REGULATORY REGION; ENHANCER ELEMENTS; TRANSGENIC MICE	To date, the molecular mechanisms that govern hepatic-specific transcription of the human cholesterol 7 alpha-hydroxylase (CYP7A1) gene are poorly understood. We recently reported that the region extending from -1888 to +46, which includes the promoter, is not capable of conferring expression to human CYP7A1 promoter lacZ transgenes in the livers of mice, but that expression is observed with transgenes containing the entire structural gene. To locate liver-specific elements in other segments of the human gene, DNase I hypersensitivity studies were performed with transcriptionally active, liver derived HepG2 cells and with transcriptionally inactive HeLa cells. Three DNase I hypersensitivity sites were detected within the first intron of the human CYP7A1 gene, but only in HepGa cells. Transient transfection experiments with HepG2 cells revealed a transcriptional repressor within intron 1. Five binding sites for the CAAT displacement protein (CDP) were detected within intron 1. Since CDP is a nuclear matrix protein, two methods were employed to localize nuclear matrix attachment sites within intron 1 of the human CYP7A1 gene. A matrix attachment site was found throughout the entirety of intron 1. Gel retardation experiments and cell transfection studies provided evidence for the repression mechanism. Repression is achieved by displacement by CDP of two hepatic activators, namely HNF-1 alpha and C/EBP alpha, that bind to three different sites within intron 1. Additionally, CDP represses transactivation mediated by these two activators.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Stanford Univ, Dept Med, Div Gastroenterol, Stanford, CA 94303 USA	Palo Alto Medical Foundation Research Institute; Stanford University	Levy-Wilson, B (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.			Antes, Travis/0000-0002-2294-8797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054775] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54775] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; COOPER AD, 1992, SEMIN LIVER DIS, V12, P386, DOI 10.1055/s-2008-1040408; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; Goodart SA, 1999, BIOCHEM BIOPH RES CO, V266, P454, DOI 10.1006/bbrc.1999.1799; Hoover T, 1996, NUCLEIC ACIDS RES, V24, P1895, DOI 10.1093/nar/24.10.1895; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KAI MH, 1995, J LIPID RES, V36, P367; KAS E, 1987, J MOL BIOL, V198, P677, DOI 10.1016/0022-2836(87)90209-9; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Massimi M, 1998, HEPATOLOGY, V28, P1064, DOI 10.1002/hep.510280422; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RONIG H, 1994, EUR J BIOCHEM, V221, P411; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Stunkel W, 2000, J VIROL, V74, P2489, DOI 10.1128/JVI.74.6.2489-2501.2000; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DM, 1996, J LIPID RES, V37, P2117; WANG DP, 1994, GENOMICS, V20, P320, DOI 10.1006/geno.1994.1177; Wang ZY, 1999, MOL CELL BIOL, V19, P284	47	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26649	26660		10.1074/jbc.M002852200	http://dx.doi.org/10.1074/jbc.M002852200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10869351	hybrid			2022-12-25	WOS:000088999700104
J	Tcherepanova, I; Bhattacharyya, L; Rubin, CS; Freedman, JH				Tcherepanova, I; Bhattacharyya, L; Rubin, CS; Freedman, JH			Aspartic proteases from the nematode Caenorhabditis elegans - Structural organization and developmental and cell-specific expression of asp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; ONCHOCERCA-VOLVULUS; CYSTEINE PROTEASE; CATHEPSIN-D; HAEMONCHUS-CONTORTUS; REGULATED EXPRESSION; GENE-EXPRESSION; VIT-2 PROMOTER; C-ELEGANS; CLONING	A Caenorhabditis elegans gene (asp-1) and cDNA that encode a homologue of cathepsin D aspartic protease were cloned and characterized. The asp-1 mRNA is transcribed from a single exon, and it begins with the SL1 trans-splice leader sequence. The protein (ASP-1) is expressed as a 396-amino acid, 42.7-kDa pre-pro-peptide that is post-translationally processed into a similar to 40-kDa lysosomal protein. ASP-1 shares similar to 60% sequence identity with the aspartic protease precursor from the nematode Strongyloides stercoralis. The amino acid sequences adjacent to the two active site aspartic acid residues in ASP-1 are 100% identical to those in other eukaryotic aspartic proteases. In addition, ASP-1 contains conserved, potential disulfide bond-forming cysteine residues and N-glycosylation sites. The asp-1 gene is exclusively transcribed in the intestinal cells, with the highest levels of expression observed at late embryonic and early larval stages of development. asp-1 transcription is not observed in adult nematodes or mature larvae. Furthermore, transcription predominantly occurs in eight anterior cells of the intestine (int6-int8). Analyses of ASP-1 nucleotide and amino acid sequences revealed the presence of five additional C. elegans aspartic proteases.	Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Yeshiva Univ Albert Einstein Coll Med, Atran Labs, Dept Mol Pharmacol, Bronx, NY 10461 USA	Duke University; Duke University; Yeshiva University; Albert Einstein College of Medicine	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu			NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1998, CURRENT PROTOCOLS MO; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; Delany NS, 1998, MOL BIOCHEM PARASIT, V97, P177, DOI 10.1016/S0166-6851(98)00148-0; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; Favello A, 1995, METHOD CELL BIOL, V48, P551; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 1996, DEV BIOL, V178, P276, DOI 10.1006/dbio.1996.0218; Gallego SG, 1998, ACTA TROP, V71, P17, DOI 10.1016/S0001-706X(98)00050-3; Geier G, 1999, EUR J BIOCHEM, V264, P872, DOI 10.1046/j.1432-1327.1999.00679.x; Gomez-Escobar N, 1998, EXP PARASITOL, V88, P200, DOI 10.1006/expr.1998.4248; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; HU ED, 1990, J BIOL CHEM, V265, P5072; IRVINE M, 1994, MOL BIOCHEM PARASIT, V65, P135, DOI 10.1016/0166-6851(94)90122-8; IslasTrejo A, 1997, J BIOL CHEM, V272, P6629, DOI 10.1074/jbc.272.10.6629; JACOBSON LA, 1988, GENETICS, V119, P355; Jolodar A, 1997, INT J PARASITOL, V27, P1087, DOI 10.1016/S0020-7519(97)00069-6; Jolodar A, 1998, BBA-PROTEIN STRUCT M, V1382, P13, DOI 10.1016/S0167-4838(97)00141-6; KAGEYAMA T, 1995, ADV EXP MED BIOL, V362, P211; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRIEGER TJ, 1992, BIOCHEMISTRY-US, V31, P4223, DOI 10.1021/bi00132a011; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Liao VHC, 1998, J BIOL CHEM, V273, P31962, DOI 10.1074/jbc.273.48.31962; Liddell S, 1998, PARASITOLOGY, V116, P383, DOI 10.1017/S0031182098002418; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; Loukas A, 1998, MOL BIOCHEM PARASIT, V92, P275, DOI 10.1016/S0166-6851(97)00245-4; MACMORRIS M, 1992, MOL CELL BIOL, V12, P1652, DOI 10.1128/MCB.12.4.1652; MACMORRIS M, 1994, MOL CELL BIOL, V14, P484, DOI 10.1128/MCB.14.1.484; MCGHEE JD, 1990, GENETICS, V125, P505; Mello C, 1995, METHOD CELL BIOL, V48, P451; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; SLICE LW, 1990, J BIOL CHEM, V265, P256; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SOMMERFELT MA, 1992, J VIROL, V66, P4220, DOI 10.1128/JVI.66.7.4220-4227.1992; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; SULSTON J, 1988, NEMATODE CAENORHABDI, P608; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waterston Robert H., 1997, V33, P23; White J., 1988, NEMATODE CAENORHABDI, V17, P81; [No title captured]	65	56	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26359	26369		10.1074/jbc.M000956200	http://dx.doi.org/10.1074/jbc.M000956200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854422	hybrid			2022-12-25	WOS:000088999700066
J	Mackie, GA				Mackie, GA			Stabilization of circular rpsT mRNA demonstrates the 5 '-end dependence of RNase E action in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; CLEAVAGE SITES; IN-VITRO; DEGRADATION; SEQUENCE; RIBOZYMES; INTRON	RNase E is the major intracellular endonuclease in Escherichia coli. Its ability to cleave susceptible substrates in vitro depends on both the cleavage site itself and the availability of an unstructured 5' terminus. To test whether RNase E activity is 5'-end-dependent in vivo in the presence of all the components of the RNA degradative machinery, a known substrate, the rpsT mRNA, has been embedded in a permuted group I intron to permit its efficient, precise circularization in E. coli. Circular rpsT mRNAs are 4-6-fold more stable in vivo than their linear counterparts. Even partial inactivation of RNase E activity further enhances this stability 6-fold. However, the stabilization of circular rpsT mRNAs depends strongly on their efficient translation. These results show unambiguously the importance of an accessible 5'-end in controlling mRNA stability in vivo and support a two-step ("looping") model for RNase E action in which the first step is end recognition and the second is actual cleavage.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mackie, GA (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, DH Copp Bldg,2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	gamackie@interchange.ubc.ca						Belasco J, 1993, CONTROL MESSENGER RN, P3; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; Goodrich AF, 1999, RNA, V5, P972, DOI 10.1017/S1355838299990398; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; Jiang XQ, 2000, J BACTERIOL, V182, P2468, DOI 10.1128/JB.182.9.2468-2475.2000; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; Mackie GA, 1997, J BIOL CHEM, V272, P609; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; PARSONS GD, 1988, J BACTERIOL, V170, P2485, DOI 10.1128/jb.170.6.2485-2492.1988; Perriman R, 1998, RNA, V4, P1047, DOI 10.1017/S135583829898061X; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5357, DOI 10.1093/nar/20.20.5357; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; Tanner MA, 1997, RNA, V3, P1037; Tock MR, 2000, J BIOL CHEM, V275, P8726, DOI 10.1074/jbc.275.12.8726	24	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25069	25072		10.1074/jbc.C000363200	http://dx.doi.org/10.1074/jbc.C000363200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10871599	hybrid			2022-12-25	WOS:000088849400005
J	Di Marzo, V; Hill, MP; Bisogno, T; Crossman, AR; Brotchie, JM				Di Marzo, V; Hill, MP; Bisogno, T; Crossman, AR; Brotchie, JM			Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease	FASEB JOURNAL			English	Article						anandamide; 2-arachidonoyl glycerol; cannabinoids; dopamine; receptors	MOUSE NEUROBLASTOMA-CELLS; BASAL GANGLIA; RECEPTOR AGONIST; BRAIN; ANANDAMIDE; RAT; NEURONS; 2-ARACHIDONOYLGLYCEROL; ENDOCANNABINOIDS; BIOSYNTHESIS	In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids) have been identified within the brain. The high density of CB1 cannabinoid receptors within the basal ganglia suggests a potential role for endocannabinoids in the control of voluntary movement and in basal ganglia-related movement disorders such as Parkinson's disease. However, whether endocannabinoids play a role in regulating motor behavior in health and disease is unknown. Here we report the presence in two regions of the basal ganglia, the g-lobus pallidus and substantia nigra, of the endocannabinoids 2-arachidonoylglycerol (2AG) and anandamide. The levels of the latter compound are similar to threefold higher than those previously reported in any other brain region. In the reserpine-treated rat, an animal model of Parkinson's disease, suppression of locomotion is accompanied by a sevenfold increase in the levels of the 2AG in the globus pallidus, but not in the other five brain regions analyzed. Stimulation of locomotion in the reserpine-treated rat by either of the two selective agonists of D2 and D1 dopamine receptors, quinpirole and R-(+/-)-3-allyl-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (Cl-APB), respectively, results in the reduction of both anandamide and 2AG levels in the g-lobus pallidus. Finally, full restoration of locomotion in the reserpine-treated rat is obtained by coadministration of quinpirole and the selective antagonist of the cannabinoid CB1 receptor subtype, SR141716A. These findings indicate a link between endocannabinoid signaling in the globus pallidus and symptoms of Parkinson's disease in the reserpine-treated rat, and suggest that modulation of the endocannabinoid signaling system might prove useful in treating this or other basal ganglia-related movement disorders.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco, Naples, Italy; Motac Neurosci Ltd, Manchester M13 9XX, Lancs, England	University of Manchester; Consiglio Nazionale delle Ricerche (CNR)	Di Marzo, V (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Bisogno, Tiziana/B-7891-2015; Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Brotchie, Jonathan/0000-0003-2337-0816				Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; COLPAERT FC, 1987, NEUROPHARMACOLOGY, V26, P1431, DOI 10.1016/0028-3908(87)90110-9; Consroe P, 1998, NEUROBIOL DIS, V5, P534, DOI 10.1006/nbdi.1998.0220; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DiMarzo V, 1996, BIOCHEM BIOPH RES CO, V227, P281, DOI 10.1006/bbrc.1996.1501; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; FERRE S, 1991, EUR J PHARMACOL, V192, P25, DOI 10.1016/0014-2999(91)90064-W; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, EUR J NEUROSCI, V9, P199, DOI 10.1111/j.1460-9568.1997.tb01390.x; HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Maneuf YP, 1996, EUR J PHARMACOL, V308, P161, DOI 10.1016/0014-2999(96)00326-3; Maneuf YP, 1997, EXP NEUROL, V148, P265, DOI 10.1006/exnr.1997.6645; Maneuf YP, 1996, SYNAPSE, V22, P382; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Penney J B Jr, 1986, Mov Disord, V1, P3, DOI 10.1002/mds.870010102; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PERTWEE RG, 1991, NEUROPHARMACOLOGY, V30, P237, DOI 10.1016/0028-3908(91)90150-A; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROMERO J, 1995, LIFE SCI, V56, P2033, DOI 10.1016/0024-3205(95)00186-A; Smith Y, 1998, NEUROSCIENCE, V86, P353; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; TRUGMAN JM, 1991, BRAIN, V114, P1429, DOI 10.1093/brain/114.3.1429; USHIJIMA I, 1988, PSYCHOPHARMACOLOGY, V95, P29	31	248	258	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1432	1438		10.1096/fj.14.10.1432	http://dx.doi.org/10.1096/fj.14.10.1432			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877836				2022-12-25	WOS:000087932200018
J	Chen, B; Borinstein, SC; Gillis, J; Sykes, VW; Bogler, O				Chen, B; Borinstein, SC; Gillis, J; Sykes, VW; Bogler, O			The glioma-associated protein SETA interacts with AIP1/Alix and AZIG-2 and modulates apoptosis in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ALG-3; IN-VITRO; TRANSFORMATION; CLONING	Expression of the are homology 3 (SH3) domain-containing expressed in tumorigenic astrocytes (SETA) gene is associated with the tumorigenic state in astrocytes. SETA encodes a variety of adapter proteins containing either one or two SH3 domains, as suggested by the sequence heterogeneity of isolated cDNAs, Using both SH3 domains in a yeast two-hybrid screen of a glial progenitor cell cDNA library, we isolated the rat homolog of the ALG-2-interacting protein 1 or ALG-2-interacting protein X (AIP1/Alix), In vitro confrontation experiments showed that the SH3-N domain of SETA interacted with the proline-rich C terminus of AIP1, In co-immunoprecipitation experiments, SETA and AIP1 interacted and could form a complex with apoptosis-linked gene 2 protein, Endogenous SETA and AIP1 proteins showed similar patterns of staining in primary rat astrocytes, Misexpression of a variety of SETA protein isoforms in these astrocytes revealed that they localized to the actin cytoskeleton. Furthermore, SETA proteins containing the SH3-N domain were able to sensitize astrocytes to apoptosis induced by UV irradiation. Expression of the isolated SH3-N domain had the greatest effect in these experiments, indicating that interference in the interaction between endogenous SETA and AIP1 sensitizes astrocytes to apoptosis in response to DNA damage.	Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Bogler, O (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd, Detroit, MI 48202 USA.			Bogler, Oliver/0000-0002-3700-0480				Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; BOGLER O, 1995, CANCER RES, V55, P2746; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Lacana E, 1997, J IMMUNOL, V158, P5129; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; SUGIMOTO Y, 1994, BIO-TECHNOL, V12, P694, DOI 10.1038/nbt0794-694; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521	14	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19275	19281		10.1074/jbc.M908994199	http://dx.doi.org/10.1074/jbc.M908994199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858458	hybrid			2022-12-25	WOS:000087815900086
J	Panse, VG; Vogel, P; Trommer, WE; Varadarajan, R				Panse, VG; Vogel, P; Trommer, WE; Varadarajan, R			A thermodynamic coupling mechanism for the disaggregation of a model peptide substrate by chaperone SecB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; MOLTEN GLOBULE; TRANSLOCATION; AGGREGATION; INVITRO; LIGAND; STATE; FRAME	Molecular chaperones prevent protein aggregation in vivo and in vitro. In a few cases, multichaperone systems are capable of dissociating aggregated state(s) of substrate proteins, although little is known of the mechanism of the process. SecB is a cytosolic chaperone, which forms part of the precursor protein translocation machinery in Escherichia coli, We have investigated the interaction of the B-chain of insulin with chaperone SecB by light scattering, pyrene excimer fluorescence, and electron spin resonance spectroscopy. We show that SecB prevents aggregation of the B-chain of insulin. We show that SecB is capable of dissociating soluble B-chain aggregates as monitored by pyrene fluorescence spectroscopy. The kinetics of dissociation of the B-chain aggregate by SecB has been investigated to understand the mechanism of dissociation. The data suggests that SecB does not act as a catalyst in dissociation of the aggregate to individual B-chains, rather it binds the small population of free B-chains with high affinity, thereby shifting the equilibrium from the ensemble of the aggregate toward the individual B-chains, Thus SecB can rescue aggregated, partially folded/misfolded states of target proteins by a thermodynamic coupling mechanism when the free energy of binding to SecB is greater than the stability of the aggregate, Pyrene excimer fluorescence and ESR methods have been used to gain insights on the bound state conformation of the B chain to chaperone SecB, The data suggests that the B chain is bound to SecB in a flexible extended state in a hydrophobic cleft on SecB and that the binding site accommodates approximately 10 residues of substrate.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem Biol Unit, Bangalore 560004, Karnataka, India; Univ Kaiserslautern, Fachbereich Chem Biochem, D-67663 Kaiserslautern, Germany	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); University of Kaiserslautern	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	varadar@mbu.iisc.ernet.in		Panse, Vikram/0000-0001-7950-5746; Vogel, Pia/0000-0002-8135-4649				ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BREUKINK E, 1992, EUR J BIOCHEM, V208, P419, DOI 10.1111/j.1432-1033.1992.tb17203.x; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Creighton T. E., 1990, PROTEIN STRUCTURE PR, P155; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Joachimiak A, 1997, NAT STRUCT BIOL, V4, P430, DOI 10.1038/nsb0697-430; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2420, DOI 10.1021/bi992065o; Panse VG, 1998, BIOCHEMISTRY-US, V37, P14477, DOI 10.1021/bi980777t; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; Schuler J, 1999, BIOPHYS J, V77, P1117, DOI 10.1016/S0006-3495(99)76962-6; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Stopar D, 1996, BIOCHEMISTRY-US, V35, P15467, DOI 10.1021/bi961770j; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; Zhao M, 1999, BIOCHEMISTRY-US, V38, P15970, DOI 10.1021/bi991754x	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18698	18703		10.1074/jbc.275.25.18698	http://dx.doi.org/10.1074/jbc.275.25.18698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858444	hybrid			2022-12-25	WOS:000087815900013
J	Jones, PC; Hermolin, J; Jiang, WP; Fillingame, RH				Jones, PC; Hermolin, J; Jiang, WP; Fillingame, RH			Insights into the rotary catalytic mechanism of F0F1 ATP synthase from the cross-linking of subunits b and c in the Escherichia coli enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; POLAR LOOP REGION; EPSILON-SUBUNIT; PROPIONIGENIUM-MODESTUM; PROTON TRANSLOCATION; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ENERGY TRANSDUCTION; MOLECULAR MACHINE; F-0 COMPLEX	The transmembrane sector of the F0F1 rotary ATP synthase is proposed to organize with an oligomeric ring of c subunits, which function as a rotor, interacting with two b subunits at the periphery of the ring, the b subunits functioning as a stator, In this study, cysteines were introduced into the C-terminal region of subunit c and the N-terminal region of subunit b, Cys of N2C subunit b was cross-linked with Cys at positions 74, 75, and 78 of subunit c, In each case, a maximum of 50% of the b subunit could be cross-linked to subunit c, which suggests that either only one of the two b subunits lie adjacent to the c-ring or that both b subunits interact with a single subunit c, The results support a topological arrangement of these subunits, in which the respective Nand C-terminal ends of subunits b and c extend to the periplasmic surface of the membrane and cAsp-61 lies at the center of the membrane, The cross-linking of Cys between bN2C and cV78C was shown to inhibit ATP-driven proton pumping, as would be predicted from a rotary model for ATP synthase function, but unexpectedly, cross-linking did not lead to inhibition of ATPase activity. ATP hydrolysis and proton pumping are therefore uncoupled in the cross-linked enzyme. The c subunit lying adjacent to subunit b was shown to be mobile and to exchange with c subunits that initially occupied non-neighboring positions. The movement or exchange of subunits at the position adjacent to subunit b was blocked by dicyclohexylcarbodiimide. These experiments provide a biochemical verification that the oligomeric c-ring can move with respect to the b-stator and provide further support for a rotary catalytic mechanism in the ATP synthase.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@facstaff.wise.edu			NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Birkenhager R, 1999, EUR J BIOCHEM, V264, P385, DOI 10.1046/j.1432-1327.1999.00652.x; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; UNLIN U, 1997, STRUCTURE, V5, P1219; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1994, J BIOL CHEM, V269, P5473; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	71	44	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31340	31346		10.1074/jbc.M003687200	http://dx.doi.org/10.1074/jbc.M003687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882728	hybrid			2022-12-25	WOS:000089762700084
J	Piper, MD; Hong, SP; Ball, GE; Dawes, IW				Piper, MD; Hong, SP; Ball, GE; Dawes, IW			Regulation of the balance of one-carbon metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-13 NMR ANALYSIS; MOLECULAR CHARACTERIZATION; GLYCINE; GENE; SERINE; PROTEIN; COMPARTMENTATION; TRANSCRIPTION; BIOSYNTHESIS; ACTIVATION	One-carbon metabolism in yeast is an essential process that relies on at least one of three one-carbon donor molecules: serine, glycine, or formate, By a combination of genetics and biochemistry we have shown how cells regulate the balance of one-carbon mow between the donors by regulating cytoplasmic serine hydroxymethyltransferase activity in a side reaction occurring in the presence of excess glycine, This control governs the level of 5,10-methylene tetrahydrofolate (5,10-CH2-H(4)folate) in the cytoplasm, which has a direct role in signaling transcriptional control of the expression of key genes, particularly those encoding the unique components of the glycine decarboxylase complex (GCV1, GCV2, and GCV3), Based on these and other observations, we propose a model for how cells balance the need to supplement their one-carbon pools when charged folates are limiting or when glycine is in excess. We also propose that under normal conditions, cytoplasmic 5,10-CH2-H(4)folate is mainly directed to generating methyl groups via methionine, whereas one-carbon units generated from glycine in mitochondria are more directed to purine biosynthesis, When glycine is in excess, 5,10-CH2-H(4)folate is decreased, and the regulation loop shifts the balance of generation of one-carbon units into the mitochondrion.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Univ New S Wales, NMR Facil, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.		Piper, Matthew/C-1714-2008; Ball, Graham/L-6638-2015	Piper, Matthew/0000-0003-3245-7219; Ball, Graham/0000-0002-0716-2286				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BARLOWE C K, 1989, Biofactors, V2, P57; BARLOWE C K, 1988, Biofactors, V1, P171; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; Buc PS, 1999, YEAST, V15, P1347, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1347::AID-YEA461>3.0.CO;2-A; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Hong SP, 1999, J BIOL CHEM, V274, P10523, DOI 10.1074/jbc.274.15.10523; HONG SP, 1999, THESIS U NEW S WALES; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; MCKENZIE KQ, 1977, GENETICS, V86, P85; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; McNeil JB, 1996, GENETICS, V142, P371; Nagarajan L, 1997, J BIOL CHEM, V272, P4444, DOI 10.1074/jbc.272.7.4444; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P7166, DOI 10.1021/bi00189a020; Pasternack LB, 1996, ARCH BIOCHEM BIOPHYS, V326, P158, DOI 10.1006/abbi.1996.0060; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; SINCLAIR DA, 1994, MOL CELL BIOL, V14, P214, DOI 10.1128/MCB.14.1.214; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1995, THESIS U NEW S WALES; STOVER P, 1990, J BIOL CHEM, V265, P14227; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; ZAROW C, 1983, PREP BIOCHEM, V12, P381	30	64	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30987	30995		10.1074/jbc.M004248200	http://dx.doi.org/10.1074/jbc.M004248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10871621	hybrid			2022-12-25	WOS:000089762700037
J	Giallourakis, C; Kashiwada, M; Pan, PY; Danial, N; Jiang, H; Cambier, J; Coggeshall, KM; Rothman, P				Giallourakis, C; Kashiwada, M; Pan, PY; Danial, N; Jiang, H; Cambier, J; Coggeshall, KM; Rothman, P			Positive regulation of interleukin-4-mediated proliferation by the SH2-containing inositol-5 '-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATASE SHIP; PROTEIN-KINASE-B; FC-GAMMA-RIIB; PHOSPHOTYROSINE-BINDING DOMAIN; INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; IL-4 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CYTOKINE STIMULATION	The SH2-containing inositol 5'-phosphatase (SHIP) is tyrosine-phosphorylated in response to cytokines such as interleukin (LL)-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor. SHIP has been shown to modulate negatively these cytokine signalings; however, a potential role in IL-4 signaling remains uncharacterized, It has been recently shown that IL-4 induces tyrosine phosphorylation of SKIP, implicating the phosphatase in IL-4 processes. Tyrosine kinases, Jak1 and Jak3, involved in IL-4 signaling can associate with SHIP, yet only Jak1 can tyrosine-phosphorylate SHIP when co-expressed. In functional studies, cells overexpressing wild type SHIP are found to be hyperproliferative in response to IL-4 in comparison to parental cells. In contrast, cells expressing catalytically inactive form, SHIP(D672A), show reduced proliferation in response to IL-4. These changes in IL-4-induced proliferation correlate with alterations in phosphatidylinositol 3,4,5-triphosphate levels. However, no differential activation of STAT6, Akt, IRS-2, or p70(S6k), in response to IL-4, was observed in these cells. These data suggest that the catalytic activity of SHIP acts in a novel manner to influence IL-4 signaling. In addition, these data support recent findings that suggest there are uncharacterized signaling pathways downstream of phosphatidylinositol 3,4,5-triphosphate.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Columbia University; Columbia University; National Jewish Health; University System of Ohio; Ohio State University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,P&S 8-425, New York, NY 10032 USA.			Cambier, John/0000-0002-7803-242X	NCI NIH HHS [CA64628] Funding Source: Medline; NIAID NIH HHS [AI33450, AI41447] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033450, R01AI041447, R01AI033450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Howell BW, 1999, MOL CELL BIOL, V19, P5179; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Ingham RJ, 1999, J IMMUNOL, V163, P5891; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nakamura K, 2000, J IMMUNOL, V164, P631, DOI 10.4049/jimmunol.164.2.631; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAUL WE, 1991, BLOOD, V77, P1859; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; Reichel M, 1997, J IMMUNOL, V158, P5860; Rohrschneider LR, 2000, GENE DEV, V14, P505; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stenmark H, 1999, J CELL SCI, V112, P4175; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang HY, 1997, J IMMUNOL, V158, P1037; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zamorano J, 1998, J IMMUNOL, V161, P859	60	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29275	29282		10.1074/jbc.M002853200	http://dx.doi.org/10.1074/jbc.M002853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875931	hybrid			2022-12-25	WOS:000089439800015
J	Phelps, CB; Sengchanthalangsy, LL; Huxford, T; Ghosh, G				Phelps, CB; Sengchanthalangsy, LL; Huxford, T; Ghosh, G			Mechanism of I kappa B alpha binding to NF-kappa B dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEAR-LOCALIZATION; PHOSPHORYLATION; HOMODIMER; DNA; DEGRADATION; ACTIVATION; SEQUENCES; PROTEINS; COMPLEX	X-ray crystal structures of the NF-kappa B I kappa B alpha complex revealed an extensive and complex protein-protein interface involving independent structural elements present in both I kappa B alpha and NF-kappa B. In this study, we employ a gel electrophoretic mobility shift assay to assess and quantitate the relative contributions of the observed interactions toward overall complex binding affinity. I kappa B alpha preferentially binds to the p50/p65 heterodimer and p65 homodimer, with binding to p50 homodimer being significantly weaker. Our results indicate that the nuclear localization sequence and the region C-terminal to it of the NF-kappa B p65 subunit is a major contributor to NF-kappa B I kappa B alpha complex formation. Additionally, there are no contacts between the corresponding nuclear localization signal tetrapeptide of p50 and I kappa B alpha. A second set of interactions involving the acidic C-terminal/PEST-like region of I kappa B alpha and the NF-kappa B p65 subunit N-terminal domain also contributes binding energy toward formation of the complex. This interaction is highly dynamic and nonspecific in nature, as shown by oxidative cysteine cross-linking. Phosphorylation of the C-terminal/ PEST-like region by casein kinase II further enhances binding.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, MC 0359,9500 Gilman Dr, La Jolla, CA 92093 USA.			Huxford, Tom/0000-0002-1939-7373	NCI NIH HHS [CA-78749] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM07240-2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	22	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29840	29846		10.1074/jbc.M004899200	http://dx.doi.org/10.1074/jbc.M004899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882738	hybrid			2022-12-25	WOS:000089439800090
J	Berardini, M; Mazurek, A; Fishel, R				Berardini, M; Mazurek, A; Fishel, R			The effect of O-6-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2-hMSH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR SYSTEM; DRUG-RESISTANCE; HMUTS-ALPHA; MAMMALIAN-CELLS; BASE PAIRS; MUTS-ALPHA; DAMAGE; RECOGNITION; CISPLATIN; CANCER	The human homologs of prokaryotic mismatch repair have been shown to mediate the toxicity of certain DNA damaging agents; cells deficient in the mismatch repair pathway exhibit resistance to the killing effects of several of these agents. Although previous studies have suggested that the human MutS homologs, hMSH2-hMSH6, bind to DNA containing a variety of DNA adducts, as well as mispaired nucleotides, a number of studies have suggested that DNA binding does not correlate with repair activity. In contrast, the ability to process adenosine nucleotides by MutS homologs appears to be fundamentally linked to repair activity. In this study oligonucleotides containing a single well defined O-6-methylguanine adduct were used to examine the extent of lesion-provoked DNA binding, single-step ADP --> ATP exchange, and steady-state ATPase activity by hMSH2-hMSH3 and hMSH2-hMSH6 heterodimers. Interestingly, O-6-methylguanine lesions when paired with either a C or T were found to stimulate ADP --> ATP exchange, as well as the ATPase activity of purified hMSH2-hMSH6, whereas there was no significant stimulation of hMSH2-hMSH3. These results suggest that O-6-methylguanine uniquely activates the molecular switch functions of hMSH2-hMSH6.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, 233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fink D, 1996, CANCER RES, V56, P4881; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gong JG, 1999, NATURE, V399, P806; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HAWN MT, 1995, CANCER RES, V55, P3721; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Jiricny J, 1996, CANCER SURV, V28, P47; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moreland NJ, 1999, CANCER RES, V59, P2102; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; Umar A, 1997, CANCER RES, V57, P3949; Vaisman A, 1998, CANCER RES, V58, P3579; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Zhang H, 1999, CANCER RES, V59, P3021	41	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27851	27857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878012				2022-12-25	WOS:000089197100046
J	Hazra, TK; Izumi, T; Venkataraman, R; Kow, YW; Dizdaroglu, M; Mitra, S				Hazra, TK; Izumi, T; Venkataraman, R; Kow, YW; Dizdaroglu, M; Mitra, S			Characterization of a novel 8-oxoguanine-DNA glycosylase activity in Escherichia coli and identification of the enzyme as endonuclease VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; BASE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; FPG PROTEIN; DAMAGE; CLONING; SUBSTRATE; HOMOLOG; GUANINE; TRANSVERSIONS	8-Oxoguanine (G*), induced by reactive oxygen species, is mutagenic because it mispairs with A. The major G*-DNA glycosylase (OGG), namely, OGG1 in eukaryotes, or MutM in Escherichia coli, excises G* when paired in DNA with C, G, and T, but not A, presumably because removal of G* from a G*.A pair would be mutagenic. However, repair of G* will prevent mutation when it is incorporated in the nascent strand opposite A. This could be carried out by a second OGG, OGG2, identified in yeast and human cells. We have characterized a new OGG activity in E, coli and then identified it to be endonuclease VIII (Nei), discovered as a damaged py. rimidine-specific DNA glycosylase, Nei shares sequence homology and reaction mechanism with MutM and is similar to human OGG2 in being able to excise G* when paired with A (or G), Kinetic analysis of wild type Nei showed that it has significant activity for excising G* relative to dihydrouracil, The presence of OGG2 type enzyme in both E. coli and eukaryotes, which is at least as efficient in excising G* from a G*.A (or G) pair as from a G*.C pair, supports the possibility of G* repair in the nascent DNA strand.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Emory Univ, Dept Radiat Oncol, Atlanta, GA 30335 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Emory University; National Institute of Standards & Technology (NIST) - USA	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6 136 Med Res Bldg,Rt 1079, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA081063, R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA53791, R01 CA81063] Funding Source: Medline; NIEHS NIH HHS [R01 ES08457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; DEOLIVEIRA R, 1994, NUCLEIC ACIDS RES, V22, P3760, DOI 10.1093/nar/22.18.3760; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HALLIWELL B, 1992, FREE RADICAL RES COM, V16, P75, DOI 10.3109/10715769209049161; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Izumi T, 1999, J MOL BIOL, V287, P47, DOI 10.1006/jmbi.1999.2573; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 1997, BIOCHEM J, V325, P1; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	39	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27762	27767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862773				2022-12-25	WOS:000089197100034
J	Nakamura, N; Suzuki, Y; Ikeda, Y; Notoya, M; Hirose, S				Nakamura, N; Suzuki, Y; Ikeda, Y; Notoya, M; Hirose, S			Complex structure and regulation of expression of the rat gene for inward rectifier potassium channel Kir7.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; K+ CHANNEL; GENOMIC ORGANIZATION; MESSENGER-RNAS; TRANSCRIPTION; PROMOTER; SUBUNIT; CLONING; NA+,K+-ATPASE; THYROTROPIN	Genomic organization of the rat inward rectifier K+ channel Kir7.1 was determined in an attempt to clarify how multiple species of its mRNA are generated in a tissue-specific manner and how its expression is regulated. The rat Kir7.1 gene spans >40 kilobases (kb) and consists of eight exons; the first four exons encode the 5'-untranslated region that is unusually Long (similar to 3 kb), The coding region is located in exons 5 and 6. In the testis, exon 4 is processed as four exons (4a-4d), whereas it is recognized as a single exon in the small intestine. The three major species of rat Kir7.1 mRNA (1.4, 2.2, and 3.2 kb) were found to arise from alternative usage of the two promoters and polyadenylation signals and by alternative splicing of the 5'-noncoding exons, The splicing pattern of the 5'-noncoding exons is quite complex and highly tissue-specific, suggesting that complex mechanisms may operate to regulate the Kir7.1 expression. Deletion and mutational analysis of the promoter activity indicated that the rat Kir7.1 gene is regulated by cAMP through a CCAAT element. The cAMP induction was also demonstrated using the rat follicular cell line FRTL-5 endogenously expressing Kir7.1.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Nakamura, Nobuhiro/C-4265-2015	Nakamura, Nobuhiro/0000-0002-0249-2665; SUZUKI, YOSHIRO/0000-0003-0010-1867				Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bock JH, 1997, GENE, V188, P9, DOI 10.1016/S0378-1119(96)00759-7; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Derst C, 1998, GENOMICS, V54, P560, DOI 10.1006/geno.1998.5598; Doring F, 1998, J NEUROSCI, V18, P8625; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Erginel-Unaltuna N, 1998, GENE, V211, P71, DOI 10.1016/S0378-1119(98)00086-9; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Karschin C, 1996, J NEUROSCI, V16, P3559; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; Kawahara K, 1997, JPN J PHYSIOL, V47, P1, DOI 10.2170/jjphysiol.47.1; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kurachi Y., 1999, POTASSIUM ION CHANNE, V1st; MARUYAMA K, 1994, GENE, V138, P171; Nakamura N, 1999, BIOCHEM J, V342, P329, DOI 10.1042/0264-6021:3420329; OOKATA K, 2000, IN PRESS J AM SOC NE; Partiseti M, 1998, FEBS LETT, V434, P171, DOI 10.1016/S0014-5793(98)00972-7; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; PRESSLEY TA, 1995, AM J PHYSIOL-CELL PH, V268, pC1252, DOI 10.1152/ajpcell.1995.268.5.C1252; Redell JB, 1998, J BIOL CHEM, V273, P22807, DOI 10.1074/jbc.273.35.22807; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; Salkoff L, 1999, CURR TOP MEMBR, V46, P9; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Schoots O, 1997, GENOMICS, V39, P279, DOI 10.1006/geno.1996.4495; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Suzuki Y, 1999, J BIOL CHEM, V274, P11376, DOI 10.1074/jbc.274.16.11376; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X	34	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28276	28284						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871613				2022-12-25	WOS:000089197100099
J	Ramsdale, M; Lakin-Thomas, PL				Ramsdale, M; Lakin-Thomas, PL			sn-1,2-diacylglycerol levels in the fungus Neurospora crassa display circadian rhythmicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CLOCK GENE-FREQUENCY; TEMPERATURE COMPENSATION; CHOLINE DEPLETION; FISSION YEAST; FATTY-ACIDS; CELL-CYCLE; DIACYLGLYCEROL; ACTIVATION; INHIBITOR	The fungus Neurospora crassa is a model organism for investigating the biochemical mechanism of circadian (daily) rhythmicity. When a choline-requiring strain (chob-1) is depleted of choline, the period of the conidiation rhythm lengthens. We have found that the levels of sn-1,2-diacylglycero1 (DAG) increase in proportion to the increase in period. Other clock mutations that change the period do not affect the levels of DAG. Membrane-permeant DAGs and inhibitors of DAG kinase were found to further lengthen the period of choline-depleted cultures. The level of DAG oscillates with a period comparable to the rhythm of conidiation in wild-type strains, choline-depleted cultures, and frq mutants, including a null frq strain. The DAG rhythm is present at the growing margin and also persists in older areas that have completed development. The phase of the DAG rhythm can be set by the Light-to-dark transition, but the level of DAG is not immediately affected by light. Our results indicate that rhythms in DAG levels in Neurospora are driven by a light-sensitive circadian oscillator that does not require the frq gene product. High levels of DAG may feed back on that oscillator to lengthen its period.	Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	University of Cambridge; University of Aberdeen	Lakin-Thomas, PL (corresponding author), Univ Cambridge, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.			Lakin-Thomas, Patricia/0000-0002-0545-9561				ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Arpaia G, 1999, MOL GEN GENET, V262, P314, DOI 10.1007/s004380051089; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BLEST AD, 1994, J COMP PHYSIOL A, V175, P611; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; CHOPRA A, 1984, CRC CR REV MICROBIOL, V11, P209, DOI 10.3109/10408418409105904; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; Cote GG., 1996, MEMBRANE CIRCADIAN R, P13; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DHARMANANDA S, 1979, PLANT PHYSIOL, V63, P1049, DOI 10.1104/pp.63.6.1049; Dickman MB, 1999, FUNGAL GENET BIOL, V26, P99, DOI 10.1006/fgbi.1999.1118; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Edmunds LN, 1988, CELLULAR MOL BASES B; Feldman J.F., 1982, PHOTOCHEM PHOTOBIOL, V7, P319; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HUBBARD SC, 1975, J BIOL CHEM, V250, P7173; Jinks RN, 1996, J PHOTOCH PHOTOBIO B, V35, P45, DOI 10.1016/1011-1344(96)07307-1; Johnson CH, 1999, ANNU REV MICROBIOL, V53, P389, DOI 10.1146/annurev.micro.53.1.389; JURETIC D, 1977, BIOCHIM BIOPHYS ACTA, V469, P137, DOI 10.1016/0005-2736(77)90176-6; Lakin-Thomas PL, 2000, P NATL ACAD SCI USA, V97, P256, DOI 10.1073/pnas.97.1.256; Lakin-Thomas PL, 2000, TRENDS GENET, V16, P135, DOI 10.1016/S0168-9525(99)01945-9; Lakin-Thomas PL, 1998, J BIOL RHYTHM, V13, P268, DOI 10.1177/074873098129000101; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; LAKINTHOMAS PL, 1992, J BIOL RHYTHM, V7, P227, DOI 10.1177/074873049200700304; LAKINTHOMAS PL, 1993, BIOCHEM J, V292, P805, DOI 10.1042/bj2920805; LAKINTHOMAS PL, 1985, GENETICS, V109, P49; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LakinThomas PL, 1996, BIOL RHYTHM RES, V27, P12, DOI 10.1076/brhm.27.1.12.12933; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MAZZEI GJ, 1993, J BIOL CHEM, V268, P7401; Merrow M, 1999, NATURE, V399, P584, DOI 10.1038/21190; Nakashima H, 1996, SEMIN CELL DEV BIOL, V7, P765, DOI 10.1006/scdb.1996.0094; Oeser B, 1998, FEMS MICROBIOL LETT, V165, P273, DOI 10.1111/j.1574-6968.1998.tb13157.x; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; ROEDER PE, 1982, BIOCHEMISTRY-US, V21, P4909, DOI 10.1021/bi00263a012; SCARBOROUGH GA, 1967, J BIOL CHEM, V242, P238; Shinohara ML, 1998, J BIOL CHEM, V273, P446, DOI 10.1074/jbc.273.1.446; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; White B., 1995, FUNGAL GENET NEWSL, V42, P79	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27541	27550						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859307				2022-12-25	WOS:000089197100006
J	Lesley, J; Hascall, VC; Tammi, M; Hyman, R				Lesley, J; Hascall, VC; Tammi, M; Hyman, R			Hyaluronan binding by cell surface CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; LINK PROTEIN; ACID BINDING; T-CELLS; ACTIVATION; RECEPTOR; GLYCOSYLATION	CD44 is the primary cell surface receptor for the extracellular matrix glycosaminoglycan hyaluronan, Here we determined the relative avidities of unlabeled hyaluronan preparations for cell surface CD44 by their ability to block the binding of fluorescein-conjugated hyaluronan to a variety of cells. We show that hyaluronan binding at the cell surface is a complex interplay of multivalent binding events affected by the size of the multivalent hyaluronan ligand, the quantity and density of cell surface CD44, and the activation state of CD44 as determined by cell-specific factors and/or treatment with CD44-specific monoclonal antibody (mAb), Using low M-r hyaluronan oligomers of defined sizes, we observed monovalent binding between 6 and 18 sugars. At similar to 20 to similar to 38 sugars, there was an increase in avidity (similar to 3x), suggesting that divalent binding was occurring. In the presence of the inducing mAb IRAWS14, monovalent binding avidity was similar to that of noninduced CD44, but beginning at similar to 20 residues, there was a dramatic and progressive increase in avidity with increasing oligomer size (similar to 22 < 26 < 30 < 34 < 38 sugars). Kinetic studies of binding and dissociation of fluorescein in-conjugated hyaluronan indicated that inducing mAb treatment had little effect on the binding kinetics, but dissociation from the cell surface was greatly delayed by inducing mAb.	Salk Inst, Canc Biol Lab, San Diego, CA 92186 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	Salk Institute; Cleveland Clinic Foundation; University of Eastern Finland	Lesley, J (corresponding author), Salk Inst, Canc Biol Lab, POB 85800, San Diego, CA 92186 USA.	lesley@salk.edu			NCI NIH HHS [CA-14195] Funding Source: Medline; NIAID NIH HHS [AI-31613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARA J, 1999, P NATL ACAD SCI USA, V94, P10618; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; English NM, 1998, CANCER RES, V58, P3736; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; Lesley J, 2000, EUR J IMMUNOL, V30, P245, DOI 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.3.CO;2-O; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LIAO HX, 1995, J IMMUNOL, V155, P3938; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; Oertli B, 1998, J IMMUNOL, V161, P3431; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; Zheng Z, 1997, J CLIN INVEST, V100, P1217, DOI 10.1172/JCI119635; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; Zhou J, 1999, IN VITRO CELL DEV-AN, V35, P228	36	364	374	3	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26967	26975						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871609				2022-12-25	WOS:000089144800041
J	Wang, YP; Robledo, O; Kinzie, E; Blanchard, F; Richards, C; Miyajima, A; Baumann, H				Wang, YP; Robledo, O; Kinzie, E; Blanchard, F; Richards, C; Miyajima, A; Baumann, H			Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACUTE-PHASE RESPONSE; RAT ALPHA-2-MACROGLOBULIN GENE; CILIARY NEUROTROPHIC FACTOR; GP130 SIGNAL TRANSDUCER; PLASMA-PROTEINS; GROWTH-FACTOR; LIF RECEPTOR; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAINS	The related cytokines, interleukin-6 (IL-6), oncostatin M (OSM), and leukemia inhibitory factor (LIF) direct the formation of specific heteromeric receptor complexes to achieve signaling. Each complex includes the common signal-transducing subunit gp130. OSM and LIF also recruit the signaling competent, but structurally distinct OSMR beta and LIFR alpha subunits, respectively. To test the hypothesis that the particularly prominent cell regulation by OSM is due to signals contributed by OSMR beta, we introduced stable expression of human or mouse OSMR beta in rat hepatoma cells which have endogenous receptors for IL-6 and LIF, but not OSM. Both mouse and human OSM engaged gp130 with their respective OSMR beta subunits, but only human OSM also acted through LIFR. Signaling by OSMR beta-containing receptors was characterized by highest activation of STATE and ERK, recruitment of the insulin receptor substrate and Jun-N-terminal kinase pathways, and induction of a characteristic pattern of acute phase proteins. Since LIF together with LIFR alpha appear to form a more stable complex with gp130 than OSM with gp130 and OSMR beta, co-activation of LIFR and OSMR resulted in a predominant LIF-like response. These results suggest that signaling by IL-6 cytokines is not identical, and that a hierarchical order of cytokine receptor action exists in which LIFR ranks as dominant member.	Roswell Pk Canc Inst, Dept Cellular & Mol Biol, Buffalo, NY 14263 USA; McMaster Univ, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Roswell Park Cancer Institute; McMaster University; University of Tokyo	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Cellular & Mol Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	baumann@sc3101.med.buffalo.edu	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Richards, Carl/0000-0002-0081-2231	NATIONAL CANCER INSTITUTE [R01CA026122, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Barton BE, 1996, INFECT IMMUN, V64, P714, DOI 10.1128/IAI.64.3.714-718.1996; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; CHEN HM, 1991, J BIOL CHEM, V266, P2946; Chevalier S, 1995, ANN NY ACAD SCI, V762, P482; Clegg CH, 1999, EXP HEMATOL, V27, P712, DOI 10.1016/S0301-472X(98)00084-8; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; DAMELL JE, 1997, SCIENCE, V277, P1630; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Giordano V, 1997, J IMMUNOL, V158, P4097; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Harrison P, 1996, BRIT J HAEMATOL, V95, P443, DOI 10.1046/j.1365-2141.1996.d01-1941.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Kaibara A, 1998, CYTOKINE, V10, P452, DOI 10.1006/cyto.1997.0313; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Loy JK, 1999, TOXICOL PATHOL, V27, P151, DOI 10.1177/019262339902700201; MACKIEWICZ A, 1994, ACUTE PHASE PROTEINS, P1; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; Nakashima K, 1999, J NEUROSCI, V19, P5429; NORTHEMANN W, 1988, BIOCHEMISTRY-US, V27, P9194, DOI 10.1021/bi00426a018; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Richards CD, 1997, J IMMUNOL, V159, P2431; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schiemann WP, 1998, ONCOGENE, V16, P2671, DOI 10.1038/sj.onc.1201800; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; Shimon I, 1997, J CLIN INVEST, V100, P357, DOI 10.1172/JCI119541; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; Wallace PM, 1999, J IMMUNOL, V162, P5547; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	83	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25273	25285		10.1074/jbc.M002296200	http://dx.doi.org/10.1074/jbc.M002296200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854424	hybrid			2022-12-25	WOS:000088849400032
J	Yang, HY; Zhou, BHP; Hung, MC; Lee, MH				Yang, HY; Zhou, BHP; Hung, MC; Lee, MH			Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; TUMOR SUPPRESSION; POINT MUTATION; P27(KIP1); EXPRESSION; SURVIVAL; OVEREXPRESSION; DEGRADATION; CARCINOMA	Overexpression and activation of HER-2/neu, a proto-oncogene, play a pivotal role in cancer formation. Strong expression of HER-2/neu in cancers has been associated with poor prognosis. Reduced expression of p27(Kip1), a cyclin-dependent kinase inhibitor, correlates with poor clinical outcome in many types of carcinomas. Because many cancers with the overexpression of HER-2/neu overlap with those affected by reduced p27 expression, we studied the link between HER-2/neu oncogenic signals and p27 regulation. We found that down-regulation of p27 correlates with HER-2/neu overexpression, To address the molecular mechanism of this inverse correlation, we found that reduction of p27 is caused by enhanced ubiquitin-mediated degradation, and the HER-2/Grb2/MAPK pathway is involved in the decrease of p27 stability. Also, HER-2/neu activity causes mislocation of p27 and Jun activation domain-binding protein 1 (JAB1), an exporter of p27, into the cytoplasm, thereby facilitating p27 degradation. These results reveal that HER-2/neu signals reduce p27 stability and thus present potential points for therapeutic intervention in HER-2/neu-associated cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 18,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Baselga J, 1998, CANCER RES, V58, P2825; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERCHUCK A, 1990, CANCER RES, V50, P4087; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Masciullo V, 1999, CANCER RES, V59, P3790; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Singh SP, 1998, CANCER RES, V58, P1730; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	34	109	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24735	24739		10.1074/jbc.C000147200	http://dx.doi.org/10.1074/jbc.C000147200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10859299	hybrid			2022-12-25	WOS:000088683300069
J	Tiku, ML; Shah, R; Allison, GT				Tiku, ML; Shah, R; Allison, GT			Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation - Possible role in cartilage aging and the pathogenesis of osteoarthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; ARTICULAR CHONDROCYTES; HYALURONIC-ACID; DEPENDENT CHEMILUMINESCENCE; HYDROGEN-PEROXIDE; RADICAL FORMATION; OXIDATIVE DAMAGE; OXYGEN RADICALS; II COLLAGEN; ARTHRITIS	Reactive oxygen species (ROS) are implicated in both cartilage aging and the pathogenesis of osteoarthritis. We developed an in vitro model to study the role of chondrocyte-derived ROS in cartilage matrix protein degradation. Matrix proteins in cultured primary articular chondrocytes were labeled with [H-3]proline, and the washed cell matrix was returned to a serum-free balanced salt solution. Exposure to hydrogen peroxide resulted in oxidative damage to the cell matrix as established by monitoring the release of labeled material into the medium. Calcium ionophore treatment of chondrocytes, in a dose-dependent manner, significantly enhanced the release of labeled matrix, suggesting a chondrocyte-dependent mechanism of matrix degradation. Antioxidant enzymes such as catalase or superoxide dismutase did not influence matrix release by the calcium ionophore-activated chondrocytes. However, vitamin E, at physiological concentrations, significantly diminished the release of labeled matrix by activated chondrocytes. The fact that vitamin E is a chain-breaking antioxidant indicates that the mechanism of matrix degradation and release is mediated by the lipid peroxidation process. Lipid peroxidation was measured in chondrocytes loaded with cis-parinaric acid. Both resting and activated cells showed constitutive and enhanced levels of lipid peroxidation activity, which were significantly reduced in the presence of vitamin E. In an immunoblot analysis, malondialdehyde and hydroxynonenal adducts were observed in chondrocyte-matrix extracts, and the amount of adducts increased with calcium ionophore treatment, Furthermore, vitamin E diminished aldehyde-protein adduct formation in activated extracts, which suggests that vitamin E has an antioxidant role in preventing protein oxidation, This study provides in vitro evidence linking chondrocyte lipid peroxidation to cartilage matrix protein (collagen) oxidation and degradation and suggests that vitamin E has a preventive role. These observations indicate that chondrocyte lipid peroxidation may have a role in the pathogenesis of cartilage aging and osteoarthritis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Tiku, ML (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, 1 Robert Wood Johnson Pl,MEB-484,POB 19, New Brunswick, NJ 08903 USA.		Allison, Greg/D-3836-2013	Allison, Greg/0000-0002-4294-0442				ADKISSON HD, 1991, FASEB J, V5, P344, DOI 10.1096/fasebj.5.3.2001795; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Aruoma OI, 1996, FREE RADICAL BIO MED, V20, P675, DOI 10.1016/0891-5849(95)02110-8; BATES EJ, 1984, BIOCHEM INT, V8, P629; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; BONNER WM, 1975, ARTHRITIS RHEUM, V18, P461, DOI 10.1002/art.1780180505; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; DANIEL JC, 1984, J CELL BIOL, V99, P1960, DOI 10.1083/jcb.99.6.1960; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Girotti AW, 1998, J LIPID RES, V39, P1529; GREENWALD RA, 1979, ARTHRITIS RHEUM, V22, P251, DOI 10.1002/art.1780220307; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; GREENWALD RA, 1980, ARTHRITIS RHEUM-US, V23, P455, DOI 10.1002/art.1780230408; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HAMERMAN D, 1989, NEW ENGL J MED, V320, P1322; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; Hiran TS, 1997, FREE RADICAL BIO MED, V23, P736, DOI 10.1016/S0891-5849(97)00054-3; Hollander AP, 1995, J CLIN INVEST, V96, P2859, DOI 10.1172/JCI118357; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; Iswasaki Y, 1988, ORTHOPAEDIC T, V12, P438; KEMPSON GE, 1973, BIOCHIM BIOPHYS ACTA, V297, P465; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; Koyano Y, 1997, BIOTECHNIQUES, V22, P706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPIELLO L, 1990, P SOC EXP BIOL MED, V195, P282, DOI 10.3181/00379727-195-43149; LIPPIELLO L, 1991, METABOLISM, V40, P571, DOI 10.1016/0026-0495(91)90046-Y; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUKOSCHEK M, 1988, J ORTHOP RES, V6, P475, DOI 10.1002/jor.1100060403; MCLINDON TE, 1996, ARTHRITIS RHEUM, V39, P648; Monboisse JC, 1984, J TISSUE RES, V5, P385; MUKHOPADHYAY CK, 1994, J BIOL CHEM, V269, P30200; NORTH JA, 1994, AM J PHYSIOL, V267, pC177, DOI 10.1152/ajpcell.1994.267.1.C177; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; RATHAKRISHNAN C, 1992, J BONE MINER RES, V7, P1139; RATHAKRISHNAN C, 1993, FREE RADICAL BIO MED, V15, P143, DOI 10.1016/0891-5849(93)90053-W; ROBERTS CR, 1989, BIOCHEM J, V259, P805, DOI 10.1042/bj2590805; SAURA R, 1993, J RHEUMATOL, V20, P336; SILBERBERG M, 1950, AMA ARCH PATHOL, V50, P828; SILBERBERG M, 1965, GERONTOLOGY, V11, P179, DOI 10.1159/000211491; STANESCU R, 1981, ARTHRITIS RHEUM, V24, P965, DOI 10.1002/art.1780240718; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STOCKWELL RA, 1983, J ANAT, V136, P425; TIKU K, 1992, CELL IMMUNOL, V140, P1, DOI 10.1016/0008-8749(92)90172-L; Tiku ML, 1999, FREE RADICAL RES, V30, P395, DOI 10.1080/10715769900300431; Tiku ML, 1998, FREE RADICAL RES, V29, P177, DOI 10.1080/10715769800300211; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; VANACKER SABE, 1993, FREE RADICAL BIO MED, V15, P311, DOI 10.1016/0891-5849(93)90078-9; Watkins BA, 1996, P SOC EXP BIOL MED, V212, P153, DOI 10.3181/00379727-212-44003; XU H, 1994, LIPIDS, V29, P619, DOI 10.1007/BF02536096	52	199	214	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20069	20076		10.1074/jbc.M907604199	http://dx.doi.org/10.1074/jbc.M907604199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867027	hybrid			2022-12-25	WOS:000087941300086
J	Hacker, C; Glinski, M; Hornbogen, T; Doller, A; Zocher, R				Hacker, C; Glinski, M; Hornbogen, T; Doller, A; Zocher, R			Mutational analysis of the N-methyltransferase domain of the multifunctional enzyme enniatin synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; DEPENDENT METHYLTRANSFERASES; MOLECULAR CHARACTERIZATION; PEPTIDE SYNTHETASES; SEQUENCE MOTIFS; DNA; SUGGESTS; BINDING	N-Methylcyclopeptides Like cyclosporins and enniatins are synthesized by multifunctional enzymes representing hybrid systems of peptide synthetases and S-adenosyl-L-methionine (AdoMet)-dependent N-methyltransferases. The latter constitute a new family of N-methyltransferases sharing high homology within procaryotes and eucaryotes. Here we describe the mutational analysis of the N-methyltransferase domain of enniatin synthetase from Fusarium scirpi to gain insight into the assembly of the AdoMet-binding site. The role of four conserved motifs (I, (2085)VLEIGTGSGMIL; II/Y, (2105)SYVGLDPS; IV, (2152)DLVVFNSVVQYFTPPEYL; and V, (2194)ATNGHFLAARA) in cofactor binding as measured by photolabeling was studied. Deletion of the first 21 N-terminal amino acid residues of the N-methyltransferase domain did not affect AdoMet binding. Further shortening close to motif I resulted in loss of binding activity. Truncation of 38 amino acids from the C terminus and also internal deletions containing motif V led to complete loss of AdoMet-binding activity. Point mutations converting the conserved Tyr(223) (corresponding to position 2106 in enniatin synthetase) in motif II/Y (close to motif I) into Val, Ala, and Ser, respectively, strongly diminished AdoMet binding, whereas conversion of this residue to Phe restored AdoMet-binding activity to similar to 70%, indicating that Tyr(223) is important for AdoMet binding and that the aromatic Tyr(223) may be crucial for AdoMet binding in N-methylpeptide synthetases.	Tech Univ Berlin, Fachgebiet Biochem & Mol Biol, Max Volmer Inst BIophys Chem & Biochem, D-10587 Berlin, Germany	Technical University of Berlin	Zocher, R (corresponding author), Tech Univ Berlin, Fachgebiet Biochem & Mol Biol, Max Volmer Inst BIophys Chem & Biochem, Franklinstr 29, D-10587 Berlin, Germany.	razzo@chem.tu-berlin.de		Hacker, Christine/0000-0002-6545-0104				BILLICH A, 1987, BIOL CHEM H-S, V368, P521, DOI 10.1515/bchm3.1987.368.1.521; BILLICH A, 1987, BIOCHEMISTRY-US, V26, P8417, DOI 10.1021/bi00399a058; BILLICH A, 1990, BIOCH PEPTIDE ANTIBI, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Burmester J, 1995, BIOCHEM MOL BIOL INT, V37, P201; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; deCrecyLagard V, 1997, ANTIMICROB AGENTS CH, V41, P1904, DOI 10.1128/AAC.41.9.1904; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Fischer D, 1999, PROTEINS, P209; FRIEDMAN S, 1991, NUCLEIC ACIDS RES, V19, P5403, DOI 10.1093/nar/19.19.5403; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GLINSKI M, 1999, THESIS TU BERLIN; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; HAESE A, 1994, J MOL BIOL, V243, P116, DOI 10.1006/jmbi.1994.1634; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HIGUCHI R, 1991, PCR PROTOCOLS GUIDE, P177; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KELLER U, 1987, J BIOL CHEM, V262, P5852; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1990, J BIOL CHEM, V265, P11355; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Nishizawa T, 1999, J BIOCHEM-TOKYO, V126, P520, DOI 10.1093/oxfordjournals.jbchem.a022481; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; PEETERS H, 1983, J ANTIBIOT, V36, P1762, DOI 10.7164/antibiotics.36.1762; PIEPER R, 1995, EUR J BIOCHEM, V230, P119, DOI 10.1111/j.1432-1033.1995.tb20541.x; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schauwecker F, 2000, CHEM BIOL, V7, P287, DOI 10.1016/S1074-5521(00)00103-4; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TAKATA Y, 1992, BIOCHEMISTRY-US, V31, P4369, DOI 10.1021/bi00132a030; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; ZOCHER R, 1983, BIOCHEM BIOPH RES CO, V110, P292, DOI 10.1016/0006-291X(83)91294-9; Zocher R, 1997, ADV MICROB PHYSIOL, V38, P85; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005	42	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30826	30832		10.1074/jbc.M002614200	http://dx.doi.org/10.1074/jbc.M002614200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887181	hybrid			2022-12-25	WOS:000089762700015
J	Yieh, L; Kassavetis, G; Geiduschek, EP; Sandmeyer, SB				Yieh, L; Kassavetis, G; Geiduschek, EP; Sandmeyer, SB			The Brf and TATA-binding protein subunits of the RNA polymerase III transcription factor IIIB mediate position-specific integration of the gypsy-like element, Ty3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS-LIKE ELEMENT; FACTOR-TFIIIB; IN-VITRO; U6 GENE; YEAST; PROMOTER; BOX; INITIATION; TRANSPOSITION; COMPONENTS	Ty3 integrates into the transcription initiation sites of genes transcribed by RNA polymerase III. It is known that transcription factors (TF) IIIB and IIIC are important for recruiting Ty3 to its sites of integration upstream of tRNA genes, but that RNA polymerase III is not required. In order to investigate the respective roles of TFIIIB and TFIIIC, we have developed an in vitro integration assay in which Ty3 is targeted to the U6 small nuclear RNA gene, SNR6. Because TFIIIB can bind to the TATA box upstream of the U6 gene through contacts mediated by TATA-binding protein (TBP), TFIIIC is dispensable for in vitro transcription. Thus, this system offers an opportunity to test the role of TFIIIB independent of a requirement of TFIIIC. We demonstrate that the recombinant Brf and TBP subunits of TFIIIB, which interact over the SNR6 TATA box, direct integration at the SNR6 transcription initiation site in the absence of detectable TFIIIC or TFIIIB subunit B". These findings suggest that the minimal requirements for pol III transcription and Ty3 integration are very similar.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego; University of California System; University of California San Diego	Sandmeyer, SB (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM18386, GM33281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018386, R37GM018386, R01GM033281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CHALKER DL, 1993, P NATL ACAD SCI USA, V90, P4927, DOI 10.1073/pnas.90.11.4927; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Connolly CM, 1997, FEBS LETT, V405, P305, DOI 10.1016/S0014-5793(97)00200-7; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KAMPS MP, 1988, ONCOGENE, V2, P305; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KINSEY PT, 1995, GENETICS, V139, P81; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; Mielke C, 1996, BIOCHEMISTRY-US, V35, P2239, DOI 10.1021/bi952393y; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NICHOLS M, 1989, J BIOL CHEM, V264, P17084; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; Sandmeyer S, 1998, GENOME RES, V8, P416, DOI 10.1101/gr.8.5.416; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412	53	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29800	29807		10.1074/jbc.M003149200	http://dx.doi.org/10.1074/jbc.M003149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882723	Green Published, hybrid			2022-12-25	WOS:000089439800085
J	Bruck, I; O'Donnell, M				Bruck, I; O'Donnell, M			The DNA replication machine of a gram-positive organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; BACILLUS-SUBTILIS; SLIDING CLAMPS; GAMMA-SUBUNIT; LAGGING-STRAND; PURIFICATION; COMPLEX; LOADER	This report outlines the protein requirements and subunit organization of the DNA replication apparatus of Streptococcus pyogenes, a Gram-positive organism. Five proteins coordinate their actions to achieve rapid and processive DNA synthesis. These proteins are: the PolC DNA polymerase, tau, delta, delta', and beta. S. pyogenes dnaX encodes only the full-length tau, unlike the Escherichia coli system in which dnaX encodes two proteins, tau and gamma. The S. pyogenes tau binds PolC, but the interaction is not as firm as the corresponding interaction in E. coli, underlying the inability to purify a PolC holoenzyme from Gram-positive cells. The tau also binds the delta and delta' subunits to form a tau delta delta' "clamp loader." PolC can assemble with tau delta delta' to form a PolC.tau delta delta' complex. After PolC.tau delta delta' clamps beta to a primed site, it extends DNA 700 nucleotides/second in a highly processive fashion. Gram-positive cells contain a second DNA polymerase, encoded by dnaE, that has homology to the E. coli alpha subunit off. coli DNA polymerase III. We show here that the S. pyogenes DnaE polymerase also functions with the beta clamp.	Rockefeller Univ, Lab DNA Replicat, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Lab DNA Replicat, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	odonnell@rockvax.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; BARNES MH, 1994, MOL MICROBIOL, V13, P843, DOI 10.1111/j.1365-2958.1994.tb00476.x; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; Blinkova A, 1997, J BACTERIOL, V179, P4438, DOI 10.1128/jb.179.13.4438-4442.1997; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COZZARELLI NR, 1973, BIOCHEM BIOPH RES CO, V51, P151, DOI 10.1016/0006-291X(73)90521-4; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flett F, 1999, MOL MICROBIOL, V31, P949, DOI 10.1046/j.1365-2958.1999.01237.x; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GASS KB, 1973, P NATL ACAD SCI USA, V70, P103, DOI 10.1073/pnas.70.1.103; GASS KB, 1973, J BIOL CHEM, V248, P7688; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; LEE SH, 1991, J BIOL CHEM, V266, P594; LOW RL, 1974, P NATL ACAD SCI USA, V71, P2973, DOI 10.1073/pnas.71.8.2973; LOW RL, 1976, J BIOL CHEM, V251, P1311; MACKENZIE JM, 1973, P NATL ACAD SCI USA, V70, P512, DOI 10.1073/pnas.70.2.512; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WHEELER J, 1980, J GEN MICROBIOL, V120, P27; WU CA, 1992, J BIOL CHEM, V267, P4064; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	69	76	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28971	28983		10.1074/jbc.M003565200	http://dx.doi.org/10.1074/jbc.M003565200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878011	hybrid			2022-12-25	WOS:000089330700083
J	Patzlaff, JS; Brooker, RJ; Barry, BA				Patzlaff, JS; Brooker, RJ; Barry, BA			A reaction-induced Fourier transform-infrared spectroscopic study of the lactose permease - A transmembrane potential perturbs carboxylic acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT PROTEIN; HALOBACTERIUM-HALOBIUM; ESCHERICHIA-COLI; PURPLE MEMBRANE; AMINO-ACID; BACTERIORHODOPSIN; RECONSTITUTION; VESICLES; SPECTRA; LIPOSOMES	In chemiosmotic coupling, a transmembrane ion gradient is used as the source of energy to drive reactions. This process occurs in all cells, but the microscopic mechanism is not understood. Here, Escherichia coli lactose permease was used in a novel spectroscopic method to investigate the mechanism of chemiosmotic coupling in secondary active transporters. To provide a light-triggered electrochemical gradient, bacteriorhodopsin was co-reconstituted with the permease, and reaction-induced Fourier transform-infrared spectra were obtained from the co-reconstituted samples. The bacteriorhodopsin contributions were subtracted from these data to give spectra reflecting permease conformational changes that are induced by an electrochemical gradient. Positive bands in the 1765-1730 cm(-1) region are attributable to carboxylic acid residues in the permease and are consistent with changes of pK(a), protonation state, or environment. This is the first direct information concerning gradient-induced structural changes in the permease at the single amino acid level. Ultimately, these structural changes facilitate galactoside binding and may be involved in the storage of free energy.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Biol Proc Technol Inst, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, 1479 Gortner Ave, St Paul, MN 55108 USA.	barry@biosci.cbs.umn.edu			NIGMS NIH HHS [GM 53259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL LA, 1980, BRIT J SOCIOL EDUC, V1, P183, DOI 10.1080/0142569800010204; BRAIMAN MS, 1987, P NATL ACAD SCI USA, V84, P5221, DOI 10.1073/pnas.84.15.5221; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; DIOUMAEV AK, 1995, J AM CHEM SOC, V117, P10572, DOI 10.1021/ja00147a020; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; FLETT MS, 1962, SPECTROCHIM ACTA, V18, P1537, DOI 10.1016/S0371-1951(62)80282-3; GERBER GE, 1977, P NATL ACAD SCI USA, V74, P5426, DOI 10.1073/pnas.74.12.5426; HENDERSON R, 1977, ANNU REV BIOPHYS BIO, V6, P87, DOI 10.1146/annurev.bb.06.060177.000511; Hutchison RS, 1999, J BIOL CHEM, V274, P31987, DOI 10.1074/jbc.274.45.31987; Johnson JL, 1999, J BIOL CHEM, V274, P4074, DOI 10.1074/jbc.274.7.4074; Kaback HR, 1999, ACCOUNTS CHEM RES, V32, P805, DOI 10.1021/ar970256i; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; Kamikubo H, 1997, BIOCHEMISTRY-US, V36, P12282, DOI 10.1021/bi9712302; KASAHARA M, 1976, P NATL ACAD SCI USA, V73, P396, DOI 10.1073/pnas.73.2.396; KORENSTEIN R, 1977, NATURE, V270, P184, DOI 10.1038/270184a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LOZIER RH, 1976, BIOCHIM BIOPHYS ACTA, V440, P545, DOI 10.1016/0005-2728(76)90041-4; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; OESTERHELT D, 1982, METHOD ENZYMOL, V88, P10; OHNO K, 1977, BIOCHIM BIOPHYS ACTA, V462, P575, DOI 10.1016/0005-2728(77)90102-5; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Patzlaff JS, 1998, BIOCHEMISTRY-US, V37, P15363, DOI 10.1021/bi981142x; PEROZO E, 1993, BIOCHEMISTRY-US, V32, P10471, DOI 10.1021/bi00090a025; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; RACKER E, 1974, J BIOL CHEM, V249, P662; RAMIREZ FJ, 1995, SPECTROCHIM ACTA A, V51, P293, DOI 10.1016/0584-8539(94)00188-H; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SASAKI J, 1994, BIOCHEMISTRY-US, V33, P3178, DOI 10.1021/bi00177a006; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; WEST IC, 1973, BIOCHEM J, V132, P587, DOI 10.1042/bj1320587; WINKLER HH, 1966, J BIOL CHEM, V241, P2200	38	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28695	28700		10.1074/jbc.M005129200	http://dx.doi.org/10.1074/jbc.M005129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874047	hybrid			2022-12-25	WOS:000089330700049
J	Alam, J; Wicks, C; Stewart, D; Gong, PF; Touchard, C; Otterbein, S; Choi, AMK; Burow, ME; Tou, JS				Alam, J; Wicks, C; Stewart, D; Gong, PF; Touchard, C; Otterbein, S; Choi, AMK; Burow, ME; Tou, JS			Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells - Role of p38 kinase and Nrf2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; HEAVY-METALS; C-FOS; MEDIATED INDUCTION; OXIDATIVE STRESS; SODIUM ARSENITE; HEPATOMA-CELLS; BASAL LEVEL; EXPRESSION; IDENTIFICATION	The mouse heme oxygenase-1 (HO-1) gene, ho-1, contains two inducible enhancers, E1 and E2. Of several cell Lines tested, induction of an E1/luciferase fusion construct, pE1-luc, by CdCL2 is most pronounced in MCF-7 cells. In these cells, El, but not E2, is necessary and sufficient for ho-1 gene activation. Exposure of MCF-7 cells to 10 mu M CdCl2 stimulates phosphorylation of ERK, JNK, and p38 mitogen-activated protein kinases, implicating one or more of these signaling pathways in ho-1 gene induction. SB203580, an inhibitor of p38, diminishes cadmium-stimulated pE1-luc expression and HO-1 mRNA levels by up to 70-80%. PD098059, an ERK pathway inhibitor, does not affect HO-1 mRNA induction at the highest concentration (40 mu M) tested. Similarly, coexpression of a dominant-negative mutant of p38 alpha, but not of ERK1, ERK2, JNK1, or JNK2, reduces basal and cadmium-induced pE1-luc activity. E1 contains binding sites for the activator protein-1 (Fos/Jun), Cap'n'Collar/basic leucine zipper (CNC-bZIP), and CCAAT/enhancer-binding protein (C/EBP) families of transcription factors. A dominant-negative mutant of Nrf2 (a CNC-bZIP member), but not of c-Jun or C/EBP beta, inhibits pE1-luc activation by cadmium. Induction of the endogenous ho-1 gene is also inhibited by the Nrf2 mutant. Flutations of E1 that inhibit cadmium inducibility also suppress the trans-activation and DNA binding activities of Nrf2, and SB203580, but not PD098059, attenuates Nrf2-mediated trans-activation of pE1-luc. Taken together, these results indicate that cadmium induces ho-1 gene expression via sequential activation of the p38 kinase pathway and Nrf2.	Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Tulane Xavier Ctr Bioenvironm Res, New Orleans, LA 70112 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA	Ochsner Health System; Tulane University; Xavier University of Louisiana; Yale University	Alam, J (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, 1516 Jefferson Highway, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NHLBI NIH HHS [HL60234] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; ITOH K, 1998, GENE DEV, V13, P67; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; Matsuoka M, 1998, BIOCHEM BIOPH RES CO, V251, P527, DOI 10.1006/bbrc.1998.9487; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Numazawa S, 1997, EXP CELL RES, V237, P434, DOI 10.1006/excr.1997.3825; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; VANDELFT S, 1993, BIOCHEM BIOPH RES CO, V197, P542, DOI 10.1006/bbrc.1993.2513; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	39	358	365	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27694	27702						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874044				2022-12-25	WOS:000089197100024
J	Li, RK; Ennis, IL; Velez, P; Tomaselli, GF; Marban, E				Li, RK; Ennis, IL; Velez, P; Tomaselli, GF; Marban, E			Novel structural determinants of mu-conotoxin (GIIIB) block in rat skeletal muscle (mu 1) Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SODIUM-CHANNELS; CYSTEINE MUTAGENESIS; BINDING-SITE; CONUS-GEOGRAPHUS; OUTER VESTIBULE; PORE; PEPTIDE; TETRODOTOXIN; RESIDUES; MUTANT	mu-Conotoxin (mu-CTX) specifically occludes the pore of voltage-dependent Na+ channels. In the rat skeletal muscle Na+ channel (mu 1), we examined the contribution of charged residues between the P loops and S6 in all four domains to mu-CTX block. Conversion of the negatively charged domain II (DII) residues Asp-762 and Glu-765 to cysteine increased the IC50 for mu-CTX block by similar to 100-fold (wild-type = 22.3 +/- 7.0 nM; D762C = 2558 +/- 250 nM; E765C = 2020 +/- 379 nM). Restoration or reversal of charge by external modification of the cysteine-substituted channels with methanethiosulfonate reagents (methanethiosulfonate ethylsulfonate (MTSES) and methanethiosulfonate ethylammonium (MTSEA)) did not affect mu-CTX block (D762C: IC50, MTSEA+ = 2165.1 +/- 250 nM; IC50, MTSES- = 2753.5 +/- 456.9 nM; E765C: IC50, MTSEA+ = 2200.1 +/- 550.3 nM; IC50, (MTSES-) = 3248.1 +/- 2011.9 nM) compared with their unmodified counterparts. In contrast, the charge-conserving mutations D762E (IC50 = 21.9 +/- 4.3 nM) and E765D (IC50 = 22.0 +/- 7.0 nM) preserved wild-type blocking behavior, whereas the charge reversal mutants D762K (IC50 = 4139.9 +/- 687.9 nM) and E765K (IC50 = 4202.7 +/- 1088.0 nM) destabilized CL-CTX block even further, suggesting a prominent electrostatic component of the interactions between these DII residues and mu-CTX. Kinetic analysis of mu-CTX block. reveals that the changes in toxin sensitivity are largely due to accelerated toxin dissociation (k(off)) rates with little changes in association (k(on)) rates. We conclude that the acidic residues at positions 762 and 765 are key determinants of mu-CTX block, primarily by virtue of their negative charge. The inability of the bulky MTSES or MTSEA side chain to modify mu-CTX sensitivity places steric constraints on the sites of toxin interaction.	Johns Hopkins Univ, Sch Med, Inst Med Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Marban, E (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [R01 HL-50411, R01 HL-52768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050411, R01HL052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; CHAHINE M, 1995, RECEPTOR CHANNEL, V3, P164; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, PFLUG ARCH EUR J PHY, V422, P90, DOI 10.1007/BF00381519; HIDAKA Y, 1990, FEBS LETT, V264, P29, DOI 10.1016/0014-5793(90)80756-9; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; KONTIS KJ, 1993, MOL PHARMACOL, V43, P635; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; LI RA, 2000, BIOPHYS J, V78, P87; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SATO K, 1991, J BIOL CHEM, V266, P16989; STEPHAN MM, 1994, J MEMBRANE BIOL, V137, P1; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YANAGAWA Y, 1986, NEUROSCI LETT, V64, P7, DOI 10.1016/0304-3940(86)90654-3	43	28	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27551	27558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859326				2022-12-25	WOS:000089197100007
J	McMahon, B; Stenson, C; McPhillips, F; Fanning, A; Brady, HR; Godson, C				McMahon, B; Stenson, C; McPhillips, F; Fanning, A; Brady, HR; Godson, C			Lipoxin A(4) antagonizes the mitogenic effects of leukotriene D-4 in human renal mesangial cells - Differential activation of MAP kinases through distinct receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; THP-1 CELLS; RAT-KIDNEY; INHIBITION; PROLIFERATION; CASCADES; PATHWAY	The lipoxygenase-derived eicosanoids leukotrienes and lipoxins are well defined regulators of hemeodynamics and leukocyte recruitment in inflammatory conditions. Here, we describe a novel bioaction of lipoxin A(4) (LXA(4)), namely inhibition of leukotriene D-4 (LTD4)-induced human renal mesangial cell proliferation, and investigate the signal transduction mechanisms involved. LXA(4) blocked LTD4-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity in parallel to inhibition of LTD4-induced mesangial cell proliferation. Screening of a human mesangial cell cDNA library revealed expression of the recently described cys-leukotriene(1)/LTD4 receptor. LTD4-induced mesangial cell proliferation required both extracellular-related signal regulated kinase (erk) and PI 3-kinase activation and may involve platelet-derived growth factor receptor transactivation, LTD4-stimulated the MAP kinases erk and p38 via a pertussis toxin (PTX)-sensitive pathway dependent on PI 3-kinase and protein kinase C activation. On screening a cDNA library, mesangial cells were found to express the previously described LXA(4) receptor. In contrast to LTD4, LXA(4) showed differential activation of erk and p38. LXA(4) activation of erk was insensitive to PTX and PI 3-kinase inhibition, whereas LXA(4) activation of p38 was sensitive to PTX and could be blocked by the LTD4 receptor antagonist SKF 104353. These data suggest that LXA(4) stimulation of the MAP kinase superfamily involves two distinct receptors: one shared with LTD4 and coupled to a PTX-sensitive G protein (G(i)) and a second coupled via an alternative G protein, such as G(q) or G(12), to erk activation. These data expand on the spectrum of LXA(4) bioactions within an inflammatory milieu.	Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland	Mater Misericordiae University Hospital; University College Dublin; University College Dublin	Godson, C (corresponding author), Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland.		Fanning, Aine/Q-1084-2018	Fanning, Aine/0000-0001-8050-1769; Godson, Catherine/0000-0003-0655-1041				ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; ADOEMIT A, 1999, MOL CELL BIOL, V8, P5289; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BADR KF, 1989, AM J PHYSIOL, V257, pF280, DOI 10.1152/ajprenal.1989.257.2.F280; BADR KF, 1987, AM J PHYSIOL, V253, pF239, DOI 10.1152/ajprenal.1987.253.2.F239; BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; BRADY HR, 1990, AM J PHYSIOL, V259, pF809, DOI 10.1152/ajprenal.1990.259.5.F809; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Clarkson MR, 1998, NEPHROL DIAL TRANSPL, V13, P3043, DOI 10.1093/ndt/13.12.3043; CROOKE ST, 1989, TRENDS PHARMACOL SCI, V10, P103, DOI 10.1016/0165-6147(89)90206-X; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; GARRICK R, 1989, BIOCHEM BIOPH RES CO, V162, P626, DOI 10.1016/0006-291X(89)92356-5; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; KATOH T, 1993, J CLIN INVEST, V91, P1507, DOI 10.1172/JCI116356; KELEFIOTIS D, 1995, PROSTAGLANDINS, V49, P269, DOI 10.1016/0090-6980(95)00049-G; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lynch KR, 1999, NATURE, V399, P789; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Mayadas TN, 1996, KIDNEY INT, V49, P1342, DOI 10.1038/ki.1996.190; Meng XJ, 1997, J CLIN INVEST, V99, P2915, DOI 10.1172/JCI119486; Mondorf UF, 1999, KIDNEY INT, V55, P1359, DOI 10.1046/j.1523-1755.1999.00367.x; Morgenstern B, 1998, BIOINFORMATICS, V14, P290, DOI 10.1093/bioinformatics/14.3.290; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Ochsner M, 1996, EXPERIENTIA, V52, P856, DOI 10.1007/BF01938870; OMEARA YM, 1997, KIDNEY INT S, V58, pS56; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Papayianni A, 1996, J IMMUNOL, V156, P2264; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; Ruan XZ, 1999, KIDNEY INT, V56, P440, DOI 10.1046/j.1523-1755.1999.00587.x; Schocklmann HO, 1999, KIDNEY INT, V56, P1199, DOI 10.1046/j.1523-1755.1999.00710.x; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SIMONSON MS, 1988, AM J PHYSIOL, V255, pC771, DOI 10.1152/ajpcell.1988.255.6.C771; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; SPURNEY RF, 1991, KIDNEY INT, V39, P95, DOI 10.1038/ki.1991.12; SRAER D, 1996, KIDNEY INT, V40, P267; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Tombes RM, 1998, BIOCHEM J, V330, P1451; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YOKAMIZO T, 1997, NATURE, V387, P620	64	110	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27566	27575						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869343				2022-12-25	WOS:000089197100009
J	Tanuma, N; Nakamura, K; Shima, H; Kikuchi, K				Tanuma, N; Nakamura, K; Shima, H; Kikuchi, K			Protein-tyrosine phosphatase PTP epsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED JAK/STAT PATHWAY; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; MOLECULAR-CLONING; NEGATIVE REGULATOR; SH2 DOMAIN; ACTIVATION; KINASE; EXPRESSION	We engineered and expressed bath a wild-type and mutant cytosolic isoform of PTP epsilon (PTP epsilon C) in murine M1 leukemic cells, which can be induced to growth arrest and monocytic differentiation by interleukin (IL)-6 and leukemia inhibitory factor (LIF). Forced expression of PTP epsilon C inhibited IL-6- and LIF-induced monocytic differentiation and apoptosis in M1 cells, whereas expression of PTP epsilon M, a transmembrane isoform of PTP epsilon, did not. PTP epsilon C expression resulted in lower levels of IL-6-induced tyrosine phosphorylation of Jak1, Tyk2, gp130, and Stat3 compared with parent cells. In MI transfectants expressing an inactive mutant of PTP epsilon C, both tyrosine phosphorylation and apoptosis induced by IL-6- and LIF were potentiated rather than inhibited. These results suggest an important role for PTP epsilon C in negative regulation of IL-6- and LIF-induced Jak-STAT signaling.	Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Kikuchi, K (corresponding author), Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Tanuma, Naoyuki/V-7911-2019					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SHABO Y, 1988, BLOOD, V72, P2070; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Urushibara N, 1998, INT J ONCOL, V12, P603; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YIN TG, 1993, J IMMUNOL, V151, P2555; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	73	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28216	28221						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859312				2022-12-25	WOS:000089197100091
J	van Beest, M; Dooijes, D; van de Wetering, M; Kjaerulff, S; Bonvin, A; Nielsen, O; Clevers, H				van Beest, M; Dooijes, D; van de Wetering, M; Kjaerulff, S; Bonvin, A; Nielsen, O; Clevers, H			Sequence-specific high mobility group box factors recognize 10-12-base pair minor groove motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; TCR-ALPHA ENHANCER; HMG-BOX; TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; NUCLEOPROTEIN STRUCTURES; ACTIVATION DOMAIN; PROTEIN NHP6A; FISSION YEAST; BETA-CATENIN	Sequence-specific high mobility group (HMG) box factors bind and bend DNA via interactions in the minor groove. Three-dimensional NMR analyses have provided the structural basis for this interaction. The cognate HMG domain DNA motif is generally believed to span 6-8 bases. However, alignment of promoter elements controlled by the yeast genes ste11 and Rox1 has indicated strict conservation of a larger DNA motif, By site selection, we identify a highly specific 12-base pair motif for Ste11, AGAACAAAGAAA. Similarly, we show that Tcf1, MatMc, and Sox4 bind unique, highly specific DNA motifs of 12, 12, and 10 base pairs, respectively. Footprinting with a deletion mutant of Ste11 reveals a novel interaction between the 3' base pairs of the extended DNA motif and amino acids C-terminal to the HMG domain. The sequence-specific interaction of Ste11 with these 3' base pairs contributes significantly to binding and bending of the DNA motif.	Univ Utrecht, Med Ctr, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Copenhagen, Dept Genet, DK-1353 Copenhagen, Denmark; Univ Utrecht, Bijvoet Inst Biomol Chem, Sect NMR Spect, NL-3584 CH Utrecht, Netherlands	Utrecht University; University of Copenhagen; Utrecht University	Clevers, H (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol, Heidelberglaan 100 Rm F03-821, NL-3584 CX Utrecht, Netherlands.	h.clevers@lab.azu.nl	Nielsen, Olaf/G-4980-2012; Bonvin, Alexandre M.J.J./A-5420-2009	Nielsen, Olaf/0000-0001-7440-5201; Bonvin, Alexandre M.J.J./0000-0001-7369-1322				Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DOOIJES D, 1993, J BIOL CHEM, V268, P24813; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KJAERULFF S, 1994, MOL CELL BIOL, V14, P3895, DOI 10.1128/MCB.14.6.3895; Kjaerulff S, 1997, EMBO J, V16, P4021, DOI 10.1093/emboj/16.13.4021; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANHOUTE L, 1993, J BIOL CHEM, V268, P18083; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEMER MH, 1995, CELL, V81, P705; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	53	99	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27266	27273						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867006				2022-12-25	WOS:000089144800080
J	Malhi, H; Irani, AN; Rajvanshi, P; Suadicani, SO; Spray, DC; McDonald, TV; Gupta, S				Malhi, H; Irani, AN; Rajvanshi, P; Suadicani, SO; Spray, DC; McDonald, TV; Gupta, S			K-ATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines - Implications for liver growth control and potential therapeutic targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; DNA-SYNTHESIS; ACTIVATION; EXPRESSION; CALCIUM; OPENERS; GLIBENCLAMIDE; BINDING; SUBUNIT	To determine whether K-ATP channels control liver growth, we used primary rat hepatocytes and several human cancer cell lines for assays. K-ATP channel openers (minoxidil, cromakalim, and pinacidil) increased cellular DNA synthesis, whereas K-ATP channel blockers (quinidine and glibenclamide) attenuated DNA synthesis. The channel inhibitor glibenclamide decreased the clonogenicity of HepG2 cells without inducing cytotoxicity or apoptosis. To demonstrate the specificity of drugs for K+ channels, whole-cell patch-clamp recordings were made. Hepatocytes revealed K+ currents with K-ATP channel properties. These K+ currents were augmented by minoxidil and pinacidil and attenuated by glibenclamide as well as tetraethylammonium, in agreement with established responses of K+, channels. Reverse transcription of total cellular RNA followed by polymerase chain reaction showed expression of K-ATP channel-specific subunits in rat hepatocytes and human liver cell lines. Calcium fluxes were unperturbed in glibenclamide-treated HepG(2) cells and primary rat hepatocytes following induction with ATP and hepatocyte growth factor, respectively, suggesting that the effect of K-ATP channel activity upon hepatocyte proliferation was not simply due to indirect modulation of intracellular calcium. The regulation of mitogen-related hepatocyte proliferation by K-ATP channels advances our insights into liver growth control. The findings have implications in mechanisms concerning liver development, regeneration, and oncogenesis.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Canc Res, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Sao Judas Tadeu, BR-03166000 Sao Paulo, Brazil	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Sao Judas Tadeu	Gupta, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave,Ullmann 625, Bronx, NY 10461 USA.			Spray, David/0000-0001-8368-5073	NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIDDK NIH HHS [R01 DK46952, P33 DK41296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BAFFY G, 1992, J CELL PHYSIOL, V153, P332, DOI 10.1002/jcp.1041530213; CAMERON IL, 1989, MAGNESIUM, V8, P31; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; CHIU SY, 1989, J PHYSIOL-LONDON, V408, P199, DOI 10.1113/jphysiol.1989.sp017455; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CROOKS MJ, 1974, J PHARM PHARMACOL, V26, P304, DOI 10.1111/j.2042-7158.1974.tb09280.x; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; EDWARDS G, 1995, CARDIOVASC DRUG THER, V9, P185, DOI 10.1007/BF00878465; GRAF J, 1988, RENAL PHYSIOL BIOCH, V11, P202; GRUDER JT, 1992, GENE DEV, V6, P545; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA S, 1992, HEPATOLOGY, V15, P485, DOI 10.1002/hep.1840150322; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARMON CS, 1993, SKIN PHARMACOL, V6, P170; HENDERSON RM, 1989, AM J PHYSIOL, V256, pG1028, DOI 10.1152/ajpgi.1989.256.6.G1028; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; HUANG Y, 1994, J BIOL CHEM, V269, P31183; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE Y, 1995, EUR J PHARMACOL, V284, P77, DOI 10.1016/0014-2999(95)00368-U; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lee K, 1998, J PHYSIOL-LONDON, V510, P441, DOI 10.1111/j.1469-7793.1998.441bk.x; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Lu CW, 1997, FEBS LETT, V412, P121, DOI 10.1016/S0014-5793(97)00760-6; Luzi L, 1997, ACTA DIABETOL, V34, P239, DOI 10.1007/s005920050081; MENDOZA SA, 1988, PEDIATR NEPHROL, V2, P118, DOI 10.1007/BF00870391; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ott M, 1998, J BIOL CHEM, V273, P11954, DOI 10.1074/jbc.273.19.11954; PARTISETI M, 1993, J IMMUNOL, V151, P2462; Pon DC, 1997, J CELL PHYSIOL, V171, P87; Rajvanshi P, 1996, HEPATOLOGY, V23, P482; Russ U, 1999, J PHYSIOL-LONDON, V517, P781, DOI 10.1111/j.1469-7793.1999.0781s.x; Saw D, 1996, DIGEST DIS SCI, V41, P322, DOI 10.1007/BF02093822; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; Schofl C, 1999, AM J PHYSIOL-GASTR L, V276, pG164, DOI 10.1152/ajpgi.1999.276.1.G164; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SPURCE AE, 1985, NATURE, V316, P736; STANLEY RG, 1999, ADV 2 MESSENGER PHOS, V33, P107; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wellman GC, 1999, BRIT J PHARMACOL, V128, P909, DOI 10.1038/sj.bjp.0702868; Wondergem R, 1998, J MEMBRANE BIOL, V161, P257, DOI 10.1007/s002329900332; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; Zahler MH, 2000, J GENE MED, V2, P186	49	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26050	26057		10.1074/jbc.M001576200	http://dx.doi.org/10.1074/jbc.M001576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862612	hybrid			2022-12-25	WOS:000088999700024
J	Zhu, KJ; Debreceni, B; Li, R; Zheng, Y				Zhu, KJ; Debreceni, B; Li, R; Zheng, Y			Identification of Rho GTPase-dependent sites in the Dbl homology domain of oncogenic Dbl that are required for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING PATHWAY; GDP/GTP EXCHANGE; BINDING PROTEINS; CDC42; PRODUCT; CELL; VAV; RAS; GENE	The Dbl family guanine-nucleotide exchange factors (GEFs) for Rho GTPases share the structural array of a Dbl homology (DH) domain in tandem with a Pleckstrin homology (PH) domain. For oncogenic Dbl, the DH domain is responsible for the GEF activity, and the DH-PH module constitutes the minimum structural unit required for cellular transformation. To understand the structure-function relationship of the DH domain, we have investigated the role of specific residues of the DH domain of Dbl in interaction with Rho GTPases and in Dbl-induced transformation. Alanine substitution mutagenesis identified a panel of DH mutants made in the alpha 1, alpha 6, and alpha 9 regions and the PH junction site that suffer complete or partial loss of GEF activity toward Cdc42 and RhoA. Kinetic and binding analysis of these mutants revealed that although most displayed decreased k(cat) values in the GEF reaction, the substrate binding activities of T506A and R634A were significantly reduced. E502A Q633A, and N673A/D674A, on the other hand, retained the binding capability to the Rho GTPases but lost the GEF catalytic activity. In general, the in vitro GEF activity of the DH mutants correlated with the in vivo Cdc42- and RhoA-activating potential, and the GEF catalytic efficiency mirrored the transforming activity in MH 3T3 cells, Moreover, the N673A/D674A mutant exhibited a potent dominant-negative effect on serum-induced cell growth and caused retraction of actin structures, These studies identify important sites of the DH domain involved in binding or catalysis of Rho proteins and demonstrate that maintaining a threshold of GEF catalytic activity, in addition to the Rho GTPase binding activity, is essential for efficient transformation by oncogenic Dbl.	Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM 53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Olivo C, 2000, ONCOGENE, V19, P1428, DOI 10.1038/sj.onc.1203440; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RON D, 1991, NEW BIOL, V3, P372; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	45	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25993	26001		10.1074/jbc.M003780200	http://dx.doi.org/10.1074/jbc.M003780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854437	hybrid			2022-12-25	WOS:000088999700017
J	Nandigama, RK; Edmondson, DE				Nandigama, RK; Edmondson, DE			Influence of FAD structure on its binding and activity with the C406A mutant of recombinant human liver monoamine oxidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY-BOUND FLAVIN; GAMMA-LACTONE OXIDASE; ESCHERICHIA-COLI; KINETIC MECHANISM; ANALOGS; FLAVINYLATION; OXIDATION; PEPTIDE; STATE	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue. Expression of the C406A mutant in Saccharomyces ces cerevisiae results in the formation of an active enzyme, as found previously with the rat liver enzyme. The activity of this mutant enzyme is labile to solubilization, thus requiring all experiments to be done with membrane preparations. C406A MAO A was expressed in a rib 5(-) strain of S. cerevisiae in the presence of 16 different riboflavin analogues. Inactive apoC406A MAO A is formed by induction of the enzyme in the absence of riboflavin. FAD but not FMN or riboflavin restores catalytic activity with an apparent K-d of 62 +/- 5 nM. The results from both in vivo and in vitro reconstitution experiments show increased activity levels (up to similar to 7-fold higher) with those analogues exhibiting higher oxidation-reduction potentials than normal flavin and decreased activity levels with analogues exhibiting lower potentials. Analogues with substituents on the pyrimidine ring bind to C406A MAO A more weakly than normal FAD, suggesting specific interactions with the N(3) and N(1) positions. Analogues with substituents in the 7 and 8 positions bind to C406A MAO A with affinities comparable with that of normal FAD. These results are discussed in regard to functional significance of 8 alpha-covalent binding of flavins to proteins.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA	Emory University; Emory University	Edmondson, DE (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029433] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29433] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; BLAUT M, 1989, J BIOL CHEM, V264, P13599; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; Edmondson D.E., 1999, FLAVINS FLAVOPROTEIN, P71; Efimov I, 1998, BIOCHEMISTRY-US, V37, P9716, DOI 10.1021/bi972817j; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; GOMEZ N, 1986, BIOCHEM PHARMACOL, V35, P4467, DOI 10.1016/0006-2952(86)90765-3; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; KENNEY WC, 1976, BIOCHEM BIOPH RES CO, V71, P1194, DOI 10.1016/0006-291X(76)90780-4; KIUCHI K, 1982, BIOCHEMISTRY-US, V21, P5076, DOI 10.1021/bi00263a035; KRAJL M, 1965, BIOCHEM PHARMACOL, V14, P1684, DOI 10.1016/0006-2952(65)90025-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Miller JR, 1999, J BIOL CHEM, V274, P23515, DOI 10.1074/jbc.274.33.23515; MOORE EG, 1979, J BIOL CHEM, V254, P8173; Murthy YVSN, 1998, J BIOL CHEM, V273, P8975, DOI 10.1074/jbc.273.15.8975; NAGY J, 1981, ARCH BIOCHEM BIOPHYS, V208, P388, DOI 10.1016/0003-9861(81)90523-3; NISHIKIMI M, 1994, BIOCHEM MOL BIOL INT, V33, P313; OCARROLL AM, 1989, BIOCHEM PHARMACOL, V38, P901, DOI 10.1016/0006-2952(89)90278-5; RAMSAY RR, 1991, BIOCHEMISTRY-US, V30, P4624, DOI 10.1021/bi00232a038; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; SPENCER R, 1993, BIOCHEMISTRY-US, V16, P3594; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WU HF, 1993, MOL PHARMACOL, V43, P888	29	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20527	20532		10.1074/jbc.M002132200	http://dx.doi.org/10.1074/jbc.M002132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877844	hybrid			2022-12-25	WOS:000088084500044
J	Apel, ED; Lewis, RM; Grady, RM; Sanes, JR				Apel, ED; Lewis, RM; Grady, RM; Sanes, JR			Syne-1, a dystrophin- and klarsicht-related protein associated with synaptic nuclei at the neuromuscular junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE MUSK; DREIFUSS MUSCULAR-DYSTROPHY; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; MOLECULAR-CLONING; DROSOPHILA EYE; AGRIN; EXPRESSION; FIBERS; GENE	We describe a novel protein, Syne-1, that is associated with nuclear envelopes in skeletal, cardiac, and smooth muscle cells. Syne-1 contains multiple spectrin repeats similar to those found in dystrophin and utrophin, as well as a domain homologous to the carboxyl-terminal of Klarsicht, a protein associated with nuclei and required for a subset of nuclear migrations in Drosophila. In adult skeletal muscle fibers, levels of Syne-1 are highest in the nuclei that lie beneath the postsynaptic membrane at: the neuromuscular junction. These nuclei are transcriptionally specialized, expressing genes for synaptic components at higher levels than extrasynaptic nuclei in the same cytoplasm. Syne-1 is the first protein found to be selectively associated with synaptic nuclei. Syne-1 becomes concentrated in synaptic nuclei postnatally. It remains synaptically enriched following denervation or degeneration/regeneration, and is also present at high levels in the central nuclei of dystrophic myotubes. The location and structure of Syne-1 suggest that it may participate in the migration of myonuclei in myotubes and/or their anchoring at the postsynaptic apparatus. Finally, we identify a homologous gene, syne-2, that is expressed in an overlapping but distinct pattern.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	sanesj@pcg.wustl.edu						Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Brosamle C, 1996, J EXP BIOL, V199, P2359; BRUNER JM, 1986, DEV BIOL, V115, P35, DOI 10.1016/0012-1606(86)90225-3; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; COUTEAUX R, 1981, J NEUROCYTOL, V10, P947, DOI 10.1007/BF01258523; COUTEAUX R, 1973, STRUCTURE FUNCTION M, V2, P483; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; ENGLANDER LL, 1987, J CELL BIOL, V104, P87, DOI 10.1083/jcb.104.1.87; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, P NATL ACAD SCI USA, V94, P8848, DOI 10.1073/pnas.94.16.8848; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; JASMIN BJ, 1990, NATURE, V344, P673, DOI 10.1038/344673a0; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; Mosley-Bishop KL, 1999, CURR BIOL, V9, P1211, DOI 10.1016/S0960-9822(99)80501-6; MOSS BL, 1987, J NEUROBIOL, V18, P101, DOI 10.1002/neu.480180108; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Okuda T, 1999, BIOCHEM BIOPH RES CO, V264, P568, DOI 10.1006/bbrc.1999.1538; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PIETTE J, 1993, DEV BIOL, V157, P205, DOI 10.1006/dbio.1993.1124; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Sun YP, 1999, J BIOL CHEM, V274, P33522, DOI 10.1074/jbc.274.47.33522; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Welte MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZACK S, 1973, MOTOR ENDPLATE; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	54	213	224	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31986	31995		10.1074/jbc.M004775200	http://dx.doi.org/10.1074/jbc.M004775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10878022	hybrid			2022-12-25	WOS:000089858900061
J	Matsumoto, M; Sudo, T; Saito, T; Osada, A; Tsujimoto, M				Matsumoto, M; Sudo, T; Saito, T; Osada, A; Tsujimoto, M			Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; BONE MORPHOGENETIC PROTEIN-2; LYMPH-NODE ORGANOGENESIS; DEFECTIVE INTERLEUKIN-1; TRANSDUCTION PATHWAY; POTENT STIMULATOR; MARROW CULTURES; CELL-FORMATION; MAP KINASES	The receptor activator of NF-kappa B ligand (RANKL) induces osteoclast differentiation from bone marrow cells in the presence of macrophage colony-stimulating factor, We found that treatment of bone marrow cells with SB203580 inhibited osteoclast differentiation via inhibition of the RANKL-mediated signaling pathway. To elucidate the role of p38 mitogen-activated protein (MAP) kinase pathway in osteoclastogenesis, we employed RAW264 cells which could differentiate into osteoclastlike cells following treatment with RANKL. In a dose-dependent manner, SB203580 but not PD98059, inhibited RANKL-induced differentiation. Among three MAP kinase families tested, this inhibition profile coincided only with the activation of p38 MAP kinase. Expression in RAW264 cells of the dominant negative form of either p38 alpha MAP kinase or MAP kinase kinase (MKK) 6 significantly inhibited RAM(L-induced differentiation of the cells, These results indicate that activation of the p38 MAP kinase pathway plays an important role in RANKL-induced osteoclast differentiation of precursor bone marrow cells.	RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; RIKEN, Lab Antibiot, Wako, Saitama 3510198, Japan	RIKEN; RIKEN	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tsujimot@postman.riken.go.jp	Matsumoto, Masahito/AGS-0755-2022; Osada, Hiroyuki/N-4305-2014					ABE E, 1983, P NATL ACAD SCI-BIOL, V80, P5583, DOI 10.1073/pnas.80.18.5583; AKATSU T, 1989, ENDOCRINOLOGY, V125, P20, DOI 10.1210/endo-125-1-20; AKATSU T, 1989, J BONE MINER RES, V4, P29; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097-4652(199703)170:3<241::AID-JCP4>3.0.CO;2-O; Hayashi SI, 1998, BIOCHEM CELL BIOL, V76, P911; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KURIHARA N, 1989, BLOOD, V74, P1295; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SHERR CJ, 1990, BLOOD, V75, P1; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	57	449	464	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31155	31161		10.1074/jbc.M001229200	http://dx.doi.org/10.1074/jbc.M001229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859303	hybrid			2022-12-25	WOS:000089762700058
J	Baker, RO; Murata, LB; Dodson, MS; Hall, JD				Baker, RO; Murata, LB; Dodson, MS; Hall, JD			Purification and characterization of OF-1, a host factor implicated in herpes simplex replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; SINGLE-STRANDED-DNA; CORE SEQUENCE; VIRAL ORIGIN; I ORIGIN; VIRUS-1; ORIS; INITIATION; COMPLEX	A human cellular factor (OF-1) has been previously implicated in replication of herpes simplex virus, type 1. This protein binds to three conserved regions (Boxes I, II, and III) in the viral replication origin and appears to be required for viral DNA synthesis (Dabrowski, C. C., Carmillo, P. J., and Schaffer, P. A. (1994) Mol. Cell. Biol. 14, 2545-2555). In the present study, we have partially purified and characterized OF-1 from human cells. This protein appears to consist of a tetramer composed of two heterodimers with subunits of 73 and 90 kDa. The smaller subunit contains the DNA binding activity. We have investigated the binding specificity of OF-1 using a mobility shift analysis. These studies reveal that binding is specific for both duplex and single-stranded Box I sequences and that the strongest preference is for the bottom strand of Box I. We present evidence suggesting that the binding of OF-1 to Box I DNA is enhanced in the presence of the herpes simplex-encoded UL9 protein, which also binds to Box I in oriS and is required for viral replication. Implications of these findings for the initiation step in viral replication are discussed.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Hall, JD (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	jdhall@u.arizona.edu						Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; AVRAHAMI D, 1995, P NATL ACAD SCI USA, V92, P10511, DOI 10.1073/pnas.92.23.10511; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON MS, 1993, J BIOL CHEM, V268, P1213; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; Francon P, 1999, FEBS LETT, V452, P87, DOI 10.1016/S0014-5793(99)00585-2; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Ikeda M, 1996, EUR J BIOCHEM, V238, P38, DOI 10.1111/j.1432-1033.1996.0038q.x; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Murata LB, 1999, J BIOL CHEM, V274, P37079, DOI 10.1074/jbc.274.52.37079; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; TAKAI T, 1994, NUCLEIC ACIDS RES, V22, P5576, DOI 10.1093/nar/22.25.5576; Toone WM, 1997, ANNU REV MICROBIOL, V51, P125, DOI 10.1146/annurev.micro.51.1.125; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VOET D, 1995, BIOCHEMISTRY-US, P218; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409	27	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30050	30057		10.1074/jbc.M002154200	http://dx.doi.org/10.1074/jbc.M002154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10878004	hybrid			2022-12-25	WOS:000089577900019
J	Sinnett-Smith, J; Santiskulvong, C; Duque, J; Rozengurt, E				Sinnett-Smith, J; Santiskulvong, C; Duque, J; Rozengurt, E			[D-Arg(1),D-Trp(5,7,9),Leu(11)]substance P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; LUNG-CANCER CELLS; ACTIVATED PROTEIN-KINASE; STIMULATES TYROSINE PHOSPHORYLATION; ESTERS RAPIDLY STIMULATE; STRESS FIBER FORMATION; PHORBOL ESTERS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING	Substance P (SP) analogues including [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP are broad spectrum neuropeptide antagonists and potential anticancer agents, but their mechanism of action is not fully understood. Here, we examined the mechanism of action of [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP as an inhibitor of G protein-coupled receptor (GPCR)-mediated signal transduction and cellular DNA synthesis in Swiss 3T3 cells. Addition of [D-Arg(1),D-Trp(5,7.9),Leu(11)]SP, at 10 mu M, caused a striking rightward shift in the dose-response curves of DNA synthesis induced by bombesin, bradykinin, or vasopressin and markedly inhibited the activation of p42(mapk) (ERK-2) and p44(mapk) (ERK-1) induced by these GPCR agonists. In addition, this SP analogue also prevented the protein kinase C-dependent activation of protein kinase D induced by these agonists. [D-Arg(1),D-Trp(5,) (7,9),Leu(11)]SP, at a concentration (10 mu M) that inhibited these G(q)-mediated events, also prevented GPCR agonist-induced responses mediated through the G proteins of the G(12) subfamily. These include bombesin-induced assembly of focal adhesions, formation of parallel arrays of actin stress fibers, increase in the tyrosine phosphorylation of focal adhesion kinase (FAK), p130(Cas), and paxillin, and formation of a complex between FAK and Src. We conclude that [D-Arg(1),D-Trp(5,7,9),Leu11]SP acts as a mitogenic antagonist of neuropeptide GPCRs blocking signal transduction via both G(q) and G(12).	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu						Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BEPLER G, 1988, PEPTIDES, V9, P1367, DOI 10.1016/0196-9781(88)90204-5; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1994, CANCER RES, V54, P3602; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charlesworth A, 1996, ONCOGENE, V12, P1337; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; EVERARD MJ, 1993, EUR J CANCER, V29A, P1450, DOI 10.1016/0959-8049(93)90019-C; Flinn HM, 1996, J CELL SCI, V109, P1133; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; ITO S, 1994, BIOCHEM BIOPH RES CO, V200, P756, DOI 10.1006/bbrc.1994.1515; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kaufmann R, 1997, NEUROPEPTIDES, V31, P573, DOI 10.1016/S0143-4179(97)90003-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LANGDON S, 1992, CANCER RES, V52, P4554; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nyeki O, 1998, J PEPT SCI, V4, P486, DOI 10.1002/(SICI)1099-1387(199812)4:8<486::AID-PSC168>3.3.CO;2-E; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Paolucci L, 1999, CANCER RES, V59, P572; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; QIN YF, 1994, CANCER RES, V54, P1035; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seckl MJ, 1997, CANCER RES, V57, P51; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETHI T, 1991, CANCER RES, V51, P3621; Seufferlein T, 1996, CANCER RES, V56, P5758; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Withers DJ, 1997, J BIOL CHEM, V272, P2509; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	72	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30644	30652		10.1074/jbc.M003702200	http://dx.doi.org/10.1074/jbc.M003702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10880515	hybrid			2022-12-25	WOS:000089577900100
J	Braybrooke, JP; Spink, KG; Thacker, J; Hickson, ID				Braybrooke, JP; Spink, KG; Thacker, J; Hickson, ID			The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; REPAIR GENE; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; PROKARYOTIC RECA; MAMMALIAN-CELLS; PROTEIN; MOUSE	The Rad51 protein in eukaryotic cells is a structural and functional homolog of Escherichia coli RecA with a role in DNA repair and genetic recombination, Several proteins showing sequence similarity to Rad51 have previously been identified in both yeast and human cells. In Saccharomyces cerevisiae, two of these proteins, Rad55p and Rad57p, form a heterodimer that can stimulate Rad51-mediated DNA strand exchange, Here, we report the purification of one of the representatives of the RAD51 family in human cells. We demonstrate that the purified RAD51L3 protein possesses single-stranded DNA binding activity and DNA-stimulated ATPase activity, consistent with the presence of "Walker box" motifs in the deduced RAD51L3 sequence. We have identified a protein complex in human cells containing RAD51L3 and a second RAD51 family member, XRCC2. By using purified proteins, we demonstrate that the interaction between RAD51L3 and XRCC2 is direct. Given the requirements for XRCC2 in genetic recombination and protection against DNA-damaging agents, we suggest that the complex of RAD51L3 and XRCC2 is likely to be important for these functions in human cells.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020	Braybrooke, Jeremy/0000-0003-1943-7360; Hickson, Ian/0000-0002-0583-566X				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Kawabata M, 1998, BBA-GENE STRUCT EXPR, V1398, P353, DOI 10.1016/S0167-4781(98)00061-X; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	45	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29100	29106		10.1074/jbc.M002075200	http://dx.doi.org/10.1074/jbc.M002075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871607	hybrid			2022-12-25	WOS:000089330700098
J	Dua, R; Edwards, S; Levy, DL; Campbell, JL				Dua, R; Edwards, S; Levy, DL; Campbell, JL			Subunit interactions within the Saccharomyces cerevisiae DNA polymerase epsilon (pol epsilon) complex - Demonstration of a dimeric pol epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; CHROMOSOMAL REPLICATION; PURIFICATION; YEAST; DELTA; HOLOENZYME; CLONING; DPB11; IDENTIFICATION; PROTEINS	Saccharomyces cerevisiae DNA polymerase epsilon (pol epsilon) is essential for chromosomal replication. A major form of pol epsilon purified from yeast consists of at least four subunits: Pol2p, Dpb2p, Dpb3p, and Dpb4p. We have investigated the protein/protein interactions between these polypeptides by using expression of individual subunits in baculovirus-infected Sf9 insect cells and by using the yeast two-hybrid assay. The essential subunits, Pol2p and Dpb2p, interact directly in the absence of the other two subunits, and the C-terminal half of POL2, the only essential portion of Pol2p, is sufficient for interaction with Dpb2p. Dpb3p and Dpb4p, non-essential subunits, also interact directly with each other in the absence of the other two subunits. We propose that Pol2p Dpb2p and Dpb3p.Dpb4p complexes interact with each other and document several interactions between individual members of the two respective complexes. We present biochemical evidence to support the proposal that pol epsilon may be dimeric in vivo. Gel filtration of the Pol2p.Dpb2p complexes reveals a novel heterotetrameric form, consisting of two heterodimers of Pol2p.Dpb2p. Dpb2p, but not Pol2p, exists as a homodimer, and thus the Pol2p dimerization may be mediated by Dpb2p. The pol2-E and pol2-F mutations that cause replication defects in vivo weaken the interaction between Pol2p and Dpb2p and also reduce dimerization of Pol2p. This suggests, but does not prove, that dimerization may also occur in vivo and be essential for DNA replication.	CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA.		Levy, Daniel/AAA-7205-2019	Levy, Daniel/0000-0002-7853-3275	PHS HHS [25508] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BUDD ME, 1989, J BIOL CHEM, V264, P6557; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; Frei C, 2000, GENE DEV, V14, P81; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jessberger R, 1996, MUTAT RES-FUND MOL M, V350, P217, DOI 10.1016/0027-5107(95)00106-9; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Makiniemi M, 1999, TRENDS BIOCHEM SCI, V24, P14, DOI 10.1016/S0968-0004(98)01327-9; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NIRANJANAKUMARI S, 1993, J BIOL CHEM, V268, P15557; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Smith JS, 1999, MOL CELL BIOL, V19, P3184; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WINTERSBERGER U, 1970, EUR J BIOCHEM, V13, P11, DOI 10.1111/j.1432-1033.1970.tb00893.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28816	28825		10.1074/jbc.M002376200	http://dx.doi.org/10.1074/jbc.M002376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878005	hybrid			2022-12-25	WOS:000089330700064
J	Gomez, M; Scales, SJ; Kreis, TE; Perez, F				Gomez, M; Scales, SJ; Kreis, TE; Perez, F			Membrane recruitment of coatomer and binding to dilysine signals are separate events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; VESICULAR STOMATITIS-VIRUS; PUTATIVE CARGO RECEPTORS; EARLY SECRETORY PATHWAY; COP-COATED VESICLES; TO-GOLGI TRANSPORT; ENDOPLASMIC-RETICULUM; EPSILON-COP; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEIN	It has previously been shown that transport of newly synthesized proteins and the structure of the Golgi complex are affected in the Chinese hamster ovary cell line IdlF, which bears a temperature-sensitive mutation in the Coat protein I (COPI) subunit E-COP (Guo, &,, Vasile, E., and Krieger, M. (1994) J. Cell Biol. 125, 1213-1224; Hobble, L., Fisher, A. S., Lee, S., Flint, k, and Krieger, M, (1994) J. Biol. Chen. 269, 20958-20970). Here, we pinpoint the site of the secretory block to an intermediate compartment between the endoplasmic reticulum (ER) and the Golgi complex and show that the distributions of ER-Golgi recycling proteins, such as KDEL receptor and p23, as well as resident Golgi proteins, such as mannosidase II, are accordingly affected. At the nonpermissive temperature, neither the stability of the COPI complex nor its recruitment to donor Golgi membranes is affected. However, the binding of coatomer to the dilysine-based ER-retrieval motif is impaired in the absence of epsilon-COP, suggesting that dilysine signal binding is not the major means of COPI recruitment. Because expression of the exogenous chimera of E-COP and green fluorescent protein in IdlF cells at nonpermissive temperature rapidly restores the wild type properties, E-COP is likely to play an important role in the cargo selection events mediated by COPI.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Perez, F (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Scales, Suzie J./H-4507-2019; Perez, Franck/A-1558-2014	Scales, Suzie J./0000-0003-2544-0283; Perez, Franck/0000-0002-9129-9401				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duden R, 1998, EMBO J, V17, P985, DOI 10.1093/emboj/17.4.985; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GODLBERG J, 2000, CELL, V100, P671; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scales SJ, 2000, INT REV CYTOL, V195, P67; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	63	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29162	29169		10.1074/jbc.M003630200	http://dx.doi.org/10.1074/jbc.M003630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864930	hybrid			2022-12-25	WOS:000089330700106
J	Shearwin, KE; Egan, JB				Shearwin, KE; Egan, JB			Establishment of lysogeny in bacteriophage 186 - DNA binding and transcriptional, activation by the CII protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; ANALYTICAL ULTRACENTRIFUGATION; INTERDOMAIN LINKER; OPERATOR COMPLEX; GENE-EXPRESSION; CLONING VECTORS; COLIPHAGE 186; ARAC PROTEIN; REPRESSOR	The CII protein of bacteriophage 186 is a transcriptional activator of the helix-turn helix family required for establishment of the lysogenic state. DNA binding by 186 CII is unusual in that the invertedly repeated half sites are separated by 20 base pairs, or two turns of the DNA helix, rather than the one turn usually associated with this class of proteins. Here, we investigate quantitatively the DNA binding properties of CII and its interaction with RNA polymerase at the establishment promoter, p(E). The stoichiometry of CII binding was determined by sedimentation equilibrium experiments using a fluorescein-labeled oligonucleotide and purified CII, These experiments indicate that the CII species bound to DNA is a dimer, with additional weak binding of a tetrameric species at high concentrations. Examination of the thermodynamic linkages between CII self-association and DNA binding shows that CII binds to the DNA as a preformed dimer (binding free energy, 9.9 kcal/mol at 4 degrees C) rather than by association of monomers on the DNA, CII binding induces in the DNA a bend of 41 (+/- 5) degrees. The spacing between the binding half sites was shown to be important for CII binding, insertion or removal of just 1 base pair significantly reducing the affinity for CII, Removal of 5 or 10 base pairs between binding half sites eliminated binding, as did insertion of an additional 10 base pairs. CII binding at p(E) was improved marginally by the presence of RNA polymerase (Delta Delta G = -0.5 (+/- 0.3) kcal/mol). In contrast, the binding of RNA polymerase at p(E) was undetectable in the absence of CII but was improved markedly by the presence of CII, Thus, CII appears to recruit RNA polymerase to the promoter. The nature of the base pair changes in mutant phage, selected by their inability to establish lysogeny, are consistent with this mechanism of CII action.	Univ Adelaide, Dept Biochem, Adelaide, SA 5001, Australia	University of Adelaide	Shearwin, KE (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5001, Australia.		Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742				ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ARGAET VP, 1994, J BIOL CHEM, V269, P5171; Artsimovitch I, 1996, J BIOL CHEM, V271, P32343, DOI 10.1074/jbc.271.50.32343; Bailey MF, 1996, J MOL BIOL, V263, P671, DOI 10.1006/jmbi.1996.0607; BRENOWITZ M, 1989, CURRENT PROTOCOLS MO, V2; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; COX EC, 1982, GENETICS, V100, P7; DalmaWeiszhausz DD, 1996, BIOCHEMISTRY-US, V35, P3735, DOI 10.1021/bi952408s; DEBOER HA, 1984, GENE, V30, P251, DOI 10.1016/0378-1119(84)90129-X; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; DODD IB, 1999, ENCY VIROLOGY, P1087; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; HAGMAR P, 1995, BBA-GEN SUBJECTS, V1244, P259, DOI 10.1016/0304-4165(95)00015-4; HO YS, 1992, J BIOL CHEM, V267, P14388; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HO YS, 1982, J BIOL CHEM, V257, P9128; HOCHSCHILD A, 1994, CURR BIOL, V4, P440, DOI 10.1016/S0960-9822(00)00097-X; JACOB F, 1956, ANN I PASTEUR PARIS, V91, P486; Jorgensen CI, 1998, MOL MICROBIOL, V27, P41, DOI 10.1046/j.1365-2958.1998.00655.x; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Koudelka GB, 1998, NUCLEIC ACIDS RES, V26, P669, DOI 10.1093/nar/26.2.669; LAMONT I, 1993, J BACTERIOL, V175, P5286, DOI 10.1128/JB.175.16.5286-5288.1993; LAUE TM, 1993, BIOCHEMISTRY-US, V32, P2469, DOI 10.1021/bi00061a003; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Neufing PJ, 1996, MOL MICROBIOL, V21, P751, DOI 10.1046/j.1365-2958.1996.351394.x; NUEZ B, 1992, P NATL ACAD SCI USA, V89, P11401, DOI 10.1073/pnas.89.23.11401; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Rusinova E, 1997, BIOCHEMISTRY-US, V36, P12994, DOI 10.1021/bi971368k; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Steinmetzer K, 1998, J MOL BIOL, V283, P595, DOI 10.1006/jmbi.1998.2122; Streaker ED, 1998, BIOCHEMISTRY-US, V37, P3210, DOI 10.1021/bi9715019; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SzalewskaPalasz A, 1996, FEMS MICROBIOL LETT, V144, P21, DOI 10.1016/0378-1097(96)00332-1; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; Wulff DL, 1983, LAMBDA, VII, P53; Xu J, 1998, J BIOL CHEM, V273, P24165, DOI 10.1074/jbc.273.37.24165; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZWIEB C, 1994, METHODS MOL BIOL, V30	51	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29113	29122		10.1074/jbc.M004574200	http://dx.doi.org/10.1074/jbc.M004574200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871623	hybrid			2022-12-25	WOS:000089330700100
J	Costet, P; Luo, Y; Wang, N; Tall, AR				Costet, P; Luo, Y; Wang, N; Tall, AR			Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; REVERSE CHOLESTEROL TRANSPORT; TANGIER-DISEASE; NUCLEAR RECEPTOR; CELLULAR CHOLESTEROL; RESPONSE PATHWAY; LXR-ALPHA; EFFLUX; GENE; OXYSTEROLS	Tangier disease, a condition characterized by low levels of high density lipoprotein and cholesterol accumulation in macrophages, is caused by mutations in the ATP-binding cassette transporter ABC1. In cultured macrophages, ABC1 mRNA was induced in an additive fashion by 22(R)-hydroxycholesterol and 9-cis-retinoic acid (9CRA), suggesting induction by nuclear hormone receptors of the liver X receptor (LXR) and retinoid X receptor (RXR) family. We cloned the 5'-end of the human ABC1 transcript from cholesterol-loaded THP1 macrophages. When transfected into RAW macrophages, the upstream promoter was induced 7-fold by 22(R)-hydrosyeholesterol, 8-fold by 9CRA, and 37-fold by 9CRA and 22(R)-hydroxycholesterol. Furthermore, promoter activity was increased in a sterol-responsive fashion when cotransfected with LXR alpha/RXR or LXR beta/RXR, Further experiments identified a direct repeat spaced by four nucleotides (from -70 to -55 base pairs) as a binding site for LXR alpha/RXR or LXR beta/RXR, Mutations in this element abolished the sterol-mediated activation of the promoter. The results show sterol-dependent transactivation of the ABC1 promoter by LXR/RXR and suggest that small molecule agonists of LXR could be useful drugs to reverse foam cell formation and atherogenesis.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		costet, philippe/A-5314-2010; Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, P50HL056984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Feltkamp D, 1999, J BIOL CHEM, V274, P10421, DOI 10.1074/jbc.274.15.10421; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hulten LM, 1996, J CLIN INVEST, V97, P461, DOI 10.1172/JCI118436; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; Sambrook J., 2002, MOL CLONING LAB MANU; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	39	826	859	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28240	28245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10858438				2022-12-25	WOS:000089197100094
J	Guan, KL; Figueroa, C; Brtva, TR; Zhu, TQ; Taylor, J; Barber, TD; Vojtek, AB				Guan, KL; Figueroa, C; Brtva, TR; Zhu, TQ; Taylor, J; Barber, TD; Vojtek, AB			Negative regulation of the serine/threonine kinase B-Raf by Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; ACTIVATION; DIFFERENTIATION; PHOSPHORYLATION; EXPRESSION; COMPLEXITY; MECHANISM; PATHWAY	B-Raf contains multiple Akt consensus sites located within its amino-terminal regulatory domain. One site, Ser(364), is conserved with c-Raf but two additional sites, Ser(428) and Thr(439), are unique to B-Raf, We have investigated the role of both the conserved and unique phosphorylation sites in the regulation of B-Raf activity in vitro and in vivo. We show that phosphorylation of B-Raf by Abt occurs at multiple residues within its aminoterminal regulatory domain, at both the conserved and unique phosphorylation sites. The alteration of the serine residues within the Akt consensus sites to alanines results in a progressive increase in enzymatic activity in vitro and in vivo. Furthermore, expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity, suggesting that Akt negatively regulates B-Raf in vivo. Our results demonstrate that B-Raf activity can be negatively regulated by Akt through phosphorylation in the amino-terminal regulatory domain of B-Raf. This cross-talk between the B-Raf and Akt serine/threonine kinases is likely to play an important role in modulating the signaling specificity of the Ras/Raf pathway and in promoting biological outcome.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, 3323 MSRB III Box 0606, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190	NIGMS NIH HHS [GM51586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	21	206	220	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27354	27359						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869359				2022-12-25	WOS:000089144800092
J	Babaev, VR; Patel, MB; Semenkovich, CF; Fazio, S; Linton, MF				Babaev, VR; Patel, MB; Semenkovich, CF; Fazio, S; Linton, MF			Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; IV HYPERTRIGLYCERIDEMIC VLDL; SMOOTH-MUSCLE CELLS; OXIDIZED LDL; KNOCKOUT MICE; PPAR-GAMMA; IN-VIVO; METABOLISM; INCREASES; LESIONS	The role of macrophage lipoprotein lipase (LPL) expression in atherosclerotic lesion formation was examined in low density lipoprotein receptor (LDLR-/-) mice using dietary conditions designed to induce either fatty streak lesions or complex atherosclerotic lesions. First, LDLR-/- mice chimeric for macrophage LPL expression were created by transplantation of lethally irradiated female LDLR-/- mice with LPL-/- (n = 12) or LPL+/+ (n = 14) fetal liver cells as a source of hematopoietic cells. To induce fatty streak lesions, these mice were fed a Western diet for 8 weeks, resulting in severe hypercholesterolemia, There were no differences in plasma postheparin LPL activity, serum lipid levels, or lipoprotein distribution between these two groups. The mean lesion area in the proximal aorta in LPL-/- --> LDLR-/- mice was significantly reduced by 33% compared with LPL+/+ --> LDLR-/- mice, and a similar reduction (38%) in lesion area was found by en face analysis of the aortae. To induce complex atherosclerotic lesions, female LDLR-/- mice were lethally irradiated, transplanted with LPL-/-(n = 14), LPL+/- (n = 13), or LPL+/+ (n = 14) fetal liver cells, and fed the Western diet for 19 weeks. Serum cholesterol and triglyceride levels did not differ between the three groups. After 19 weeks of diet, the lesions in the proximal aorta were complex with relatively few macrophages expressing LPL protein and mRNA in LPL+/+ --> LDLR-/- mice. Analysis of cross-sections of the proximal aorta demonstrated no differences in the extent of lesion area between the groups, whereas en face analysis of the aortae revealed a dose-dependent effect of macrophage LPL on mean aortic lesion area in LPL-/- --> LDLR-/-, LPL-/+ --> LDLR-/-, and LPL+/+ --> LDLR-/- mice (1.8 +/- 0,2%, 3.5 +/- 0.5% and 5.9 +/- 0,8%, respectively). Taken together, these data indicate that macrophage LPL expression in the artery wall promotes atherogenesis during foam cell lesion formation, but this impact may be limited to macrophage-rich lesions.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Med,Div Cardiovasc Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Washington Univ, St Louis, MO 63110 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Washington University (WUSTL)	Fazio, S (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Med,Div Cardiovasc Med, Rm 312,Med Res Bldg 2, Nashville, TN 37232 USA.		Patel, Mayur/K-2363-2013	Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053989, R01HL058427] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427, HL53989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1988, J BIOL CHEM, V263, P15416; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Balagopalakrishna C, 1999, J LIPID RES, V40, P1347; Beisiegel U, 1996, ATHEROSCLEROSIS, V124, P1, DOI 10.1016/0021-9150(95)05792-7; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Brunzell JD, 1995, METABOLIC BASIS INHE, P1913; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goldberg IJ, 1996, J LIPID RES, V37, P693; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; Makoveichuk E, 1998, BIOCHEM BIOPH RES CO, V252, P703, DOI 10.1006/bbrc.1998.9596; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MULDER M, 1993, J BIOL CHEM, V268, P9369; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; OBREIN KD, 1992, J CLIN INVEST, V89, P1544; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SAXENA U, 1992, BIOCHEM BIOPH RES CO, V189, P1653, DOI 10.1016/0006-291X(92)90267-O; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; TABAS I, 1993, J BIOL CHEM, V268, P20419; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Whitman SC, 1998, J LIPID RES, V39, P1008; Whitman SC, 1999, J LIPID RES, V40, P1017; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	40	134	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26293	26299		10.1074/jbc.M002423200	http://dx.doi.org/10.1074/jbc.M002423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858435	hybrid			2022-12-25	WOS:000088999700057
J	Chrestensen, CA; Starke, DW; Mieyal, JJ				Chrestensen, CA; Starke, DW; Mieyal, JJ			Acute cadmium exposure inactivates thioltransferase (glutaredoxin), inhibits intracellular reduction of protein-glutathionyl-mixed disulfides, and initiates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Experimental Biology 99 Meeting	APR 17-21, 1999	WASHINGTON, D.C.				S-THIOLATION; OXIDATIVE STRESS; IN-VITRO; MAMMALIAN THIOREDOXIN; ENDOTHELIAL-CELLS; REDOX REGULATION; SYSTEM; HEPATOCYTES; PURIFICATION; DETHIOLATION	Oxidative stress broadly impacts cells, initiating regulatory pathways as well as apoptosis and necrosis. A key molecular event is protein S-glutathionylation, and thioltransferase (glutaredoxin) is a specific and efficient catalyst of protein-SSG reduction. In this study 30-min exposure of H9 and Jurkat cells to cadmium inhibited intracellular protein-SSG reduction, and this correlated with inhibition of the thioltransferase system, consistent with thioltransferase being the primary intracellular catalyst of deglutathionylation. The thioredoxin system contributed very little to total deglutathionylase activity. Thioltransferase and GSSG reductase in situ displayed similar dose-response curves (50% inhibition near 10 mu M cadmium in extracellular buffer). Acute cadmium exposure also initiated apoptosis, with H9 cells being more sensitive than Jurkat. Moreover, transfection with antisense thioltransferase cDNA was incompatible with cell survival. Collectively, these data suggest that thioltransferase has a vital role in sulfhydryl homeostasis and cell survival. In separate experiments, cadmium inhibited the isolated component enzymes of the thioltransferase and thioredoxin systems, consistent with the vicinal dithiol nature of their active sites: thioltransferase (IC50 approximate to 1 mu M), GSSG reductase (IC50 approximate to mu M), thioredoxin (IC50 approximate to 8 mu M), thioredoxin reductase (IC50 approximate to 0.2 mu M) Disruption of the vicinal dithiol on thioltransferase (via oxidation to C22-SS-C25; or C25S mutation) protected against cadmium, consistent with a dithiol chelation mechanism of inactivation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.	jjm5@po.cwru.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36219] Funding Source: Medline; NIA NIH HHS [AG15885] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELLO PA, 1994, SHOCK, V2, P79, DOI 10.1097/00024382-199408000-00001; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Baker A, 2000, BIOCHEM BIOPH RES CO, V268, P78, DOI 10.1006/bbrc.1999.1908; Baker A, 1997, CANCER RES, V57, P5162; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Biaglow JE, 2000, ANAL BIOCHEM, V281, P77, DOI 10.1006/abio.2000.4533; Biswal SS, 2000, TOXICOL SCI, V53, P77, DOI 10.1093/toxsci/53.1.77; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Dafre AL, 1996, ARCH BIOCHEM BIOPHYS, V332, P288, DOI 10.1006/abbi.1996.0344; DAVIS DA, 1995, ARCH BIOCHEM BIOPHYS, V322, P127, DOI 10.1006/abbi.1995.1444; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Di Simplicio P, 1998, ARCH BIOCHEM BIOPHYS, V355, P145, DOI 10.1006/abbi.1998.0694; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Jung R, 1997, PLANT CELL, V9, P2037, DOI 10.1105/tpc.9.11.2037; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; MANNERVIK B, 1983, BIOCHEM J, V213, P519, DOI 10.1042/bj2130519; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P177; Meyer EB, 1999, FREE RADICAL BIO MED, V26, P770, DOI 10.1016/S0891-5849(98)00247-0; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MULLER L, 1986, TOXICOL LETT, V30, P259, DOI 10.1016/0378-4274(86)90164-5; OCHI T, 1987, MUTAT RES, V180, P257, DOI 10.1016/0027-5107(87)90222-3; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SATO N, 1995, J IMMUNOL, V154, P3194; SCHUPPEKOISTINEN I, 1994, ARCH BIOCHEM BIOPHYS, V315, P226, DOI 10.1006/abbi.1994.1494; Seres T, 1996, J IMMUNOL, V156, P1973; SHIN SH, 1993, PLANTA, V189, P557, DOI 10.1007/BF00198219; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; SRINIVASAN U, 1998, THESIS CASE W RESERV; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STEFFENSEN IL, 1994, GEN PHARMACOL-VASC S, V25, P1621, DOI 10.1016/0306-3623(94)90364-6; THOMAS JA, 1995, METHOD ENZYMOL, V251, P423, DOI 10.1016/0076-6879(95)51145-8; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; *US DEP HLTH HUM S, 1997, TOXICOLOGICAL PROFIL; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	63	258	264	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26556	26565		10.1074/jbc.M004097200	http://dx.doi.org/10.1074/jbc.M004097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	348RF	10854441	hybrid			2022-12-25	WOS:000088999700093
J	Pan, Y; Haines, DS				Pan, Y; Haines, DS			Identification of a tumor-derived p53 mutant with novel transactivating selectivity	ONCOGENE			English	Article						p53; MDM2; p53 target genes	WILD-TYPE P53; CELL-CYCLE ARREST; DNA-BINDING SITE; GENE-EXPRESSION; P53-INDEPENDENT ROLE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TERMINAL DOMAIN; LEUKEMIC-CELLS; TARGET GENES	MDM2 is a p53-responsive molecule that when overexpressed, can alter growth control pathways via p53-dependent and independent mechanisms. We have identified a mutant p53 containing line that expresses high levels of transcripts that are regulated by the p53-responsive promoter of the MDM2 gene. Analysis of cloned product obtained from these tumor cells revealed that they harbor a mutant p53 protein (possessing an Arg to Gin substitution at codon 213) that is a potent transactivator of MDM2 expression. Consistent with this activity, the R213Q mutant was found to have the ability to interact with DIVA sequences located within the MDM2 promoter. In contrast to previously described tumor-derived p53 mutants which retain MDM2 transactivation function and possess partial growth suppressive activity, the R213Q mutant is severely compromised in its ability to induce p53-regulated transcripts that encode for proteins involved in cell-cycle arrest and apoptosis. The R213Q mutant can also be expressed at high levels in stably transfected cells and cells that harbor this mutant possess elevated levels of MDM2 protein. The R213Q mutant was also found to be able to up-regulate MDM2 during a genotoxic stress response. R213Q is the first described tumor-derived p53 mutant that is deficient at up-regulating both cell cycle arrest and apoptotic factors, but is highly proficient at inducing the growth-promoting molecule MDM2.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Haines, DS (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [CA70165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bull EK, 1998, ONCOGENE, V16, P2249, DOI 10.1038/sj.onc.1201757; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DUTHU A, 1992, ONCOGENE, V7, P2161; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pan Y, 1999, CANCER RES, V59, P2064; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	46	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3095	3100		10.1038/sj.onc.1203663	http://dx.doi.org/10.1038/sj.onc.1203663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871862				2022-12-25	WOS:000087903900007
J	Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB				Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB			Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappa B, AP-1, JNK, MAPKK and apoptosis	ONCOGENE			English	Article						anethole; TNF; NF-kappa B; AP-1; JNK; apoptosis	LIPID-PEROXIDATION; TRANSCRIPTION FACTOR; POTENT INHIBITOR; TERMINAL KINASE; COLON-CANCER; ACTIVATION; EUGENOL; CELLS; CHEMOPREVENTION; OVEREXPRESSION	Anethole, a chief constituent of anise, camphor, and fennel, has been shown to block both inflammation and carcinogenesis, but just how these effects are mediated is not known, One possibility is TNF-mediated signaling, which has also been associated with both inflammation and carcinogenesis. In the present report we show that anethole is a potent inhibitor of TNF-induced NF-kappa B activation (an early response) as monitored by electrophoretic mobility shift assay I kappa B alpha phosphorylation and degradation, and NF-kappa B reporter gene expression. Suppresaon of I kappa B alpha phosphorylation and NF-kappa B reporter gene expression induced by TRAF2 and NIK, suggests that anethole acts on I kappa B alpha kinase, Anethole also blocked the NF-kappa B activation induced by a variety of other inflammatory agents. Besides NF-kappa B, anethole also suppressed TNF-induced activation of the transcription factor AP-1, c-jun N-terminal kinase and MAPK-kinase, In addition, anethole abrogated TNF-induced apoptosis as measured by both caspase activation and cell viability. The anethole analogues eugenol and isoeugenol also blocked TNF signaling. Anethole suppressed TNF-induced both lipid peroxidation and ROI generation. Overall, our results demonstrate that anethole inhibits TNF-induced cellular responses,,which mag explain its role in suppression of inflammation and carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Chainy, Gagan B.N./G-7020-2012; Aggarwal, Bharat B/G-3388-2013	Chainy, Gagan/0000-0002-6418-0480				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALHARBI MM, 1995, EUR J CANCER PREV, V4, P307, DOI 10.1097/00008469-199508000-00006; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Bouthillier L, 1996, TOXICOL APPL PHARM, V139, P177, DOI 10.1006/taap.1996.0156; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Budavari S., 1996, MERCK INDEX, P108; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drukarch B, 1997, EUR J PHARMACOL, V329, P259, DOI 10.1016/S0014-2999(97)89187-X; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanna S, 1998, BIOCHEM PHARMACOL, V56, P61, DOI 10.1016/S0006-2952(98)00113-0; KO FN, 1995, BBA-LIPID LIPID MET, V1258, P145; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LUBET RA, 1997, INT J CANCER, P7295; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MANSUY D, 1986, BIOCHEM BIOPH RES CO, V135, P1015, DOI 10.1016/0006-291X(86)91029-6; NAGABABU E, 1994, FREE RADICAL RES, V20, P253, DOI 10.3109/10715769409147521; NAIDU KA, 1995, PROSTAG LEUKOTR ESS, V53, P381, DOI 10.1016/0952-3278(95)90060-8; RAJAKUMAR DV, 1993, BIOCHEM PHARMACOL, V46, P2067, DOI 10.1016/0006-2952(93)90649-H; Reddy BS, 1996, PREV MED, V25, P48, DOI 10.1006/pmed.1996.0017; Reddy BS, 1997, ADV EXP MED BIOL, V400, P931; REDDY BS, 1993, CANCER RES, V53, P3493; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; ROMPELBERG CJM, 1993, FOOD CHEM TOXICOL, V31, P637, DOI 10.1016/0278-6915(93)90046-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SHARMA JN, 1994, PHARMACOLOGY, V49, P314, DOI 10.1159/000139248; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; STOHS SJ, 1986, MECH AGEING DEV, V37, P137, DOI 10.1016/0047-6374(86)90071-0; Suganuma M, 1996, CANCER RES, V56, P3711; TAIRA J, 1992, FREE RADICAL RES COM, V16, P197, DOI 10.3109/10715769209049172; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	40	146	150	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2943	2950		10.1038/sj.onc.1203614	http://dx.doi.org/10.1038/sj.onc.1203614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871845				2022-12-25	WOS:000087544500008
J	Pardali, K; Kurisaki, A; Moren, A; ten Dijke, P; Kardassis, D; Moustakas, A				Pardali, K; Kurisaki, A; Moren, A; ten Dijke, P; Kardassis, D; Moustakas, A			Role of smad proteins and transcription factor Sp1 in p21(Wafl/Cip1) regulation by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; HUMAN P21(WAF1/CIP1) GENE; TGF-BETA; DNA-BINDING; FUNCTIONAL INTERACTIONS; FAMILY MEMBERS; CDK INHIBITOR; PROMOTER; ACTIVATION; EXPRESSION	Transforming growth factor-beta (TGF-beta) inhibits cell cycle progression, in part through up-regulation of gene expression of the p21(WAF1/Cip1) (p21) cell cycle inhibitor. Previously we have reported that the intracellular effecters of TGF-beta, Smad3 and Smad4, functionally cooperate with Sp1 to activate the human p21 promoter in hepatoma HepG2 cells. In this study we show that Smad3 and Smad4 when overexpressed in HaCaT keratinocytes lead to activation of the p21 promoter. Activation requires the binding sites for the ubiquitous transcription factor Sp1 on the proximal promoter. Induction of the endogenous HaCaT p21 gene by TGF-beta 1 is further enhanced after overexpression of Smad3 and Smad4, whereas dominant negative mutants of Smad3 and Smad4 and the inhibitory Smad7 all inhibit p21 induction by TGF-beta 1 in a dose-dependent manner. We show that Sp1 expressed in the Sp1-deficient Drosophila SL-2 cells binds to the proximal promoter sequences, whereas Smad proteins do not. In support of this finding, we show that DNA-binding domain mutants of Smad3 and Smad4 are capable of transactivating the p21 promoter as efficiently as wild type Smads. Co-expression of Smad3 with Smad4 and Sp1 in SL-2 cells or coincubation of phosphorylated Smad3, Smad4, and Sp1 in vitro results in enhanced binding of Sp1 to the p21 proximal promoter sequences. We demonstrate that Sp1 physically and directly interacts with Smad2, Smad3, and weakly with Smad4 via their amino-terminal (Mad-Homology 1) domain. Finally, by using GAL4 fusion proteins we show that the glutamine-rich sequences in the transactivation domain of Sp1 contribute to the cooperativity with Smad proteins. In conclusion, Smad proteins play important roles in regulation of the p21 gene by TGF-beta, and the functional cooperation of Smad proteins with Sp1 involves the physical interaction of these two types of transcription factors.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	Ludwig Institute for Cancer Research; Netherlands Cancer Institute; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Moustakas, A (corresponding author), Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Pardali, Katerina/0000-0002-4360-730X				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Hunt KK, 1998, CANCER RES, V58, P5656; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iavarone A, 1997, NATURE, V387, P417; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, J CELL SCI, V112, P4557; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	62	327	346	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29244	29256		10.1074/jbc.M909467199	http://dx.doi.org/10.1074/jbc.M909467199			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10878024	hybrid			2022-12-25	WOS:000089439800011
J	Stopa, M; Anhuf, D; Terstegen, L; Gatsios, P; Gressner, AM; Dooley, S				Stopa, M; Anhuf, D; Terstegen, L; Gatsios, P; Gressner, AM; Dooley, S			Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7 - The TGF-beta response element of the promotor requires functional Smad binding element and E-box sequences for transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR-1 PROMOTER; TUMOR-SUPPRESSOR; GENE; PROTEINS; ACTIVIN; IDENTIFICATION; ANTAGONIST; FAMILY; DNA	Smad7 has recently been identified as a player that antagonizes transforming growth factor beta (TGF-beta) signals by acting downstream of TGF-beta receptors, TGF-beta rapidly induces expression of Smad7 mRNA in a variety of cell types, suggesting participation in a negative feedback loop to control TGF-beta beta responses. We have previously described the genomic locus of rat Smad7 including the promoter region. Here we report polymerase chain reaction cloning of the corresponding promoter regions of human and murine Smad7 genes and functional characterization of the rat Smad7 promoter. Using transient transfection experiments of HepG2 cells, we identified the TGF-beta response element within a strongly conserved region, containing a perfect Smad binding element (SBE; GTCTAGAC). Performing electrophoretic mobility shift assay and cotransfection experiments, we were able to delineate DNA-binding complexes and identified Smad3, Smad4, and Smad2. Mutation of the SBE completely abolished TGF-beta inducibility of Smad7 in HepG2 cells, indicating that this sequence is necessary for TGF-beta-induced transcription. Furthermore, a 3-base pair adjacent E-box is additionally essential for TGF-beta-dependent promoter activation and an overlapping AP1 site is also involved. We conclude that regulation of Smad7 transcription by TGF-beta is mediated via a specific constellation of recognition motifs localized around the SBE, which is conserved in human, rat, and murine genes.	Rhein Westfal TH Klinikum, Inst Klin Chem & Pathobiochem, D-52074 Aachen, Germany; Rhein Westfal TH Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Dooley, S (corresponding author), Rhein Westfal TH Klinikum, Inst Klin Chem & Pathobiochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Dooley, Steven/T-6491-2018; Stopa, Marcin/R-2772-2018	Dooley, Steven/0000-0002-4840-6240; Stopa, Marcin/0000-0001-9540-9500				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Roijer E, 1998, CYTOGENET CELL GENET, V81, P189, DOI 10.1159/000015026; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	29	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29308	29317		10.1074/jbc.M003282200	http://dx.doi.org/10.1074/jbc.M003282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887185	hybrid			2022-12-25	WOS:000089439800019
J	Miao, F; Bouziane, M; Dammann, R; Masutani, C; Hanaoka, F; Pfeifer, G; O'Connor, TR				Miao, F; Bouziane, M; Dammann, R; Masutani, C; Hanaoka, F; Pfeifer, G; O'Connor, TR			3-methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; METHYLPURINE-DNA GLYCOSYLASE; DIHYDROFOLATE-REDUCTASE GENE; COCKAYNE-SYNDROME PATIENTS; UBIQUITIN-LIKE DOMAIN; HUMAN-CELLS; POLYMERASE-BETA; MAMMALIAN-CELLS; N-METHYLPURINES	Human 3-methyladenine-DNA glycosylase (MPG protein) initiates base excision repair by severing the glycosylic bond of numerous damaged bases. In comparison, homologues of the Rad23 proteins (hHR23) and the hXPC protein are involved in the recognition of damaged bases in global genome repair, a subset of nucleotide excision repair. In this report, we show that the hHR23A and -B also interact with the MPG protein and can serve as accessory proteins for DNA damage recognition in base excision repair. Furthermore, the MPG.hHR23 protein complex elevates the rate of MPG protein-catalyzed excision from hypoxanthine-containing substrates. This increased excision rate is correlated with a greater binding affinity of the MPG protein-hHR23 protein complex for damaged DNA. These data suggest that the hHR23 proteins function as universal DNA damage recognition accessory proteins in both of these major excision repair pathways.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Osaka Univ, Dept Mol & Cellular Biol, Suita, Osaka 565, Japan	City of Hope; Beckman Research Institute of City of Hope; Osaka University	O'Connor, TR (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; O'Connor, Timothy/0000-0001-5848-3592	NATIONAL CANCER INSTITUTE [P30CA033572, P01CA069449] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA33572, 1PO11CA69449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; BOHR VA, 1987, CANCER RES, V47, P6426; Bouziane M, 1998, ACTA BIOCHIM POL, V45, P191, DOI 10.18388/abp.1998_4333; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; James P, 1996, GENETICS, V144, P1425; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; LARMINAT F, 1993, J BIOL CHEM, V268, P2649; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; MITCHELL DL, 1988, MUTAT RES, V194, P227, DOI 10.1016/0167-8817(88)90024-7; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Sambrook J., 2002, MOL CLONING LAB MANU; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; SNYDERWINE EG, 1992, CANCER RES, V52, P4182; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TANG MS, 1989, J BIOL CHEM, V264, P14455; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; WANG W, 1995, BIOCHEMISTRY-US, V34, P1798, DOI 10.1021/bi00005a037; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138	62	108	110	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28433	28438		10.1074/jbc.M001064200	http://dx.doi.org/10.1074/jbc.M001064200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10854423	hybrid			2022-12-25	WOS:000089330700015
J	Sakash, JB; Kantrowitz, ER				Sakash, JB; Kantrowitz, ER			The contribution of individual interchain interactions to the stabilization of the T and R states of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; HETEROTROPIC INTERACTIONS; QUATERNARY STRUCTURE; CATALYTIC SUBUNIT; REGULATORY CHAIN; CARBAMOYLTRANSFERASE; BINDING; SITE; PURIFICATION; CRYSTAL	Stabilization of the T and R allosteric states of Escherichia coli aspartate transcarbamoylase is governed by specific intra- and interchain interactions. The six interchain interactions between Glu-239 in one catalytic chain of one catalytic trimer with both Lys-164 and Tyr-165 of a different catalytic chain in the other catalytic trimer have been shown to be involved in the stabilization of the T state. In this study a series of hybrid versions of aspartate transcarbamoylase was studied to determine the minimum number of these Glu-239 interactions necessary to maintain homotropic cooperativity and the T allosteric state. Hybrids with zero, one, and two Glu-239 stabilizing interactions do not exhibit cooperativity, whereas the hybrids with three or more Glu-239 stabilizing interactions exhibit cooperativity, The hybrid enzymes with one or more of the Glu-239 stabilizing interactions also exhibit heterotropic interactions. Two hybrids with three Glu-239 stabilizing interactions, in different geometric relationships, had identical properties. From this and previous studies, it is concluded that the 239 stabilizing interactions play a critical role in the manifestation of homotropic cooperativity in aspartate transcarbamoylase by the stabilization. of the T state of the enzyme. As substrate binding energy is utilized, more and more of the T state stabilizing interactions are relaxed, and finally the enzyme shifts to the R state. In the case of the Glu-239 stabilizing interactions more than three of the interactions must be broken before the enzyme shifts to the R state. The interactions between the catalytic and regulatory chains and between the two catalytic trimers of aspartate transcarbamoylase provide a global set of interlocking interactions that stabilize the T and R states of the enzyme. The substrate-induced local conformational changes observed in the structure of the isolated catalytic subunit drive the quaternary T to R transition of aspartate transcarbamoylase and functionally induced homotropic cooperativity.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; Endrizzi JA, 2000, P NATL ACAD SCI USA, V97, P5077, DOI 10.1073/pnas.090087197; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P389, DOI 10.1021/bi00454a013; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1984, J BIOL CHEM, V259, P3906; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	30	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28701	28707		10.1074/jbc.M005079200	http://dx.doi.org/10.1074/jbc.M005079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10875936	hybrid			2022-12-25	WOS:000089330700050
J	Benzing, T; Yaffe, MB; Arnould, T; Sellin, L; Schermer, B; Schilling, B; Schreiber, R; Kunzelmann, K; Leparc, GG; Kim, E; Walz, G				Benzing, T; Yaffe, MB; Arnould, T; Sellin, L; Schermer, B; Schilling, B; Schreiber, R; Kunzelmann, K; Leparc, GG; Kim, E; Walz, G			14-3-3 Interacts with regulator of G protein signaling proteins and modulates their activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; KINASE-ACTIVITY; RGS PROTEINS; 14-3-3-PROTEINS; BINDING; PHOSPHORYLATION; INHIBITION; MECHANISM; SURVIVAL; FAMILY	Regulator of G protein signaling (RGS) proteins function as GTPase-activating proteins (GAPs) that stimulate the inactivation of heterotrimeric G proteins. We have recently shown that RGS proteins may be regulated on a post-translational level (Benzing, T., Brandes, R., Sellin, L., Schermer, B,, Lecker, S., Walt, G., and Kim, E. (1999) Naf. Med. 5, 913-918). However, mechanisms controlling the GAP activity of RGS proteins are poorly understood. Here we show that 14-3-3 proteins associate with RGS7 and RGS3, Binding of 14-3-3 is mediated by a conserved phosphoserine located in the G alpha-interacting portion of the RGS domain; interaction with 14-3-3 inhibits the GAP activity of RGS7, depends upon phosphorylation of a conserved residue within the RGS domain, and results in inhibition of GAP function. Collectively, these data indicate that phosphorylation-dependent binding of 14-3-3 may act as molecular switch that controls the GAP activity keeping a substantial fraction of RGS proteins in a dormant state.	Univ Hosp Freiburg, Dept Med, D-79106 Freiburg, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Univ Freiburg, Dept Physiol, D-79106 Freiburg, Germany	University of Freiburg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Freiburg	Walz, G (corresponding author), Univ Hosp Freiburg, Dept Med, Hugstetterstr 55, D-79106 Freiburg, Germany.		Schreiber, Robert/Q-7550-2019; Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014	Schermer, Bernhard/0000-0002-5194-9000; Kunzelmann, Karl/0000-0002-4583-7037	NHLBI NIH HHS [HL03601] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Song L, 1999, J BIOL CHEM, V274, P29689, DOI 10.1074/jbc.274.42.29689; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	26	94	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28167	28172						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862767				2022-12-25	WOS:000089197100084
J	Palmer, HR; Bedford, JJ; Leader, JP; Smith, RAJ				Palmer, HR; Bedford, JJ; Leader, JP; Smith, RAJ			P-31 and H-1 NMR studies of the effect of the counteracting osmolyte trimethylamine-N-oxide on interactions of urea with ribonuclease A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTROSCOPY; PROTEIN; EVOLUTION; TISSUES; PROGRAM; FISHES	P-31 NMB spectroscopy has been used to show that the activity of RNase A, which is lowered in the presence of urea, can be recovered with trimethylamine-N-oxide (TMAO). A 1:1 ratio of TMAO:urea was sufficient to recover the enzyme activity. H-1 nuclear Overhauser effect spectroscopy NMR studies with RNase A have shown that even at relatively low effective concentrations of TMAO, some modification of the three-dimensional structure of the biomolecule is apparent.	Univ Otago, Dept Chem, Dunedin 9001, New Zealand; Univ Otago, Sch Med, Dept Physiol, Dunedin 9001, New Zealand	University of Otago; University of Otago	Smith, RAJ (corresponding author), Univ Otago, Dept Chem, POB 56, Dunedin 9001, New Zealand.							Bedford JJ, 1998, COMP BIOCHEM PHYS B, V119, P521, DOI 10.1016/S0305-0491(98)00013-3; Bedford JJ, 1998, J COMP PHYSIOL B, V168, P123, DOI 10.1007/s003600050128; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burg MB, 1998, AM J PHYSIOL-RENAL, V274, pF762, DOI 10.1152/ajprenal.1998.274.4.F762; Burg MB, 1997, AM J PHYSIOL-RENAL, V273, pF1048, DOI 10.1152/ajprenal.1997.273.6.F1048; BURG MB, 1996, KIDNEY INT S57, V57, P100; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PERRIN DD, 1965, DISSOCIATION CONSTAN, P32; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Wimmer R, 1997, J BIOMOL NMR, V9, P101, DOI 10.1023/A:1018631903764; Wimmer R, 1997, J BIOTECHNOL, V55, P85, DOI 10.1016/S0168-1656(97)00061-8; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; [No title captured]	22	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27708	27711						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862769				2022-12-25	WOS:000089197100026
J	Bennett, RJ; Noirot-Gros, MF; Wang, JC				Bennett, RJ; Noirot-Gros, MF; Wang, JC			Interaction between yeast Sgs1 helicase and DNA topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNERS-SYNDROME GENES; ESCHERICHIA-COLI; SYNDROME PROTEIN; BLOOMS-SYNDROME; SACCHAROMYCES-CEREVISIAE; RECQ; RECOMBINATION; EXONUCLEASE; PRODUCT; MITOSIS	The Saccharomyces cerevisiae Sgs1 protein is a member of the RecQ family of DNA helicases that includes the human Bloom's syndrome and Werner's syndrome proteins. In this work, we report studies on the interaction between Sgs1 and DNA topoisomerase III in vitro and in vivo, Affinity chromatography experiments with various fragments of Sgs1, a 1447-amino acid polypeptide, suggested that its N-terminal one-fifth was sufficient for interaction with DNA topoisomerase III. Gel electrophoretic mobility shift assays also indicated that a fragment Sgs1(1-283), containing residues 1-283, inhibited the binding of DNA topoisomerase III to single-stranded DNA. A shorter protein fragment containing residues 1-107 also showed partial inhibition in these assays. Studies of a sgs1 top1 double mutant lacking both Sgs1 and DNA topoisomerase I showed that the slow growth phenotype of this double mutant is suppressed by expressing full-length Sgs1, but not Sgs1 without the N-terminal 107 amino acid residues. In sgs1 top3 cells devoid of DNA topoisomerase III, however, expression of full-length Sgs1 or Sgs1 lacking the N-terminal 107 amino acid residues has the same effect of reducing the growth rate of the double mutant. These in vitro and in vivo data indicate that Sgs1 and DNA topoisomerase III physically interact and that this interaction is physiologically significant.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	jcwang@fas.harvard.edu	noirot-gros, marie-francoise/C-5051-2011; Noirot-Gros, Marie-Françoise/AAY-1001-2021	Bennett, Richard/0000-0001-7563-484X	NIGMS NIH HHS [GM 24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Duguet M, 1997, J CELL SCI, V110, P1345; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; KUYKENDALL JR, 1992, MUTAT RES, V283, P131, DOI 10.1016/0165-7992(92)90145-8; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LU J, 1996, SCIENCE, V383, P678; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Mullen JR, 2000, GENETICS, V154, P1101; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	39	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26898	26905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862619				2022-12-25	WOS:000089144800033
J	Jain, RK; Joyce, PBM; Gorr, SU				Jain, RK; Joyce, PBM; Gorr, SU			Aggregation chaperones enhance aggregation and storage of secretory proteins in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED AGGREGATION; SECRETOGRANIN-II; CHROMOGRANIN-B; IN-VITRO; PITUITARY; GRANULES; PH; MECHANISMS; PATHWAY; 7B2	calcium-induced aggregation has been proposed to play a role in the sorting and storage of secretory proteins in secretary granules of endocrine cells. The regulation of this process is not known. Hexahistidine epitope tags were used to create aggregation chaperones that enhance the calcium-induced aggregation of secretary granule proteins in vitro. Indeed, 100% recovery of the aggregating target protein was achieved without any modification of the target protein. The aggregation chaperone is not trapped in the aggregates. Go-expression of His(6)-tagged secreted alkaline phosphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin storage in secretary granules, and stimulated secretion of chromogranin A increased 50%. However, secretion of secreted alkaline phosphatase was not affected by the hexahistidine epitope tag. Thus, calcium-induced aggregation is not a passive process; rather, aggregation and sorting of secretory proteins can be regulated by aggregation chaperones in the secretary pathway of endocrine cells.	Univ Louisville, Hlth Sci Ctr, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Ctr Struct & Funct Genomics, Montreal, PQ H3G 1M8, Canada	University of Louisville; University of Louisville; Concordia University - Canada; Concordia University - Canada	Gorr, SU (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA.		Joyce, Paul/K-3989-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053367] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 53367] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1987, BONE MINER, V2, P251; Gorr SU, 1999, BIOCHEM BIOPH RES CO, V257, P545, DOI 10.1006/bbrc.1999.0504; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; Gorr SU, 1996, J BIOL CHEM, V271, P3575; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kleene R, 1999, DIGESTION, V60, P305, DOI 10.1159/000007676; Klumperman J, 1996, J NEUROSCI, V16, P7930; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LINARD CG, 1995, MOL CELL BIOCHEM, V151, P39, DOI 10.1007/BF01076894; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Shennan KIJ, 1996, BIOCHEM SOC T, V24, P535, DOI 10.1042/bst0240535; Thiele C, 1997, CURR BIOL, V7, P496; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6	23	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27032	27036						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862758				2022-12-25	WOS:000089144800050
J	Yu, G; Chen, FS; Nishimura, M; Steiner, H; Tandon, A; Kawarai, T; Arawaka, S; Supala, A; Song, YQ; Rogaeva, E; Holmes, E; Zhang, DM; Milman, P; Fraser, PE; Haass, C; St George-Hyslop, P				Yu, G; Chen, FS; Nishimura, M; Steiner, H; Tandon, A; Kawarai, T; Arawaka, S; Supala, A; Song, YQ; Rogaeva, E; Holmes, E; Zhang, DM; Milman, P; Fraser, PE; Haass, C; St George-Hyslop, P			Mutation of conserved aspartates affects maturation of both aspartate mutant and endogenous presenilin 1 and presenilin 2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; TRANSFECTED CELLS; BETA-CATENIN; MISSENSE MUTATIONS; TRANSGENIC MICE; IN-VIVO; NOTCH; DEFICIENCY; GENE	Presenilin (PS1 and PS2) holoproteins are transiently incorporated into low molecular weight (MW) complexes. During subsequent incorporation into a higher MW complex, they undergo endoproteolysis to generate stable N- and C-terminal fragments. Mutation of either of two conserved aspartate residues in transmembrane domains inhibits both presenilin endoproteolysis and the proteolytic processing of beta-amyloid precursor protein and Notch. We show that although PS1/PS2 endoproteolysis is not required for inclusion into the higher MW N- and C-terminal fragment-containing complex, aspartate mutant holoprotein presenilins are not incorporated into the high MW complexes. Aspartate mutant presenilin holoproteins also preclude entry of endogenous wild type PS1/PS2 into the high MW complexes but do not affect the incorporation of wild type holoproteins into lower MW holoprotein complexes. These data suggest that the loss of function effects of the aspartate mutants result in altered PS complex maturation and argue that the functional presenilin moieties are contained in the high molecular weight complexes.	Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Hlth Network, Toronto Western Hosp, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Munich, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Munich	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Rm 118,Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Song, You-Qiang/0000-0001-9407-2256; Arawaka, Shigeki/0000-0002-1505-3012				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CHEN F, 2000, IN PRESS J BIOL CHEM; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kim TW, 1997, J BIOL CHEM, V272, P11006; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	35	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27348	27353						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856299				2022-12-25	WOS:000089144800091
J	Hsing, A; Faller, DV; Vaziri, C				Hsing, A; Faller, DV; Vaziri, C			DNA-damaging aryl hydrocarbons induce mdm2 expression via p53-independent post-transcriptional mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC GROWTH-FACTORS; MURINE 3T3 FIBROBLASTS; MESSENGER-RNA; P53; GENE; RECEPTOR; ADDUCTS; PROTEIN; TRANSACTIVATION; CARCINOGENESIS	During previous studies, we found that mdm2 mRNA levels were elevated in benzo[a]pyrene (BaP, a polycyclic aryl hydrocarbon)-treated cells under conditions of DNA damage-induced cell cycle arrest (Vaziri, C,, and Faller, D, V, (1997) J. Biol, Chem. 272, 2762-2769), We have identified potential aryl-hydrocarbon receptor-binding sites in the mdm2 promoter. However, we show that induction of mdm2 mRNA by BaP is entirely dependent upon aryl-hydrocarbon-induced genotoxicity and does not involve direct aryl-hydrocarbon receptor-mediated transcriptional activation of the mdm2 gene. Heterologous mdm2 promoter-reporter constructs containing p53-response elements were not responsive to BaP treatment. Therefore the p53-response elements in the mdm2 promoter are insufficient to confer DNA damage-dependent expression of mdm2, Furthermore, mdm2 transcripts were induced by BaP in p53 null cells from transgenic mice (although both basal and BaP-induced mdm2 expression levels were reduced in these cells relative to p53(+/+) cultures). These data show that p53-mediated mechanisms cannot account for BaP/DNA damage-induced mdma expression. Mdm2 promoter-reporter gene assays and nuclear run-off analyses of nascent mdm2 transcripts showed that transcriptional induction was unable to account for the large changes in mdma transcript levels following BaP treatment. However, mdm2 mRNA half-life measurements showed stabilization of the mdm2 transcript (from similar to 1 h to >4 h) in response to BaP, To our knowledge, this is the first report of control of mdma at the post-transcriptional level and in a p53-independent manner. Transient ectopic expression of mdm2 strongly augmented aryl-hydrocarbon-induced apoptosis, demonstrating that mdma levels can have a profound effect on the cellular response to DNA damage. Overall, our results suggest a potentially important link between DNA damage signaling and RNA stability that may be relevant to cell cycle regulation, tumor suppression, and environmental carcinogenesis.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Vaziri, C (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St, Boston, MA 02118 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R15ES005998] Funding Source: NIH RePORTER; NCI NIH HHS [CA50454] Funding Source: Medline; NIEHS NIH HHS [ES05998] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAUM EJ, 1978, POLYCYCLIC HYDROCARB, P45; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CONNEY AH, 1982, CANCER RES, V42, P4875; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007; JUVEN T, 1993, ONCOGENE, V8, P3411; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mastrangelo G, 1996, ENVIRON HEALTH PERSP, V104, P1166, DOI 10.2307/3432909; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PRICE BD, 1994, CANCER RES, V54, P896; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wu JX, 1999, MOL CELL BIOL, V19, P8292; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	32	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26024	26031		10.1074/jbc.M002455200	http://dx.doi.org/10.1074/jbc.M002455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856296	hybrid			2022-12-25	WOS:000088999700021
J	Kuraoka, I; Kobertz, WR; Ariza, RR; Biggerstaff, M; Essigmann, JM; Wood, RD				Kuraoka, I; Kobertz, WR; Ariza, RR; Biggerstaff, M; Essigmann, JM; Wood, RD			Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; ENDONUCLEASE; OLIGONUCLEOTIDES; PROMOTES; PROTEIN; MUTANTS	Interstrand DNA cross-link damage is a severe challenge to genomic integrity. Nucleotide excision repair plays some role in the repair of DNA cross-links caused by psoralens and other agents. However, in mammalian cells there is evidence that the ERCC1-XPF nuclease has a specialized additional function during interstrand DNA cross-link repair, beyond its role in nucleotide excision repair. We placed a psoralen monoadduct or interstrand cross-link in a duplex, 4-6 bases from a junction with unpaired DNA. ERCC1-XPF endonucleolytically cleaved within the duplex on either side of the adduct, on the strand having an unpaired 3' tail. Crosslinks that were cleaved only on the 5' side were purified and reincubated with ERCC1-XPF, A second cleavage was then observed on the 3' side. Relevant partially unwound structures near a cross-link may be expected to arise frequently, for example at stalled DNA replication forks. The results show that the single enzyme ERCC1-XPF can release one arm of a cross-link and suggest a novel mechanism for interstrand cross-link repair.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wood, RD (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	wood@icrf.icnet.uk	; Wood, Richard/M-6319-2018	Kuraoka, Isao/0000-0001-6391-3411; Wood, Richard/0000-0002-9495-6892; Rodriguez Ariza, Rafael/0000-0002-0338-7306	NCI NIH HHS [R01 CA086061, CA80024] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA080024, R01CA086061, R01CA080024] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Busch DB, 1997, MUTAT RES-DNA REPAIR, V383, P91, DOI 10.1016/S0921-8777(96)00048-1; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CHENG S, 1988, J BIOL CHEM, V263, P15110; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; HOY CA, 1985, CANCER RES, V45, P1737; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; KAYE J, 1980, CANCER RES, V40, P696; Kobertz WR, 1997, J AM CHEM SOC, V119, P5960, DOI 10.1021/ja9703178; Melton DW, 1998, J CELL SCI, V111, P395; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077	21	248	250	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26632	26636		10.1074/jbc.C000337200	http://dx.doi.org/10.1074/jbc.C000337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10882712	hybrid			2022-12-25	WOS:000088999700102
J	Moir, RD; Puglia, KV; Willis, IM				Moir, RD; Puglia, KV; Willis, IM			Interactions between the tetratricopeptide repeat-containing transcription factor TFIIIC131 and its ligand, TFIIIB70 - Evidence for a conformational change in the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; TFIIB-RELATED FACTOR; YEAST TFIIIB; ACETYLTRANSFERASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FUNCTIONAL DOMAINS; DNA COMPLEXES	In the transcription of tRNA and 5 S genes by RNA polymerase Ill, recruitment of the transcription factor (TF)IIIB is mediated by the promoter-bound assembly factor TFIIIC. A critical limiting step in this process is the interaction between the tetratricopeptide repeat (TPR)-containing subunit of TFIIIC (TFIIIC131) and the TFIIB-related factor Brf1p/TFIIIB70. To facilitate biochemical studies of this interaction, we expressed a fragment of TFIIIC131, TFIIIC131-(1-580), that includes the minimal TFIIIB70 interaction domain defined by two-hybrid studies together with adjacent sequences, up to the end of TPR9, implicated in the assembly reaction. TFIIIC131-(1-580) interacts with TFIIIB70 in solution and inhibits the formation of TFIIIB70 TFIIIC DNA complexes. In a coupled equilibrium binding assay, the formation of TFIIIC131-(1-580) TFIIIB70 complexes was adequately described by a single-site binding model and yielded an apparent equilibrium dissociation constant of 334 +/- 23 nM. CD spectroscopy and limited proteolysis experiments defined a well structured and largely protease-resistant core in TFIIIC131-(1-580) comprising part of the hydrophilic amino terminus, TPR1-5, the intervening non-TPR region, and TPR6-8, CD spectra showed that trifluoroethanol induced significant alpha-helical structure in TFIIIC131-(1-580). A more modest monovalent ion-dependent CD difference was observed in mixtures of TFIIIC131-(1-580) and TFIIIB70, suggesting that formation of the binary complex may proceed with the acquisition of alpha-helicity.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P217; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Persinger J, 1999, MOL CELL BIOL, V19, P5218; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SETHY I, 1995, J BIOL CHEM, V270, P28463; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WHITE RJ, 1998, RNA POLYMERASE 3 TRA, P82	42	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26591	26598		10.1074/jbc.M003991200	http://dx.doi.org/10.1074/jbc.M003991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859316	hybrid			2022-12-25	WOS:000088999700097
J	Matsuo, K; Shintani, S; Tsuji, T; Nagata, E; Lerman, M; McBride, J; Nakahara, Y; Ohyama, H; Todd, R; Wong, DTW				Matsuo, K; Shintani, S; Tsuji, T; Nagata, E; Lerman, M; McBride, J; Nakahara, Y; Ohyama, H; Todd, R; Wong, DTW			p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase	FASEB JOURNAL			English	Article						pol-alpha; primase complex; cell cycle regulator; DNA replication	SIMIAN VIRUS-40 DNA; REPLICATION IN-VITRO; TUMOR-SUPPRESSOR; CELL-CYCLE; ENZYMOLOGICAL CHARACTERIZATION; MUTATION ANALYSIS; ALPHA-PRIMASE; GENE; PHOSPHORYLATION; DOC-1	p12(DOC-1) is a growth suppressor identified and isolated from normal keratinocytes. Ectopic expression of p12(DOC-1) in squamous carcinoma cells led to the reversion of in vitro transformation phenotypes including anchorage independence, doubling time, and morphology. Here we report that p12(DOC-1) associates with DNA polymerase alpha/primase (pol-alpha: primase) in vitro and in cells. The pol-alpha:primase binding domain in p12(DOC-1) is mapped to the amino-terminal six amino acid (MSYKPN). The biological effect of p12(DOC-1) on pol-alpha:primase was examined using in vitro DNA replication assays. Using the SV40 DNA replication assay, p12(DOC-1) suppresses DNA replication, leveling at similar to 50%. Similar results were obtained using the M13 single-stranded DNA synthesis assay. Analysis of the DNA replication products revealed that p12(DOC-1) affects the initiation step, not the elongation phase. The p12(DOC-1) suppression of DNA replication is likely to be mediated either by a direct inhibitory effect on pol-alpha:primase or by its effect on cyclin-dependent kinase 2 (CDK2), a recently identified p12(DOC-1)-associated protein known to stimulate DNA replication by phosphorylating pol-alpha:primase. p12(DOC-1) suppresses CDK2-mediated phosphorylation of pol-alpha:primase. These data support a role of p12(DOC-1) as a regulator of DNA replication by direct inhibition of pol-alpha:primase or by negatively regulating the CDK2-mediated phosphorylation of pol-alpha:primase.	Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Lab Oral & Maxillofacial Surg, Boston, MA 02115 USA; NCI, Immunobiol Lab, DBS, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, 188 Longwood Ave, Boston, MA 02115 USA.				NIDCR NIH HHS [R01 DE08680, P01 DE12467, R29 DE 11983] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		COPELAND WC, 1991, J BIOL CHEM, V266, P22739; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; Daigo Y, 1997, GENE CHROMOSOME CANC, V20, P204, DOI 10.1002/(SICI)1098-2264(199710)20:2<204::AID-GCC12>3.0.CO;2-Q; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; DUTTA A, 1996, CELL CYCLE MAT METHO, P175; GORDON HM, 1992, J IMMUNOL, V148, P4021; Harlow ED., 1999, USING ANTIBODIES; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MILLER MA, 1988, NUCLEIC ACIDS RES, V16, P7961, DOI 10.1093/nar/16.16.7961; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Sambrook J, 1989, MOL CLONING LAB MANU, VII; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WONG SW, 1986, J BIOL CHEM, V261, P7958; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148	22	47	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1318	1324		10.1096/fj.14.10.1318	http://dx.doi.org/10.1096/fj.14.10.1318			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877824				2022-12-25	WOS:000087932200006
J	Straub, RH; Linde, HJ; Mannel, DN; Scholmerich, J; Falk, W				Straub, RH; Linde, HJ; Mannel, DN; Scholmerich, J; Falk, W			A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-alpha and IL-6 secretion in the spleen	FASEB JOURNAL			English	Article						Pseudomonas aeruginosa; macrophage; tumor necrosis factor alpha; interleukin 6; norepinephrine; adrenoreceptor	GRAM-NEGATIVE BACTERIA; NECROSIS-FACTOR-ALPHA; MURINE SPLEEN; INTERLEUKIN-6 SECRETION; NERVOUS-SYSTEM; TRANSLOCATION; EXPRESSION; SHOCK; LIPOPOLYSACCHARIDE; GLUCOCORTICOIDS	It is believed that an inflammation-induced activation of the CNS leads to an inhibition of overshooting immune responses to prevent extensive local cytokine secretion. However, immunosuppression by the sympathetic nervous system may be unfavorable when bacteria are present locally and when TNF-alpha is necessary to overcome infection. We now report in a superfusion model, using mouse spleen slices, that although local Pseudomonas aeruginosa increased splenic TNF-alpha and IL-6 secretion severalfold over basal levels, electrically released neurotransmitters attenuated cytokine secretion to similar basal level as under bacteria-free conditions. Bacteria reversed noradrenergic inhibitory effector mechanisms: Under bacteria-free conditions, TNF-alpha secretion was very low and IL-6 secretion was mainly inhibited by alpha(2)-adrenoreceptor ligation. In the presence of bacteria, TNF-alpha and IL-6 secretion were high and IL-6 secretion was mainly inhibited by beta-adrenoreceptor ligation. The alpha- to beta-adrenoswitch of IL-6 inhibition in the presence of bacteria was mediated by the prior adrenergic regulation of TNF-alpha. In vivo, chemical abrogation of sympathetic inhibition reduced accumulation of bacteria in the spleen, which depended at least in part on TNF-alpha. This suggests that activation of the sympathetic nervous system may be a forerunner for accumulation of bacteria in tissue and consecutively sepsis due to intensified inhibition of TNF-alpha secretion.	Univ Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, D-93042 Regensburg, Germany; Univ Regensburg, Inst Med Microbiol, D-93042 Regensburg, Germany; Univ Regensburg, Inst Pathol Immunol, D-93042 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Straub, RH (corresponding author), Univ Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.	rainer.straub@klinik.uni-regensburg.de		Straub, Rainer H/0000-0003-1165-4555				BAKER JW, 1988, J TRAUMA, V28, P896, DOI 10.1097/00005373-198807000-00002; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berg Rodney D., 1995, Trends in Microbiology, V3, P149, DOI 10.1016/S0966-842X(00)88906-4; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; COTECCHIA S, 1984, LIFE SCI, V35, P2359, DOI 10.1016/0024-3205(84)90528-9; De Luigi A, 1998, NEUROSCIENCE, V83, P1245, DOI 10.1016/S0306-4522(97)00381-3; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; FERNANDES LB, 1988, EUR J PHARMACOL, V157, P135, DOI 10.1016/0014-2999(88)90376-7; Freestone PPE, 1999, FEMS MICROBIOL LETT, V172, P53, DOI 10.1111/j.1574-6968.1999.tb13449.x; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; ICHIJO T, 1994, BRAIN RES BULL, V34, P547, DOI 10.1016/0361-9230(94)90139-2; JONES WG, 1990, ANN SURG, V211, P399, DOI 10.1097/00000658-199004000-00004; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kale IT, 1998, J TRAUMA, V44, P171, DOI 10.1097/00005373-199801000-00024; Kinney KS, 1999, MICROB PATHOGENESIS, V26, P85, DOI 10.1006/mpat.1998.0251; Koch T, 1996, INTENS CARE MED, V22, P637; Korn SH, 1998, BIOCHEM PHARMACOL, V56, P1561, DOI 10.1016/S0006-2952(98)00179-8; Licinio J, 1997, J CLIN INVEST, V100, P2941, DOI 10.1172/JCI119846; LYTE M, 1992, LIFE SCI, V50, P203, DOI 10.1016/0024-3205(92)90273-R; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; Munck A, 1986, Adv Exp Med Biol, V196, P81; NIIJIMA A, 1991, J AUTONOM NERV SYST, V36, P183, DOI 10.1016/0165-1838(91)90042-2; Obermeier F, 1999, CLIN EXP IMMUNOL, V116, P238; Panetta R, 1999, BIOCHEM BIOPH RES CO, V259, P550, DOI 10.1006/bbrc.1999.0817; REITHMANN C, 1991, EUR J PHARM-MOLEC PH, V206, P53, DOI 10.1016/0922-4106(91)90146-9; RENZ H, 1988, J IMMUNOL, V141, P2388; RICE P, 1999, NEUROIMMUNOMODULAT, V6, P244; SEVERN A, 1992, J IMMUNOL, V148, P3441; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; STRAUB RH, 1995, J NEUROIMMUNOL, V61, P53, DOI 10.1016/0165-5728(95)00073-B; Straub RH, 1996, J NEUROIMMUNOL, V71, P37, DOI 10.1016/S0165-5728(96)00126-9; Straub RH, 1997, J NEUROCHEM, V68, P1633; Straub RH, 1998, AM J PHYSIOL-REG I, V274, pR997, DOI 10.1152/ajpregu.1998.274.4.R997; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	40	48	53	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1380	1388		10.1096/fj.14.10.1380	http://dx.doi.org/10.1096/fj.14.10.1380			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877831				2022-12-25	WOS:000087932200013
J	Crisp, RJ; Knauer, DJ; Knauer, MF				Crisp, RJ; Knauer, DJ; Knauer, MF			Roles of the heparin and low density lipid receptor-related protein-binding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism - The PN1 heparin-binding site mediates complex retention and degradation but not cell surface binding or internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PLASMINOGEN-ACTIVATOR; ANTITHROMBIN-III; THROMBIN; LIPOPROTEIN; IDENTIFICATION; PURIFICATION; MECHANISM; COFACTOR; PEPTIDE	We have previously described thrombin (Th)-protease nexin 1 (PN1) inhibitory complex binding to cell surface heparins and subsequent low density lipid receptor-related protein (LRP)-mediated internalization. Our present studies examine the catabolism of urinary plasminogen activator (uPA)-PN1 inhibitory complexes, which, unlike Th PN1 complexes, bind almost exclusively through the uPA receptor. In addition, the binding site in PN1 required for the LRP-mediated internalization of Th PN1 complexes is not required for the LRP-mediated internalization of uPA.PN1 complexes. Thus, the protease moiety of the complex partially determines the mechanistic route of entry. Because cell surface heparins are only minimally involved in the binding and internalization of uPA.PN1 complexes, we then predicted that complexes between uPA and the heparin binding-deficient PN1 variant, PN1(K7E), should be catabolized at the same rate as complexes formed with native PN1. Surprisingly, the uPA.PN1(K7E) complexes were degraded at only a fraction of the rate of native complexes. Internalization studies revealed that both uPA.PN1(K7E) and native uPA.PN1 complexes were initially internalized at the same rate, but uPA.PN1(K7E) complexes were rapidly retro-endocytosed in an intact form. By examining the pH dependence of complex binding in the range of 4.0-7.0, it was determined that the uPA.PN1 inhibitory complexes must specifically bind to endosomal heparins at pH 5.5 to be retained and sorted to lysosomes. These studies are the first to document a role for heparins in the catabolism of SERPIN-protease complexes at a point further in the pathway than cell surface binding, and this role may extend to other heparin-binding LRP-internalized ligands.	Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA	University of California System; University of California Irvine	Knauer, MF (corresponding author), Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; Bochaton-Piallat ML, 1998, CIRC RES, V82, P1086, DOI 10.1161/01.RES.82.10.1086; COHEN AB, 1977, P NATL ACAD SCI USA, V74, P4311, DOI 10.1073/pnas.74.10.4311; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CUNNINGHAM DD, 1992, ADV EXP MED BIOL, V313, P297; Cunningham DD, 1997, ADV EXP MED BIOL, V425, P67; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SMITH JW, 1987, J BIOL CHEM, V262, P11964; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009	37	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19628	19637		10.1074/jbc.M909172199	http://dx.doi.org/10.1074/jbc.M909172199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867020	hybrid			2022-12-25	WOS:000087941300027
J	Fribourg, S; Kellenberger, E; Rogniaux, H; Poterszman, A; Van Dorsselaer, A; Thierry, JC; Egly, JM; Moras, D; Kieffer, B				Fribourg, S; Kellenberger, E; Rogniaux, H; Poterszman, A; Van Dorsselaer, A; Thierry, JC; Egly, JM; Moras, D; Kieffer, B			Structural characterization of the cysteine-rich domain of TFIIH p44 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; DNA-REPAIR; 26S PROTEASOME; BINDING DOMAIN; ZINC-FINGER; CSB PROTEIN	In an effort to understand the structure function relationship of TFIIH, a transcription/repair factor, we focused our attention on the p44 subunit, which plays a central role in both mechanisms. The amino-terminal portion of p44 has been shown to be involved in the regulation of the XPD helicase activity; here we show that its carboxyl-terminal domain is essential for TFIIH transcription activity and that it binds three zinc atoms through two independent modules. The first contains a C4 zinc finger motif, whereas the second is characterized by a CX(2)CX(2-4)FCADCD motif, corresponding to interleaved zinc binding sites. The solution structure of this second module reveals an unexpected homology with the regulatory domain of protein kinase C and provides a framework to study its role at the molecular level.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; Ecole Super Biotechnol Strasbourg, CNRS UPR 9004, Communaunte Urbaine Strasbourg, F-67400 Illkirch Graffenstaden, France; Ecole Super Biotechnol Strasbourg, CNRS UPR 9004, Lab Resonance Magnet, F-67400 Illkirch Graffenstaden, France; ULP, CNRS UMR 7509, Lab Spectrometrie Masse Bio Organ, F-67008 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,Boite Postale 163, F-67404 Illkirch, France.		Fribourg, Sebastien/M-7418-2014; Kieffer, Bruno/AAE-8999-2019	Fribourg, Sebastien/0000-0003-4112-7510; Kieffer, Bruno/0000-0002-2033-4679; POTERSZMAN, Arnaud/0000-0002-6702-5777				Adachi N, 1999, YEAST, V15, P255; Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Billeter M, 1995, J BIOMOL NMR, V5, P1; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BRUNGER AT, 1992, XPLOR SOFTWARE MANUA; Coin F, 1998, COLD SPRING HARB SYM, V63, P105, DOI 10.1101/sqb.1998.63.105; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; DAIKUN GP, 1986, NATURE, V324, P698; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LAFITTE D, 1995, BIOCHEMISTRY-US, V34, P13825, DOI 10.1021/bi00042a014; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rogniaux H, 1999, J AM SOC MASS SPECTR, V10, P635, DOI 10.1016/S1044-0305(99)00030-6; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHANG ZG, 1989, BIOCHEMISTRY-US, V28, P9790, DOI 10.1021/bi00451a037; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Takayama K, 1996, AM J HUM GENET, V58, P263; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhao XF, 1999, J BIOL CHEM, V274, P1388, DOI 10.1074/jbc.274.3.1388	48	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31963	31971		10.1074/jbc.M004960200	http://dx.doi.org/10.1074/jbc.M004960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882739	hybrid			2022-12-25	WOS:000089858900058
J	Harbeck, B; Huttelmaier, S; Schluter, K; Jockusch, BM; Illenberger, S				Harbeck, B; Huttelmaier, S; Schluter, K; Jockusch, BM; Illenberger, S			Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN PLATELETS; MICROFILAMENT PROTEIN VASP; FOCAL-ADHESION; SMOOTH-MUSCLE; IN-VITRO; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODY; ENA/VASP FAMILY; CELL-ADHESION; BINDING SITE	The vasodilator-stimulated phosphoprotein (VASP) is a major substrate for cyclic nucleotide-dependent kinases in platelets and other cardiovascular cells. It promotes actin nucleation and binds to actin filaments in vitro and associates with stress fibers in cells. The VASP-actin interaction is salt-sensitive, arguing for electrostatic interactions. Hence, phosphorylation may significantly alter the actin binding properties of VASP. This hypothesis was investigated by analyzing complex formation of recombinant murine VASP with actin after phosphorylation with cAMP-dependent kinase in different assays. cAMP-dependent kinase phosphorylation had a negative effect on both actin nucleation and VASP interaction with actin filaments, with the actin nucleating capacity being more affected than actin filament binding and bundling. Replacing VASP residues known to be phosphorylated in vivo by acidic residues to mimic phosphorylation had similar although less dramatic effects on VASP-actin interactions. In contrast, phosphorylation had no significant effect on VASP oligomerization or its interaction with its known ligands profilin, vinculin, and zyxin. When overexpressing VASP mutants in eukaryotic cells, they all showed targeting to focal contacts and stress fibers, Our results imply that VASP phosphorylation may act as an immediate negative regulator of actin dynamics.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, Dept Cell Biol, Bioctr, D-38092 Braunschweig, Germany	Braunschweig University of Technology	Illenberger, S (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, Dept Cell Biol, Bioctr, Spielmannstr 7, D-38092 Braunschweig, Germany.	S.Illenberger@tu-bs.de						ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NORTH AJ, 1994, J CELL SCI, V107, P437; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Schluter K, 1998, J CELL SCI, V111, P3261; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; Tang JX, 1997, EUR J BIOCHEM, V247, P432, DOI 10.1111/j.1432-1033.1997.00432.x; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	42	203	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30817	30825		10.1074/jbc.M005066200	http://dx.doi.org/10.1074/jbc.M005066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882740	hybrid			2022-12-25	WOS:000089762700014
J	Huang, MC; Zollner, O; Moll, T; Maly, P; Thall, AD; Lowe, JB; Vestweber, D				Huang, MC; Zollner, O; Moll, T; Maly, P; Thall, AD; Lowe, JB; Vestweber, D			P-selectin glycoprotein ligand-1 and E-selectin ligand-1 are differentially modified by fucosyltransferases Fuc-TIV and Fuc-TVII in mouse neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELAM-1-DEPENDENT CELL-ADHESION; HAMSTER OVARY CELLS; ROLLING IN-VIVO; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; EXPRESSION CLONING; MYELOID CELLS; LEWIS-X; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; TYROSINE SULFATION	P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-l (ESL-1) are the two major selectin ligands on mouse neutrophils, Transfection experiments demonstrate that each ligand requires alpha 1,3-fucosylation for selectin-binding. However, the relative contributions made by the two known myeloid alpha 1,3-fucosyltransferases Fuc-TVII or Fuc-TIV to this alpha 1,3-fucosylation are not yet clear. To address this issue, we have used mice deficient in Fuc-TIV and/or Fuc-TVII to examine how these enzymes generate selectin-binding glycoforms of PSGL-1 and ESL-1 in mouse neutrophils, Selectin binding was analyzed by affinity isolation experiments using recombinant, antibody-like forms of the respective endothelial selectins, We observe essentially normal binding of E- or P-selectin to PSGL-1 expressed by Fuc-TIV-deficient neutrophils but find that PSGL-1 expressed by Fuc-TVII-deficient neutrophils is not bound by E- or P-selectin, By contrast, E-selectin binds with normal efficiency to ESL-1 on Fuc-TVII-deficient neutrophils but exhibits an 80% reduction in its ability to bind ESL-I isolated from Fuc-TIV-deficient neutrophils, The same specificity with which Fuc-TVII and Fuc-TIV generate selectin-binding forms of PSGL-1 and ESL-I was found in transfection experiments with CHO-Pro(-)5 cells. In contrast, each fucosyltransferase alone could generate selectin-binding glycoforms of each of the two ligands in CHO-DUKX-B1 cells. Our data imply that in mouse neutrophils and their precursors, Fuc-TVII exclusively directs expression of PSGL-1 glycoforms bound with high affinity by P-selectin, By contrast, Fuc-TIV preferentially directs expression of ESL-1 glycoforms that exhibit high affinity for E-selectin, This substrate specificity can be mimicked in CHO-Pro(-)5 cells.	Univ Munster, Inst Cell Biol, ZMBE, D-48149 Munster, Germany; Max Planck Inst Physiol & Clin Res, D-48149 Munster, Germany; Univ Michigan, Howard Hughes Med Inst, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Munster; Max Planck Society; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Vestweber, D (corresponding author), Univ Munster, Inst Cell Biol, ZMBE, Von Esmarch Str 56, D-48149 Munster, Germany.		Malý, Petr/H-5962-2014	Malý, Petr/0000-0001-8118-0581; HUANG, MIN-CHUAN/0000-0002-0704-3447; Vestweber, Dietmar/0000-0002-3517-732X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KUMAR R, 1991, J BIOL CHEM, V266, P21777; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1997, ADV VASC BIOL, V3, P143; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI S, 1994, EXP NEPHROL, V2, P269; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Steegmaier M, 1997, J CELL SCI, V110, P687; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; TEREILE H, 1990, NATURE, V348, P649; VESTWEBER D, 1997, SELECTINS, V3, P225; Wagers AJ, 1997, J IMMUNOL, V159, P1917; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	43	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31353	31360		10.1074/jbc.M005449200	http://dx.doi.org/10.1074/jbc.M005449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882744	hybrid			2022-12-25	WOS:000089762700086
J	Samson, ML				Samson, ML			Drosophila arginase is produced from a nonvital gene that contains the elav locus within its third intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MELANOGASTER; PROTEIN; REGION; GENOME; NO; HYBRIDIZATION; MUTATIONS; APOPTOSIS; SEQUENCE	A Drosophila gene encoding a 351-amino acid-long predicted arginase (40% identity with vertebrate arginases) is reported. Interestingly, the third intron of the arginase gene includes the elav locus, whose coding sequence is on the complementary DNA strand to that of the arginase. Terrestrial vertebrates produce two arginases from duplicated genes. One form, essentially present in the liver, is a key enzyme of the urea cycle and eliminates excess ammonia through the excretion of urea. The function of the extrahepatic arginase, more ubiquitous, is not well understood. In macrophages, arginase competes with nitric-oxide synthase, which converts arginine into nitric oxide. Most organisms, including insects, produce only one type of arginase, whose function is not centered on ammonia detoxification. A Drosophila cDNA encoding a predicted arginase was isolated. It produces a 1.3-kilobase transcript present with highest levels toward the end of embryogenesis and thereafter. During embryogenesis, the arginase transcripts localize to the fat body. The first mutant allele of the Drosophila arginase gene was identified. It is predicted to produce a 199-amino acid-long C-terminally truncated protein, likely to be inactive. Preliminary characterization of the mutation shows that this recessive allele causes a developmental delay but does not affect viability.	Univ Paris 11, UPRES A 8080, Lab Embryol Mol & Expt, F-91405 Orsay, France; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	UDICE-French Research Universities; Universite Paris Saclay; University of Nebraska System; University of Nebraska Medical Center	Samson, ML (corresponding author), Univ Paris 11, UPRES A 8080, Lab Embryol Mol & Expt, Batiment 445, F-91405 Orsay, France.	Marie-Laure.Samson@emex.u-psud.fr						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ash DE, 1998, MOL GENET METAB, V64, P243, DOI 10.1006/mgme.1998.2677; Ashburner M, 1999, GENETICS, V153, P179; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Braissant O, 1999, MOL BRAIN RES, V70, P231, DOI 10.1016/S0169-328X(99)00151-5; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMPOS AR, 1987, EMBO J, V6, P425, DOI 10.1002/j.1460-2075.1987.tb04772.x; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Durner J, 1999, P NATL ACAD SCI USA, V96, P14206, DOI 10.1073/pnas.96.25.14206; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; GREEN SM, 1990, J BIOL CHEM, V265, P1601; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; Ignarro L., 1995, NITRIC OXIDE BIOCH M; ITOH N, 1985, DROS INF SERVICE, V61, P89; JENKINSON CP, 1996, EMBO J, V114, P107; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; Maglott DR, 2000, NUCLEIC ACIDS RES, V28, P126, DOI 10.1093/nar/28.1.126; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; OUZOUNIS CA, 1994, J MOL EVOL, V39, P101; PATTERTON D, 1994, J BIOL CHEM, V269, P25328; PEROZICH J, 1998, BIOCHIM BIOPHYS ACTA, V15, P23; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Riechmann V, 1998, DEVELOPMENT, V125, P713; Rizki TM, 1978, GENETICS BIOL DROSOP; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Rouzaut A, 1999, BBA-MOL CELL RES, V1451, P319, DOI 10.1016/S0167-4889(99)00106-8; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; SAMSON ML, 1995, GENETICS, V141, P1101; Samson ML, 1998, GENETICS, V150, P723; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAO KM, 1991, MOL CELL BIOL, V11, P2994, DOI 10.1128/MCB.11.6.2994; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; Zinke I, 1999, DEVELOPMENT, V126, P5275; 1999, TRENDS GENET, V15, P51	48	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31107	31114		10.1074/jbc.M001346200	http://dx.doi.org/10.1074/jbc.M001346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878001	hybrid			2022-12-25	WOS:000089762700052
J	Tu, G; Kirchmaier, AL; Liggitt, D; Liu, Y; Liu, SQ; Yu, WH; Heath, TD; Thor, A; Debs, RJ				Tu, G; Kirchmaier, AL; Liggitt, D; Liu, Y; Liu, SQ; Yu, WH; Heath, TD; Thor, A; Debs, RJ			Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE GROWTH TRANSFORMATION; CYTOTOXIC T-LYMPHOCYTES; FIREFLY LUCIFERASE GENE; LONG-TERM EXPRESSION; NUCLEAR ANTIGEN-1; TRANSGENE EXPRESSION; SKELETAL-MUSCLE; MAMMALIAN-CELLS; VECTOR; MICE	To date, no gene transfer vector has produced prolonged gene expression following a single intravenous injection and then efficiently re-expressed the delivered gene following repeated systemic injection into immunocompetent hosts. To overcome these limitations, a gene therapy regimen using non-replicating Epstein-Barr virus (EBV)-based expression plasmids was developed. One plasmid contains the FR (EBV family of repeats) sequence and the expressed gene. The other encodes Epstein-Barr nuclear antigen 1 (EBNA-1), but lacks FR. Although unable to replicate in mice, intravenous co-injection of EBV-based plasmids in cationic liposome-DNA complexes (CLDCs) substantially prolonged luciferase gene expression. The use of a two-vector system limited host exposure to the EBNA-1 gene product. Furthermore, this EBV-based vector system could be intravenously re-injected multiple times into immunocompetent mice without loss of transfection efficiency. Use of this vector system significantly improved the therapeutic efficacy of the biologically important human granulocyte colony-stimulating factor gene. Delivery of the human granulocyte colony-stimulating factor gene in EBV-based plasmids increased circulating white blood counts for at least 2 months following a single CLDC-based intravenous co-injection. Conversely, white blood counts were never elevated following injection of CLDCs lacking EBV-derived elements. Thus, this EBV-based plasmid vector system both markedly prolongs gene expression at therapeutic levels and efficiently and repeatedly re-transfects immunocompetent hosts. These properties of EBV-based plasmid vectors appear to be due, at least in part, to the documented abilities of the EBNA-1 protein both to retain FR-containing DNA intracellularly and within the nucleus and to block anti-EBNA-1 cytotoxic T cell responses.	Calif Pacific Med Res Inst, San Francisco, CA 94115 USA; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Northwestern Univ, Sch Med, Dept Pathol, Evanston, IL 60201 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Wisconsin System; University of Wisconsin Madison; University of Washington; University of Washington Seattle; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Debs, RJ (corresponding author), Calif Pacific Med Res Inst, 2330 Clay St, San Francisco, CA 94115 USA.		Liu, Shu Q/B-7626-2009	Kirchmaier, Ann/0000-0001-9938-9105	NCI NIH HHS [CA07175, R01 CA82575, CA22443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082575, P30CA007175, P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bicknell R, 1992, Semin Cancer Biol, V3, P399; Bonham L, 1996, HUM GENE THER, V7, P1423, DOI 10.1089/hum.1996.7.12-1423; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; Clark KR, 1997, HUM GENE THER, V8, P659, DOI 10.1089/hum.1997.8.6-659; Cooper MJ, 1997, P NATL ACAD SCI USA, V94, P6450, DOI 10.1073/pnas.94.12.6450; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038/bjc.1982.16; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; Goddard CA, 1997, GENE THER, V4, P1231, DOI 10.1038/sj.gt.3300515; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JANKELEVICH S, 1992, EMBO J, V11, P1165, DOI 10.1002/j.1460-2075.1992.tb05157.x; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; KIRCHMAIER AL, 2000, EBV PROTOCOLS; KIRCHMAIER AL, 1997, THESIS U WISCONSIN M; KRYSAN PJ, 1993, GENE, V136, P137, DOI 10.1016/0378-1119(93)90457-E; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; Langle-Rouault F, 1998, J VIROL, V72, P6181; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu Y, 1999, J BIOL CHEM, V274, P13338, DOI 10.1074/jbc.274.19.13338; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; Mittal SK, 1996, J GEN VIROL, V77, P1, DOI 10.1099/0022-1317-77-1-1; MITTAL SK, 1993, VIRUS RES, V28, P67, DOI 10.1016/0168-1702(93)90090-A; Mizuguchi H, 2000, FEBS LETT, V472, P173, DOI 10.1016/S0014-5793(00)01450-2; Mukherjee S, 1998, J EXP MED, V187, P445, DOI 10.1084/jem.187.3.445; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Saeki Y, 1998, GENE THER, V5, P1031, DOI 10.1038/sj.gt.3300711; SCHIRMBECK R, 1992, EUR J IMMUNOL, V22, P759, DOI 10.1002/eji.1830220320; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; SOLDEVILA G, 1995, J IMMUNOL, V155, P5590; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WU GY, 1991, J BIOL CHEM, V266, P14338; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	58	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30408	30416		10.1074/jbc.M004782200	http://dx.doi.org/10.1074/jbc.M004782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10856307	hybrid			2022-12-25	WOS:000089577900067
J	Carter, MS; Sarnow, P				Carter, MS; Sarnow, P			Distinct mRNAs that encode La autoantigen are differentially expressed and contain internal ribosome entry sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; CAP-INDEPENDENT TRANSLATION; TERMINATION FACTOR LA; TRANS-ACTING FACTORS; 5' NONCODING REGION; SS-B AUTOANTIGEN; LUPUS ANTIGEN-LA; NF-KAPPA-B; LA/SS-B; TRANSCRIPTION TERMINATION	Analysis by reverse transcription-polymerase chain reaction has suggested the existence of at least two La autoantigen-encoding mRNAs that contain different 5' noncoding regions (NCRs) linked to the same La coding region (Troster, H,, Metzger, T, E,, Semsei, I., Schwemmle, M,, Winterpacht, A., Zabel, B,, and Bachmann, M. (1994) J, Exp. Med. 180, 2059-2067). Laencoding transcripts La1 and La1' contain 115- and 483-nucleotide 5' NCRs, respectively. To determine whether the various La transcripts are functional mRNAs, the expression and polysomal association of natural La1 and La1' RNAs were examined. Although La1 transcripts were ubiquitously expressed in human tissues, La1' transcripts were predominantly expressed in peripheral blood leukocytes, especially in B, T, and natural killer cells. Both La1 and La1' transcripts associated with polysomes in natural killer cells, suggesting that these transcripts were functional mRNAs, Upon activation of B cells with the mitogens phorbol 12-myristate 13-acetate and ionomycin, the amount of La1' mRNA, but not La1, declined. In contrast, after chemical activation of T cells, the amount of La 1 mRNA, but not La1', declined. The mechanism by which the La1 and La1' 5' NCRs initiate translation initiation was tested in cultured human HeLa cells and in two different in vitro translation systems. It was found that both 5' NCRs can mediate translation initiation by internal initiation. These findings indicate that the constitutive expression of La1 mRNA and the tissue-specific expression of La1' mRNA can both allow La protein synthesis under conditions when cap-dependent translation is compromised, such as inflammation, apoptosis, or certain viral infections.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Sarnow, P (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild Sci Bldg, Stanford, CA 94305 USA.	psarnow@leland.stanford.edu		Sarnow, Peter/0000-0002-2043-2770	NIGMS NIH HHS [R01 GM55979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1975, J CLIN INVEST, V55, P1067, DOI 10.1172/JCI108007; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bai CY, 2000, NUCLEIC ACIDS RES, V28, P1078, DOI 10.1093/nar/28.5.1078; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; CHAMBERS JC, 1983, J BIOL CHEM, V258, P1438; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Grolz D, 1998, BBA-GENE STRUCT EXPR, V1396, P278, DOI 10.1016/S0167-4781(97)00201-7; Grolz D, 1997, J BIOL CHEM, V272, P12076, DOI 10.1074/jbc.272.18.12076; HAMBIDGE SJ, 1991, J VIROL, V65, P6312, DOI 10.1128/JVI.65.11.6312-6315.1991; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Hilker M, 1996, CELL TISSUE RES, V284, P383, DOI 10.1007/s004410050599; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Jackson RJ, 1995, RNA, V1, P985; JANEWAY CA, 1997, IMMUNOBIOLOGY IMMUNE, P1; Jitrapakdee S, 1998, J BIOL CHEM, V273, P34422, DOI 10.1074/jbc.273.51.34422; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KLEIN E, 1968, CANCER RES, V28, P1300; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kremerskothen J, 1998, DNA CELL BIOL, V17, P751, DOI 10.1089/dna.1998.17.751; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SCHIBLER U, 1982, ADV EXP MED BIOL, V158, P381; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TROSTER H, 1994, J EXP MED, V180, P2059, DOI 10.1084/jem.180.6.2059; Van Horn DJ, 1997, RNA, V3, P1434; Wallace JC, 1998, INT J BIOCHEM CELL B, V30, P1, DOI 10.1016/S1357-2725(97)00147-7; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, J IMMUNOL, V133, P123; Xue DH, 2000, EMBO J, V19, P1650, DOI 10.1093/emboj/19.7.1650; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	62	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28301	28307						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871624				2022-12-25	WOS:000089197100102
J	Wang, Y; Shen, JS; Arenzana, N; Tirasophon, W; Kaufman, RJ; Prywes, R				Wang, Y; Shen, JS; Arenzana, N; Tirasophon, W; Kaufman, RJ; Prywes, R			Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; FAMILIAL ALZHEIMERS-DISEASE; CCAAT REGULATORY ELEMENT; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; INTRACELLULAR DOMAIN; MISSENSE MUTATIONS; GRP78/BIP PROMOTER; NUCLEAR ACCESS	ATF6 is a member of the basic-leucine zipper family of transcription factors. It contains a transmembrane domain and is located in membranes of the endoplasmic reticulum, ATF6 has been implicated in the endoplasmic reticulum (ER) stress response pathway since it can activate expression of GRP78 and other genes induced by the ER stress response. ER stress appears to activate ATF6 by cleavage from the ER membrane and translocation to the nucleus, However, direct DNA binding by ATF6 had not been demonstrated. In this report, we have identified a consensus DNA binding sequence for ATF6. This site is related to but distinct from ATF1/CREB binding sites. The site was placed in a reporter gene and was specifically activated by ATF6 overexpression and was strongly induced by the ER stress response. A dominant negative form of ATF6 blocked ER stress induction of both ATF6 site and GRP78 reporter genes. We further found that GAL4-ATF6 could be activated by ER stress. These results demonstrate that ATF6 is a direct target of the ER stress response. A proximal sensor of the ER stress response, human IRE1 (hIRE1), was sufficient to activate the ATF6 reporter gene, while a dominant negative form of hIRE1 blocked ER stress activation, suggesting that: hIRE1 is upstream of ATF6 in the ER stress signaling pathway.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Columbia University; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420,1212 Amsterdam Ave, New York, NY 10027 USA.		Longo, Kenneth A/A-5631-2010	SHEN, JINGSHI/0000-0001-9595-1148	NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MORI K, 1993, CELL, V74, P743; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROY B, 1995, MOL CELL BIOL, V15, P2263; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	44	418	447	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27013	27020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856300				2022-12-25	WOS:000089144800047
J	Tikhomirov, O; Carpenter, G				Tikhomirov, O; Carpenter, G			Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST; ONCOGENIC ACTIVATION; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; KINASE-ACTIVITY; POINT MUTATION; NEU ONCOGENE; HERBIMYCIN-A; CATHEPSIN-B	Exposure of carcinoma cell lines to the antibiotic geldanamycin induces the degradation of ErbB-2, a coreceptor tyrosine kinase that is frequently overexpressed in certain tumors. Using ErbB-2 mutants expressed as chimeric receptors or green fluorescent protein fusion proteins, we report that the kinase domain of ErbB-2 is essential for geldanamycin-induced degradation. The kinase domain of the related epidermal growth factor receptor was not sensitive to this drug. The data further indicate mechanistic aspects of ErbB-2 degradation by geldanamycin. The data show that exposure to the drug induces at least one cleavage within the cytoplasmic domain of ErbB-2 producing a 135-kDa fragment and a 23-kDa fragment. The latter represents the carboxyl-terminal domain of ErbB-2, whereas the former represents the ectodomain and part of the cytoplasmic domain. Degradation of the carboxyl-terminal fragment is prevented by proteasome inhibitors, whereas degradation of the membrane-anchored 135-kDa ErbB-2 fragment is blocked by inhibitors of the endocytosis-dependent degradation pathway. Confocal microscopy studies confirm a geldanamycin-induced localization of ErbB-2 on intracellular vesicles.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Chavany C, 1996, J BIOL CHEM, V271, P4974; Codony-Servat J, 1999, CANCER RES, V59, P1196; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Esparis-Ogando A, 1999, BIOCHEM J, V344, P339, DOI 10.1042/0264-6021:3440339; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hong RL, 1999, CLIN CANCER RES, V5, P1884; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Kirschbaum MH, 2000, J CELL BIOCHEM, P52; Li YQ, 1999, J BIOL CHEM, V274, P25651, DOI 10.1074/jbc.274.36.25651; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; MURAKAMI Y, 1988, CANCER RES, V48, P1587; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1993, ONCOGENE, V8, P3021; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; UEHARA Y, 1989, CANCER RES, V49, P780; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WHITESELL L, 1992, CANCER RES, V52, P1721; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	37	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26625	26631		10.1074/jbc.M003114200	http://dx.doi.org/10.1074/jbc.M003114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862618	hybrid			2022-12-25	WOS:000088999700101
J	Esfandyari, T; Macnaughton, WK; Quirion, R; St Pierre, S; Junien, JL; Sharkey, KA				Esfandyari, T; Macnaughton, WK; Quirion, R; St Pierre, S; Junien, JL; Sharkey, KA			A novel receptor for calcitonin gene-related peptide (CGRP) mediates secretion in the rat colon: implications for secretory function in colitis	FASEB JOURNAL			English	Article						TNBS; ion transport; CGRP receptors; adrenomedullin; amylin; mast cells; secretion	ALPHA-CALCITONIN; LIGAND SPECIFICITY; ION-TRANSPORT; ADRENOMEDULLIN; EXPRESSION; BRAIN; AMYLIN; IDENTIFICATION; INFLAMMATION; JUNCTIONS	The receptor responsible for CGRP-induced ion transport and permeability was examined in tissues from animals treated 7 days previously with trinitrobenzenesulfonic acid to induce colitis or in controls. CGRP caused a concentration-dependent increase in short circuit current (I-sc, EC50 21 nM), which was abolished in chloride-free buffer but was not blocked by CGRP(8-37) or tetrodotoxin (TTX). Amylin and adrenomedullin caused only a modest increase in I-sc. The responses to the linear CGRP(2) receptor agonists [Cys(Et)(2,7)] hCGRP alpha and [Cys(Acm)(2,7)] hCGRP alpha were considerably smaller than the response to CGRP. These responses were abolished in chloride-free buffer and were TTX sensitive. Atropine, doxantrazole, and indomethacin did not block the effects of CGRP or the CGRP, agonists. The response to [Cys(Et)(2,7)] hCGRP alpha was not affected by prior desensitization of the CGRP receptor and vice versa, Inflamed rats had a similar secretory response to CGRP (I-sc, EC50 15 nM) and [Cys(Et)(2,7)] hCGRP alpha as control tissues, while being hyporesponsive to carbachol, CGRP application increased electrical conductance of inflamed preparations. Taken together, these data suggest that CGRP may play an important role in the maintenance of host defense in colitis through an apparently novel CGRP receptor located on the colonic enterocyte.	Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Gastrointestinal Res Grp, Calgary, AB T2N 4N1, Canada; McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, Verdun, PQ H4H 1R3, Canada; Univ Quebec, Dept Chem, Montreal, PQ H3C 3P8, Canada; Ferring Res Inst, Paris, France	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; McGill University; University of Quebec; University of Quebec Montreal	Sharkey, KA (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Neurosci Res Grp, Room 2113,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	ksharkey@ucalgary.ca		Sharkey, Keith/0000-0001-9560-1711				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; Asfaha S, 1999, AM J PHYSIOL-GASTR L, V276, pG703, DOI 10.1152/ajpgi.1999.276.3.G703; BELL CJ, 1995, AM J PHYSIOL-GASTR L, V268, pG622, DOI 10.1152/ajpgi.1995.268.4.G622; Belloni AS, 1999, ENDOCR RES, V25, P29, DOI 10.1080/07435809909066127; Berin MC, 1999, AM J TROP MED HYG, V60, P16, DOI 10.4269/ajtmh.1999.60.16; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Bulloch K, 1998, ANN NY ACAD SCI, V840, P551, DOI 10.1111/j.1749-6632.1998.tb09594.x; CHATTERJEE TK, 1995, CAN J PHYSIOL PHARM, V73, P968, DOI 10.1139/y95-134; COOKE HJ, 1992, ANN NY ACAD SCI, V657, P313, DOI 10.1111/j.1749-6632.1992.tb22778.x; COX HM, 1989, BRIT J PHARMACOL, V97, P996, DOI 10.1111/j.1476-5381.1989.tb12553.x; COX HM, 1995, CAN J PHYSIOL PHARM, V73, P974, DOI 10.1139/y95-135; DENNIS T, 1991, BRAIN RES, V539, P59, DOI 10.1016/0006-8993(91)90686-P; DENNIS T, 1989, J PHARMACOL EXP THER, V251, P718; Dumont Y, 1997, CAN J PHYSIOL PHARM, V75, P671, DOI 10.1139/cjpp-75-6-671; ENTZEROTH M, 1995, LIFE SCI, V56, P19; EVANGELISTA S, 1992, LIFE SCI, V50, pPL13, DOI 10.1016/0024-3205(92)90441-Q; Fries W, 1999, LAB INVEST, V79, P49; GIULIANI S, 1992, BRIT J PHARMACOL, V107, P510, DOI 10.1111/j.1476-5381.1992.tb12775.x; Hall JM, 1998, TRENDS PHARMACOL SCI, V19, P303, DOI 10.1016/S0165-6147(98)01234-6; Hallgren A, 1998, AM J PHYSIOL-GASTR L, V275, pG95, DOI 10.1152/ajpgi.1998.275.1.G95; HOKFELT T, 1992, ANN NY ACAD SCI, V657, P119; HOLZER P, 1995, ADV EXP MED BIOL, V371, P891; Holzer P, 1998, DIGESTION, V59, P269, DOI 10.1159/000007504; JOLICOEUR FB, 1992, ANN NY ACAD SCI, V657, P155, DOI 10.1111/j.1749-6632.1992.tb22764.x; KACHUR JF, 1995, INFLAMMATION, V19, P245, DOI 10.1007/BF01534465; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LIBERT F, 1990, NUCLEIC ACIDS RES, V18, P1917, DOI 10.1093/nar/18.7.1917; LONGMORE J, 1994, EUR J PHARMACOL, V265, P53, DOI 10.1016/0014-2999(94)90222-4; MacNaughton WK, 1998, AM J PHYSIOL-GASTR L, V275, pG1353, DOI 10.1152/ajpgi.1998.275.6.G1353; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MAGGI CA, 1991, EUR J PHARMACOL, V192, P85, DOI 10.1016/0014-2999(91)90072-X; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; MCCULLOCH CR, 1989, REGUL PEPTIDES, V24, P87, DOI 10.1016/0167-0115(89)90214-0; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miampamba M, 1999, NEUROGASTROENT MOTIL, V11, P193; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; PHILLIPS TE, 1987, CELL TISSUE RES, V247, P547, DOI 10.1007/BF00215748; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; QUIRION R, 1992, ANN NY ACAD SCI, V657, P88, DOI 10.1111/j.1749-6632.1992.tb22759.x; ROSENFELD MG, 1992, ANN NY ACAD SCI, V657, P1, DOI 10.1111/j.1749-6632.1992.tb22754.x; Sarkar A, 1997, J NEUROCHEM, V69, P455; Sato A, 1997, BIOCHEM BIOPH RES CO, V230, P311, DOI 10.1006/bbrc.1996.5952; Saunders PR, 1997, AM J PHYSIOL-GASTR L, V273, pG486, DOI 10.1152/ajpgi.1997.273.2.G486; SEXTON PM, 1988, NEUROCHEM INT, V12, P323, DOI 10.1016/0197-0186(88)90171-4; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; STERNINI C, 1992, ANN NY ACAD SCI, V657, P170, DOI 10.1111/j.1749-6632.1992.tb22766.x; Tu Y, 1998, EUR J GASTROEN HEPAT, V10, P317, DOI 10.1097/00042737-199804000-00008; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40	56	21	21	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1439	1446		10.1096/fj.14.10.1439	http://dx.doi.org/10.1096/fj.14.10.1439			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877837				2022-12-25	WOS:000087932200019
J	Walsh, SW; Vaughan, JE; Wang, Y; Roberts, LJ				Walsh, SW; Vaughan, JE; Wang, Y; Roberts, LJ			Placental isoprostane is significantly increased in preeclampsia	FASEB JOURNAL			English	Article						placenta; malondialdehyde; oxidative stress; isoprostanes	LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; THROMBOXANE; PLASMA; VASOCONSTRICTION; PROSTACYCLIN; ENDOTHELIN; PREGNANCY; F2-ALPHA; PRODUCTS	We determined placental tissue levels, production rates, and secretion rates of isoprostanes for placentas obtained from women with normal pregnancies and women with preeclampsia, a hypertensive disorder of pregnancy. Isoprostanes are markers of oxidative stress that exert biological actions such as vasoconstriction. Placental tissue was rinsed and immediately frozen in liquid nitrogen to determine tissue levels of total and free isoprostane. Placental tissue pieces were also incubated in serum-free DMEM for 48 h at 37 degrees C in 95% air/5% CO2 to determine production rates. Isolated placental cotyledons were perfused for the determination of secretion rates. All samples were analyzed by EIA for isoprostane using an antibody specific for 8-Iso-PGF(2) (15-F-2t-IsoP). In addition, medium samples were analyzed for malondialdehyde (MDA), a breakdown product of lipid peroxidation. We found that tissue levels of free isoprostane and total isoprostane (free plus esterified forms) were significantly higher for preeclamptic placentas than for normal placentas. Concentrations of isoprostane and MDA in the medium increased progressively during 48 h of incubation of placental explants, At 48 h of incubation, the mean concentrations of both isoprostane and MDA were significantly higher for the placentas from preeclamptic women than for the placentas from normal pregnant women. Concentrations of MDA were highly correlated with those of isoprostane. Induction of oxidative stress with xanthine plus xanthine oxidase increased placental production of isoprostane by normal tissue to a level similar to that of preeclamptic tissue. Placental secretion of isoprostane was eightfold greater toward the maternal side of the placenta than toward the fetal side, and was increased sixfold on the maternal side and twofold on the fetal side by inducing oxidative stress with t-butyl hydroperoxide. This study presents new information that isoprostanes are formed and secreted by the human placenta and provides convincing evidence that oxidative stress and lipid peroxidation are abnormally increased in placentas of preeclamptic women.	Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Virginia Commonwealth University; Virginia Commonwealth University; Vanderbilt University	Walsh, SW (corresponding author), Virginia Commonwealth Univ, Dept Obstet & Gynecol, Sanger Hall,Rm 11-039,1101 E Marshall St, Richmond, VA 23298 USA.				NICHD NIH HHS [HD20973] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD020973, R01HD020973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, P01GM015431, R37GM042056, P50GM015431] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 1996, FREE RADICAL BIO MED, V20, P619, DOI 10.1016/0891-5849(95)02087-X; Barden A, 1996, CLIN SCI, V91, P711, DOI 10.1042/cs0910711; Cueto SM, 1997, J SOC GYNECOL INVEST, V4, P64, DOI 10.1016/S1071-5576(97)00010-5; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; JENDRYCZKO A, 1990, ZBL GYNAKOL, V112, P889; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; KANG KH, 1993, J APPL PHYSIOL, V74, P460, DOI 10.1152/jappl.1993.74.1.460; Leitch I, 1999, J SOC GYNECOL INVEST, V6, p195A; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Mobert J, 1997, J CARDIOVASC PHARM, V29, P789, DOI 10.1097/00005344-199706000-00012; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; NOVA A, 1991, AM J OBSTET GYNECOL, V165, P724, DOI 10.1016/0002-9378(91)90317-K; Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675; Walsh SW, 1996, HYPERTENS PREGNANCY, V15, P101, DOI 10.3109/10641959609015693; WALSH SW, 1993, AM J OBSTET GYNECOL, V169, P1007, DOI 10.1016/0002-9378(93)90044-J; WALSH SW, 1994, HYPERTENS PREGNANCY, V13, P1, DOI 10.3109/10641959409084168; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; WALSH SW, 1993, AM J OBSTET GYNECOL, V169, P1462, DOI 10.1016/0002-9378(93)90419-J; Wang YP, 1996, J SOC GYNECOL INVEST, V3, P179, DOI 10.1016/1071-5576(96)00015-9	28	193	202	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1289	1296		10.1096/fj.14.10.1289	http://dx.doi.org/10.1096/fj.14.10.1289			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877821				2022-12-25	WOS:000087932200003
J	Frost, V; Sinclair, AJ				Frost, V; Sinclair, AJ			p27(KIP1) is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis	ONCOGENE			English	Article						p27KIP1; apoptosis; caspase; z-VAD-fmk; EBV	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; GROWTH-FACTOR-BETA; CYCLE ARREST; MDM2 ONCOPROTEIN; ACTIVATION; CLEAVAGE; PROTEIN; RAPAMYCIN; DEATH	The cyclin-dependent kinase inhibitor p27(KIP1) is a crucial component of the mammalian restriction point, and as such is subject to multiple regulatory mechanisms. It has recently been shown that the abundance of p27(KIP1) is also regulated during apoptosis; p27K'P' is cleaved by a Z-VAD-fmk-sensitive caspase during apoptosis induced by growth factor deprivation in endothelial cells, and also following exposure of myeloid leukaemia cells to etoposide. Here, we investigate p27(KIP1) regulation in B- and T-lymphoid cells undergoing apoptosis, We observe that p27(KIP1) is down-regulated following exposure to a variety of apoptotic stimuli including an agonistic anti-Fas antibody, cycloheximide and etoposide. Further investigation revealed the existence of two different routes of p27K'P' regulation in lymphoid cells undergoing apoptosis. The first pathway is utilized by lymphoid cells stimulated through Fas, is abrogated in a caspase-8-deficient T-cell line, and is blocked by the caspase inhibitors z-VAD-fmk and Boc-D-fmk. In contrast, the loss of p27(KIP1) in cells exposed to cycloheximide and etoposide occurs in the absence of caspase-8 or any z-VAD-fmk- or Boc-D-fmk-sensitive caspase activities. Thus the down-regulation of p27(KIP1) is a common occurrence in lymphoid cells undergoing apoptosis but, depending on the apoptotic trigger, this can be affected by two different mechanisms.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Frost, V (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MENEZES J, 1975, BIOMEDICINE, V22, P276; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	35	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3115	3120		10.1038/sj.onc.1203657	http://dx.doi.org/10.1038/sj.onc.1203657			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871865				2022-12-25	WOS:000087903900010
J	Ito, Y; Habuchi, O				Ito, Y; Habuchi, O			Purification and characterization of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase from the squid cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HAMSTER OVARY CELLS; SEROSAL MAST-CELLS; MOUSE BONE-MARROW; SECRETORY GRANULES; HUMAN-MONOCYTES; CULTURE-MEDIUM; GLYCOSAMINOGLYCAN; 6-SULFOTRANSFERASE; BIOSYNTHESIS	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST), which transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of N-acetylgalactosamine 4-sulfate in chondroitin sulfate and dermatan sulfate, was purified 19,600-fold to apparent homogeneity from the squid cartilage. SDS-polyacrylamide gel electrophoresis of the purified enzyme showed a broad protein band with a molecular mass of 63 kDa. The protein band coeluted with GalNAc4S-6ST activity from Toyopearl HW-55 around the position of 66 kDa, indicating that the active form of GalNAc4S-6ST may be a monomer. The purified enzyme transferred sulfate from PAPS to chondroitin sulfate A, chondroitin sulfate C, and dermatan sulfate, The transfer of sulfate to chondroitin sulfate A and dermatan sulfate occurred mainly at position 6 of the internal N-acetylgalactosamine 4-sulfate residues. Chondroitin sulfate E, keratan sulfate, heparan sulfate, and completely desulfated N-resulfated heparin were not efficient accepters of the sulfotransferase. When a trisaccharide or a pentasaccharide having sulfate groups at position 4 of N-acetylgalactosamine was used as acceptor, efficient sulfation of position 6 at the nonreducing terminal N-acetylgalactosamine 4-sulfate residue was observed.	Aichi Univ Educ, Dept Life Sci, Aichi 4488542, Japan	Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Aichi 4488542, Japan.							ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OHHASHI Y, 1984, BIOCHEM J, V217, P199, DOI 10.1042/bj2170199; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YAOITA E, 1990, J BIOL CHEM, V265, P522	44	43	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34728	34736		10.1074/jbc.M909633199	http://dx.doi.org/10.1074/jbc.M909633199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10871629	hybrid			2022-12-25	WOS:000165095300097
J	Lund, PE; Shariatmadar, R; Uustare, A; Detheux, M; Parmentier, M; Kukkonen, JP; Akerman, KEO				Lund, PE; Shariatmadar, R; Uustare, A; Detheux, M; Parmentier, M; Kukkonen, JP; Akerman, KEO			The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ADRENAL CHROMAFFIN CELLS; RAT MAST-CELLS; INOSITOL PHOSPHATES; INTRACELLULAR CA2+; G-PROTEIN; HYPOCRETIN OREXIN; HUMAN-NEUTROPHILS; STORE DEPLETION; HEK293 CELLS	Ca2+ elevations in Chinese hamster ovary cells stably expressing OX, receptors were measured using fluorescent Ca2+ indicators fura-2 and fluo-3. Stimulation with orexin-A led to pronounced Ca2+ elevations with an EC50 around 1 nM. When the extracellular [Ca2+] was reduced to a submicromolar concentration, the EC50 was increased 100-fold. Similarly, the inositol 1,4,5-trisphosphate production in the presence of 1 mM external Ca2+ was about 2 orders of magnitude more sensitive to orexin-A stimulation than in low extracellular Ca2+. The shift in the potency was not caused by depletion of intracellular Ca2+ but by a requirement of extracellular Ca2+ for production of inositol 1,4,5-trisphosphate. Fura-a experiments with the "Mn2+-quench technique" indicated a direct activation of a cation influx pathway by OX, receptor independent of Ca2+ release or pool depletion. Furthermore, depolarization of the cells to +60 mV, which almost nullifies the driving force for Ca2+ entry, abolished the Ca2+ response to low concentrations of orexin-A. The results thus suggest that OX, receptor activation leads to two responses, (i) a Ca2+ influx and (ii) a direct stimulation of phospholipase C, and that these two responses converge at the level of phospholipase C where the former markedly enhances the potency of the latter.	Univ Uppsala, Dept Cell Physiol, Dept Physiol, Biomed Ctr BMC, S-75123 Uppsala, Sweden; Euroscreen SA, B-1116 Brussels, Belgium; Free Univ Brussels, Inst Interdisciplinary Res, B-1050 Brussels, Belgium	Uppsala University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Akerman, KEO (corresponding author), Univ Uppsala, Dept Cell Physiol, Dept Physiol, Biomed Ctr BMC, POB 572, S-75123 Uppsala, Sweden.			Kukkonen, Jyrki/0000-0002-6989-1564; Parmentier, Marc/0000-0001-8081-4685				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; CHEEK TR, 1994, BIOCHEM J, V304, P469, DOI 10.1042/bj3040469; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DELRIO E, 1994, J NEUROCHEM, V63, P535; FASOLATO C, 1993, PFLUG ARCH EUR J PHY, V423, P225, DOI 10.1007/BF00374399; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kukkonen JP, 1996, J PHARMACOL EXP THER, V279, P593; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MOZHAYEVA GN, 1991, J MEMBRANE BIOL, V124, P113, DOI 10.1007/BF01870456; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PARK D, 1992, J BIOL CHEM, V267, P16048; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Peyron C, 1998, J NEUROSCI, V18, P9996; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; Tsunoda Y, 1998, J RECEPT SIGNAL TR R, V18, P281, DOI 10.3109/10799899809047748; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zerbes M, 1998, CELL CALCIUM, V23, P379, DOI 10.1016/S0143-4160(98)90094-X; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	56	134	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30806	30812		10.1074/jbc.M002603200	http://dx.doi.org/10.1074/jbc.M002603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10880509	hybrid			2022-12-25	WOS:000089762700012
J	Jacobson, KA; Xie, RY; Young, L; Chang, L; Liang, BT				Jacobson, KA; Xie, RY; Young, L; Chang, L; Liang, BT			A novel pharmacological approach to treating cardiac ischemia - Binary conjugates of A(1) and A(3) adenosine receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; RAT-BRAIN; CARDIOPROTECTION; ANTAGONISTS; ACTIVATION; INHIBITION; MYOCYTES; INJURY	Adenosine released during cardiac ischemia exerts a potent, protective effect in the heart via activation of A(1) or A(3) receptors. However, the interaction between the two cardioprotective adenosine receptors and the question of which receptor is the more important anti-ischemic receptor remain largely unexplored. The objective of this study was to test the hypothesis that activation of both receptors exerted a cardioprotective effect that was significantly greater than activation of either receptor individually. This was accomplished by using a novel design in which new binary conjugates of adenosine A(1) and A(3) receptor agonists were synthesized and tested in a novel cardiac myocyte model of adenosine-elicited cardioprotection. Binary drugs having mixed selectivity for both A(1) and A(3) receptors were created through the covalent linking of functionalized congeners of adenosine agonists, each being selective for either the A(1) or A(3) receptor subtype. MRS 1740 and MRS 1741, thiourea-linked, regioisomers of a binary conjugate, were highly potent and selective in radioligand binding assays for A(1) and A(3) receptors (K-i values of 0.7-3.5 nM) versus A(2A) receptors. The myocyte models utilized cultured chick embryo cells, either ventricular cells expressing native adenosine A(1) and A(3) receptors, or engineered atrial cells, in which either human A(3) receptors alone or both human A(1) and A(3) receptors were expressed. The binary agonist MRS 1741 coactivated A(1) and A(3) receptors simultaneously, with full cardioprotection (EC50 similar to 0.1 nM) dependent on expression of both receptors, Thus, co-activation of both adenosine A(1) and A(3) receptors by the binary A(1)/A(3) agonists represents a novel general cardioprotective approach for the treatment of myocardial ischemia.	NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Pennsylvania; University of Pennsylvania	Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-19, Bethesda, MD 20892 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20, Z01 DK031115-24, Z99 DK999999] Funding Source: Medline; NHLBI NIH HHS [R01-HL48225, R01 HL048225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031116, Z01DK031115, Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auchampach JA, 1997, CIRC RES, V80, P800; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENNIS D, 1992, AM J PHYSIOL, V262, pH661, DOI 10.1152/ajpheart.1992.262.3.H661; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; JACOBSON KA, 1987, J MED CHEM, V30, P1529, DOI 10.1021/jm00391a046; JACOBSON KA, 1985, J MED CHEM, V28, P1341, DOI 10.1021/jm00147a039; Jacobson KA, 1998, TRENDS PHARMACOL SCI, V19, P184, DOI 10.1016/S0165-6147(98)01203-6; JACOBSON KA, 1986, MOL PHARMACOL, V29, P126; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; LIANG BT, 1990, CIRC RES, V67, P406, DOI 10.1161/01.RES.67.2.406; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liang BT, 1998, BIOCHEM J, V336, P337, DOI 10.1042/bj3360337; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; OLAH ME, 1994, MOL PHARMACOL, V45, P978; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; SCHWABE U, 1980, N-S ARCH PHARMACOL, V313, P179, DOI 10.1007/BF00505731; SIDDIQI SM, 1995, BIOORGAN MED CHEM, V3, P1331, DOI 10.1016/0968-0896(95)00116-X; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; STILES GL, 1988, MOL PHARMACOL, V34, P724; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4	27	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30272	30279		10.1074/jbc.M001520200	http://dx.doi.org/10.1074/jbc.M001520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887176	Green Accepted, hybrid			2022-12-25	WOS:000089577900050
J	Yi, P; Melnyk, S; Pogribna, M; Pogribny, IP; Hines, RJ; James, SJ				Yi, P; Melnyk, S; Pogribna, M; Pogribny, IP; Hines, RJ; James, SJ			Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-HOMOCYSTEINE; SMOOTH-MUSCLE CELLS; ISOLATED RAT-LIVER; METHYL-DEFICIENT; METHYLENETETRAHYDROFOLATE REDUCTASE; METHIONINE METABOLISM; POSTMENOPAUSAL WOMEN; FOLATE-DEFICIENCY; BIOGENIC-AMINES; TISSUE-LEVELS	S-Adenosylmethionine and S-adenosylhomocysteine (SAH), as the substrate and product of essential cellular methyltransferase reactions, are important metabolic indicators of cellular methylation status. Chronic elevation of SAH, secondary to the homocysteine-mediated reversal of the SAH hydrolase reaction, reduces methylation of DNA, RNA, proteins, and phospholipids. High affinity binding of SAH to the active site of cellular methyltransferases results in product inhibition of the enzyme. Using a sensitive new high pressure liquid chromatography method with coulometric electrochemical detection, plasma SAH levels in healthy young women were found to increase linearly with mild elevation in homocysteine levels (r = 0.73; p < 0.001); however, S-adenosylmethionine levels were not affected, Plasma SAH levels were positively correlated with intracellular lymphocyte SAH levels (r = 0.81; p < 0.001) and also with lymphocyte DNA hypomethylation (r = 0.74, p < 0.001). These results suggest that chronic elevation in plasma homocysteine levels, such as those associated with nutritional deficiencies or genetic polymorphisms in the folate pathway, may have an indirect and negative effect on cellular methylation reactions through a concomitant increase in intracellular SAH levels.	US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Sch Hlth Related Profess, Little Rock, AR 72202 USA	US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	James, SJ (corresponding author), US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA.	jjames@nctr.fda.gov						AARBAKKE J, 1986, CANCER RES, V46, P5469; AUSEBEL FM, 1992, CURRENT PROTOCOL MOL; BAILEY LB, 2000, J NUTR S, V130, P919; BAILEY LB, 2000, J NUTR S, V130, P779; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORCHARDT RT, 1978, BIOCHEMISTRY-US, V17, P4145, DOI 10.1021/bi00613a007; BURKE GT, 1971, BIOCHEMISTRY-US, V10, P3079; Cantoni G.L., 1985, Progress in Clinical and Biological Research, V198, P47; Capdevila A, 1997, ARCH BIOCHEM BIOPHYS, V345, P47, DOI 10.1006/abbi.1997.0249; Carmody BJ, 1999, J VASC SURG, V30, P1121, DOI 10.1016/S0741-5214(99)70053-4; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; Chawla RK, 1996, J CELL BIOCHEM, V61, P72; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; CHIANG PK, 1981, SCIENCE, V211, P1164, DOI 10.1126/science.7466386; CHIANG PK, 1980, BIOCHEM BIOPH RES CO, V94, P174, DOI 10.1016/S0006-291X(80)80203-8; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; COX R, 1977, BIOCHIM BIOPHYS ACTA, V474, P493, DOI 10.1016/0005-2787(77)90070-3; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Dalton ML, 1997, FASEB J, V11, P703, DOI 10.1096/fasebj.11.8.9240971; DECABO SF, 1995, CYTOGENET CELL GENET, V71, P187, DOI 10.1159/000134104; DEGUCHI T, 1971, J BIOL CHEM, V246, P3175; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; DUERRE JA, 1981, BIOCHIM BIOPHYS ACTA, V678, P275, DOI 10.1016/0304-4165(81)90217-8; Eskes TKAB, 1998, NUTR REV, V56, P236, DOI 10.1111/j.1753-4887.1998.tb01755.x; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1974, ARCH BIOCHEM BIOPHYS, V165, P774, DOI 10.1016/0003-9861(74)90306-3; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; GARCIACASTRO I, 1983, J BIOL CHEM, V258, P4345; GERMAN DC, 1983, J BIOL CHEM, V258, P997; GLICK JM, 1975, NUCLEIC ACIDS RES, V2, P1639, DOI 10.1093/nar/2.10.1639; Green R, 1999, SEMIN HEMATOL, V36, P47; GREENBERG ML, 1989, J BIOL CHEM, V264, P795; HOFFMAN DR, 1981, LIPIDS, V16, P561, DOI 10.1007/BF02534900; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; James SJ, 1999, AM J CLIN NUTR, V70, P495; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; Kapusta L, 1999, J PEDIATR-US, V135, P773, DOI 10.1016/S0022-3476(99)70102-2; Koch HG, 1998, EUR J PEDIATR, V157, pS102, DOI 10.1007/PL00014294; KREDICH NM, 1977, CELL, V12, P931, DOI 10.1016/0092-8674(77)90157-X; KREDICH NM, 1979, P NATL ACAD SCI USA, V76, P2450, DOI 10.1073/pnas.76.5.2450; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; LEONARD EJ, 1978, BIOCHEM BIOPH RES CO, V84, P102, DOI 10.1016/0006-291X(78)90269-3; Loehrer FMT, 1998, NEPHROL DIAL TRANSPL, V13, P656, DOI 10.1093/ndt/13.3.656; Loehrer FMT, 1996, ARTERIOSCL THROM VAS, V16, P727, DOI 10.1161/01.ATV.16.6.727; MAREE KA, 1990, INT J VITAM NUTR RES, V60, P136; Melnyk S, 2000, CLIN CHEM, V46, P265; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; MOLLOY AM, 1992, BIOCHEM PHARMACOL, V44, P1349, DOI 10.1016/0006-2952(92)90536-R; Pastore A, 1998, CLIN CHEM, V44, P825; Pietrzik K, 1998, EUR J PEDIATR, V157, pS135, DOI 10.1007/PL00014298; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; PUGH CSG, 1982, BIOCHEMISTRY-US, V21, P1535, DOI 10.1021/bi00536a011; Radomski N, 1999, MOL BIOL CELL, V10, P4283, DOI 10.1091/mbc.10.12.4283; Rampersaud G, 1999, FASEB J, V13, pA700; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; SCHATZ RA, 1981, J NEUROCHEM, V36, P1739, DOI 10.1111/j.1471-4159.1981.tb00426.x; SCOTT JM, 1994, ACTA NEUROL SCAND, V89, P27, DOI 10.1111/j.1600-0404.1994.tb05406.x; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Smith SS, 1999, MOL CARCINOGEN, V26, P1, DOI 10.1002/(SICI)1098-2744(199909)26:1<1::AID-MC1>3.0.CO;2-P; Wagner C, 1995, FOLATE HLTH DIS, P23; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x	70	497	524	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29318	29323		10.1074/jbc.M002725200	http://dx.doi.org/10.1074/jbc.M002725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884384	hybrid			2022-12-25	WOS:000089439800020
J	Hartmann, S; Hofsteenge, J				Hartmann, S; Hofsteenge, J			Properdin, the positive regulator of complement, is highly C-mannosylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ATOM-BOMBARDMENT; RNASE U-S; I REPEATS; ALTERNATIVE-PATHWAY; MOLECULAR-CLONING; ADAMTS FAMILY; 3RD COMPONENT; CELL-ADHESION; BINDING-SITE; F-SPONDIN	Properdin is the positive regulator of the alternative pathway of complement activation. The 53-kDa protein. is essentially composed of six thrombospondin type 1 repeats, all of which contain the WXXW motif, the recognition sequence for C-mannosylation. C-Mannosylation is a post-translational modification of tryptophan residues in which, in contrast to the well known N- and O-glycosylation, the carbohydrate is attached via a C-C bond to C-2 of the indole moiety of tryptophan, C-Mannosylation was first found in human RNase 2 and interleukin-12, The terminal complement proteins C6-C9 also carry this modification as part of their thrombospondin type 1 repeats. We studied the C-mannosylation pattern of human properdin by mass spectrometry and Edman degradation. Properdin contains 20 tryptophans of which 17 are part of a WXXW motif. Fourteen tryptophans were found to be modified 100%. This is the first example of a protein in which the majority of tryptophan residues occurs in the C-mannosylated form. These results show that C-mannosylated proteins occur at several steps along the complement activation cascade. Therefore, this system would be ideal to investigate the function of C-mannosylation.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hofsteenge, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BECCHI M, 1989, BIOMED ENVIRON MASS, V18, P122, DOI 10.1002/bms.1200180207; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; DAOUDAKI ME, 1988, J IMMUNOL, V140, P1577; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEBEER T, 1995, BIOCHEMISTRY-US, V34, P11785, DOI 10.1021/bi00037a016; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FARRIES TC, 1988, BIOCHEM J, V253, P667, DOI 10.1042/bj2530667; FARRIES TC, 1989, J IMMUNOL, V142, P842; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; Gobron S, 1996, J CELL SCI, V109, P1053; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Gutsche B, 1999, BIOCHEM J, V343, P11, DOI 10.1042/0264-6021:3430011; Higashijima S, 1997, DEV BIOL, V192, P211, DOI 10.1006/dbio.1997.8760; HIGGINS JMG, 1995, J IMMUNOL, V155, P5777; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; HOLT GD, 1990, J BIOL CHEM, V265, P2852; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; LAMBRIS JD, 1984, BIOCHEM J, V217, P323, DOI 10.1042/bj2170323; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI QM, 1992, BIOL MASS SPECTROM, V21, P213, DOI 10.1002/bms.1200210406; LI WX, 1993, J BIOL CHEM, V268, P16179; Linton SM, 1999, CLIN EXP IMMUNOL, V118, P189; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; Manabe S, 1999, J AM CHEM SOC, V121, P9754, DOI 10.1021/ja990926a; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; NISHIKAWA T, 1998, SYN LETT, V1, P123; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; NOLAN KF, 1991, EUR J IMMUNOL, V21, P771, DOI 10.1002/eji.1830210333; NOLAN KF, 1992, BIOCHEM J, V287, P291, DOI 10.1042/bj2870291; PANGBURN MK, 1989, J IMMUNOL, V142, P202; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Prodinger WM, 1999, FUNDAMENTAL IMMUNOLO, P967; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHWARTZ WE, 1980, ANAL BIOCHEM, V106, P43, DOI 10.1016/0003-2697(80)90116-5; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; STANKOWSKI S, 1991, BIOCHIM BIOPHYS ACTA, V1068, P61, DOI 10.1016/0005-2736(91)90060-L; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Umemiya T, 1997, DEV BIOL, V186, P165, DOI 10.1006/dbio.1997.8591; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; [No title captured]	57	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28569	28574		10.1074/jbc.M001732200	http://dx.doi.org/10.1074/jbc.M001732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878002	hybrid			2022-12-25	WOS:000089330700033
J	Kersten, S; Mandard, S; Tan, NS; Escher, P; Metzger, D; Chambon, P; Gonzalez, FJ; Desvergne, B; Wahli, W				Kersten, S; Mandard, S; Tan, NS; Escher, P; Metzger, D; Chambon, P; Gonzalez, FJ; Desvergne, B; Wahli, W			Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA PPAR-ALPHA; TIE2 RECEPTOR; GAMMA; EXPRESSION; MICE; TISSUE; ANGIOPOIETIN-1; METABOLISM; RODENTS; LIGAND	Fasting is associated with significant changes in nutrient metabolism, many of which are governed by transcription factors that regulate the expression of rate-limiting enzymes. One factor that plays an important role in the metabolic response to fasting is the peroxisome proliferator-activated receptor alpha (PPAR alpha). To gain more insight into the role of PPAR alpha during fasting, and into the regulation of metabolism during fasting in general, a search for unknown PPAR alpha target genes was performed. Using subtractive hybridization (SABRE) comparing liver mRNA from wild-type and PPAR alpha null mice, we isolated a novel PPAR alpha target gene, encoding the secreted protein FIAF (for fasting induced adipose factor), that belongs to the family of fibrinogen/angiopoietin-like proteins. FIAF is predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver. Moreover, FIAF mRNA is decreased in white adipose tissue of PPAR gamma +/- mice. FIAF protein can be detected in various tissues and in blood plasma, suggesting that FIAF has an endocrine function. Its plasma abundance is increased by fasting and decreased by chronic high fat feeding. The data suggest that FIAF represents a novel endocrine signal involved in the regulation of metabolism, especially under fasting conditions.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Univ Louis Pasteur Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Lausanne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland.	walter.wahli@iba.unil.ch	Mandard, Stéphane/J-4800-2019; Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Kersten, Sander/A-1116-2011; Tan, Nguan Soon/A-2220-2011; Desvergne, Beatrice/C-8892-2016	Mandard, Stéphane/0000-0002-7298-821X; Wahli, Walter/0000-0002-5966-9089; Kersten, Sander/0000-0003-4488-7734; Tan, Nguan Soon/0000-0003-0136-7341; Desvergne, Beatrice/0000-0001-5483-288X; Metzger, Daniel/0000-0002-5555-046X	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CORCOS D, 1987, ONCOGENE RES, V1, P193; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Peters JM, 1998, CARCINOGENESIS, V19, P1989, DOI 10.1093/carcin/19.11.1989; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X	25	434	461	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28488	28493		10.1074/jbc.M004029200	http://dx.doi.org/10.1074/jbc.M004029200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862772	hybrid			2022-12-25	WOS:000089330700021
J	Rhodes, A; Deakin, A; Spaull, J; Coomber, B; Aitken, A; Life, P; Rees, S				Rhodes, A; Deakin, A; Spaull, J; Coomber, B; Aitken, A; Life, P; Rees, S			The generation and characterization of antagonist RNA aptamers to human oncostatin M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO SELECTION; HUMAN SYNOVIAL FIBROBLASTS; LEUKEMIA-INHIBITORY FACTOR; ACUTE-PHASE PROTEINS; EXPONENTIAL ENRICHMENT; VASCULAR-PERMEABILITY; SYSTEMATIC EVOLUTION; RHEUMATOID-ARTHRITIS; NEUTROPHIL ELASTASE	Oncostatin M (OSM) is a multifunctional member of the interleukin-6 cytokine family. OSM has been implicated as a powerful proinflammatory mediator and may represent a potentially important, novel therapeutic opportunity for treatment of established rheumatoid arthritis. To further investigate the role of OSM in inflammatory disorders, we have isolated a series of RNA aptamers that bind specifically to human OSM, The highest affinity aptamer, designated ADR58, has been characterized in a series of in vitro and cell based assays. ADR58 has an affinity of 7 nm for human OSM, and it can antagonize OSM binding to the gp130 receptor and specifically antagonize OSM mediated signaling. The aptamer has been truncated in length to 33 bases, all pyrimidine positions are substituted with 2' fluorine, and 14 of 18 purine positions have been substituted with 2' O-methyl to increase stability toward nucleases, This truncated, modified form of ADR58 retains complete affinity and functional activity for OSM, This aptamer may be used as a tool to further investigate the role of OSM in inflammatory disorders and may also have role as a therapeutic agent.	Glaxo Wellcome Res & Dev Ltd, Mol Discovery Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, In Vitro Pharmacol Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Dept Comparat Pathol, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Chem & Analyt Technol Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Dept Mol Pharmacol, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Rhodes, A (corresponding author), Glaxo Wellcome Res & Dev Ltd, Mol Discovery Dept, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	adr7003@glaxowellcome.co.uk	Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				ADAMS SM, 1991, FOCUS, V13, P56; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROWN TJ, 1991, J IMMUNOL, V147, P2175; CAWSTON TE, 1995, BIOCHEM BIOPH RES CO, V215, P377, DOI 10.1006/bbrc.1995.2476; Charlton J, 1997, BIOCHEMISTRY-US, V36, P3018, DOI 10.1021/bi962669h; Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9; Davis KA, 1996, NUCLEIC ACIDS RES, V24, P702, DOI 10.1093/nar/24.4.702; Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021; Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271; FIRESTEIN G S, 1992, Current Opinion in Rheumatology, V4, P348, DOI 10.1097/00002281-199206000-00012; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FRITZBERG AR, 1986, J NUCL MED, V27, P111; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; HAMILTON JA, 1991, BIOCHEM BIOPH RES CO, V180, P652, DOI 10.1016/S0006-291X(05)81115-5; Hnatowich D J, 1996, Q J Nucl Med, V40, P202; Hnatowich DJ, 1998, J NUCL MED, V39, P56; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Hui W, 1997, ANN RHEUM DIS, V56, P184, DOI 10.1136/ard.56.3.184; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kitchen D, 1998, BIOCHEMISTRY-US, V37, P10581, DOI 10.1021/bi9727444; Kubo Atsushi, 1998, Kaku Igaku, V35, P909; Langdon C, 1997, ARTHRITIS RHEUM-US, V40, P2139, DOI 10.1002/art.1780401207; Mannironi C, 1997, BIOCHEMISTRY-US, V36, P9726, DOI 10.1021/bi9700633; McDonnell J, 1998, BRIT J PHARMACOL, V125, P717, DOI 10.1038/sj.bjp.0702139; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; Pallela VR, 1999, J NUCL MED, V40, P352; Richards CD, 1997, J IMMUNOL, V159, P2431; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAILLEFER R, 1995, EUR J NUCL MED, V22, P453, DOI 10.1007/BF00839060; Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Uphoff KW, 1996, CURR OPIN STRUC BIOL, V6, P281, DOI 10.1016/S0959-440X(96)80045-5; Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; ZYBACK CP, 1999, ARTHRITIS RHEUM, V42, pS123	46	61	71	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28555	28561		10.1074/jbc.M002981200	http://dx.doi.org/10.1074/jbc.M002981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10882721	hybrid			2022-12-25	WOS:000089330700031
J	Jefford, G; Dubreuil, RR				Jefford, G; Dubreuil, RR			Receptor clustering drives polarized assembly of ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; MEMBRANE SKELETON; STRUCTURAL REQUIREMENTS; DROSOPHILA-MELANOGASTER; ALPHA-SPECTRIN; BETA-SPECTRIN; BINDING-SITES; L1 FAMILY; NEUROFASCIN; PROTEIN	Expression of the L1 family cell adhesion molecule neuroglian in Drosophila S2 cells leads to cell aggregation and polarized ankyrin accumulation at sites of cell-cell contact. Thus neuroglian adhesion generates a spatial cue for polarized assembly of ankyrin and the spectrin cytoskeleton. Here we characterized a chimera of the extracellular and transmembrane domains of rat CD2 fused to the cytoplasmic domain of neuroglian, The chimera was used to test the hypothesis that clustering of neuroglian at sites of adhesion generates the signal that activates ankyrin binding. Abundant expression of the chimera at the plasma membrane was not a sufficient cue to drive ankyrin assembly, since ankyrin remained diffusely distributed throughout the cytoplasm of CD2-neuroglian-expressing cells. However, ankyrin became highly enriched at sites of antibody-induced capping of CD2-neuroglian. Spectrin codistributed with ankyrin at capped sites. A green fluorescent protein-tagged ankyrin was used to monitor ankyrin distribution in Living cells. Enhanced green fluorescent protein-ankyrin behaved identically to antibody-stained endogenous ankyrin, proving that the polarized accumulation of ankyrin was not an artifact of fixing and staining cells. We propose a model in which clustering of neuroglian induces a conformational change in the cytoplasmic domain that drives polarized assembly of the spectrin cytoskeleton.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Dubreuil, RR (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.				NIGMS NIH HHS [GM49301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1992, J BIOL CHEM, V267, P8703; Bennett V, 1997, SOC GEN PHY, V52, P107; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Dubreuil RR, 1997, SOC GEN PHY, V52, P91; Dubreuil RR, 1997, MOL BIOL CELL, V8, P1933, DOI 10.1091/mbc.8.10.1933; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Hortsch M, 1998, CELL ADHES COMMUN, V5, P61, DOI 10.3109/15419069809005599; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27726	27732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871626				2022-12-25	WOS:000089197100029
J	Uddin, S; Lekmine, F; Sharma, N; Majchrzak, B; Mayer, I; Young, PR; Bokoch, GM; Fish, EN; Platanias, LC				Uddin, S; Lekmine, F; Sharma, N; Majchrzak, B; Mayer, I; Young, PR; Bokoch, GM; Fish, EN; Platanias, LC			The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of stat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; MEDIATES TYROSINE PHOSPHORYLATION; CELL ANTIGEN RECEPTOR; P38 MAP KINASE; GENE-EXPRESSION; T-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; I INTERFERONS	The p38 mitogen-activated protein (MAP) kinase is activated during engagement of the type I interferon (TFN) receptor and mediates signals essential for IFN alpha-dependent transcriptional activation via interferon-stimulated response elements without affecting formation of the ISGF3 complex. In the present study, we provide evidence that the small GTPase Rad is activated in a type I IFN-dependent manner and that its function is required for downstream engagement of the p38 MAP kinase pathway. We also demonstrate that p38 is required for IFN alpha-dependent gene transcription via GAS elements and regulates activation of the promoter of the PML gene that mediates growth inhibitory responses. In studies to determine whether the regulatory effects of p38 are mediated by serine phosphorylation of Stat1 or Stat3, we found that the p38 kinase inhibitors SB203580 or SB202190 or overexpression of a dominant negative p38 mutant do not inhibit phosphorylation of Stat1 or Stat3 on Ser-727 in several IFN alpha-sensitive cell lines. Altogether these data demonstrate that the Rac1/p38 MAP kinase signaling cascade plays a critical role in type I IFN signaling, functioning in cooperation with the Stat-pathway, to regulate transcriptional regulation of IFN alpha-sensitive genes and generation of growth inhibitory responses.	Univ Illinois, MBRB, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Adm Hosp, Chicago, IL 60607 USA; Univ Toronto, Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Dupont Pharmaceut, Dept Cardiovasc Dis, Wilmington, DE 19880 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; DuPont; Scripps Research Institute; Scripps Research Institute	Platanias, LC (corresponding author), Univ Illinois, MBRB, Hematol Oncol Sect, MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA77816, CA73381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, BIOCHEM BIOPH RES CO, V267, P692, DOI 10.1006/bbrc.1999.1978; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; Gotoh A, 1996, BLOOD, V88, P138; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Micouin A, 1998, EUR CYTOKINE NETW, V9, P356; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salojin KV, 1999, J IMMUNOL, V163, P844; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; WEN Z, 1995, CELL, V28, P241; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	57	168	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27634	27640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878008				2022-12-25	WOS:000089197100016
J	Scheidegger, KJ; James, RW; Delafontaine, P				Scheidegger, KJ; James, RW; Delafontaine, P			Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; MESSENGER-RNA LEVELS; I GENE-EXPRESSION; ATHEROSCLEROTIC LESIONS; RAT AORTA; PROLIFERATION; INCREASE; ACTIVATION; STIMULATE; MIGRATION	Low density lipoproteins (LDLs) play an important role in the pathogenesis of atherosclerosis. LDL has been shown to be mitogenic and proapoptotic for vascular smooth muscle cells. However, the mechanisms are poorly understood and may result from an alteration in intracellular mitogenic signaling either directly by LDL or indirectly through an autocrine effect involving growth factor secretion and/or growth factor receptor expression. Insulin-like growth factor-1 (IGF-1) is an autocrine/paracrine factor for vascular smooth muscle cells and has potent anti-apoptotic effects. Thus, we hypothesized that part of the proliferative responses to LDLs may be explained by its modulation of IGF-1 or IGF-1 receptor (IGF-1R) expression. Treatment of rat vascular smooth muscle cells with increasing doses of native LDL dose-dependently increased IGF-1 mRNA by up to 2.6-fold; however, native LDL had no effect on IGF-1R mRNA expression. In contrast, the same doses of oxidized LDL significantly reduced IGF-1 and IGF-1R mRNA by 80 and 61%, respectively, and reduced IGF-1 and IGF-IR protein expression by 63 and 46%. In addition, native and oxidized LDL significantly increased IGF-l-binding protein-a and IGF l-binding protein-4 expression as measured by Western ligand blot. Most interestingly, anti-IGF-l antiserum completely inhibited LDL-induced but not serum-induced increase in H-3-thymidine incorporation, indicating a requirement for IGF-I in the LDL-stimulated mitogenic signaling pathway. In summary, these results suggest that native and oxidized LDLs have differential effects on IGF-1 and IGF-1R expression. Because IGF-1 is a potent survival factor for vascular smooth muscle cells, our findings suggest that moderately oxidized LDL may favor proliferation of smooth muscle cells, whereas oxidized LDL may contribute to plaque apoptosis by local depletion of IGF-I and IGF-1R.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Endocrinol & Diabet, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.			Delafontaine, Patrice/0000-0003-3744-3617	NHLBI NIH HHS [HL45317, HL47035] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047035, R29HL045317, R01HL045317] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anwar A, 2000, ARTERIOSCL THROM VAS, V20, P370, DOI 10.1161/01.ATV.20.2.370; ANWAR A, 1994, HYPERTENSION, V24, P679, DOI 10.1161/01.HYP.24.6.679; ARKINS S, 1993, ENDOCRINOLOGY, V133, P2334, DOI 10.1210/en.133.5.2334; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BOMFELDT KE, 1994, J CLIN INVEST, V93, P1266; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chambery D, 1998, J ENDOCRINOL, V159, P227, DOI 10.1677/joe.0.1590227; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; Delafontaine P, 1997, CARDIOVASC RES, V33, P216, DOI 10.1016/S0008-6363(96)00179-4; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; Dimmeler S, 1997, CIRCULATION, V95, P1760; Duan CM, 1996, J BIOL CHEM, V271, P4280; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOCHBERG Z, 1992, ENDOCRINOLOGY, V131, P430, DOI 10.1210/en.131.1.430; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Kim HH, 1999, EUR J PHARMACOL, V383, P373, DOI 10.1016/S0014-2999(99)00552-X; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MOREL DW, 1983, J LIPID RES, V24, P1070; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; Polanco JI, 1996, BIOCHEM BIOPH RES CO, V226, P917, DOI 10.1006/bbrc.1996.1450; POLANCO JI, 1995, BIOCHEM BIOPH RES CO, V209, P182, DOI 10.1006/bbrc.1995.1487; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Steinberg D, 1996, ISRAEL J MED SCI, V32, P469; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; VERVERIS J, 1994, AM J MED SCI, V307, P77, DOI 10.1097/00000441-199402000-00001; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	57	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26864	26869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862615				2022-12-25	WOS:000089144800028
J	Puddicombe, SM; Polosa, R; Richter, A; Krishna, MT; Howarth, PH; Holgate, ST; Davies, DE				Puddicombe, SM; Polosa, R; Richter, A; Krishna, MT; Howarth, PH; Holgate, ST; Davies, DE			Involvement of the epidermal growth factor receptor in epithelial repair in asthma	FASEB JOURNAL			English	Article						phosphorylation; tyrphostin; remodeling; TGF-beta; c-erbB1	BRONCHOALVEOLAR LAVAGE FLUID; SUBEPITHELIAL FIBROSIS; BRONCHIAL-ASTHMA; FACTOR-ALPHA; AIRWAY RESPONSIVENESS; BASEMENT-MEMBRANE; MUCOSAL BIOPSIES; EXPRESSION; CELLS; LUNG	Epithelial damage and airway remodeling are consistent features of bronchial asthma and are correlated with disease chronicity, severity, and bronchial hyperreactivity. To examine the mechanisms that control bronchial epithelial repair, we investigated expression of the epidermal growth factor receptor (c-erbB1, EGFR) in asthmatic bronchial mucosa and studied repair responses in vitro. In biopsies from asthmatic subjects, areas of epithelial damage were frequently observed and exhibited strong EGFR immunostaining. EGFR expression was also high in morphologically intact asthmatic epithelium. Using image analysis, EGFR immunoreactivity (% of total epithelial area, median (range) was found to increase from 9.4 (4.1-20.4) in normal subjects (n=10) to 18.4 (9.3-28.9) in mild asthmatics (P<0.01, n=13) and 25.4 (15.4-31.8) in severe asthmatics (P<0.00, n=5). Epithelial EGFR immunoreactivity remained elevated in patients treated with corticosteroids and was positively correlated with subepithelial reticular membrane thickening. Using 16HBE 14o- bronchial epithelial cells, we found that EGF accelerated repair of scrape-wounded monolayers and that the EGFR-selective inhibitor, tyrphostin AG1478, inhibited both EGF-stimulated and basal wound closure whereas dexamethasone was without effect. Intrinsic activation of the EGFR was confirmed by analysis of tyrosine phosphorylated proteins, which revealed a rapid, damage-induced phosphorylation of the EGFR, irrespective of the presence of exogenous EGF. To assess the relationship between EGFR-mediated repair and tissue remodeling, release of the profibrogenic mediator TGF-beta 2 was also measured. Scrape wounding increased release of TGF-beta 2 from epithelial monolayers and EGF had no additional stimulatory effect. However, when repair was retarded with AG1478, the amount of TGF-beta 2 increased significantly. These data indicate that the EGFR may play an important role in bronchial epithelial repair in asthma and that impairment of this function may augment airway remodeling.	Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Med Specialties Level D,Ctr Block 810,Tremona Rd, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991; Howarth, Peter/0000-0003-0619-7927				AIDA S, 1994, RESPIRATION, V61, P161; Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; ANTONIADES HN, 1993, AM J PATHOL, V142, P1099; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARROW RE, 1993, LUNG, V171, P335, DOI 10.1007/BF00165699; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Campbell AM, 1997, ALLERGY, V52, P483, DOI 10.1111/j.1398-9995.1997.tb02591.x; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Davies DE, 1999, ALLERGY, V54, P771; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ERJEFALT JS, 1995, CELL TISSUE RES, V281, P305, DOI 10.1007/BF00583399; EVANS MJ, 1993, AM J RESP CELL MOL, V8, P188, DOI 10.1165/ajrcmb/8.2.188; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Helmrath MA, 1998, J PEDIATR SURG, V33, P229, DOI 10.1016/S0022-3468(98)90437-7; HOLGATE ST, 1996, CIBA FDN S, V206, P5; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HURD S, 1992, EUR RESPIR J, V5, P115; IRWIN CR, 1991, J PERIODONTAL RES, V26, P388, DOI 10.1111/j.1600-0765.1991.tb01727.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KHERADMAND F, 1994, AM J PHYSIOL-LUNG C, V267, pL728, DOI 10.1152/ajplung.1994.267.6.L728; Kumar RK, 1996, LUNG, V174, P171, DOI 10.1007/BF00173309; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MADTES DK, 1994, AM J RESP CELL MOL, V11, P540, DOI 10.1165/ajrcmb.11.5.7524566; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Pohunek P., 1997, European Respiratory Journal Supplement, V10, p160S; Polosa R., 1998, European Respiratory Journal, V12, p317S; POLOSA R, 1990, J ALLERGY CLIN IMMUN, V86, P265, DOI 10.1016/S0091-6749(05)80075-2; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; POLOSA R, 2000, IN PRESS AM J RESP C; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; ROCHE WR, 1989, LANCET, V1, P520; RUSCH V, 1993, CANCER RES, V53, P2379; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALYINAGY I, 1992, J INVEST DERMATOL, V99, P350, DOI 10.1111/1523-1747.ep12616672; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Zhang SL, 1999, LAB INVEST, V79, P395	59	419	438	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1362	1374		10.1096/fj.14.10.1362	http://dx.doi.org/10.1096/fj.14.10.1362			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877829				2022-12-25	WOS:000087932200011
J	Martin, ME; Hidalgo, J; Rosa, JL; Crottet, P; Velasco, A				Martin, ME; Hidalgo, J; Rosa, JL; Crottet, P; Velasco, A			Effect of protein kinase A activity on the association of ADP-ribosylation factor 1 to Gel membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; CANINE KIDNEY-CELLS; PHOSPHOLIPASE-D; COATED VESICLES; ARF PROTEINS; BREFELDIN-A; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM	The small GTP-binding protein ADP-ribosylation factor 1 (ARF1) is an essential component of the molecular machinery that catalyzes the formation of membrane-bound transport intermediates. By using an in vitro assay that reproduces recruitment of cytosolic proteins onto purified, high salt-washed Golgis membranes, we have analyzed the role of cAMP-dependent protein kinase A (PRA) on ARF1 incorporation. Addition to this assay of either pure catalytic subunits of PKA (C-PKA) or cAMP increased ARF1 binding. By contrast, ARF1 association was inhibited following C-PKA inactivation with either PKA inhibitory peptide or RII alpha as well as after cytosol depletion of C-PKA. C-PKA also stimulated recruitment and activation of a recombinant form of human ARF1 in the absence of additional cytosolic components. The binding step could be dissociated from the activation reaction and found to be independent of guanine nucleotides and saturable. This step was stimulated by C-PRA in an ATP-dependent manner. Dephosphorylated Golgis membranes exhibited a decreased ability to recruit ARF1, and this effect was reverted by addition of C-PKA. Following an increase in the intracellular level of cAMP, ARF proteins redistributed from cytosol to the perinuclear Golgi region of intact cells. Collectively, the results show that PKA exerts a key regulatory role in the recruitment of ARF1 onto Golgi membranes. In contrast, PKA modulators did not affect recruitment of beta-COP onto Golgis membranes containing prebound ARF1.	Univ Seville, Fac Biol, Dept Cell Biol, E-41012 Seville, Spain; Univ Barcelona, Dept Ciencias Fisiol 2, Barcelona 08907, Spain; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Sevilla; University of Barcelona; University of Basel	Velasco, A (corresponding author), Univ Seville, Fac Biol, Dept Cell Biol, Avd Reina Mercedes S-N, E-41012 Seville, Spain.		Martín, María/HDL-9512-2022; Rosa, Jose Luis/K-6685-2014; Martín, María/ACU-3685-2022	Rosa, Jose Luis/0000-0002-6161-5688; Martín, María/0000-0002-3204-1726				BALCH WE, 1992, J BIOL CHEM, V267, P13053; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; EKER P, 1994, J BIOL CHEM, V269, P18607; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Goretzki L, 1997, J CELL SCI, V110, P1395; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Jilling T, 1996, J BIOL CHEM, V271, P4381; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Martin ME, 1999, J CELL SCI, V112, P3869; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Monier S, 1998, J CELL SCI, V111, P3427; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Simon JP, 1998, P NATL ACAD SCI USA, V95, P1073, DOI 10.1073/pnas.95.3.1073; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TAKUMA T, 1994, J BIOL CHEM, V269, P22124; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	80	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19050	19059		10.1074/jbc.275.25.19050	http://dx.doi.org/10.1074/jbc.275.25.19050			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858454	Green Published, hybrid			2022-12-25	WOS:000087815900058
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation	ONCOGENE			English	Article						myeloid; c-myc; p53; differentiation; apoptosis	LEUKEMIA INHIBITORY FACTOR; TERMINAL DIFFERENTIATION; GROWTH-INHIBITION; DEATH; EXPRESSION; BCL-2; GENE; PROTOONCOGENES; REGULATORS; ARREST	Previously we have shown that deregulated expression of c-myc in M1 myeloid leukemic cells blocked IL-6-induced differentiation and its associated growth arrest; however, the cells proliferated at a significantly reduced rate compared to untreated cells. The basis for the increased doubling time of IL-6-treated M1myc cells was found to be due to the induction of a p53-independent apoptotic pathway. The apoptotic response was not completely penetrant; in the same population of cells both proliferation and apoptosis were continuously ongoing, Down-regulation of Bcl-2 was insufficient to account for the apoptotic response, since deregulated expression of Bcl-2 delayed, but did not block, the onset of apoptosis, Furthermore, our results indicated that the IL-6-induced partial hypophosphorylation of the retinoblastoma gene product (Rb), observed in M1myc cells, was not responsible for the apoptotic response. Finally, the findings in M1 cells were extended to myeloid cells derived from the bone marrow of wild type and p53-deficient mice, where the deregulated expression of c-myc was also shown to block terminal differentiation and induce apoptosis independent of p53, These findings provide new insights into how myc participates in the neoplastic process, and how additional mutations can promote more aggressive tumors.	Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [IROI CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Eilers M, 1999, MOL CELLS, V9, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAWLEY RG, 1994, ANN NY ACAD SCI, V716, P327, DOI 10.1111/j.1749-6632.1994.tb21724.x; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	44	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2967	2977		10.1038/sj.onc.1203638	http://dx.doi.org/10.1038/sj.onc.1203638			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871848				2022-12-25	WOS:000087581400003
J	Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S				Shimoaraiso, M; Nakanishi, T; Kubo, T; Natori, S			Transcription elongation factor S-II confers yeast resistance to 6-azauracil by enhancing expression of the SSM1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ASCITES TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; FACTOR-SII; DEPENDENT TRANSCRIPTION; PURIFICATION; COMPLEX; SEQUENCE; DNA; CLEAVAGE	Loss of function of S-II makes yeast sensitive to 6-azauracil. Here, we identified a multi-copy suppressor gene of this phenotype, termed SSM1 (suppressor of 6-azauracil sensitivity of the S-II null mutant 1), that encodes a novel protein consisting of 280 amino acid residues. Although both the SSM1 null mutant and the S-II/SSM1 double null mutant were viable under normal growth conditions, they resembled the S-II null mutant in being sensitive to 6-azauracil. Expression of the SSM1 gene was found to be repressed in the S-II null mutant but was restored by overexpression of chimeric S-II molecules that were able to stimulate transcription elongation by RNA polymerase II in vitro. Furthermore, we identified two transcription arrest sites within the transcription unit of the SSM1 gene in vitro that could be relieved by S-II. These results indicate that S-II confers yeast resistance to 6-azauracil by stimulating transcription elongation of the SSM1 gene.	Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), Inst Phys & Chem Res, Natori Special Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	natori@postman.riken.go.ap		Kubo, Takeo/0000-0002-5914-5269				AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; OHYA Y, 1991, J BIOL CHEM, V266, P12356; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PIPER PW, 1990, CURR GENET, V17, P119, DOI 10.1007/BF00312855; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shimoaraiso M, 1997, J BIOL CHEM, V272, P26550, DOI 10.1074/jbc.272.42.26550; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0	46	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29623	29627		10.1074/jbc.M910371199	http://dx.doi.org/10.1074/jbc.M910371199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10858443	hybrid			2022-12-25	WOS:000089439800060
J	Sueishi, M; Takagi, M; Yoneda, Y				Sueishi, M; Takagi, M; Yoneda, Y			The forkhead-associated domain of Ki-67 antigen interacts with the novel kinesin-like protein Hklp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FHA DOMAIN; CELL-PROLIFERATION; NUCLEAR; LOCALIZATION; CHROMOSOMES	The Ki-67 antigen (pKi-67) is widely used as a cell proliferation marker protein. Its actual role in the cell cycle progression, however, is presently unclear. Using a two-hybrid screening in yeast, a novel protein, termed Hklp2 (human kinesin-like protein 2), was identified and shown to interact with the forkhead-associated (FHA) domain of pKi-67, Hklp2 has 1388 amino acids and shows a striking similarity (a 53% identity in amino acids) to Xklp2, a plus-end directed kinesin-like motor found in Xenopus, The interaction domain of Hklp2 was mapped to the portion that comprised residues 1017-1237 and that was phosphorylated in vitro by incubating with mitotic but not interphasic HeLa cell extracts. That the interaction was striking in the mitotic extract was also verified. In addition, immunofluorescence using specific antibodies revealed an association between pKi-67 and Hklp2 at the periphery of mitotic chromosomes, largely in close proximity to the centromeres, These findings suggest that pKi-67 is involved in the progression of mitosis via its interaction with Hklp2.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takagi M, 1999, J CELL SCI, V112, P2463; VERHEIJEN R, 1989, J CELL SCI, V92, P531; Yoda K, 1996, MOL CELL BIOL, V16, P5169	13	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28888	28892		10.1074/jbc.M003879200	http://dx.doi.org/10.1074/jbc.M003879200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878014	hybrid			2022-12-25	WOS:000089330700073
J	Filipe, SR; Pinho, MG; Tomasz, A				Filipe, SR; Pinho, MG; Tomasz, A			Characterization of the murMN operon involved in the synthesis of branched peptidoglycan peptides in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; METHICILLIN RESISTANCE; CROSS-BRIDGES; GENES; FEMAB; TRANSFORMATION; MUROPEPTIDES; SEPARATION; ENCODES	The murMN operon, recently identified in the genome of Streptococcus pneumoniae, encodes for enzymes involved in the synthesis of branched structured muropeptides in the pneumococcal peptidoglycan; inactivation of murMN causes production of a peptidoglycan composed exclusively of linear muropeptides and a virtually complete loss of resistance in penicillin-resistant strains (Filipe, S. R., and Tomasz, A. (2000) Proc. Natl. Acad Sci. U.S.A. 97, 4891-4896), The experiments described in this paper follow up these observations. Primer extension analysis was used to identify the putative promoter region of the murMN operon in penicillin-susceptible and -resistant strains. Selective inactivation of the murN gene in the penicillin-resistant strain Pen6 caused production of an unusual peptidoglycan that contained only single amino acid residues in the muropeptide branches, indicating that the product of murN was involved with the addition of the second amino acid and the product of murM was involved with the addition of the first amino acid (alanine or serine) to the peptidoglycan cross-bridge. Allelic replacement of the mosaic murM gene of strain Pen6 with murM of the penicillin-susceptible laboratory strain caused enrichment of the peptidoglycan in linear muropeptides, The findings suggest that the genetic determinant primarily controlling the synthesis of branched muropeptides in the pneumococcal peptidoglycan is murM.	Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Unit, P-2780 Oeiras, Portugal	Rockefeller University; Universidade Nova de Lisboa	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.		Pinho, Mariana/B-9192-2008; Filipe, Sergio Raposo/B-9167-2008	Pinho, Mariana/0000-0002-7132-8842; Filipe, Sergio Raposo/0000-0002-4485-832X; Tomasz, Alexander/0000-0003-1520-1983	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037275] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI37275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTON ND, 1989, TECHNIQUES PROTEIN C, P273; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5414; GARCIABUSTOS JF, 1988, J BACTERIOL, V170, P2143, DOI 10.1128/jb.170.5.2143-2147.1988; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; HENZE U, 1993, J BACTERIOL, V175, P1612, DOI 10.1128/JB.175.6.1612-1620.1993; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; MAIDHOF H, 1991, J BACTERIOL, V173, P3507, DOI 10.1128/jb.173.11.3507-3513.1991; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTIN C, 1992, EMBO J, V11, P3831, DOI 10.1002/j.1460-2075.1992.tb05475.x; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Sambrook J., 2002, MOL CLONING LAB MANU; Severin A, 1996, J BACTERIOL, V178, P1788, DOI 10.1128/jb.178.7.1788-1792.1996; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; Sugai M, 1997, J BACTERIOL, V179, P4311, DOI 10.1128/jb.179.13.4311-4318.1997; Thumm G, 1997, MOL MICROBIOL, V23, P1251, DOI 10.1046/j.1365-2958.1997.2911657.x; TIRABY JG, 1973, P NATL ACAD SCI USA, V70, P3541, DOI 10.1073/pnas.70.12.3541; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Weber B, 2000, FEMS MICROBIOL LETT, V188, P81, DOI 10.1016/S0378-1097(00)00214-7; ZIGHELBOIM S, 1980, ANTIMICROB AGENTS CH, V17, P434, DOI 10.1128/AAC.17.3.434	29	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27768	27774						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869361				2022-12-25	WOS:000089197100035
J	Liu, J; Tian, J; Haas, M; Shapiro, JI; Askari, A; Xie, ZJ				Liu, J; Tian, J; Haas, M; Shapiro, JI; Askari, A; Xie, ZJ			Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE GENES; ALPHA-SUBUNIT; SODIUM-IONS; HEART-CELLS; MYOCYTES; HYPERTROPHY; EXPRESSION; CALCIUM; NA+,K+-ATPASE; MITOCHONDRIA	We hare shown previously that partial inhibition of the cardiac myocyte Na+/K+-ATPase activates signal pathways that regulate myocyte growth and growth-related genes and that increases in intracellular Ca2+ concentration ([Ca2+](i)) and reactive oxygen species (ROS) are two essential second messengers within these pathways, The aim of this work was to explore the relation between [Ca2+](i) and ROS. When myocytes were in a Ca2+-free medium, ouabain caused no change in [Ca2+](i), but it increased ROS as it did when the cells were in a Ca2+-containing medium. Ouabain-induced increase in ROS also occurred under conditions where there was little or no change in [Na+](i). Exposure of myocytes in Ca2+-free medium to monensin did not increase ROS, Increase in protein tyrosine phosphorylation, an early event induced by ouabain, was also independent of changes in [Ca2+](i) and [Na+](i). Ouabain-induced generation of ROS in myocytes was antagonized by genistein, a dominant negative Ras, and myxothiazol/diphenyleneiodonium, indicating a mitochondrial origin for the Ras-dependent ROS generation. These findings, along with our previous data, indicate that increases in [Ca2+](i) and ROS in cardiac myocytes are induced by two parallel pathways initiated at the plasma membrane: One being the ouabain-altered transient interactions of a fraction of the Na+/K+-ATPase with neighboring proteins (Src, growth factor receptors, adaptor proteins, and Ras) leading to ROS generation, and the other, inhibition of the transport function of another fraction of the Na+/K+-ATPase leading to rise in [Ca2+](i). Evidently, the gene regulatory effects of ouabain in cardiac myocytes require the downstream collaborations of ROS and [Ca2+](i).	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NHLBI NIH HHS [HL-36573, HL-63238] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063238, P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1976, J PHARMACOL EXP THER, V199, P287; AKERA T, 1976, LIFE SCI, V18, P135, DOI 10.1016/0024-3205(76)90017-5; AKERA T, 1991, LIFE SCI, V48, P97, DOI 10.1016/0024-3205(91)90402-W; Alto LE, 2000, MOL CELL BIOCHEM, V207, P87, DOI 10.1023/A:1007046316277; BHOJANI IH, 1990, J MOL CELL CARDIOL, V22, P507, DOI 10.1016/0022-2828(90)90953-Y; Eble DM, 1998, AM J PHYSIOL-CELL PH, V274, pC1226, DOI 10.1152/ajpcell.1998.274.5.C1226; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Eigel BN, 1999, AM J PHYSIOL-HEART C, V277, pH1817, DOI 10.1152/ajpheart.1999.277.5.H1817; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; Haas M, 2000, J BIOL CHEM, V275, P27832; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Jansen MA, 1998, AM J PHYSIOL-HEART C, V274, pH846, DOI 10.1152/ajpheart.1998.274.3.H846; KIM D, 1984, J PHARMACOL EXP THER, V231, P326; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu JA, 2000, BIOPHYS J, V78, p79A; MURPHY E, 1985, J MOL CELL CARDIOL, V17, P221, DOI 10.1016/S0022-2828(85)80005-5; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RuizLarrea MB, 1997, FREE RADICAL RES, V26, P63, DOI 10.3109/10715769709097785; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; YAMAMOTO K, 1993, J CLIN INVEST, V92, P1889, DOI 10.1172/JCI116781	33	294	305	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27838	27844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874029				2022-12-25	WOS:000089197100044
J	Dickinson, EK; Adams, DL; Schon, EA; Glerum, DM				Dickinson, EK; Adams, DL; Schon, EA; Glerum, DM			A human SCO2 mutation helps define the role of Sco1p in the cytochrome oxidase assembly pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COPPER RECRUITMENT; C-OXIDASE; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; YEAST; GENE; PURIFICATION; DEFICIENCY; MUTANTS; COX17	Deficiencies in cytochrome oxidase, the terminal enzyme of the mitochondrial respiratory chain, are most often caused by an inability to complete assembly of the enzyme. Pathogenic mutations in SCO2, which encodes a cytochrome oxidase assembly factor, were recently described in several cases of fatal infantile cardioencephalomyopathy. To determine the molecular etiology of these disorders, we describe the generation and characterization of the parallel mutations in the homologous yeast SCO1 gene. We show that the E155K yeast sco1 mutant is respiration-competent, whereas the S240F mutant is not. Interestingly, the S240F mutation allows partial but incorrect assembly of cytochrome oxidase, as judged by an altered cytochrome aa(3) peak, Immunoblot analysis reveals a specific absence of subunit 2 from the cytochrome oxidase in this mutant. Taken together, our data suggest that Sco1p provides copper to the Cu-A site on subunit 2 at a step occurring late in the assembly pathway. This is the first instance of a yeast cytochrome oxidase assembly mutant that is partially assembled. The S240F mutant also represents a powerful new tool with which to elucidate further steps in the cytochrome oxidase assembly pathway.	Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	University of Alberta; Columbia University; Columbia University	Glerum, DM (corresponding author), Univ Alberta, Dept Med Genet, 8-33 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	moira.glerum@ualberta.ca	Glerum, Moira/AHD-3271-2022					Adams PL, 1997, ANN NEUROL, V41, P268, DOI 10.1002/ana.410410219; Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; Glerum DM, 1998, ANAL BIOCHEM, V260, P38, DOI 10.1006/abio.1998.2683; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1988, FEBS LETT, V236, P100, DOI 10.1016/0014-5793(88)80293-X; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; ROBINSON BH, 1987, J PEDIATR-US, V110, P216, DOI 10.1016/S0022-3476(87)80157-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1974, BIOGENESIS MITOCHOND, P405	34	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26780	26785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854440				2022-12-25	WOS:000089144800017
J	Hoch, U; Falck, JR; de Montellano, PRO				Hoch, U; Falck, JR; de Montellano, PRO			Molecular basis for the omega-regiospecificity of the CYP4A2 and CYP4A3 fatty acid hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAURIC ACID; CYTOCHROME-P450 4A1; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; FUSION PROTEIN; SUBSTRATE; SITE; P450BM-3; ENZYMES; (OMEGA-1)-HYDROXYLATION	The CYP4A fatty acid omega-hydroxylases are involved in important physiological processes such as the regulation of vascular pressure. A previous study of chimeras of the rat CYP4A2 and CYP4A3 enzymes established that the regiochemistry of fatty acid hydroxylation is deter mined by the first 119 amino acid residues (Hoch, U,, Zhang, Z. P,, Kroetz, D, L,, and Ortiz de Montellano, P. R. (2000) Arch. Biochem. Biophys. 373, 63-71), The role of the individual amino acid differences in this region has therefore been examined by site-specific mutagenesis to determine which residues actually control the omega- versus (omega-1)-regiospecificity. The results indicate that regio-specificity is controlled by the presence or absence of a three-residue insert (Ser-114, Gly-115, Ile-116) in CYP4A3 and by the residue at position 119 (CYP4A3 numbering). Furthermore, analysis of the absolute stereochemistry of the 11-hydroxylauric acid product indicates that this stereochemistry is not very sensitive to changes in the residues that line the substrate access channel, These results define a model of the specificity determinants of an important class of cytochrome P450 enzymes.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu		Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM031278, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515, GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTERMAN MA, 1995, BIOCHEM BIOPH RES CO, V214, P1089, DOI 10.1006/bbrc.1995.2397; ALTERMAN MA, 1995, ARCH BIOCHEM BIOPHYS, V320, P289, DOI 10.1016/0003-9861(95)90012-8; AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; Bambal RB, 1996, BIOCHEM BIOPH RES CO, V219, P445, DOI 10.1006/bbrc.1996.0253; Bambal RB, 1996, ARCH BIOCHEM BIOPHYS, V334, P59, DOI 10.1006/abbi.1996.0429; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Capdevila JH, 2000, J LIPID RES, V41, P163; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; CASTLE PJ, 1995, DRUG METAB DISPOS, V23, P1037; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; Dierks EA, 1998, J BIOL CHEM, V273, P23055, DOI 10.1074/jbc.273.36.23055; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; FUKUDA T, 1994, J BIOCHEM-TOKYO, V115, P338, DOI 10.1093/oxfordjournals.jbchem.a124339; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; Helvig C, 1998, BIOCHEMISTRY-US, V37, P12546, DOI 10.1021/bi981048g; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; IMAOKA S, 1989, BIOCHEM INT, V18, P731; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Oliver CF, 1997, BIOCHEMISTRY-US, V36, P1567, DOI 10.1021/bi962826c; OMURA T, 1964, J BIOL CHEM, V239, P2370; Orrenius S, 1972, Biochem Soc Symp, V34, P55; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Truan G, 1999, ARCH BIOCHEM BIOPHYS, V366, P192, DOI 10.1006/abbi.1999.1156; Von Wachenfeldt C, 1995, CYTOCHROME P450 STRU, P183	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26952	26958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869363				2022-12-25	WOS:000089144800039
J	Bader, MW; Xie, T; Yu, CA; Bardwell, JCA				Bader, MW; Xie, T; Yu, CA; Bardwell, JCA			Disulfide bonds are generated by quinone reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; IN-VIVO; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN; FORMATION INVIVO; PROTEIN DSBD; ISOMERASE; PATHWAY	The chemistry of disulfide exchange in biological systems is well studied. However, very little information is available concerning the actual origin of disulfide bonds. Here we show that DsbB, a protein required for disulfide bond formation in vivo, uses the oxidizing power of quinones to generate disulfides de novo, This is a novel catalytic activity, which to our knowledge has not yet been described. This catalytic activity is apparently the major source of disulfides in vivo. We developed a new assay to characterize further this previously undescribed enzymatic activity, and we show that quinones get reduced during the course of the reaction. DsbB contains a single high affinity quinone-binding site. We reconstitute oxidative folding in vitro in the presence of the following components that are necessary in vivo: DsbA, DsbB, and quinone. We show that the oxidative refolding of ribonuclease A is catalyzed by this system in a quinone-dependent manner. The disulfide isomerase DsbC is required to regain ribonuclease activity suggesting that the DsbA-DsbB system introduces at least some non-native disulfide bonds. We show that the oxidative and isomerase systems are kinetically isolated in vitro. This helps explain how the cell avoids oxidative inactivation of the disulfide isomerization pathway.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	University of Michigan System; University of Michigan; Oklahoma State University System; Oklahoma State University - Stillwater	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu			NIGMS NIH HHS [GM 30721, GM 57039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057039, R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Darby NJ, 1998, BIOCHEMISTRY-US, V37, P783, DOI 10.1021/bi971888f; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Glockshuber R, 1999, NATURE, V401, P30, DOI 10.1038/43344; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; YU CA, 1982, J BIOL CHEM, V257, P6127; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	37	127	133	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26082	26088		10.1074/jbc.M003850200	http://dx.doi.org/10.1074/jbc.M003850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854438	hybrid			2022-12-25	WOS:000088999700028
J	Li, DP; Periyasamy, S; Jones, TJ; Sanchez, ER				Li, DP; Periyasamy, S; Jones, TJ; Sanchez, ER			Heat and chemical shock potentiation of glucocorticoid receptor transactivation requires heat shock factor (HSF) activity - Modulation of HSF by vanadate and wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEDIATED GENE-EXPRESSION; NF-KAPPA-B; TUMOR VIRUS TRANSCRIPTION; MESSENGER-RNA EXPRESSION; HAMSTER OVARY CELLS; DNA-BINDING; CROSS-TALK; FUNCTIONAL ANTAGONISM; INDUCED APOPTOSIS	Heat shock and other forms of stress increase glucocorticoid receptor (GR) activity in cells, suggesting cross-talk between the heat shock and GR signal pathways. An unresolved question concerning this cross-talk is whether heat shock factor (HSF1) activity is required for this response, We addressed this issue by modulating HSF1 activity with compounds acting by distinct mechanisms: sodium vanadate (SV), an inhibitor of protein phosphatases; and wortmannin, an inhibitor of DNA-dependent protein kinase, Using HSF1- and OR-responsive CAT reporters, we demonstrate that SV inhibits both HSF1 activity and the stress potentiation of GR, while having no effect on the hormone-free GR or HSF1, Paradoxically, SV increased hormone-induced GR activity in the absence of stress. In contrast, wortmannin increased HSF1 activity in stressed cells and had no effect on HSF1 in the absence of stress. Using the pMMTV-CAT reporter containing the negative regulatory element 1 site for DNA-dependent protein kinase, wortmannin was found to increase the GR response. However, in cells expressing a minimal promoter lacking negative regulatory element 1 sites, wortmannin had no effect on the GR in the absence of stress but increased the stress potentiation of GR, Our results show that the mechanism by which CR activity is increased in stressed cells requires intrinsic HSF1 activity.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Sanchez, ER (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	esanchez@mco.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867, R29DK043867] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043867, DK43867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DREANO M, 1986, GENE, V49, P1, DOI 10.1016/0378-1119(86)90380-X; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; EDWARDS DP, 1992, BIOCHEMISTRY-US, V31, P2482, DOI 10.1021/bi00124a007; END DW, 1987, RES COMMUN CHEM PATH, V56, P75; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRAZIANI Y, 1979, BIOCHEM PHARMACOL, V28, P397, DOI 10.1016/0006-2952(79)90105-9; GSCHWENDT M, 1983, BIOCHEM BIOPH RES CO, V117, P444, DOI 10.1016/0006-291X(83)91220-2; He LS, 1999, RADIAT RES, V151, P283, DOI 10.2307/3579940; Hu JL, 1996, CELL STRESS CHAPERON, V1, P197, DOI 10.1379/1466-1268(1996)001<0197:EOGRMG>2.3.CO;2; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; Izzard RA, 1999, CANCER RES, V59, P2581; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4951, DOI 10.1021/bi00668a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; Li DP, 1999, CELL STRESS CHAPERON, V4, P223; LIU W, 1995, MOL CELL BIOL, V15, P1005; MATIC G, 1995, CELL BIOL INT, V19, P203, DOI 10.1006/cbir.1995.1063; Matic G, 1995, JUGOSLAV MED BIOHEM, V14, P89; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MIVECHI NF, 1995, CANCER RES, V55, P5512; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEN P, 1993, J STEROID BIOCHEM, V47, P55, DOI 10.1016/0960-0760(93)90057-4; SHI YH, 1995, MOL CELL BIOL, V15, P4309; Sivo J, 1996, J IMMUNOL, V156, P3450; Smets LA, 1998, LEUKEMIA, V12, P406, DOI 10.1038/sj.leu.2400941; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZOU J, 1995, MOL CELL BIOL, V15, P4319; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2	64	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26058	26065		10.1074/jbc.M004502200	http://dx.doi.org/10.1074/jbc.M004502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862623	hybrid			2022-12-25	WOS:000088999700025
J	Zhao, RB; Titus, S; Gao, F; Moran, RG; Goldman, ID				Zhao, RB; Titus, S; Gao, F; Moran, RG; Goldman, ID			Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED FOLATE CARRIER; GAMMA-GLUTAMATE SYNTHETASE; GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; ONE-CARBON METABOLISM; METHOTREXATE RESISTANCE; DIHYDROFOLATE-REDUCTASE; LYMPHOBLASTIC-LEUKEMIA; ANTIFOLATE RESISTANCE; THYMIDYLATE SYNTHASE; MEMBRANE-TRANSPORT	Four L1210 murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate (DDATHF) and other folate analogs, but sensitive to continuous exposure to methotrexate, were developed by chemical mutagenesis followed by DDATHF selective pressure. Endogenous folate pools were modestly reduced but polyglutamate derivatives of DDATHF and ALIMTA (LY231514, MTA) were markedly decreased in these mutant cell lines. Membrane transport was not a factor in drug resistance; rather, folypolyglutamate synthetase (FPGS) activity was decreased by >98%. In each cell line, FPGS mRNA expression was unchanged but both alleles of the FPGS gene bore a point mutation in highly conserved domains of the coding region. Four mutations were in the predicted ATP-, folate-, and/or glutamate-binding sites of FPGS, and two others were clustered in a peptide predicted to be beta sheet 5, based on the crystal structure of the Lactobacillus casei enzyme. Transfection of cDNAs for three mutant enzymes into FPGS-null Chinese hamster ovary cells restored a reduced level of clonal growth, whereas a T339I mutant supported growth at a level comparable to that of the wild-type enzyme. The two mutations predicted to be in beta sheet 5, and one in the loop between NH2- and COOH-terminal domains did not support cell growth. When sets of mutated cDNAs were co-transfected into FPGS-null cells to mimic the genotype of drug-selected resistant cells, clonal growth was restored. These results demonstrate for the first time that single amino acid substitutions in several critical regions of FPGS can cause marked resistance to tetrahydrofolate antimetabolites, while still allowing cell survival.	Albert Einstein Coll Med, Ctr Comprehens Canc, Bronx, NY 10461 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Yeshiva University; Albert Einstein College of Medicine; Virginia Commonwealth University; Virginia Commonwealth University	Goldman, ID (corresponding author), Albert Einstein Coll Med, Ctr Comprehens Canc, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu			NCI NIH HHS [CA-82621, CA-39687, CA-39807] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807, R01CA039687, R01CA082621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONSSON B, 1990, ANAL BIOCHEM, V186, P8, DOI 10.1016/0003-2697(90)90563-O; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Atkinson IJ, 1998, PHYTOCHEMISTRY, V49, P2221, DOI 10.1016/S0031-9422(98)00317-3; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; Boyer J, 1996, YEAST, V12, P1575, DOI 10.1002/(SICI)1097-0061(199612)12:15<1575::AID-YEA45>3.0.CO;2-E; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; FRY DW, 1982, J BIOL CHEM, V257, P1890; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; JACKMAN AL, 1993, INHIBITION THYMIDYLA, P274; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; LACKS SA, 1995, J BACTERIOL, V177, P66, DOI 10.1128/jb.177.1.66-74.1995; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; LIN BF, 1993, J BIOL CHEM, V268, P21674; MARGOLIS PS, 1993, J BACTERIOL, V175, P528, DOI 10.1128/JB.175.2.528-540.1993; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1995, BLOOD, V85, P500; MCBURNEY MW, 1974, CELL, V2, P183, DOI 10.1016/0092-8674(74)90092-0; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1983, DEV TARGET ORIENTED, P97; Mendelsohn LG, 1996, INVEST NEW DRUG, V14, P287, DOI 10.1007/BF00194532; MORAN RG, 1989, J BIOL CHEM, V264, P21047; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1988, CANCER RES, V48, P2149; RHEE MS, 1993, CANCER RES, V53, P2227; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sanghani PC, 2000, PROTEIN EXPRES PURIF, V18, P36, DOI 10.1006/prep.1999.1173; Sanghani SP, 1999, J BIOL CHEM, V274, P27018, DOI 10.1074/jbc.274.38.27018; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHANE B, 1989, VITAM HORM, V45, P263; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Sierra EE, 1998, BIOCHEM PHARMACOL, V55, P1505, DOI 10.1016/S0006-2952(97)00673-4; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; Spinella MJ, 1996, BIOCHEM PHARMACOL, V52, P703, DOI 10.1016/0006-2952(96)00347-4; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; TAYLOR EC, 1992, J MED CHEM, V35, P4450, DOI 10.1021/jm00101a023; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TOY J, 1994, ARCH BIOCHEM BIOPHYS, V314, P344, DOI 10.1006/abbi.1994.1452; TOY J, 1990, J BIOL CHEM, V265, P2492; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yoshioka S, 1997, DNA Res, V4, P363, DOI 10.1093/dnares/4.6.363; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	65	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26599	26606		10.1074/jbc.M002580200	http://dx.doi.org/10.1074/jbc.M002580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856298	hybrid			2022-12-25	WOS:000088999700098
J	Bazzoni, G; Martinez-Estrada, OM; Orsenigo, F; Cordenonsi, M; Citi, S; Dejana, E				Bazzoni, G; Martinez-Estrada, OM; Orsenigo, F; Cordenonsi, M; Citi, S; Dejana, E			Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PERIPHERAL COMPONENT; MEMBRANE-PROTEINS; ATP DEPLETION; DOMAIN; CADHERIN; IDENTIFICATION; INVOLVEMENT; UVOMORULIN; DISTINCT	Junctional adhesion molecule (JAM) is an integral membrane protein that has been reported to colocalize with the tight junction molecules occludin, ZO-1, and cingulin. However, evidence for the association of JAM with these molecules is missing. Transfection of Chinese hamster ovary cells with JAM (either alone or in combination with occludin) resulted in enhanced junctional localization of both endogenous ZO-1 and cotransfected occludin. Additionally, JAM was coprecipitated with ZO-1 in the detergent-insoluble fraction of Caco-2 epithelial cells. A putative PDZ-binding motif at the cytoplasmic carboxyl terminus of JAM was required for mediating the interaction of JAM with ZO-1, as assessed by in vitro binding and coprecipitation experiments. JAM was also coprecipitated with cingulin, another cytoplasmic component of tight junctions, and this association required the amino-terminal globular head of cingulin. Taken together, these data indicate that JAM is a component of the multiprotein complex of tight junctions, which may facilitate junction assembly.	Mario Negri Inst Pharmacol Res, Lab Vasc Biol, I-20157 Milan, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Studi Insubria, Fac Med & Chirurg, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Padua; University of Insubria	Bazzoni, G (corresponding author), Mario Negri Inst Pharmacol Res, Lab Vasc Biol, Via Eritrea 62, I-20157 Milan, Italy.	bazzoni@irfmn.mnegri.it	Citi, Sandra/E-4514-2014; Martinez-Estrada, Ofelia M/V-4733-2017; Cordenonsi, Michelangelo/K-7692-2016	Martinez-Estrada, Ofelia M/0000-0002-1814-1974; Cordenonsi, Michelangelo/0000-0002-8253-5724; Orsenigo, Fabrizio/0000-0001-9135-8478; DEJANA, ELISABETTA/0000-0002-0007-0426; Citi, Sandra/0000-0002-6537-4818				Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Balda MS, 1998, J CELL SCI, V111, P541; Bazzoni G, 1999, TRENDS CARDIOVAS MED, V9, P147, DOI 10.1016/S1050-1738(99)00022-5; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CITI S, 1989, J CELL SCI, V93, P107; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CITI S, 1999, ADV MOL CEL, V28, P203; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DOYLE JP, 1995, J CELL BIOL, V131, P465, DOI 10.1083/jcb.131.2.465; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Grignani F, 1998, CANCER RES, V58, P14; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Introna M, 1998, BRIT J HAEMATOL, V103, P449, DOI 10.1046/j.1365-2141.1998.01020.x; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 1998, J CELL SCI, V111, P511; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Ohsugi M, 1997, DEV BIOL, V185, P261, DOI 10.1006/dbio.1997.8560; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SEDAR AW, 1964, J CELL BIOL, V22, P173, DOI 10.1083/jcb.22.1.173; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEVENSON BR, 1989, AM J PHYSIOL, V257, pC621, DOI 10.1152/ajpcell.1989.257.4.C621; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1984, J CELL BIOL, V98, P1209, DOI 10.1083/jcb.98.4.1209; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; VanItallie CM, 1997, J CELL SCI, V110, P1113; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	54	341	351	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20520	20526		10.1074/jbc.M905251199	http://dx.doi.org/10.1074/jbc.M905251199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877843	hybrid, Green Published			2022-12-25	WOS:000088084500043
J	Saupe, KW; Spindler, M; Hopkins, JCA; Shen, WQ; Ingwall, JS				Saupe, KW; Spindler, M; Hopkins, JCA; Shen, WQ; Ingwall, JS			Kinetic, thermodynamic, and developmental consequences of deleting creatine kinase isoenzymes from the heart - Reaction kinetics of the creatine kinase isoenzymes in the intact heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLES; MITOCHONDRIAL; ENERGY; MICE; RESPIRATION; DEFICIENT; SHUTTLE	Creatine kinase (CK) exists as a family of isoenzymes in excitable tissue. We studied isolated perfused hearts from mice lacking genes for either the main muscle isoform of CK (M-CK) or both M-CK and the main mitochondrial isoform (Mt-CK) to determine 1) the biological significance of CK isoenzyme shifts, 2) the necessity of maintaining a high CK reaction rate, and 3) the role of CK isoenzymes in establishing the thermodynamics of ATP hydrolysis, P-31 NMR was used to measure [ATP], [PCr], [P-i], [ADP], pH, as well as the unidirectional reaction rate of PCr --> [gamma-P]ATP. Developmental changes in the main fetal isoform of CK (BB-CK) were unaffected by loss of other CK isoenzymes, In hearts lacking both M- and Mt-CK, the rate of ATP synthesis from PCr was only 9% of the rate of ATP synthesis from oxidative phosphorylation demonstrating a lack of any high energy phosphate shuttle. We also found that the intrinsic activities of the BB-CK and the MM-CK isoenzymes were equivalent. Finally, combined loss of M- and Mt-CK (but not loss of only M-CK) prevented the amount of free energy released from ATP hydrolysis from increasing when pyruvate was provided as a substrate for oxidative phosphorylation.	Boston Univ, Sch Med, Cardiac Muscle Res Lab, Boston, MA 02118 USA; Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, NMR Lab Physiol Chem, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Boston University; University of Wurzburg; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Eli Lilly	Ingwall, JS (corresponding author), NMR Lab, 221 Longwood Ave,BLI 247, Boston, MA 02115 USA.	jingwall@rics.bwh.harvard.edu						Aliev MK, 1997, BIOPHYS J, V73, P428, DOI 10.1016/S0006-3495(97)78082-2; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P3123, DOI 10.1006/jmcc.1997.0539; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; FRIEDRICH J, 1993, MAGNET RESON MED, V30, P45, DOI 10.1002/mrm.1910300108; GIBBS C, 1985, J MOL CELL CARDIOL, V17, P727, DOI 10.1016/S0022-2828(85)80034-1; INGWALL JS, 1980, HEART CREATINE KINAS, P9; KAMMERME.H, 1973, ANAL BIOCHEM, V56, P341, DOI 10.1016/0003-2697(73)90199-1; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; POLIMENI PI, 1988, J MOL CELL CARDIOL, V20, P15, DOI 10.1016/S0022-2828(88)80175-5; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Qin WN, 1998, MOL CELL BIOCHEM, V184, P153, DOI 10.1023/A:1006807515892; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; Saupe KW, 1998, CIRC RES, V82, P898; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Tian R, 1996, AM J PHYSIOL-HEART C, V270, pH1207, DOI 10.1152/ajpheart.1996.270.4.H1207; Van Dorsten FA, 1998, AM J PHYSIOL-HEART C, V275, pH1191, DOI 10.1152/ajpheart.1998.275.4.H1191; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; vanDorsten FA, 1996, BBA-BIOENERGETICS, V1274, P59, DOI 10.1016/0005-2728(96)00010-2; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; Wallimann T, 1985, Cell Muscle Motil, V6, P239	24	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19742	19746		10.1074/jbc.M001932200	http://dx.doi.org/10.1074/jbc.M001932200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867023	hybrid			2022-12-25	WOS:000087941300043
J	Lin, FB; Wang, HY; Malbon, CC				Lin, FB; Wang, HY; Malbon, CC			Gravin-mediated formation of signaling complexes in beta(2)-adrenergic receptor desensitization and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE-C; AGONIST-INDUCED DESENSITIZATION; COUPLED RECEPTORS; ADENYLATE-CYCLASE; PHORBOL ESTER; ARRESTIN/CLATHRIN INTERACTION; BETA-2-ADRENERGIC RECEPTOR; LINKED RECEPTORS; PHOSPHORYLATION	Agonist-induced desensitization and resensitization of G-protein-linked receptors involve the interaction of receptors with protein kinases, phosphatases, beta-arrestin, and clathrin organized by at least one scaffold protein. The dynamic composition of the signaling complexes and the role of the scaffold protein AKAP250 (gravin) in agonist-induced attenuation and recovery of beta-adrenergic receptors were explored by co-immunoprecipitation of target elements, antisense suppression, and confocal microscopy. Gravin associated with unstimulated receptor, and the association was increased significantly after agonist stimulation for up to 60 min. Agonist stimulation also induced a robust association of the receptor-gravin complex with protein kinases A and C, G-protein-linked receptor kinase-2, beta-arrestin, and clathrin, Confocal microscopy of the green fluorescence protein-tagged beta(2)-adrenergic receptor showed that the receptor underwent sequestration after agonist stimulation. Suppression of gravin expression via antisense oligodeoxynucleotides disrupted agonist-induced association of the receptor with G-protein-linked receptor kinase-2, beta-arrestin, and clathrin as well as receptor recovery from desensitization. Gravin deficiency also inhibited agonist-induced sequestration. These data reveal that gravin-mediated formation of signaling complexes with protein kinases/phosphatases, beta-arrestin, and clathrin is essential in agonist-induced internalization and resensitization of G-protein-linked receptors.	SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COWLEN MS, 1987, J PHARMACOL EXP THER, V243, P527; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; HANSON AS, 1995, AM J PHYSIOL-RENAL, V268, pF553, DOI 10.1152/ajprenal.1995.268.4.F553; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HO AK, 1988, J BIOL CHEM, V263, P9292; HO AK, 1988, BIOCHEM PHARMACOL, V37, P1015, DOI 10.1016/0006-2952(88)90503-5; Hosey MM, 1996, PROG BRAIN RES, V109, P169; HOUSLAY MD, 1992, CLIN ENDOCRINOL, V36, P525, DOI 10.1111/j.1365-2265.1992.tb02260.x; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KASHLES O, 1987, BIOCHEM PHARMACOL, V36, P1531, DOI 10.1016/0006-2952(87)90122-5; KILFEATHER SA, 1991, LIFE SCI, V49, P713, DOI 10.1016/0024-3205(91)90103-I; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Neill JD, 1998, ENDOCRINOLOGY, V139, P1781, DOI 10.1210/en.139.4.1781; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; REUPCKE C, 1993, CARDIOVASC RES, V27, P2179, DOI 10.1093/cvr/27.12.2179; Scott JD, 1997, SOC GEN PHY, V52, P227; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1; SIBLEY DR, 1984, J BIOL CHEM, V259, P9742; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	51	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19025	19034		10.1074/jbc.275.25.19025	http://dx.doi.org/10.1074/jbc.275.25.19025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858453	hybrid			2022-12-25	WOS:000087815900055
J	Pinzar, E; Miyano, M; Kanaoka, Y; Urade, Y; Hayaishi, O				Pinzar, E; Miyano, M; Kanaoka, Y; Urade, Y; Hayaishi, O			Structural basis of hematopoietic prostaglandin D synthase activity elucidated by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; D SYNTHETASE; 3-DIMENSIONAL STRUCTURE; CATALYTIC PROPERTIES; D-ISOMERASE; RESIDUE; CELLS; D-2; PURIFICATION; ACTIVATION	Hematopoietic prostaglandin (PG) D synthase (PGDS) is the first identified vertebrate ortholog in the Sigma class of the glutathione S-transferase (GST) family and catalyzes both isomerization of PGH, to PGD, and conjugation of glutathione to 1-chloro-2,4-dinitrobenzene. We introduced site directed mutations of Tyr(8), Arg(14), Trp(104), Lys(112), Tyr(152), Cys(156), Lys(198), and Leu(199), which are presumed to participate in catalysis or PGH(2) substrate binding based on the crystallographic structure. Mutants were analyzed in terms of structure, GST and PGDS activities, and activation of the glutathione thiol group. Of all the mutants, only Y8F, W104I, K112E, and L199F showed minor but substantial differences in their far-UV circular dichrcoism spectra from the wild-type enzyme, Y8F, R14K/E, and W104I were completely inactive. C156L/Y selectively lost only PGDS activity. K112E reduced GST activity slightly and PGDS activity markedly, whereas K198E caused a selective decrease in PODS activity and K-m for glutathione and PGH(2) in the PODS reaction. No significant changes were observed in the catalytic activities of Y152F and L199F, although their K-m for glutathione was increased. Using 5,5'-dithiobis(2-nitrobenzoic acid) as an SE-selective agent, we found that only Y8F and R14E/K did not accelerate the reactivity of the glutathione thiol group under the low reactivity condition of pH 5.0. These results indicate that Lys(112), Cys(156) and Lys(198) are involved in the binding of PGH,; Trp(104) is critical for structural integrity of the catalytic center for GST and PODS activities; and Tyr(8) and Arg(14), essential for activation of the thiol group of glutathione.	Osaka Biosci Inst, Japan Sci Technol Corp, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan; Osaka Biosci Inst, Japan Sci Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650874, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Takatsuki, Osaka 5691125, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Tobacco Inc.	Hayaishi, O (corresponding author), Osaka Biosci Inst, Japan Sci Technol Corp, Dept Mol Behav Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.		Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175				ALVING K, 1991, ACTA PHYSIOL SCAND, V143, P93, DOI 10.1111/j.1748-1716.1991.tb09204.x; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; DARIUS H, 1994, EUR J PHARMACOL, V258, P207, DOI 10.1016/0014-2999(94)90482-0; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dumitrascu D, 1996, Rom J Intern Med, V34, P159; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JACOBY WB, 1990, J BIOL CHEM, V265, P20715; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KANAOKA Y, 1999, CELL, V96; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LIU SX, 1992, J BIOL CHEM, V267, P4296; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; Minami T, 1996, J PHARMACOL EXP THER, V278, P1146; Prade L, 1997, STRUCTURE, V5, P1287, DOI 10.1016/S0969-2126(97)00281-5; Pregel MJ, 1997, J BIOL CHEM, V272, P23552, DOI 10.1074/jbc.272.38.23552; Ram A, 1997, BRAIN RES, V751, P81, DOI 10.1016/S0006-8993(96)01401-1; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SASAKI H, 1994, ANTI-CANCER DRUG, V5, P131, DOI 10.1097/00001813-199404000-00002; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TERAO A, 1995, J NEUROCHEM, V65, P2742; Thomson AM, 1998, BIOCHEM J, V333, P317, DOI 10.1042/bj3330317; UENO R, 1982, P NATL ACAD SCI-BIOL, V79, P6093, DOI 10.1073/pnas.79.19.6093; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1990, J BIOL CHEM, V265, P371; URADE Y, 1999, BIOCHIM BIOPHYS ACTA, V1436, P605; WANG RW, 1993, J BIOL CHEM, V268, P23981; WANG SW, 1992, PROG NAT SCI, V2, P267	40	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31239	31244		10.1074/jbc.M000750200	http://dx.doi.org/10.1074/jbc.M000750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10871602	hybrid			2022-12-25	WOS:000089762700070
J	Lee, H; Mok, KH; Muhandiram, R; Park, KH; Suk, JE; Kim, DH; Chang, J; Sung, YC; Choi, KY; Han, KH				Lee, H; Mok, KH; Muhandiram, R; Park, KH; Suk, JE; Kim, DH; Chang, J; Sung, YC; Choi, KY; Han, KH			Local structural elements in the mostly unstructured transcriptional activation domain of human p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; HYDROPHOBIC AMINO-ACIDS; TRANSACTIVATION DOMAIN; ALPHA-HELIX; PROTEIN; BINDING; SENSITIVITY; VP16; RESONANCE; SEQUENCE	DNA transcription is initiated by a small regulatory region of transactivators known as the transactivation domain. In contrast to the rapid progress made on the functional aspect of this promiscuous domain, its structural feature is still poorly characterized. Here, our multidimensional NMR study reveals that an unbound full-length p53 transactivation domain, although similar to the recently discovered group of loosely folded proteins in that it does not have tertiary structure, is nevertheless populated by an amphipathic helix and two nascent turns. The helix is formed by residues Thr(18)-Leu(26) (Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu), whereas the two turns are formed by residues Me(t4)0-Met(44) and Asp(48)- Trp(53), respectively. It is remarkable that these local secondary structures are selectively formed by functionally critical and positionally conserved hydrophobic residues present in several acidic transactivation domains. This observation suggests that such local structures are general features of acidic transactivation domains and may represent "specificity determinants" (Ptashne, M., and Gann, A. A. F. (1997), Nature 386, 569-577) that are important for transcriptional activity.	Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Taejon 305600, South Korea; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Prot Engn Network Ctr Excellence, Toronto, ON M5S 1A8, Canada; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Ctr Biofunct Mol, Pohang 790784, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Toronto; University of Toronto; University of Toronto; University of Toronto; Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, POB 115, Taejon 305600, South Korea.		Mok, K. Hun/C-2607-2009	CHANG, JUN/0000-0002-8423-5987; Kim, Do-Hyung/0000-0002-2924-4370; Mok, K Hun/0000-0003-3663-2002; Lee, Hyun/0000-0003-2570-8120				Blommers MJJ, 1997, J AM CHEM SOC, V119, P3425, DOI 10.1021/ja9633171; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Cho HS, 1996, PROTEIN SCI, V5, P262; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAN KH, 1986, J MOL BIOL, V189, P541, DOI 10.1016/0022-2836(86)90323-2; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Nagadoi A, 1999, J MOL BIOL, V287, P593, DOI 10.1006/jmbi.1999.2620; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RAHDAKRISNAN I, 1997, CELL, V91, P741; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	60	273	278	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29426	29432		10.1074/jbc.M003107200	http://dx.doi.org/10.1074/jbc.M003107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884388	hybrid			2022-12-25	WOS:000089439800035
J	Anneren, C; Reedquist, KA; Bos, JL; Welsh, M				Anneren, C; Reedquist, KA; Bos, JL; Welsh, M			GTK, a Src-related tyrosine kinase, induces nerve growth factor-independent neurite outgrowth in PC12 cells through activation of the Rap1 pathway - Relationship to Shb tyrosine phosphorylation and elevated levels of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN SHB; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; EXCHANGE FACTOR; RAS EFFECTOR; ONCOGENE; BINDING; GENE	The rat pheochromocytoma cell line PC12 is extensively used as a model for studies of neuronal cell differentiation. These cells develop a sympathetic neuronlike phenotype when cultured in the presence of nerve growth factor. The present study was performed in or der to assess the role of mouse GTK (previously named BSK/IYK), a cytoplasmic tyrosine kinase belonging to the Src family, for neurite outgrowth in PC12 cells. We report that PC12 cells stably overexpressing GTK exhibit a larger fraction of cells with neurites as compared with control cells, and this response is not accompanied by an increased ERK activity. Treatment of the cells with the MEK inhibitor PD98059 did not reduce the GTK-dependent increased in neurite outgrowth. GTK expression induces a nerve growth factor-independent Rap1 activation, probably through altered CrkII signaling. We observe increased CrkII complex formation with p130(Cas), focal adhesion kinase (FAK), and Shb in PC12-GTK cells. The expression of GTK also correlates with a markedly increased content of FAK, phosphorylation of the adaptor protein Shb, and an association between these two proteins. Transient transfection of GTK-over-expressing cells with RalGDS-RBD or Rap1GAP, inhibitors of the Rap1 pathway, reduces the GTK-dependent neurite outgrowth. These data suggest that GTK participates in a signaling pathway, perhaps involving Shb, FAK and Rap1, that induces neurite outgrowth in PC12 cells.	Uppsala Univ, Biomedicum, Dept Med Cell Biol, S-75123 Uppsala, Sweden; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Uppsala University; Utrecht University; Utrecht University	Welsh, M (corresponding author), Uppsala Univ, Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.	Michael.Welsh@medcellbiol.uu.se	Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Anneren, Cecilia/0000-0003-3600-6650				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Anneren C, 2000, GROWTH FACTORS, V17, P233, DOI 10.3109/08977190009028969; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Giasson BI, 1999, J NEUROCHEM, V72, P1081, DOI 10.1046/j.1471-4159.1999.0721081.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1998, CELL GROWTH DIFFER, V9, P757; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Oberg-Welsh C, 1998, GROWTH FACTORS, V16, P111; OBERGWELSH C, 1995, GENE, V152, P239, DOI 10.1016/0378-1119(94)00718-8; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PIZON V, 1988, ONCOGENE, V3, P201; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; THUVESON M, 1995, BIOCHEM BIOPH RES CO, V209, P582, DOI 10.1006/bbrc.1995.1540; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	51	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29153	29161		10.1074/jbc.M003926200	http://dx.doi.org/10.1074/jbc.M003926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878015	hybrid			2022-12-25	WOS:000089330700105
J	Paik, JH; Ju, JH; Lee, JY; Boudreau, MD; Hwang, DH				Paik, JH; Ju, JH; Lee, JY; Boudreau, MD; Hwang, DH			Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase - Mediation through different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NECROSIS-FACTOR-ALPHA; COLON-CANCER CELLS; SODIUM-SALICYLATE; MESSENGER-RNA; COMPLEMENTARY-DNA; EPITHELIAL-CELLS	The efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) is considered to be a result of their inhibitory effect on cyclooxygenase (COX) activity. Here, we report that flufenamic acid shows two opposing effects on COX-2 expression; it induces COX-2 expression in the colon cancer cell line (HT-29) and macrophage cell line (RAW 264.7); conversely, it inhibits tumor necrosis factor alpha (TNF alpha)- or lipopolysaccharide (LPS)-induced COX-2 expression. This inhibition correlates with the suppression of TNF alpha- or LPS-induced NF kappa B activation by flufenamic acid. The inhibitor of extracellular signal-regulated protein kinase, p38, or NF kappa B does not affect the NSAID-induced COX-2 expression. These results suggest that the NSAID-induced COX-2 expression is not mediated through activation of NF kappa B and mitogen-activated protein kinases, An activator of peroxisome proliferator activated receptor gamma, 15-deoxy-Delta(12,14)-prostaglandin J(2), also induces COX-2 expression and inhibits TNF alpha-induced NF kappa B activation and COX-2 expression, Flufenamic acid and 15-deoxy-Delta(12,14)-prostaglandin J(2) also inhibit LPS-induced expression of inducible form of nitric-oxide synthase and interleukin-1 alpha in RAW 264.7 cells. Together, these results indicate that the NSAIDs inhibit mitogen-induced COX-2 expression while they induce COX-2 expression. Furthermore, the results suggest that the anti-inflammatory effects of flufenamic acid and some other NSAIDs are due to their inhibitory action on the mitogen-induced expression of COX-2 and downstream markers of inflammation in addition to their inhibitory effect on COX enzyme activity.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Hwang, DH (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Boudreau, Mary/E-4721-2015		NCI NIH HHS [CA-75613] Funding Source: Medline; NIDDK NIH HHS [DK-41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Ferreira V, 1999, J IMMUNOL, V162, P6442; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCEVOY GK, 1997, AHFS 97 DRUG INFORMA; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	43	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28173	28179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10866999				2022-12-25	WOS:000089197100085
J	Cicmil, M; Thomas, JM; Sage, T; Barry, FA; Leduc, M; Bon, C; Gibbins, JM				Cicmil, M; Thomas, JM; Sage, T; Barry, FA; Leduc, M; Bon, C; Gibbins, JM			Collagen, convulxin, and thrombin stimulate aggregation-independent tyrosine phosphorylation of CD31 in platelets - Evidence for the involvement of Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; RECEPTOR-GAMMA-CHAIN; MEDIATED SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GLYCOPROTEIN-VI; PECAM-1 CD31; ENDOTHELIAL-CELLS; T-CELLS; ACTIVATION; PROTEIN	Platelet endothelial cell adhesion molecule-1 (CD31) is a 130-kDa glycoprotein receptor present on the surface of platelets, neutrophils, monocytes, certain T-lymphocytes, and vascular endothelial cells, CD31 is involved in adhesion and signal transduction and is implicated in the regulation of a number of cellular processes. These include transendothelial migration of leukocytes, integrin regulation, and T-cell function, although its function in platelets remains unclear, In this study, we demonstrate the ability of the platelet agonists collagen, convulxin, and thrombin to induce tyrosine phosphorylation of CD31, Furthermore, we show that this event is independent of platelet aggregation and secretion and is accompanied by an increase in surface expression of CD31, A kinase capable of phosphorylating CD31 was detected in CD31 immunoprecipitates, and its activity was increased following activation of platelets. CD31 tyrosine phosphorylation was reduced or abolished by the Src family kinase inhibitor PP2, suggesting a role for these enzymes. In accordance with this, each of the Src family members expressed in platelets, namely Fyn, Lyn, Src, Yes, and Hck, was shown to co-immunoprecipitate with CD31. The involvement of Src family kinases in this process was confirmed through the study of mouse platelets deficient in Fyn.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Inst Pasteur, Unite Venins, F-75724 Paris 15, France	University of Reading; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gibbins, JM (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Gibbins, Jonathan/0000-0002-0372-5352				ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; BRIER G, 1996, BLOOD, V87, P630; Buckley CD, 1996, J CELL SCI, V109, P437; BURG DL, 1994, J BIOL CHEM, V269, P28136; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CRAMER EM, 1994, BLOOD, V84, P1722; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Deaglio S, 1998, J IMMUNOL, V160, P395; Duchemin AM, 1997, J IMMUNOL, V158, P865; Duncan GS, 1999, J IMMUNOL, V162, P3022; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Matsumura T, 1997, J IMMUNOL, V158, P3408; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Newton-Nash DK, 1999, J IMMUNOL, V163, P682; OHTO H, 1985, BLOOD, V66, P873; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Wang R, 1998, BLOOD, V92, p548A	49	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27339	27347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858437				2022-12-25	WOS:000089144800090
J	Dong, MQ; Asmann, YW; Zang, MW; Pinon, DI; Miller, LJ				Dong, MQ; Asmann, YW; Zang, MW; Pinon, DI; Miller, LJ			Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE (PTH)/PTH-RELATED PEPTIDE; PHOTOAFFINITY CROSS-LINKING; PARATHYROID-HORMONE; AGONIST-BINDING; TRANSMEMBRANE HELICES; VIP RECEPTOR; FAMILY; ACTIVATION	The carboxyl-terminal domains of secretin family peptides have been shown to contain key determinants for high affinity binding to their receptors. In this work, we have examined the interaction between carboxyl-terminal residues within secretin and the prototypic secretin receptor. We previously utilized photoaffinity labeling to demonstrate spatial approximation between secretin residue 22 and the receptor domain that includes the first 30 residues of the amino terminus (Dong, M., Wang, Y., Pinon, D. I., Hadac, E. M., and Miller, L. J. (1999) J. Biol. Chem. 274, 903-909), Here, we further refined the site of labeling with the p-benzoyl-phenylalanine (Bpa(22)) probe to receptor residue Leu(17) using progressive cleavage of wild type and mutant secretin receptors (V13M and V16M) and sequence analysis, We also developed a new probe incorporating a photolabile Bpa at position 26 of secretin, closer to its carboxyl terminus. This analogue was also a potent agonist (EC50 = 72 +/- 6 pM) and bound to the secretin receptor specifically and with high affinity (K-i = 10.3 +/- 2.4 nM). It covalently labeled the secretin receptor at a single site saturably and specifically. This was localized to the segment between residues Gly(34) and Ala(41) using chemical and enzymatic cleavage of labeled wild type and A41M mutant receptor constructs and immunoprecipitation of epitope-tagged receptor fragments. Radiochemical sequencing identified the site of covalent attachment as residue Leu(36), These new insights, along with our recent report of contact between residue 6 within the aminoterminal half of secretin and this same amino-terminal region of this receptor (Dong, M,, Wang, Y,, Hadac, E, M., Pinon, D, I., Holicky, E. L., and Miller, L. J. (1999) J. Biol. Chem. 274, 19161-19167), support a key role for this region, making the molecular details of this interaction of major interest.	Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Guggenheim 17, Rochester, MN 55905 USA.	miller@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BODANSZKY M, 1986, PEPTIDES, V7, P43, DOI 10.1016/0196-9781(86)90162-2; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRONENBORN AM, 1987, FEBS LETT, V215, P88, DOI 10.1016/0014-5793(87)80119-9; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN M, 1989, EUR J BIOCHEM, V186, P95, DOI 10.1111/j.1432-1033.1989.tb15182.x; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Knudsen SM, 1997, FEBS LETT, V412, P141, DOI 10.1016/S0014-5793(97)00714-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Momany FA, 1996, ANN NY ACAD SCI, V805, P172; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pang RTK, 1999, ENDOCRINOLOGY, V140, P5102, DOI 10.1210/en.140.11.5102; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; ROBBERECHT P, 1984, BIOCHIM BIOPHYS ACTA, V773, P271, DOI 10.1016/0005-2736(84)90091-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Tams JW, 1997, RECEPTOR CHANNEL, V5, P79; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Wulff B, 1997, FEBS LETT, V413, P405, DOI 10.1016/S0014-5793(97)00942-3; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	45	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26032	26039		10.1074/jbc.M000612200	http://dx.doi.org/10.1074/jbc.M000612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859300	hybrid			2022-12-25	WOS:000088999700022
J	Ott, CM; Smith, BD; Portis, AR; Spreitzer, RJ				Ott, CM; Smith, BD; Portis, AR; Spreitzer, RJ			Activase region on chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase - Nonconservative substitution in the large subunit alters species specificity of protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CHLAMYDOMONAS-REINHARDTII; CO2/O-2 SPECIFICITY; OXYGENASE RUBISCO; 1,5-BISPHOSPHATE; TOBACCO; GENE	In the active form of ribulose-1,5 bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39), a carbamate at lysine 201 binds Mg2+, which then interacts with the carboxylation transition state. Rubisco activase facilitates this spontaneous carbamylation/metal-binding process by removing phosphorylated inhibitors from the Rubisco active site. Activase from Solanaceae plants (e.g. tobacco) fails to activate Rubisco from non-Solanaceae plants (e.g. spinach and Chlamydomonas reinhardtii), and non-Solanaceae activase fails to activate Solanaceae Rubisco. Directed mutagenesis and chloroplast transformation previously showed that a proline 89 to arginine substitution on the surface of the large subunit of Chlamydomonas Rubisco switched its specificity from non-Solanaceae to Solanaceae activase activation. To define the size and function of this putative activase binding region, substitutions were created at positions flanking residue 89. As in the past, these substitutions changed the identities of Chlamydomonas residues to those of tobacco. Whereas an aspartate 86 to arginine substitution had little effect, aspartate 94 to lysine Rubisco was only partially activated by spinach activase but now fully activated by tobacco activase. In an attempt to eliminate the activase/tubisco interaction, proline 89 was changed to alanine, which is not present in either non-Solanaceae or Solanaceae Rubisco. This substitution also caused reversal of activase specificity, indicating that amino acid identity alone does not determine the specificity of the interaction.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; ARS, Photosynth Res Unit, USDA, Urbana, IL 61801 USA	University of Nebraska System; University of Nebraska Lincoln; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.							Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; BERRY JA, 1987, P NATL ACAD SCI USA, V84, P734, DOI 10.1073/pnas.84.3.734; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1991, PLANT PHYSIOL, V95, P604, DOI 10.1104/pp.95.2.604; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; MATE CJ, 1993, PLANT PHYSIOL, V102, P1119, DOI 10.1104/pp.102.4.1119; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; ROBINSON SP, 1988, FEBS LETT, V233, P413, DOI 10.1016/0014-5793(88)80473-3; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Spalding MH, 1998, MOL BIOL CHLOROPLAST, P529; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6293, DOI 10.1073/pnas.80.20.6293; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; van de Loo FJ, 1998, BIOCHEMISTRY-US, V37, P4621, DOI 10.1021/bi972566e; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yen A, 1998, ACTA CRYSTALLOGR D, V54, P668, DOI 10.1107/S0907444997016211; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	38	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26241	26244		10.1074/jbc.M004580200	http://dx.doi.org/10.1074/jbc.M004580200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858441	hybrid			2022-12-25	WOS:000088999700050
J	Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU				Keusch, JJ; Manzella, SM; Nyame, KA; Cummings, RD; Baenziger, JU			Cloning of Gb(3) synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1,4-glycosyltransferases conserved in plants, insects, and mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-P; SHIGA TOXIN; EXPRESSION CLONING; GLYCOLIPID ANTIGEN; BIOSYNTHESIS; TYPE-1; CELLS; GLYCOSYLTRANSFERASES; VEROTOXIN; RECEPTORS	We have cloned Gb, synthase, the key alpha 1,4-galactosyl-transferase in globe-series glycosphingolipid (GSL) synthesis, via a phenotypic screen, which previously yielded iGb(3) synthase, the alpha 1,3-galactosyltransferase required in iso-globe-series GSL (Keusch, J,J., Manzella, S. M., Nyame, K. A., Cummings, R. D., and Baenziger, J. U. (2000) J. Biol. Chem. 33), Both transferases act on lactosylceramide, Gal beta 1,4Glc beta 1Cer (LacCer), to produce Gb(3) (Gal alpha 1,4LacCer) or iGb(3) (Ga1 alpha 1,3LacCer), respectively. GalNAc can be added sequentially to either Gb(3) or iGb(3) yielding globoside and Forssman from Gb,, and isogloboside and isoForssman hem iGb(3). Gb, synthase is not homologous to iGb(3) synthase but shows 43% identity to a human alpha 1,4GlcNAc transferase that transfers a UDP-sugar in an alpha 1,4-linkage to a beta-linked Gal found in mucin. Extensive homology (35% identity) is also present between Gb, synthase and genes in Drosophila melanogaster and Arabidopsis thaliana, supporting conserved expression of an alpha 1,4-glycosyltransferase, possibly Gb, synthase, throughout evolution. The isolated Gb, synthase cDNA encodes a type II transmembrane glycosyltransferase of 360 amino acids. The highest tissue expression of Gb, synthase RNA is found in the kidney, mesenteric lymph node, spleen, and brain. Gb, glycolipid, also called pk antigen or CD77, is a known receptor for verotoxins. CHO cells that do not express Gb, and are resistant to verotoxin become susceptible to the toxin following transfection with Gb, synthase cDNA.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center	Keusch, JJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	jkeusch@pathbox.wustl.edu	Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK 41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1995, J LIPID RES, V36, P611; BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cooling LLW, 1998, INFECT IMMUN, V66, P4355; DENNIS RD, 1985, J BIOL CHEM, V260, P5370; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GLASGOW J, 1998, P 6 INT C INT SYST M, P175; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; JACEWICZ MS, 1994, J INFECT DIS, V169, P538, DOI 10.1093/infdis/169.3.538; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KISHIMOTO T, 1997, LEUKOCYTE TYPING, V6, P175; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kolter T, 1998, BRAIN PATHOL, V8, P79; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Li YT, 1999, ANAL BIOCHEM, V273, P1, DOI 10.1006/abio.1999.4191; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; Lingwood CA, 1999, BBA-MOL BASIS DIS, V1455, P375, DOI 10.1016/S0925-4439(99)00062-9; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MAKITA A, 1964, J BIOCHEM-TOKYO, V55, P269, DOI 10.1093/oxfordjournals.jbchem.a127880; MAKITA A, 1962, J BIOCHEM, V51, P124, DOI 10.1093/oxfordjournals.jbchem.a127509; MANGENEY M, 1993, CANCER RES, V53, P5314; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MOBASSALEH M, 1994, AM J PHYSIOL-GASTR L, V267, pG618, DOI 10.1152/ajpgi.1994.267.4.G618; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; STOFFYN P, 1973, BIOCHIM BIOPHYS ACTA, V306, P283, DOI 10.1016/0005-2760(73)90233-6; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Wiels J, 1996, GLYCOCONJUGATE J, V13, P529, DOI 10.1007/BF00731440; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YANG ZT, 1994, J BIOL CHEM, V269, P14620	41	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25315	25321		10.1074/jbc.M002630200	http://dx.doi.org/10.1074/jbc.M002630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10854428	hybrid			2022-12-25	WOS:000088849400037
J	Haj-Yehia, A; Nassar, T; Sachais, BS; Kuo, A; Bdeir, K; Al-Mehdi, AB; Mazar, A; Cines, DB; Higazi, AA				Haj-Yehia, A; Nassar, T; Sachais, BS; Kuo, A; Bdeir, K; Al-Mehdi, AB; Mazar, A; Cines, DB; Higazi, AA			Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo	FASEB JOURNAL			English	Article						smooth muscle cell; intracellular calcium; vascular contractility; rat aorta	SINGLE-CHAIN UROKINASE; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; COMPLEMENT RECEPTOR-TYPE-3; PROTEOLYTIC CLEAVAGE; MELANOMA-CELLS; PRO-UROKINASE; IN-VITRO; EXPRESSION	We examined the effect of urokinase (uPA) and its fragments on vascular smooth muscle cell contraction, Single-chain uPA inhibits phenylepherine (PE) -induced contraction of rat aortic rings, whereas two-chain uPA exerts the opposite effect. Two independent epitopes mediating these opposing activities were identified. Angstrom 6, a capped peptide corresponding to amino acids 136-143 (KPSSPPEE) of uPA, increased the EC50 of PE induced vascular contraction sevenfold by inhibiting the release of calcium from intracellular stores. Angstrom 6 activity was abolished by deleting the carboxyl-terminal Glu or by mutating the Ser corresponding to position 138 in uPA to Glu. A single-chain uPA variant lacking amino acids 136-143 did not induce vasorelaxation, A second epitope within the kringle of uPA potentiated PE-induced vasoconstriction. This epitope was exposed when single-chain uPA was converted to a two-chain molecule by plasmin. The isolated uPA kringle augmented vasoconstriction, whereas uPA variant lacking the kringle had no procontractile activity. These studies reveal previously undescribed vasoactive domains within urokinase and its naturally derived fragments.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Hebrew Univ Jerusalem, Hadassah Med Ctr, Sch Pharm, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Angstrom Pharmaceut Inc, Dept Biol, San Diego, CA 92121 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Higazi, AA (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	higazi@mail.med.upenn.edu	Al-Mehdi, Abu-Bakr/A-8636-2009; Sachais, Bruce/D-1236-2009		NHLBI NIH HHS [HL-60169, T32 HL007775] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775, R01HL060169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; CAO DR, 1995, J IMMUNOL, V154, P1817; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; CHANG KSK, 1992, BRIT J PHARMACOL, V107, P983, DOI 10.1111/j.1476-5381.1992.tb13395.x; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; Franco P, 1998, J BIOL CHEM, V273, P27734, DOI 10.1074/jbc.273.42.27734; Franco P, 1997, J CELL BIOL, V137, P779, DOI 10.1083/jcb.137.3.779; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; GUREWICH V, 1987, SEMIN THROMB HEMOST, V13, P146, DOI 10.1055/s-2007-1003485; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; Higazi AAR, 1996, THROMB RES, V84, P243, DOI 10.1016/S0049-3848(96)00184-3; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; Ikeda M, 1998, CELL CALCIUM, V24, P49, DOI 10.1016/S0143-4160(98)90088-4; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KIRSCHHEIMER JC, 1987, FED AM SOC EXP BIOL, V1, P125; KOIZUMI T, 1994, J CLIN INVEST, V94, P2275, DOI 10.1172/JCI117590; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; KYONG SK, 1992, BRIT J PHARMACOL, V107, P983; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; MARCOTTE PA, 1992, J BIOL CHEM, V267, P13803; MAZAR AP, 1995, FIBRINOLYSIS S1, V6, P49; Min HY, 1996, CANCER RES, V56, P2428; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; OYAMA Y, 1986, EUR J PHARMACOL, V132, P75, DOI 10.1016/0014-2999(86)90013-0; PANNELL R, 1987, BLOOD, V69, P22; Pedersen TL, 1996, BRIT J HAEMATOL, V95, P45; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHWARTZ BS, 1994, J BIOL CHEM, V269, P8319; Shireman PK, 1997, J VASC SURG, V25, P157, DOI 10.1016/S0741-5214(97)70333-1; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Sitrin RG, 1999, J IMMUNOL, V163, P6193; STAHL A, 1994, CANCER RES, V54, P3066; Tozawa K, 1999, ANTIOXID REDOX SIGN, V1, P145, DOI 10.1089/ars.1999.1.2-145; Ugwu F, 1998, BIOCHEMISTRY-US, V37, P7231, DOI 10.1021/bi9728708; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; van Hinsbergh V W, 1997, EXS, V79, P391; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; YOHTARO O, 1987, EUR J PHARMACOL, V131, P75; Zlatnik MG, 1999, AM J OBSTET GYNECOL, V180, P1191, DOI 10.1016/S0002-9378(99)70615-0	68	36	40	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1411	1422		10.1096/fj.14.10.1411	http://dx.doi.org/10.1096/fj.14.10.1411			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877834				2022-12-25	WOS:000087932200016
J	Qin, KF; Yang, DS; Yang, Y; Chishti, MA; Meng, LJ; Kretzschmar, HA; Yip, CM; Fraser, PE; Westaway, D				Qin, KF; Yang, DS; Yang, Y; Chishti, MA; Meng, LJ; Kretzschmar, HA; Yip, CM; Fraser, PE; Westaway, D			Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP - Effect of protein age and deamidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEIN; SECONDARY STRUCTURE; ASPARTYL RESIDUES; COPPER-BINDING; NONENZYMATIC DEAMIDATION; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; INFECTED BRAIN; BOVINE BRAIN; N-TERMINUS	While PrPC rearranges in the area of codons 104-113 to form PrPSc during prion infections, the events that initiate sporadic Creutzfeldt-Jakob disease are undefined. AS Cu(II) is a putative ligand for PrPC and has been implicated in the pathogenesis of Creutzfeldt-Jakob disease and other neurodegenerative diseases, we investigated the structural effects of binding. Incubation of brain microsomes with Cu(II) generated similar to 30-kDa proteinase K-resistant PrP. Cu(II) had little effect on fresh recombinant PrP23-231, but aged protein characterized by conversion of Asn-107 to Asp decreased cu-helical content by similar to 30%, increased beta-sheet content 100%, formed aggregates, and acquired proteinase K resistance in the presence of Cu(II), These transitions took place without need for acid pH, organic solvents, denaturants, or reducing agents. Since conversion of Asn to Asp proceeds by a spontaneous pathway involving deamidation, our data suggest that covalent variants of PrPC arising in this manner may, in concert with Cu(II), generate PrPSc-like species capable of initiating sporadic prion disease.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Modern Med Res Ctr, Mass Spectrometry Lab, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3H2, Canada; Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 3H2, Canada; Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Gottingen	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca		Yip, Christopher/0000-0003-4507-556X				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BLACKWELL RQ, 1972, BIOCHIM BIOPHYS ACTA, V278, P482, DOI 10.1016/0005-2795(72)90008-6; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brennan T. V., 1995, DEAMIDATION ISOASPAR, P66; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1996, PRION DIS, P223; Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CLARKE S, 1992, STABILITY PROTEIN PH, P1; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GEIGER T, 1987, J BIOL CHEM, V262, P785; Gibbs C.J., 1979, SLOW TRANSMISSIBLE D, V1, P87; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kanyo ZF, 1999, J MOL BIOL, V293, P855, DOI 10.1006/jmbi.1999.3193; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1994, PHILOS T R SOC B, V343, P425, DOI 10.1098/rstb.1994.0039; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LAN S, 1971, J BIOL CHEM, V246, P5938; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Maeda H, 1997, LANGMUIR, V13, P4150, DOI 10.1021/la962105e; Marcotte EM, 1999, BIOCHEMISTRY-US, V38, P667, DOI 10.1021/bi981487f; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; McIntire WE, 1998, BIOCHEMISTRY-US, V37, P14651, DOI 10.1021/bi981642q; MCKINLEY M P, 1987, P197; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; Negro A, 1997, FEBS LETT, V412, P359, DOI 10.1016/S0014-5793(97)00798-9; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Paleari R, 1999, CLIN CHEM, V45, P21; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; POTTER SM, 1992, BIOCHEMISTRY-US, V31, P6339, DOI 10.1021/bi00142a025; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sandmeier E, 1999, BIOCHEM BIOPH RES CO, V261, P578, DOI 10.1006/bbrc.1999.1056; Shaked Y, 1999, J BIOL CHEM, V274, P32153, DOI 10.1074/jbc.274.45.32153; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SULKOWSKI E, 1992, FEBS LETT, V307, P129, DOI 10.1016/0014-5793(92)80750-B; Takemoto LJ, 1995, DEAMIDATION ISOASPAR, P157; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; WAJCMAN H, 1992, BIOCHIM BIOPHYS ACTA, V1138, P127, DOI 10.1016/0925-4439(92)90052-O; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; Weber DJ, 1998, BIOCHEM BIOPH RES CO, V246, P606, DOI 10.1006/bbrc.1998.8672; WESTAWAY D, 1989, TRENDS NEUROSCI, V12, P221, DOI 10.1016/0166-2236(89)90126-4; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Wong BS, 1999, BIOCHEM BIOPH RES CO, V259, P352, DOI 10.1006/bbrc.1999.0802; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; Xie ML, 1999, J PHARM SCI, V88, P8, DOI 10.1021/js9802493	88	142	149	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19121	19131		10.1074/jbc.275.25.19121	http://dx.doi.org/10.1074/jbc.275.25.19121			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858456	hybrid			2022-12-25	WOS:000087815900067
J	Kim, SH; Forman, AP; Mathews, MB; Gunnery, S				Kim, SH; Forman, AP; Mathews, MB; Gunnery, S			Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR	ONCOGENE			English	Article						PKR; breast cancer; translation; p58; eIF2B	TETRATRICOPEPTIDE REPEAT PROTEIN; SYNTHESIS INITIATION-FACTOR; RNA-BINDING PROTEIN; NF-KAPPA-B; MALIGNANT TRANSFORMATION; CELLULAR INHIBITOR; EXPRESSION; APOPTOSIS; PATHWAY; P68	PKR is a double-stranded (ds) RNA activated protein kinase whose expression is induced by interferon. Activated PKR phosphorylates its cellular substrate, eIF2, an essential initiation factor of translation. Prior evidence from a murine model system suggested that PKR may act as a tumor suppressor, but the evidence from human tumors is equivocal. To study PKR function in human breast cancer, PKR activity was measured in mammary carcinoma cell lines and nontransformed mammary epithelial cell lines. If PKR functioned as a tumor suppressor in this system, its activity would be higher in nontransformed cells than in carcinoma cells. On the contrary, PKR autophosphorylation and the phosphorylation of its substrate, the v.-subunit of eLF2, is 7 - 40-fold higher in lysates prepared from breast carcinoma cell lines than in those from nontransformed epithelial cell lines. Correspondingly, a larger proportion of eIF2 alpha is present in a phosphorylated state in carcinoma cell lines than in nontransformed cell lines. Protein synthesis is not inhibited by the high eIF2 alpha phosphorylation in carcinoma cells, probably because they contain higher levels of eIF2B, the initiation factor that is inhibited by eIF2 alpha phosphorylation, The dramatically lower PKR activity in nontransformed cell lines is partially due to lower PKR protein levels (2-4-fold) as well as to the presence of a PKR inhibitor. The nontransformed cells contain P58, a known cellular inhibitor of PKR that physically interacts with PKR and may be responsible for the low PKR activity in these cells. Taken together, these observations call into question the role of PKR as a tumor suppressor and suggest a positive regulatory role of PKR in growth control of breast cancer cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gunnery, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Basu S, 1997, CANCER RES, V57, P943; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Beretta L, 1996, ONCOGENE, V12, P1593; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Harlow E, 1998, ANTIBODIES LAB MANUA; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Shimada A, 1998, CANCER RES, V58, P4434; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	41	94	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3086	3094		10.1038/sj.onc.1203632	http://dx.doi.org/10.1038/sj.onc.1203632			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871861				2022-12-25	WOS:000087903900006
J	Xie, MH; Aggarwal, S; Ho, WH; Foster, J; Zhang, ZM; Stinson, J; Wood, WI; Goddard, AD; Gurney, AL				Xie, MH; Aggarwal, S; Ho, WH; Foster, J; Zhang, ZM; Stinson, J; Wood, WI; Goddard, AD; Gurney, AL			Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; PHOSPHORYLATION; SPECIFICITY; COMPLEXES; PATHWAY; STAT3; MICE	We report the identification of a novel human cytokine, distantly related to interleukin (IL)-10, which we term IL-22, IL-22 is produced by activated T cells. IL-22 is a ligand for CRF2-4, a member of the class II cytokine receptor family. No high affinity ligand has yet been reported for this receptor, although it has been reported to serve as a second component in IL-10 signaling, A new member of the interferon receptor family, which we term IL-22R, functions as a second component together with CRF2-4 to enable IL-22 signaling. IL-22 does not bind the IL-10R, Cell lines were identified that respond to IL-22 by activation of STATs 1, 3, and 5, but were unresponsive to IL-10, In contrast to IL-10, IL-22 does not inhibit the production of proinflammatory cytokines by monocytes in response to LPS nor does it impact IL-10 function on monocytes, but it has modest inhibitory effects on IL-4 production from Th2 T cells.	Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Gurney, AL (corresponding author), Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA.							ADAMS RL, 1999, Patent No. 9907848; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Gibbs VC, 1997, GENE, V186, P97, DOI 10.1016/S0378-1119(96)00690-7; Grotzinger J, 1997, PROTEINS, V27, P96; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LOK S, 1999, Patent No. 5965704; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485	19	428	535	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31335	31339		10.1074/jbc.M005304200	http://dx.doi.org/10.1074/jbc.M005304200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10875937	hybrid			2022-12-25	WOS:000089762700083
J	Arfin, SM; Long, AD; Ito, ET; Tolleri, L; Riehle, MM; Paegle, ES; Hatfield, GW				Arfin, SM; Long, AD; Ito, ET; Tolleri, L; Riehle, MM; Paegle, ES; Hatfield, GW			Global gene expression profiling in Escherichia coli K12 - The effects of integration host factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; ILVGMEDA OPERON; TRANSCRIPTIONAL ACTIVATION; HIMD SUBUNITS; GROWTH-PHASE; FACTOR IHF; IN-VITRO; PROMOTER; FNR; SITES	We have used nylon membranes spotted in duplicate with full-length polymerase chain reaction-generated products of each of the 4,290 predicted Escherichia coli K12 open reading frames (ORFs) to measure the gene expression profiles in otherwise isogenic integration host factor IHF+ and IHF- strains. Our results demonstrate that random hexamer rather than 3' ORF-specific priming of cDNA probe synthesis is required for accurate measurement of gene expression levels in bacteria. This is explained by the fact that the currently available set of 4,290 unique 3' ORF-specific primers do not hybridize to each ORF with equal efficiency and by the fact that widely differing degradation rates (steady-state levels) are observed for the 25-base pair region of each message complementary to each ORF-specific primer. To evaluate the DNA microarray data reported here, we used a linear analysis of variance (ANOVA) model appropriate for our experimental design. These statistical methods allowed us to identify and appropriately correct for experimental variables that affect the reproducibility and accuracy of DNA microarray measurements and allowed us to determine the statistical significance of gene expression differences between our IRF+ and IHF- strains. Our results demonstrate that small differences in gene expression levels can be accurately measured and that the significance of differential gene expression measurements cannot be assessed simply by the magnitude of the fold difference. Our statistical criteria, supported by excellent agreement between previously determined effects of IHF on gene expression and the results reported here, have allowed us to identify new genes regulated by IHF with a high degree of confidence.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Biol Sci, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Engn, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Arfin, SM (corresponding author), Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA.			Long, Tony/0000-0002-5007-8514	NIGMS NIH HHS [GM55073] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ARFIN SM, 1969, J BIOL CHEM, V244, P2250; AVIV M, 1994, MOL MICROBIOL, V14, P1021, DOI 10.1111/j.1365-2958.1994.tb01336.x; BENDER RA, 1977, J BACTERIOL, V129, P1001, DOI 10.1128/JB.129.2.1001-1009.1977; Benham CJ, 1996, COMPUT APPL BIOSCI, V12, P375; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; Chao GL, 1997, J BACTERIOL, V179, P4299, DOI 10.1128/jb.179.13.4299-4304.1997; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DITTO MD, 1994, J BACTERIOL, V176, P3738, DOI 10.1128/JB.176.12.3738-3748.1994; Dubrac S, 2000, J BACTERIOL, V182, P3802, DOI 10.1128/JB.182.13.3802-3808.2000; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; Ellenberger T, 1997, STRUCTURE, V5, P153, DOI 10.1016/S0969-2126(97)00174-3; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Futcher B, 1999, MOL CELL BIOL, V19, P7357; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; GILADI H, 1992, J MOL BIOL, V224, P937, DOI 10.1016/0022-2836(92)90461-R; Goodman SD, 1999, J BACTERIOL, V181, P3246, DOI 10.1128/JB.181.10.3246-3255.1999; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; Green J, 1997, MICROBIOL-SGM, V143, P2865, DOI 10.1099/00221287-143-9-2865; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; HASSAN HM, 1992, P NATL ACAD SCI USA, V89, P3217, DOI 10.1073/pnas.89.8.3217; HAUSER CA, 1984, P NATL ACAD SCI-BIOL, V81, P76, DOI 10.1073/pnas.81.1.76; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; Hiszczynska-Sawicka E, 1997, PLASMID, V38, P174, DOI 10.1006/plas.1997.1307; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; JACOB F, 1961, COLD SPRING HARB SYM, V26, P193, DOI 10.1101/SQB.1961.026.01.024; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; MARTIN RG, 1967, J BIOL CHEM, V242, P1168; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; MOITOSO DV, 1989, SCIENCE, V244, P1457; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P1310; OBERTO J, 1994, BIOCHIMIE, V76, P901, DOI 10.1016/0300-9084(94)90014-0; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PARK SJ, 1995, J BACTERIOL, V177, P6255, DOI 10.1128/jb.177.21.6255-6262.1995; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; Park SJ, 1997, J BACTERIOL, V179, P4138, DOI 10.1128/jb.179.13.4138-4142.1997; PRESUTTI DG, 1995, MOL GEN GENET, V246, P228, DOI 10.1007/BF00294686; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; Sheridan SD, 1999, J BIOL CHEM, V274, P8169, DOI 10.1074/jbc.274.12.8169; VANBOGELEN RA, 1996, ESCHERICHIA COLI SAL, P2067; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WERNER MH, 1994, CURR BIOL, V4, P477, DOI 10.1016/S0960-9822(00)00108-1; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZABLEWSKA B, 1995, GENE, V160, P131, DOI 10.1016/0378-1119(95)00252-2; ZULIANELLO L, 1994, EMBO J, V13, P1534, DOI 10.1002/j.1460-2075.1994.tb06415.x	54	206	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29672	29684		10.1074/jbc.M002247200	http://dx.doi.org/10.1074/jbc.M002247200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871608	hybrid			2022-12-25	WOS:000089439800067
J	El Khattabi, M; Van Gelder, P; Bitter, W; Tommassen, J				El Khattabi, M; Van Gelder, P; Bitter, W; Tommassen, J			Role of the lipase-specific foldase of Burkholderia glumae as a steric chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; GRAM-NEGATIVE BACTERIA; PRO-REGION; PSEUDOMONAS-AERUGINOSA; ACTIVE-SITE; ACTIVATION; PROPEPTIDE; SECRETION; ELASTASE; SEQUENCE	Most lipases of Gram-negative bacteria require a lipase-specific foldase (Lif) in order to fold in the periplasm into their active, protease-resistant conformation prior to their secretion. The periplasmic domain of the Lif (amino acids 44-353) of Burkholderia glumae was purified as a His-tagged protein, and its function in the folding of lipase was studied In vitro, Refolding of the denatured lipase into its active conformation was dependent on the presence of the Lif, Circular dichroism revealed that the lipase refolded in the absence of Lif into a form with a native-like conformation, which was more stable against heat-induced denaturation than the native form, but was enzymatically inactive. This form of the protein could he activated by adding Lif after several hours, which demonstrates that the function of this chaperone is to help lipase to overcome an energetic barrier in the productive folding pathway rather than to prevent it from entering a non-productive pathway. The Lif was shown to interact with the native lipase in protease-protection experiments as well as by affinity chromatography, consistent with a role of the Lif late in the folding process. These results demonstrate that the Lif functions in a way analogous to the propeptides of many bacterial proteases and indicate that the amino acid sequence of the lipase does not contain all the information required for the protein to adopt its three-dimensional structure.	Univ Utrecht, Dept Mol Microbiol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Utrecht University; Utrecht University; University of Basel	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol Microbiol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Bitter, Wilbert/ABG-3726-2020; Bitter, W/CAJ-5778-2022; Tommassen, Jan/I-1690-2016; Bitter, Wilbert/AAA-6872-2019	Bitter, Wilbert/0000-0001-8347-6511; Tommassen, Jan/0000-0001-7633-4945; Van Gelder, Patrick/0000-0003-1785-4435				AAMAND JL, 1994, MOL GEN GENET, V245, P556, DOI 10.1007/BF00282218; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Braun P, 1998, TRENDS MICROBIOL, V6, P6, DOI 10.1016/S0966-842X(97)01188-8; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; El Khattabi M, 1999, MOL GEN GENET, V261, P770; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P468, DOI 10.1016/S0968-0004(98)01324-3; FRENKEN LGJ, 1993, MOL MICROBIOL, V9, P591, DOI 10.1111/j.1365-2958.1993.tb01719.x; Gerritse G, 1998, APPL ENVIRON MICROB, V64, P2644; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOBSON AH, 1993, P NATL ACAD SCI USA, V90, P5682, DOI 10.1073/pnas.90.12.5682; HOBSON AH, 1995, J BIOCHEM, V118, P575, DOI 10.1093/oxfordjournals.jbchem.a124948; IHARA F, 1995, J BACTERIOL, V177, P1254, DOI 10.1128/jb.177.5.1254-1258.1995; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Kagami Y, 1998, MOL MICROBIOL, V27, P221, DOI 10.1046/j.1365-2958.1998.00679.x; KESSLER E, 1994, J BIOL CHEM, V269, P22726; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; Michel G, 2000, J BACTERIOL, V182, P696, DOI 10.1128/JB.182.3.696-703.2000; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; NOBLE MEM, 1994, PROTEIN ENG, V7, P559, DOI 10.1093/protein/7.4.559; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rariy RV, 1997, P NATL ACAD SCI USA, V94, P13520, DOI 10.1073/pnas.94.25.13520; Sambrook J., 2002, MOL CLONING LAB MANU; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; Shibata H, 1998, J BIOCHEM-TOKYO, V123, P136; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; STARK GR, 1960, J BIOL CHEM, V235, P3177; TOMMASSEN J, 1992, FEMS MICROBIOL LETT, V103, P73; Yang JH, 2000, J BACTERIOL, V182, P295, DOI 10.1128/JB.182.2.295-302.2000	38	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26885	26891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859310				2022-12-25	WOS:000089144800031
J	Salvador, N; Aguado, C; Horst, M; Knecht, E				Salvador, N; Aguado, C; Horst, M; Knecht, E			Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; PEPTIDE SEQUENCES; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRACELLULAR PROTEINS; PRECURSOR PROTEIN; SELECTIVE UPTAKE; DEGRADATION; MITOCHONDRIA; BINDING; TRANSLOCATION	We have analyzed the folding state of cytosolic proteins imported in vitro into lysosomes, using an approach originally developed by filers and Schatz, (Eilers, M., and Schatz, G. (1986) Nature 322, 228-232) to investigate protein import into mitochondria. The susceptibility toward proteases of mouse dihydrofolate reductase (DHFR), synthesized in a coupled transcription-translation system with rabbit reticulocytes, decreased in the presence of its substrate analogue, methotrexate. This analogue complexes with high affinity with the in vitro synthesized DHFR and locks it into a protease-resistant folded conformation. DHFR was taken up by freshly isolated rat liver lysosomes and methotrexate reduced this uptake by about 80%. A chimeric DHFR protein, which carries the N-terminal presequence of subunit 9 of ATP synthase preprotein from Neurospora crassa fused to its N terminus, was taken up by lysosomes more efficiently. Again, methotrexate abolished the lysosomal uptake of the fusion protein, which was partially restored by washing of methotrexate from DHFR or by adding together methotrexate and dihydrofolate, the natural substrate of DHFR. Immunoblot analysis with anti-DHFR of liver lysosomes and of other fractions, isolated from rats starved for 88 h and treated with lysosomal inhibitors, suggests that DHFR is degraded by chaperone-mediated autophagy, Competition with ribonuclease A and stimulation by ATP/Mg2+ and the heat shock cognate protein of 73 kDa show that the lysosomal uptake of the fusion protein also occurs by this pathway. It is concluded that the lysosomal uptake of cytosolic proteins by chaperone-mediated autophagy mainly occurs by passage of the unfolded proteins through the lysosomal membrane. Therefore, this mechanism is different from protein transport into peroxisomes, but similar to the import of proteins into the endoplasmic reticulum and mitochondria.	Fdn Valenciana Invest Biomed, Inst Invest Citol, Valencia, Spain; Univ Basel, Fac Phil II, CH-4055 Basel, Switzerland	University of Basel	Knecht, E (corresponding author), Fdn Valenciana Invest Biomed, Inst Invest Citol, Amadeo Saboya 4, Valencia, Spain.		Knecht, Erwin/A-9366-2014; Knecht, Erwin/K-2432-2014; Aguado, Carmen/K-4354-2014	Knecht, Erwin/0000-0002-7208-3832; Aguado, Carmen/0000-0002-3113-4269				Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Aniento F, 1997, ELECTROPHORESIS, V18, P2638, DOI 10.1002/elps.1150181420; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BENNETT JP, 1982, TECHNIQUES LIFE SC B, V4, P15; Blobel G, 1995, COLD SPRING HARB SYM, V60, P1; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; DAEMS WT, 1972, LYSOSOMES LAB HDB, P156; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; deLlano CJM, 1996, ANAL BIOCHEM, V243, P210; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; HOLTZMANN E, 1976, LYSOSOMES SURVEY; Horst M, 1999, MOL BIOL CELL, V10, P2879, DOI 10.1091/mbc.10.9.2879; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; Huang SH, 1999, NAT STRUCT BIOL, V6, P1132; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Knecht E, 1998, ADV MOL CEL, V27, P201, DOI 10.1016/S1569-2558(08)60462-2; KOMINAMI E, 1983, J BIOL CHEM, V258, P6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1991, EUR J CELL BIOL, V56, P201; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; Teter SA, 1999, TRENDS CELL BIOL, V9, P428, DOI 10.1016/S0962-8924(99)01652-9; Ueno T, 1999, J BIOL CHEM, V274, P15222, DOI 10.1074/jbc.274.21.15222; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Wilson AJ, 1993, PROCEDURES ELECT MIC; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165	51	171	176	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27447	27456						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862611				2022-12-25	WOS:000089144800103
J	Cheriyath, V; Roy, AL				Cheriyath, V; Roy, AL			Alternatively spliced isoforms of TFII-I - Complex formation, nuclear translocation, and differential gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; WILLIAMS-BEUREN-SYNDROME; V-BETA PROMOTER; NF-KAPPA-B; BINDING PROTEIN; TRANSCRIPTION INITIATION; EXPRESSION; ELEMENT; IDENTIFICATION	TFII-I is a multifunctional phosphoprotein with roles in transcription and signal transduction. Here we report characterization of three additional alternatively spliced isoforms of TFII-I. Employing isoform-specific antibodies, we show that the isoforms form a stable complex in vivo preferentially in the nucleus compared with the cytoplasm. We further show that both homomeric and heteromeric interactions are possible and that the heteromeric interactions between a wild type and a nuclear localization-deficient mutant result in nuclear translocation of the complex, leading us to postulate that complex formation might aid in nuclear translocation. In functional assays all four isoforms individually bind to DNA and transactivate reporter genes to a similar extent. However, although co-expression of different TFII-I isoforms leads to enhanced basal activity, it results in attenuated signal responsive activity. Thus, TFII-I might differentially regulate its target genes via complex or subcomplex formation.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA	Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.	aroy@opal.tufts.edu						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Novina CD, 1997, METHODS, V12, P254, DOI 10.1006/meth.1997.0477; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	28	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26300	26308		10.1074/jbc.M002980200	http://dx.doi.org/10.1074/jbc.M002980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854432	hybrid			2022-12-25	WOS:000088999700058
J	Goukassian, D; Gad, F; Yaar, M; Eller, MS; Nehal, US; Gilchrest, BA				Goukassian, D; Gad, F; Yaar, M; Eller, MS; Nehal, US; Gilchrest, BA			Mechanisms and implications of the age-associated decrease in DNA repair capacity	FASEB JOURNAL			English	Article						aging; DNA damage repair; DNA photoproducts; nucleotide excision repair	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; REPLICATION PROTEIN-A; NONMELANOMA SKIN-CANCER; ULTRAVIOLET-B RADIATION; BASAL-CELL CARCINOMA; NERVE GROWTH-FACTOR; UV-RADIATION; P53 PROTEIN; TRANSCRIPTIONAL ACTIVITY	Skin cancer incidence is clearly linked to UV irradiation and increases exponentially with age, We studied the rate of removal of thymine dimers and (6-4) photoproducts in UV-irradiated human dermal fibroblasts derived from donors of different ages. There was a significant decrease with aging in the repair rates of both thymine dimers and (6-4) photoproducts. (P<0.001). In addition, there was an age-associated decrease in the protein levels of ERCC3, PCNA, RPA, XPA, and p53 that participate in nucleotide excision repair. Moreover, the mRNA levels of XPA, ERCC3, and PCNA were significantly reduced with aging, suggesting that these decreases are often regulated at the mRNA level. Furthermore, with age induction of p53 after UV irradiation was significantly reduced. Taken together, our data suggest that the age-associated decrease in the repair of UV-induced DNA damage results at least in part from decreased levels of proteins that participate in the repair process.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu		Goukassian, David/0000-0001-5270-5270	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000115] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07562] Funding Source: Medline; NIA NIH HHS [T32AG00115] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; ALCALAY J, 1990, J INVEST DERMATOL, V95, P506, DOI 10.1111/1523-1747.ep12504707; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; BERG RJW, 1995, CARCINOGENESIS, V16, P2455, DOI 10.1093/carcin/16.10.2455; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; Crowley DJ, 1998, J BACTERIOL, V180, P3345, DOI 10.1128/JB.180.13.3345-3352.1998; Dumaz N, 1998, CARCINOGENESIS, V19, P1701, DOI 10.1093/carcin/19.9.1701; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; ELLER MS, 1992, EXP CELL RES, V198, P328, DOI 10.1016/0014-4827(92)90387-N; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GILCHREST BA, 1983, J INVEST DERMATOL, V81, pS184, DOI 10.1111/1523-1747.ep12541084; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; Gilchrest BA, 1997, FASEB J, V11, P322, DOI 10.1096/fasebj.11.5.9141498; GILCHREST BA, 1980, J GERONTOL, V35, P537, DOI 10.1093/geronj/35.4.537; GILCHREST BA, IN PRESS ROLE DNA DA; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; GROSSMAN L, 1995, CLIN CHEM, V41, P1854; Guo ZM, 1998, EXP CELL RES, V245, P228, DOI 10.1006/excr.1998.4269; HALL PA, 1993, ONCOGENE, V8, P203; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JEEVES WP, 1986, CARCINOGENESIS, V7, P381, DOI 10.1093/carcin/7.3.381; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY MK, 1990, J BIOL CHEM, V265, P769; KING CM, 1994, MUTAT RES-DNAGING G, V316, P79, DOI 10.1016/0921-8734(94)90010-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1998, NUCLEIC ACIDS RES, V26, P4662, DOI 10.1093/nar/26.20.4662; KOCHEVAR IE, 1993, DERMATOLOGY GEN MED, P1627; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; LAMBERT B, 1979, CANCER RES, V39, P2792; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; LI L, 1995, MOL CELL BIOL, V15, P5396; Lu X, 1996, ONCOGENE, V13, P413; LYTLE CD, 1976, MUTAT RES, V36, P257, DOI 10.1016/0027-5107(76)90235-9; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEDRANO EE, 1995, CANCER RES, V55, P4047; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mitchell David L., 1993, P345; MITCHELL DL, 1990, J INVEST DERMATOL, V95, P55, DOI 10.1111/1523-1747.ep12873312; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MULLAART E, 1988, J INVEST DERMATOL, V90, P346, DOI 10.1111/1523-1747.ep12456316; MULLENDERS LHF, 1993, MUTAT RES, V299, P271, DOI 10.1016/0165-1218(93)90103-K; NETTE EG, 1984, MECH AGEING DEV, V24, P283; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PLAZA S, 1991, PHOTOCHEM PHOTOBIOL, V53, P217, DOI 10.1111/j.1751-1097.1991.tb03926.x; Reenstra WR, 1996, EXP CELL RES, V227, P252, DOI 10.1006/excr.1996.0274; ROBINSON DR, 1994, MUTAT RES-ENVIR MUTA, V313, P227, DOI 10.1016/0165-1161(94)90053-1; ROSENSTEIN BS, 1991, RADIAT RES, V126, P338, DOI 10.2307/3577923; RUVEN HJT, 1993, CANCER RES, V53, P1642; RUVEN HJT, 1994, ONCOGENE, V9, P3427; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sancar Gwendolyn B., 1996, Mutation Research, V362, P127, DOI 10.1016/0921-8777(95)00029-1; SCOTTO J, 1981, US DEP HLTH HUMAN SE; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; Tron V A, 1998, J Cutan Med Surg, V3, P16; Ueda M, 1996, PHOTODERMATOL PHOTO, V12, P22, DOI 10.1111/j.1600-0781.1996.tb00239.x; Van Remmen Holly, 1995, P171; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEI QY, 1995, J INVEST DERMATOL, V104, P933, DOI 10.1111/1523-1747.ep12606207; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4; Zeng L, 1997, GENE THER, V4, P1077, DOI 10.1038/sj.gt.3300495; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	95	163	171	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1325	1334		10.1096/fj.14.10.1325	http://dx.doi.org/10.1096/fj.14.10.1325			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877825				2022-12-25	WOS:000087932200007
J	Du, J; Mitch, WE; Wang, XN; Price, SR				Du, J; Mitch, WE; Wang, XN; Price, SR			Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN; PROTEOLYSIS; DEGRADATION; PROTEINS; PATHWAY; ACTIVATION; RATS; TRANSACTIVATION; REPRESSION; INHIBITORS	Muscle wasting in catabolic conditions results from activation of the ubiquitin-proteasome proteolytic pathway by a process that requires glucocorticoids and is generally associated with increased levels of mRNAs encoding components of this proteolytic system. In L6 muscle cells, dexamethasone stimulates proteolysis and increases the amount of the proteasome C3 subunit protein by augmenting its transcription. Transfection studies with human C3 promoter-luciferase reporter genes and electrophoretic mobility shift assays revealed that a NF-kappa B-protein complex containing Rel A is abundant in L6 muscle cell nuclei, Glucocorticoids stimulate C3 subunit expression by antagonizing the interaction of this NF-kappa B protein with an NF-kappa B response element in the C3 subunit promoter region. Dexamethasone also increased the cytosolic amounts of the NF-kappa B p65 subunit and the I kappa B alpha inhibitor proteins in L6 cells. Incubation of L6 cells with a cytokine mixture not only increased the amount of activated NF-kappa B but also decreased C3 promoter activity and lowered endogenous C3 subunit mRNA. Thus, NP-kappa B is a repressor of C3 proteasome subunit transcription in muscle cells, and glucocorticoids stimulate C3 subunit expression by opposing this suppressor action.	Emory Univ, Div Renal, Atlanta, GA 30322 USA	Emory University	Price, SR (corresponding author), Emory Univ, Div Renal, Rm 388 WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL045317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037175, R01DK050740, R37DK037175] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45317] Funding Source: Medline; NIDDK NIH HHS [DK37175, R37 DK037175, DK50740] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JL, 1995, AM J PHYSIOL-CELL PH, V269, pC706, DOI 10.1152/ajpcell.1995.269.3.C706; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BEDARD S, 1997, BIOCHEM J, V325, P467; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Chang HR, 1998, JPEN-PARENTER ENTER, V22, P156, DOI 10.1177/0148607198022003156; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND BK, 1995, AM J PHYSIOL-CELL PH, V268, pC1395, DOI 10.1152/ajpcell.1995.268.6.C1395; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; GULVE EA, 1989, BIOCHEM J, V260, P377, DOI 10.1042/bj2600377; HAIRE MF, 1995, ARCH BIOCHEM BIOPHYS, V318, P15, DOI 10.1006/abbi.1995.1198; Isozaki Y, 1996, P NATL ACAD SCI USA, V93, P1967, DOI 10.1073/pnas.93.5.1967; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; TAMURA T, 1994, J MOL BIOL, V244, P117, DOI 10.1006/jmbi.1994.1710; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Tiao Gregory M., 1995, Surgical Forum, V46, P10; WING SS, 1993, AM J PHYSIOL, V264, P668	33	114	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19661	19666		10.1074/jbc.M907258199	http://dx.doi.org/10.1074/jbc.M907258199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867022	hybrid			2022-12-25	WOS:000087941300031
J	Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R				Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R			Generation of structurally and functionally distinct factors from the basic helix-loop-helix gene Hes3 by alternative first exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MAMMALIAN NEURONAL DIFFERENTIATION; ACHAETE-SCUTE HOMOLOG-1; TRANSCRIPTION FACTORS; CHROMOSOMAL LOCUS; PROMOTER ANALYSIS; DROSOPHILA HAIRY; WRPW MOTIF; STEM-CELLS; ENHANCER	The basic helix-loop-helix gene Hes3 is expressed by differentiating and mature Purkinje cells in the cerebellum and by neural precursor cells in the embryonal nervous system. We here found that the transcript of cerebellar Hes3, designated Hes3a, has a distinct 5'-terminal structure from that of embryonal Hes3, designated Hes3b, and that the two types of Hes3 transcripts are generated from different first exons. Hes3a lacks the amino-terminal half of the basic region and thus does not bind to the DNA, whereas Hes3b contains a complete basic region and binds to the N box sequence with a high affinity like Hes1, another member of the Hes family. Both types of Hes3 proteins functionally antagonize the neuronal determination factor Mash1, but only Hes3b represses transcription from the N box-containing promoter like Hes1. Furthermore, misexpression of Hes3b with retrovirus in neural precursor cells inhibits neuronal differentiation like Hes1, whereas Hes3a does not, Thus, alternative promoters and first exons that are differentially utilized during neural development generate structurally and functionally distinct proteins from a single Hes3 gene locus.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Shogoin Kawahara, Kyoto 6068507, Japan.			Hirata, Hiromi/0000-0002-3769-7441				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Allen T, 1999, CELL MOL BIOL, V45, P687; Anderson D, 1997, MOL CELLULAR APPROAC, P26; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaugrund E, 1996, DEVELOPMENT, V122, P309; Brown NL, 1998, DEVELOPMENT, V125, P4821; Casarosa S, 1999, DEVELOPMENT, V126, P525; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cau E, 1997, DEVELOPMENT, V124, P1611; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Guillemot F, 1995, BIOL CELL, V84, P3, DOI 10.1016/0248-4900(96)81312-8; HOJO M, 2000, IN PRESS DEVELOPMENT; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito M, 1984, CEREBELLUM NEURAL CO; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lobe CG, 1997, MECH DEVELOP, V62, P227, DOI 10.1016/S0925-4773(97)00665-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SAKAGAMI T, 1994, BIOCHEM BIOPH RES CO, V203, P594, DOI 10.1006/bbrc.1994.2224; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Torii MA, 1999, DEVELOPMENT, V126, P443; Tsuda H, 1998, J BIOL CHEM, V273, P6327, DOI 10.1074/jbc.273.11.6327; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	46	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19083	19089		10.1074/jbc.M001075200	http://dx.doi.org/10.1074/jbc.M001075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858455	hybrid			2022-12-25	WOS:000087815900062
J	Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F				Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F			Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines	ONCOGENE			English	Article						anti-cancer drug; FTI; Cdk inhibitor; apoptosis	FARNESYL-PROTEIN TRANSFERASE; CYCLIN-DEPENDENT KINASES; RAS-TRANSFORMED CELLS; TRANSGENIC MICE; SELECTIVE-INHIBITION; CYTOCHROME-C; TUMOR-CELLS; GROWTH; DEATH; ACTIVATION	Farnesyltransferase inhibitor (FTI) induces apoptosis of transformed cells. This involves changes in mitochondria, including decrease of mitochondrial membrane potential and the release of cytochrome c, The released cytochrome c then induces events leading to the activation of caspase-3, In this study, we report that purine derivative cyclin-dependent kinase (Cdk) inhibitors, roscovitine and olomoucine, dramatically enhance this FTI-induced apoptosis of human cancer cell lines. We noticed the synergy between Cdk inhibitors and FTI through our screen to identify compounds that enhance FTI-induced apoptosis of promyelocytic leukemic cell line HL-60, The Cdk inhibitors by themselves do not induce apoptosis at the concentrations used, Roscovitine synergizes with FTI to release cytochrome c from mitochondria, In addition, we detected synergistic effects of FTI and roscovitine to inhibit hyperphosphorylation of retinoblastoma protein. Enhancement of FTI-induced apoptosis by roscovitine is not unique to HL-60 cells, since similar synergy was observed with a leukemic cell line CEM and a prostate cancer cell line LNCaP, In LNCaP cells, in addition to roscovitine and olomoucine, phophatidylinositol 3-kinase (PI 3-kinase) inhibitor, LY294002, was effective in enhancing FTI-induced apoptosis, However, the effects of roscovitine appear to be distinct from those of LY294002, since roscovitine did not affect Akt activity while LY294002 significantly decreased the activity of Akt, Our finding of the synergy between FTI and Cdk inhibitor is significant for understanding the mechanism of action of FTI as well as for clinical use of FTI.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA.			Edamatsu, Hironori/0000-0002-1335-4217	NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DER CJ, 1996, ANTI-CANCER DRUG, V7, P165; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Du W, 1999, CANCER RES, V59, P4208; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; Hung WC, 1998, INT J ONCOL, V12, P137; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Liu M, 1998, CANCER RES, V58, P4947; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; NAGASU T, 1995, CANCER RES, V55, P5310; Norgaard P, 1999, CLIN CANCER RES, V5, P35; OKADA T, 1994, J BIOL CHEM, V269, P3563; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Strickland CL, 1999, J MED CHEM, V42, P2125, DOI 10.1021/jm990030g; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	100	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3059	3068		10.1038/sj.onc.1203625	http://dx.doi.org/10.1038/sj.onc.1203625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871858				2022-12-25	WOS:000087903900003
J	Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T				Giannakakou, P; Poy, G; Zhan, ZR; Knutsen, T; Blagosklonny, MV; Fojo, T			Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer	ONCOGENE			English	Article						paclitaxel; p53; tubulin; drug resistance; human cancer	ANTICANCER-DRUG; P53-EXPRESSING ADENOVIRUS; GENOMIC INSTABILITY; HUMAN-CELLS; GENE; TAXOL; SENSITIVITY; CHECKPOINT; EXPRESSION; APOPTOSIS	The efficacy of anticancer therapy is limited by the development of drug resistance. While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed. In this study me examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired P-tubulin mutations which impair paclitaxel's interaction with tubulin, In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive. Two of the resistant sublines expressed high levels of transcriptionally inactive p53 protein, each with a distinct point mutation in codons 236 and 239 of the DNA binding domain. The third subline presented a novel p53 pseudo-null phenotype as a result of markedly decreased wt p53 mRNA expression, Introduction of ectopic wt p53 had no effect on PTX sensitivity in both parental and resistant cells, while it induced p21(WAF1/CIP1), demonstrating an intact p53 pathway, While PTX resistance is primarily conferred by the tubulin mutations, the loss of functional p53 observed in all clones, suggests that this loss may facilitate the development of resistance potentially by providing a clonal advantage which promotes the isolation of paclitaxel resistant cells.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Giannakakou, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X				Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1998, J CLIN ENDOCR METAB, V83, P2516, DOI 10.1210/jc.83.7.2516; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Debernardis D, 1997, CANCER RES, V57, P870; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAVRE PA, 1995, CANCER RES, V55, P4420; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; KASTAN MB, 1991, CANCER RES, V51, P6304; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu PK, 1996, ONCOGENE, V12, P2267; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIYASHITA T, 1995, CELL, V80, P293; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OConnor PM, 1997, CANCER RES, V57, P4285; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	33	60	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3078	3085		10.1038/sj.onc.1203642	http://dx.doi.org/10.1038/sj.onc.1203642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871860	Green Submitted			2022-12-25	WOS:000087903900005
J	Reddy, TR				Reddy, TR			A single point mutation in the nuclear localization domain of Sam68 blocks the Rev/RRE-mediated transactivation	ONCOGENE			English	Article						Sam68; nuclear localization signal; RRE-mediated transactivation; HIV-1 inhibition	RNA-BINDING PROTEIN; KH DOMAIN; HIV-1 REV; SRC; MITOSIS; REPLICATION; GENE	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, we have shown that the C-terminal deletion mutants of Sam68 act with a transdominant negative phenotype in HIV replication, Previously, an Arginine429 mutation within the C-terminal domain of Sam68 has been reported to be critical for the localization of Sam68 in the nucleus. However, these studies were done in the context of truncated protein in which C-terminal amino acids 420-443 of Sam68 were fused to GFP. In contrast, we now report that the full length Sam68 protein having the same mutation (Arginine429 --> Alanine) is completely localized in the nucleus while another Sam68 (Proline439-->Arginine) mutant is found in the cytoplasm. The localization of these Sam68 mutant proteins also correlates,vith their function in RRE-mediated reporter gene expression, i.e. Sam68 mutant protein that is localized in the cytoplasm failed to enhance RRE-mediated transactivation. Furthermore, we demonstrate that Sam68 P439-->R inhibited the transactivation of RRE-mediated gene expression by both wild type Sam68 and Rev. These results indicate that the proline residue at position 439 unlike arginine at position 429, mag play a critical role in targeting Sam68 protein to nucleus. We propose that these negative dominant mutants of Sam68 may have potential as anti-viral agents to combat AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30AI36214-06] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0	15	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3110	3114		10.1038/sj.onc.1203637	http://dx.doi.org/10.1038/sj.onc.1203637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871864				2022-12-25	WOS:000087903900009
J	Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M				Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M			Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis	ONCOGENE			English	Article						H-ras mutant; skin papilloma; chemical carcinogenesis	CHEMICAL CARCINOGENESIS; MALIGNANT PROGRESSION; ANIMAL-MODEL; KI-RAS; ACTIVATION; INITIATION; ONCOGENES; MICE; MUTAGENESIS; MUTATIONS	To clarify the role of the H-Ras in vivo, we generated H-ras null mutant mice by gene targeting. In spite of the importance of the Ras in cell proliferation and differentiation, H-ras null mutant mice grew normally and were fertile. The oldest H-ras mutant mice grew to be more than 30 months old. We used the H-ras deficient mice to study the importance of the H-ras and other ras genes in the development of skin tumors induced by initiation with 7,12-dimethylbenz(a)anthracene (DMBA) followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), We showed that H-ras null mutant mice develop approximately six times less papillomas compared with wild-type littermates after 20 weeks of TPA treatment. While all papillomas examined (17 out of 17) in wild-type mice have mutations of H-ras at codon 61, 13 (62%) out of 21 papillomas in H-ras null mutant mice have mutations of K-vas gene at codon 12, 13, or 61 and another eight (38%) papillomas have no mutations in these codons of K-ras or N-ras genes. This suggests that the activation of H-ras gene is critical in the wild-type mice, but the activation of K-ras gene can replace the H-ras activation in the initiation step of skin tumor development in the H-ras deficient mice.	Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, Tokyo 1088638, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Core Res Evolut Sci & Technol, Tokyo 1088639, Japan; Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Cell Biol, Fukuoka 8128582, Japan; Med Ctr Canc & Cardiovasc Dis, Osaka 5378511, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2440804, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo; Kyushu University; RIKEN	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088638, Japan.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; zhong wei, he gui/0000-0002-3066-3564; Aiba, Atsu/0000-0002-8192-0778; Ichise, Taeko/0000-0002-1441-1463				BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROOKES P, 1988, MOL CARCINOGEN, V1, P82, DOI 10.1002/mc.2940010203; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HECKER E, 1982, CARCINOGENESIS COMPR; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANAM S, 1992, CANCER RES, V52, P3347; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	26	103	104	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2951	2956		10.1038/sj.onc.1203600	http://dx.doi.org/10.1038/sj.onc.1203600			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871846				2022-12-25	WOS:000087581400001
J	Norlin, M; Andersson, U; Bjorkhem, I; Wikvall, K				Norlin, M; Andersson, U; Bjorkhem, I; Wikvall, K			Oxysterol 7 alpha-hydroxylase activity by cholesterol 7 alpha-hydroxylase (CYP7A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BILE-ACID BIOSYNTHESIS; NUCLEAR RECEPTOR LXR; STEROL 27-HYDROXYLASE; MOLECULAR-CLONING; SIDE-CHAIN; 27-HYDROXYCHOLESTEROL; IDENTIFICATION; PATHWAY; BRAIN	A 7 alpha -hydroxylation is necessary for conversion of both cholesterol and 27-hydroxycholesterol into bile acids. According to current, theories, cholesterol 7 alpha -hydroxylase (CYP7A) is responsible for the former and oxysterol 7 alpha -hydroxylase (CYP7B) for the latter reaction. CYP7A is believed to have a very high substrate specificity whereas CYP7B is active toward oxysterols, dehydroepiandrosterone, and pregnenolone, In the present study, 7 alpha -hydroxylation of various oxysterols in liver and kidney was investigated. Surprisingly, human cholesterol 7 alpha -hydroxylase, CYP7A, expressed as a recombinant in Escherichia coli and COS cells, was active toward 20(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol, This enzyme has previously been thought to be specific for cholesterol and cholestanol, A partially purified and reconstituted cholesterol 7 alpha -hydroxylase enzyme fraction from pig liver showed 7 alpha -hydroxylase activity toward the same oxysterols as metabolized by expressed recombinant human and rat CYP7A. The 7 alpha -hydroxylase activity toward 20(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol in rat Liver was significantly increased by treatment with cholestyramine, an inducer of CYP7A From the present results it may be concluded that CYP7A is able to function as an oxysterol 7 alpha -hydroxylase, in addition to the previously known human oxysterol 7 alpha -hydroxylase, CYP7B. These findings may have implications for oxysterol-mediated regulation of gene expression and for pathways of bile acid biosynthesis, A possible use of 20(S)-hydroxycholesterol as a marker substrate for CYP7A is proposed.	Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, S-75123 Uppsala, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, S-14186 Huddinge, Sweden	Uppsala University; Karolinska Institutet	Norlin, M (corresponding author), Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, Box 578, S-75123 Uppsala, Sweden.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190; Norlin, Maria/0000-0003-4348-6269				ANDERSON CD, 1985, PHOTODERMATOLOGY, V2, P111; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; Babiker A, 1999, J LIPID RES, V40, P1417; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BROWN MJG, 1974, EUR J BIOCHEM, V44, P37, DOI 10.1111/j.1432-1033.1974.tb03455.x; Coon M J, 1978, Methods Enzymol, V52, P109; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JOHANSSO.G, 1970, EUR J BIOCHEM, V17, P292, DOI 10.1111/j.1432-1033.1970.tb01167.x; KARAM WG, 1994, J LIPID RES, V35, P1222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND E, 1992, J BIOL CHEM, V267, P12462; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; Norlin M, 1998, BBA-LIPID LIPID MET, V1390, P269, DOI 10.1016/S0005-2760(97)00193-8; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; Parish EJ, 1999, CRIT REV BIOCHEM MOL, V34, P265, DOI 10.1080/10409239991209291; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SCHEER I, 1956, J AM CHEM SOC, V78, P4733, DOI 10.1021/ja01599a054; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SCHWARTZ MA, 1983, J LIPID RES, V24, P28; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TOLL A, 1992, FEBS LETT, V296, P73, DOI 10.1016/0014-5793(92)80406-7; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu ZL, 1999, J LIPID RES, V40, P2195; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZHANG J, 1995, CR ACAD SCI III-VIE, V318, P345	42	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34046	34053		10.1074/jbc.M002663200	http://dx.doi.org/10.1074/jbc.M002663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10882719	hybrid			2022-12-25	WOS:000165095300009
J	Kopf, E; Plassat, JL; Vivat, V; de The, H; Chambon, P; Rochette-Egly, C				Kopf, E; Plassat, JL; Vivat, V; de The, H; Chambon, P; Rochette-Egly, C			Dimerization with retinoid x receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LIGAND-BINDING DOMAIN; TERATOCARCINOMA STEM-CELLS; ACTIVATION FUNCTION AF-1; RAR-ALPHA; NUCLEAR RECEPTORS; F9 CELLS; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; TRANSCRIPTION FACTOR	In eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for targeted degradation of proteins. We show that, in F9 cells and in transfected COS-I cells, the nuclear retinoid receptors, retinoic acid receptor gamma2 (RAR gamma2), RAR alpha1, and retinoid X receptor alpha1 (RXR alpha1) are degraded in a retinoic acid-dependent manner through the ubiquitin-proteasome pathway. The degradation of RAR gamma2 is entirely dependent on its phosphorylation and an its heterodimerization with liganded RXR alpha1. In contrast. RAR alpha1 degradation can occur in the absence of heterodimerization, whereas it is inhibited by phosphorylation, and heterodimerization reverses that inhibition. RXR alpha1 degradation is also modulated by heterodimerization. Thus, each partner of RAR gamma /RXR alpha and RAR alpha /RXR alpha heterodimers modulates the degradation of the other. We conclude that the ligand-dependent degradation of RARs and RXRs by the ubiquitin-proteasome pathway, which is regulated by heterodimerization and by phosphorylation, could be important for the regulation of the magnitude and duration of the effects of retinoid signals.	Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, F-67404 Illkirch Graffenstaden, France; Hop St Louis, CNRS, UPR 9051, F-75475 Paris 10, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Rochette-Egly, C (corresponding author), Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Haas AL, 1997, FASEB J, V11, P1257; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Rubin DM, 1997, MOL BIOL REP, V24, P17; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Scita G, 1996, J BIOL CHEM, V271, P6502, DOI 10.1074/jbc.271.11.6502; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WILLY PJ, 1999, HORMONE SIGNALING, P307; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	69	123	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33280	33288		10.1074/jbc.M002840200	http://dx.doi.org/10.1074/jbc.M002840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10869350	hybrid			2022-12-25	WOS:000090104600017
J	Clabecq, A; Henry, JP; Darchen, F				Clabecq, A; Henry, JP; Darchen, F			Biochemical characterization of Rab3-GTPase-activating protein reveals a mechanism similar to that of Ras-GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TRANSITION-STATE ANALOG; STRUCTURAL BASIS; CA2+-DEPENDENT EXOCYTOSIS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; RAB3 SUBFAMILY; BINDING; COMPLEX; IDENTIFICATION	Small G proteins of the Rab family are regulators of intracellular vesicle traffic. Their intrinsic rate of GTP hydrolysis is very low but is enhanced by specific GTPase-activating proteins (GAPs) that switch G proteins to their inactive form. We have characterized the activity of recombinant Rab3-GAP on Rab3A in solution. The K-m and K-d values (75 mu M) indicate a low affinity of Rab3-GAP for its substrate. The affinity is higher for the transition state analog Rab3A:GDP:AlFX (15 mu M). The k(cat) (1 s(-1)) is within the range of values reported for other GAPs. A mutation in the switch I region of Rab3A disrupted the interaction with Rab3-GAP. Furthermore, Rabphilin, a putative target of Rab3, inhibited the activity of Rab3-GAP on Rab3, Therefore, the Rab3-GAP-binding site involves the switch I region of Rab3 and overlaps with the Rabphilin-binding domain. Substitution of a single arginine residue (Arg-728) of Rab3-GAP disrupted its catalytic activity but not its interaction with Rab3A We propose that Rab3-GAP, like Ras- and Rho-GAPs, stabilizes the transition state of Rab3 and provides a critical arginine residue to accelerate the GTPase reaction.	Inst Biol Physicochim, CNRS, UPR 1929, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Darchen, F (corresponding author), Inst Biol Physicochim, CNRS, UPR 1929, 13 Rue P & M Curie, F-75005 Paris, France.							Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Johannes L, 1996, EUR J BIOCHEM, V239, P362, DOI 10.1111/j.1432-1033.1996.0362u.x; Johannes L, 1998, J NEUROCHEM, V71, P1127; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Jones S, 1998, MOL BIOL CELL, V9, P2819, DOI 10.1091/mbc.9.10.2819; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOLLOY DP, 1995, FEBS LETT, V368, P297, DOI 10.1016/0014-5793(95)00657-U; Nagano F, 1998, J BIOL CHEM, V273, P24781, DOI 10.1074/jbc.273.38.24781; Oishi H, 1998, J BIOL CHEM, V273, P34580, DOI 10.1074/jbc.273.51.34580; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vollmer P, 1999, EUR J BIOCHEM, V260, P284, DOI 10.1046/j.1432-1327.1999.00192.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	43	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31786	31791		10.1074/jbc.M003705200	http://dx.doi.org/10.1074/jbc.M003705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10859313	hybrid			2022-12-25	WOS:000089858900035
J	Pluskota, E; Chen, YM; D'Souza, SE				Pluskota, E; Chen, YM; D'Souza, SE			Src homology domain 2-containing tyrosine phosphatase 2 associates with intercellular adhesion molecule 1 to regulate cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; FIBRINOGEN BINDING; PROTEIN; RECEPTOR; ICAM-1; ACTIVATION; SHP-2; INTEGRIN	Intercellular adhesion molecule-1 (ICAM-1) binds to the plasma protein fibrinogen (Fg) to mediate leukocyte/ endothelial cell interactions. In our studies, the ligation of Fg to ICAM-1 on tumor necrosis factor-alpha-stimulated endothelial cells resulted in the tyrosine phosphorylation of Src homology domain 2 (SH2)-containing phosphatase-2 (SHP-2). The ICAM-1 cytoplasmic sequence IKKYRLQ conforms poorly to the concensus immunoreceptor tyrosine based inhibition motifs found in receptors that bind SHP-2. Nevertheless, the tyrosine phosphorylated sequence (IKKpYRLQ) bound specifically to the SH2 domain proximal to the NH2-terminal of SHP-2 (SHP-2-N) but not to the SH2 domain proximal on the COOH-terminal side (SHP-2-C). Phosphorylated ICAM-1 bound SHP-2-N. In immunoprecipitation experiments, SHP-2 associated with phosphorylated ICAM-1. Cells expressing truncated ICAM-1 that lacked the cytoplasmic sequence (ICAM-1(TR)) failed to associate with SHP-2. ICAM-1 containing the tyrosine to alanine substitution at position 485 (ICAM-1(Y485A)) associated weakly with SHP-2. Cells expressing ICAM-1(TR) and ICAM-1(Y485A) underwent apoptosis upon adhesion to Fg, whereas the wild type ICAM-1 maintained cell survival. These results indicate that ICAM-1 interactions with SHP-2 allow better cellular survival mediated through Fg-ICAM-1 ligation.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	D'Souza, SE (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Lerner Res Inst, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.				NCRR NIH HHS [RR-00080] Funding Source: Medline; NHLBI NIH HHS [HL 43721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043721, R29HL043721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson P, 1999, J IMMUNOL, V162, P2964; ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DSouza SE, 1996, J BIOL CHEM, V271, P24270, DOI 10.1074/jbc.271.39.24270; Duperray A, 1997, J BIOL CHEM, V272, P435; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne S, 1998, J IMMUNOL, V161, P5755; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Gardiner EE, 1999, J BIOL CHEM, V274, P11930, DOI 10.1074/jbc.274.17.11930; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holland J, 1997, J BIOL CHEM, V272, P9108; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Huyer G, 1999, CURR BIOL, V9, pR129, DOI 10.1016/S0960-9822(99)80080-3; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Olcese L, 1996, J IMMUNOL, V156, P4531; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Philosof-Oppenheimer R, 2000, EUR J BIOCHEM, V267, P703, DOI 10.1046/j.1432-1327.2000.01044.x; Pluskota E, 1999, BLOOD, V94, p226A; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; vandeStolpe A, 1996, THROMB HAEMOSTASIS, V75, P182; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035	54	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30029	30036		10.1074/jbc.M000240200	http://dx.doi.org/10.1074/jbc.M000240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10864922	hybrid			2022-12-25	WOS:000089577900016
J	Kampranis, SC; Damianova, R; Atallah, M; Toby, G; Kondi, G; Tsichlis, PN; Makris, AM				Kampranis, SC; Damianova, R; Atallah, M; Toby, G; Kondi, G; Tsichlis, PN; Makris, AM			A novel plant glutathione S-transferase/peroxidase suppresses Bax lethality in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; PROGRAMMED CELL-DEATH; PROAPOPTOTIC PROTEIN BAX; MAMMALIAN-CELLS; HYPERSENSITIVE RESPONSE; MITOCHONDRIAL CONTROL; HYDROGEN-PEROXIDE; FATTY-ACIDS; APOPTOSIS; TRANSFERASES	The mammalian inducer of apoptosis Bax is lethal when expressed in yeast and plant cells. To identify potential inhibitors of Bax in plants we transformed yeast cells expressing Bax with a tomato cDNA library and we selected for cells surviving after the induction of Bax. This genetic screen allows for the identification of plant genes, which inhibit either directly or indirectly the lethal phenotype of Bax. Using this method a number of cDNA clones were isolated, the more potent of which encodes a protein homologous to the class theta glutathione S-transferases. This Bax-inhibiting (BI) protein was expressed in Escherichia coli and found to possess glutathione S-transferase (GST) and weak glutathione peroxidase (GPX) activity. Expression of Bax in yeast decreases the intracellular levels of total glutathione, causes a substantial reduction of total cellular phospholipids, diminishes the mitochondrial membrane potential, and alters the intracellular redox potential. Co-expression of the BI-GST/GPX protein brought the total glutathione levels back to normal and re-established the mitochondrial membrane potential but had no effect on the phospholipid alterations. Moreover, expression of BI-GST/GPX in yeast was found to significantly enhance resistance to H2O2-induced stress. These results underline the relationship between oxidative stress and Bax-induced death in yeast cells and demonstrate that the yeast-based genetic strategy described here is a powerful tool for the isolation of novel antioxidant and anti-apoptotic genes.	Mediterranean Agron Inst Chania, Alsyll Agrokep, Khania 73100, Greece; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	CIHEAM; CIHEAM IAM Chania; Fox Chase Cancer Center; Jefferson University	Kampranis, SC (corresponding author), Mediterranean Agron Inst Chania, Alsyll Agrokep, POB 85, Khania 73100, Greece.		Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684	NCI NIH HHS [R01CA57436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Asoh S, 1998, J BIOL CHEM, V273, P11384, DOI 10.1074/jbc.273.18.11384; BARRY MA, 1993, CANCER RES, V53, P2349; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Callard D, 1996, PLANT PHYSIOL, V112, P705, DOI 10.1104/pp.112.2.705; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GODIARD L, 1994, CURR OPIN GENET DEV, V4, P662, DOI 10.1016/0959-437X(94)90132-M; Golemis E A, 1997, Methods Mol Biol, V63, P197; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; KOMAGATA K, 1987, METHOD MICROBIOL, V19, P161; KOPRIVA S, 1995, PLANT PHYSIOL, V107, P271, DOI 10.1104/pp.107.1.271; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MITTLER R, 1995, PLANT PHYSIOL, V108, P489, DOI 10.1104/pp.108.2.489; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Richberg MH, 1998, CURR OPIN PLANT BIOL, V1, P480, DOI 10.1016/S1369-5266(98)80039-3; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; SATO N, 1995, J IMMUNOL, V154, P3194; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; UCKER DS, 1991, NEW BIOL, V3, P103; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WELCH JW, 1973, J BACTERIOL, V115, P464, DOI 10.1128/JB.115.1.464-466.1973; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	57	176	202	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29207	29216		10.1074/jbc.M002359200	http://dx.doi.org/10.1074/jbc.M002359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10859306	hybrid			2022-12-25	WOS:000089439800006
J	Kronman, C; Chitlaru, T; Elhanany, E; Velan, B; Shafferman, A				Kronman, C; Chitlaru, T; Elhanany, E; Velan, B; Shafferman, A			Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins - Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; RECOMBINANT HUMAN ACETYLCHOLINESTERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; HAMSTER OVARY CELLS; MOLECULAR-FORMS; MASS-SPECTROMETRY; ACTIVE-CENTER; HUMAN BUTYRYLCHOLINESTERASE; QUATERNARY ASSOCIATIONS; MONOCLONAL-ANTIBODIES	The tetrameric form of native serum-derived bovine acetylcholinesterase is retained in the circulation for much longer periods (mean residence time, MRT = 1390 min) than recombinant bovine acetylcholinesterase (rBoAChE) produced in the HEK-293 cell system (MRT = 57 min). Extensive matrix-assisted laser desorption ionization-time of flight analyses established that the basic structures of the N-glycans associated with the native and recombinant enzymes are similar (the major species (50-60%) are of the biantennary fucosylated type and 20-30% are of the triantennary type), yet the glycan termini of the native enzyme are mostly capped with sialic acid (82%) and alpha-galactose (12%), whereas glycans of the recombinant enzyme exhibit a high level of exposed beta-galactose residues (50%) and a lack of alpha-galactose, Glycan termini of both fetal bovine serum and rBoAChE were altered in vitro using exoglycosidases and sialyltransferase or in vivo by a HEK-293 cell line developed specifically to allow efficient sialic acid capping of beta-galactose-exposed termini, In addition, the dimeric and monomeric forms of rBoAChE were quantitatively converted to tetramers by complexation with a synthetic peptide representing the human ColQ-derived proline-rich attachment domain. Thus by controlling both the level and nature of N-glycan capping and subunit assembly, we generated and characterized 9 distinct bovine AChE glycoforms displaying a 400-fold difference in their circulatory lifetimes (MRT = 3.5-1390 min). This revealed some general rules and a hierarchy of post-translation factors determining the circulatory profile of glycoproteins, Accordingly, an rBoAChE was generated that displayed a circulatory profile indistinguishable from the native form.	Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-74100 Ness Ziona, Israel		Shafferman, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-74100 Ness Ziona, Israel.	avigdor@iibr.gov.il						ALLEMAND P, 1981, J NEUROCHEM, V36, P860, DOI 10.1111/j.1471-4159.1981.tb01673.x; Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; ASHANI Y, 1991, BIOCHEM PHARMACOL, V41, P37, DOI 10.1016/0006-2952(91)90008-S; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; ATACK JR, 1987, J NEUROCHEM, V48, P1845, DOI 10.1111/j.1471-4159.1987.tb05746.x; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BORREBAECK CAK, 1993, IMMUNOL TODAY, V14, P477, DOI 10.1016/0167-5699(93)90259-N; Borrebaeck CAK, 1999, NAT BIOTECHNOL, V17, P621, DOI 10.1038/10798; Bourne Y, 1999, J BIOL CHEM, V274, P30370, DOI 10.1074/jbc.274.43.30370; Chitlaru T, 1998, BIOCHEM J, V336, P647, DOI 10.1042/bj3360647; Douchet J.-C., 1982, TRAV SCI, V3, P342; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FISCHER M, 1993, CELL MOL NEUROBIOL, V13, P25, DOI 10.1007/BF00712987; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Giles K, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P442; HOSSNER KL, 1981, ENDOCRINOLOGY, V108, P1780, DOI 10.1210/endo-108-5-1780; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Junghans RP, 1999, NAT BIOTECHNOL, V17, P938, DOI 10.1038/13593; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRONMAN C, 1995, BIOCHEM J, V311, P959, DOI 10.1042/bj3110959; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Laub PB, 1996, J PHARM SCI, V85, P393, DOI 10.1021/js9503744; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LEFORT GP, 1984, ENDOCRINOLOGY, V115, P1551, DOI 10.1210/endo-115-4-1551; LEGAY C, 1993, FEBS LETT, V315, P163, DOI 10.1016/0014-5793(93)81155-S; LOCKRIDGE O, 1982, J BIOL CHEM, V257, P2012; Massoulie J, 1999, CHEM-BIOL INTERACT, V119, P29, DOI 10.1016/S0009-2797(99)00011-3; MAXWELL DM, 1992, TOXICOL APPL PHARM, V115, P44, DOI 10.1016/0041-008X(92)90365-Y; Mendelson I, 1998, BIOCHEM J, V334, P251, DOI 10.1042/bj3340251; Millard CB, 1998, BIOCHEMISTRY-US, V37, P237, DOI 10.1021/bi972057c; Monica TJ, 1997, GLYCOBIOLOGY, V7, P515, DOI 10.1093/glycob/7.4.515; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Okafo G, 1996, ANAL CHEM, V68, P4424, DOI 10.1021/ac960721+; Okafo G, 1997, ANAL CHEM, V69, P4985, DOI 10.1021/ac9707139; Ordentlich A, 1999, BIOCHEMISTRY-US, V38, P3055, DOI 10.1021/bi982261f; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; Powell AK, 1996, RAPID COMMUN MASS SP, V10, P1027; RALSTON JS, 1985, J BIOL CHEM, V260, P4312; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; Rowland M, 2011, CLIN PHARMACOKINET, V4, P201; Saxena A, 1998, MOL PHARMACOL, V53, P112, DOI 10.1124/mol.53.1.112; Saxena A, 1997, BIOCHEMISTRY-US, V36, P7481, DOI 10.1021/bi963156d; Shafferman A, 1996, BIOCHEM J, V318, P833, DOI 10.1042/bj3180833; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; STIEGER S, 1989, J NEUROCHEM, V52, P1188, DOI 10.1111/j.1471-4159.1989.tb01865.x; TANIGAWARA Y, 1990, CHEM PHARM BULL, V38, P517, DOI 10.1248/cpb.38.517; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR PB, 1981, J BIOL CHEM, V256, P3827; THOMAS P, 1983, DIGEST DIS SCI, V28, P216, DOI 10.1007/BF01295116; VELAN B, 1991, J BIOL CHEM, V266, P23977; VIGNY M, 1979, J NEUROCHEM, V33, P559, DOI 10.1111/j.1471-4159.1979.tb05188.x; VOSTAL JG, 1991, THROMB RES, V63, P299, DOI 10.1016/0049-3848(91)90133-H; Weikert S, 1999, NAT BIOTECHNOL, V17, P1116, DOI 10.1038/15104; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Weiss P, 1989, Prog Clin Biol Res, V300, P169; WOLFE AD, 1987, FUND APPL TOXICOL, V9, P266, DOI 10.1016/0272-0590(87)90048-0; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	70	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29488	29502		10.1074/jbc.M004298200	http://dx.doi.org/10.1074/jbc.M004298200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10867010	hybrid			2022-12-25	WOS:000089439800043
J	Harris, VK; Coticchia, CM; List, HJ; Wellstein, A; Riegel, AT				Harris, VK; Coticchia, CM; List, HJ; Wellstein, A; Riegel, AT			Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HUMAN CANCERS; PROMOTER ELEMENTS; IN-VIVO; MYC; GENE; METHYLATION; USF; FAMILY; HYPOMETHYLATION	The fibroblast growth factor-binding protein (FGF-BP) stimulates FGP-2-mediated angiogenesis and is thought to play an important role in the progression of squamous cell, colon, and breast carcinomas, 12-O-Tetradecanoylphorbol-13-acetate (TPA) induction of the FGF-BP gene occurs through transcriptional mechanisms involving Sp1, AP-1, and CCAATT/enhancer-binding protein sites in the proximal FGF-BP gene promoter. The level of TPA induction, however, is limited due to the presence of a repressor element that shows similarity to a non-canonical E-box (AACGTG), Mutation or deletion of the repressor element led to enhanced induction by TPA or epidermal growth factor in cervical squamous cell and breast carcinoma cell lines. Repression was dependent on the adjacent AP-1 site, without discernible alteration in the binding affinity or composition of AP-1, We investigated the following two possible mechanisms for E-box-mediated repression: 1) CpG methylation of the core of the E-box element, and 2) binding of a distinct protein complex to this site. Point mutation of the CpG methylation site in the E-box showed loss of repressor activity. Conversely, in vitro methylation of this site significantly reduced TPA induction. In vitro gel shift analysis revealed distinct and TPA-dependent binding of USF1 and USF2 to the repressor element that required nucleotides within the E-box. Furthermore, chromatin immunoprecipitation assay showed that USF, c-Myc, and Max proteins were associated with the FGF-BP promoter in vivo, Overall, these findings suggested that the balance between trans-activation by AP-1 and repression through the E-box is an important control mechanism for fine-tuning the angiogenic response to growth factor-activated pathways.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Ctr, REs Bldg,Rm E307,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU DQ, 1991, J BIOL CHEM, V266, P16778	28	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28539	28548		10.1074/jbc.M001677200	http://dx.doi.org/10.1074/jbc.M001677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871606	hybrid			2022-12-25	WOS:000089330700029
J	Hazebrouck, S; Camoin, L; Faltin, Z; Strosberg, AD; Eshdat, Y				Hazebrouck, S; Camoin, L; Faltin, Z; Strosberg, AD; Eshdat, Y			Substituting selenocysteine for catalytic cysteine 41 enhances enzymatic activity of plant phospholipid hydroperoxide glutathione peroxidase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; UGA CODON; THIOREDOXIN REDUCTASE; FORMATE DEHYDROGENASE; SECIS ELEMENTS; GENE; PROTEIN; INSERTION; CITRUS; STRESS	The citrus phospholipid hydroperoxide glutathione peroxidase (cit-PHGPx) was the first plant peroxidase demonstrated to exhibit PHGPx-specific enzymatic activity, although it was 500-fold weaker than that of the pig heart analog. This relatively low activity is accounted for the catalytic residue of cit-PHGPx, which was found to be cysteine and not the rare selenocysteine (Sec) present in animal enzymes. Sec incorporation into proteins is encoded by a UGA codon, usually a STOP codon, which, in prokaryotes, is suppressed by an adjacent downstream mRNA stem-loop structure, the Sec insertion sequence (SECIS). By performing appropriate nucleotide substitutions into the gene encoding cit-PHGPx, we introduced bacterial-type SECIS elements that afforded the substitution of the catalytic Cys(41) by Sec, as established by mass spectrometry, while preserving the functional integrity of the peroxidase. The recombinant enzyme, whose synthesis is selenium-dependent, displayed a 4-fold enhanced peroxidase activity as compared with the Cys-containing analog, thus confirming the higher catalytic power of Sec compared with Cys in cit-PHGPx active site. The study led also to refinement of the minimal sequence requirements of the bacterial-type SECIS, and, for the first time, to the heterologous expression in Escherichia coli of a eukaryotic selenoprotein containing a SECIS in its open reading frame.	Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel; Inst Cochin Genet Mol, CNRS UPR 415, F-75014 Paris, France	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Eshdat, Y (corresponding author), Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, POB 6, IL-50250 Bet Dagan, Israel.		Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787				Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Baron Christian, 1995, P529; BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BENHAYYIM G, 1993, PLANT SCI, V88, P129, DOI 10.1016/0168-9452(93)90084-D; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Boschi-Muller S, 1998, FEBS LETT, V439, P241, DOI 10.1016/S0014-5793(98)01377-5; CHEN GT, 1992, MOL MICROBIOL, V6, P781, DOI 10.1111/j.1365-2958.1992.tb01528.x; CHU FF, 1992, BLOOD, V79, P3233; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Faltin Z, 1998, PHYSIOL PLANTARUM, V104, P741, DOI 10.1034/j.1399-3054.1998.1040432.x; Flohe L., 1982, LIPID PEROXIDES BIOL, P149; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HOLLAND D, 1994, FEBS LETT, V337, P52, DOI 10.1016/0014-5793(94)80628-4; Kromayer M, 1996, J MOL BIOL, V262, P413, DOI 10.1006/jmbi.1996.0525; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Liu JQ, 1998, BIOTECHNOL LETT, V20, P693, DOI 10.1023/A:1005378709179; Liu ZS, 1998, NUCLEIC ACIDS RES, V26, P896, DOI 10.1093/nar/26.4.896; Liu ZS, 1999, J MOL BIOL, V294, P1073, DOI 10.1006/jmbi.1999.3307; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Sandman KE, 2000, NUCLEIC ACIDS RES, V28, P755, DOI 10.1093/nar/28.3.755; SHEN QC, 1993, J BIOL CHEM, V268, P11463; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Tormay P, 1997, J BACTERIOL, V179, P576, DOI 10.1128/jb.179.3.576-582.1997; Tormay P, 1996, MOL MICROBIOL, V21, P1253, DOI 10.1046/j.1365-2958.1996.881450.x; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wilting R, 1998, ARCH MICROBIOL, V169, P71; ZINONI F, 1987, P NATL ACAD SCI USA, V84, P3156, DOI 10.1073/pnas.84.10.3156; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	38	60	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28715	28721		10.1074/jbc.M004985200	http://dx.doi.org/10.1074/jbc.M004985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874045	hybrid			2022-12-25	WOS:000089330700052
J	Chauhan, D; Pandey, P; Hideshima, T; Treon, S; Raje, N; Davies, FE; Shima, Y; Tai, YT; Rosen, S; Avraham, S; Kharbanda, S; Andersons, KC				Chauhan, D; Pandey, P; Hideshima, T; Treon, S; Raje, N; Davies, FE; Shima, Y; Tai, YT; Rosen, S; Avraham, S; Kharbanda, S; Andersons, KC			SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; ADHESION KINASE; PYK2; PATHWAY; IDENTIFICATION; EXPRESSION; MECHANISM	Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. However, the mechanism whereby IL-6 inhibits Dex-induced apoptosis is undefined. In this study, we demonstrate that protein-tyrosine phosphatase SHP2 mediates this protective effect. me show that IL-6 triggers selective activation of SHP2 and its association with RAFTK in Dex-treated MM cells. SHP2 interacts with RAFTK through a region other than its Src homology 2 domains. We demonstrate that RAFTK is a direct substrate of SHP2 both in vitro and in vivo, and that Tyr(906) in the C-terminal domain of RAFTK mediates its interaction with SHP2. Moreover, overexpression of dominant negative SHP2 blocked the protective effect of IL-6 against Dex-induced apoptosis. These findings demonstrate that SHP2 mediates the anti-apoptotic effect of IL-6 and suggest SHP2 as a novel therapeutic target in MM.	Dana Farber Canc Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Andersons, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu		Davies, Faith/0000-0002-3971-2393	NCI NIH HHS [CA 50947, CA 75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947, R01CA075216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson K, 1999, SEMIN ONCOL, V26, P10; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HARDIN J, 1994, BLOOD, V84, P3063; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kim H, 1999, MOL CELL BIOL, V19, P5326; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MOALLI PA, 1992, BLOOD, V79, P213; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ogata A, 1997, J IMMUNOL, V159, P2212; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	36	154	162	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27845	27850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10880513				2022-12-25	WOS:000089197100045
J	Thomas, MG; Thompson, TB; Rayment, I; Escalante-Semerena, JC				Thomas, MG; Thompson, TB; Rayment, I; Escalante-Semerena, JC			Analysis of the adenosylcobinamide kinase/adenosylcobinamidephosphate guanylyltransferase (CobU) enzyme of Salmonella typhimurium LT2 - Identification of residue his-46 as the site of guanylylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS GUANYLYLTRANSFERASE; MESSENGER-RNA GUANYLYLTRANSFERASE; GTP-GTP GUANYLYLTRANSFERASE; BRINE SHRIMP ARTEMIA; RECA PROTEIN; PHOSPHATE GUANYLYLTRANSFERASE; ESCHERICHIA-COLI; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; GUANYLATE INTERMEDIATE	CobU is a bifunctional enzyme involved in adenosylcobalamin (coenzyme B-12) biosynthesis in Salmonella typhimurium LT2, In this bacterium, CobU is the adenosylcobinamide kinase/adenosyleobinamide-phosphate guanylyltransferase needed to convert cobinamide to adenosylcobinamide-GDP during the late steps of adenosylcobalamin biosynthesis, The guanylyltransferase reaction has been proposed to proceed via a covalently modified CobU-GMP intermediate. Here we show that CobU requires a nucleoside upper ligand on cobinamide for substrate recognition, with the nucleoside base, but not the 2'-OH group of the ribose, being important for this recognition. During the kinase reaction, both the nucleotide base and the 2'-OH group of the ribose are important for gamma-phosphate donor recognition, and GTP is the only nucleotide competent for the complete nucleotidyltransferase reaction, Analysis of the ATP:adenosylcobinamide kinase reaction shows CobU becomes less active during this reaction due to the formation of a covalent CobU-AMP complex that holds CobU in an altered conformation, Characterization of the GTP:adenosylcobinamide-phosphate guanylyltransferase reaction shows the covalent CobU-GMP intermediate is on the reaction pathway for the generation of adenosylcobinamide-GDP. Identification of a modified histidine and analysis of cobU mutants indicate that histidine 46 is the site of guanylylation.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Enzyme Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Thompson, Thomas/0000-0002-7041-5047	NIGMS NIH HHS [GM58218, GM40413, GM08293, R01 GM040313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHE F, 1991, J BACTERIOL, V173, P6052, DOI 10.1128/jb.173.19.6052-6057.1991; Brushaber KR, 1998, J BIOL CHEM, V273, P2684, DOI 10.1074/jbc.273.5.2684; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; Cartwright JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P101, DOI 10.1006/abbi.1998.0970; Ellouze C, 1999, EUR J BIOCHEM, V262, P88, DOI 10.1046/j.1432-1327.1999.00357.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GALLAGHER SR, 1996, CURRENT PROTOCOLS MO, V2; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; KAHN R, 1984, J BIOL CHEM, V259, P7495; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LIU JJ, 1994, J BIOL CHEM, V269, P11787; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; OTOOLE GA, 1996, ESCHERICHIA COLI SAL, V1, P710; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; RONZIO RA, 1967, BIOCHEMISTRY-US, V6, P2344, DOI 10.1021/bi00860a009; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; Schafer DA, 1998, CELL MOTIL CYTOSKEL, V39, P166, DOI 10.1002/(SICI)1097-0169(1998)39:2<166::AID-CM7>3.0.CO;2-4; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; Thompson TB, 1999, BIOCHEMISTRY-US, V38, P12995, DOI 10.1021/bi990910x; Thompson TB, 1998, BIOCHEMISTRY-US, V37, P7686, DOI 10.1021/bi973178f; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; Trzebiatowski JR, 1997, J BIOL CHEM, V272, P17662, DOI 10.1074/jbc.272.28.17662; Tuhackova Z, 1996, BIOCHEM BIOPH RES CO, V218, P61, DOI 10.1006/bbrc.1996.0012; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; YANG SLL, 1979, BIOCHEMISTRY-US, V18, P2980, DOI 10.1021/bi00581a011; [No title captured]	38	23	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27576	27586						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869342				2022-12-25	WOS:000089197100010
J	Bhattacharjee, G; Asplin, IR; Wu, SM; Gawdi, G; Pizzo, SV				Bhattacharjee, G; Asplin, IR; Wu, SM; Gawdi, G; Pizzo, SV			The conformation-dependent interaction of alpha(2)-macroglobulin with vascular endothelial growth factor - A novel mechanism of alpha(2)-macroglobulin/growth factor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RECOGNIZED ALPHA-2-MACROGLOBULIN; PROLIFERATIVE DIABETIC-RETINOPATHY; RHEUMATOID-ARTHRITIS; ALPHA-MACROGLOBULIN; PROTEASE INHIBITORS; HUMAN-PLASMA; FACTOR-BETA; FAST FORMS; SERUM; PROTEINS	alpha(2)-Macroglobulin (alpha(2)M) is a highly conserved proteinase inhibitor present in human plasma at high concentration (2-4 mg/ml), alpha(2)M exists in two conformations, a native form and an activated, receptor-recognized form. While alpha(2)M binds to numerous cytokines and growth factors, in most cases, the nature of the alpha(2)M interaction with these factors is poorly understood. We examined in detail the interaction between alpha(2)M and vascular endothelial growth factor (VEGF) and found a novel and unexpected mechanism of interaction as demonstrated by the following observations: 1) the binding of VEGF to alpha(2)M occurs at a site distinct from the recently characterized growth factor binding site; 2) VEGF binds different forms of alpha(2)M with distinct spatial arrangement, namely to the interior of methylamine or ammonia-treated alpha(2)M and to the exterior of native and proteinase-converted alpha(2)M; and 3) VEGF (molecular mass similar to 40 kDa) can access the interior of receptor-recognized alpha(2)M in the absence of proteinase trapped within the molecule. VEGF bound to receptor-recognized forms of alpha(2)M is internalized VEGF bound to receptor-recognized forms of alpha(2)M is internalize and degraded by macrophages via the alpha(2)M receptor, the low density lipoprotein receptor-related protein, Oxidation of both native and receptor-recognized alpha(2)M results in significant inhibition of VEGF binding. We also examined the biological significance of this interaction by studying the effect of alpha(2)M On VEGF-induced cell proliferation and VEGF-induced up-regulation of intracellular Ca2+ levels. We demonstrate that under physiological conditions, alpha(2)M does not impact the ability of VEGF to induce cell proliferation or up-regulate Ca2+.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.			Wu, Sean/0000-0002-0000-3821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; ADES EW, 1982, SCAND J IMMUNOL, V15, P109, DOI 10.1111/j.1365-3083.1982.tb00628.x; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bhattacharjee G, 1999, BBA-PROTEIN STRUCT M, V1432, P49, DOI 10.1016/S0167-4838(99)00072-2; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1989, J BIOL CHEM, V264, P5818; CAWSTON TE, 1987, BRIT J RHEUMATOL, V26, P354; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; CUMMINGS HS, 1983, ANN NY ACAD SCI, V421, P143, DOI 10.1111/j.1749-6632.1983.tb18101.x; CUMMINGS HS, 1984, BIOCHEMISTRY-US, V23, P105, DOI 10.1021/bi00296a017; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; Dean RT, 1997, BIOCHEM J, V324, P1; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GEOKAS MC, 1977, J BIOL CHEM, V252, P61; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Gron H, 1998, BIOCHEMISTRY-US, V37, P6009, DOI 10.1021/bi973027c; Gron H, 1996, BIOCHEM J, V318, P539, DOI 10.1042/bj3180539; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUSSAIN A, 1970, J PHARM SCI, V59, P1168, DOI 10.1002/jps.2600590824; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; KOCH AE, 1994, J IMMUNOL, V152, P4149; LAMARRE J, 1990, LAB INVEST, V62, P545; MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028; MATSUDA T, 1989, J IMMUNOL, V142, P148; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MULLERTZ S, 1974, BIOCHEM J, V143, P273; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSADA T, 1987, BIOCHEM BIOPH RES CO, V146, P26, DOI 10.1016/0006-291X(87)90685-1; PEJOVIC M, 1995, BRIT J RHEUMATOL, V34, P520; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RINDERKNECHT H, 1975, BIOCHIM BIOPHYS ACTA, V377, P158, DOI 10.1016/0005-2744(75)90296-X; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SOKER S, 1993, J BIOL CHEM, V268, P7685; STRAUSS S, 1992, LAB INVEST, V66, P223; TAKESHITA S, 1994, CIRCULATION, V90, P228; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; Webb DJ, 1998, J BIOL CHEM, V273, P13339, DOI 10.1074/jbc.273.21.13339; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265; Wu SM, 1997, J BIOL CHEM, V272, P20627, DOI 10.1074/jbc.272.33.20627; Wu SM, 1998, J IMMUNOL, V161, P4356	57	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26806	26811						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862607				2022-12-25	WOS:000089144800021
J	Bochkareva, E; Korolev, S; Bochkarev, A				Bochkareva, E; Korolev, S; Bochkarev, A			The role for zinc in replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING DOMAIN; 70-KDA SUBUNIT; CRYSTAL-STRUCTURE; A INTERACTIONS; METAL-IONS; FINGER; COMPLEXES; REVEALS; 3'-END	Heterotrimeric human single stranded DNA (ssDNA)binding protein, replication protein A (RPA), is a central player in DNA replication, recombination, and repair. The C terminus of the largest subunit, RPA70, contains a putative zinc-binding motif and is implicated in complex formation with two smaller subunits, RPA14 and RPA32, The C-terminal domain of RPA70 (RPA70-CTD) was characterized using proteolysis and x-ray fluorescence emission spectroscopy. The proteolytic core of this domain comprised amino acids 432-616, X-ray fluorescence spectra revealed that RPA70-CTD possesses a coordinated Zn(II). The trimeric complex of RPA70-CTD, the ssDNA-binding domain of RPA32 (amino acids 43-171), and RPA14 had strong DNA binding activity. When properly coordinated with zinc, the trimer's affinity to ssDNA was only 3-10-fold less than that of the ssDNA-binding domain in the middle of RPA70. However, the DNA-binding activity of the trimer was dramatically reduced in the presence of chelating agents. Our data indicate that (i) Zn(II) is essential to stabilize the tertiary structure of RPA70-CTD; (ii) RPA70-CTD possesses DNA-binding activity, which is modulated by Zn(II); and (iii) ssDNA binding by the trimer is a synergistic effect generated by the RPA70-CTD and RPA32.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; United States Department of Energy (DOE); Argonne National Laboratory	Bochkarev, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC-466, Oklahoma City, OK 73190 USA.		Korolev, Sergey/ABA-7517-2020	Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061192] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61192-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BEARDEN JA, 1967, REV MOD PHYS, V39, P78, DOI 10.1103/RevModPhys.39.78; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; DEWALD HD, 1986, ANAL CHEM, V58, P2968, DOI 10.1021/ac00127a016; Dong JW, 1999, BIOCHEM J, V337, P311, DOI 10.1042/0264-6021:3370311; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HAINAUT P, 1993, CANCER RES, V53, P1739; Hard T, 2000, J MOL BIOL, V296, P169, DOI 10.1006/jmbi.1999.3433; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	33	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27332	27338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856290				2022-12-25	WOS:000089144800089
J	Leitolf, H; Tong, KPT; Grossmann, M; Weintraub, BD; Szkudlinski, MW				Leitolf, H; Tong, KPT; Grossmann, M; Weintraub, BD; Szkudlinski, MW			Bioengineering of human thyrotropin superactive analogs by site-directed "lysine-scanning" mutagenesis - Cooperative effects between peripheral loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-STIMULATING HORMONE; HUMAN CHORIONIC-GONADOTROPIN; ALPHA-SUBUNIT; GLYCOPROTEIN HORMONES; BETA-SUBUNIT; HUMAN CHORIOGONADOTROPIN; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; RECEPTOR; BINDING	We have previously engineered the first superactive analogs of human thyrotropin (hTSH) by using a novel design strategy. In this study, we have applied homology comparisons focusing on the alpha L3 loop of the common alpha-subunit of human glycoprotein hormones. Seven highly variable amino acid residues were identified, and charge-scanning mutagenesis revealed three previously unrecognized modification permissive domains and four gain-of-function lysine substitutions. Such gain-of-function mutations were hormone- and receptor-specific and dependent on location and basic charge. Cooperativity of individual substitutions was established in double and triple lysine mutants, In combinations of the most potent alpha L3 loop analog with two previously characterized loop analogs, a higher degree of cooperativity for the alpha L3 loop analog compared with both the alpha L1 loop analog and the hTSH-beta L3 loop analog was observed. We demonstrated that spatially distinct regions of the common alpha-subunit contribute differentially to the interaction of hTSH with its receptor and that combinations of two modified loops on the same and on opposite sides of the hTSH molecule display similar increases in in vitro biopotency. In addition, combination of all three superactive loops showed cooperativity in receptor binding and activation resulting in the most potent hTSH superactive analog described to date.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol,Sect Prot Engn, Inst Human Virol,Div Basic Sci,Lab Mol Endocrinol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Endocrinol Diab & Nutr, Mol Endocrinol Lab, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Szkudlinski, MW (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol,Sect Prot Engn, Inst Human Virol,Div Basic Sci,Lab Mol Endocrinol, Rm N457,725 W Lombard St, Baltimore, MD 21201 USA.	szkudlin@umbi.umd.edu						Arnold CJ, 1998, BIOCHEMISTRY-US, V37, P1762, DOI 10.1021/bi971816o; Bidart JM, 1997, ANN ENDOCRINOL-PARIS, V58, P125; BLITHE DL, 1991, ENDOCRINOLOGY, V129, P2257, DOI 10.1210/endo-129-4-2257; CHENG KW, 1973, J BIOL CHEM, V248, P7930; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLE ES, 1993, BIO-TECHNOL, V11, P1014, DOI 10.1038/nbt0993-1014; EASTPALMER J, 1995, THYROID, V5, P55, DOI 10.1089/thy.1995.5.55; Fares FA, 1996, ENDOCRINOLOGY, V137, P555, DOI 10.1210/en.137.2.555; GRIFFITH DL, 1994, J MOL BIOL, V244, P657, DOI 10.1006/jmbi.1994.1761; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Grossmann M, 1998, NAT BIOTECHNOL, V16, P871, DOI 10.1038/nbt0998-871; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; KRYSTEK SR, 1992, PEPTIDE RES, V5, P165; LADENSON PW, 1997, NEW ENGL J MED, V337, P688; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MEIER CA, 1994, J CLIN ENDOCR METAB, V78, P188, DOI 10.1210/jc.78.1.188; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PARSONS TF, 1979, J BIOL CHEM, V254, P6010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROTH KE, 1995, MOL CELL ENDOCRINOL, V109, P143, DOI 10.1016/0303-7207(95)03494-R; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shao K, 1996, MOL CELL ENDOCRINOL, V122, P173, DOI 10.1016/0303-7207(96)03882-8; Shao K, 1997, MOL CELL ENDOCRINOL, V127, P179, DOI 10.1016/S0303-7207(97)04007-0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Szkudlinski MW, 1996, TRENDS ENDOCRIN MET, V7, P277, DOI 10.1016/S1043-2760(96)00129-4; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; SZKUDLINSKI MW, 1997, CURR OPIN ENDOCRINOL, V4, P354, DOI DOI 10.1097/00060793-199710000-00007; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; VAITUKAITIS JL, 1975, ENDOCRINOLOGY, V97, P215, DOI 10.1210/endo-97-1-215; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEINER RS, 1990, ENDOCRINOLOGY, V127, P573, DOI 10.1210/endo-127-2-573; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27457	27465						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10859314				2022-12-25	WOS:000089144800104
J	Kohler, K; Forster, IC; Lambert, G; Biber, J; Murer, H				Kohler, K; Forster, IC; Lambert, G; Biber, J; Murer, H			The functional unit of the renal type IIa Na+/P-i cotransporter is a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; XENOPUS-LAEVIS OOCYTES; P-I; MOLECULAR-SIZE; SUBUNIT STOICHIOMETRY; RAT-KIDNEY; PHOSPHATE COTRANSPORTER; RADIATION-INACTIVATION; TRANSPORTER; NAPI-2	The composition of the functional unit of the rat renal type IIa Na+/P-i cotransporter (NaPi-IIa) was investigated by using two approaches based on the differential sensitivities of the wild type (WT) and mutant S460C proteins to 2-aminoethyImethanethiosulfonate hydrobromide (MTSEA), a charged cysteine modifier. Transport activity of S460C is completely blocked after incubation in MTSEA, whereas that of the WT remains unaffected. First, Xenopus laevis oocytes were coinjected with cRNAs coding for the WT and S460C in different proportions, and the transport inhibition after MTSEA incubation was assayed by electrophysiology. The relationship between MTSEA inhibition and proportion of cRNA was consistent with that for a functional monomer, Second, concatameric proteins were constructed that either comprised two WT proteins (WT-WT), two S460C mutants (S460C-S460C), or one of each (WT-S460C), Western blots of oocytes injected with fusion protein cRNA showed bands at similar to 200 kDa, whereas a main band at similar to 90 kDa was obtained for the WT cRNA alone. The kinetic properties of concatamers were the same as for the single proteins. Transport activity of the WT-WT concatamer was unaffected by MTSEA incubation, fully inhibited for S460C-S460C, but 50% inhibited for WT-S460C, This behavior was also consistent with NaPi-IIa being a functional monomer.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Forster, IC (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Forster, Ian/0000-0003-3087-9952				Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; Busch AE, 1995, J AM SOC NEPHROL, V6, P1547; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; DELISLE MC, 1994, BIOCHEMISTRY-US, V33, P9105, DOI 10.1021/bi00197a012; DELISLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1104, P132, DOI 10.1016/0005-2736(92)90141-8; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; FOSTER I, 2000, BIOPHYS J, V79, P215; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Jette M, 1996, BIOCHEMISTRY-US, V35, P15209, DOI 10.1021/bi960940p; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lambert G, 1999, J GEN PHYSIOL, V114, P637, DOI 10.1085/jgp.114.5.637; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Murer H, 1999, AM J PHYSIOL-RENAL, V277, pF676, DOI 10.1152/ajprenal.1999.277.5.F676; MURER H, 2000, IN PRESS PHYSL REV; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; Tatsumi S, 1998, J BIOL CHEM, V273, P28568, DOI 10.1074/jbc.273.44.28568; TENENHOUSE HS, 1990, BIOCHEM BIOPH RES CO, V170, P1288, DOI 10.1016/0006-291X(90)90533-S; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WERNER A, 1990, J BIOL CHEM, V265, P12331; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	36	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26113	26120		10.1074/jbc.M003564200	http://dx.doi.org/10.1074/jbc.M003564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859311	hybrid, Green Accepted			2022-12-25	WOS:000088999700033
J	Liu, J; Brautigan, DL				Liu, J; Brautigan, DL			Glycogen synthase association with the striated muscle glycogen-targeting subunit of protein phosphatase-1 - Synthase activation involves scaffolding regulated by beta-adrenergic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; BINDING SUBUNIT; PHOSPHORYLASE ACTIVITY; CLYCOGEN PARTICLE; CATALYTIC SUBUNIT; CYCLIC-AMP; MECHANISM; KINASE; TYPE-1	Glycogen-binding subunits for protein phosphatase-1 (PP1) target the PP1 catalytic subunit (PP1C) to glycogen particles, where the enzymes glycogen synthase and glycogen phosphorylase are concentrated. Here we identify sites within the striated muscle glycogen-binding subunit (GM) that mediate direct binding to glycogen synthase, Both PP1C and glycogen synthase were coimmunoprecipitated with a full-length FLAG-tagged GM transiently expressed in COS7 cells or C2C12 myotubes, Deletion and mutational analysis of a glutathione S-transferase (GST) fusion of the N-terminal domain of GM (residues 1-240) identified two putative sites for binding to glycogen synthase, one of which is the WXNXGX-NYX(I/L) motif that is conserved among the family of PP1 glycogen-binding subunits. Either deletion of this motif or Ala substitution of Asn-228 in this motif disrupted the binding of glycogen synthase, Expression of full-length FLAG-G(M) in cells increased the activity of endogenous glycogen synthase, but protein disabled in either PP1 binding or glycogen synthase binding did not produce synthase activation. The results show that efficient activation of glycogen synthase requires a scaffold function of G(M) that involves simultaneous binding of both PP1C and glycogen synthase. Isoproterenol and forskolin treatment of cells decreased glycogen synthase binding to FLAG-G(M), thereby limiting synthase activation by PP1, This response was insensitive to inhibition by H-89, therefore probably not involving cAMP-dependent protein kinase, but did require inclusion of microcystin-LR during cell lysis, implying that phosphorylation was modulating binding of glycogen synthase, Phosphorylation control of binding to a scaffold site on the G(M) subunit of PP1 offers a new mechanism for regulation of muscle glycogen synthase in response to beta-adrenergic signals.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng C, 1997, YEAST, V13, P1; COHEN P, 1986, ENZYMES, P461; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIETZ MR, 1980, J BIOL CHEM, V255, P2301; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HASCHKE RH, 1970, J BIOL CHEM, V245, P6657; HEILMEYER LM, 1970, J BIOL CHEM, V245, P6649; Hirano K, 1997, BBA-PROTEIN STRUCT M, V1339, P177, DOI 10.1016/S0167-4838(97)00048-4; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; MEYER F, 1970, J BIOL CHEM, V245, P6642; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Souchet M, 1999, PROTEIN SCI, V8, P2570; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26074	26081		10.1074/jbc.M003843200	http://dx.doi.org/10.1074/jbc.M003843200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856301	hybrid			2022-12-25	WOS:000088999700027
J	Gijon, MA; Spencer, DM; Siddiqi, AR; Bonventre, JV; Leslie, CC				Gijon, MA; Spencer, DM; Siddiqi, AR; Bonventre, JV; Leslie, CC			Cytosolic phospholipase a, is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium - Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A(2) regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN PLATELETS; C2 DOMAIN; PHOSPHORYLATION SITES; NUCLEAR-ENVELOPE; MAP KINASE; CELLS; IDENTIFICATION; TRANSLOCATION; INDUCTION; MEMBRANE	The 85-kDa cytosolic phospholipase A(2) (cPLA(2)) mediates agonist-induced arachidonic acid release and eicosanoid production. Calcium and phosphorylation on Ser-505 by mitogen-activated protein kinases (MAPKs) regulate cPLA(2). Arachidonic acid release and eicosanoid production induced by stimuli that do (A23187, zymosan) or do not (phorbol myristate acetate (PMA), okadaic acid) mobilize calcium were quantitatively suppressed in cPLA(2)-deficient mouse peritoneal macrophages. The contribution of MAPKs to cPLA(2)-mediated arachidonic acid release was investigated. Both extracellular signal-regulated kinases (ERKs) and p38 contributed to cPLA(2) phosphorylation on Ser-505. However, although ERK inhibition did not affect A23187-induced arachidonic acid release, it suppressed zymosan-, PMA-, and okadaic acid-induced arachidonic acid release under conditions where phosphorylation of cPLA(2) on Ser-505 was unaffected. This indicates an additional regulatory mechanism for the ERK pathway. A role for transcriptional regulation is suggested by data showing that cycloheximide and actinomycin D inhibited arachidonic acid release induced by zymosan, PMA and, okadaic acid but not by A23181, Our results show that MAPK pathways contribute to arachidonic acid release in macrophages through alternative mechanisms in addition to their ability to phosphorylate cPLA(2) on Ser-505 and suggest a role for new protein synthesis.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Harvard Univ, Massachusetts Gen Hosp E, Sch Med, Dept Med, Charlestown, MA 02129 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NHLBI NIH HHS [P01 HL034303, HL61378, HL34308] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; AMBS P, 1995, BIOCHEM J, V311, P189, DOI 10.1042/bj3110189; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Bayon Y, 1997, BIOCHEM J, V323, P281, DOI 10.1042/bj3230281; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNEY RJ, 1980, BIOCHIM BIOPHYS ACTA, V633, P410, DOI 10.1016/0304-4165(80)90199-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim JH, 1999, J IMMUNOL, V163, P5462; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1437, P157, DOI 10.1016/S1388-1981(99)00012-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XU XX, 1994, J BIOL CHEM, V269, P31693	64	192	207	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20146	20156		10.1074/jbc.M908941199	http://dx.doi.org/10.1074/jbc.M908941199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867029	hybrid			2022-12-25	WOS:000087941300096
J	Brown, A; Browes, G; Mitchell, M; Montano, X				Brown, A; Browes, G; Mitchell, M; Montano, X			c-abl is involved in the association of p53 and trk A	ONCOGENE			English	Article						c-abl; phosphorylation; p53 and trk A association; c-abl and trk A association	NERVE GROWTH-FACTOR; WILD-TYPE P53; TYROSINE KINASE-ACTIVITY; DNA-DAMAGE; PC12 CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; GENOTOXIC STRESS; PROTEIN-BINDING	The p53 tumour suppressor phosphoprotein associates with proteins involved in DNA replication, transcription, cell cycle machinery and regulation of its own expression, Recently it has been shown that p53 can also bind to trk A tyrosine kinase which is the receptor for nerve growth factor (NGF). This study demonstrates that p53 appears to associate with trk A via c-abl, Endogenous c-abl was detected when the trk A and p53 complex was immunoprecipitated from lysates of NGF stimulated NIH3T3 cells expressing trk A or NIH3T3 cells expressing trk A and a temperature sensitive p53 (val 135), Endogenous c-abl and trk A association was observed in NGF stimulated p53 negative fibroblasts transfected with trk A alone; suggesting that c-abl can independently bind to trk A in the absence of p53. Interestingly, association between endogenous p53 and trk A was not detected in NGF stimulated abl negative fibroblasts transfected with trk A or when these cells were exposed to gamma radiation, This result suggests that p53 preferentially binds to trk A in the presence of c-abl and that p53 and trk A do not appear to associate directly even if p53 is activated and its levels increased by gamma radiation, Overall, these data suggest that c-abl is possibly acting as an adaptor or bridge between p53 and trk A.	Newcastle Univ, Sch Med, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England	Newcastle University - UK; Cancer Research UK	Montano, X (corresponding author), Newcastle Univ, Sch Med, Canc Res Unit, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							Agami R, 1999, NATURE, V399, P809; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; GOGA A, 1995, ONCOGENE, V11, P791; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATTIONI T, 1995, ONCOGENE, V10, P1325; MICHALOWITZ D, 1990, CELL, V620, P671; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZERRAHN J, 1992, ONCOGENE, V7, P1371	62	18	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3032	3040		10.1038/sj.onc.1203619	http://dx.doi.org/10.1038/sj.onc.1203619			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871855				2022-12-25	WOS:000087581400010
J	Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B				Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B			Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src	ONCOGENE			English	Article						MET; c-Src; papillary renal cancer	FACTOR SCATTER FACTOR; PAPILLARY RENAL CARCINOMAS; TYROSINE KINASE RECEPTOR; ROUS-SARCOMA VIRUS; C-SRC; PROTOONCOGENE PRODUCT; ACTIVATING MUTATIONS; CELL CARCINOMA; RON RECEPTOR; GROWTH	We recently described germline and somatic mutations in the MET gene associated with papillary renal carcinoma type 1, MET mutation M1268T was Located in a codon highly conserved among receptor tyrosine kinases, and homologous to the codon mutated in multiple endocrine neoplasia type 2B, and many cases of sporadic medullary carcinoma of the thyroid gland (Ret M918T), Ret M918T and MET M1268T have previously been shown to be highly active in mouse NIH3T3 transformation assays, and to change the substrate specificity of the kinase. We studied the mechanism of transformation mediated by MET M1268T by analysing a clone, F4, derived from NIH3T3 cells transformed by MET M1268T, In contrast to NIH3T3 cells, F4 cells grew in suspension in tissue culture, and rapidly formed tumors in nude mice. We found that c-Src was constitutively bound to MET proteins in F4 cells, and that Src kinase activity was elevated. Transfection of dominant negative Src constructs into F4 cells eliminated the ability of F4 cells to grow in suspension culture and retarded the growth of F4 cells in vivo. The ability of transfected dominant negative Src constructs to inhibit the growth of F4 cells correlated with the inhibition of phosphorylation of paxillin and focal adhesion kinase, Transfection of dominant negative Src constructs into F4 cells had no effect on Grb2 binding or PLC gamma phosphorylation, The results suggest that c-Src participates in the tumorigenic phenotype induced in NIH3T3 cells by MET M1268T by signaling through focal adhesion kinase and paxillin.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Zbar, B (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bentz M, 1996, CYTOGENET CELL GENET, V75, P17, DOI 10.1159/000134448; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WEEMINK PAO, 1995, J BIOL CHEM, V270, P2264; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; ZHU H, 1994, J BIOL CHEM, V269, P29943	31	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2996	3002		10.1038/sj.onc.1203628	http://dx.doi.org/10.1038/sj.onc.1203628			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871851				2022-12-25	WOS:000087581400006
J	Li, RX; Manela, J; Kong, Y; Ladisch, S				Li, RX; Manela, J; Kong, Y; Ladisch, S			Cellular gangliosides promote growth factor-induced proliferation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; GLUCOSYLCERAMIDE SYNTHASE; IMMUNOSUPPRESSIVE ACTIVITY; TYROSINE PHOSPHORYLATION; MEDIATED MODULATION; CELLS; GLYCOSPHINGOLIPIDS; INHIBITION; CERAMIDE	Cell surface gangliosides have been proposed as modulators of transmembrane signaling. In this study, we used two complementary approaches to investigate the function of cellular gangliosides in the response of mammalian fibroblasts to growth factors. First, inhibition of glucosyl ceramide synthase by a new specific inhibitor of D-1-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol-HCl (glucosylceramide synthase), which depletes cellular gangliosides at a concentration of 1 muM without causing an increase in ceramide levels, blocked epidermal growth factor-stimulated proliferation of fibroblasts. Similarly, responses to several other growth factors that activate receptor tyrosine kinases, including fibroblast growth factor, insulin-like growth factor-I, and platelet-derived growth factor, were inhibited by 50-100%. Conversely, enrichment of cellular gangliosides by preincubation of the mouse and human fibroblasts with exogenously added gangliosides enhanced growth factor-elicited cell proliferation. Novel findings of this study, distinguishing it from previous similar studies, include differential effects of preincubation versus continuous incubation of cells with gangliosides on growth factor-dependent cell proliferation and the growth factor-like action of NeuNAc alpha2-3Gal beta1-3GalNAc beta1-4(NeuNAc alpha2-3)Gal beta1-4Glc beta1-1Cer when cells are pretreated with the ganglioside.	Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; George Washington Univ, Sch Med, Dept Biochem Mol Biol, Washington, DC 20052 USA	George Washington University; George Washington University	Ladisch, S (corresponding author), Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, 111 Michigan Ave NW, Washington, DC 20010 USA.	SLadisch@cnmc.org			NCI NIH HHS [CA61010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE A, 1995, J LIPID RES, V36, P611; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505; ENDO K, 1991, CANCER RES, V51, P1613; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HYNDS DL, 1995, J NEUROCHEM, V65, P2251; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kong Y, 1998, BBA-LIPID LIPID MET, V1394, P43, DOI 10.1016/S0005-2760(98)00096-4; LADISCH S, 1994, P NATL ACAD SCI USA, V91, P1974, DOI 10.1073/pnas.91.5.1974; LADISCH S, 1995, BIOCHEMISTRY-US, V34, P1197, DOI 10.1021/bi00004a012; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LADISCH S, 1994, BIOCHEM BIOPH RES CO, V203, P1102, DOI 10.1006/bbrc.1994.2296; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meuillet EJ, 1999, CANCER RES, V59, P234; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Oderfeld-Nowak B, 1998, NEUROCHEM RES, V23, P443, DOI 10.1023/A:1022482106152; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; QUARLES RH, 1971, J NEUROCHEM, V18, P1809, DOI 10.1111/j.1471-4159.1971.tb09586.x; RADIN NS, 1993, ADV LIPID RES, V26, P183; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; SAQR HE, 1993, J NEUROCHEM, V61, P395; Slevin M, 1999, INT J CANCER, V82, P412, DOI 10.1002/(SICI)1097-0215(19990730)82:3<412::AID-IJC15>3.0.CO;2-J; Sorice M, 1997, J LIPID RES, V38, P969; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Yamaguchi S, 1997, GLYCOCONJUGATE J, V14, P707, DOI 10.1023/A:1018517400380; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	44	68	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34213	34223		10.1074/jbc.M906368199	http://dx.doi.org/10.1074/jbc.M906368199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10859325	hybrid			2022-12-25	WOS:000165095300031
J	Reichard, P; Eliasson, R; Ingemarson, R; Thelander, L				Reichard, P; Eliasson, R; Ingemarson, R; Thelander, L			Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALF THYMUS; PROTEIN R1; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; RECOMBINANT MOUSE; PURIFICATION; MUTANT; ENZYMES; CELLS	We compared the allosteric regulation and effector binding properties of wild type R1 protein and R1 protein with a mutation in the "activity site" (D57N) of mouse ribonucleotide reductase, Wild type R1 had two effector-binding sites per polypeptide chain: one site (activity site) for dATP and ATP, with dATP-inhibiting and ATP-stimulating catalytic activity; and a second site (specificity site) for dATP, ATP, dTTP, and dGTP, directing substrate specificity. Binding of dATP to the specificity site had a 20-fold higher affinity than to the activity site. In all these respects, mouse R1 resembles Escherichia cold R1, Results with D57N were complicated by the instability of the protein, but two major changes were apparent. First, enzyme activity was stimulated by both dATP and ATP, suggesting that D57N no longer distinguished between the two nucleotides. Second, the two binding sites for dATP both had the same low affinity for the nucleotide, similar to that of the activity site of wild type R1, Thus the mutation in the activity site had decreased the affinity for dATP at the specificity site, demonstrating the interaction between the two sites.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; Karolinska Inst, Med Nobel Inst, Dept Biochem 1, MBB, SE-17177 Stockholm, Sweden	Umea University; Karolinska Institutet	Thelander, L (corresponding author), Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden.	lars.thelander@medchem.umu.se						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1981, J BIOL CHEM, V256, P193; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; ORMO M, 1990, ANAL BIOCHEM, V182, P674; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; THELANDER L, 1980, J BIOL CHEM, V255, P7426; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ULLMAN B, 1981, J BIOL CHEM, V256, P189	27	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33021	33026		10.1074/jbc.M005337200	http://dx.doi.org/10.1074/jbc.M005337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884394	hybrid			2022-12-25	WOS:000090003800088
J	Stachelek, SJ; Kowalik, TF; Farwell, AP; Leonard, JL				Stachelek, SJ; Kowalik, TF; Farwell, AP; Leonard, JL			Myosin V plays an essential role in the thyroid hormone-dependent endocytosis of type II iodothyronine 5 '-deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC DISSECTION; SUBSTRATE-BINDING SUBUNIT; STIMULATED GLIAL-CELLS; ACTIN-BASED TRANSPORT; RAT CEREBRAL-CORTEX; UNCONVENTIONAL MYOSINS; ENZYME INACTIVATION; DILUTE MELANOCYTES; REGION MUTATIONS; TAIL REGION	In astrocytes, thyroxine modulates type II iodothyronine 5'-deiodinase levels by initiating the binding of the endosomes containing the enzyme to microfilaments, followed by actin-based endocytosis. Myosin V is a molecular motor thought to participate in vesicle trafficking in the brain. In this report, we developed an in vitro actin-binding assay to characterize the thyroid hormone-dependent binding of endocytotic vesicles to microfilaments. Thyroxine and reverse triiodothyronine (EC,, levels similar to 1 nM) were >100-fold more potent than 3,5,3'-triiodothyronine in initiating vesicle binding to actin fibers in vitro, Thyroxine-dependent vesicle binding was calcium-, magnesium-, and ATP-dependent, suggesting the participation of one or more myosin motors, presumably myosin V. Addition of the myosin V globular tail, lacking the actin-binding head, specifically blocked thyroid hormone-dependent vesicle binding, and direct binding of the myosin V tail to enzyme-containing endosomes was thyroxine-dependent, Progressive NH2-terminal deletion of the myosin V tail and domain-specific antibody inhibition studies revealed that the thyroxine-dependent vesicle-tethering domain was localized to the last 21 amino acids of the COOP terminus. These data show that myosin V is responsible for thyroid hormone-dependent binding of primary endosomes to the microfilaments and suggest that this motor mediates the actin-based endocytosis of the type II iodothyronine deiodinase.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.			Farwell, Alan/0000-0001-7716-2719				Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Evans LL, 1997, J CELL SCI, V110, P439; Evans LL, 1998, J CELL SCI, V111, P2055; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Huang JD, 1998, GENETICS, V148, P1951; Huang JD, 1998, GENETICS, V148, P1963; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford GM, 1998, BRAIN RES REV, V28, P1, DOI 10.1016/S0165-0173(98)00020-4; Leonard DM, 2000, J BIOL CHEM, V275, P25194, DOI 10.1074/jbc.M002036200; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; LEONARD JL, 1983, ENDOCRINOLOGY, V112, P1153, DOI 10.1210/endo-112-3-1153; MANI F, 1994, BRAZ J MED BIOL RES, V27, P2639; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Miller KE, 2000, J BIOL CHEM, V275, P2598, DOI 10.1074/jbc.275.4.2598; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; Tabb JS, 1998, J CELL SCI, V111, P3221; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	39	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31701	31707		10.1074/jbc.M004221200	http://dx.doi.org/10.1074/jbc.M004221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882730	hybrid			2022-12-25	WOS:000089858900024
J	Nowotny, M; Bhattacharya, S; Filipek, A; Krezel, AM; Chazin, W; Kuznicki, J				Nowotny, M; Bhattacharya, S; Filipek, A; Krezel, AM; Chazin, W; Kuznicki, J			Characterization of the interaction of calcyclin (S100A6) and calcyclin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES-TUMOR-CELLS; ANNEXIN-II; MOLECULAR-CLONING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRONG HOMOLOGY; GROWTH-FACTOR; IDENTIFICATION; EXPRESSION; TARGET; COMPLEX	Calcyclin (S100A6) is an S100 calcium-binding protein whose expression is up-regulated in proliferating and differentiating cells. A novel 30-kDa protein exhibiting calcium dependent calcyclin-binding (calcyclin-binding protein, CacyBP) had been identified, purified, and cloned previously (Filipek, A, and Kuznicki, J, (1998) J. Neurochem. 70, 1793-1798). Here, we have defined the calcyclin binding region using limited proteolysis and a set of deletion mutants of CacyBP. A fragment encompassing residues 178-229 (CacyBP-(178-229)) was capable of full binding to calcyclin, CacyBP-(178-229) was expressed in Escherichia coli as a glutathione S-transferase fusion protein and purified. The protein fragment cleaved from the glutathione S-transferase fusion protein was shown by CD to contain 5% alpha-helix, 15% beta-sheet, and 81% random coil. Fluorescence spectroscopy was used to determine calcyclin dissociation constants of 0.96 and 1.2 mu M for intact CacyBP and CacyBP-(178-229), respectively, indicating that the fragment can be used for characterization of calcyclin-CacyBP interactions. NMR analysis of CacyBP-(178-229) binding-induced changes in the chemical shifts of N-15-enriched calcyclin revealed that CacyBP binding occurs at a discrete site on calcyclin with micromolar affinity.	M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland; Vanderbilt Univ, Dept Biol Mol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Vanderbilt University; Vanderbilt University	Kuznicki, J (corresponding author), M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, 3 Pasteur St, PL-02093 Warsaw, Poland.	jacek@nencki.gov.pl	Kuznicki, Jacek/AAW-9239-2020	Kuznicki, Jacek/0000-0001-6486-0657; Filipek, Anna/0000-0001-9484-9555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062112] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-62112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GUO XJ, 1990, CELL GROWTH DIFFER, V1, P333; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KUZNICKI J, 1989, BIOCHEM J, V263, P951; KUZNICKI J, 1987, BIOCHEM J, V247, P663, DOI 10.1042/bj2470663; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; TOKUMITSU H, 1992, BIOCHEM BIOPH RES CO, V186, P1227, DOI 10.1016/S0006-291X(05)81537-2; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TONINI GP, 1991, CANCER RES, V51, P1733; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	34	39	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31178	31182		10.1074/jbc.M001622200	http://dx.doi.org/10.1074/jbc.M001622200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10884380	hybrid			2022-12-25	WOS:000089762700061
J	Camoretti-Mercado, B; Liu, HW; Halayko, AJ; Forsythe, SM; Kyle, JW; Li, B; Fu, YP; McConville, J; Kogut, P; Vieira, JE; Patel, NM; Hershenson, MB; Fuchs, E; Sinha, S; Miano, JM; Parmacek, MS; Burkhardt, JK; Solway, J				Camoretti-Mercado, B; Liu, HW; Halayko, AJ; Forsythe, SM; Kyle, JW; Li, B; Fu, YP; McConville, J; Kogut, P; Vieira, JE; Patel, NM; Hershenson, MB; Fuchs, E; Sinha, S; Miano, JM; Parmacek, MS; Burkhardt, JK; Solway, J			Physiological control of smooth muscle-specific gene expression through regulated nuclear translocation of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; DNA-BINDING ACTIVITY; ALPHA-ACTIN EXPRESSION; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; MYOGENIC DIFFERENTIATION; TRANSGENIC MICE; CASEIN KINASE; GLUCOCORTICOID RECEPTOR; FOS-EXPRESSION	Prolonged serum deprivation induces a structurally and functionally contractile phenotype in about 1/6 of cultured airway myocytes, which exhibit morphological elongation and accumulate abundant contractile apparatus-associated proteins. We tested the hypothesis that transcriptional activation of genes encoding these proteins accounts for their accumulation during this phenotypic transition by measuring the transcriptional activities of the murine SM22 and human smooth muscle myosin heavy chain promoters during transient transfection in subconfluent, serum fed or 7 day serum-deprived cultured canine tracheal smooth muscle cells. Contrary to our expectation, SM22 and smooth muscle myosin heavy chain promoter activities (but not viral murine sarcoma virus-long terminal repeat promoter activity) were decreased in long term serum-deprived myocytes by at least 8-fold. Because serum response factor (SRF) is a required transcriptional activator of these and other smooth muscle-specific promoters, we evaluated the expression and function of SRF in subconfluent and long term serum-deprived cells. Whole cell SRP mRNA and protein were maintained at high levels in serum-deprived myocytes, but SRF transcription-promoting activity, nuclear SRF binding to consensus CArG sequences, and nuclear SRF protein were reduced. Furthermore, immunocytochemistry revealed extranuclear redistribution of SRF in serum-deprived myocytes; nuclear localization of SRF was restored after serum refeeding. These results uncover a novel mechanism for physiological control of smooth muscle-specific gene expression through extranuclear redistribution of SRF and consequent down-regulation of its transcription-promoting activity.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Rochester; University of Pennsylvania	Solway, J (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.		vieira, joaquim e/D-3147-2013; Solway, Julian/B-1116-2008; Miano, Joseph/L-5634-2018	vieira, joaquim e/0000-0002-6225-8985; Solway, Julian/0000-0002-0898-8530; Halayko, Andrew/0000-0002-7865-4552; Miano, Joseph/0000-0001-7522-3207	NHLBI NIH HHS [HL56399, HL63314, HL64095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063314, R01HL064095, P50HL056399] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; CHAUHAN D, 1995, LEUKEMIA RES, V19, P337, DOI 10.1016/0145-2126(94)00132-T; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Galigniana MD, 1999, J BIOL CHEM, V274, P16222, DOI 10.1074/jbc.274.23.16222; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIU SH, 1993, J BIOL CHEM, V268, P21147; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1997, J BIOL CHEM, V272, P29842, DOI 10.1074/jbc.272.47.29842; Madsen CS, 1998, CIRC RES, V82, P908; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Meyyappan M, 1996, BIOL SIGNAL, V5, P130; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Moessler H, 1996, DEVELOPMENT, V122, P2415; MOKENTIN JD, 1996, CURR OPIN GENE DEV, V6, P445; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1923; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Solway J, 1998, AM J RESP CRIT CARE, V158, pS100, DOI 10.1164/ajrccm.158.supplement_2.13tac500; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Strubing C, 1999, J GEN PHYSIOL, V113, P239, DOI 10.1085/jgp.113.2.239; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; VAN AL, 1997, GENE DEV, V11, P2295; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	59	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30387	30393		10.1074/jbc.M000840200	http://dx.doi.org/10.1074/jbc.M000840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10866994	hybrid			2022-12-25	WOS:000089577900064
J	Ruiz-Gomez, A; Humrich, J; Murga, C; Quitterer, U; Lohse, MJ; Mayor, F				Ruiz-Gomez, A; Humrich, J; Murga, C; Quitterer, U; Lohse, MJ; Mayor, F			Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MICROSOMAL-MEMBRANES; HIGH-AFFINITY; ACTIVATION; BINDING; INHIBITION; TRANSDUCIN; REGULATOR; GRK2; DESENSITIZATION	G protein-coupled receptor kinase 2 (GRK2) is able to phosphorylate a variety of agonist-occupied G protein-coupled receptors (GPCR) and plays an important role in GPCR modulation, However, recent studies suggest additional cellular functions for GRK2. Phosducin and phosducin-like protein (PhLP) are cytosolic proteins that bind G beta gamma subunits and act as regulators of G-protein signaling. In this report, we identify phosducin and PhLP as novel GRK2 substrates, The phosphorylation of purified phosducin and PhLP by recombinant GRK2 proceeds rapidly and stoichiometrically (0.82 +/- 0.1 and 0.83 +/- 0.09 mol of P-i/mol of protein, respectively). The phosphorylation reactions exhibit apparent K-m values in the range of 40-100 nM, strongly suggesting that both proteins could be endogenous targets for GRK2 activity. Our data show that the site of phosducin phosphorylation by GRK2 is different and independent from that previously reported for the cAMP-dependent protein kinase. Analysis of GRK2 phosphorylation of a variety of deletion mutants of phosducin and PhLP indicates that the critical region for GRK2 phosphorylation is localized in the C-terminal domain of both phosducin and PhLP (between residues 204 and 245 and 195 and 218, respectively). This region is important for the interaction of these proteins with G beta gamma subunits, Phosphorylation of phosducin by GRK2 markedly reduces its G beta gamma binding ability, suggesting that GRK2 may modulate the activity of the phosducin protein family by disrupting this interaction. The identification of phosducin and PhLP as new substrates for GRK2 further expands the cellular roles of this kinase and suggests new mechanisms for modulating GPCR signal transduction.	Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Wurzburg	Mayor, F (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain.	fmayor@cbm.uam.es	Mayor, Federico/N-7644-2016; Ruiz-Gomez, Ana/ABF-3079-2021; Ruiz-Gómez, Ana/H-2092-2015; Lohse, Martin J/A-7160-2012; Murga, Cristina/E-1965-2014	Ruiz-Gómez, Ana/0000-0002-1646-3072; Lohse, Martin J/0000-0002-0599-3510; Murga, Cristina/0000-0002-8964-4077; Mayor Menendez, Federico/0000-0003-1434-8449				Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HAGA K, 1994, J BIOL CHEM, V269, P12594; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; Iacovelli L, 1999, FASEB J, V13, P1; KIM CM, 1993, J BIOL CHEM, V268, P15412; KRUPNICK JG, 1998, ANN REV PHARM TOXICO, V38, P238; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mayor F, 1998, TRENDS CARDIOVAS MED, V8, P234, DOI 10.1016/S1050-1738(98)00008-5; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 1999, MOL VIS, V5, pU13; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	48	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29724	29730		10.1074/jbc.M001864200	http://dx.doi.org/10.1074/jbc.M001864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884381	hybrid			2022-12-25	WOS:000089439800073
J	Pluciennik, A; Iyer, RR; Parniewski, P; Wells, RD				Pluciennik, A; Iyer, RR; Parniewski, P; Wells, RD			Tandem duplication - A novel type of triplet repeat instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; HEREDITARY-DISEASE GENES; GRAM-NEGATIVE BACTERIA; REPLICATION IN-VIVO; RNA-DNA HYBRID; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; CTG REPEATS; SUPERCOILED DNA; MISMATCH REPAIR	Triplet repeat sequence (TRS) inserts containing (CTG.CAG)(n) (17-175 units in length) were tandemly duplicated when propagated in plasmids in Escherichia coli, The products of this novel type of TRS genetic instability are tracts of as many as 34 multiple units, which contain the entire TRS as well as 129 base pairs of nonrepetitive flanking sequence. The duplication process required the presence of two or more TRS-containing units. Close proximity (170 base pairs) of the TRS to the R6K gamma origin of replication of the pUTminiTn5Cm-derived constructs stimulated the tandem duplication process. These events are proposed to occur due to secondary structure formation, stalling of DNA synthesis, and slippage-mediated misalignment of the complementary strands relative to each other during DNA replication. This mechanism may account for the TRS-associated duplications in protein kinase and metalloprotease genes in neuroblastomas and melanomas, as well as the massive repeat expansions in type II triplet repeat neurological diseases.	Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; ARMOUR JAL, 1994, HUM MOL GENET, V3, P599, DOI 10.1093/hmg/3.4.599; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; Bichara M, 2000, GENETICS, V154, P533; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BURD JF, 1975, J BIOL CHEM, V250, P6002; BURD JF, 1975, J BIOL CHEM, V250, P5109; Canceill D, 1999, J BIOL CHEM, V274, P27481, DOI 10.1074/jbc.274.39.27481; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; Chen DZ, 1998, J MOL BIOL, V282, P775, DOI 10.1006/jmbi.1998.2055; DALENCON E, 1994, EMBO J, V13, P2725, DOI 10.1002/j.1460-2075.1994.tb06563.x; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Feschenko VV, 1998, J MOL BIOL, V276, P559, DOI 10.1006/jmbi.1997.1566; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; Filutowicz M, 1998, GENE, V223, P195, DOI 10.1016/S0378-1119(98)00367-9; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gao XL, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P623; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HIASA H, 1994, J BIOL CHEM, V269, P6058; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; LOVETT ST, 1993, GENETICS, V135, P631; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; PEARSON CE, 1996, AM J HUM GENET, V59, P244; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkar PS, 1998, CELL, V95, P531, DOI 10.1016/S0092-8674(00)81620-7; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STANTON DJ, 1994, GENETICS, V137, P233; Stoike LL, 1998, GENETICS, V149, P347; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SULLIVAN KM, 1988, NUCLEIC ACIDS RES, V16, P1079, DOI 10.1093/nar/16.3.1079; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; SULLIVAN KM, 1988, J BIOL CHEM, V263, P13074; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532	76	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28386	28397		10.1074/jbc.M000154200	http://dx.doi.org/10.1074/jbc.M000154200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10877999	hybrid			2022-12-25	WOS:000089330700009
J	Benkusky, NA; Fergus, DJ; Zucchero, TM; England, SK				Benkusky, NA; Fergus, DJ; Zucchero, TM; England, SK			Regulation of the Ca2+-sensitive domains of the maxi-K channel in the mouse myometrium during gestation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMOOTH-MUSCLE; BETA-SUBUNIT; CA CHANNELS; CELLS; SENSITIVITY; MODULATION; EXPRESSION; PREGNANCY; ISOFORMS	Large conductance Ca2+-activated K+ channels (maxi-K channels) are known to modulate uterine activity during gestation. Electrophysiological recordings demonstrate that myometrial maxi-K current is suppressed in term-pregnant compared to non-pregnant mice. We sought to determine whether maxi-K current suppression is due to reduction of maxi-K channel protein or differential expression of maxi-K channel isoforms that vary in their Ca2+ and voltage sensitivities. Immunoblot analyses show an increase of maxi-K channel protein throughout gestation. Polymerase chain reaction of mouse myometrial cDNA identified four alternatively spliced sites within the maxi-K transcript and three within the Ca2+-sensitive "tail" domain. Ribonuclease protection analyses demonstrate that total channel transcript levels mimic protein expression; however transcript levels of alternatively spliced regions of regulatory domains that alter sensitivity to voltage and Ca2+ differ in their gestational expression. An insert that increases the maxi-K channel sensitivity to voltage and Ca2+ is present at steady levels throughout gestation, differing from total channel transcript regulation. The insert-less form of this transcript, which reduces the channel voltage and Ca2+ sensitivity, is not detected until midterm pregnancy. These findings verify that multiple isoforms of the maxi-K channel are present in the mouse myometrium and are regulated differentially during gestation, which is a likely mechanism for modulation of myometrial excitability during pregnancy.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	England, SK (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-660 Bowen Sci Bldg, Iowa City, IA 52242 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037831] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-37831] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Hanaoka K, 1999, J MEMBRANE BIOL, V172, P193, DOI 10.1007/s002329900596; Jackson WF, 1997, MICROCIRCULATION-LON, V4, P35, DOI 10.3109/10739689709148316; Khan RN, 1998, HUM REPROD, V13, P208, DOI 10.1093/humrep/13.1.208; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V251, P9, DOI 10.1098/rspb.1993.0002; KNAUS HG, 1995, J BIOL CHEM, V270, P22434, DOI 10.1074/jbc.270.38.22434; Knittle TJ, 1996, AM J PHYSIOL-CELL PH, V270, pC688, DOI 10.1152/ajpcell.1996.270.2.C688; LUDMIR J, 1993, MICROSC RES TECHNIQ, V25, P134, DOI 10.1002/jemt.1070250206; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; Okawa T, 1999, AM J OBSTET GYNECOL, V181, P649, DOI 10.1016/S0002-9378(99)70508-9; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; SANBORN BM, 1995, SEMIN PERINATOL, V19, P31, DOI 10.1016/S0146-0005(95)80045-X; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; SPERELAKIS N, 1992, CAN J PHYSIOL PHARM, V70, P491, DOI 10.1139/y92-064; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TORO L, 1990, P NATL ACAD SCI USA, V87, P2892, DOI 10.1073/pnas.87.8.2892; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wang SY, 1998, J GEN PHYSIOL, V112, P737, DOI 10.1085/jgp.112.6.737; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	29	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27712	27719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871603				2022-12-25	WOS:000089197100027
J	Gouedard, L; Chen, YG; Thevenet, L; Racine, C; Borie, S; Lamarre, I; Josso, N; Massague, J; di Clemente, N				Gouedard, L; Chen, YG; Thevenet, L; Racine, C; Borie, S; Lamarre, I; Josso, N; Massague, J; di Clemente, N			Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; INHIBITING SUBSTANCE; OSTEOGENIC PROTEIN-1; MOUSE EMBRYOGENESIS; LEYDIG-CELLS; KINASE; EXPRESSION; APOPTOSIS; DIFFERENTIATION; ACTIVATION	Anti-Mullerian hormone induces the regression of fetal Mullerian ducts and inhibits the transcription of gonadal steroidogenic enzymes. It belongs to the transforming growth factor-p family whose members signal through a pair of serine/threonine kinase receptors and Smad effecters. Only the anti-Mullerian hormone type II receptor has been identified. Our goal was to determine whether anti-Mullerian hormone could share a type I receptor with another family member. Co-immunoprecipitation of known type I receptors with anti-Mullerian hormone type II receptor clearly showed that the bone morphogenetic protein type LB receptor was the only cloned type I receptor interacting in a ligand-dependent manner with this type II receptor. Anti-Mullerian hormone also activates the bone morphogenetic protein-specific Smad1 pathway and the XVent2 reporter gene, an anti-Mullerian hormone type II receptor-dependent effect abrogated by a dominant negative version of bone morphogenetic protein type LB receptor. Reverse amplification experiments showed that bone morphogenetic protein type IB receptor is co-expressed with anti-Mullerian hormone type II receptor in most anti-Mullerian hormone target tissues. Our data support a model in which a ligand, anti-Mullerian hormone, gains access to a shared type I receptor and Smad1 system through a highly restricted type II receptor.	Ecole Normale Super, Dept Biol, INSERM, Unite Rech Endocrinol Dev, F-92120 Montrouge, France; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	di Clemente, N (corresponding author), Ecole Normale Super, Dept Biol, INSERM, Unite Rech Endocrinol Dev, 1 Rue Maurice Arnoux, F-92120 Montrouge, France.			Massague, Joan/0000-0001-9324-8408; di Clemente, Nathalie/0000-0001-9087-3486; Racine, Chrystele/0000-0003-0250-5355				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baur ST, 2000, DEVELOPMENT, V127, P605; Belville C, 1999, AM J MED GENET, V89, P218, DOI 10.1002/(SICI)1096-8628(19991229)89:4<218::AID-AJMG6>3.0.CO;2-E; Candia AF, 1997, DEVELOPMENT, V124, P4467; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dutertre M, 1997, MOL CELL ENDOCRINOL, V136, P57, DOI 10.1016/S0303-7207(97)00214-1; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Gu ZY, 1999, DEVELOPMENT, V126, P2551; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lee MM, 1999, ENDOCRINOLOGY, V140, P2819, DOI 10.1210/en.140.6.2819; LIU F, 1995, MOL CELL BIOL, V15, P3479; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; Roberts LM, 1999, DEV BIOL, V208, P110, DOI 10.1006/dbio.1998.9190; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rouiller-Fabre V, 1998, ENDOCRINOLOGY, V139, P1213, DOI 10.1210/en.139.3.1213; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schmidt C, 1998, DEV BIOL, V202, P253, DOI 10.1006/dbio.1998.9011; Teixeira J, 1999, ENDOCRINOLOGY, V140, P4732, DOI 10.1210/en.140.10.4732; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yi SE, 2000, DEVELOPMENT, V127, P621; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	49	130	140	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27973	27978						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10854429				2022-12-25	WOS:000089197100061
J	Jezewska, MJ; Rajendran, S; Bujalowski, W				Jezewska, MJ; Rajendran, S; Bujalowski, W			Escherichia coli replicative helicase PriA protein-single-stranded DNA complex - Stoichiometries, free energy of binding, and cooperativities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMENSIONAL HOMOGENEOUS LATTICE; FLUORESCENT NUCLEOTIDE ANALOGS; FACTOR-Y; DEPENDENT ATPASE; LARGE LIGANDS; NUCLEIC-ACID; SITE; ENZYME; MACROMOLECULE; HEXAMER	Analyses of interactions of the Escherichia coli replicative helicase, PriA protein, with a single-stranded (ss) DNA have been performed, using the quantitative fluorescence titration technique. The stoichiometry of the PriA helicase.ssDNA complex has been examined in binding experiments with a series of ssDNA oligomers. The total site-size of the PriA.ssDNA complex, i.e. the maximum number of nucleotide residues occluded by the PriA helicase in the complex, is 20 +/- 3 residues per protein monomer, However, the protein can efficiently form a complex with a minimum of 8 nucleotides, Thus, the enzyme has a strong ssDNA-binding site that engages in direct interactions with a significantly smaller number of nucleotides than the total site-size, The ssDNA-binding site is located in the center of the enzyme molecule, with the protein matrix protruding over a distance of similar to 6 nucleotides on both sides of the binding site. The analysis of the binding of two PriA molecules to long oligomers was performed using statistical thermodynamic models that take into account the overlap of potential binding sites, cooperative interactions, and the protein.ssDNA complexes with different stoichiometries. The intrinsic affinity depends little upon the length of the ssDNA. Moreover, the binding is accompanied by weak cooperative interactions.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Bujalowski, W (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.				NIGMS NIH HHS [GM-46679, GM-58675] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BM, 1978, BIOPOLYMERS, V17, P1361, DOI 10.1002/bip.1978.360170519; Bujalowski W, 2000, BIOCHEMISTRY-US, V39, P2106, DOI 10.1021/bi992413m; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; Bujalowski W, 2000, J MOL BIOL, V295, P831, DOI 10.1006/jmbi.1999.3378; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILL TL, 1985, COOPERATIVITY THEORY, P34; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2117, DOI 10.1021/bi952344l; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; KORNBERG A, 1992, DNA REPLICATION, P275; KUBOTA Y, 1983, BIOPHYS CHEM, V18, P233, DOI 10.1016/0301-4622(83)80036-2; Lakowicz JR., 1999, PRINCIPLES FLUORESCE, P25; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEDNEVA RK, 1978, NUCLEIC ACIDS RES, V5, P4225, DOI 10.1093/nar/5.11.4225; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; TOLMAN GL, 1974, BIOCHEMISTRY-US, V13, P4869, DOI 10.1021/bi00721a001; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27865	27873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875934				2022-12-25	WOS:000089197100048
J	Rumsey, SC; Daruwala, R; Al-Hasani, H; Zarnowski, MJ; Simpson, IA; Levine, M				Rumsey, SC; Daruwala, R; Al-Hasani, H; Zarnowski, MJ; Simpson, IA; Levine, M			Dehydroascorbic acid transport by GLUT4 in Xenopus oocytes and isolated rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; GROWTH-FACTOR-I; ASCORBIC-ACID; VITAMIN-C; DIABETES-MELLITUS; HUMAN NEUTROPHILS; CELL-SURFACE; SUGAR-TRANSPORT; SKELETAL-MUSCLE; INSULIN	Dehydroascorbic acid (DHA), the first stable oxidation product of vitamin C, was transported by GLUT1 and GLUT3 in Xenopus laevis oocytes with transport rates similar to that of P-deoxyglucose (2-DG), but due to inherent difficulties with GLUT4 expression in oocytes it was uncertain whether GLUT4 transported DHA (Rumsey, S, C., Kwon, O., Xu, G. W., Burant, C. F., Simpson, I., and Levine, M. (1997) J. Biol. Chem. 272, 18982-18989). We therefore studied DHA and 2-DG transport in rat adipocytes, which express GLUT4. Without insulin, rat adipocytes transported 2-DG 2-3-fold faster than DHA. Preincubation with insulin (0.67 mu M) increased transport of each substrate similarly: 7-10-fold for 2-DG and 6-8-fold for DHA, Because intracellular reduction of DHA in adipocytes was complete before and after insulin stimulation, increased transport of DHA was not explained by increased internal reduction of DHA to ascorbate, To determine apparent transport kinetics of GLUT4 for DHA, GLUT4 expression in Xenopus oocytes was reexamined. Preincubation of oocytes for >4 h with insulin (1 mu M) augmented GLUT4 transport of 2-DG and DKA by up to 5-fold. Transport of both substrates was inhibited by cytochalasin B and displayed saturable kinetics. GLUT4 had a higher apparent transport affinity (K-m of 0.98 versus 5.2 mM) and lower maximal transport rate (V-max of 66 versus 880 pmol/oocyte/10 min) for DHA compared with 2-DG. The lower transport rate for DHA could not be explained by binding differences at the outer membrane face, as shown by inhibition with ethylidene glucose, or by transporter trans-activation and therefore was probably due to substrate-specific differences in transporter/substrate translocation or release. These novel data indicate that the insulin-sensitive transporter GLUT4 transports DHA in both rat adipocytes and Xenopus oocytes, Alterations of this mechanism in diabetes could have clinical implications for ascorbate utilization.	NIDDK, Digest Dis Branch, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, Expt Diabet Metab & Nutr Sect, NIH, Bethesda, MD 20892 USA; Mead Johnson Nutr, Evansville, IN USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Levine, M (corresponding author), NIDDK, Digest Dis Branch, Mol & Clin Nutr Sect, NIH, Bldg 10 Rm 4D52 MSC 1372, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506, ZIADK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; Cunningham JJ, 1998, J AM COLL NUTR, V17, P105, DOI 10.1080/07315724.1998.10718734; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Detaille D, 1999, EUR J PHARMACOL, V377, P127, DOI 10.1016/S0014-2999(99)00413-6; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Hauner H, 1998, INT J OBESITY, V22, P448, DOI 10.1038/sj.ijo.0800606; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JANICOT M, 1989, P NATL ACAD SCI USA, V86, P2642, DOI 10.1073/pnas.86.8.2642; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KELLER K, 1990, BIOMED BIOCHIM ACTA, V49, P1201; KELLER RJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P40, DOI 10.1016/0003-9861(89)90253-1; Lindsay RM, 1998, DIABETOLOGIA, V41, P516, DOI 10.1007/s001250050940; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Miele C, 1997, DIABETOLOGIA, V40, P421, DOI 10.1007/s001250050696; MORA S, 1995, BIOCHEM J, V311, P59, DOI 10.1042/bj3110059; Mora S, 1997, BIOCHEM J, V324, P455, DOI 10.1042/bj3240455; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Nagano S, 1996, J NUTR SCI VITAMINOL, V42, P1, DOI 10.3177/jnsv.42.1; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; SINCLAIR AJ, 1994, DIABETIC MED, V11, P893, DOI 10.1111/j.1464-5491.1994.tb00375.x; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; Weber T. M., 1988, INSULIN RECEPTORS B, P171; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; Will JC, 1996, NUTR REV, V54, P193, DOI 10.1111/j.1753-4887.1996.tb03932.x; ZORZANO A, 1996, DIABETES, V45, P70	44	153	158	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28246	28253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862609				2022-12-25	WOS:000089197100095
J	Yarmola, EG; Somasundaram, T; Boring, TA; Spector, I; Bubb, MR				Yarmola, EG; Somasundaram, T; Boring, TA; Spector, I; Bubb, MR			Actin-latrunculin A structure and function - Differential modulation of actin-binding protein function by latrunculin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOSIN BETA-4; ACANTHAMOEBA-PROFILIN; FILAMENTOUS ACTIN; MONOMERIC ACTIN; CYTOCHALASIN-D; F-ACTIN; POLYMERIZATION; SITES; INTERACTS; NUCLEOTIDES	Latrunculin A is used extensively as an agent to sequester monomeric actin in living cells. We hypothesize that additional activities of latrunculin A may be important for its biological activity. Our data are consistent with the formation of a 1:1 stoichiometric complex with an equilibrium dissociation constant of 0.2 to 0.4 mu M and provide no evidence that the actin-latrunculin A complex participates in the elongation of actin filaments. Profilin and latrunculin A bind independently to actin, whereas binding of thymosin beta(4) to actin is inhibited by latrunculin A. Potential implications of this differential effect on actin-binding proteins are discussed. From a structural perspective, if latrunculin A binds to actin at a site that sterically influences binding by thymosin beta(4), then the observation that latrunculin A inhibits nucleotide exchange on actin implies an allosteric effect on the nucleotide binding cleft. Alternatively, if, as previously postulated, latrunculin A binds in the nucleotide cleft of actin, then its ability to inhibit binding by thymosin beta(4) is a surprising result that suggests that significant allosteric changes affect the thymosin beta(4) binding site. We show that latrunculin A and actin form a crystalline structure with orthorhombic space group P2(1)2(1)2(1) and diffraction to 3.10 Angstrom. A high resolution structure with optimized crystallization conditions should provide insight regarding these remarkable allosteric properties.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Vet Affairs Med Ctr, Malcolm Randall Dept, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; State University System of Florida; Florida State University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.			Somasundaram, Thayumanasamy/0000-0002-3629-5117				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ballweber E, 1997, BIOCHEM J, V327, P787, DOI 10.1042/bj3270787; Belmont LD, 1999, J CELL SCI, V112, P1325; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Davoodian K, 1997, BIOCHEMISTRY-US, V36, P9637, DOI 10.1021/bi9711487; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KIRSCHNER MW, 1971, BIOCHEMISTRY-US, V10, P1900, DOI 10.1021/bi00786a027; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuznetsova I, 1996, FEBS LETT, V383, P105, DOI 10.1016/0014-5793(96)00238-4; LAL AA, 1985, J BIOL CHEM, V260, P132; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLZAR B, 1989, EUR J BIOCHEM, V182, P267, DOI 10.1111/j.1432-1033.1989.tb14826.x; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; Reichert A, 1996, J BIOL CHEM, V271, P1301, DOI 10.1074/jbc.271.3.1301; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Terry DR, 1997, J BIOL CHEM, V272, P7841, DOI 10.1074/jbc.272.12.7841; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WESTBROOK EM, 1985, METHOD ENZYMOL, V114, P187; Young JD, 1999, NAT MED, V5, P1424; YU FX, 1993, J BIOL CHEM, V268, P502	39	209	211	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28120	28127						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10859320				2022-12-25	WOS:000089197100078
J	Raman, V; Tamori, A; Vali, M; Zeller, K; Korz, D; Sukumar, S				Raman, V; Tamori, A; Vali, M; Zeller, K; Korz, D; Sukumar, S			HOXA5 regulates expression of the progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENES; MAMMARY-GLAND	The majority of breast carcinomas show reduced or no expression of the transcription factor, HOXA5. Recently, we have shown that HOXA5 is a potent transactivator of p53 in breast cells and thus may affect the response of breast cancer cells to DNA damage. To determine whether HOXA5 played a role in growth and homeostasis in breast cells, we studied its interaction with the progesterone receptor. The progesterone receptor (PR) belongs to the superfamily of nuclear receptors whose members co-ordinate morphogenesis of the mammary gland in response to binding to their cognate ligands. An increased expression of the endogenous PR gene was seen in MCF-7 cells following induced expression of an exogenously transfected HOXA5 gene. HOXA5, but not HOXB4, -B5, or -B7 activated the PR promoter in two breast cancer cell lines, MCF-7 and Hs578T. Deletion and mutation analysis of the promoter identified a single HOXA5-binding site required for transactivation of the PR gene by HOXA5. HOXA5 binds directly to this site in the PR promoter. Thus, HOXA5 may behave as a transcriptional regulator of multiple target genes, two among which are p53 and the progesterone receptor.	Johns Hopkins Oncol Ctr, Breast Canc Program, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Sukumar, S (corresponding author), Johns Hopkins Oncol Ctr, Breast Canc Program, 1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [T32CA009630] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA8943, T32 CA09630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATTERSBY S, 1992, BRIT J CANCER, V65, P601, DOI 10.1038/bjc.1992.122; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Conneely OM, 2000, J SOC GYNECOL INVEST, V7, pS25, DOI 10.1016/S1071-5576(99)00062-3; Greer JM, 2000, NATURE, V403, P661, DOI 10.1038/35001077; Katzenellenbogen BS, 2000, J SOC GYNECOL INVEST, V7, pS33, DOI 10.1177/1071557600007001S10; Korach KS, 2000, J SOC GYNECOL INVEST, V7, pS16, DOI 10.1177/1071557600007001S06; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Moutsatsou P, 1997, ANN NY ACAD SCI, V816, P99, DOI 10.1111/j.1749-6632.1997.tb52134.x; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAMAN V, 1993, INT J DEV BIOL, V37, P499; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963	15	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26551	26555		10.1074/jbc.C000324200	http://dx.doi.org/10.1074/jbc.C000324200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10875927	hybrid			2022-12-25	WOS:000088999700092
J	Schleef, RR; Chuang, TL				Schleef, RR; Chuang, TL			Protease inhibitor 10 inhibits tumor necrosis factor alpha-induced cell death - Evidence for the formation of intracellular high M-r protease inhibitor 10-containing complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; HUMAN SERPIN; TYPE-2; IDENTIFICATION; INSERTION; MECHANISM; APOPTOSIS; TRYPSIN; BOMAPIN	Protease inhibitor 10 (PI10) is a member of the ovalbumin family of serine protease inhibitors (ov-serpin) that is expressed at elevated levels in patients with acute myeloid leukemia and chronic myelomonocytic leukemia. Based upon the ability of the related serpin plasminogen activator inhibitor 2 (PAI-8) to protect cells against tumor necrosis factor alpha (TNF alpha)-induced cell death, this study was initiated to investigate the potential cytoprotective activity of PI10, Two different expression systems (i.e. plasmids encoding either PI10 alone or PI10 fused to the tag: enhanced green fluorescent protein, EG;FP) were utilized to stably transfect an eukaryotic model cell system (i.e. HeLa cells) that neither expresses PAI-2 nor PI10. The level of PI10 expression in the stable transfectants was found to correlate with their resistance to TNF alpha-induced cell death. Immunoprecipitation/immunoblotting experiments demonstrated that PI10 is able to form SDS-stable complexes (i.e, M-r >100,000) with a cytosolic protein(s). Increased levels of the PI10-containing complexes can be detected by TNF alpha treatment by preventing intracellular degradative activities with the proteasome inhibitor N-carbobenzyloxy-leucine-leucine-norvalinal. PI10-containing complexes are dissociated with conditions known to separate classical protease-serpin complexes (i.e., 1.5 hz ammonium hydroxide in the presence of SDS). These data support a role for the regulation of intracellular protease activities by ov-serpins.	Scripps Res Inst, Dept Vasc Biol VB1, La Jolla, CA 92037 USA	Scripps Research Institute	Schleef, RR (corresponding author), Scripps Res Inst, Dept Vasc Biol VB1, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P175; Chuang TL, 1999, J BIOL CHEM, V274, P11194, DOI 10.1074/jbc.274.16.11194; DANIELSSON A, 1982, BIOCHEM J, V207, P21, DOI 10.1042/bj2070021; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; KUMAR S, 1991, J BIOL CHEM, V266, P20960; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; Ny T, 1997, ADV EXP MED BIOL, V425, P123; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PHILIPS M, 1984, BIOCHIM BIOPHYS ACTA, V802, P99, DOI 10.1016/0304-4165(84)90039-4; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; Riewald M, 1996, J BIOL CHEM, V271, P7160, DOI 10.1074/jbc.271.12.7160; Riewald M, 1998, BLOOD, V91, P1256, DOI 10.1182/blood.V91.4.1256; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; WIMAN B, 1979, J BIOL CHEM, V254, P9291	20	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26385	26389		10.1074/jbc.C000389200	http://dx.doi.org/10.1074/jbc.C000389200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10871600	hybrid			2022-12-25	WOS:000088999700069
J	Tibbetts, AS; Appling, DR				Tibbetts, AS; Appling, DR			Characterization of two 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase isozymes from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; SUBUNIT STRUCTURE; ESCHERICHIA-COLI; PROTEIN BAS1P; GENE-PRODUCT; YEAST-CELLS; IN-VIVO; EXPRESSION; DNA; TRANSFORMATION	The Saccharomyces cerevisiae ADE16 and ADE17 genes encode 5-aminoimidazole-4-carboxamide ribonucleotide transformylase isozymes that catalyze the penultimate step of the de novo purine biosynthesis pathway. Disruption of these two chromosomal genes results in adenine auxotrophy, whereas expression of either gene alone is sufficient to support growth without adenine. In this work, me show that an ade16 ade17 double disruption also leads to histidine auxotrophy, similar to the adenine/histidine auxotrophy of ade3 mutant yeast strains. We also report the purification and characterization of the ADE16 and ADE17 gene products (Ad16p and Ade17p). Like their counterparts in other organisms, the yeast isozymes are bifunctional, containing both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities, and exist as homodimers based on cross-linking studies. Both isozymes are localized to the cytosol, as shown by subcellular fractionation experiments and immunofluorescent staining. Epitope-tagged constructs were used to study expression of the two isozymes, The expression of Ade17p is repressed by the addition of adenine to the media, whereas Ade16p expression is not affected by adenine. Ade16p was observed to be more abundant in cells grown on nonfermentable carbon sources than in glucose-grown cells, suggesting a role for this isozyme in respiration or sporulation.	Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Inst Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA.	dappling@mail.utexas.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009276] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09276] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; Beardsley GP, 1998, ADV EXP MED BIOL, V431, P221; BLACK SL, 1978, ANAL BIOCHEM, V90, P397, DOI 10.1016/0003-2697(78)90042-8; Cleland W W, 1979, Methods Enzymol, V63, P103; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Eisinger DP, 1997, BIOTECHNIQUES, V22, P250, DOI 10.2144/97222bm11; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P394, DOI 10.1006/abio.1993.1346; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KOEPP DM, 1998, CELLS LAB MANUAL; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Pinson B, 1998, NUCLEIC ACIDS RES, V26, P3977, DOI 10.1093/nar/26.17.3977; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; ROMAN H, 1956, CR TRAV LAB CARLS P, V26, P299; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rowe P.B, 1971, METHODS ENZYMOL B, V18, P733; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Springer C, 1996, J BIOL CHEM, V271, P29637, DOI 10.1074/jbc.271.47.29637; Tibbetts AS, 1997, ARCH BIOCHEM BIOPHYS, V340, P195, DOI 10.1006/abbi.1997.9919; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	34	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20920	20927		10.1074/jbc.M909851199	http://dx.doi.org/10.1074/jbc.M909851199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877846	hybrid			2022-12-25	WOS:000088084500098
J	Harendza, S; Lovett, DH; Stahl, RAK				Harendza, S; Lovett, DH; Stahl, RAK			The hematopoietic transcription factor PU.1 represses gelatinase A transcription in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; MURINE TISSUE MACROPHAGES; BETA-C GENE; MATRIX METALLOPROTEINASE-2; IV COLLAGENASE; DNA-BINDING; EXPRESSION; PROMOTER; RAT; ACTIVATION	The matrix metalloproteinase gelatinase A plays a key role in the evolution of glomerular injury and is a major contributing factor to the development of glomerulosclerosis, Prior studies have focused on a potent cis-acting enhancer element located in the near 5'-flanking region of the rat and human gelatinase A genes (Harendza, S., Pollock, A. S., Mertens, P. R., and Lovett, D. H. (1995) J. Biol. Chem. 270, 18286-18796; Mertens, P. R., Alfonso-Jaume, M. A., Steinmann, K., and Lovett, D. H. (1999) J. Am. Soc. Nephrol. 10, 2480-2487). Given the combinatorial nature of transcriptional regulation, we examined additional regions of the 5'-flanking region of the rat gelatinase A gene to identify further regulatory elements. In this study the identification of a silencing element located between -1903 and -1847 base pairs of the 5'-flanking region of the rat gelatinase A gene is reported. Sequence analysis, electrophoretic mobility studies, and transfection experiments demonstrate that a specific binding sequence for the hematopoietic transcription factor PU.1 is present within the silencing sequence. PU.1 activity is absolutely required for the expression of silencing activity within the context of transfected glomerular mesangial cells. Western blots identify the PU.1 protein within nuclear extracts of mesangial cells, and cotransfection with a PU.1 expression vector directly augments silencing activity. These studies underscore the complex patterns of gelatinase A transcriptional regulation and also strongly suggest that glomerular mesangial cells are ultimately derived from bone marrow cells.	Univ Hamburg, Dept Med, Div Nephrol, D-20246 Hamburg, Germany; Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA	University of Hamburg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Harendza, S (corresponding author), Univ Hamburg, Krankenhaus Eppendorf, Med Klin, Abt Nephrol & Osteol, Pavillon 61,Martinistr 52, D-20246 Hamburg, Germany.	harendza@uke.uni-hamburg.de			NIDDK NIH HHS [DK 39776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Antalis TM, 1996, BLOOD, V88, P3686, DOI 10.1182/blood.V88.10.3686.bloodjournal88103686; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CAROME MA, 1994, J AM SOC NEPHROL, V5, P1391; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; Harendza S, 1997, NEPHROL DIAL TRANSPL, V12, P2537, DOI 10.1093/ndt/12.12.2537; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 1999, NEPHROL DIAL TRANSPL, V14, P2873, DOI 10.1093/ndt/14.12.2873; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; Lodie TA, 1997, J IMMUNOL, V158, P1848; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; LOVETT DH, 1992, AM J PATHOL, V141, P85; Marecki S, 1999, J IMMUNOL, V163, P2713; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; McKercher SR, 1999, J LEUKOCYTE BIOL, V66, P727, DOI 10.1002/jlb.66.5.727; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ogbourne S, 1998, BIOCHEM J, V331, P1; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; RADEKE HH, 1994, KIDNEY INT, V45, P763, DOI 10.1038/ki.1994.101; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; TUREK J, 1996, J BIOL CHEM, V25, P15074; UTSUNOMIYA Y, 1999, J AM SOC NEPHROL, V10, P406; van Dijk TB, 1999, J IMMUNOL, V163, P2674; van Dijk TB, 1998, BLOOD, V92, P3636, DOI 10.1182/blood.V92.10.3636.422k45_3636_3646; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xue Y, 1999, BIOCHEM BIOPH RES CO, V254, P211, DOI 10.1006/bbrc.1998.9905; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	43	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19552	19559		10.1074/jbc.M001322200	http://dx.doi.org/10.1074/jbc.M001322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867017	hybrid			2022-12-25	WOS:000087941300018
J	Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF				Rizos, H; Darmanian, AP; Mann, GJ; Kefford, RF			Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization	ONCOGENE			English	Article						p14ARF; nucleolar localization; hdm2; p53	MELANOMA-PRONE FAMILIES; CELL-CYCLE ARREST; GERMLINE MUTATIONS; NUCLEAR EXPORT; INK4A LOCUS; P53 PROTEIN; MDM2; P19(ARF); GENE; P16(INK4A)	The INK4a/ARF locus encodes two distinct tumour suppressors, p16(INK4a) and p14ARF, that regulate cell cycle progression via the pRB and p53 pathways, respectively, The ARF protein inhibits hdm2 activity, leading to the stabilization of the p53 tumour suppressor and cell cycle inhibition, The amino-terminal domain of human p14ARF and of the mouse homologue, p19ARF, is sufficient for these effects, This domain is also sufficient for the nucleolar localization of the mouse ARF protein. In contrast, we show that the human ARF protein requires two arginine rich domains, one in the amino- and the other in the carboxy-terminus, for nucleolar targeting. The amino-terminal nucleolar-targeting domain of p14ARF is also important for ARF-hdm2 binding and cell cycle inhibition, The carboxy-terminal p14ARF nucleolar localization domain lies within the shared INK4a/ARF exon 2, and is mutated in a small number of melanoma-prone kindreds, The INK4a/ARF exon2-mutations could affect the function of both the p16(INK4a) and p14ARF tumour suppressors.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney	Rizos, H (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lee JY, 1997, BIOCHEM BIOPH RES CO, V237, P667, DOI 10.1006/bbrc.1997.7212; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parry D, 1996, MOL CELL BIOL, V16, P3844; Piccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	89	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2978	2985		10.1038/sj.onc.1203629	http://dx.doi.org/10.1038/sj.onc.1203629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871849				2022-12-25	WOS:000087581400004
J	Fontoura, BMA; Blobel, G; Yaseen, NR				Fontoura, BMA; Blobel, G; Yaseen, NR			The nucleoporin Nup98 is a site for GDP/GTP exchange on Ran and termination of karyopherin beta 2-mediated nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; ACUTE MYELOID-LEUKEMIA; PORE COMPLEX PROTEIN; MESSENGER-RNA; CHROMOSOME-TRANSLOCATION; BIOGENESIS PATHWAY; BINDING-PROTEIN; HOMEOBOX GENE; P62 COMPLEX	Karyopherin beta 2 (Kap beta 2, transportin) binds the MS sequence of human ribonucleoprotein Al and mediates its nuclear import. Here we show a role for the nucleoporin Nup98 in the disassembly of Kap beta 2 import complexes at the nuclear side of the nuclear pore complex (NPC). Kap beta 2 bound to a region at the N terminus of Nup98 that contains an MS-like sequence. The human ribonucleoprotein Al MS sequence competed with Nup98 for binding to Kap beta 2, indicating that Nup98 can dissociate Kappa from its substrate. Binding of Kap beta 2 to Nup98 was inhibited by Ran loaded with guanylyl imidophosphate, suggesting that RanGTP dissociates Kappa from Nup98, RanGTP is produced from RanGDP through nucleotide exchange mediated by RanGEF (RCC1). Immunoelectron microscopy and nucleotide exchange assays revealed functional RanGEF on both sides of the NPC. On the nuclear side, the localization of RanGEF coincided with that of Nup98. RanGEF bound to Nup98 at a region adjacent to the Kappa-binding site. These findings suggest a model where 1) import substrate is released from Kap beta 2 at the nucleoplasmic side of the NPC by competition with the Nup98 MS-like site, 2) Nup98-bound RanGEF catalyzes the formation of RanGTP, and 3) RanGTP dissociates Kappa from Nup98 allowing repeated cycles of import.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	blobel@rockvax.rockefeller.edu		Yaseen, Nabeel/0000-0001-6902-5116	NCI NIH HHS [K08 CA72959] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; Avis JM, 1996, J CELL SCI, V109, P2423; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUSS F, 1994, J CELL SCI, V107, P631; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; Emtage JLT, 1997, J CELL SCI, V110, P911; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hatano Y, 1999, BRIT J HAEMATOL, V107, P600, DOI 10.1046/j.1365-2141.1999.01754.x; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Hussey DJ, 1999, BLOOD, V94, P2072; Ikeda T, 1999, INT J HEMATOL, V69, P160; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kwong YL, 1999, GENE CHROMOSOME CANC, V25, P70, DOI 10.1002/(SICI)1098-2264(199905)25:1<70::AID-GCC11>3.0.CO;2-E; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RIS H, 1991, EMSA B, V21, P54; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Seki T, 1996, J BIOCHEM, V120, P207; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wong KF, 1999, CANCER GENET CYTOGEN, V115, P70, DOI 10.1016/S0165-4608(99)00085-0; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	72	70	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31289	31296		10.1074/jbc.M004651200	http://dx.doi.org/10.1074/jbc.M004651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10875935	hybrid			2022-12-25	WOS:000089762700077
J	Benning, MM; Hong, SB; Raushel, FM; Holden, HM				Benning, MM; Hong, SB; Raushel, FM; Holden, HM			The binding of substrate analogs to phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BACTERIAL PHOSPHOTRIESTERASE	Phosphotriesterase (PTE) from Pseudomonas diminuta catalyzes the detoxification of organophosphates such as the widely utilized insecticide paraoxon and the chemical warfare agent sarin. The three-dimensional structure of the enzyme is known from high resolution x-ray crystallographic analyses. Each subunit of the homodimer folds into a so-called TIM barrel, with eight strands of parallel beta-sheet. The two zinc ions required for activity are positioned at the C-terminal portion of the beta P-barrel. Here, we describe the three dimensional structure of PTE complexed with the inhibitor diisopropyl methyl phosphonate, which serves as a mimic for sarin. Additionally, the structure of the enzyme complexed with triethyl phosphate is also presented. In the case of the PTE-diisopropyl methyl phosphonate complex, the phosphoryl oxygen of the inhibitor coordinates to the more solvent-exposed zinc ion (2.5 Angstrom), thereby lending support to the presumed catalytic mechanism involving metal coordination of the substrate. In the PTE-triethyl phosphate complex, the phosphoryl oxygen of the inhibitor is positioned at 3.4 Angstrom from the more solvent-exposed zinc ion. The two structures described in this report provide additional molecular understanding for the ability of this remarkable enzyme to hydrolyze such a wide range of organophosphorus substrates.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Triad Therapeut, San Diego, CA 92121 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33894, GM55513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; CALDWELL SR, 1991, APPL BIOCHEM BIOTECH, V31, P59, DOI 10.1007/BF02922126; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Hong SB, 1999, BIOCHEMISTRY-US, V38, P1159, DOI 10.1021/bi982204m; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; Raushel FM, 2000, ADV ENZYMOL RAMB, V74, P51; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	16	79	109	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30556	30560		10.1074/jbc.M003852200	http://dx.doi.org/10.1074/jbc.M003852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10871616	hybrid			2022-12-25	WOS:000089577900088
J	Nurcombe, V; Smart, CE; Chipperfield, H; Cool, SM; Boilly, B; Hondermarck, H				Nurcombe, V; Smart, CE; Chipperfield, H; Cool, SM; Boilly, B; Hondermarck, H			The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR RECEPTOR KINASE; TYROSINE PHOSPHORYLATION; MAP KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; MAMMARY-GLAND; HUMAN-TUMORS	To explore how heparan sulfate (HS) controls the responsiveness of the breast cancer cell lines MCF-7 and MDA-MB-231 to fibroblast growth factors (FGFs), we have exposed them to HS preparations known to have specificity for FGF-1 (HS glycosaminoglycan (HSGAG A)) or FGF-2 (HSGAGB). Proliferation assays confirmed that MCF-7 cells were highly responsive to FGF-2 complexed with GAGB, whereas migration assays indicated that FGF-1/HSGAGA combinations were stimulatory for the highly invasive MDA-MB-231 cells. Quantitative polymerase chain reaction for the levels of FGF receptor (PGFR) isoforms revealed that MCF-7 cells have greater levels of FGFR1 and that MDA-MB-231 cells have greater relative levels of FGFR2. Cross-linking demonstrated that FGF-2/HSGAGB primarily activated FGFR1, which in turn up regulated the activity of mitogen-activated protein kinase; in contrast, FGF-1/HSGAGA led to the phosphorylation of equal proportions of both FGFR1 and FGFR2, which in turn led to the up-regulation of Src and p125(FAK). MDA-MB-231 cells were particularly responsive to vitronectin substrates in the presence of FGF-1/HSGAGA, and blocking antibodies established that they used the alpha(v)beta(3) integrin to bind to it. These results suggest that the clustering of particular FGFR configurations on breast cancer cells induced by different HS chains leads to distinct phenotypic behaviors.	Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia; Univ Sci & Technol Lille, Dev Biol Lab, UPRES 1033, Grp Facteurs Croissance, F-59655 Villeneuve Dascq, France	University of Queensland; Universite de Lille - ISITE; Universite de Lille	Nurcombe, V (corresponding author), Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia.	v.nurcombe@mailbox.uq.edu.au	Cool, Simon/W-1257-2018; Smart, Chanel E/C-9583-2011; Cool, Simon McKenzie/AAG-4346-2021	Cool, Simon/0000-0001-8543-3056; 				BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; Burgess AW, 1998, PHILOS T ROY SOC B, V353, P903, DOI 10.1098/rstb.1998.0254; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Garfinkel S, 1996, BBA-MOL CELL RES, V1314, P109, DOI 10.1016/S0167-4889(96)00105-X; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONCALVES LM, 1998, REV PORT CARDIOL S2, V17, P11; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hill DJ, 1998, DIABETES CARE, V21, pB60; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; ILIE D, 1995, NATURE, V377, P539; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jang JH, 1997, IN VITRO CELL DEV-AN, V33, P819; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KE YQ, 1993, J CELL SCI, V106, P135; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin HY, 1996, J NEUROSCI, V16, P4579; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; MURGUE B, 1994, CANCER RES, V54, P5206; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Palmantier R, 1996, CANCER RES, V56, P2206; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P887, DOI 10.1177/41.6.7686196; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Szebenyi G, 1999, INT REV CYTOL, V185, P45; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Uruno T, 1998, SEIKAGAKU, V70, P446; van der Pluijm G, 1997, LAB INVEST, V77, P665; Walz A, 1997, DEVELOPMENT, V124, P2421; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	66	73	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30009	30018		10.1074/jbc.M003038200	http://dx.doi.org/10.1074/jbc.M003038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862617	hybrid			2022-12-25	WOS:000089577900014
J	Hussain, MM; Obunike, JC; Shaheen, A; Hussain, MJ; Shelness, GS; Goldberg, IJ				Hussain, MM; Obunike, JC; Shaheen, A; Hussain, MJ; Shelness, GS; Goldberg, IJ			High affinity binding between lipoprotein lipase and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; TERMINALLY TRUNCATED FORMS; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODY; CELLS; SECRETION; SITE; EXPRESSION; ASSOCIATION	Lipoprotein lipase (LPL) physically associates with lipoproteins and hydrolyzes triglycerides. To characterize the binding of LPL to lipoproteins, we studied the binding of low density lipoproteins (LDL), apolipoprotein (apo) B17, and various apoB-FLAG (DYKDDDDK octapeptide) chimeras to purified LPL. LDL bound to LPL with high affinity (K-d values of 10(-12) M) similar to that observed for the binding of LDL to its receptors and 1D1, a monoclonal antibody to LDL, and was greater than its affinity for microsomal triglyceride transfer protein. LDL-LPL binding was sensitive to both salt and detergents, indicating the involvement of both hydrophobic and hydrophilic interactions. In contrast, the N-terminal 17% of apoB interacted with LPL mainly via ionic interactions. Binding of various apoB fusion peptides suggested that LPL bound to apoB at multiple sites within apoB17, Tetrahydrolipstatin, a potent enzyme activity inhibitor, had no effect on apoB-LPL binding, indicating that the enzyme activity was not required for apoB binding. LDL-LPL binding was inhibited by monoclonal antibodies that recognize amino acids 380-410 in the C-terminal region of LPL, a region also shown to interact with heparin and LDL receptor-related protein. The LDL-LPL binding was also inhibited by glycosaminoglycans (GAGs); heparin inhibited the interactions by similar to 50% and removal of trace amounts of heparin from LPL preparations increased LDL binding. Thus, we conclude that the high affinity binding between LPL and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity and is modulated by GAGs. It is proposed that LPL contains a surface exposed positively charged amino acid cluster that may be important for various physiological interactions of LPL with different biologically important molecules. Moreover, we postulate that by binding to this cluster, GAGs modulate the association between LDL and LPL and the in vivo metabolism of LPL.	SUNY Hlth Sci Ctr, Dept Anat & Cell Biol & Pediat, Brooklyn, NY 11203 USA; Med Coll Penn & Hahnemann Univ, Sch Med, Dept Biochem, Philadelphia, PA 19129 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Drexel University; Wake Forest University; Wake Forest Baptist Medical Center; Columbia University	Hussain, MM (corresponding author), SUNY Hlth Sci Ctr, Dept Anat & Cell Biol & Pediat, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA.	mahmoodhussain@netmail.hscbklyn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062301, R01HL064272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046900, R29DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62301, HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; BENGTSSON G, 1983, BIOCHIM BIOPHYS ACTA, V751, P254, DOI 10.1016/0005-2760(83)90180-7; Bhatnagar D, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P737; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; Chang SF, 1998, J LIPID RES, V39, P2350; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; DU EZ, 1994, J BIOL CHEM, V269, P24169; Goldberg IJ, 1998, J BIOL CHEM, V273, P35355, DOI 10.1074/jbc.273.52.35355; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HADVARY P, 1991, J BIOL CHEM, V266, P2021; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; Pang L, 1996, J BIOL CHEM, V271, P19518, DOI 10.1074/jbc.271.32.19518; PEASE RJ, 1990, J BIOL CHEM, V265, P553; Segrest JP, 1998, J LIPID RES, V39, P85; Segrest JP, 1999, J LIPID RES, V40, P1401; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; Tietge UJF, 1999, J LIPID RES, V40, P2134; WANG HX, 1994, J BIOL CHEM, V269, P18514; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yin BY, 1997, J CLIN INVEST, V100, P649, DOI 10.1172/JCI119576	38	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29324	29330		10.1074/jbc.M005317200	http://dx.doi.org/10.1074/jbc.M005317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882743	hybrid			2022-12-25	WOS:000089439800021
J	Mouledous, L; Topham, CM; Mazarguil, H; Meunier, JC				Mouledous, L; Topham, CM; Mazarguil, H; Meunier, JC			Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AMINO-TERMINAL TAIL; P NK-1 RECEPTOR; DYNORPHIN-A; NOCICEPTIN/ORPHANIN FQ; ORL1 RECEPTOR; ORPHANIN-FQ; SECRETIN RECEPTOR; SUBSTANCE-P; DOMAINS	The heptadecapeptide nociceptin, also known as orphanin FQ, is the endogenous agonist of the opioid receptor-like 1 (ORL1) G protein-coupled receptor, An affinity labeling approach has been implemented to probe the interactions of the neuropeptide with the receptor using the photolabile nociceptin derivative, [p-benzoyl-L-Phe(10),Tyr(14)]nociceptin ([Bpa(10),Tyr(14)]noc). In recombinant Chinese hamster ovary cells expressing the human ORL1 receptor, [Bpa(10),Tyr(14)]noc binds the receptor with high affinity (K-i similar to 0.7 nM) and is as potent as nociceptin in the inhibition of forskolin-induced cAMP synthesis (EC50 similar to 0.5 nM). UV irradiation at 365 nm of the complex formed by the ORL1 receptor and radioiodinated [Bpa(10),Tyr(14)]noc results in the irreversible labeling of a glycoprotein of similar to 65 kDa, determined by SDS-polyacrylamide gel electrophoresis. Complete digestion of the partially purified 65-kDa complex with kallikrein generates a single labeled fragment (similar to 6.5 kDa) that is readily cleaved by endoproteinase Glu-C to yield a labeled fragment of similar to 3.2 kDa, Kallikrein treatment of the photoaffinity cross-linked Glu(295) --> Asp mutant receptor also yields a single labeled fragment of similar to 6.5 kDa but is resistant to further cleavage by endoproteinase Glu-C. Based upon the expected proteolytic fingerprint of the labeled receptor, the photoreactive region can be identified as ORL1-(296-302; residues Thr-Ala-Val-Ala-Ile-Leu-Arg) spanning the C terminus of extracellular loop 3 and the N terminus of transmembrane helix VII. Molecular modeling of the ORL1 receptor complex with [Bpa(10)]noc suggests that reaction of the Bpa carbonyl group may occur with the side chain of Ile(300) within the experimentally identified photoreactive region.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Meunier, JC (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.	jcm@ipbs.fr		Mouledous, Lionel/0000-0002-7675-3493				ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Becker JAJ, 1999, J BIOL CHEM, V274, P27513, DOI 10.1074/jbc.274.39.27513; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Butour JL, 1997, EUR J PHARMACOL, V321, P97, DOI 10.1016/S0014-2999(96)00919-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Darland T, 1998, TRENDS NEUROSCI, V21, P215, DOI 10.1016/S0166-2236(97)01204-6; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Dooley CT, 1996, LIFE SCI, V59, pPL23, DOI 10.1016/0024-3205(96)00261-5; Dooley CT, 1997, J PHARMACOL EXP THER, V283, P735; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRISCH MJ, 1995, GAUSSIAN 94; Guerrini R, 1997, J MED CHEM, V40, P1789, DOI 10.1021/jm970011b; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapalu S, 1997, FEBS LETT, V417, P333, DOI 10.1016/S0014-5793(97)01318-5; Lapalu S, 1998, FEBS LETT, V427, P296, DOI 10.1016/S0014-5793(98)00452-9; LAPALU S, 1999, THESIS U P SABATIER; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; Meunier JC, 2000, EXPERT OPIN THER PAT, V10, P371, DOI 10.1517/13543776.10.4.371; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Meunier JC, 1997, EUR J PHARMACOL, V340, P1, DOI 10.1016/S0014-2999(97)01411-8; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Mollereau C, 1999, MOL PHARMACOL, V55, P324, DOI 10.1124/mol.55.2.324; Mouledous L, 2000, MOL PHARMACOL, V57, P495, DOI 10.1124/mol.57.3.495; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Reinscheid RK, 1998, J BIOL CHEM, V273, P1490, DOI 10.1074/jbc.273.3.1490; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; Topham CM, 1998, PROTEIN ENG, V11, P1163, DOI 10.1093/protein/11.12.1163; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216	44	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29268	29274		10.1074/jbc.M004971200	http://dx.doi.org/10.1074/jbc.M004971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10880520	hybrid			2022-12-25	WOS:000089439800014
J	Yang, YZ; Xia, ZP; Liu, YH				Yang, YZ; Xia, ZP; Liu, YH			SNAP-25 functional domains in SNARE core complex assembly and glutamate release of cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MEMBRANE-FUSION COMPLEX; T-SNARE; SYNTAXIN; EXOCYTOSIS; PALMITOYLATION; SYNAPTOBREVIN; SYNAPTOTAGMIN; MACHINERY; NEURONS	Synaptosomal associated protein of 25 kDa (SNAP-25) is a member of the SNARE protein complex that has been implicated in synaptic vesicle docking and fusion, In this report, we have generated SNAP-25 mutants and assayed their functions in SNARE complex formation and glutamate release from cultured rat cerebellar granule cells. In vitro binding studies show that a deletion mutant lacking the C-terminal 181-206 amino acid sequence inhibits the formation of the SNARE core complex. Additional deletion of an N-terminal 1-31 amino acid sequence abolished this inhibitory activity. Adenovirus-mediated gene transfer is used to overexpress wild-type and mutant SNAP-25 in cerebellar granule cells. Neurons overexpressing the wild-type protein show slight reductions in glutamate release, ranging from 10 to 15% in both the developing and mature granule cells. A 30-35% inhibition is obtained with the C-terminal deletion mutant, and the inhibitory effect is abolished in the N- and C-terminal double deletion mutant. These results demonstrate that the SNARE core complex exists in a dynamic and reversible state, and the formation of the core complex is necessary for neurotransmitter release in neurons.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Liu, YH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, POB 26901, Oklahoma City, OK 73190 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035167] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35167] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Lane SR, 1997, J NEUROCHEM, V69, P1864; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Owe-Larsson B, 1999, EUR J NEUROSCI, V11, P1981, DOI 10.1046/j.1460-9568.1999.00614.x; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, NEURON, V13, P355; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Venkatakrishnan A, 1996, J CHROMATOGR B, V676, P1, DOI 10.1016/0378-4347(95)00403-3; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	34	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29482	29487		10.1074/jbc.M003237200	http://dx.doi.org/10.1074/jbc.M003237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882724	hybrid			2022-12-25	WOS:000089439800042
J	Hahn, H; Wojnowski, L; Specht, K; Kappler, R; Calzada-Wack, J; Potter, D; Zimmer, A; Muller, U; Samson, E; Quintanilla-Martinez, L; Zimmer, A				Hahn, H; Wojnowski, L; Specht, K; Kappler, R; Calzada-Wack, J; Potter, D; Zimmer, A; Muller, U; Samson, E; Quintanilla-Martinez, L; Zimmer, A			Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; SIGNALING PATHWAY; SONIC HEDGEHOG; GENE; EXPRESSION; CANCER; TUMORIGENESIS; RECEPTOR; DISEASE	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children (Dagher, R., and Helman, L, (1999) Oncologist 4, 34-44), whereas medulloblastoma, a highly malignant tumor of the cerebellum, accounts for 20% of childhood brain tumors (Goodrich, L, V,, and Scott, M. P. (1998) Neuron 21, 1243-1257), Both tumors are associated with a deficiency in the tumor suppressor Patched (PTCH) in Gorlin syndrome (Gorlin, R, J, (1987) Medicine (Baltimore) 66, 98-113), and they are present in the corresponding murine models. RMS in Ptch mutant mice consistently contain elevated levels of the tumor growth-promoting insulin-like growth factor 2 (Igf2), We have investigated the mechanism of Igf2 overexpression and its significance in medulloblastoma and RMS tumorigenesis, Here we report that Igf2 is indispensable for the formation of medulloblastoma and RMS in Ptch mutants. Overexpression of Igf2 in RMS in these mice does not involve loss of imprinting, uniparental disomy, amplification of the Igf2 locus, or polyploidy, Since Igf2 is also overexpressed in non-tumor tissue deficient in Ptch, these observations suggest that Ptch regulates Igf2 levels through a transcriptional mechanism. They also identify Igf2 as a potential target for medulloblastoma and RMS.	Tech Univ Munich, Inst Pathol, GSF, Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; NIMH, Vet Med & Resources Branch, NIH, Bethesda, MD 20892 USA; Univ Bonn, Psychiat Clin, D-53105 Bonn, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Bonn	Hahn, H (corresponding author), Tech Univ Munich, Inst Pathol, GSF, Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany.	heidi.hakn@gsf.de	Zimmer, Andreas/B-8357-2009	Calzada, Julia/0000-0003-0816-9305; Kappler, Roland/0000-0002-8581-2803				Bleyer WA, 1997, EUR J CANCER, V33, P1439, DOI 10.1016/S0959-8049(97)00249-9; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Dagher R, 1999, Oncologist, V4, P34; Davis TL, 1998, DEV GENET, V23, P111, DOI 10.1002/(SICI)1520-6408(1998)23:2&lt;111::AID-DVG3&gt;3.0.CO;2-9; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hassan AB, 2000, CANCER RES, V60, P1070; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 1998, CURR OPIN GENET DEV, V8, P88, DOI 10.1016/S0959-437X(98)80067-1; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; LEE JE, 1990, DEVELOPMENT, V110, P151; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Miyaki M, 1998, NAT MED, V4, P1236, DOI 10.1038/3214; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Zhan S, 1998, NAT MED, V4, P559, DOI 10.1038/nm0598-559	29	172	174	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28341	28344		10.1074/jbc.C000352200	http://dx.doi.org/10.1074/jbc.C000352200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10884376	hybrid			2022-12-25	WOS:000089330700001
J	Mimuro, H; Suzuki, T; Suetsugu, S; Miki, H; Takenawa, T; Sasakawa, C				Mimuro, H; Suzuki, T; Suetsugu, S; Miki, H; Takenawa, T; Sasakawa, C			Profilin is required for sustaining efficient intra- and intercellular spreading of Shigella flexneri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; N-WASP; LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; F-ACTIN; DEPOLYMERIZING PROTEIN; FOCAL ADHESION; CELLS; PLASMID; BINDING	The ability of Shigella to mediate actin-based motility within the host cell is a prominent pathogenic feature of bacillary dysentery. The ability is dependent on the interaction of VirG with neural Wiskott-Aldrich syndrome protein (N-WASP), which in turn mediates recruitment of Arp2/3 complex and several actin-related proteins. In the present study, we show that profilin I is essential to the rapid movement of Shigella in epithelial cells, for which the capacity of profilin to interact with G-actin and N-WASP is critical. In COS-7 cells overexpressing either mutated profilin H119E, which failed to bind G-actin, or H133S, which is unable to interact with poly-L-proline, Shigella motility was significantly inhibited. Similarly, depletion of profilin from Xenopus egg extracts resulted in a decrease in bacterial motility that was completely rescued by adding back profilin I but not R119E or H133S. In COS-7 cells overexpressing a N-WASP mutant lacking the proline-rich domain (Delta p) unable to interact with profilin, the actin tail formation of intracellular Shigella was inhibited. In N-WASP-depleted extracts, addition of hp but not full-length N-WASP was unable to restore the bacterial motility, Furthermore, in a plaque formation assay with Madin-Darby canine kidney cell monolayers infected by Shigella, Madin-Darby canine kidney cells stably expressing H119E, H133S, or Delta p reduced the bacterial cell-to-cell spreading. These results indicate that profilin I associated with N-WASP is an essential host factor for sustaining efficient intra- and intercellular spreading of Shigella.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Bacterial Infect,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Bacterial Toxicol, Suita, Osaka 5650871, Japan	University of Tokyo; University of Tokyo; Osaka University	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Bacterial Infect,Minato Ku, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; 				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BjorkegrenSjogren C, 1997, FEBS LETT, V418, P258, DOI 10.1016/S0014-5793(97)01376-8; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GOLDBERG MB, 1993, INFECT IMMUN, V61, P4941, DOI 10.1128/IAI.61.12.4941-4946.1993; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; Kaiser DA, 1999, J CELL SCI, V112, P3779; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; Purich DL, 1999, METHOD ENZYMOL, V308, P93; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Southwick FS, 2000, CELL MOTIL CYTOSKEL, V45, P272, DOI 10.1002/(SICI)1097-0169(200004)45:4<272::AID-CM3>3.0.CO;2-E; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Suzuki T, 2000, J EXP MED, V191, P1905, DOI 10.1084/jem.191.11.1905; Suzuki T, 1996, J BIOL CHEM, V271, P21878, DOI 10.1074/jbc.271.36.21878; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; Theriot JA, 1998, METHOD ENZYMOL, V298, P114, DOI 10.1016/S0076-6879(98)98013-2; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Zeile WL, 1996, J CELL BIOL, V133, P49, DOI 10.1083/jcb.133.1.49; Zigmond SH, 1998, CURR BIOL, V8, pR654, DOI 10.1016/S0960-9822(07)00415-0	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28893	28901		10.1074/jbc.M003882200	http://dx.doi.org/10.1074/jbc.M003882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867004	hybrid			2022-12-25	WOS:000089330700074
J	Sorensen, TLM; Andersen, JP				Sorensen, TLM; Andersen, JP			Importance of stalk segment S5 for intramolecular communication in the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CALCIUM-PUMP; AMINO-ACIDS; DIVALENT-CATION; SKELETAL-MUSCLE; ATP HYDROLYSIS; CA2+ TRANSPORT; BINDING; CA-2+-ATPASE	Sixteen residues in stalk segment S5 of the Ca2+- ATPase of sarcoplasmic reticulum were studied by site-directed mutagenesis, The rate of the Ca2+ binding transition, determined at 0 degrees C, was enhanced relative to wild type in mutants Ile(743) --> Ala, Val(747) --> Ala, Glu(748) --> Ala, Glu(749) --> Ala, Met(757) --> Gly, and Gln(759) --> Ala and reduced in mutants Asp(737) --> Ala, Asp(738) --> Ala, Ala(752) --> Leu, and Tyr(754) --> Ala, In mutant Arg(762) --> Ile, the rate of the Ca2+ binding transition was wild type like at 0 degrees C, whereas it was 3.5-fold reduced relative to wild type at 25 degrees C. The rate of dephosphorylation of the ADP-insensitive phosphoenzyme was increased conspicuously in mutants Ile(743) --> Ala and Tyr(754) --> Ala (close to 10-fold in the absence of K+) and increased to a lesser extent in Asn(739) --> Ala, Glu(749) --> Ala, Gly(760) --> Ala, Ala(752) --> Gly, Met(757) --> Gly, and Arg(762) --> Ile, whereas it was reduced in mutants Asp(737) --> Ala, Val(744) --> Gly, Val(744) --> Ala, Val(747) --> Ala, and Ala(752) --> Leu. In mutants Ile(743) --> Ale, Tyr754, Ala, and Arg(762) --> Ile, the apparent affinities for vanadate were enhanced 23-, 30-, and le-fold, respectively, relative to wild type, The rate of Ca2+ dissociation was Ii-fold increased in Gly(750) --> Ala and 2-fold reduced in Val(747) --> Ala. Mutants with alterations to Arg(751) either were not expressed at a significant level or were completely nonfunctional. The findings show that S5 plays a crucial role in mediating communication between the Ca2+ binding pocket and the catalytic domain and that Arg(751) is important for both structural and functional integrity of the enzyme.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Andersen, Jens Peter/0000-0003-0654-4300; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; FORGE V, 1993, J BIOL CHEM, V268, P10961; HARA H, 1986, J BIOL CHEM, V261, P6584; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LUND S, 1988, J BIOL CHEM, V263, P1654; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Mintz E, 1995, BIOSCIENCE REP, V15, P377, DOI 10.1007/BF01788369; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; REED PW, 1972, J BIOL CHEM, V247, P6970; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6947; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28954	28961		10.1074/jbc.M004072200	http://dx.doi.org/10.1074/jbc.M004072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871620	hybrid			2022-12-25	WOS:000089330700081
J	Babu, PS; Krishnamurthy, H; Chedrese, PJ; Sairam, MR				Babu, PS; Krishnamurthy, H; Chedrese, PJ; Sairam, MR			Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor - Role in hormone signaling and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR FOLLITROPIN RECEPTOR; DEOXYRIBONUCLEIC-ACID SYNTHESIS; HUMAN CHORIONIC-GONADOTROPIN; SPLICED MESSENGER-RNA; FSH RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; PROTEIN-KINASES	Follicle-stimulating hormone (FSH) regulated growth and function of the ovarian follicle was previously thought to be mediated solely through activation of G(s)-coupled receptors, In this study, we show for the first time that this function is predominantly mediated through the alternatively spliced and novel growth factor type 1 receptor (oFSH-R3) that is also present in the ovary. Immortalized granulosa cells lacking endogenous FSH receptors, when transfected with either oFSH-R3 cDNA (JC-RS) or the G(s)-coupled oFSH-R1 (JC-R1), expressed the corresponding glycosylated receptor. In JC-R3 or JC-R1 cells labeled with bromodeoxyuridine or [H-3]thymidine, FSH: stimulated the cells to progress through S-phase and divide. The growth promoting effect of recombinant FSH in JC-R3 cells was preceded by the rapid activation of ERK1 and ERK2. This effect was hormone-specific and transient. In JC-R3 cells inhibitors like calphostin C, PD98059, Ag 18, or calcium chelators EGTA or 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/AM inhibited both mitogen-activated protein kinase activation and bromodeoxyuridine incorporation, FSH induced phosphorylation of the FSH-R3 receptor was blocked by pretreating cells with calphostin C, There was no cAMP induction by FSH in JC-R3 cells. The cAMP independent growth promoting effect of FSH is mediated by activation of Ca2+ and mitogen-activated protein kinase-dependent pathways. Thus, alternative splicing of a G-protein coupled receptor creates the expression of a novel receptor motif that can mediate a widely recognized function of the glycoprotein hormone.	Clin Res Inst Montreal, Mol Reprod Res Lab, Montreal, PQ H2W 1R7, Canada; Univ Saskatchewan, Dept Obstet Gynecol & Reprod Sci, Saskatoon, SK S7N 0W8, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Saskatchewan	Sairam, MR (corresponding author), Clin Res Inst Montreal, Mol Reprod Res Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ascoli M, 1996, BIOCHEM PHARMACOL, V52, P1647, DOI 10.1016/S0006-2952(96)00553-9; Babu P S, 1999, Mol Cell Biol Res Commun, V2, P21, DOI 10.1006/mcbr.1999.0139; Bley MA, 1997, J STEROID BIOCHEM, V62, P11, DOI 10.1016/S0960-0760(97)00021-6; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; CAMP TA, 1991, MOL ENDOCRINOL, V5, P1405, DOI 10.1210/mend-5-10-1405; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Chedrese PJ, 1998, J MOL ENDOCRINOL, V20, P287, DOI 10.1677/jme.0.0200287; Chew SL, 1997, TRENDS ENDOCRIN MET, V8, P405, DOI 10.1016/S1043-2760(97)00167-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DATTATREYAMURTY B, 1992, ENDOCRINOLOGY, V131, P2437, DOI 10.1210/en.131.5.2437; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; DELIDOW BC, 1990, ENDOCRINOLOGY, V126, P2302, DOI 10.1210/endo-126-5-2302; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FRISWOLD MD, 1993, SORTOLI CELL, P493; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GASINSKA A, 1988, BRIT J RADIOL, V61, P133, DOI 10.1259/0007-1285-61-722-133; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; Khan H, 1997, J MOL ENDOCRINOL, V19, P183, DOI 10.1677/jme.0.0190183; KHAN H, 1993, BIOCHEM BIOPH RES CO, V190, P888, DOI 10.1006/bbrc.1993.1132; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; LAPOLT PS, 1992, ENDOCRINOLOGY, V130, P1289, DOI 10.1210/en.130.3.1289; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOGANZO F, 1992, MOL ENDOCRINOL, V6, P1259, DOI 10.1210/me.6.8.1259; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Miller TM, 1997, J BIOL CHEM, V272, P9847; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; Moudgal NR, 1997, ENDOCRINOLOGY, V138, P3065, DOI 10.1210/en.138.7.3065; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; PENNYBACKER M, 1991, MOL CELL ENDOCRINOL, V80, P11, DOI 10.1016/0303-7207(91)90138-I; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P508; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rodway MR, 1999, MOL CELL ENDOCRINOL, V148, P87, DOI 10.1016/S0303-7207(98)00233-0; ROY SK, 1993, FERTIL STERIL, V59, P783; Sairam MR, 1996, BIOCHEM BIOPH RES CO, V226, P717, DOI 10.1006/bbrc.1996.1419; Sairam MR, 1997, MOL REPROD DEV, V48, P480, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;480::AID-MRD8&gt;3.0.CO;2-M; Sairam MR, 1997, MOL REPROD DEV, V48, P471, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;471::AID-MRD7&gt;3.0.CO;2-N; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHIBATA EF, 1992, ENDOCRINOLOGY, V131, P979, DOI 10.1210/en.131.2.979; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TERRY NHA, 1991, CYTOMETRY, V12, P234, DOI 10.1002/cyto.990120305; THEMMEN APN, 1994, MOL CELL ENDOCRINOL, V100, P15, DOI 10.1016/0303-7207(94)90272-0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Touraine P, 1999, MOL ENDOCRINOL, V13, P1844, DOI 10.1210/me.13.11.1844; Touyz RM, 2000, BIOL REPROD, V62, P1067, DOI 10.1095/biolreprod62.4.1067; Yarney TA, 1997, MOL REPROD DEV, V48, P458, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;458::AID-MRD6&gt;3.0.CO;2-P; YARNEY TA, 1993, MOL CELL ENDOCRINOL, V93, P219, DOI 10.1016/0303-7207(93)90127-6; Yarney TA, 1997, J MOL ENDOCRINOL, V18, P113, DOI 10.1677/jme.0.0180113	64	93	95	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27615	27626						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869352				2022-12-25	WOS:000089197100014
J	Rodrigues-Lima, F; Fensomes, AC; Josephs, M; Evans, J; Veldman, RJ; Katan, M				Rodrigues-Lima, F; Fensomes, AC; Josephs, M; Evans, J; Veldman, RJ; Katan, M			Structural requirements for catalysis and membrane targeting of mammalian enzymes with neutral sphingomyelinase and lysophospholipid phospholipase C activities - Analysis by chemical modification and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS SPHINGOMYELINASE; MULTIPLE SEQUENCE ALIGNMENT; PROTEIN SECONDARY STRUCTURE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; DISULFIDE BRIDGE; ACID-RESIDUES; IDENTIFICATION; DEHYDROGENASE; REDUCTION	The sequence similarity with bacterial neutral sphingomyelinase resulted in the isolation of putative mammalian counterparts and, subsequently, identification of similar molecules in a number of other eukaryotic organisms. Based on sequence similarities and previous characterization of the mammalian enzymes, we have chemically modified specific residues and pet-formed site-directed mutagenesis in order to identify critical catalytic residues and determinants for membrane localization, Modification of histidine residues and the substrate protection experiments demonstrated the presence of reactive histidine residues within the active site. Site directed mutagenesis suggested an essential role in catalysis for two histidine residues (His-136 and His-272), which are conserved in all sequences. Mutations of two additional histidines (His-138 and His-151), consented only in eukaryotes, resulted in reduced neutral sphingomyelinase activity. In addition to sphingomyelin, the enzyme also hydrolyzed lysophosphatidylcholine, Exposure to an oxidizing environment or modification of cysteine residues using several specific compounds also inactivated the enzyme. Site-directed mutagenesis of eight cysteine residues and gel-shift analysis demonstrated that these residues did not participate in the catalytic reaction and suggested the involvement of cysteines in the formation/breakage of disulfide bonds, which could underlie the reversible inactivation by the oxidizing compounds. Cellular localization studies of a series of deletion mutants, expressed as green fluorescent protein fusion proteins, demonstrated that the transmembrane region contains determinants for the endoplasmic reticulum localization.	Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; CHU Rangueil, INSERM, U466, Biochim Lab, F-31403 Toulouse 4, France	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Dziewanowska K, 1996, ARCH BIOCHEM BIOPHYS, V335, P102, DOI 10.1006/abbi.1996.0486; Fensome AC, 2000, J BIOL CHEM, V275, P1128, DOI 10.1074/jbc.275.2.1128; Fischer D, 1996, PROTEIN SCI, V5, P947; Fischer D, 1999, PROTEINS, P209; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUTERER S, 1984, BIOCHIM BIOPHYS ACTA, V794, P1, DOI 10.1016/0005-2760(84)90290-X; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Kronke M, 1999, CHEM PHYS LIPIDS, V102, P157, DOI 10.1016/S0009-3084(99)00084-5; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Shriver Z, 1998, J BIOL CHEM, V273, P10160, DOI 10.1074/jbc.273.17.10160; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOMITA M, 1993, BIOCHIM BIOPHYS ACTA, V1203, P85, DOI 10.1016/0167-4838(93)90039-T; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664	40	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28316	+						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871611				2022-12-25	WOS:000089197100104
J	Turner, RJ; Lovato, M; Schimmel, P				Turner, RJ; Lovato, M; Schimmel, P			One of two genes encoding glycyl-tRNA synthetase in Saccharomyces cerevisiae provides mitochondrial and cytoplasmic functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SPECIES-SPECIFIC AMINOACYLATION; ASPARTYL-TRANSFER RNA; THERMUS-THERMOPHILUS; BINDING DOMAINS; LYSYL-TRANSFER; MESSENGER-RNA; BOMBYX-MORI; YEAST; SEQUENCE	In the yeast Saccharomyces cerevisiae, two genes (GRS1 and GRS2) encode glycyl-tRNA synthetase (GlyRS1 and GlyRS2, respectively). 59% of the sequence of GlyRS2 is identical to that of GlyRS1. Others have proposed that GRS1 and GRS2 encode the cytoplasmic and mitochondrial enzymes, respectively. In this work, we show that GRS1 encodes both functions, whereas GRS2 is dispensable. In addition, both cytoplasmic and mitochondrial phenotypes of the knockout allele of GRS1 in S. cerevisiae are complemented by the expression of the only known gene for glycyl-tRNA synthetase in Schizosaccharomyces pombe, Thus, a single gene for glycyl-tRNA synthetase likely encodes both cytoplasmic and mitochondrial activities in most or all yeast. Phylogenetic analysis shows that GlyRS2 is a predecessor of all yeast GlyRS homologues, Thus, GRS1 appears to be the result of a duplication of GRS2, which itself is pseudogene-like.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,Mail Code BCC 379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHATTON B, 1988, J BIOL CHEM, V263, P52; Chihade JW, 1999, P NATL ACAD SCI USA, V96, P12316, DOI 10.1073/pnas.96.22.12316; CHIU MI, 1992, GENETICS, V132, P987; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; COHEN SS, 1958, P NATL ACAD SCI USA, V44, P1004, DOI 10.1073/pnas.44.10.1004; Coligan JE., 1998, CURRENT PROTOCOLS PR; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DANNEBERG PB, 1958, CANCER RES, V18, P329; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; DUCHENE AM, 1997, PLANT PHYSIOL, V115, P1730; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FELSENSTEIN J, 1993, PHYLIP VERSION 3 573; GAMPEL A, 1989, P NATL ACAD SCI USA, V86, P6023, DOI 10.1073/pnas.86.16.6023; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glasfeld E, 1997, BIOCHEMISTRY-US, V36, P6739, DOI 10.1021/bi970151n; Glasfeld E, 1996, BIOCHEMISTRY-US, V35, P4139, DOI 10.1021/bi9527810; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; HOHMANN S, 1992, GENE, V120, P43, DOI 10.1016/0378-1119(92)90007-C; Hopper AK, 1998, SCIENCE, V282, P2003, DOI 10.1126/science.282.5396.2003; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; John TR, 1997, YEAST, V13, P37, DOI 10.1002/(SICI)1097-0061(199701)13:1<37::AID-YEA55>3.0.CO;2-L; KERN D, 1981, BIOCHEMISTRY-US, V20, P122, DOI 10.1021/bi00504a021; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Magrath C, 1999, GENETICS, V152, P129; MANNHAUPT G, 1994, YEAST, V10, P1363, DOI 10.1002/yea.320101014; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; Mazauric MH, 1999, BIOCHEMISTRY-US, V38, P13094, DOI 10.1021/bi991392t; Mazauric MH, 1998, EUR J BIOCHEM, V251, P744, DOI 10.1046/j.1432-1327.1998.2510744.x; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MIRANDE M, 1986, BIOCHIMIE, V68, P1001, DOI 10.1016/S0300-9084(86)80043-8; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NADA S, 1993, J BIOL CHEM, V268, P7660; Nameki N, 1997, J MOL BIOL, V268, P640, DOI 10.1006/jmbi.1997.0993; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSTREM DL, 1970, P NATL ACAD SCI USA, V67, P1967, DOI 10.1073/pnas.67.4.1967; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SELLAMI M, 1986, NUCLEIC ACIDS RES, V14, P1657, DOI 10.1093/nar/14.4.1657; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Shiba K, 1997, TRENDS BIOCHEM SCI, V22, P453, DOI 10.1016/S0968-0004(97)01135-3; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; SURGUCHOV AP, 1975, EUR J BIOCHEM, V54, P175, DOI 10.1111/j.1432-1033.1975.tb04127.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; TZAGOLOFF A, 1995, EUR J BIOCHEM, V230, P582; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000	66	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27681	27688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874035				2022-12-25	WOS:000089197100022
J	Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM				Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM			Cross-talk between the proto-oncogenes Met and Ron	ONCOGENE			English	Article						Met; Ron; cross talk; scatter factors; tyrosine kinase	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; SIGNAL-TRANSDUCTION; MEDIATED TRANSFORMATION; GASTRIC-CARCINOMA; MET/HGF RECEPTOR	Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase receptors encoded by the proto-oncogenes MET and RON. Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Roll, and Vice ver sn. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). The transphosphorylation specifically takes place for the receptor subfamily, as it is not observed between Met or Ron and ErbB1, ErbB2 or TrkA. Cross-linking experiments show that non-covalent Met-Roll complexes are present on the cell surface, before ligand-induced dimerization. Go-expression of a kinase inactive Ron receptor with naturally-occurring oncogenic Met mutants suppresses the transforming phenotype, suggesting a dominant negative role for the inefficient kinase partner. These data show that, while specific for their ligands, scatter factor receptors cross-talk and cooperate in intracellular signaling.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Follenzi, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		Comoglio, Paolo/G-6323-2011; Gual, Philippe/P-9833-2019	Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Banu N, 1996, J IMMUNOL, V156, P2933; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blechman JM, 1995, ANN NY ACAD SCI, V766, P344, DOI 10.1111/j.1749-6632.1995.tb26685.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FALETTO DL, 1992, ONCOGENE, V7, P1149; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GAUDINO G, 1995, ONCOGENE, V11, P2527; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Michieli P, 1996, ONCOGENE, V12, P775; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; TARTARE S, 1991, FEBS LETT, V295, P219, DOI 10.1016/0014-5793(91)81422-5; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Westermark B, 1989, CURR OPIN CELL BIOL, V1, P279, DOI 10.1016/0955-0674(89)90101-4; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	73	153	157	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3041	3049		10.1038/sj.onc.1203620	http://dx.doi.org/10.1038/sj.onc.1203620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871856				2022-12-25	WOS:000087903900001
J	Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y				Ono, Y; Nakanishi, H; Nishimura, M; Kakizaki, M; Takahashi, K; Miyahara, M; Satoh-Horikawa, K; Mandai, K; Takai, Y			Two actions of frabin: direct activation of Cdc42 and indirect activation of Rac	ONCOGENE			English	Article						frabin; Rac; Cdc42; filopodia; lamellipodia; membrane ruffles	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; EXPRESSION CLONING; PROTEIN-KINASE; RHO; CYTOSKELETON; GTPASES; GENE; DBL; FILOPODIA	Frabin is an actin filament-binding protein which shows GDP/GTP exchange activity specific for Cdc42 small G protein and induces filopodium-like microspike formation and c-Jun N-terminal kinase (JNK) activation presumably through the activation of Cdc42. Frabin has one actin filament-binding (FAB) domain, one Dbl homology (DH) domain, first pleckstrin homology (PH) domain adjacent to the DH domain, one cysteine-rich FYVE domain, and second PH domain from the N-terminus to the C-terminus in this order. Different domains of frabin are involved in the microspike formation and the JNK activation, and the association of frabin with the actin cytoskeleton through the FAB domain is necessary for the microspike formation, but not for the JNK activation. We have found here that frabin induces the formation of not only filopodium-like microspikes but also lamellipodium-like structures in NIH3T3 and L fibroblasts. We have analysed the mechanism of frabin in these two actions and found that frabin induces filopodium-like microspike formation through the direct activation of Cdc42 and lamellipodium-like structure formation through the Cdc42-independent indirect activation of Pac small G protein. The FAB domain of frabin in addition to the DH domain and the first PH domain is necessary for the filopodium-like microspike formation, but not for the lamellipodium-like structure formation. The FYVE domain and the second PH domain in addition to the DH domain and the first PH domain are necessary for the lamellipodium-like structure formation. We show here these two actions of frabin in the regulation of cell morphology.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nagata K, 1998, J BIOL CHEM, V273, P15453, DOI 10.1074/jbc.273.25.15453; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Onishi M, 1996, EXP HEMATOL, V24, P324; PASTERIS NG, 1994, CELL, V79, P669; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	21	54	57	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3050	3058		10.1038/sj.onc.1203631	http://dx.doi.org/10.1038/sj.onc.1203631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871857				2022-12-25	WOS:000087903900002
J	Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P				Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P			Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration	ONCOGENE			English	Article						pancreatic cancer; Ras; MAPK; signal transduction; growth factors	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CANCER CELLS; FACTOR RECEPTOR; FACTOR-ALPHA; N-RAS; MAMMALIAN-CELLS; BINDING DOMAIN; HUMAN-COLON; HA-RAS	Human ductal adenocarcinoma of the pancreas frequently carry activating point mutations in the K-ras protooncogene. We have anal! sed the activity of the Ras-Raf-MEK-MAPK cascade in the human pancreatic carcinoma cell line PANC-1 carrying an activating K-ras mutation. Serum-starved cells and cells grown in medium with serum did not show constitutively activated c-Raf, MEK-1, or p42 MAPK. Stimulation bf cells with epidermal growth factor (EGF) or fetal calf serum (FCS) resulted in activation of N-Ras, but not K-Ras, as well as activation of c-Raf, MEK-1, and p42 MAPK. Preincubation of serum-starved cells with MEK-1 inhibitor PD98059 abolished EGF- and FCS-induced MAPK activation, identifying MEK as the upstream activator of MAPK. PANC-1 cells exhibited marked serum-dependence of anchorage-dependent and -independent cell growth as well as cell migration. EGF, alone or in combination with insulin and transferrin, did not induce cell proliferation of serum-starved PANC-1 cells, indicating that activation of MAPK alone was not sufficient to induce cell proliferation, FCS-induced DNA synthesis was inhibited by 40% by the MEK-1 inhibitor. On the other hand, treatment with either FCS or EGF alone resulted in marked, MEK-dependent increase of directed cell migration. Collectively, our results show that the activating K-ras mutation in PANC-1 cells does not result in constitutively increased Raf-MEK-MAPK signaling. Signal transduction via the Ras-Raf-MEK-MAPK cascade is maintained in these cells and is required for growth factor-induced cell proliferation and directed cell migration.	Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany	Ulm University; Ulm University	Giehl, K (corresponding author), Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany.							AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; Brat DJ, 1997, AM J PATHOL, V150, P383; Buard A, 1996, INT J CANCER, V67, P539, DOI 10.1002/(SICI)1097-0215(19960807)67:4<539::AID-IJC13>3.0.CO;2-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALDAS C, 1995, INT J PANCREATOL, V18, P1; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; COX AD, 1995, METHOD ENZYMOL, V255, P195; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FREEDMAN RR, 1995, MENOPAUSE, V2, P163; Friess H, 1996, J MOL MED-JMM, V74, P35, DOI 10.1007/BF00202070; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GILLESPIE J, 1993, BRIT J CANCER, V68, P1122, DOI 10.1038/bjc.1993.491; Grewe M, 1999, CANCER RES, V59, P3581; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Longnecker DS, 1998, PANCREAS, V17, P323, DOI 10.1097/00006676-199811000-00001; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; Moepps B, 1999, GENOMICS, V60, P199, DOI 10.1006/geno.1999.5901; Okada S, 1998, PANCREAS, V16, P349, DOI 10.1097/00006676-199804000-00023; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RODRIGUEZ VP, 1997, CELL, V89, P457; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, J BIOL CHEM, V267, P24796; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUMI S, 1994, PANCREAS, V9, P657, DOI 10.1097/00006676-199409000-00018; TAN MH, 1986, CANCER INVEST, V4, P15, DOI 10.3109/07357908609039823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271	63	99	105	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2930	2942		10.1038/sj.onc.1203612	http://dx.doi.org/10.1038/sj.onc.1203612			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871844				2022-12-25	WOS:000087544500007
J	Sato, H; Ogata, H; De Luca, LM				Sato, H; Ogata, H; De Luca, LM			Annexin V inhibits the 12-O-tetradecanoylphorbol-13-acetate-induced activation of Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of Shc in MCF-7 cells	ONCOGENE			English	Article						annexin V; MAPK; TPA; signal transduction; PKC	BREAST-CANCER CELLS; PROTEIN-KINASE; CARCINOMA-CELLS; MAP KINASE; RAF-1 KINASE; C ACTIVITY; IN-VITRO; RAS; EXPRESSION; PHOSPHORYLATION	Annexin V is a Ca2+-dependent phospholipid binding protein. Although it has been shown to inhibit protein kinase C (PKC) in cell-free systems, its role in the intact cell is unclear, A stable,MCF-7 human breast cancer cell overexpression system was established to investigate the function of annexin V, In these cells, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced phosphorylation and kinase activity of ERK1/2 were suppressed. Morphological changes induced by TPA were reduced by annexin V overexpression as well as by the pan-PKC inhibitor, bisindolylmaleimide I, and by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor, PD98059, TPA-induced MEK1/2 and Raf-l phosphorylation were reduced in these cells, The TP,S-enhanced active Ras, and its association with Raf-1, were reduced. TPA treatment of MCF-7 cells caused an increased association of She with Grb2, However, this increased association was prevented in the annexin V-overexpressors. p21(WAF/CIPI) is responsible for inhibition of cell cycle progression in MICF-7 cells. TPA induced the expression of p21(WAF/CIPI) to a greater extent in MCF-7 parent and control plasmid cells than in annexin V overexpressors, PD98059 inhibited this increase, suggesting that TPA upregulation of p21(WAF/CIPI) occurs via the MEK pathway, and that annexin V overexpression blunts it, This work shows that annexin V overexpression suppresses the TPA-induced Ras/ERK; signaling by inhibiting at/or upstream of She, possibly through the inhibition of PkCs.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	De Luca, LM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA.							ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buckland AG, 1998, BBA-LIPID LIPID MET, V1391, P367, DOI 10.1016/S0005-2760(98)00026-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COMERA C, 1989, J CELL BIOCHEM, V40, P361, DOI 10.1002/jcb.240400312; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KARUBE A, 1995, GYNECOL ONCOL, V58, P295, DOI 10.1006/gyno.1995.1233; KATO S, 1988, EXP CELL RES, V179, P31, DOI 10.1016/0014-4827(88)90345-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MENAPACE L, 1987, BIOCHEM BIOPH RES CO, V148, P1295, DOI 10.1016/S0006-291X(87)80274-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RAYNAL P, 1993, BIOCHEM J, V292, P759, DOI 10.1042/bj2920759; ROTHHUT B, 1995, EUR J BIOCHEM, V232, P865; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Shibata S, 1997, GYNECOL ONCOL, V66, P217, DOI 10.1006/gyno.1997.4746; SHIBATA S, 1992, J BIOCHEM-TOKYO, V112, P552, DOI 10.1093/oxfordjournals.jbchem.a123937; SHIBATA S, 1992, TOHOKU J EXP MED, V166, P479, DOI 10.1620/tjem.166.479; SOZERI O, 1992, ONCOGENE, V7, P2259; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Utsumi T, 1992, Nihon Sanka Fujinka Gakkai Zasshi, V44, P793; VALETTE A, 1987, CANCER RES, V47, P1615; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WINKELSTEIN A, 1986, EXP HEMATOL, V14, P1023; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	27	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2904	2912		10.1038/sj.onc.1203615	http://dx.doi.org/10.1038/sj.onc.1203615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871841				2022-12-25	WOS:000087544500004
J	Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH				Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - I. Analysis of Leu-rich repeats of human luteinizing hormone/chorionic gonadotropin receptor and follicle-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; AMINO-TERMINAL REGION; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LIGAND-BINDING	The luteinizing hormone receptor (LHR) and follicle-stimulating hormone receptor (FSHR) have an similar to 350-amino acid-long, N-terminal extracellular exodomain, This exodomain binds hormone with high affinity and specificity and contains eight to nine putative Leu-rich repeat (LRR) sequences. LRRs are known to assume the horseshoe structure in ribonuclease inhibitors, and the inner lining of the horseshoe consists of the P-stranded Leu/Ile-X-Leu/Ile motif. In the case of ribonuclease inhibitors, these beta strands interact with ribonuclease, However, it is unclear whether the putative LRRs of LHR and FSHR play any role in the structure and function. In this work, the P-stranded Leu/Ile residues in all LRRs of the human LHR and FSHR were Ale-scanned and characterized. In addition, the 23 residues around LRR2 of LHR were Ala-scanned, The results show that beta -stranded Leu and Ile residues in all LRRs are important but not equally. These Leu/Ile-X-Leu/Ile motifs appear to form the hydrophobic core of the LRR loop, crucial for the LRR structure. Interestingly, the hot spots are primarily in the upstream and downstream LRRs of the LHR exodomain, whereas important LRRs spread throughout the FSHR exodomain. This may explain the distinct hormone specificity despite the structural similarity of the two receptors.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	University of Kentucky; Seoul National University (SNU); University of Glasgow	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; ADASHI EY, 1996, REPROD ENDOCRINOLOGY, V1, P17; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GRISWOLD MD, 1993, SERTOLI CELLS, P496; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HSUEH AJW, 1983, J REPROD FERTIL, V69, P325, DOI 10.1530/jrf.0.0690325; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI T, 1996, GONADOTROPIN RECEPTO, P21; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	51	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3426	3435		10.1074/jbc.M003772200	http://dx.doi.org/10.1074/jbc.M003772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10880516	hybrid			2022-12-25	WOS:000166784900058
J	Ostergaard, H; Rasmussen, SK; Roberts, TH; Hejgaard, J				Ostergaard, H; Rasmussen, SK; Roberts, TH; Hejgaard, J			Inhibitory serpins from wheat grain with reactive centers resembling glutamine-rich repeats of prolamin storage proteins - Cloning and characterization of five major molecular forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE INHIBITORS; PLANT SERPIN; BARLEY ENDOSPERM; MANDUCA-SEXTA; CENTER LOOP; INSECTS; CHYMOTRYPSIN; SUPERFAMILY; EXPRESSION; HOMOLOGY	Genes encoding proteins of the serpin superfamily are widespread in the plant kingdom, but the properties of very few plant serpins have been studied, and physiological functions have not been elucidated. Six distinct set-pins have been identified in grains of hexaploid bread wheat (Triticum aestivum L.) by partial purification and amino acid sequencing. The reactive centers of all but one of the serpins resemble the glutamine-rich repetitive sequences in prolamin storage proteins of wheat grain. Five of the serpins, classified into two protein Z subfamilies, WSZ1 and WSZ2, have been cloned, expressed in Escherichia coli, and purified. Inhibitory specificity toward 17 proteinases of mammalian, plant, and microbial origin was studied. All five serpins were suicide substrate inhibitors of chymotrypsin and cathepsin G. WSZ1a and WSZ1b inhibited at the unusual reactive center P-1-P-1' Gln-Gln, and WSZ2b at P-2-P-1 Leu-Arg-one of two overlapping reactive centers. WSZ1c with P-1-P-1' Leu-Gln was the fastest inhibitor of chymotrypsin (k(a) = 1.3 x 10(6) M-1 s(-1)). WSZ1a was as efficient an inhibitor of chymotrypsin as WSZ2a (k(a) similar to 10(5) M-1 s(-1)), which has P-1-P-1' Leu-Ser-a reactive center common in animal serpins. WSZ2b inhibited plasmin at P-1-P-1' Arg-Gln (k(a) similar to 10(3) M-1 s(-1)). None of the five serpins inhibited Bacillus subtilisin A, Fusarium trypsin, or two subtilisin-like plant serine proteinases, hordolisin from barley green malt and cucumisin D from honeydew melon. Possible functions involving interactions with endogenous or exogenous proteinases adapted to prolamin degradation are discussed.	Tech Univ Denmark, Dept Biochem & Nutr, DK-2800 Lyngby, Denmark; Riso Natl Lab, Plant Biol & Biogeochem Dept, DK-4000 Roskilde, Denmark	Technical University of Denmark; Technical University of Denmark	Hejgaard, J (corresponding author), Tech Univ Denmark, Dept Biochem & Nutr, Bldg 224, DK-2800 Lyngby, Denmark.		Rasmussen, Soren K./F-6728-2014; Roberts, Thomas H/H-2071-2012	Rasmussen, Soren K./0000-0001-6169-2504; Roberts, Thomas H/0000-0003-3831-3240				BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; Dahl SW, 1996, FEBS LETT, V394, P165, DOI 10.1016/0014-5793(96)00940-4; Dahl SW, 1996, J BIOL CHEM, V271, P25083, DOI 10.1074/jbc.271.41.25083; Davy A, 1998, PLANT PHYSIOL, V117, P255, DOI 10.1104/pp.117.1.255; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Gauthier M, 1997, ANAL BIOCHEM, V248, P228, DOI 10.1006/abio.1997.2133; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Goodwin RL, 1996, MOL BIOL EVOL, V13, P346, DOI 10.1093/oxfordjournals.molbev.a025594; GUTIERREZ C, 1990, PLANT SCI, V72, P37, DOI 10.1016/0168-9452(90)90184-P; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HEJGAARD J, 1982, PHYSIOL PLANTARUM, V54, P174, DOI 10.1111/j.1399-3054.1982.tb06322.x; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; LONGSTAFF C, 1992, BLOOD COAGUL FIBRIN, V3, P89, DOI 10.1097/00001721-199202000-00013; LUNDGARD R, 1989, CARLSBERG RES COMMUN, V54, P173, DOI 10.1007/BF02904471; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rasmussen SK, 1996, BBA-PROTEIN STRUCT M, V1297, P127, DOI 10.1016/S0167-4838(96)00115-X; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; ROSENKRANDS I, 1994, FEBS LETT, V343, P75, DOI 10.1016/0014-5793(94)80610-1; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sambrook J., 2002, MOL CLONING LAB MANU; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SHEWRY PR, 2000, SEED PROTEINS; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Terp N, 2000, J PLANT PHYSIOL, V156, P468, DOI 10.1016/S0176-1617(00)80161-3; THOMAS JC, 1995, PLANT PHYSIOL BIOCH, V33, P611; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; UCHIKOBA T, 1993, PHYTOCHEMISTRY, V33, P1005, DOI 10.1016/0031-9422(93)85012-G; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V295, P651, DOI 10.1006/jmbi.1999.3375; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725	38	102	105	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33272	33279		10.1074/jbc.M004633200	http://dx.doi.org/10.1074/jbc.M004633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10874043	hybrid			2022-12-25	WOS:000090104600016
J	Garon, L; Rousseau, F; Gagnon, E; Isenring, P				Garon, L; Rousseau, F; Gagnon, E; Isenring, P			Cloning and functional characterization of a cation-Cl(-)cotransporter-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; CHLORIDE COTRANSPORTER; BUMETANIDE BINDING; MOLECULAR-CLONING; EXPRESSION; CELLS; LOCALIZATION; RAT; GLYCOSYLATION; TRANSPORT	To date, the cation-Cl- cotransporter (CCC) family comprises two branches of homologous membrane proteins. One branch includes the Na+-K+-Cl- cotransporters (NKCCs) and the Na+-Cl- cotransporter, and the other branch includes the K+-Cl- cotransporters. Here, we have isolated the first member of a third CCC family branch. This member shares similar to 25% identity in amino acid sequence with each of the other known mammalian CCCs. The corresponding cDNA, obtained from a human heart library and initially termed WO3.3 encodes a 914-residue polypeptide of 96.2 kDa (calculated mass). Sequence analyses predict a 12-transmembrane domain (tm) region, two N-linked glycosylation sites between tm, and tm,, and a large intracellular carboxyl terminus containing protein kinase C phosphorylation sites. Northern blot analysis uncovers an similar to 3.7-kilobase pair transcript present in muscle, placenta, brain, and kidney. With regard to function, WO3.3 expressed either in HEK-293 cells or Xenopus laevis oocytes does not increase Rb+-, Na+-, and Cl--coupled transport during 5-or 6-h fluxes, respectively. In the oocyte, however, WO3.3 specifically inhibits human NKCC1-mediated Rb-86(+) flux In addition, coimmunoprecipitation studies using lysates from WO3.3-transfected HEK-293 cells suggest a direct interaction of WO3.3 with endogenous NKCC. Thus, we have cloned and characterized the first putative heterologous CCC-interacting protein (CIP) known at present. CIP1 may be part of a novel family of proteins that modifies the activity or kinetics of CCCs through heterodimer formation.	Univ Laval, Fac Med, Grp Rech Nephrol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Med, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1R 2J6, Canada	Laval University; Laval University; Laval University; Laval University	Garon, L (corresponding author), CHUQ, Hotel Dieu, Res Ctr, 10 Rue McMahon,Rm 3852, Quebec City, PQ G1R 2J6, Canada.							Bartter FC, 1998, J AM SOC NEPHROL, V9, P516; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; ICHINOSE M, 1999, J AM SOC NEPHROL, V10, P34; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; ISENRING P, 1992, HYPERTENSION, V19, P371, DOI 10.1161/01.HYP.19.4.371; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; JACOBY SC, 1999, AM J PHYSIOL, V277, pC6845; Karet FE, 1997, RECENT PROG HORM RES, V52, P263; Karpa KD, 1999, MOL PHARMACOL, V56, P1071, DOI 10.1124/mol.56.5.1071; Kelley SJ, 1996, AM J PHYSIOL-CELL PH, V270, pC1122; KRACKE GR, 1990, P NATL ACAD SCI USA, V87, P8575, DOI 10.1073/pnas.87.21.8575; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYTLE C, 1992, J BIOL CHEM, V267, P25428; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MATTHEWS JB, 1994, J BIOL CHEM, V269, P15703; MITANI A, 1992, AM J PHYSIOL, V263, pH333, DOI 10.1152/ajpheart.1992.263.2.H333; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	37	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32027	32036		10.1074/jbc.M000108200	http://dx.doi.org/10.1074/jbc.M000108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10871601	hybrid			2022-12-25	WOS:000089858900066
J	Stimmel, JB; Merrill, BM; Kuyper, LF; Moxham, CP; Hutchins, JT; Fling, ME; Kull, FC				Stimmel, JB; Merrill, BM; Kuyper, LF; Moxham, CP; Hutchins, JT; Fling, ME; Kull, FC			Site-specific conjugation on serine -> cysteine variant monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED HUMAN-IGG; ANTIGEN; PROTEIN; TUMOR; CARBOHYDRATE; CAMPATH-1H; THERAPY; CANCER; ACID	We have engineered a cysteine residue at position 442 (EU/OU numbering) in the third constant domain (C(H)3) of the heavy chain of several IgGs with different specificities, isoforms, and variants with the intent to introduce a site for chemical conjugation. The variants were expressed in NS0 mouse myeloma cells, where monomeric IgG is the major form and formation of aggregate was minimal. Monomeric IgG contained no free thiol; however, it was discovered that the engineered thiols were reversibly blocked and could be reduced under controlled conditions. Following reduction, reactive thiol was conjugated with a cysteine-specific bifunctional chelator, bromoacetyl-TMT to a humanized 323/A3 IgG4 variant. Conjugation had no significant effect on antibody affinity. To prove that the conjugation was site-specific, an antibody-TMT conjugate was labeled with lutetium-177 and subjected to peptide mapping followed by sequence analysis. Glu-C digestion demonstrated that 91% of the label was recovered in the COOH-terminal peptide fragment containing the engineered cysteine.	Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Discovery Genet, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Stimmel, JB (corresponding author), Glaxo Wellcome Inc, Dept Mol Sci, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ACKERMAN E, 1979, MED PROG TECHNOL, V6, P81; BODMER M, 1993, Patent No. 5219996; Boyd PN, 1995, MOL IMMUNOL, V32, P1311, DOI 10.1016/0161-5890(95)00118-2; CARON PC, 1992, J EXP MED, V176, P1191, DOI 10.1084/jem.176.4.1191; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DESHPANDE SV, 1990, J NUCL MED, V31, P473; EDWARDS DP, 1986, CANCER RES, V46, P1306; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDMAN A, 1984, J PEDIATR-US, V105, P252, DOI 10.1016/S0022-3476(84)80122-5; HOARE DG, 1966, J AM CHEM SOC, V88, P2057, DOI 10.1021/ja00961a045; Hutchins JT, 1995, P NATL ACAD SCI USA, V92, P11980, DOI 10.1073/pnas.92.26.11980; ISAACS JD, 1992, J IMMUNOL, V148, P3062; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KHAW BA, 1980, SCIENCE, V209, P295, DOI 10.1126/science.7384803; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; LYONS A, 1990, PROTEIN ENG, V3, P703, DOI 10.1093/protein/3.8.703; MEARES CF, 1984, ANAL BIOCHEM, V142, P68, DOI 10.1016/0003-2697(84)90517-7; MEARES CF, 1990, BR J CANC S, P21; MOLDOFSKY PJ, 1984, NEW ENGL J MED, V311, P106, DOI 10.1056/NEJM198407123110207; MORRISON RT, 1984, INT J NUCL MED BIOL, V11, P184, DOI 10.1016/0047-0740(84)90059-7; OSHANNESSY DJ, 1987, J IMMUNOL METHODS, V99, P153, DOI 10.1016/0022-1759(87)90120-7; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; RAINSBURY RM, 1983, LANCET, V2, P934; RODWELL JD, 1986, P NATL ACAD SCI USA, V83, P2632, DOI 10.1073/pnas.83.8.2632; SCHEINBERG DA, 1982, SCIENCE, V215, P1511, DOI 10.1126/science.7199757; SHOPES B, 1992, J IMMUNOL, V148, P2918; SHOPES B, 1993, MOL IMMUNOL, V30, P603, DOI 10.1016/0161-5890(93)90035-A; Stimmel JB, 1998, NUCL MED BIOL, V25, P117, DOI 10.1016/S0969-8051(97)00151-0; TAO MH, 1989, J IMMUNOL, V143, P2595; THIERS R E, 1957, Methods Biochem Anal, V5, P273; TONER JL, 1989, Patent No. 4859777; TRAIL PA, 1995, DRUG DEVELOP RES, V34, P196, DOI 10.1002/ddr.430340209; Weber RW, 1990, BIOCONJUGATE CHEM, V1, P431, DOI 10.1021/bc00006a010; Wilder RB, 1996, J CLIN ONCOL, V14, P1383, DOI 10.1200/JCO.1996.14.4.1383; YAMADA H, 1981, BIOCHEMISTRY-US, V20, P4836, DOI 10.1021/bi00520a005	37	56	96	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30445	30450		10.1074/jbc.M001672200	http://dx.doi.org/10.1074/jbc.M001672200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10880507	hybrid			2022-12-25	WOS:000089577900072
J	Huang, L; Grammatikakis, N; Yoneda, M; Banerjee, SD; Toole, BP				Huang, L; Grammatikakis, N; Yoneda, M; Banerjee, SD; Toole, BP			Molecular characterization of a novel intracellular hyaluronan-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; SMOOTH-MUSCLE CELLS; MONOCLONAL-ANTIBODY; HEPARAN-SULFATE; IN-VIVO; CD44; LOCALIZATION; GLYCOSAMINOGLYCANS; IDENTIFICATION; EXPRESSION	Hyaluronan has well defined functions in extracellular matrices and at the surface of cells. However, several studies have now shown that significant pools of hyaluronan are also present intracellularly, but its function therein is unknown. One avenue of investigation that may assist in defining the function of intracellular hyaluronan is to identify intracellular hyaluronan-binding proteins. In previous studies we identified CDC37, a cell cycle regulatory protein, using a monoclonal antibody that recognizes a novel group of hyaluronan-binding proteins. In this study, we have identified a second hyaluronan-binding protein with this antibody and characterized its properties. This protein, which we have termed IHABP4, was also found to be an intracellular and a specific hyaluronan-binding protein, containing several hyaluronan-binding motifs: (R/K)X-7(R/K) (where R/K denotes arginine or lysine and X denotes non-acidic amino acids). Furthermore, we have determined the gene organization of IHABP4 and cloned cDNAs for the chick, mouse, and human homologs. Comparison of the deduced chick, mouse, and human protein sequences showed that the hyaluronan-binding motifs, (R/K)X-7(R/ K), in these sequences are conserved; both chick and mouse IHABP4 were shown directly to bind hyaluronan. Biochemical fractionation and immunofluorescent localization of epitope-tagged IHABP4 indicated that it is mainly present in the cytoplasm. These data support the possibility that intracellular hyaluronan and its binding proteins may play important roles in cell behavior.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.				NCI NIH HHS [CA82867, CA73839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073839, R01CA082867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assmann V, 1998, J CELL SCI, V111, P1685; BANERJEE SD, 1991, DEV BIOL, V146, P186, DOI 10.1016/0012-1606(91)90459-G; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Collis L, 1998, FEBS LETT, V440, P444, DOI 10.1016/S0014-5793(98)01505-1; CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; EGGLI PS, 1995, J HISTOCHEM CYTOCHEM, V43, P689, DOI 10.1177/43.7.7608523; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FURUKAWA K, 1979, BIOCHIM BIOPHYS ACTA, V585, P575, DOI 10.1016/0304-4165(79)90190-9; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; Huang L, 1998, J BIOL CHEM, V273, P3598, DOI 10.1074/jbc.273.6.3598; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Itano N, 1999, CANCER RES, V59, P2499; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Kobarg J, 1997, EXP CLIN IMMUNOGENET, V14, P273; Kosaki R, 1999, CANCER RES, V59, P1141; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Lord JM, 1998, J CELL BIOL, V140, P733; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Pavasant P, 1996, J CELL SCI, V109, P327; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; ROHDE D, 1992, AM J PATHOL, V140, P473; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; Takada Y, 1999, CELL TISSUE RES, V298, P317, DOI 10.1007/s004419900082; TOOLE BP, 1999, GUIDEBOOK EXTRACELLU, P430; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	44	63	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29829	29839		10.1074/jbc.M002737200	http://dx.doi.org/10.1074/jbc.M002737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887182	hybrid			2022-12-25	WOS:000089439800089
J	Pratt, MB; Husain, SS; Miller, KW; Cohen, JB				Pratt, MB; Husain, SS; Miller, KW; Cohen, JB			Identification of sites of incorporation in the nicotinic acetylcholine receptor of a photoactivatible general anesthetic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; NONCOMPETITIVE ANTAGONIST; AMINO-ACID; GLYCINE RECEPTORS; ION-CHANNEL; M2 SEGMENT; GABA(A); ALCOHOL; MUTATIONS; ETOMIDATE	Most general anesthetics including long chain aliphatic alcohols act as noncompetitive antagonists of the nicotinic acetylcholine receptor (nAChR), To locate the sites of interaction of a long chain alcohol with the Torpedo nAChR, we have used the photoactivatible alcohol 3-[H-3]azioctanol, which inhibits the nAChR and photoincorporates into nAChR subunits. At 1 and 275 mu M, 3-[H-3]azioctanol photoincorporated into nAChR subunits with increased incorporation in the rw-subunit in the desensitized state. The incorporation into the cu-subunit was mapped to two large proteolytic fragments. One fragment of similar to 20 kDa (alpha V8-20), containing the M1, M2, and M3 transmembrane segments, showed enhanced incorporation in the presence of agonist whereas the other of similar to 10 kDa (alpha V8-10), containing the M4 transmembrane segment, did not show agonist-induced incorporation of label. Within alpha V8-20, the primary site of incorporation was alpha Glu-262 at the C-terminal end of alpha M2, labeled preferentially in the desensitized state. The incorporation at alpha Glu-262 approached saturation between 1 mu M, with similar to 6% labeled, and 215 mu M, With similar to 30% labeled. Low level incorporation was seen in residues at the agonist binding site and the protein-lipid interface at similar to 1% of the levels in alpha Glu-262. Therefore, the primary binding site of 3-azioctanol is within the ion channel with additional lower affinity interactions within the agonist binding site and at the protein-lipid interface.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; Birnir B, 1997, J MEMBRANE BIOL, V155, P157, DOI 10.1007/s002329900167; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DILGER JP, 1995, EUR J ANAESTH, V12, P31; DILGER JP, 1994, MOL PHARMACOL, V46, P169; FIRESTONE LL, 1994, MOL PHARM, V46, P449; Forman SA, 1997, BIOPHYS J, V72, P2170, DOI 10.1016/S0006-3495(97)78860-X; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; McGurk KA, 1998, BRIT J PHARMACOL, V124, P13, DOI 10.1038/sj.bjp.0701787; MEDYNSKI DC, 1983, THESIS HARVARD U; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Moody EJ, 1997, J NEUROCHEM, V69, P1310; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; Pedersen SE, 1995, J BIOL CHEM, V270, P31141, DOI 10.1074/jbc.270.52.31141; Pistis M, 1999, J PHYSIOL-LONDON, V515, P3, DOI 10.1111/j.1469-7793.1999.003ad.x; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; WOOD SC, 1995, MOL PHARMACOL, V47, P121; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	35	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29441	29451		10.1074/jbc.M004710200	http://dx.doi.org/10.1074/jbc.M004710200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10859324	hybrid			2022-12-25	WOS:000089439800037
J	Szymczyna, BR; Arrowsmith, CH				Szymczyna, BR; Arrowsmith, CH			DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein-DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; MURINE ETS-1; PU.1; EXPRESSION; MOTIF; SITES; GENE; IDENTIFICATION; SEQUENCES	Members of the ETS family of transcription factors are involved in several developmental and physiological processes, and, when overexpressed or misexpressed, can contribute to a variety of cancers. Each family member has a conserved DNA-binding domain that recognizes DNA sequences containing a G-G-A trinucleotide, Discrimination between potential ETS-binding sites appears to be governed by both the nucleotides flanking the G-G-A sequence and protein-protein interactions. We have used an adaptation of the "length-encoded multiplex" approach (Desjarlais, J. R., and Berg, J. M. (1994) Proc. Natl, Acad Sci. U.S. A. 91, 11099-11103) to define DNA binding specificities for four ETS proteins: Fli-1, SAP-1, PU.1, and TEL. Our results support a model in which cooperative effects among neighboring bases flanking the central G-G-A site contribute to the formation of stable ETS/DNA complexes. These results are consistent with a mechanism for specific DNA binding that is partially governed by an indirect read-out of the DNA sequence, in which a sequence-specific DNA conformation is sensed or induced.	Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bemark M, 1999, J BIOL CHEM, V274, P10259, DOI 10.1074/jbc.274.15.10259; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; Brown LA, 1999, ONCOGENE, V18, P7985, DOI 10.1038/sj.onc.1203197; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FISHER RJ, 1991, ONCOGENE, V6, P2249; Gross P, 1998, BIOCHEMISTRY-US, V37, P5129, DOI 10.1021/bi972591k; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAROULAKOU IG, 1994, ONCOGENE, V9, P151; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Pio F, 1999, PROTEIN SCI, V8, P2098, DOI 10.1110/ps.8.10.2098; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; RAYGALLET D, 1995, ONCOGENE, V11, P303; SAMBROOK J, 1989, MOL CLONING LAB APPR; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; StraussSoukup JK, 1997, J BIOL CHEM, V272, P31570, DOI 10.1074/jbc.272.50.31570; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	42	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28363	28370		10.1074/jbc.M004294200	http://dx.doi.org/10.1074/jbc.M004294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867009	hybrid			2022-12-25	WOS:000089330700006
J	Lin, KM; Mejillano, M; Yin, HL				Lin, KM; Mejillano, M; Yin, HL			Ca2+ regulation of gelsolin by its C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING DOMAIN; PLASMA GELSOLIN; F-ACTIN; CALCIUM; IDENTIFICATION; PROTEIN; SITES; FILAMENTS; COMPLEX; GCAP39	Gelsolin is activated by Ca2+ to sever actin filaments. Ca2+ regulation is conferred on the N-terminal half by the C-terminal half. This paper seeks to understand how Ca2+ regulates gelsolin by testing the "tail helix latch hypothesis," which is based on the structural data showing that gelsolin has a C-terminal tail helix that contacts the N-terminal half in the absence of Ca2+. Ca2+ activation of gelsolin at 37 degrees C occurs in three steps, with apparent K-d for Ca2+ of 0.1, 0.3, and 6.4 x 10(-6) M. Tail helix truncation decreases the apparent Ca2+ requirement for severing to 10(-7) M and eliminates the conformational change observed at 10(-6) M Ca2+. The large decrease in Ca2+ requirement for severing is not due to a change in Ca2+ binding nor to Ca2+-independent activation of the C-terminal half per se. Thus, the tail helix latch is primarily responsible for transmitting micromolar Ca2+ information from the gelsolin C-terminal half to the N-terminal half. Occupation of submicromolar Ca2+-binding sites primes gelsolin for severing, but gelsolin cannot sever because the fail latch is still engaged. Unlatching the tail helix by 10(-6) M Ca2+ releases the final constraint to initiate the severing cascade.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hyin@mednet.swmed.edu			NIGMS NIH HHS [R01-GM5112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Allen PG, 1997, FEBS LETT, V401, P89, DOI 10.1016/S0014-5793(96)01439-1; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; LIU YT, 1998, G PROTEINS CYTOSKELE; Lueck A, 2000, BIOCHEMISTRY-US, V39, P5274, DOI 10.1021/bi992871v; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; PATKOWSKI A, 1990, BIOPOLYMERS, V30, P427, DOI 10.1002/bip.360300320; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUN HQ, 1998, PHAGOCYTOSIS PATHOGE, V5, P319; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; WEEDS AG, 1986, EUR J BIOCHEM, V161, P69, DOI 10.1111/j.1432-1033.1986.tb10125.x; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1981, J BIOL CHEM, V256, P9693; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	40	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27746	27752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862770				2022-12-25	WOS:000089197100032
J	Vial, D; Okazaki, H; Siraganian, RP				Vial, D; Okazaki, H; Siraganian, RP			The NH2-terminal region of focal adhesion kinase reconstitutes high affinity IgE receptor-induced secretion in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DROSOPHILA-MELANOGASTER; PROTEIN; MIGRATION; DOMAIN; FAK; PP125(FAK); SRC; ASSOCIATION	Focal adhesion kinase (FAK) is tyrosine-phosphorylated by adherence of cells and also by Fc epsilon RI aggregation in RBL-2H3 mast cells. Using phosphorylation site-specific antibodies, we observed that Fc epsilon RI activation in these cells led to an increase in FAK phosphorylation at the same tyrosine residues that are phosphorylated by integrin-induced activation. Previous studies in the 3B6 line, a FAK-deficient variant of the RBL-2H3 cells, suggest that FAK plays a role in Fc epsilon RI-induced secretion. Stable cell lines expressing either full-length or truncated forms of FAK were isolated after transfection of the FAK-deficient 3B6 variant cells. The NH2 domain of FAK, which lacks the enzymatic and the COOH-terminal regions, was sufficient to reconstitute secretion. The different truncated forms of FAK were still tyrosine-phosphorylated after Fc epsilon RI aggregation. Therefore, the kinase domain and the COOH-terminal region are not essential for Fc epsilon RI-induced tyrosine phosphorylation of FAK or for secretion. Taken together, our data demonstrate that the reconstitution of secretion is dissociated from FAK activation and that the NH2-terminal region of FAK is the only critical element that may play a role in Fc epsilon RI-induced secretion by acting as an adaptor or linker molecule.	NIDCR, OIIB, Receptors & Signal Transduct Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Vial, D (corresponding author), NIDCR, OIIB, Receptors & Signal Transduct Sect, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000696, ZIADE000696] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Fujimoto J, 1999, J BIOL CHEM, V274, P29196, DOI 10.1074/jbc.274.41.29196; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; ILLC D, 1995, NATURE, V377, P539; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 1999, J CELL SCI, V112, P2677; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Zhang J, 1998, J IMMUNOL, V161, P4366; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28269	28275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862765				2022-12-25	WOS:000089197100098
J	Wan, YJY; Cai, Y; Lungo, W; Fu, P; Locker, J; French, S; Sucov, HM				Wan, YJY; Cai, Y; Lungo, W; Fu, P; Locker, J; French, S; Sucov, HM			Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; PPAR-ALPHA; RXR-ALPHA; SIGNALING PATHWAYS; ADAPTIVE RESPONSE; FATTY-ACIDS; MUTANT MICE; RAT-LIVER; GENE; EXPRESSION	Retinoid x receptor alpha (RXR alpha) serves as an active partner of peroxisome proliferator-activated receptor (PPAR alpha). In order to dissect the functional role of RXR alpha and PPAR alpha in PPAR alpha-mediated pathways, the hepatocyte PPAR alpha deficient mice have been challenged with physiological and pharmacological stresses, fasting and Wy14,643, respectively. The data demonstrate that RXR alpha and PPAR alpha deficiency are different in several aspects. At the basal untreated level, RXR alpha deficiency resulted in marked induction of apolipoprotein A-I and C-III (apoA-I and apoC-III) mRNA levels and serum cholesterol and triglyceride levels, which was not found in PPAR alpha-null mice. Fasting-induced PPAR alpha activation was drastically prevented in the absence of hepatocyte RXR alpha. Wy14,643-mediated pleiotropic effects were also altered due to the absence of hepatocyte RXR alpha. Hepatocyte RXR alpha deficiency did not change the basal acyl-CoA oxidase, medium chain acyl-CoA dehydrogenase, and malic enzyme mRNA levels, However, the inducibility of those genes by Wy14,643 was markedly reduced in the mutant mouse livers. In contrast, the basal cytochrome P450 4A1, liver fatty acid-binding protein, and apoA-I and apoC-III mRNA levels were significantly altered in the mutant mouse livers, but the regulatory effect of Wy14,643 on expression of those genes remained the same, Wy14,643-induced hepatomegaly was partially inhibited in hepatocyte RXR alpha-deficient mice. Wy14,643-induced hepatocyte peroxisome proliferation was preserved in the absence of hepatocyte RXRa. These data suggested that in comparison to PPAR alpha, hepatocyte RXR alpha has its unique role in lipid homeostasis and that the effect of RXR alpha, -beta, and -gamma is redundant in certain aspects.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, Torrance, CA 90509 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol & Cell & Neurobiol, Los Angeles, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Southern California	Wan, YJY (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA.			Sucov, Henry/0000-0002-3792-3795	NCI NIH HHS [CA53596, R01 CA053596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053596, R29CA053596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; Chen J, 1998, DEVELOPMENT, V125, P1943; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAN CY, 1999, HEPATOLOGY ELSEWHERE, V29, P606; GE RW, 1994, J BIOL CHEM, V269, P13185; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HERTZ R, 1996, BIOCHEM J, V319, P341; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7356; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; Ohata M, 2000, EXP MOL PATHOL, V68, P13, DOI 10.1006/exmp.1999.2284; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SOHLENIUS AK, 1995, BBA-LIPID LIPID MET, V1258, P257, DOI 10.1016/0005-2760(95)00123-T; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Ulven SM, 1998, EUR J CELL BIOL, V77, P111, DOI 10.1016/S0171-9335(98)80078-2; VU DN, 1996, MOL CELL BIOL, V16, P3350; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Westin S, 1997, MOL CELL ENDOCRINOL, V129, P169, DOI 10.1016/S0303-7207(97)04055-0	38	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28285	28290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10866995				2022-12-25	WOS:000089197100100
J	Langton, KP; McKie, N; Curtis, A; Goodship, JA; Bond, PM; Barker, MD; Clarke, M				Langton, KP; McKie, N; Curtis, A; Goodship, JA; Bond, PM; Barker, MD; Clarke, M			A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in sorsby's fundus dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; PROGELATINASE-A; TERMINAL DOMAIN; IV COLLAGENASE; CELL-DEATH; TIMP-3; EXPRESSION; CLONING; GENE; ACTIVATION	Sorsby's fundus dystrophy (SFD) is a dominantly inherited degenerative disease of the retina that leads to loss of vision in middle age, It has been shown to be caused by mutations in the gene for tissue inhibitor of metalloproteinases-3 (TIMP-3). Five different mutations have previously been identified, all introducing an extra cysteine residue into exon 5 (which forms part of the C-terminal domain) of the TIMP-3 molecule; however, the significance of these mutations to the disease phenotype was unknown. In this report, we describe the expression of several of these mutated genes, together with a previously unreported novel TIMP-3 mutation from a family with SFD that results in truncation of most of the C-terminal domain of the molecule. Despite these differences, all of these molecules are expressed and exhibit characteristics of the normal protein, including inhibition of metalloproteinases and binding to the extracellular matrix. However, unlike wild-type TIMP-3, they all form dimers, These observations, together with the recent finding that expression of TIMP-3 is increased, rather than decreased, in eyes from patients with SFD, provides compelling evidence that dimerized TIMP-3 plays an active role in the disease process by accumulating in the eye. Increased expression of TIMP-3 is: also observed in other degenerative retinal diseases, including the more severe forms of age-related macular degeneration, the most common cause of blindness in the elderly in developed countries. We hypothesize that overexpression of TIMP-5 may prove to be a critical step in the progression of a variety of degenerative retinopathies.	Univ Sheffield, Sch Med, Pathol Sect, Div Oncol & Cellular Pathol, Sheffield S10 2RX, S Yorkshire, England; Univ Newcastle Upon Tyne, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; No Genet Serv, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Sheffield; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Barker, MD (corresponding author), Univ Sheffield, Sch Med, Pathol Sect, Div Oncol & Cellular Pathol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.							Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Felbor U, 1997, AM J HUM GENET, V60, P57; Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; JOMARY C, 1995, J NEUROCHEM, V64, P2370; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1994, AM J RESP CRIT CARE, V150, pS165, DOI 10.1164/ajrccm/150.6_Pt_2.S165; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267	35	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27027	27031						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854443				2022-12-25	WOS:000089144800049
J	Gasa, R; Jensen, PB; Berman, HK; Brady, MJ; DePaoli-Roach, AA; Newgard, CB				Gasa, R; Jensen, PB; Berman, HK; Brady, MJ; DePaoli-Roach, AA; Newgard, CB			Distinctive regulatory and metabolic properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, G(L), G(M)/R-G1) expressed in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MAGNETIC-RESONANCE; DIABETES-MELLITUS; LIVER-GLYCOGEN; GLUCOKINASE; GLUCOSE; ACTIVATION; MECHANISM; BINDING; RAT	Glycogen-targeting subunits of protein phosphatase-1 facilitate interaction of the phosphatase with enzymes of glycogen metabolism. We have shown that overexpression of one member of the family, protein targeting to glycogen (PTG), causes large increases in glycogen storage in isolated hepatocytes or intact rat liver. In the current study, we have compared the metabolic and regulatory properties of PTG (expressed in many tissues), with two other members of the gene family, G(L) (expressed primarily in liver) and G(M)/R-G1 (expressed primarily in striated muscle). Adenovirus-mediated expression of these proteins in hepatocytes led to the following hey observations. 1) G(L) has the highest glycogenic potency among the three forms studied. 2) Glycogen synthase activity ratio is much higher in G(L)- overexpressing cells than in PTG or G(M)/R-G1-overexpressing cells. Thus, at moderate levels of Cf, overexpression, glycogen synthase activity is increased by insulin treatment, but at higher levels of G(L) expression, insulin is no longer required to achieve maximal synthase activity. In contrast, cells with high levels of PTG overexpression retain dose-dependent regulation of glycogen synthesis and glycogen synthase enzyme activity by insulin. 3) G(L)- and G(M)/R-G1-overexpressing cells exhibit a strong glycogenolytic response to forskolin, whereas PTG-overexpressing cells are less responsive. This difference may be explained in part by a lesser forskolin-induced increase in glycogen phosphorylase activity in PTG-overexpressing cells. Based on these re suits, we suggest that expression of either G(L) or G(M)/R-G1 in liver of diabetic animals may represent a strategy for lowering of blood glucose levels in diabetes.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Cell Biol, Ann Arbor, MI 48105 USA; Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pfizer; Indiana University System; Indiana University-Purdue University Indianapolis	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Jensen, Per Bo/0000-0002-2277-1135	NIDDK NIH HHS [P01 DK58398, DK 36569] Funding Source: Medline; PHS HHS [P50 H2598801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398, R01DK036569] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 1999, ANNU REV NUTR, V19, P511, DOI 10.1146/annurev.nutr.19.1.511; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; COATS WS, 1991, J BIOL CHEM, V266, P16113; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; TANG PM, 1991, J BIOL CHEM, V266, P15782; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974	26	68	73	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26396	26403		10.1074/jbc.M002427200	http://dx.doi.org/10.1074/jbc.M002427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862764	hybrid			2022-12-25	WOS:000088999700071
J	Vereker, E; Campbell, V; Roche, E; McEntee, E; Lynch, MA				Vereker, E; Campbell, V; Roche, E; McEntee, E; Lynch, MA			Lipopolysaccharide inhibits long term potentiation in the rat dentate gyrus by activating caspase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST; INDUCED APOPTOSIS; HIPPOCAMPAL SLICES; GLUTAMATE RELEASE; ARACHIDONIC-ACID; BRAIN-REGIONS; MESSENGER-RNA; CYTOCHROME-C; AGED RATS; PROTEIN	Lipopolysaccharide, a component of the cell wall of Gram-negative bacteria, may be responsible for at least some of the pathophysiological sequelae of bacterial infections, probably by inducing an increase in interleukin-1 beta (IL-1 beta) concentration. We report that intraperitoneal injection of lipopolysaccharide increased hippocampal caspase-1 activity and IL-1 beta concentration; these changes were associated with increased activity of the stress-activated kinase c-Jun NH2-terminal kinase, decreased glutamate release, and impaired long term potentiation. The degenerative changes in hippocampus and entorhinal cortical neurones were consistent with apoptosis because translocation of cyto chrome c and poly(ADP-ribose) polymerase cleavage were increased. Inhibition of caspase-1 blocked these changes, suggesting that IL-1 beta mediated the lipopolysaccharide-induced changes.	Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland	Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie		Lynch, Marina/0000-0002-4631-0499				Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANEVARI L, 1994, BRAIN RES, V667, P115, DOI 10.1016/0006-8993(94)91720-5; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; FARRAR WL, 1987, IMMUNOL REV, V100, P361, DOI 10.1111/j.1600-065X.1987.tb00539.x; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; HAMPTON MB, 1989, ANN NY ACAD SCI, V854, P328; IANOTTI F, 1993, J CEREB BLOOD FLOW S, V13, P125; Ilyin SE, 1998, BRAIN RES BULL, V45, P507, DOI 10.1016/S0361-9230(97)00437-1; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kong LY, 1997, NEUROCHEM INT, V30, P491, DOI 10.1016/S0197-0186(96)00086-1; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Linthorst ACE, 1998, ANN NY ACAD SCI, V840, P139, DOI 10.1111/j.1749-6632.1998.tb09558.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767; Maroney AC, 1998, J NEUROSCI, V18, P104; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; MODY I, 1989, NEUROSCI LETT, V96, P70, DOI 10.1016/0304-3940(89)90245-0; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1998, J NEUROSCI, V18, P2974; Nguyen KT, 1998, J NEUROSCI, V18, P2239; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; QUAN N, 1994, J NEUROIMMUNOL, V49, P125, DOI 10.1016/0165-5728(94)90188-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Schulz JB, 1996, J NEUROSCI, V16, P4696; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tenneti L, 1998, J NEUROCHEM, V71, P946; Tingsborg S, 1996, BRAIN RES, V712, P153, DOI 10.1016/0006-8993(95)01525-6; Van Dam AM, 1998, ANN NY ACAD SCI, V840, P128, DOI 10.1111/j.1749-6632.1998.tb09557.x; VEREKER E, 2000, IN PRESS J NEUROSCI; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	53	149	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26252	26258		10.1074/jbc.M002226200	http://dx.doi.org/10.1074/jbc.M002226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856294	hybrid			2022-12-25	WOS:000088999700052
J	Blackshaw, S; Sawa, A; Sharp, AH; Ross, CA; Snyder, SH; Khan, AA				Blackshaw, S; Sawa, A; Sharp, AH; Ross, CA; Snyder, SH; Khan, AA			Type 3 inositol 1,4,5-trisphosphate receptor modulates cell death	FASEB JOURNAL			English	Article						nerve growth factor; dorsal root ganglia; PCD; IP(3)R3 expression	SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; ANTIGEN RECEPTOR; NERVOUS-SYSTEM; APOPTOSIS; EXPRESSION; COMMITMENT; ACTIVATION; CALCIUM	Mechanisms accounting for the cellular entry of calcium that mediates cellular proliferation and apoptosis have been obscure. Previously we reported selective augmentation of type 3 inositol (1,4,5) trisphosphate receptors (IP(3)R3) in lymphocytes undergoing programmed cell death, which was prevented by antisense constructs to IP(3)R3. We now report increases in mRNA and protein levels for IP(3)R3 associated with cell death in several apoptotic paradigms in diverse tissues. Elevations of IP,RS occur during developmental apoptosis in early postnatal cerebellar granule cells, dorsal root gang-lia, embryonic hair follicles, and intestinal villi. Neurotoxic damage elicited by the glutamate agonist kainate is also associated with IP(3)R3 augmentation. In chick dorsal root ganglia neurons undergoing apoptosis due to deprivation of nerve growth factor, levels of IP(3)R3 are selectively increased and cell death is selectively prevented by antisense oligonucleotides to IP(3)R3. Thus, IP(3)R3 appears to participate actively in cell death in a diversity of tissues.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Blackshaw S, 1997, J NEUROSCI, V17, P8074; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; DAVIES AM, 1987, DEVELOPMENT, V101, P185; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GOLDSTEIN RS, 1993, J NEUROBIOL, V24, P1121, DOI 10.1002/neu.480240810; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MINAMIDE S, 1995, HISTOCHEM CELL BIOL, V103, P339, DOI 10.1007/BF01457808; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Sanders EJ, 1995, INT REV CYTOL, V163, P105, DOI 10.1016/S0074-7696(08)62210-X; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Sharp AH, 1999, J COMP NEUROL, V406, P207; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	30	75	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1375	1379		10.1096/fj.14.10.1375	http://dx.doi.org/10.1096/fj.14.10.1375			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877830				2022-12-25	WOS:000087932200012
J	Seipelt, J; Liebig, HD; Sommergruber, W; Gerner, C; Kuechler, E				Seipelt, J; Liebig, HD; Sommergruber, W; Gerner, C; Kuechler, E			2A proteinase of human rhinovirus cleaves cytokeratin 8 in infected HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA; ENCODED PROTEASE 3C(PRO); POLIOVIRUS INFECTION; RNA TRANSLATION; IN-VITRO; POLY(A)-BINDING PROTEIN; INTERMEDIATE FILAMENTS; MEDIATED STIMULATION; CELLULAR PROTEINS	Rhino- and enteroviruses encode two proteinases, 2A and 3C, which are responsible for the processing of the viral polyprotein and for cleavage of several cellular proteins. To identify further targets of the 2A proteinase of human rhinovirus serotype 2 (HRV2), an in vitro cleavage assay followed by two-dimensional electrophoresis was employed. Cytokeratin 8, a member of the intermediate filament group of proteins, was found to be proteolytically cleaved in vitro by the 2A proteinase of HRV2 and of coxsackievirus B4 and in vivo during HRV2 infection of HeLa cells. The cleavage results in removal of 14 amino acids from the N-terminal head domain of cytokeratin 8. However, other intermediate filament proteins (cytokeratins 7 and 18 and vimentin) were not cleaved in the course of the HRV2 infection. Compared with the processing of the eucaryotic translation initiation factors 4GI and 4GII, cleavage of cytokeratin 8 occurs late in the infection cycle at the time of the onset of the cytopathic effect.	Univ Vienna, Inst Med Biochem, Div Biochem, A-1030 Vienna, Austria; Boehringer Ingelheim Austria, A-1123 Vienna, Austria; Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna; Boehringer Ingelheim; University of Vienna	Kuechler, E (corresponding author), Univ Vienna, Inst Med Biochem, Div Biochem, Dr Bohrgasse 9-3, A-1030 Vienna, Austria.	kuechler@bch.univie.ac.at		Gerner, Christopher/0000-0003-4964-0642; Seipelt, Joachim/0000-0001-9865-814X				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOEDENS J, 1994, ARCH VIROL, P159; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; Hunt SL, 1999, VIRUS RES, V62, P119, DOI 10.1016/S0168-1702(99)00039-8; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JOACHIMS M, 1995, VIROLOGY, V211, P451, DOI 10.1006/viro.1995.1427; JOACHIMS M, 1992, J VIROL, V66, P5797, DOI 10.1128/JVI.66.10.5797-5804.1992; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Morley SJ, 1997, RNA, V3, P1085; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; SCHECHTER I, 1966, BIOCHEMISTRY-US, V5, P3371, DOI 10.1021/bi00874a041; SHOEMAN RL, 1991, ADV EXP MED BIOL, V306, P533; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; SOMMERGRUBER W, 1992, J BIOL CHEM, V267, P22639; SONENBERG N, 1990, ENZYME, V44, P278, DOI 10.1159/000468765; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; TESAR M, 1990, VIROLOGY, V174, P364, DOI 10.1016/0042-6822(90)90090-E; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yalamanchili P, 1997, VIROLOGY, V239, P176, DOI 10.1006/viro.1997.8862; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; YAN RQ, 1992, J BIOL CHEM, V267, P23226; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994; ZIEGLER E, 1995, VIROLOGY, V213, P549	49	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20084	20089		10.1074/jbc.275.26.20084	http://dx.doi.org/10.1074/jbc.275.26.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867028	hybrid			2022-12-25	WOS:000087941300088
J	Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y				Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y			p51A (TAp63 gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation	ONCOGENE			English	Article						p51; p63; p53; p21(wafI); Bax; DNA damage	TEMPERATURE-SENSITIVE MUTANT; KINASE C-ABL; MUTATIONAL ANALYSIS; IONIZING-RADIATION; APOPTOTIC RESPONSE; IN-VIVO; GENE; P63; PHOSPHORYLATION; PROLIFERATION	p51A, or TAp63 gamma, a translation product of gene p51, or p63, was identified as a homolog of p53 in its primary structure and transactivating function. p53 plays a decision-making role in inducing either cell cycle arrest or apoptosis in response to DNA damage, and thereby preserves genome integrity of living cells, To compare the biological activities between p51A and p53, cell lines with low-level, constitutive expression of each protein were obtained by cDNA transfection of mouse erythroleukemic cells. Production of p51A with an apparent molecular mass of 57-kilodalton (kD) accompanied induction of p21(wafl) and appearance of hemoglobin-producing cells. After DNA-damaging treatment either with ultraviolet light (UV) irradiation or with actinomycin D, the p51A protein accumulated in time courses corresponding to those of wild-type p53, and caused an increase in the hemoglobin-positive cell count. In contrast, p53-accumulated cells underwent apoptosis without exhibiting the feature of erythroid differentiation, The mode of p21(wafl) and Bax-alpha upregulations varied between p51A- and p53-expressing cells and between the types of DNA damage. These results suggest the possibility that p51A induces differentiation under genotoxic circumstances. There may be cellular factors that control p51A protein stability and transactivating ability.	Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1138510, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan.		井川, 俊太郎/L-5911-2015					Agami R, 1999, NATURE, V399, P809; AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hagiwara K, 1999, CANCER RES, V59, P4165; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimada A, 1999, CANCER RES, V59, P2781; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	34	84	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3126	3130		10.1038/sj.onc.1203644	http://dx.doi.org/10.1038/sj.onc.1203644			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871867				2022-12-25	WOS:000087903900012
J	Murakami, M; Naraba, H; Tanioka, T; Semmyo, N; Nakatani, Y; Kojima, F; Ikeda, T; Fueki, M; Ueno, A; Oh-ishi, S; Kudo, I				Murakami, M; Naraba, H; Tanioka, T; Semmyo, N; Nakatani, Y; Kojima, F; Ikeda, T; Fueki, M; Ueno, A; Oh-ishi, S; Kudo, I			Regulation of prostaglandin E-2 biosynthesis by inducible membrane-associated prostaglandin E-2 synthase that acts in concert with cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RAT PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; H SYNTHASE-1; FUNCTIONAL-ASPECTS; MESSENGER-RNA; COLON-CANCER; MAST-CELLS; EXPRESSION	Here we report the molecular identification of membrane-bound glutathione (GSH)-dependent prostaglandin (PG) E-2 synthase (mPGES), a terminal enzyme of the cyclooxygenase (COX)-2-mediated PGE(2) biosynthetic pathway. The activity of mPGES was increased markedly in macrophages and osteoblasts following proinflammatory stimuli. cDNA for mouse and rat mPGESs encoded functional proteins that showed high homology with the human ortholog (microsomal glutathione S-transferase-like 1). mPGES expression was markedly induced by proinflammatory stimuli in various tissues and cells and was down-regulated by dexamethasone, accompanied by changes in COX-2 expression and delayed PGE(2) generation. Arg(110), a residue well conserved in the microsomal GSH S-transferase family, was essential for catalytic function, mPGES was functionally coupled with COX-2 in marked preference to COX-1, particularly when the supply of arachidonic acid was limited. Increased supply of arachidonic acid by explosive activation of cytosolic phospholipase A(2) allowed mPGES to be coupled with COX-1. mPGES colocalized with both COX isozymes in the perinuclear envelope. Moreover, cells stably cotransfected with COX-2 and mPGES grew faster, were highly aggregated, and exhibited aberrant morphology. Thus, COX-2 and mPGES are essential components for delayed PGE(2) biosynthesis, which may be linked to inflammation, fever, osteogenesis, and even cancer.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Pharmacol, Minato Ku, Tokyo 1080072, Japan	Showa University; Kitasato University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Harada Y, 1996, PROSTAG OTH LIPID M, V51, P19, DOI 10.1016/0090-6980(95)00168-9; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Higashi S, 2000, INFLAMM RES, V49, P102, DOI 10.1007/s000110050566; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LIN LL, 1992, J BIOL CHEM, V267, P23451; MARNETT LJ, 1992, CANCER RES, V52, P5575; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Naraba H, 1998, J IMMUNOL, V160, P2974; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Raisz L G, 1993, Osteoporos Int, V3 Suppl 1, P136, DOI 10.1007/BF01621888; RAO CV, 1995, CANCER RES, V55, P1464; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Salinas AE, 1999, CURR MED CHEM, V6, P279; SANO H, 1995, CANCER RES, V55, P3785; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Watanabe K, 1997, BIOCHEM BIOPH RES CO, V235, P148, DOI 10.1006/bbrc.1997.6708; Weinander R, 1997, J BIOL CHEM, V272, P8871; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	55	794	837	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32783	32792		10.1074/jbc.M003505200	http://dx.doi.org/10.1074/jbc.M003505200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10869354	hybrid			2022-12-25	WOS:000090003800057
J	Collazo, R; Fan, LZ; Hu, MC; Zhao, H; Wiederkehr, MR; Moe, OW				Collazo, R; Fan, LZ; Hu, MC; Zhao, H; Wiederkehr, MR; Moe, OW			Acute regulation of Na+/H+ exchanger NHE3 by parathyroid hormone via NHE3 phosphorylation and dynamin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; PROTEIN-KINASE-A; CAMP-MEDIATED INHIBITION; OPOSSUM KIDNEY-CELLS; PROXIMAL TUBULE CELLS; H+ EXCHANGER; CALCIUM-TRANSPORT; APICAL MEMBRANE; ISOFORM NHE3; BICARBONATE ABSORPTION	Parathyroid hormone (PTH) is a potent inhibitor of mammalian renal proximal tubule Na+ transport via its action on the apical membrane Na+/H+ exchanger NHE3. In the opossum kidney cell line, inhibition of NHE3 activity was detected from 5 to 45 min after PTH addition. Increase in NHE3 phosphorylation on multiple serines was evident after 5 min of PTH, but decrease in surface NHE3 antigen was not detectable until after 30 min of PTH. The decrease in surface NHE3 antigen was due to increased NHE3 endocytosis. When endocytic trafficking was arrested with a dominant negative dynamin mutant (K44A), the early inhibition (5 min) of NHE3 activity by PTH was not affected, whereas the late inhibition (30 min) and decreased surface NHE3 antigen induced by PTH were abrogated. We conclude that PTH acutely inhibits NHE3 activity in a biphasic fashion by NHE3 phosphorylation followed by dynamin-dependent endocytosis.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Affairs Med Ctr, Med Serv, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048482, R01DK054396, R29DK048482, T32DK007257] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48482, DK-54396, T32 DK07257-17] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUS ZS, 1973, AM J PHYSIOL, V224, P1143, DOI 10.1152/ajplegacy.1973.224.5.1143; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BANK N, 1976, J CLIN INVEST, V58, P336, DOI 10.1172/JCI108477; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; BIEMESDERFER D, 1997, J AM SOC NEPHROL, V8, P3; BINDELS RJM, 1993, J EXP BIOL, V184, P89; BOURDEAU JE, 1993, SEMIN NEPHROL, V13, P191; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Chow CW, 1999, J BIOL CHEM, V274, P10481, DOI 10.1074/jbc.274.15.10481; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; IINO Y, 1979, AM J PHYSIOL, V236, pF387, DOI 10.1152/ajprenal.1979.236.4.F387; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LIU FY, 1989, J CLIN INVEST, V84, P83, DOI 10.1172/JCI114174; MARONE CC, 1983, J LAB CLIN MED, V101, P264; MCKINNEY TD, 1980, AM J PHYSIOL, V239, pF127, DOI 10.1152/ajprenal.1980.239.2.F127; MCKINNEY TD, 1980, AM J PHYSIOL, V238, pF166, DOI 10.1152/ajprenal.1980.238.3.F166; MILLER RT, 1987, J BIOL CHEM, V262, P9115; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Moe OW, 1997, CURR OPIN NEPHROL HY, V6, P440, DOI 10.1097/00041552-199709000-00006; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MORAN A, 1988, BIOCHIM BIOPHYS ACTA, V969, P48, DOI 10.1016/0167-4889(88)90087-0; MORI Y, 1992, PHARMACOL TOXICOL, V70, P201, DOI 10.1111/j.1600-0773.1992.tb00457.x; MRKIC B, 1992, J MEMBRANE BIOL, V130, P205; MRKIC B, 1993, PFLUG ARCH EUR J PHY, V424, P377, DOI 10.1007/BF00374897; Nath SK, 1999, AM J PHYSIOL-CELL PH, V276, pC873, DOI 10.1152/ajpcell.1999.276.4.C873; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PASTORIZAMUNOZ E, 1992, J CLIN INVEST, V89, P1485, DOI 10.1172/JCI115739; Peng Y, 1999, AM J PHYSIOL-CELL PH, V276, pC938, DOI 10.1152/ajpcell.1999.276.4.C938; PENG Y, 1999, J AM SOC NEPHROL, V10, P459; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PRIESIG PA, 1987, J CLIN INVEST, V80, P970; PUSCHETT JB, 1976, KIDNEY INT, V9, P501, DOI 10.1038/ki.1976.64; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; SASAKI S, 1991, AM J PHYSIOL, V260, pF883; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Seldin DW, 1999, NEPHRON, V81, P2, DOI 10.1159/000046292; SUKI WN, 1979, AM J PHYSIOL, V237, pF1, DOI 10.1152/ajprenal.1979.237.1.F1; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; TALOR Z, 1988, RES COMMUN CHEM PATH, V61, P335; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P11, DOI 10.1007/BF01872815; WEINMAN EJ, 1986, J MEMBRANE BIOL, V93, P133, DOI 10.1007/BF01870805; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Yip KP, 1998, AM J PHYSIOL-RENAL, V275, pF565, DOI 10.1152/ajprenal.1998.275.4.F565; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; Zhang YB, 1998, AM J PHYSIOL-CELL PH, V274, pC1090, DOI 10.1152/ajpcell.1998.274.4.C1090; Zhang YBB, 1998, J AM SOC NEPHROL, V9, P531; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753; [No title captured]	86	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31601	31608		10.1074/jbc.M000600200	http://dx.doi.org/10.1074/jbc.M000600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10866993	hybrid			2022-12-25	WOS:000089858900009
J	Anderson, RF; Jang, MH; Hille, R				Anderson, RF; Jang, MH; Hille, R			Radiolytic studies of trimethylamine dehydrogenase - Spectral deconvolution of the neutral and anionic flavin semiquinone, and determination of rate constants for electron transfer in the one-electron reduced enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; XANTHINE-OXIDASE; SUBSTRATE; FLAVOPROTEIN; INHIBITOR; CLUSTER; BINDING	Trimethylamine dehydrogenase from the pseudomonad Methylophilus methylotrophus has been examined using the technique of pulse radiolysis to rapidly introduce a single reducing equivalent into the enzyme. Using enzyme that has had its iron-sulfur center rendered redox-inert by prior reaction with ferricenium hexafluorophosphate, we determined the spectral change associated with formation of both the anionic and neutral forms that were generated at high and low pH, respectively, of the unique 6-cysteinyl-FMN of the enzyme. With native enzyme, electron transfer was observed within the radiolytically generated one-electron reduced enzyme but only at low pH (6.0). The kinetics and thermodynamics of this electron transfer in one-electron reduced enzyme may be compared with that studied previously in the two-electron reduced enzyme. In contrast to previous studies with two-electron reduced enzyme in which a pK(a) of similar to 8 was determined for the flavin semiquinone, in the one-electron reduced enzyme the semiquinone was not substantially protonated even at pH 6.0. These results indicate that reduction of the iron-sulfur center of the enzyme significantly decreases the pK(a) of the flavin semiquinone of the active site. This provides further evidence, in conjunction with the strong magnetic interaction known to exist between the centers in the two-electron reduced enzyme, that the two redox-active centers in trimethylamine dehydrogenase are in intimate contact with one another in the active site of the enzyme.	Univ Auckland, Dept Chem, Auckland, New Zealand; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Auckland; Ohio State University	Anderson, RF (corresponding author), Univ Auckland, Dept Chem, Private Bag 92019, Auckland, New Zealand.				NIGMS NIH HHS [GM58481] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1997, FLAVINS FLAVOPROTEIN, P865; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Conrads T, 1998, BIOCHEMISTRY-US, V37, P7787, DOI 10.1021/bi972387x; Fournel A, 1998, J CHEM PHYS, V109, P10905, DOI 10.1063/1.477786; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P4559, DOI 10.1021/bi00232a028; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1991, J BIOL CHEM, V266, P5608; Huang LX, 1996, J BIOL CHEM, V271, P13401, DOI 10.1074/jbc.271.23.13401; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; Jang MH, 1999, J BIOL CHEM, V274, P13147, DOI 10.1074/jbc.274.19.13147; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM KW, 1988, J BIOL CHEM, V268, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; Roberts P, 1999, BIOCHEMISTRY-US, V38, P14927, DOI 10.1021/bi9914098; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026	31	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30781	30786		10.1074/jbc.M001256200	http://dx.doi.org/10.1074/jbc.M001256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10859304	hybrid			2022-12-25	WOS:000089762700008
J	Born, TL; Smith, DE; Garka, KE; Renshaw, BR; Bertles, JS; Sims, JE				Born, TL; Smith, DE; Garka, KE; Renshaw, BR; Bertles, JS; Sims, JE			Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family - Delineation of a new class of IL-1R-related proteins based on signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TOLL PROTEIN; MAP KINASE KINASE; NF-KAPPA-B; ACCESSORY PROTEIN; MOLECULAR-CLONING; CULTURED-CELLS; HUMAN MYD88; ACTIVATION; GENE; IRAK	Two novel members of the interleukin-1 receptor (IL-1R) family, identified by homology searches of human genomic sequence data bases, are described. The genes have been named according to their structural features: TIGIRR-1 (three immunoglobulin domain-containing IL-1 receptor-related) and TIGIRR-2. TIGIRR-2 has recently been identified as causing mental retardation when mutated (Carrie, A., Jun, L., Bienvenu, T., Vinet, M. C., McDonell, N., Couvert, P., Zemni, R., Cardona, A., Van Buggenhout, G., Frints, S., Hamel, B., Moraine, C., Ropers, H. H., Strom, T., Howell, G. R., Whittaker, A., Boss, M. T., Kahn, A., Fryns, J. P., Beldjord, C., Marynen, P., and Chelly, J. (1999) Nat. Genet. 23, 25-31) and called IL1RAPL, a name we will also use henceforth. Neither receptor alone was able to mediate transcriptional activation of NF-kappa B in response to IL-1 alpha, IL-1 beta, or IL-18. In order to begin to elucidate the function of these and other orphan IL-1R family members, we have developed a functional assay utilizing a panel of chimeric receptors containing the extracellular and transmembrane domains of either type I IL-1R or IL-1R accessory protein (AcP) coupled to the cytoplasmic domains of all family members. Coexpression of each IL-1R chimera with each AcP chimera and an NF-kappa B-responsive reporter demonstrated that the cytoplasmic domains could be classified as IL-1R-like, AcP-like, or neither. Any IL-1R-like cytoplasmic domain could cooperate with any AcP-like cytoplasmic domain. The TIGIRR-1 and IL1RAPL cytoplasmic domains, however, were unable to signal as either IL-1R-like or AcP-like components, suggesting that they function as a new class of receptors within this family.	Immunex Corp, Seattle, WA 98101 USA	Immunex Corporation	Sims, JE (corresponding author), Immunex Corp, 51 Univ St, Seattle, WA 98101 USA.	simsj@immunex.com		Sims, John/0000-0002-5667-9185				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Born TL, 2000, J IMMUNOL, V164, P3246, DOI 10.4049/jimmunol.164.6.3246; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hardiman G, 1996, ONCOGENE, V13, P2467; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LORD KA, 1990, ONCOGENE, V5, P1095; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NORRIS JL, 1995, GENE DEV, V9, P358, DOI 10.1101/gad.9.3.358; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Ridley SH, 1997, J IMMUNOL, V158, P3165; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Thomas JA, 1999, J IMMUNOL, V163, P978; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1998, FEBS LETT, V429, P303, DOI 10.1016/S0014-5793(98)00468-2; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U	59	77	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29946	29954		10.1074/jbc.M004077200	http://dx.doi.org/10.1074/jbc.M004077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882729	hybrid			2022-12-25	WOS:000089577900006
J	Provost, PR; Tremblay, Y				Provost, PR; Tremblay, Y			Length increase of the human alpha-globin 3 '-untranslated region disrupts stability of the pre-mRNA but not that of the mature mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID LEVELS; RNA 3'-END FORMATION; MESSENGER-RNA; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; GENE-EXPRESSION; TRANSGENIC MICE; SIMIAN VIRUS-40; SITE SELECTION; LAST INTRON; IN-VIVO	Polyadenylation increases the stability of mRNA molecules. By studying the effect of the length of 3'-untranslated region (UTR) on mRNA levels, we have found that alpha-globin pre-mRNA is stabilized by a mechanism that does not modulate the half-life of mature mRNA. The insertion of DNA fragments of various unrelated sequences into the 3'-UTR of the human alpha-globin gene strongly reduces mRNA abundance upon transfection into choriocarcinoma JEG-3 cells. We found an inverse relationship between mRNA levels and the length of the introduced fragments. In fact, mRNA levels as low as 1% were observed after inserting a 477-nucleotide (nt) fragment, whereas inserting a fragment of 86 nt at the same position had no effect on mRNA accumulation. DNA insertion induced no change in transcription rate or in half-life of mature mRNA. Semi-quantitative reverse transcription-polymerase chain reaction revealed that inserting a 477-nt fragment in the 3'-UTR resulted in decreased levels of nuclear pre-mRNA in proportion to that observed for mature mRNA. In contrast, the insertion of the 477-nt exogenous DNA in the last intron had no effect on mRNA levels despite the presence of intronic sequences in the pre-mRNA. This shows that the reduction of pre-mRNA level was not due to the insertion of putative ribonuclease cleavage sites or the insertion of a segment DNA that reduces the elongation efficiency. Taken together, our results strongly support the existence of a pre-mRNA stabilizing mechanism that can be disrupted by increasing the length of the 3'-UTR. The fact that the half-life of mature mRNA is not affected by DNA insertion is compatible with a pre-mRNA-specific stabilizing mechanism that acts specifically before polyadenylation.	CHU Quebec, Lab Ontogeny & Reprod, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, Y (corresponding author), CHU Laval, Res Ctr, Lab Otogeny & Reprod CRBR, Room T-1-58,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	yves.tremblay@crchul.ulaval.ca						AKAHANE K, 1992, BLOOD, V79, P3188; Antoniou M, 1998, NUCLEIC ACIDS RES, V26, P721, DOI 10.1093/nar/26.3.721; ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; Beaudoin C, 1997, J ENDOCRINOL, V154, P379, DOI 10.1677/joe.0.1540379; BEAUDOIN C, 1995, ENDOCRINOLOGY, V136, P3807, DOI 10.1210/en.136.9.3807; Beaudoin C, 1997, MOL CELL ENDOCRINOL, V133, P63, DOI 10.1016/S0303-7207(97)00143-3; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHIOU HC, 1991, J VIROL, V65, P6677, DOI 10.1128/JVI.65.12.6677-6685.1991; ElMeskini R, 1997, ENDOCRINOLOGY, V138, P5256, DOI 10.1210/en.138.12.5256; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GRUSS P, 1979, P NATL ACAD SCI USA, V76, P4317, DOI 10.1073/pnas.76.9.4317; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMER DH, 1979, CELL, V18, P1299, DOI 10.1016/0092-8674(79)90240-X; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LIU XD, 1993, NUCLEIC ACIDS RES, V21, P5256, DOI 10.1093/nar/21.22.5256; Luu The V, 1989, Mol Endocrinol, V3, P1301; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MILLER JT, 1992, J VIROL, V66, P4242, DOI 10.1128/JVI.66.7.4242-4251.1992; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Moore M., 1993, RNA WORLD, P303; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NEUBERGER MS, 1988, NUCLEIC ACIDS RES, V16, P6713, DOI 10.1093/nar/16.14.6713; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAYMOND V, 1989, ONCOGENE RES, V5, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; TREMBLAY Y, 1988, P NATL ACAD SCI USA, V85, P8890, DOI 10.1073/pnas.85.23.8890; TREMBLAY Y, 1993, MOL ENDOCRINOL, V7, P355, DOI 10.1210/me.7.3.355; TREMBLAY Y, 1989, J BIOL CHEM, V264, P20458; TREMBLAY Y, 1994, DNA CELL BIOL, V13, P1199, DOI 10.1089/dna.1994.13.1199; VILLARREAL LP, 1983, MOL CELL BIOL, V3, P1381, DOI 10.1128/MCB.3.8.1381; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647	46	5	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30248	30255		10.1074/jbc.M002969200	http://dx.doi.org/10.1074/jbc.M002969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10867002	hybrid			2022-12-25	WOS:000089577900047
J	Paul, MF; Barrientos, A; Tzagoloff, A				Paul, MF; Barrientos, A; Tzagoloff, A			A single amino acid change in subunit 6 of the yeast mitochondrial ATPase suppresses a null mutation in ATP10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE F-0 SECTOR; ESCHERICHIA-COLI; MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; GENE; TOPOGRAPHY; IDENTIFICATION; CLEAVAGE; PROTEINS	In an earlier study, the ATP10 gene of Saccharomyces cerevisiae was shown to code for an inner membrane protein required for assembly of the F-0 sector of the mitochondrial ATPase complex (Ackerman, S., and Tzagoloff, A. (1990) J. Biol. Chem. 265, 9952-9959). To gain additional insights into the function of Atp10p, we have analyzed a revertant of an atp10 null mutant that displays partial recovery of oligomycin-sensitive ATPase and of respiratory competence. The suppressor mutation in the revertant has been mapped to the OLI2 locus in mitochondrial DNA and shown to be a single base change in the C-terminal coding region of the gene. The mutation results in the substitution of a valine for an alanine at residue 249 of subunit 6 of the ATPase. The ability of the subunit 6 mutation to compensate for the absence of Atp10p implies a functional interaction between the two proteins. Such an interaction is consistent with evidence indicating that the C-terminal region with the site of the mutation and the extramembrane domain of Atp10p are both on the matrix side of the inner membrane. Subunit 6 has been purified from the parental wild type strain, from the atp10 null mutant, and from the revertant. The N-terminal sequences of the three proteins indicated that they all start at Ser(11), the normal processing site of the subunit 6 precursor. Mass spectral analysis of the wild type and mutants subunit 6 failed to reveal any substantive difference of the wild type and mutant proteins when the mass of the latter was corrected for Ala --> Val mutation. These data argue against a role of Atp10p in post-translational modification of subunit 6. Although post-translational modification of another ATPase subunit interacting with subunit 6 cannot be excluded, a more likely function for Atp10p is that it acts as a subunit 6 chaperone during F-0 assembly.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet.bio.columbia.edu			NHLBI NIH HHS [R01 HL022174, HL 22174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL022174, R37HL022174, R01HL022174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BIZZOZERO O, 1982, J CHROMATOGR, V227, P33, DOI 10.1016/S0378-4347(00)80353-9; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; DIECKMANN CL, 1983, METHOD ENZYMOL, V97, P361; Douglas M, 1979, Methods Enzymol, V56, P58; DUJON B, 1980, MOL BIOL YEAST SACCH, P505; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FOURY F, 1976, EUR J BIOCHEM, V68, P113, DOI 10.1111/j.1432-1033.1976.tb10769.x; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; MULLER PP, 1984, J MOL BIOL, V175, P431, DOI 10.1016/0022-2836(84)90178-5; NORAIS N, 1991, J BIOL CHEM, V266, P16541; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2000, BIOCHEMISTRY-US, V39, P4199, DOI 10.1021/bi992438l; PAYNE MJ, 1991, CURR GENET, V19, P343, DOI 10.1007/BF00309594; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1970, J BIOL CHEM, V245, P1545; Tzagoloff A, 1979, Methods Enzymol, V55, P351; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Velours J, 1998, BIOCHIMIE, V80, P793, DOI 10.1016/S0300-9084(00)88873-2; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	37	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29238	29243		10.1074/jbc.M004546200	http://dx.doi.org/10.1074/jbc.M004546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10867012	hybrid			2022-12-25	WOS:000089439800010
J	Sasaki, A; Yasukawa, H; Shouda, T; Kitamura, T; Dikic, I; Yoshimura, A				Sasaki, A; Yasukawa, H; Shouda, T; Kitamura, T; Dikic, I; Yoshimura, A			CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; INDUCIBLE SH2 PROTEIN; JANUS TYROSINE KINASE; NEGATIVE REGULATORS; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; CYTOKINE; GENE; ACTIVATION; FAMILY	The cytokine-inducible SH2 protein-3 (CIS3/SOCS-3/SSI-3) has been shown to inhibit the JAK/STAT pathway and act as a negative regulator of fetal liver erythropoiesis. Here, we studied the molecular mechanisms by which CIS3 regulates the erythropoietin (EPO) receptor (EPOR) signaling in erythroid progenitors and Ba/F3 cells expressing the EPOR (BF-ER). CIS3 binds directly to the EPOR as well as JAK2 and inhibits EPO-dependent proliferation and STAT5 activation. We have identified the region containing Tyr(401) in the cytoplasmic domain of the EPOR as a direct binding site for CIS3. Deletion of the Tyr401 legion of the EPOR reduced the inhibitory effect of CIS3, suggesting that binding of CIS3 to the EPOR augmented the negative effect of CIS3. Both N- and C-terminal regions adjacent to the SH2 domain of CIS3 were necessary for binding to EPOR and JAK2. In the N-terminal region of CIS3, the amino acid Gly(45) was critical for binding to the EPOR but not to JAK2, while Leu(22) was critical for binding to JAK2. The mutation of G45A partially reduced ability of CIS3 to inhibit EPO-dependent proliferation and STATE activation, while L22D mutant CIS3 was completely unable to suppress EPOR signaling. Moreover, overexpression of STAT5, which also binds to Tyr401, reduced the binding of CIS3 to the EPOR, and the inhibitory effect of CISB against EPO signaling, while it did not affect JAB/SOCS-1/SSI-1. These data demonstrate that binding of CIS3 to the EPOR augments the inhibitory effect of CIS3. CIS3 binding to both EPOR and JAK2 may explain a specific regulatory role of CIS3 in erythropoiesis.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Fac Med, Dept Orthoped Surg, Kurume, Fukuoka 8300011, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Kurume University; Kurume University; Kurume University; University of Tokyo; Ludwig Institute for Cancer Research	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.		Yoshimura, Akihiko/K-5515-2013; Dikic, Ivan/O-4650-2015; Kitamura, Toshio/AAA-2071-2021	Dikic, Ivan/0000-0001-8156-9511; Sasaki, Atsuo/0000-0003-2963-4501				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Orkin SH, 1998, INT J DEV BIOL, V42, P927; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SPANGLER R, 1992, BLOOD, V79, P52; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	54	248	265	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29338	29347		10.1074/jbc.M003456200	http://dx.doi.org/10.1074/jbc.M003456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882725	hybrid			2022-12-25	WOS:000089439800023
J	Jovanovic, T; Ascenso, C; Hazlett, KRO; Sikkink, R; Krebs, C; Litwiller, R; Benson, LM; Moura, I; Moura, JJG; Radolf, JD; Huynh, BH; Naylor, S; Rusnak, F				Jovanovic, T; Ascenso, C; Hazlett, KRO; Sikkink, R; Krebs, C; Litwiller, R; Benson, LM; Moura, I; Moura, JJG; Radolf, JD; Huynh, BH; Naylor, S; Rusnak, F			Neelaredoxin, an iron-binding protein from the syphilis spirochete, Treponema pallidum, is a superoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; COMPLETE GENOME SEQUENCE; CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; ALKYL-HYDROPEROXIDE REDUCTASE; SEXUALLY-TRANSMITTED DISEASES; PLASMA EMISSION-SPECTROSCOPY; IONIZATION MASS-SPECTROMETRY; AMINO-ACID-SEQUENCE; RBO GENE-PRODUCT; ESCHERICHIA-COLI	Treponema pallidum, the causative agent of venereal syphilis, is a microaerophilic obligate pathogen of humans. As it disseminates hematogenously and invades a wide range of tissues, T. pallidum presumably must tolerate substantial oxidative stress. Analysis of the T. pallidum genome indicates that the syphilis spirochete lacks most of the iron-binding proteins present in many other bacterial pathogens, including the oxidative defense enzymes superoxide dismutase, catalase, and peroxidase, but does possess an orthologue (TP0823) for neelaredoxin, an enzyme of hyperthermophilic and sulfate-reducing anaerobes shown to possess superoxide reductase activity. To analyze the potential role of neelaredoxin in treponemal oxidative defense, we examined the biochemical, spectroscopic, and antioxidant properties of recombinant T, pallidum neelaredoxin. Neelaredoxin was shown to be expressed in T. pallidum by reverse transcriptase-polymerase chain reaction and Western blot analysis. Recombinant neelaredoxin is a 26-kDa alpha(2) homodimer containing, on average, 0.7 iron atoms/subunit. Mossbauer and EPR analysis of the purified protein indicates that the iron atom exists as a mononuclear center in a mixture of high spin ferrous and ferric oxidation states. The fully oxidized form, obtained by the addition of K-3(Fe(CN)(6)), exhibits an optical spectrum with absorbances at 280, 320, and 656 nm; the last feature is responsible for the protein's blue color, which disappears upon ascorbate reduction. The fully oxidized protein has a A(280)/A(656) ratio of 10.3. Enzymatic studies revealed that T. pallidum neelaredoxin is able to catalyze a redox equilibrium between superoxide and hydrogen peroxide, a result consistent with it being a superoxide reductase. This finding, the first description of a T. pallidum iron-binding protein, indicates that the syphilis spirochete copes with oxidative stress via a primitive mechanism, which, thus far, has not been described in pathogenic bacteria.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Hematol Res Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry & Funct Proteom Facil, Rochester, MN 55905 USA; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2825 Monte De Caparica, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Ctr Quim Fina & Biotecnol, P-2825 Monte De Caparica, Portugal; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	Mayo Clinic; Mayo Clinic; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University of Connecticut; University of Connecticut; Emory University	Rusnak, F (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Hematol Res Sect, 200 1st St SW, Rochester, MN 55905 USA.		Krebs, Carsten/D-4773-2009; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Krebs, Carsten/0000-0002-3302-7053; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Jovanovic-Talisman, Tijana/0000-0003-1928-4763; Ascenso, Carla/0000-0001-5134-7387	NIAID NIH HHS [AI 26756] Funding Source: Medline; NIGMS NIH HHS [GM58778] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026756, R37AI026756, R01AI026756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058778] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonomi F, 1998, J BIOL INORG CHEM, V3, P595, DOI 10.1007/s007750050272; BRUMLIK MJ, 1990, J BACTERIOL, V172, P7289, DOI 10.1128/jb.172.12.7289-7292.1990; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; COVER WH, 1982, SEX TRANSM DIS, V9, P1, DOI 10.1097/00007435-198201000-00001; COX CD, 1983, PATHOGENESIS IMMUNOL, P57; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; Crapo J D, 1978, Methods Enzymol, V53, P382; CZAJA C, 1995, J BIOL CHEM, V270, P20273, DOI 10.1074/jbc.270.35.20273; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Devreese B, 1996, FEBS LETT, V385, P138, DOI 10.1016/0014-5793(96)00364-X; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FASSEL VA, 1978, SCIENCE, V202, P183, DOI 10.1126/science.202.4364.183; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Higuchi M, 1999, J BACTERIOL, V181, P5940, DOI 10.1128/JB.181.19.5940-5947.1999; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MOURA I, 1990, J BIOL CHEM, V265, P21596; Nakashima AK, 1996, SEX TRANSM DIS, V23, P16, DOI 10.1097/00007435-199601000-00006; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; NIXON DE, 1986, CLIN CHEM, V32, P1660; NORRIS SJ, 1978, INFECT IMMUN, V22, P689, DOI 10.1128/IAI.22.3.689-697.1978; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; PERINE PL, 1994, MED J AUSTRALIA, V160, P358, DOI 10.5694/j.1326-5377.1994.tb138239.x; PETILLOT Y, 1993, BIOCHEM J, V296, P657, DOI 10.1042/bj2960657; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; Posey JE, 1999, P NATL ACAD SCI USA, V96, P10887, DOI 10.1073/pnas.96.19.10887; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Radolf JD, 1999, TRENDS MICROBIOL, V7, P7, DOI 10.1016/S0966-842X(98)01422-X; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; SAWYER DT, 1974, EXPT ELECTROCHEMISTR, P41; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEINER B, 1984, BRIT J VENER DIS, V60, P14; STEINER BM, 1984, CAN J MICROBIOL, V30, P1467, DOI 10.1139/m84-234; TABOR S, 1990, CURRENT PROTOCOLS MO; TAVARES P, 1994, J BIOL CHEM, V269, P10504; TRAMONT EC, 1994, PRINCIPLES PRACTICE, P2117; VALENTINE JS, 1994, BIOINORG CHEM, P253; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	51	91	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28439	28448		10.1074/jbc.M003314200	http://dx.doi.org/10.1074/jbc.M003314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874033	hybrid			2022-12-25	WOS:000089330700016
J	Woo, PL; Cercek, A; Desprez, PY; Firestone, GL				Woo, PL; Cercek, A; Desprez, PY; Firestone, GL			Involvement of the helix-loop-helix protein Id-1 in the glucocorticoid regulation of tight junctions in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; DOMINANT-NEGATIVE REGULATOR; TUMOR-CELLS; ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3-KINASE; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; EXPRESSION; SUPPRESSION; CADHERIN	Mammary epithelial cell-cell junctions undergo morphological and structural differentiation during pregnancy and lactation, but little is known about the transcriptional regulators that are involved in this process. In Con8 mammary epithelial tumor cells, we have previously documented that the synthetic glucocorticoid, dexamethasone, induces the reorganization of the tight junction and adherens junction and stimulates the monolayer transepithelial electrical resistance (TER), a reliable in vitro measurement of tight junction sealing. Western blots demonstrated that dexamethasone treatment rapidly and strongly stimulated the level of the Id-1 protein, which is a serum-inducible helix-loop-helix transcriptional repressor. The steroid induction of Id-1 was robust by 4 h of treatment and maintained over a 24-h period. Isopropyl-1-thio-beta-D-galactopyranoside-inducible expression of exogenous Id-1 in Con8 cells was shown to strongly facilitate the dexamethasone induction of TER in the absence of serum without altering the dexamethasone-dependent reorganization of ZO-1, beta-catenin, or F-actin. Ectopic overexpression of Id-1 in the SCp2 nontumorigenic mammary epithelial cells, which does not undergo complete dexamethasone-dependent tight junction reorganization, enhanced the dexamethasone-induced ZO-1 tight junction localization and stimulated the monolayer TER. Moreover, antisense reduction of Id-1 protein in SCp2 cells prevented the apical junction reorganization and dexamethasone-stimulated TER. Our results implicate Id-1 as acting as a critical regulator of mammary epithelial cell-cell interactions at an early step in the glucocorticoid-dependent signaling pathway that controls tight junction integrity.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; California Pacific Medical Center	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09041] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DB, 1993, CANCER RES, V53, P1808; Baonza A, 1999, MECH DEVELOP, V80, P133, DOI 10.1016/S0925-4773(98)00198-1; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; Chen HP, 1999, BIOCHEM BIOPH RES CO, V256, P614, DOI 10.1006/bbrc.1999.0386; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DEED RW, 1993, ONCOGENE, V8, P599; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARA E, 1994, J BIOL CHEM, V269, P2139; Ishiguro A, 1995, LEUKEMIA RES, V19, P989, DOI 10.1016/0145-2126(95)00084-4; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Israel MA, 1999, CANCER RES, V59, p1726S; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 1999, INT REV CYTOL, V186, P117; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rescan PY, 1997, EUR J BIOCHEM, V247, P870, DOI 10.1111/j.1432-1033.1997.00870.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawai S, 1997, MECH DEVELOP, V65, P175, DOI 10.1016/S0925-4773(97)00071-3; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILSON R, 1995, MECH DEVELOP, V49, P211, DOI 10.1016/0925-4773(94)00319-I; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHU WJ, 1995, MOL BRAIN RES, V30, P312, DOI 10.1016/0169-328X(95)00017-M	73	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28649	28658		10.1074/jbc.M910373199	http://dx.doi.org/10.1074/jbc.M910373199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878025	hybrid			2022-12-25	WOS:000089330700043
J	Kunz, WS; Kudin, A; Vielhaber, S; Elger, CE; Attardi, G; Villani, G				Kunz, WS; Kudin, A; Vielhaber, S; Elger, CE; Attardi, G; Villani, G			Flux control of cytochrome c oxidase in human skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL DISEASES; IN-VIVO; ENCEPHALOMYOPATHIES; RESPIRATION; INHIBITOR; PHENOTYPE; MUTATION; GENOTYPE; FIBERS; CELL	In the present work, by titrating cytochrome c oxidase (COX) with the specific inhibitor KCN, the flux control coefficient and the metabolic reserve capacity of COX have been determined in human saponin-permeabilized muscle fibers. In the presence of the substrates glutamate and malate, a 2.3 +/- 0.2-fold excess capacity of COX was observed in ADP-stimulated human skeletal muscle fibers. This value was found to be dependent on the mitochondrial substrate supply. In the combined presence of glutamate, malate, and succinate, which supported an approximately 1.4-fold higher rate of respiration, only a 1.4 +/- 0.2-fold excess capacity of COX was determined, In agreement with these findings, the flux control of COX increased, in the presence of the three substrates, from 0.27 +/- 0.03 to 0.36 +/- 0.08. These results indicate a tight in vivo control of respiration by COX in human skeletal muscle. This tight control may have significant implications for mitochondrial myopathies, In support of this conclusion, the analysis of skeletal muscle fibers from two patients with chronic progressive external ophthalmoplegia, which carried deletions in 11 and 49% of their mitochondrial DNA, revealed a substantially lowered reserve capacity and increased flux control coefficient of COX, indicating severe rate limitations of oxidative phosphorylation by this enzyme.	Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany; Univ Magdeburg, Med Ctr, Dept Neurol 2, D-39120 Magdeburg, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	University of Bonn; Otto von Guericke University; California Institute of Technology; Universita degli Studi di Bari Aldo Moro	Kunz, WS (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; KACSER H, 1973, RATE CONTROL BIOL PR, P65; Kadenbach B, 1999, FEBS LETT, V447, P131, DOI 10.1016/S0014-5793(99)00229-X; Kuznetsov AV, 1996, J BIOL CHEM, V271, P283, DOI 10.1074/jbc.271.1.283; Kuznetsov AV, 1997, BBA-MOL BASIS DIS, V1360, P142, DOI 10.1016/S0925-4439(96)00072-5; Kuznetsov AV, 1998, J CELL BIOL, V140, P1091, DOI 10.1083/jcb.140.5.1091; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; Mootha VK, 1997, AM J PHYSIOL-HEART C, V272, pH769, DOI 10.1152/ajpheart.1997.272.2.H769; Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5; Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Schroder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353; SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; Tracey I, 1997, MUSCLE NERVE, V20, P1352; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; VILLANI G, 2000, IN PRESS FREE RADIC; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; Wiedemann FR, 1998, FEBS LETT, V422, P33, DOI 10.1016/S0014-5793(97)01586-X; Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434	30	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27741	27745						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869362				2022-12-25	WOS:000089197100031
J	VanDuijn, MM; Tijssen, K; VanSteveninck, J; Van den Broek, PJA; Van der Zee, J				VanDuijn, MM; Tijssen, K; VanSteveninck, J; Van den Broek, PJA; Van der Zee, J			Erythrocytes reduce extracellular ascorbate free radicals using intracellular ascorbate as an electron donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULE MEMBRANE; DEHYDROASCORBIC ACID; VITAMIN-C; THIOREDOXIN REDUCTASE; PLASMA-MEMBRANE; HUMAN NEUTROPHILS; ALPHA-TOCOPHEROL; TRANSPORT; NADH; FERRICYANIDE	Ascorbate is readily oxidized in aqueous solution by ascorbate oxidase. Ascorbate radicals are formed, which disproportionate to ascorbate and dehydroascorbic acid. Addition of erythrocytes with increasing intracellular ascorbate concentrations decreased the oxidation of ascorbate in a concentration-dependent manner. Concurrently, it was found, utilizing electron spin resonance spectroscopy, that extracellular ascorbate radical levels were decreased. Control experiments showed that these results could not be explained by leakage of ascorbate from the cells, inactivation of ascorbate oxidase, or oxygen depletion. Thus, this means that intracellular ascorbate is directly responsible for the decreased oxidation of extracellular ascorbate. Exposure of ascorbate-loaded erythrocytes to higher levels of extracellular ascorbate radicals resulted in the detection of intracellular ascorbate radicals. Moreover, efflux of dehydroascorbic acid was observed under these conditions. These data confirm the view that intracellular ascorbate donates electrons to extracellular ascorbate free radical via a plasma membrane redox system. Such a redox system enables the cells to effectively counteract oxidative processes and thereby prevent depletion of extracellular ascorbate.	Leiden Univ, Med Ctr, Sylvius Lab, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Van den Broek, PJA (corresponding author), Leiden Univ, Med Ctr, Sylvius Lab, Dept Mol Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.			van Duijn, Martijn/0000-0002-6654-994X				ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V856, P408, DOI 10.1016/0005-2736(86)90055-6; BIANCHI J, 1986, TOXICOLOGY, V40, P75, DOI 10.1016/0300-483X(86)90047-8; BLOCK G, 1991, AM J CLIN NUTR, V54, pS1310, DOI 10.1093/ajcn/54.6.1310s; BODE AM, 1990, CLIN CHEM, V36, P1807; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; DILIBERTO EJ, 1982, J NEUROCHEM, V39, P563, DOI 10.1111/j.1471-4159.1982.tb03982.x; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; GERSHOFF SN, 1993, NUTR REV, V51, P313, DOI 10.1111/j.1753-4887.1993.tb03757.x; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; GOLDENBERG H, 1983, BIOCHEM INT, V6, P1; Himmelreich U, 1998, BIOCHEMISTRY-US, V37, P7578, DOI 10.1021/bi970765s; Jung CH, 1998, ARCH BIOCHEM BIOPHYS, V355, P9, DOI 10.1006/abbi.1998.0713; May JM, 1999, BBA-BIOMEMBRANES, V1421, P19, DOI 10.1016/S0005-2736(99)00107-8; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 2000, BIOCHEM BIOPH RES CO, V267, P118, DOI 10.1006/bbrc.1999.1906; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MEHLHORN RJ, 1991, J BIOL CHEM, V266, P2724; Mendiratta S, 1998, FREE RADICAL BIO MED, V25, P221, DOI 10.1016/S0891-5849(98)00060-4; MOMSEN G, 1981, ARCH BIOCHEM BIOPHYS, V210, P160, DOI 10.1016/0003-9861(81)90176-4; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; PENCE LA, 1979, TOXICOL APPL PHARM, V50, P57, DOI 10.1016/0041-008X(79)90492-7; PRUSS RM, 1987, NEUROSCIENCE, V22, P149, DOI 10.1016/0306-4522(87)90205-3; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; ROSE RC, 1992, LIFE SCI, V50, P1543, DOI 10.1016/0024-3205(92)90145-F; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Schweinzer E, 1996, CELL BIOCHEM FUNCT, V14, P27, DOI 10.1002/(SICI)1099-0844(199603)14:1<27::AID-CBF635>3.3.CO;2-P; SRIVASTAVA M, 1984, J BIOL CHEM, V259, P8072; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; Van Duijn MM, 1998, PROTOPLASMA, V205, P122, DOI 10.1007/BF01279302; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VILLALBA JM, 1993, J BIOENERG BIOMEMBR, V25, P411, DOI 10.1007/BF00762467; WAGNER TC, 1994, ANAL BIOCHEM, V222, P417, DOI 10.1006/abio.1994.1511; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9746; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5	44	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27720	27725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871632				2022-12-25	WOS:000089197100028
J	Chiravuri, M; Lee, H; Mathieu, SL; Huber, BT				Chiravuri, M; Lee, H; Mathieu, SL; Huber, BT			Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSINASE-C; COILED-COIL; ACTIVATION; CLEAVAGE; DOMAIN; DIMERIZATION; HYDROXYLASE; CHEMOKINE; PROTEASE; PATHWAY	Quiescent cell proline dipeptidase (QPP) is an intracellular serine protease that is also secreted upon cellular activation. This enzyme cleaves N-terminal Xaa-Pro dipeptides from proteins, an unusual substrate specificity shared with dipeptidyl peptidase IV (CD26/DPPIV), QPP is a 58-kDa protein that elutes as a 120-130-kDa species from gel filtration, indicating that it forms a homodimer, We analyzed this dimerization with in vivo co-immunoprecipitation assays. The amino acid sequence of QPP revealed a putative leucine zipper motif, and mutational analyses indicated that this leucine zipper is required for homodimerization. The leucine zipper mutants showed a complete lack of enzymatic activity, suggesting that homodimerization is important for QPP function. On the other hand, an enzyme active site mutant retained its ability to homodimerize. These data are the first to demonstrate a role for a leucine zipper motif in a proteolytic enzyme and suggest that leucine zipper motifs play a role in mediating dimerization of a diverse array of proteins.	Tufts Univ, Sch Med, Dept Pathol, Program Immunol, Boston, MA 02111 USA	Tufts University	Huber, BT (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Program Immunol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043469, R01AI036696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43469, AI36696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chiravuri M, 1999, J IMMUNOL, V163, P3092; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; INOUE H, 1991, J BIOL CHEM, V266, P11896; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; TAN FL, 1993, J BIOL CHEM, V268, P16631; Underwood R, 1999, J BIOL CHEM, V274, P34053, DOI 10.1074/jbc.274.48.34053; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; von Bonin A, 1998, IMMUNOL REV, V161, P43; VRANA KE, 1994, J NEUROCHEM, V63, P2014; Watson B, 1997, GENOMICS, V44, P365, DOI 10.1006/geno.1997.4883	23	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26994	26999						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867015				2022-12-25	WOS:000089144800044
J	Cho, KH; Jonas, A				Cho, KH; Jonas, A			A key point mutation (V156E) affects the structure and functions of human apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HIGH-DENSITY-LIPOPROTEIN; PHOSPHOLIPID-BINDING; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; ACTIVATION; PROTEIN; MUTANTS; DISKS; PHOSPHATIDYLCHOLINE	A naturally occurring point mutant of human apolipoprotein A-I (apoA-I), V156E, which is associated with extremely low plasma apoA-I and high density lipoprotein (HDL) levels, and coronary artery disease (Huang, W., Sasaki, J., Matsunaga, A., Nanimatsu, Il., Moriyama, K., Hen, H. Kugi, M., Koga, T., Yamaguchi, K., and Arakawa, K. (1998) Arterioscler. Throm. Vase. Biol. 18, 389-396), was produced in an Escherichia coli expression system. The purified recombinant proapoA-I V156E mutant was examined in its structural and functional properties, both, in the lipid-free and lipid-bound states. In the lipid-free form the mutant protein exhibited small changes in conformation, but was more stable, and quite resistant to self-association, compared with control apoA-I. The V156E mutant was able to interact with phospholipid (PL) at high PL:protein ratios (95:1, mol/mol), but was inefficient in forming reconstituted HDL (rHDL) complexes at lower PL:protein ratios (40:1). In the lipid-bound, rHDL state, the mutant protein was somewhat more alpha-helical and formed a larger complex (110 Angstrom) than control apoA-I (97 Angstrom). Furthermore, the rHDL particles containing the V156E mutant did not rearrange to smaller particles in the presence of low density lipoproteins, and had minimal reactivity with lecithin-cholesterol acyltransferase (LCAT), compared with rHDL particles made with control apoA-I. These results suggest a key role for Val-156, or the adjacent central region of apoA-I in the modulation of apoA-I conformation, stability, and self-association in solution, and in the formation of small HDL, the conformational adaptability of apoA-I leading to structural rearrangements of HDL, and the activation of LCAT.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Jonas, A (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 506 S Mathews Ave, Urbana, IL 61801 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939, R01HL016059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16059, HL 29939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4586, DOI 10.1021/bi00839a053; BARBEAU DL, 1979, BIOCHEMISTRY-US, V18, P362, DOI 10.1021/bi00569a021; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; BURKYBILEKOSEK A, 1999, BIOCHEM BIOPH RES CO, V258, P548; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Durbin DM, 1999, J LIPID RES, V40, P2293; FIELDING CJ, 1995, J LIPID RES, V36, P211; HEIDER JG, 1978, J LIPID RES, V19, P514; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Huang W, 1998, ARTERIOSCL THROM VAS, V18, P389, DOI 10.1161/01.ATV.18.3.389; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Jin LH, 1997, J LIPID RES, V38, P1085; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; Jonas A, 1998, PROG LIPID RES, V37, P209, DOI 10.1016/S0163-7827(98)00007-1; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; LEROY A, 1994, BBA-LIPID LIPID MET, V1212, P285, DOI 10.1016/0005-2760(94)90202-X; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; McGuire KA, 1996, J LIPID RES, V37, P1519; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; RYE KA, 1992, J LIPID RES, V33, P215; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1997, J BIOL CHEM, V272, P7278, DOI 10.1074/jbc.272.11.7278; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Xu SZ, 1997, J LIPID RES, V38, P1289; ZORICH N, 1985, J BIOL CHEM, V260, P8831	43	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26821	26827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858436				2022-12-25	WOS:000089144800023
J	Ghayor, C; Herrouin, JF; Chadjichristos, C; Ala-Kokko, L; Takigawa, M; Pujol, JP; Galera, P				Ghayor, C; Herrouin, JF; Chadjichristos, C; Ala-Kokko, L; Takigawa, M; Pujol, JP; Galera, P			Regulation of human COL2A1 gene expression in chondrocytes - Identification of C-Krox-responsive elements and modulation by phenotype alteration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(II) COLLAGEN GENE; TISSUE-SPECIFIC EXPRESSION; RABBIT ARTICULAR CHONDROCYTES; CHONDROSARCOMA CELL-LINE; TRANSCRIPTION FACTOR SP1; II COLLAGEN; TRANSGENIC MICE; ACTIVATES TRANSCRIPTION; PROCOLLAGEN GENE; MAMMALIAN-CELLS	To identify control motifs involved in human type II collagen gene transcription in both differentiated and dedifferentiated rabbit articular chondrocytes, transient transfection experiments were performed, A 715-base pair (bp) region of the first intron (+2127/+2842), including a 153-bp sequence so far uncharacterized (+2689/+2842), was found to mediate enhancer activity. In dedifferentiated chondrocytes, this enhancer activity was shown to be less effective than in primary cultures but still present. We then demonstrated that a zinc finger protein, C-Krox, activates COL2A1 gene transcription in differentiated chondrocytes through the enhancer region, whereas in subcultured cells, it inhibited the gene activity via a 266-bp promoter. Multicopies of the C-Krox binding site were found to mediate transactivation in both primary cultures and passaged cells, whereas C-Krox overexpression inhibited transcription in dedifferentiated chondrocytes. Additionally, we showed that C-Krox binds to several cis sequences that mediate its transcriptional effects. During chondrocyte dedifferentiation, the protein levels and binding activity of C-Krox were reduced, whereas those of NF-KB were increased. This was not associated with variations of mRNA levels, suggesting that post-transcriptional regulatory mechanisms could be involved in C-Krox expression. These results suggest that C-Krox plays a major role in type II collagen expression and the chondrocyte phenotype modulation.	CHU Caen, Fac Med, Lab Biochim Tissu Conjonctif, F-14032 Caen, France; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 700, Japan	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Oulu; University of Oulu; Okayama University	Galera, P (corresponding author), CHU Caen, Fac Med, Lab Biochim Tissu Conjonctif, Ave Cote Nacre, F-14032 Caen, France.		Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Ghayor, Chafik/0000-0002-3016-3412				Adolphe, 1992, BIOL REGULATION CHON, P33; ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER CW, 1990, J CELL SCI, V97, P361; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1986, DEV BIOL, V118, P296, DOI 10.1016/0012-1606(86)90096-5; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Boumediene K, 1998, EXP CELL RES, V243, P173, DOI 10.1006/excr.1998.4129; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P104; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P153; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLWASSER M, 1982, CLIN ORTHOP RELAT R, V167, P296; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; KUETTNER KE, 1982, J CELL BIOL, V93, P751, DOI 10.1083/jcb.93.3.751; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; NIMNI M, 1973, SCIENCE, V181, P751, DOI 10.1126/science.181.4101.751; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SEGHATOLESLAMI MR, 1994, MATRIX BIOL, V14, P753; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TAKIGAWA M, 1989, CANCER RES, V49, P3996; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WANG LQ, 1991, J BIOL CHEM, V266, P19878; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	59	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27421	27438						18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856292				2022-12-25	WOS:000089144800101
J	Humphreys, BD; Rice, J; Kertesy, SB; Dubyak, GR				Humphreys, BD; Rice, J; Kertesy, SB; Dubyak, GR			Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; EXTRACELLULAR ATP; MEDIATED ACTIVATION; P2X(7) RECEPTOR; CELL-DEATH; KAPPA-B; SIGNAL-TRANSDUCTION; POTASSIUM-DEPLETION; P2Z PURINORECEPTOR	In human and rodent macrophages, activation of the P2X7 nucleotide receptor stimulates interleukin-1 beta processing and release, apoptosis, and killing of intracellular Mycobacterium tuberculosis. Signaling pathways downstream of this ionotropic ATP receptor are poorly understood Here we describe the rapid activation of the stress-activated protein kinase (SAPK)/JNK pathway in BAC1 murine macrophages stimulated by extracellular ATP, Brief exposure of the cells to ATP (10-30 min) was sufficient to trigger a rapid accumulation of activated SAPK that was then sustained for >120 min. Several observations indicated that the P2X7 receptor mediated this effect. 1) ATP and 3'-O-(4-benzoyl)benzoyl-ATP were the only agonistic nucleotides, 2) The effect was inhibited by oxidized ATP and the isoquinoline KN-62, two known P2X7 receptor antagonists. 3) ATP-induced SAPK activation could be recapitulated in P2X7 receptor-transfected HEK293 cells, but not in wild-type HEK293 cells. Because P2X7 receptor stimulation can rapidly activate caspase family proteases that have been implicated in the induction of the SAPK pathway, we investigated whether ATP-dependent SAPK activation involved such proteases, Brief exposure of BAC1 macrophages to extracellular ATP induced DNA fragmentation, alpha-fodrin breakdown, and elevated levels of caspase-3-type activity. Asp-Glu-Val-Asp-cho a caspase-3 inhibitor, inhibited ATP-induced DNA fragmentation and alpha-fodrin proteolysis, but had no effect on ATP-induced SAPK activation. Tyr-Val-Ala-Asp-chloromethyl ketone, a caspase-1 inhibitor, prevented ATP-induced release of processed interleukin-1 beta, but not ATP-dependent SAPK activity. We conclude that activation of ionotropic P2X7 nucleotide receptors triggers a strong activation of SAPK via a pathway independent of caspase-1- or caspase-3-like proteases.	Case Western Reserve Univ, Sch Med E565, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Dubyak, GR (corresponding author), Case Western Reserve Univ, Sch Med E565, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.			Barclay, Janet/0000-0003-1643-6901; Dubyak, George/0000-0001-9720-4226	NIGMS NIH HHS [GM36387, GM07250-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD DK, 1995, J CELL BIOCHEM, V57, P452, DOI 10.1002/jcb.240570311; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; HKAKH BS, 1999, NAT NEUROSCI, V2, P322; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; Kuroki DW, 1996, CANCER RES, V56, P637; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC755, DOI 10.1152/ajpcell.1999.277.4.C755; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Schulze-Lohoff E, 1998, AM J PHYSIOL-RENAL, V275, pF962, DOI 10.1152/ajprenal.1998.275.6.F962; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Sikora A, 1999, J IMMUNOL, V163, P558; Solini A, 1999, J CELL SCI, V112, P297; Surprenant A, 1996, CIBA F SYMP, V198, P208; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Warny M, 1999, AM J PHYSIOL-CELL PH, V276, pC717, DOI 10.1152/ajpcell.1999.276.3.C717; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	57	181	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26792	26798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854431				2022-12-25	WOS:000089144800019
J	Borlongan, CV; Yamaoto, M; Takei, N; Kumazaki, M; Ungsuparkorn, C; Hida, H; Sanberg, PR; Nishino, H				Borlongan, CV; Yamaoto, M; Takei, N; Kumazaki, M; Ungsuparkorn, C; Hida, H; Sanberg, PR; Nishino, H			Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia	FASEB JOURNAL			English	Article						stroke; gliosis; astrocytes; cell death; free radicals	MIDBRAIN DOPAMINERGIC-NEURONS; TRANSIENT FOREBRAIN ISCHEMIA; PROTECTS PRIMARY CULTURES; CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; 3-NITROPROPIONIC ACID; REGIONAL DIFFERENCES; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; IN-VITRO	The role of glial cells in neuronal death has become a major research interest. Glial cell activation has been demonstrated to accompany cerebral ischemia. However, there is disagreement whether such gliosis is a cell death or a neuroprotective response. In the present study, we examined alterations in glial cell responses to the reported neuroprotective action of the free radical scavenger, melatonin, against cerebral ischemia. Adult male Wistar rats were given oral injections of either melatonin (26 mu mol/rat) or saline just prior to 1 h occlusion of the middle cerebral artery (MCA), then once daily for 11 or 19 consecutive days. At 11 and 19 days after reperfusion of the MCA, randomly selected animals were killed and their brains removed for immunohistochemical assays. Melatonin significantly enhanced survival of glial cells (as revealed by glial cell specific markers, glial fibrillary acidic protein and aquaporin-4 immunostaining) at both time periods postischemia, and the preservation of these glial cells in the ischemic penumbra corresponded with a markedly reduced area of infarction (detected by immunoglobulin G and hematoxylin-eosin staining), as well as increased neuronal survival. The ischemia-induced locomotor deficits were partially ameliorated in melatonin-treated animals. In vitro replications of ischemia by serum deprivation or by exposure to free radical-producing toxins (sodium nitroprusside and 3-nitropropionic acid) revealed that melatonin (10 mu g/ml or 100 mu M) treatment of pure astrocytic cultures significantly reduced astrocytic cell death. These results suggest a potential strategy directed at enhancing glial cell survival as an alternative protective approach against ischemic damage.	NIDA, Cellular Neurobiol Branch, NIH, Baltimore, MD 21224 USA; Univ S Florida, Coll Med, Dept Neurol Surg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Program Neurosci, Tampa, FL 33612 USA; Nagoya City Univ, Sch Med, Dept Physiol, Nagoya, Aichi 467, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Nagoya City University	Borlongan, CV (corresponding author), NIDA, Cellular Neurobiol Branch, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.		Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782				AIHARA N, 1994, BRAIN RES BULL, V33, P483, DOI 10.1016/0361-9230(94)90072-8; Blanc EM, 1998, J NEUROCHEM, V70, P958; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Borlongan CV, 1998, EXP NEUROL, V151, P203, DOI 10.1006/exnr.1998.6790; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; CHENG HW, 1994, NEUROSCIENCE, V62, P425, DOI 10.1016/0306-4522(94)90377-8; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Colombo JA, 1996, INT J DEV NEUROSCI, V14, P497, DOI 10.1016/0736-5748(95)00104-2; Cuzzocrea S, 1998, J PINEAL RES, V25, P78, DOI 10.1111/j.1600-079X.1998.tb00543.x; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Diamond JS, 1998, NEURON, V21, P425, DOI 10.1016/S0896-6273(00)80551-6; DIEMER NH, 1977, ACTA NEUROPATHOL, V39, P59, DOI 10.1007/BF00690386; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Fawcett JW, 1998, TRENDS NEUROSCI, V21, P179, DOI 10.1016/S0166-2236(98)01241-7; Fiorina P, 1996, LANCET, V347, P692, DOI 10.1016/S0140-6736(96)91246-5; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; Fukuda A, 1998, NEUROSCIENCE, V87, P497, DOI 10.1016/S0306-4522(98)00139-0; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; HANSSON E, 1995, FASEB J, V9, P343, DOI 10.1096/fasebj.9.5.7534736; Hirata H, 1998, SYNAPSE, V30, P150, DOI 10.1002/(SICI)1098-2396(199810)30:2<150::AID-SYN4>3.0.CO;2-B; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Horellou P, 1997, MOL NEUROBIOL, V15, P241, DOI 10.1007/BF02740636; Iacovitti L, 1997, BRAIN RES, V768, P317, DOI 10.1016/S0006-8993(97)00668-9; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; LANGEVELD CH, 1995, NEUROSCI LETT, V192, P13, DOI 10.1016/0304-3940(95)11596-O; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; LEROUX PD, 1995, NEUROSCI LETT, V198, P5, DOI 10.1016/0304-3940(95)11946-T; LEROUX PD, 1995, J NEUROBIOL, V27, P97, DOI 10.1002/neu.480270110; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Luscher C, 1998, NEURON, V21, P435, DOI 10.1016/S0896-6273(00)80552-8; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mawatari C, 1996, NEUROSCIENCE, V73, P201, DOI 10.1016/0306-4522(96)00025-5; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miller JW, 1996, FREE RADICAL BIO MED, V21, P241, DOI 10.1016/0891-5849(96)00033-0; Muramatsu K, 1997, STROKE, V28, P2281, DOI 10.1161/01.STR.28.11.2281; Nielsen S, 1997, J NEUROSCI, V17, P171; Nishino H, 1998, NEUROSCI RES, V30, P303, DOI 10.1016/S0168-0102(98)00010-8; Nishino Hitoo, 1994, Neurobiology (Budapest), V2, P223; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Peinado MA, 1997, ANAT REC, V247, P420; PENG MT, 1979, GERONTOLOGY, V25, P205, DOI 10.1159/000212341; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tan DX, 1993, ENDOCR J, V1, P57; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Wang Y, 1997, J NEUROSCI, V17, P4341; WHITE HS, 1992, CAN J PHYSIOL PHARM, V70, pS263, DOI 10.1139/y92-271; Zhang HW, 1999, CHEM RES TOXICOL, V12, P526, DOI 10.1021/tx980243t; Zoli M, 1997, STROKE, V28, P1049, DOI 10.1161/01.STR.28.5.1049	67	122	137	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1307	1317		10.1096/fj.14.10.1307	http://dx.doi.org/10.1096/fj.14.10.1307			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877823				2022-12-25	WOS:000087932200005
J	Smith, E; Redman, RA; Logg, CR; Coetzee, GA; Kasahara, N; Frenkel, B				Smith, E; Redman, RA; Logg, CR; Coetzee, GA; Kasahara, N; Frenkel, B			Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle - Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; GROWTH-FACTOR-I; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MESSENGER-RNA; BONE-CELLS; C-MYC; SUBCELLULAR-LOCALIZATION; INDUCED OSTEOPOROSIS	Unique cell cycle control is instituted in confluent osteoblast cultures, driving growth to high density. The postconfluent dividing cells share features with cells that normally exit the cell cycle; p27(kip1) is increased, p21(waf1/cip1) is decreased, free E2F DNA binding activity is reduced, and E2F4 is primarily nuclear. E2F4-p130 becomes the predominant E2F-pocket complex formed on E2F sites, but, unlike the complex that typifies resting cells, cyclin A and CDK2 are also present. Administration of dexamethasone at this, but not earlier stages, results in reduction of cyclin A and CDK2 levels with a parallel decrease in the associated kinase activity, dissociation of cyclin A-CDK2 from the E2F4-p130 complexes, and inhibition of G(1)/S transition. The glucocorticoid-mediated cell cycle attenuation is also accompanied by, but not attributable to, increased p27(kip1) and decreased p21(waf1/cip1) levels. The attenuation of osteoblast growth to high density by dexamethasone is associated with severe impairment of mineralized extracellular matrix formation, unless treatment commences in cultures that have already grown to high density. Both the antimitotic and the antiphenotypic effects are reversible, and both are antagonized by RU486. Thus, glucocorticoids induce premature attenuation of the osteoblast cell cycle, possibly contributing to the osteoporosis induced by these drugs in vivo.	Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Coetzee, Gerhard/AAG-8439-2019; coetzee, Gerhard/AAT-6203-2020	Coetzee, Gerhard/0000-0001-8820-8364; Kasahara, Noriyuki/0000-0002-6069-9082	NATIONAL CANCER INSTITUTE [T32CA009659] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo-112-3-931; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen TL, 1999, CALCIFIED TISSUE INT, V64, P304, DOI 10.1007/s002239900624; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; CHEN TL, 1977, ENDOCRINOLOGY, V100, P619, DOI 10.1210/endo-100-3-619; Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097-4644(19960501)61:2<182::AID-JCB3>3.0.CO;2-Q; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOE J, 1978, J STEROID BIOCHEM, V9, P265, DOI 10.1016/0022-4731(78)90160-7; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Corroyer S, 1997, ENDOCRINOLOGY, V138, P3677, DOI 10.1210/en.138.9.3677; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776; Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LUKERT B, 1997, OSTEOPOROSIS, P801; Lukert Barbara P., 1996, P533; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; Meagher LC, 1996, J IMMUNOL, V156, P4422; MIESFELD RL, 1997, INHALED GLUCOCORTICO, P3; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1992, ONCOGENE, V7, P1681; POCKWINSE SM, 1995, EXP CELL RES, V216, P244, DOI 10.1006/excr.1995.1031; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; RHEE K, 1995, CELL GROWTH DIFFER, V6, P691; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Sharrock WJ, 1998, J BONE MINER RES, V13, P537, DOI 10.1359/jbmr.1998.13.4.537; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEFFEN M, 1988, CANCER RES, V48, P7212; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; WONG GL, 1979, J BIOL CHEM, V254, P6337; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	67	89	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19992	20001		10.1074/jbc.M001758200	http://dx.doi.org/10.1074/jbc.M001758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867026	hybrid			2022-12-25	WOS:000087941300077
J	Sohlenkamp, C; de Rudder, KEE; Rohrs, V; Lopez-Lara, IM; Geiger, O				Sohlenkamp, C; de Rudder, KEE; Rohrs, V; Lopez-Lara, IM; Geiger, O			Cloning and characterization of the gene for phosphatidylcholine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PHOSPHATIDYLSERINE SYNTHASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; RHIZOBIUM-MELILOTI; ESCHERICHIA-COLI; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; RHODOBACTER-SPHAEROIDES; SINORHIZOBIUM-MELILOTI; EXPRESSION; MUTAGENESIS	Phosphatidylcholine (PC) is the major membrane-forming phospholipid in eukaryotes and can be synthesized by either of two pathways, the CDP-choline pathway or the methylation pathway. In prokaryotes only the methylation pathway was thought to occur. Recently, however, we could demonstrate (de Rudder, K. E. E., Sohlenkamp, C., and Geiger, O. (1999) J. Biol. Chem. 274, 20011-20016) that a second pathway for phosphatidylcholine biosynthesis exists in Sinorhizobium (Rhizobium) meliloti involving a novel enzymatic activity, phosphatidylcholine synthase, that condenses choline and CDP-diacylglyceride in one step to form PC and CMP, Using a colony autoradiography method we have isolated mutants of S. meliloti deficient in phosphatidylcholine synthase and which are no longer able to incorporate radiolabeled choline into PC. Complementation of such mutants with a sinorhizobial cosmid gene bank, subcloning of the complementing fragment, and sequencing of the subclone led to the identification of a gene coding for a presumptive CDP-alcohol phosphatidyltransferase, Amplification of this gene and its expression in Escherichia coli demonstrates that it codes for phosphatidylcholine synthase, Genomes of some pathogens (Pseudomonas aeruginosa and Borrelia burgdorferi) contain genes similar to the sinorhizobial gene (pcs) for phosphatidylcholine synthase, Although pcs-deficient S. meliloti knock-out mutants show wild type-like growth and lipid composition, they are unable to perform rapid PC biosynthesis that normally is achieved via the phosphatidylcholine synthase pathway in S. meliloti wild type.	Univ Nacl Autonoma Mexico, Ctr Invest Fijac Nitrogeno, Cuernavaca 62210, Morelos, Mexico; Tech Univ Berlin, Inst Biotechnol, D-13353 Berlin, Germany	Universidad Nacional Autonoma de Mexico; Technical University of Berlin	Geiger, O (corresponding author), Univ Nacl Autonoma Mexico, Ctr Invest Fijac Nitrogeno, Apdo Postal 565-A, Cuernavaca 62210, Morelos, Mexico.		Geiger, Otto/F-6356-2019; Sohlenkamp, Christian/C-6219-2018; Lopez-Lara, Isabel/E-3153-2016	Geiger, Otto/0000-0002-7794-1568; Sohlenkamp, Christian/0000-0002-9962-2859; Lopez-Lara, Isabel/0000-0002-5066-3158				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; de Rudder KEE, 1999, J BIOL CHEM, V274, P20011, DOI 10.1074/jbc.274.28.20011; deRudder KEE, 1997, J BACTERIOL, V179, P6921, DOI 10.1128/jb.179.22.6921-6928.1997; DEWEY RE, 1994, PLANT CELL, V6, P1495, DOI 10.1105/tpc.6.10.1495; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; Dryden SC, 1996, J BACTERIOL, V178, P1030, DOI 10.1128/jb.178.4.1030-1038.1996; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FINAN TM, 1984, J BACTERIOL, V159, P120, DOI 10.1128/JB.159.1.120-124.1984; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Ge ZM, 1997, J BACTERIOL, V179, P4970, DOI 10.1128/jb.179.16.4970-4976.1997; Geiger O, 1999, MOL MICROBIOL, V32, P63, DOI 10.1046/j.1365-2958.1999.01325.x; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; Hofmann M, 1996, J BACTERIOL, V178, P6140, DOI 10.1128/jb.178.21.6140-6144.1996; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; Osteras M, 1998, P NATL ACAD SCI USA, V95, P11394, DOI 10.1073/pnas.95.19.11394; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; RUVKUN GB, 1981, NATURE, V289, P85, DOI 10.1038/289085a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; Spaink HP, 1998, MOL BIOL MODEL PLANT; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THONYMEYER L, 1999, BIOSPEKTRUM, V5, P185; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	59	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18919	18925		10.1074/jbc.M000844200	http://dx.doi.org/10.1074/jbc.M000844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858449	hybrid			2022-12-25	WOS:000087815900042
J	Ivanov, VN; Ronai, Z				Ivanov, VN; Ronai, Z			p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappa B activity and Fas expression	ONCOGENE			English	Article						p38; stress kinases; NF-kappa B; UV-irradiation; radiation resistance; TNF	NECROSIS-FACTOR-ALPHA; TERMINAL KINASE JNK; SIGNAL-TRANSDUCTION; LIGAND EXPRESSION; MAP KINASE; T-CELLS; TRANSCRIPTIONAL REGULATION; ACTIVATION; INHIBITION; PROMOTER	Identifying mechanisms that underlie the resistance of human melanoma to radiation and chemotherapy is expected to assist in developing new strategies for the treatment of this tumor type. We recently demonstrated that through up-regulation of TNF alpha, ATF2 increases the resistance of late stage melanoma cells to apoptosis induced by UV-irradiation, In elucidating the role of ATF2 kinases, we now demonstrate that ASK1/MKK6/p38 elicits suppression of Fas expression. ASK1/p38 downregulates the expression of a Fas via NF-kappa B/SP1 site on the Fas promoter. Deletion or mutation of NF-kappa B/SP1 within the Fas promoter abrogates p38 effect. ASK1/p38 silences the Fas promoter by inhibition of I kappa B alpha phosphorylation - thereby limiting NF-kappa B activity. Forced expression of a dominant negative form of p38 (p38-ASP) or treatment with p38 pharmacological inhibitor, SB203580, increases NF-kappa B activity, Fas expression and the levels of UVC-induced apoptosis in late stage melanoma cells. Inhibition of p38 activity also restored NF-kappa B activity and Fas expression in early-phase melanoma cells, suggesting that p38 elicited suppression of Fas expression is not restricted to late phase melanoma, Identifying p38-mediated down-regulation of Fas expression illustrates a novel regulatory pathway by which ASK1/MKK6/p38 alters the degree and nature of the UV-induced apoptosis of melanoma cells.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cain BS, 1999, J SURG RES, V83, P7, DOI 10.1006/jsre.1998.5548; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh S, 1999, J IMMUNOL, V162, P7434; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOGUCHI K, 1999, J BIOL CHEM, V274, P32850; Ozes ON, 1999, NATURE, V401, P82; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Schafer PH, 1999, J IMMUNOL, V162, P659; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	60	108	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3003	3012		10.1038/sj.onc.1203602	http://dx.doi.org/10.1038/sj.onc.1203602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871852	Green Published			2022-12-25	WOS:000087581400007
J	Komine, M; Rao, LMS; Kaneko, T; Tomic-Canic, M; Tamaki, K; Freedberg, IM; Blumenberg, M				Komine, M; Rao, LMS; Kaneko, T; Tomic-Canic, M; Tamaki, K; Freedberg, IM; Blumenberg, M			Inflammatory versus proliferative processes in epidermis - Tumor necrosis factor alpha induces K6b keratin synthesis through a transcriptional complex containing NF kappa B and C/EBP ss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTICALLY ACTIVATE TRANSCRIPTION; GROWTH-FACTOR-ALPHA; NUCLEAR-FACTOR; TNF RECEPTOR; HUMAN SKIN; NUDE-MICE; PACHYONYCHIA-CONGENITA; ICAM-1 EXPRESSION; PSORIATIC SKIN; FAMILY MEMBERS	Epidermal keratinocytes respond to injury by becoming activated, i.e. hyperproliferative, migratory, and proinflammatory. These processes are regulated by growth factors and cytokines. One of the markers of activated keratinocytes is keratin K6. We used a novel organ culture system to show that tumor necrosis factor alpha (TNF alpha) induces the expression of K6 protein and mRNA in human skin. Multiple isoforms of K6 are encoded by distinct genes and have distinct patterns of expression. By having shown previously that proliferative signals, such as epidermal growth factor (EGF), induce expression of the cytoskeletal protein keratin K6b, we here demonstrate that the same isoform, K6b, is also induced by TNF alpha, a proinflammatory cytokine. Specifically, TNF alpha induces the transcription of the K6b gene promoter. By using co-transfection, specific inhibitors, and antisense oligonucleotides, we have identified NF kappa B and C/EBP beta as the transcription factors that convey the TNFa! signal. Both transcription factors are necessary for the induction of K6b by TNFa and act as a complex, although only C/EBP beta binds the K6b promoter DNA. By using transfection, site-directed mutagenesis, and footprinting, we have mapped the site that responds to TNF alpha, NF kappa B, and C/EBP beta. This site is separate from the one responsive to EGF and AP1. Our results show that the proinflammatory (TNF alpha) and the proliferative (EGF) signals in epidermis separately and independently regulate the expression of the same K6b keratin isoform. Thus, the cytoskeletal responses in epidermal cells can be precisely tuned by separate proliferative and inflammatory signals to fit the nature of the injuries that caused them.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA; NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc, New York, NY 10016 USA; Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 113, Japan	New York University; New York University; New York University; New York University; University of Tokyo	Blumenberg, M (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.			Komine, Mayumi/0000-0002-1086-1803; Blumenberg, Miroslav/0000-0002-8672-7774	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850, R01AR040522, R01AR030682] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30682, AR41850, AR40522] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bernerd Francoise, 1993, Gene Expression, V3, P187; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; BOWDEN PE, 1995, NAT GENET, V10, P363, DOI 10.1038/ng0795-363; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DICKINSON AM, 1994, BONE MARROW TRANSPL, V13, P65; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Gilhar A, 1996, CLIN EXP IMMUNOL, V106, P134, DOI 10.1046/j.1365-2249.1996.d01-802.x; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KATARANOVSKI M, 1999, ACTA DERM-VENEREOL, V8, P131; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Komine M, 1996, J INVEST DERMATOL, V107, P569, DOI 10.1111/1523-1747.ep12582820; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; KUTSCH CL, 1993, J INVEST DERMATOL, V101, P79, DOI 10.1111/1523-1747.ep12360119; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ma SH, 1997, GENE EXPRESSION, V6, P361; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Maniatis T., 1989, MOL CLONING LAB MANU; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Matsumoto K, 1997, EXP DERMATOL, V6, P13, DOI 10.1111/j.1600-0625.1997.tb00140.x; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MIDDLETON MH, 1995, J INVEST DERMATOL, V104, P489, DOI 10.1111/1523-1747.ep12605923; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MUTASIM DF, 1993, J INVEST DERMATOL, V101, P624, DOI 10.1111/1523-1747.ep12366084; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NESTLE FO, 1994, J INVEST DERMATOL, V103, P569, DOI 10.1111/1523-1747.ep12396876; NICKOLOFF BJ, 1993, AM J PATHOL, V143, P325; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; PILLAI S, 1989, J CLIN INVEST, V83, P816, DOI 10.1172/JCI113963; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; RAY A, 1995, DNA CELL BIOL, V14, P795, DOI 10.1089/dna.1995.14.795; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REUNING U, 1995, NUCLEIC ACIDS RES, V23, P3887, DOI 10.1093/nar/23.19.3887; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rothnagel JA, 1999, DIFFERENTIATION, V65, P119, DOI 10.1046/j.1432-0436.1999.6520119.x; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Schweizer Juergen, 1993, P33; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SELLS SF, 1995, MOL CELL BIOL, V15, P682; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; Smith FJD, 1998, HUM MOL GENET, V7, P1143, DOI 10.1093/hmg/7.7.1143; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Takahashi K, 1998, GENOMICS, V53, P170, DOI 10.1006/geno.1998.5476; Takahashi K, 1997, J BIOL CHEM, V272, P11979, DOI 10.1074/jbc.272.18.11979; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; VALYINAGY I, 1992, J INVEST DERMATOL, V99, P350, DOI 10.1111/1523-1747.ep12616672; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WETZELS RHW, 1991, AM J PATHOL, V138, P751; White PJ, 1999, J INVEST DERMATOL, V112, P887, DOI 10.1046/j.1523-1747.1999.00593.x; Wojcik SM, 1999, DIFFERENTIATION, V65, P97, DOI 10.1046/j.1432-0436.1999.6520097.x; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	89	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32077	32088		10.1074/jbc.M001253200	http://dx.doi.org/10.1074/jbc.M001253200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10887174	hybrid			2022-12-25	WOS:000089858900073
J	Gamez, A; Perez, B; Ugarte, M; Desviat, LR				Gamez, A; Perez, B; Ugarte, M; Desviat, LR			Expression analysis of phenylketonuria mutations - effect on folding and stability of the phenylalanie hydroxylase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; DEHYDROGENASE; ENZYME; DEGRADATION; DISEASE; BACTERIAL; PHENOTYPE; MECHANISM; GENOTYPE; DOMAIN	Phenylketonuria is an autosomal recessive human genetic disease caused by mutations in the phenylalanine hydroxylase (PAH) gene. In the present work we have used different expression systems to reveal folding defects of the PAH protein caused by phenylketonuria mutations L348V, S349L, and V388M. The amount of mutant proteins and/or the residual activity can be rescued by chaperonin co-overexpression in Escherichia coli or growth at low temperature in COS cells. Thermal stability profiles and degradation time courses of PAH expressed in E. coli show that the mutant proteins are less stable than the wild-type enzyme, also confirmed by pulse-chase experiments using a coupled in vitro transcription-translation system. Size exclusion chromatography shows altered oligomerization, partially corrected with chaperonins coexpression, except for the S349L mutant protein, which is recovered as inactive aggregates. PAH subunit interaction is affected in the S349L protein, as demonstrated in a mammalian two-hybrid assay. In conclusion, serine 349, located in the three-dimensional structure lining the active site and involved in the structural maintenance of the iron binding site, is essential for the structural stability and assembly and also for the catalytic properties of the PAH enzyme, whereas the L348V and V388M mutations affect the folding properties and stability of the protein. The experimental modulation of mutant residual activity provides a potential explanation for the existing inconsistencies in the genotype-phenotype correlations.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Dept Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ugarte, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Dept Biol Mol, Campus Cantoblanco, E-28049 Madrid, Spain.	mugarte@cbm.uam.es	Gamez, Alejandra/T-6898-2017; DESVIAT, LOURDES R/L-3055-2013	Gamez, Alejandra/0000-0002-2414-2586; DESVIAT, LOURDES R/0000-0003-0492-3323				Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; Corydon MJ, 1996, PEDIATR RES, V39, P1059, DOI 10.1203/00006450-199606000-00021; De Lucca M, 1998, HUM MUTAT, V11, P354; Desviat LR, 1999, EUR J HUM GENET, V7, P386, DOI 10.1038/sj.ejhg.5200312; DESVIAT LR, 1995, AM J HUM GENET, V57, P337; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; GULBERG P, 1998, AM J HUM GENET, V63, P71; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JENSEN TG, 1995, HUM MUTAT, V6, P226, DOI 10.1002/humu.1380060305; Kayaalp E, 1997, AM J HUM GENET, V61, P1309, DOI 10.1086/301638; Kleppe R, 1999, J BIOL CHEM, V274, P33251, DOI 10.1074/jbc.274.47.33251; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; Levy HL, 1999, P NATL ACAD SCI USA, V96, P1811, DOI 10.1073/pnas.96.5.1811; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Nowacki PM, 1998, NUCLEIC ACIDS RES, V26, P220, DOI 10.1093/nar/26.1.220; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; Waters PJ, 1999, J INHERIT METAB DIS, V22, P208, DOI 10.1023/A:1005533825980; Waters PJ, 1998, HUM MUTAT, V11, P4; Waters PJ, 2000, MOL GENET METAB, V69, P101, DOI 10.1006/mgme.2000.2965; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110	31	72	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29737	29742		10.1074/jbc.M003231200	http://dx.doi.org/10.1074/jbc.M003231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875932	hybrid			2022-12-25	WOS:000089439800075
J	Nadimpalli, R; Yalpani, N; Johal, GS; Simmons, CR				Nadimpalli, R; Yalpani, N; Johal, GS; Simmons, CR			Prohibitins, stomatins, and plant disease response genes compose a protein superfamily that controls cell proliferation, ion channel regulation, and death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; EXPRESSION; CHROMOSOME-17; LYMPHOCYTES; ACTIVATION; ALIGNMENT; PROGRAMS; MEMBRANE; TOBACCO; CLUSTAL	Prohibitins, stomatins, and a group of plant defense response genes are demonstrated to belong to a novel protein superfamily, This superfamily is bound by similar primary and secondary predicted protein structures and hydropathy profiles. A PROSITE-formatted regular expression was generated that is highly predictive for identifying members of this superfamily using PHI-BLAST. The superfamily is named PID (proliferation, ion, and death) because prohibitins are involved in proliferation and cell cycle control, stomatins are involved in ion channel regulation, and the plant defense-related genes are involved in cell death. The plant defense gene family is named HIR (hypersensitive induced reaction) because its members are associated with hypersensitive reactions involving cell death and pathogen resistance. For this study, eight novel maize genes were introduced: four closely related to prohibitins (Zm-phb1, Zm-phb2, Zm-phb3, and Zm-phb4), one to stomatins (Zm-stm1), and three to a gene implicated in plant disease responses (Zm-hir1, Zm-hir2, and Zm-hir3). The maize Zm-hir3 gene transcript is up-regulated in a disease lesion mimic mutation (Les9), supporting a role in maize defense responses. Members of this gene superfamily are involved in diverse functions, but their structural similarity suggests a conserved molecular mechanism, which we postulate to be ion channel regulation.	Pioneer HiBred Int Inc, Bioinformat Dept, Johnston, IA 50131 USA; Pioneer HiBred Int Inc, Dis Resistance Dept, Johnston, IA 50131 USA; Hoffmann La Roche Inc, Vitamins Div, Nutley, NJ 07110 USA	DuPont; DuPont; Roche Holding	Simmons, CR (corresponding author), Pioneer HiBred Int Inc, Bioinformat Dept, 7250 NW 62nd Ave,OB 552, Johnston, IA 50131 USA.	simmonscr@phibred.com	Johal, Guri/F-5056-2017	Johal, Guri/0000-0001-8101-8410				Agrios G.N., 2005, PLANT PATHOL, V5th; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; Atlante A, 1998, NEUROSCI LETT, V245, P127, DOI 10.1016/S0304-3940(98)00195-5; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Grundy WN, 1997, BIOCHEM BIOPH RES CO, V231, P760, DOI 10.1006/bbrc.1997.6193; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOISINGTON DA, 1986, MAIZE GENET COOP NEW, V60, P51; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; Karrer EE, 1998, PLANT MOL BIOL, V36, P681, DOI 10.1023/A:1005949304445; King RD, 1997, COMPUT APPL BIOSCI, V13, P473; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LEGGETT B, 1995, BRIT J CANCER, V71, P1070, DOI 10.1038/bjc.1995.206; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Neuenschwander U, 1996, PLANT MICROBE INTERA, V1, P81; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; ROSS KD, 1996, PROTEIN SCI, V5, P2298; RYALS JA, 1997, Patent No. 5614395; SATO T, 1992, CANCER RES, V52, P1643; Schulz JB, 1998, NEUROSCI LETT, V245, P9, DOI 10.1016/S0304-3940(98)00166-9; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; Stewart GW, 1997, INT J BIOCHEM CELL B, V29, P271, DOI 10.1016/S1357-2725(96)00072-6; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; Zong ZP, 1998, CELL STRUCT FUNCT, V23, P231, DOI 10.1247/csf.23.231	44	135	151	6	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29579	29586		10.1074/jbc.M002339200	http://dx.doi.org/10.1074/jbc.M002339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10862763	hybrid			2022-12-25	WOS:000089439800054
J	Rivard, A; Berthou-Soulie, L; Principe, N; Kearney, M; Curry, C; Branellec, D; Semenza, GL; Isner, JM				Rivard, A; Berthou-Soulie, L; Principe, N; Kearney, M; Curry, C; Branellec, D; Semenza, GL; Isner, JM			Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; UBIQUITIN-PROTEASOME PATHWAY; SMOOTH-MUSCLE CELLS; FACTOR 1-ALPHA; GENE-EXPRESSION; ERYTHROPOIETIN; TRANSCRIPTION; VEGF; STABILIZATION; ANGIOGENESIS	Previous studies have indicated that advanced age is associated with impaired angiogenesis in part because of reduced levels of vascular endothelial growth factor (VEGF) expression. To investigate potential mechanisms responsible for this age-dependent defect in VEGF expression, aortic smooth muscle cells isolated from young rabbits (ages 6-8 months) or old rabbits (ages 4-5 years) were exposed to normoxic (21% oxygen) or hypoxic (0.1% oxygen) conditions, Hypoxia-induced VEGF expression was significantly lower in old versus young cells. VEGF mRNA stability in hypoxic conditions was similar in both young and old cells. However, transient transfection with a luciferase reporter gene that was transcriptionally regulated by the VEGF promoter revealed a significant defect in VEGF up-regulation following hypoxia in old versus young cells (a 43 versus 117% increase in luciferase activity, p < 0.05); this difference was not seen when a deletion construct lacking the hypoxia-inducible 1 (HIF-1) binding site was used. Moreover, although HIF-1 alpha-mRNA expression was shown to be similar in young and old smooth muscle cells, HIF-1 alpha protein and DNA binding activity were significantly reduced in old versus young smooth muscle cells that were exposed to hypoxia. We propose that age-dependent reduction in hypoxia-induced VEGF expression results from reduced HIF-1 activity and may explain the previously described age-dependent impairment of angiogenesis in response to ischemia.	Tufts Univ, Sch Med, St Elizabeth Med Ctr, Dept Med Cardiol, Boston, MA 02136 USA; Rhone Poulenc Rorer Gencell, Dept Rech Cardiovasc, F-94403 Vitry Sur Seine, France; Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	St. Elizabeth's Medical Center; Tufts University; Sanofi-Aventis; Johns Hopkins University; Johns Hopkins University	Isner, JM (corresponding author), St Elizabeth Med Ctr, Dept Med Cardiol, 736 Cambridge St, Brighton, MA 02135 USA.							BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Bunn HF, 1998, J EXP BIOL, V201, P1197; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frenkel-Denkberg G, 1999, FEBS LETT, V462, P341, DOI 10.1016/S0014-5793(99)01552-5; GERSHON H, 1973, P NATL ACAD SCI USA, V70, P909, DOI 10.1073/pnas.70.3.909; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MADER SL, 1992, J GERONTOL, V47, pB32, DOI 10.1093/geronj/47.2.B32; NAFZIGER J, 1993, AM J HEMATOL, V43, P172, DOI 10.1002/ajh.2830430303; REISS U, 1976, EUR J BIOCHEM, V63, P617, DOI 10.1111/j.1432-1033.1976.tb10266.x; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Roy AK, 1997, MOL MED, V3, P496, DOI 10.1007/BF03401696; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RY, 1996, J GERONTOL A-BIOL, V51, pB434, DOI 10.1093/gerona/51A.6.B434; WEISBROTH SH, 1974, NEOPLASTIC DIS BIOL, P331; Zhong H, 1999, CANCER RES, V59, P5830	38	226	228	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29643	29647		10.1074/jbc.M001029200	http://dx.doi.org/10.1074/jbc.M001029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882714	hybrid			2022-12-25	WOS:000089439800063
J	Pasquet, JM; Quek, L; Pasquet, S; Poole, A; Matthews, JR; Lowell, C; Watson, SP				Pasquet, JM; Quek, L; Pasquet, S; Poole, A; Matthews, JR; Lowell, C; Watson, SP			Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ADHESION MOLECULE-1 PECAM-1; GAMMA-CHAIN; PHOSPHOLIPASE C-GAMMA-2; INHIBITORY RECEPTORS; INOSITOL PHOSPHATES; BINDING MOTIFS; B-LYMPHOCYTES; ASSOCIATION; PHOSPHORYLATION	The Src homology (SH)2 domain-containing protein-tyrosine phosphatase SHP-1 is tyrosine phosphorylated in platelets in response to the glycoprotein VI (GPVI)-selective agonist collagen-related peptide (CRP), collagen, and thrombin. Two major unidentified tyrosine-phosphorylated bands of 28 and 32 kDa and a minor band of 130 kDa coprecipitate with SHP-1 in response to all three agonists. Additionally, tyrosine-phosphorylated proteins of 50-55 and 70 kDa specifically associate with SHP-1 following stimulation by CRP and collagen. The tyrosine kinases Lyn, which exists as a 53 and 56-kDa doublet, and Syk were identified as major components of these bands, respectively. Kinase assays on SHP-1 immunoprecipitates performed in the presence of the Src family kinase inhibitor PP1 confirmed the presence of a Src kinase in CRP- but not thrombin-stimulated cells. Lyn, Syk, and SLP-76, along with tyrosine-phosphorylated 28-, 32-, and 130-kDa proteins, bound selectively to a glutathione S-transferase protein encoding the SH2 domains of SHP-1, suggesting that this is the major site of interaction. Platelets isolated from motheaten viable mice (mev/mev) revealed the presence of a heavily tyrosine-phosphorylated 26-kDa protein that was not found in wild-type platelets. CRP-stimulated mev/mev platelets manifested hypophosphorylation of Syk and Lyn and reduced P-selectin expression relative to controls. These observations provide evidence of a functional role for SHP-1 in platelet activation by GPVI.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; Univ Coll N Wales, Dept Med, Cardiff CF4 4XX, S Glam, Wales; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 91443 USA	University of Oxford; University of Bristol; Bangor University; University of California System; University of California San Francisco	Watson, SP (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		PASQUET, JEAN-MAX/I-9702-2014; Watson, Stephen P/Q-6292-2016; PASQUET, JEAN-MAX/T-4906-2019	Watson, Stephen P/0000-0002-7846-7423; PASQUET, JEAN-MAX/0000-0002-1345-3776; Poole, Alastair/0000-0002-0868-297X	NHLBI NIH HHS [HL54467] Funding Source: Medline; NIDDK NIH HHS [DK50267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014-5793(94)80575-X; Briddon SJ, 1999, BLOOD, V93, P3847, DOI 10.1182/blood.V93.11.3847.411k17_3847_3855; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DEFRANCO AL, 1995, SCIENCE, V268, P263, DOI 10.1126/science.7716518; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falet H, 1998, BIOCHEM BIOPH RES CO, V252, P51, DOI 10.1006/bbrc.1998.9593; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Farndale RW, 1995, EQUINE VET J, V27, P407, DOI 10.1111/j.2042-3306.1995.tb04419.x; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; MIZUNO K, 1996, J EXP MED, V184; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Pasquet JM, 1998, BIOCHEM J, V333, P591, DOI 10.1042/bj3330591; Presek P, 1997, HANDB EXP PHARM, V126, P263; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; Thomas M L, 1995, Semin Immunol, V7, P279, DOI 10.1006/smim.1995.0032; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Yang WT, 1998, BLOOD, V91, P3746	32	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28526	28531		10.1074/jbc.M001531200	http://dx.doi.org/10.1074/jbc.M001531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871605	hybrid			2022-12-25	WOS:000089330700027
J	Yamaguchi, K; Subramanian, AR				Yamaguchi, K; Subramanian, AR			The plastid ribosomal proteins - Identification of all the proteins in the 50 S subunit of an organelle ribosome (chloroplast)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RNA-BINDING-PROPERTIES; SPINACH-CHLOROPLASTS; CYTOPLASMIC PRECURSOR; NUCLEOTIDE-SEQUENCE; RECYCLING FACTOR; GENE-EXPRESSION; PURIFICATION; TRANSLATION; EVOLUTION	We have completed identification of all the ribosomal proteins (RPs) in spinach plastid (chloroplast) ribosomal 50 S subunit via a proteomic approach using two-dimensional electrophoresis, electroblotting/protein sequencing, high performance liquid chromatography purification, polymerase chain reaction-based screening of cDNA library/nucleotide sequencing, and mass spectrometry (reversed-phase HPLC coupled to electrospray ionization mass spectrometry and electrospray ionization mass spectrometry), Spinach plastid 50 S subunit comprises 33 proteins, of which 31 are orthologues of Escherichia coli RPs and two are plastid-specific RPs (PSRP-5 and PSRP-6) having no homologues in other types of ribosomes, Orthologues of E. coli L25 and L30 are absent in spinach plastid ribosome. 25 of the plastid 50 S RPs are encoded in the nuclear genome and synthesized on cytosolic ribosomes, whereas eight of the plastid RPs are encoded in the plastid organelle genome and synthesized on plastid ribosomes, Sites for transit peptide cleavages in the cytosolic RP precursors and formyl Met processing in the plastid-synthesized RPs were established. Post-translational modifications were observed in several mature plastid RPs, including multiple forms of L10, L18, L31, and PSRP-5 and N-terminal/internal modifications in L2, L11 and L16. Comparison of the RPs in gradient-purified 70 S ribosome with those in the 30 and 50 S subunits revealed an additional protein, in approximately stoichiometric amount, specific to the 70 S ribosome, It was identified to be plastid ribosome recycling factor. Combining with our recent study of the proteins in plastid 30 S subunit (Yamaguchi, K,, von Knoblauch, K,, and Subramanian, A R. (2000) J, Biol, Chem, 275, 28455-28465), we show that spinach plastid ribosome comprises 59 proteins (33 in 50 S subunit and 25 in 30 S subunit and ribosome recycling factor in 70 S), of which 53 are E. coli orthologues and 6 are plastid-specific proteins (PSRP-1 to PSRP-6), We propose the hypothesis that PSRPs were evolved to perform functions unique to plastid translation and its regulation, including protein targeting/translocation to thylalroid membrane via plastid 50 S subunit.	Univ Arizona, Dept Biochem, Tucson, AZ 85712 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University of Arizona; Max Planck Society	Subramanian, AR (corresponding author), 5110 E Woodgate Ln, Tucson, AZ 85712 USA.							Agafonov DE, 1999, P NATL ACAD SCI USA, V96, P12345, DOI 10.1073/pnas.96.22.12345; Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BOGORAD L, 1975, SCIENCE, V188, P891, DOI 10.1126/science.1138359; BROSIUS J, 1976, FEBS LETT, V68, P105, DOI 10.1016/0014-5793(76)80415-2; BROSIUS J, 1978, BIOCHEMISTRY-US, V17, P501, DOI 10.1021/bi00596a020; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; BUBUNENKO MG, 1994, J MOL BIOL, V240, P28, DOI 10.1006/jmbi.1994.1415; CAROL P, 1993, NUCLEIC ACIDS RES, V21, P635, DOI 10.1093/nar/21.3.635; CAROL P, 1991, GENE, V103, P139, DOI 10.1016/0378-1119(91)90266-E; DABBS ER, 1985, STRUCTURE FUNCTION G, P733; DOGNIN MJ, 1980, EUR J BIOCHEM, V112, P131, DOI 10.1111/j.1432-1033.1980.tb04995.x; Eistetter AJ, 1999, FEMS MICROBIOL LETT, V180, P345, DOI 10.1111/j.1574-6968.1999.tb08816.x; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Freyer R, 1997, P NATL ACAD SCI USA, V94, P6285, DOI 10.1073/pnas.94.12.6285; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GANTT JS, 1988, CURR GENET, V14, P519, DOI 10.1007/BF00521278; *GEN COMP GROUP, 1998, WISC PACK VERS 10 0; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GRAY PN, 1972, EUR J BIOCHEM, V28, P412, DOI 10.1111/j.1432-1033.1972.tb01927.x; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; GUITTON C, 1984, BIOCHEM BIOPH RES CO, V121, P297, DOI 10.1016/0006-291X(84)90722-8; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KAMP RM, 1984, FEBS LETT, V167, P59, DOI 10.1016/0014-5793(84)80832-7; KAMP RM, 1987, BIOCHEMISTRY-US, V26, P5866, DOI 10.1021/bi00392a043; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; KAVOUSI M, 1995, THESIS FREE U BERLIN; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; Maki Y, 2000, PLANT CELL PHYSIOL, V41, P289, DOI 10.1093/pcp/41.3.289; MALONE P, 1988, J CELL BIOL, V106, P609; Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; POSNO M, 1984, CURR GENET, V8, P147, DOI 10.1007/BF00420227; RAMAGOPA.S, 1974, P NATL ACAD SCI USA, V71, P2136, DOI 10.1073/pnas.71.5.2136; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; Sambrook J., 2002, MOL CLONING LAB MANU; Sato N, 1998, PLANT CELL PHYSIOL, V39, P1367, DOI 10.1093/oxfordjournals.pcp.a029343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT J, 1992, PLANT MOL BIOL, V20, P459, DOI 10.1007/BF00040605; SCHMIDT J, 1996, THESIS FREE U BERLIN; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; SMOOKER PM, 1990, BIOCHEMISTRY-US, V29, P9733, DOI 10.1021/bi00493a032; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P5394, DOI 10.1021/bi00618a012; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUBRAMAN.AR, 1968, P NATL ACAD SCI USA, V61, P761, DOI 10.1073/pnas.61.2.761; SUBRAMANIAN AR, 1974, EUR J BIOCHEM, V45, P541, DOI 10.1111/j.1432-1033.1974.tb03579.x; SUBRAMANIAN AR, 1985, ESSAYS BIOCHEM, V21, P45; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; SUBRAMANIAN AR, 1997, PLANT MOL BIOL BIOTE, P86; SUBRAMANIAN AR, 1990, MOL BIOL PLASTIDS, P191; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; TAKAIWA F, 1982, EUR J BIOCHEM, V124, P13, DOI 10.1111/j.1432-1033.1982.tb05901.x; TOUKIFIMPA R, 1989, BIOCHEMISTRY-US, V28, P5840, DOI 10.1021/bi00440a021; Trifa Y, 1998, J BIOL CHEM, V273, P3980, DOI 10.1074/jbc.273.7.3980; VOGEL DW, 1984, FEBS LETT, V169, P67, DOI 10.1016/0014-5793(84)80291-4; Wada A, 1998, GENES CELLS, V3, P203, DOI 10.1046/j.1365-2443.1998.00187.x; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; WEGLOHNER W, 1994, J BIOL CHEM, V269, P7330; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WITTMANN HG, 1982, ANNU REV BIOCHEM, V51, P155, DOI 10.1146/annurev.bi.51.070182.001103; WITTMANN HG, 1980, RIBOSOMES STRUCTURE, P51; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; Yu NJ, 1998, J BIOL CHEM, V273, P3871, DOI 10.1074/jbc.273.7.3871; ZHOU DX, 1989, MOL GEN GENET, V216, P439, DOI 10.1007/BF00334388; ZURAWSKI G, 1984, NUCLEIC ACIDS RES, V12, P6547, DOI 10.1093/nar/12.16.6547	83	185	229	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28466	28482		10.1074/jbc.M005012200	http://dx.doi.org/10.1074/jbc.M005012200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874046	hybrid			2022-12-25	WOS:000089330700019
J	Carter, KB; Hunninghake, GW				Carter, KB; Hunninghake, GW			A constitutive active MEK -> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR-IIB; NECROSIS-FACTOR-ALPHA; IMMEDIATE-EARLY GENE; PRO-INFLAMMATORY CYTOKINES; MAP KINASES; IN-VIVO; TYROSINE-PHOSPHATASE; FAMILY MEMBERS; T-CELLS	Endotoxin-induced cytokine gene expression is regulated, in part, by NF-kappa B. We have shown that both the ERK and p38 mitogen-activated protein (MAP) kinases are necessary for cytokine gene transcription and that the p38 MAP kinase is required for NF-kappa B-driven transcription, so we hypothesized that the MEK --> ERK pathway regulated NF-kappa B-driven transcription as well. We found that a constitutive active MEK --> ERK pathway inhibited NF-kappa B-driven transcription. In addition, both PD 98059 and a dominant negative ERK2 augmented NF-kappa B-driven transcription; however, neither PD 98059 nor MEK1 altered NF-kappa B activation at any level. The constitutive active MEK --> ERK pathway inhibited the phosphorylation of TBP, which is necessary for both interaction with RelA and binding to the TATA box. Due to the fact that we have shown that the p38 MAP kinase modulates TBP activation, we evaluated the effect of the constitutive active MEK --> ERK pathway on p38 MAP kinase activity. We found that the MEK --> ERK pathway negatively regulates NF-kappa B-driven transcription, in part, by inhibiting p38 MAP kinase activity. Thus, the ERK and p38 MAP kinases have differential effects on NF-kappa B-driven transcription.	Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Carter, KB (corresponding author), Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, C33 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03860, HL60316] Funding Source: Medline; NIAID NIH HHS [AI35018] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen D, 1999, J IMMUNOL, V163, P5796; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feng GJ, 1999, J IMMUNOL, V163, P6403; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 1999, J IMMUNOL, V162, P3005; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; REIMANN T, 1994, J IMMUNOL, V153, P5740; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	61	110	111	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27858	27864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878013				2022-12-25	WOS:000089197100047
J	Ebnet, K; Schulz, CU; Brickwedde, MKMZ; Pendl, GG; Vestweber, D				Ebnet, K; Schulz, CU; Brickwedde, MKMZ; Pendl, GG; Vestweber, D			Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PUTATIVE RAS EFFECTOR; TIGHT-JUNCTION; ADHERENS JUNCTIONS; BINDING PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; TARGET AF-6; OCCLUDIN; IDENTIFICATION; CADHERIN	We have identified the PDZ domain protein AF-6 as an intracellular binding partner of the junctional adhesion molecule (JAM), an integral membrane protein located at cell contacts. Binding of AF-6 to JAM: required the presence of the intact C terminus of JAM, which represents a classical type II PDZ domain-binding motif. Although JAM did not interact with the single PDZ domains of ZO-1 or of CASK, we found that a ZO-1 fragment containing PDZ domains 2 and 3 bound to JAM in vitro in a PDZ domain-dependent manner. AF-6 as well as ZO-1 could be coprecipitated with JAM. from endothelial cell extracts, demonstrating the association of the endogenously expressed molecules in vivo. Targeting of JAM to sites of cell contacts could be affected by the loss of the PDZ domain-binding C terminus. Full-length mouse JAM co-distributed with endogenous AF-6 in human Caco-2 cells at sites of cell contact independent of whether adjacent cells expressed mouse JAM as an extracellular binding partner. In contrast, truncated JAM lacking the PDZ domain-binding C terminus did not co-distribute with endogenous AF-6, but was restricted to cell contacts between cells expressing mouse JAM. Our results suggest that JAM can be recruited to intercellular junctions by its interaction with the PDZ domain-containing proteins AF-6 and possibly ZO-1.	Univ Muenster, ZMBE, Inst Cell Biol, D-48149 Muenster, Germany; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany	Max Planck Society	Vestweber, D (corresponding author), Univ Muenster, ZMBE, Inst Cell Biol, Von Esmarch Str, D-48149 Muenster, Germany.		Ebnet, Klaus T/C-8314-2009	Ebnet, Klaus T/0000-0002-0417-7888; Vestweber, Dietmar/0000-0002-3517-732X				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Saito S, 1998, DNA Res, V5, P115, DOI 10.1093/dnares/5.2.115; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; VanItallie CM, 1997, J CELL SCI, V110, P1113; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watari Y, 1998, GENE, V224, P53, DOI 10.1016/S0378-1119(98)00527-7; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	51	325	334	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27979	27988						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856295				2022-12-25	WOS:000089197100062
J	Komeima, K; Hayashi, Y; Naito, Y; Watanabe, Y				Komeima, K; Hayashi, Y; Naito, Y; Watanabe, Y			Inhibition of neuronal nitric-oxide synthase by calcium/calmodulin-dependent protein kinase II alpha through Ser(847) phosphorylation in NG108-15 neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; ENDOTHELIAL NO SYNTHASE; BINDING DOMAIN; CDNA CLONING; IDENTIFICATION; LOCALIZATION; EXPRESSION; PURIFICATION; ACTIVATION; SYSTEM	We have previously demonstrated that phosphorylation of neuronal nitric-oxide synthase (nNOS) at Ser(847) by Ca2+/calmodulin-dependent protein kinases (CaM kinases) attenuates the catalytic activity of the enzyme in vitro (Hayashi Y,, Nishio M., Naito Y., Yokokura H., Nimura Y,, Hidaka H,, and Watanabe Y, (1999) J, Biol, Chem. 274, 20597-20602), In the present study we determined that CaM kinase II alpha (CaM-K II alpha) can directly phosphorylate nNOS on Sers(847), leading to a reduction of nNOS activity in cells, The phosphorylation abilities of purified CaM kinase I alpha (CaM-K I alpha), CaM-K II alpha, and CaM-kinase IV (CaM-K TV) on Ser(847) mere analyzed using the synthetic peptide nNOS-(836-859) (Glu-Glu-Arg-Lys-Ser-Tyr-Lys-Val-Arg-Phe-Asn-Ser-Val- Ser-Asp-Ser-Arg-Lys-Ser-Ser-Gly) from nNOS as substrate. The relative V-max/K-m ratios of CaM kinases for nNOS-(836-859) were found to be as follows: CaM-K II alpha, 100; CaM-K I alpha 54.5; CaM-K IV, 9.1, Co-transfection of constitutively active CaM-K II alpha 1-274 but not inactive CaM-K II alpha 1-274, generated by mutation of Lys(42) to Ala, with nNOS into NG108-15 cells, resulted in increased Ser(847) phosphorylation in the presence of okadaic acid, an inhibitor of protein phosphatase (PP)1 and PP2A, with a concomitant inhibition of NOS enzyme activity. In addition, this latter decrease could be reversed by treatment with exogenous PP2A. Cells expressing mutant nNOS (S847A) proved resistant to phosphorylation and a decrease of NOS activity. Thus, our results indicate that Ca2+ triggers cross-talk signal transduction between CaM kinase and NO and CaM-K II alpha phosphorylating nNOS on Ser(847), which in turn decreases the gaseous second messenger NO in neuronal cells.	Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Watanabe, Y (corresponding author), Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan.			Watanabe, Yasuo/0000-0003-2232-0091				ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Watanabe Y, 1997, FEBS LETT, V403, P75, DOI 10.1016/S0014-5793(97)00012-4; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	47	146	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28139	28143						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874031				2022-12-25	WOS:000089197100080
J	Kroner, C; Eybrechts, K; Akkerman, JWN				Kroner, C; Eybrechts, K; Akkerman, JWN			Dual regulation of platelet protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; MOLECULAR-CLONING; THROMBIN RECEPTOR; ACTIVATION; AKT; BINDING; PHOSPHORYLATION; IDENTIFICATION	Protein kinase B (PKB) is a serine/threonine kinase that is activated by growth hormones and implicated in prevention of apoptosis, glycogen metabolism, and glucose uptake. A key enzyme in PKB activation is phosphatidylinositide 3-kinase (PI-3K), which triggers the dual phosphorylation of PKB by phosphatidylinositol-dependent kinases (PDKs). Here we report that the major PKB subtype in platelets is PKB alpha, which is activated by phosphorylation of Thr(308) and Ser(473) and has a constitutively phosphorylated Thr(450) that does not contribute to PKB activation. alpha-Thrombin and thrombopoietin activate PKB alpha via PI-3K and trigger the concurrent phosphorylation of Thr(308) (via PDK1) and Ser473 (via a not vet identified PDK2). In addition, alpha-thrombin activates a PI-3K-independent pathway involving phospholipase C beta and calcium-dependent protein kinase C subtypes (PKC alpha/beta). This route is specific for phosphorylation of Ser(473) and can be initiated by direct PRC activation with phorbol ester or purified active PKC catalytic fragment in platelet lysate. Different degrees of Ser(473) and Thr(308) phosphorylation correlate with different degrees of enzyme activity. These data reveal a PI-3K-independent PKB activation in which PKC alpha/beta regulates the phosphorylation of Ser(473) in PKB alpha. The independent control of the two phosphorylation sites may contribute to fine regulation of PKB alpha activity.	Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Haematol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	Kroner, C (corresponding author), Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Haematol, POB 85500,3508 GA Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KOHN AD, 1995, EMBO J, V14, P4286; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ogura T, 1997, J NEUROSCI, V17, P3580; Parker PJ, 1999, PHARMACOL THERAPEUT, V82, P263, DOI 10.1016/S0163-7258(98)00047-3; RodriguezLinares B, 1996, BIOCHEM J, V316, P93, DOI 10.1042/bj3160093; Rossler P, 1998, EUR J CELL BIOL, V77, P253; SABLE CL, 1997, FEBS LETT, V409, P252; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; VANWILLIGEN G, 1995, BIOCHEM BIOPH RES CO, V214, P254, DOI 10.1006/bbrc.1995.2282; VIGNON I, 1993, BLOOD, V82, P877; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	42	113	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27790	27798		10.1074/jbc.M000540200	http://dx.doi.org/10.1074/jbc.M000540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874027	hybrid			2022-12-25	WOS:000089197100038
J	Dorman, CM; Johnson, SE				Dorman, CM; Johnson, SE			Activated Raf inhibits myogenesis through a mechanism independent of activator protein 1-mediated myoblast transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; SIGNALING PATHWAYS; MULTIPLE MECHANISMS; DNA-BINDING; AP-1; PROMOTER; EXPRESSION; GROWTH; GENE; JUN	Skeletal myogenesis is acutely affected by growth factors and subsequent activation of their respective intracellular signaling cascades. Components of the mitogenic Ras/Raf/mitogen-activated protein kinase (MAPK) signaling module are potent inhibitors of myoblast differentiation. However, the means by which these kinases prevent myocyte formation and activation of the muscle gene program is unknown. Activator protein 1 (AP-1) is a transcriptional regulator the actions of which are up-regulated by signaling events, including elevated MAPK, Because activated Raf inhibits avian myogenesis in a MAPK-dependent fashion, we investigated the role of AP-1 as a mediator of the Raf-imposed block to myogenesis. Avian myoblasts overexpressing activated Raf contain elevated levels of AP 1 DNA binding and transcriptional activity, Introduction of an AP-1 dominant inhibitory protein (AFOS) into Raf-expressing myoblasts prevented Requisition of a transformed morphology. Interestingly, these cells remained differentiation-defective. Myogenic cells cotransduced with RCAS(A)-Raf BXB and RCAS(B)-AFOS remained mononuclear and myosin-negative and did not activate significantly muscle-specific reporter genes. These results argue that Raf inhibits muscle differentiation independent of AP-1-mediated cell transformation. Our results provide evidence for AP-1 as a critical component of the transforming capacity of activated Raf and evidence that AP-1 is not involved in the myogenic inhibitory effects of the kinase.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA.	sej4@psu.edu						ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Blagden CS, 1999, CELL TISSUE RES, V296, P141, DOI 10.1007/s004410051275; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR A, 1996, CURR OPIN NEUROBIOL, V6, P445; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SU HY, 1991, ONCOGENE, V6, P1759; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Zhang YJ, 1999, NUCLEIC ACIDS RES, V27, P4090, DOI 10.1093/nar/27.20.4090	35	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27481	27487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867013				2022-12-25	WOS:000089144800107
J	Sasaki, K; Taura, F; Shoyama, Y; Morimoto, S				Sasaki, K; Taura, F; Shoyama, Y; Morimoto, S			Molecular characterization of a novel beta-glucuronidase from Scutellaria baicalensis georgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDASE ESCHERICHIA-COLI; ACTIVE-SITE; MAMMALIAN HEPARANASE; CLONING; EXPRESSION; CDNA; GENE; MUCOPOLYSACCHARIDOSIS; PURIFICATION; DEFICIENCY	We cloned a gene encoding Scutellaria P-glucuronidase (sGUS) that is involved in the initiation of H2O2 metabolism in skullcap (Scutellaria baicalensis). This gene consists of a 1581-nucleotide open reading frame, the deduced amino acid sequence of which contains an ATP/GTP binding site and a leucine zipper motif. sGUS has apparent similarity to the heparan sulfate-metabolizing beta-glucuronidase heparanase but no homology to family 2 beta-glucuronidases. In addition, neither the family 2 glycosylhydrolase signature nor family 2 acid-base catalyst was found in this enzyme. These results suggested that sGUS does not belong to the family 2 beta-glucuronidases. We modified several residues predicted to act as the acid-base or nucleophilic residue of sGUS by site-directed mutagenesis. Mutations at Glu(212) or Glu(329) resulted in much lower k(cat)/K-m values in the mutants as compared with the wild-type enzyme, indicating that these are the acid-base and nucleophilic residues of the active site, respectively. Moreover, similar site-directed mutagenesis confirmed that Tyr(281) is also involved in the beta-glucuronidase activity. The amino acid sequences of small regions containing these active site residues were conserved in heparanases. As sGUS has various structural characteristics in common with heparanase, we concluded that sGUS and heparanase belong to the same new family.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan	Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.				NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907, R01CA056819] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-56819, CA-71907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; Fyfe JC, 1999, GENOMICS, V58, P121, DOI 10.1006/geno.1999.5825; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HODAL L, 1992, PLANT SCI, V87, P115, DOI 10.1016/0168-9452(92)90199-V; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Inoue K, 1996, FEBS LETT, V389, P273, DOI 10.1016/0014-5793(96)00601-1; Islam MR, 1999, J BIOL CHEM, V274, P23451, DOI 10.1074/jbc.274.33.23451; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LEVVY GA, 1954, BIOCHEM J, V56, P462; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; Malburg SRC, 1997, APPL ENVIRON MICROB, V63, P2449, DOI 10.1128/AEM.63.6.2449-2453.1997; Morimoto S, 1999, J BIOL CHEM, V274, P26192, DOI 10.1074/jbc.274.37.26192; Morimoto S, 1998, J BIOL CHEM, V273, P12606, DOI 10.1074/jbc.273.20.12606; MORIMOTO S, 1995, PLANTA, V195, P535, DOI 10.1007/BF00195712; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; Ray J, 1998, GENOMICS, V48, P248, DOI 10.1006/geno.1997.5189; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SCHULZ M, 1987, PHYTOCHEMISTRY, V26, P933, DOI 10.1016/S0031-9422(00)82320-1; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518	34	36	38	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27466	27472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858442				2022-12-25	WOS:000089144800105
J	Seachrist, JL; Anborgh, PH; Ferguson, SSG				Seachrist, JL; Anborgh, PH; Ferguson, SSG			beta(2)-adrenergic receptor internalization, endosomal sorting, and plasma membrane recycling are regulated by Rab GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; ENDOCYTIC PATHWAY; BETA-2-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; COATED PITS; SEQUESTRATION; RESENSITIZATION; MECHANISMS; DEPHOSPHORYLATION	Rab GTPases are recognized as critical regulatory factors involved in vesicular membrane transport and endosomal fusion. For example, Rab5 directs the transport and fusion of endocytic vesicles to and with early endosomes, whereas Rab4 is thought to control protein trafficking from early endosomes back to the plasma membrane. In the present study, we investigated the role of Rab5 and Rab4 GTPases in regulating the endocytosis, intracellular sorting, and the plasma membrane recycling of the beta(2)AR. In cells expressing the dominant-negative Rab5-S34N mutant, beta(2)AR internalization was impaired, and beta(2)AR-bearlng endocytic vesicles remained in either close juxtaposition or physically attached to the plasma membrane. In contrast, a constitutively active Rab5-Q79L mutant redirected internalized beta(2)AR to enlarged endosomes but did not prevent beta(2)AR dephosphorylation and recycling, The expression of either wild-type Rab4 or a Rab4-N121I mutant did not prevent beta(2)AR dephosphorylation. However, the dominant-negative Rab4-N121I mutant blocked beta(2)AR resensitization by blocking receptor recycling from endosomes back to the cell surface. Our data indicate that, in addition to regulating the intracellular trafficking and fusion of beta(2)AR-bearing endocytic vesicles, Rab5 also contributes to the formation and/or budding of clathrin coated vesicles. Furthermore, beta(2)AR dephosphorylation occurs as the receptor transits between Rab5- and Rab4-positive compartments.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.							BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOORE RH, 1995, J CELL SCI, V108, P2983; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	31	142	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27221	27228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10854436				2022-12-25	WOS:000089144800074
J	Sessa, RA; Bennett, MH; Lewis, MJ; Mansfield, JW; Beale, MH				Sessa, RA; Bennett, MH; Lewis, MJ; Mansfield, JW; Beale, MH			Metabolite profiling of sesquiterpene lactones from Lactuca species - Major latex components are novel oxalate and sulfate conjugates of lactucin and its derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAPUS SSP OLEIFERA; MOLECULAR-BIOLOGY; BREMIA-LACTUCAE; VIROSA L; LETTUCE; CHICORY; BIOSYNTHESIS; BIOCHEMISTRY; COTYLEDONS; CULTURE	Wounding leaves or stems of Lactuca species releases a milky latex onto the lent surface. We have examined the constituents of latex from Lactuca sativa (lettuce) cv, Diana, The major components were shown to be novel 15-oxalyl and 8-sulfate conjugates of the guaianolide sesquiterpene lactones, lactucin, deoxylactucin, and lactucopicrin. The oxalates were unstable, reverting to the parent sesquiterpene lactone on hydrolysis, Oxalyl derivatives have been reported rarely from natural sources, The sulfates were stable and are the first reported sesquiterpene sulfates from plants. Unusual tannins based on 4-hydroxyphenylacetyl conjugates of glucose were also identified. Significant qualitative and quantitative variation was found in sesquiterpene lactone profiles in different lettuce varieties and in other Lactuca spp, The proportions of each conjugate in latex also changed depending on the stage of plant development. A similar profile was found in chicory, in which oxalyl conjugates were identified, but the 8-sulfate conjugates were notably absent. The presence of the constitutive sesquiterpene lactones was not correlated with resistance to pathogens but may have a significant bearing on the molecular basis of the bitter taste of lettuce and related species. The induced sesquiterpene lactone phytoalexin, lettucenin A, was found in the Lactuca spp, but not in chicory.	Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England; Univ London Wye Coll, Dept Biol Sci, Ashford TN25 5AH, Kent, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol; Imperial College London	Mansfield, JW (corresponding author), Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England.							ADEGAWA S, 1985, CHEM PHARM BULL, V33, P4906; Bell EA, 1996, PHYTOCHEMISTRY, V43, P1003, DOI 10.1016/S0031-9422(96)00425-6; BENNETT MH, 1994, PHYSIOL MOL PLANT P, V44, P321, DOI 10.1016/S0885-5765(05)80046-3; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; Bones AM, 1996, PHYSIOL PLANTARUM, V97, P194, DOI [10.1034/j.1399-3054.1996.970128.x, 10.1111/j.1399-3054.1996.tb00497.x]; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; CURTIS IS, 1994, J EXP BOT, V45, P1441, DOI 10.1093/jxb/45.10.1441; de Kraker JW, 1998, PLANT PHYSIOL, V117, P1381, DOI 10.1104/pp.117.4.1381; Esau K, 1965, PLANT ANATOMY, V2, P429; EVANS CS, 1985, PHYTOCHEMISTRY, V24, P2273, DOI 10.1016/S0031-9422(00)83025-3; FAGG J, 1991, PHYSIOL MOL PLANT P, V38, P105, DOI 10.1016/S0885-5765(05)80129-8; Fischer N, 1991, METHODS PLANT BIOCH, P187; GIAMOUSTARIS A, 1995, ANN APPL BIOL, V126, P347, DOI 10.1111/j.1744-7348.1995.tb05371.x; Giamoustaris A, 1997, PLANT PATHOL, V46, P271, DOI 10.1046/j.1365-3059.1997.d01-222.x; GORSKI PM, 1995, PHYSIOL MOL PLANT P, V47, P339, DOI 10.1006/pmpp.1995.1063; GRAYER RJ, 1994, PHYTOCHEMISTRY, V37, P19, DOI 10.1016/0031-9422(94)85005-4; GROMEK D, 1992, PHYTOTHER RES, V6, P285, DOI 10.1002/ptr.2650060514; GROMEK D, 1989, POL J CHEM, V63, P297; GROSS GG, 1999, COMPREHENSIVE NATURA, V3, P799; Hall JL, 1982, PLANT CELL STRUCTURE; HARBORNE JB, 1977, PROGR PHYTOCHEM, V4, P189; Haslam E., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P527; Kisiel W, 1997, PHYTOCHEMISTRY, V45, P365, DOI 10.1016/S0031-9422(96)00820-5; KISIEL W, 1995, PHYTOCHEMISTRY, V40, P1139, DOI 10.1016/0031-9422(95)00433-8; KUO YH, 1991, PHYTOCHEMISTRY, V30, P3241, DOI 10.1016/0031-9422(91)83184-M; MAHMOUD ZF, 1986, PHYTOCHEMISTRY, V25, P747, DOI 10.1016/0031-9422(86)88039-6; NISHIMURA K, 1986, CHEM PHARM BULL, V34, P2518; ONEILL TM, 1982, T BRIT MYCOL SOC, V79, P229, DOI 10.1016/S0007-1536(82)80108-3; Peters AM, 1998, J AM SOC HORTIC SCI, V123, P326, DOI 10.21273/JASHS.123.2.326; PICMAN AK, 1986, BIOCHEM SYST ECOL, V14, P255, DOI 10.1016/0305-1978(86)90101-8; Pink D., 1993, GENETIC IMPROVEMENT, P543; PRICE KR, 1990, J SCI FOOD AGR, V53, P185, DOI 10.1002/jsfa.2740530206; REES SB, 1985, PHYTOCHEMISTRY, V24, P2225, DOI 10.1016/S0031-9422(00)83015-0; SAVONA G, 1983, J NAT PROD, V46, P277, DOI 10.1021/np50026a025; SCHENCK G, 1939, ARCH PHARM, V277, P137; SETO M, 1988, CHEM PHARM BULL, V36, P2423, DOI 10.1248/cpb.36.2423; SKORCZYNSKI SS, 1986, BIOCHEM BIOPH RES CO, V141, P1051, DOI 10.1016/S0006-291X(86)80150-4; TAKASUGI M, 1985, J CHEM SOC CHEM COMM, P621, DOI 10.1039/c39850000621; TAMAKI H, 1995, J AGR FOOD CHEM, V43, P6, DOI 10.1021/jf00049a002; VANBEEK TA, 1990, J AGR FOOD CHEM, V38, P1035, DOI 10.1021/jf00094a026; Zidorn C, 1999, PHYTOCHEMISTRY, V51, P991, DOI 10.1016/S0031-9422(99)00163-6; [No title captured]; [No title captured]	43	125	128	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26877	26884						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10858433				2022-12-25	WOS:000089144800030
J	Avvakumov, GV; Muller, YA; Hammond, GL				Avvakumov, GV; Muller, YA; Hammond, GL			Steroid-binding specificity of human sex hormone-binding globulin is influenced by occupancy of a zinc-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIZATION DOMAINS; PROLACTIN RECEPTOR; GROWTH-HORMONE; HUMAN PLASMA; PROTEIN; SERUM; TESTOSTERONE; EXPRESSION; EPITHELIUM; ESTRADIOL	One calcium-binding site (site I) and a second poorly defined metal-binding site (site II) have been observed previously within the amino-terminal laminin G-like domain (G domain) of human sex hormone-binding globulin (SHBG). By soaking crystals of this structure in 2.5 mM ZnCl2, site II and a new metal-binding site (site III) were found to bind Zn2+. Site II is located close to the steroid-binding site, and Zn2+ is coordinated by the side chains of His(83) and His(136) and the carboxylate group of Asp(65). In this site, Zn2+ prevents Asp(65) from interacting with the steroid 17 beta-hydroxy group and alters the conformations of His(83) and His(136), as well as a disordered region over the steroid-binding site. Site III. is formed by the side chains of His(101) and the carboxylate group of Asp(117) and the distance between them (2.7 Angstrom) is increased to 3.7 Angstrom in the presence of Zn2+. The affinity of SHBG for estradiol is reduced in the presence of 0.1-1 mM Zn2+, whereas its affinity for androgens is unchanged, and chemically-related metal ions (Cd2+ and Hg2+) have similar but less pronounced effects. This is not observed when Zn2+ coordination at site II is modified by substituting Gln for His(136). An alteration in the steroid-binding specificity of human SHBG by Zn2+ occupancy of site II may be relevant in male reproductive tissues where zinc concentrations are very high.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, MRC, Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Max Delbruck Ctr Mol Med, Forsch Grp Kristallog, D-13092 Berlin, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghammond@julian.uwo.ca	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertini I., 1994, BIOINORG CHEM, P37; BOCCHINFUSO WP, 1994, BIOCHEMISTRY-US, V33, P10622, DOI 10.1021/bi00201a008; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chia SE, 2000, J ANDROL, V21, P53; COWAN RA, 1976, J ENDOCRINOL, V71, P121, DOI 10.1677/joe.0.0710121; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HABIB FK, 1976, J ENDOCRINOL, V71, P133, DOI 10.1677/joe.0.0710133; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1986, J STEROID BIOCHEM, V24, P815, DOI 10.1016/0022-4731(86)90442-5; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; HARRIS WR, 1989, J NUTR, V119, P1677, DOI 10.1093/jn/119.11.1677; HILDEBRAND C, 1995, BIOCHEMISTRY-US, V34, P3231, DOI 10.1021/bi00010a012; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Janne M, 1998, MOL ENDOCRINOL, V12, P123; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH DR, 1994, VITAM HORM, V49, P197; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIEG M, 1993, J CLIN ENDOCR METAB, V77, P375, DOI 10.1210/jc.77.2.375; LAHTONEN R, 1985, PROSTATE, V6, P177, DOI 10.1002/pros.2990060208; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; NAMKUNG PC, 1990, J BIOL CHEM, V265, P18345; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSNER W, 1974, BIOCHIM BIOPHYS ACTA, V351, P92, DOI 10.1016/0005-2795(74)90068-3; ROSNER W, 1991, J STEROID BIOCHEM, V40, P813, DOI 10.1016/0960-0760(91)90307-Q; ROSS JBA, 1985, J PROTEIN CHEM, V4, P299, DOI 10.1007/BF01025495; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432	35	37	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25920	25925		10.1074/jbc.M004484200	http://dx.doi.org/10.1074/jbc.M004484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859323	hybrid			2022-12-25	WOS:000088999700007
J	Baer, M; Johnson, PF				Baer, M; Johnson, PF			Generation of truncated C/EBP beta isoforms by in vitro proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATOR PROTEIN; NF-KAPPA-B; CELL-PROLIFERATION; LEUCINE-ZIPPER; POSTTRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; MAMMARY-GLAND; DNA-BINDING	Multiple forms of the transcriptional regulator CCAAT/enhancer-binding protein beta (C/EBP beta) with molecular masses of approximately 38, 34, 20, and 14 kDa have been observed in cell extracts. It has been proposed that these proteins arise by alternative initiation at in-frame AUG codons. The truncated C/EBP beta isoforms (p14 and p20/LIP) lack transactivation domains but retain DNA-binding and dimerization sequences and are therefore assumed to function as competitive inhibitors of C/EBP-mediated transcription in vivo. By comparing various extraction procedures to analyze endogenous and overexpressed C/EBP beta proteins, we determined that p20-C/EBP beta is generated predominantly by in vitro proteolytic cleavage during isolation from cells and that p14-C/EBP beta is produced exclusively by this mechanism. In transfected cells, the full-length (p34 and p38) isoforms but not the truncated proteins were detectable in the cytoplasm, indicating that the latter are not primary translation products. In addition, the C/EBP beta leucine zipper dimerization domain was essential for the appearance of the truncated species, demonstrating that protein folding or dimerization are critical determinants of proteolytic sensitivity. Our findings suggest that the presence of truncated C/EBP beta proteins in cell extracts must be interpreted with caution and that assumptions about the in vivo relevance of these isoforms should be re-evaluated.	NCI, Frederick Canc Res & Dev Ctr, Eukaryot Transcript Regulat Sect, Adv BioSci Labs,Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Johnson, PF (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				An MR, 1996, MOL CELL BIOL, V16, P2295; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; CALKHOVEN CF, 1992, NUCLEIC ACIDS RES, V20, P4093, DOI 10.1093/nar/20.15.4093; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fattori E, 1995, ANN NY ACAD SCI, V762, P262; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lee YM, 1996, MOL CELL BIOL, V16, P4257; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Raught B, 1996, CANCER RES, V56, P4382; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Welm AL, 1999, MOL CELL BIOL, V19, P1695; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	37	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26582	26590		10.1074/jbc.M004268200	http://dx.doi.org/10.1074/jbc.M004268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10856306	hybrid			2022-12-25	WOS:000088999700096
J	Saha, AK; Schwarsin, AJ; Roduit, R; Masse, F; Kaushik, V; Tornheim, K; Prentki, M; Ruderman, NB				Saha, AK; Schwarsin, AJ; Roduit, R; Masse, F; Kaushik, V; Tornheim, K; Prentki, M; Ruderman, NB			Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; SOLEUS MUSCLE; CARBOXYLASE; HEART; DIACYLGLYCEROL; PURIFICATION; CLONING; CELL; MCD	Alterations in the concentration of malonyl-CoA, an inhibitor of carnitine palmitoyltransferase I, have been linked to the regulation of fatty acid oxidation in skeletal muscle. During contraction decreases in muscle malonyl-CoA concentration have been related to activation of AMP-activated protein kinase (AMPK), which phosphorylates and inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in malonyl-CoA formation. We report here that the activity of malonyl-CoA decarboxylase (MCD) is increased in contracting muscle, Using either immunopurified enzyme or enzyme partially purified by (NH4)(2)SO4 precipitation, 2-3-fold increases in the V-max of MCD and a 40% decrease in its K-m for malonyl-CoA (190 versus 119 mu M) were observed in rat gastrocnemius muscle after 5 min of contraction, induced by electrical stimulation of the sciatic nerve. The increase in MCD activity was markedly diminished when immunopurified enzyme was treated with protein phosphatase 2A or when phosphatase inhibitors were omitted from the homogenizing solution and assay mixture. Incubation of extensor digitorum longus muscle for 1 h with 2 mM 5-aminoimidazole-4-carboxamide-1-beta-D-rib furanoside, a cell-permeable activator of AMPK, increased MCD activity g-fold, Here, too, addition of protein phosphatase 2A to the immunopellets reversed the increase of MCD activity. The results strongly suggest that activation of AMPK during muscle contraction leads to phosphorylation of MCD and an increase in its activity. They also suggest a dual control of malonyl-CoA concentration by ACC and MCD, via AMPK, during exercise.	Boston Med Ctr, Diabet Unit, Endocrinol Sect, Boston, MA 02118 USA; Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Med Ctr, Dept Physiol, Boston, MA 02118 USA; Boston Med Ctr, Dept Biochem, Boston, MA 02118 USA; Univ Montreal, Dept Nutr, Mol Nutr Unit, Montreal, PQ H2L 4M1, Canada; Univ Montreal, CR CHUM, Montreal, PQ H2L 4M1, Canada	Boston Medical Center; Boston Medical Center; Boston Medical Center; Boston Medical Center; Universite de Montreal; Universite de Montreal	Saha, AK (corresponding author), Boston Med Ctr, Diabet & Metab Unit, 650 Albany St,EBRC-827, Boston, MA 02118 USA.		Roduit, Raphael/AAC-3890-2021	Roduit, Raphael/0000-0001-7440-2799; Tornheim, Keith/0000-0002-6235-5128; Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, R01DK049147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49147, DK 19514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN KS, 1994, AM J PHYSIOL, V266, pE479, DOI 10.1152/ajpendo.1994.266.3.E479; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Dyck JRB, 1998, AM J PHYSIOL-HEART C, V275, pH2122, DOI 10.1152/ajpheart.1998.275.6.H2122; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hutber C. Adrian, 1997, American Journal of Physiology, V272, pE262; JANG SH, 1989, J BIOL CHEM, V264, P3500; KIM YS, 1979, INT J BIOCHEM, V10, P551; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P234, DOI 10.1016/0003-9861(78)90273-4; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Rasmussen BB, 1997, J APPL PHYSIOL, V83, P1104, DOI 10.1152/jappl.1997.83.4.1104; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Saha AK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1030, DOI 10.1152/ajpendo.1999.276.6.E1030; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Voilley N, 1999, BIOCHEM J, V340, P213, DOI 10.1042/0264-6021:3400213; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299	25	158	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24279	24283		10.1074/jbc.C000291200	http://dx.doi.org/10.1074/jbc.C000291200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10854420	hybrid			2022-12-25	WOS:000088683300008
J	Lametsch, R; Rasmussen, JT; Johnsen, LB; Purup, S; Sejrsen, K; Petersen, TE; Heegaard, CW				Lametsch, R; Rasmussen, JT; Johnsen, LB; Purup, S; Sejrsen, K; Petersen, TE; Heegaard, CW			Structural characterization of the fibroblast growth factor-binding protein purified from bovine prepartum mammary gland secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; RETINOIC ACID; IN-VIVO; ANGIOGENESIS; EXPRESSION; RELEASE; FGF; COMPLEX; IDENTIFICATION; PURIFICATION	A novel heparin-binding protein was purified to homogeneity from bovine prepartum mammary gland secretion using heparin-Sepharose chromatography and reverse-phase high performance liquid chromatography successively. Structural information obtained by N-terminal amino acid sequencing of a series of proteolytically generated peptides permitted the cloning of the corresponding cDNA. The isolated cDNA was 1170 base pairs long and consisted of an 83-base pair 5'-untranslated region followed by a 702-base pair coding region and a 385-base pair 3'-untranslated region. The open reading frame resulted in a protein comprising 234-amino acid residues, including a signal sequence. Instead of Lys(24) as the predicted N terminus, Edman degradation of the native protein revealed N-terminal processing at two sites as follows: a primary site between Arg(31)-Gly(32) and a secondary site between Arg(51)-Ser(52). The amino acid sequence showed a significant similarity with that of human (60%) and mouse (53%) fibroblast growth factor-binding protein (FGF-BP). Accordingly, ligand blotting experiments revealed that bovine FGF-BP bound FGF-2. The theoretical mass of the protein predicted from the cDNA sequence is 22.5 kDa. However, the molecular mass of the purified protein was estimated to 28.6 kDa by mass spectrometry and 36 kDa by electrophoresis, The apparent molecular weight differences are most likely due to post-transcriptional modifications, shown to involve N- and O-glycosylation of Asn(155) and Ser(172), respectively. All 10 cysteine residues in the protein participated in disulfide bonds, and the pattern was identified as Cys(71)-Cys(88), Cys(97)-Cys(130), Cys(106)-Cys(142), Cys(198)-Cys(234), and Cys(214)-Cys(222). As the 10 cysteines of the three known FGF-BPs are positionally conserved, the disulfide bond pattern of bovine FGF-BP may be regarded as representative for the FGF-BP family.	Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, DK-8000 Aarhus C, Denmark; Danish Inst Anim Sci, Res Ctr Foulum, DK-8830 Tjele, Denmark	Aarhus University; Aarhus University	Heegaard, CW (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, Sci Pk,Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	cwh@imsb.au.dk	Heegaard, Christian W/A-4814-2019; Lametsch, René/E-6174-2015; Lametsch, René/AAQ-4582-2021	Lametsch, René/0000-0002-4189-806X; Lametsch, René/0000-0002-4189-806X; Wurtz Heegaard, Christian/0000-0002-7989-2624; Purup, Stig/0000-0003-0653-4751; Rasmussen, Jan Trige/0000-0002-2809-7225				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Dinbergs ID, 1996, J BIOL CHEM, V271, P29822, DOI 10.1074/jbc.271.47.29822; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Jackson D, 1997, J CELL SCI, V110, P1261; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klein S, 1997, EXS, V79, P159; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lavandero S, 1998, FEBS LETT, V439, P351, DOI 10.1016/S0014-5793(98)01370-2; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Plath A, 1998, J DAIRY SCI, V81, P2604, DOI 10.3168/jds.S0022-0302(98)75818-7; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDOWSKI Y, 1993, LIVEST PROD SCI, V35, P35, DOI 10.1016/0301-6226(93)90180-P; Talhouk RS, 1996, J REPROD FERTIL, V106, P221, DOI 10.1530/jrf.0.1060221; Wang XC, 1998, BIOCHEM MOL BIOL INT, V46, P81; WU DQ, 1991, J BIOL CHEM, V266, P16778	34	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19469	19474		10.1074/jbc.M002550200	http://dx.doi.org/10.1074/jbc.M002550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867016	hybrid			2022-12-25	WOS:000087941300007
J	Colucci-D'Amato, GL; D'Alessio, A; Califano, D; Cali, G; Rizzo, C; Nitsch, L; Santelli, G; de Franciscis, V				Colucci-D'Amato, GL; D'Alessio, A; Califano, D; Cali, G; Rizzo, C; Nitsch, L; Santelli, G; de Franciscis, V			Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; PROTEIN-TYROSINE-PHOSPHATASE; MEDULLARY-THYROID CARCINOMA; CELL-LINES; PC12 CELLS; SIGNALING PATHWAY; MEN 2A; PROTOONCOGENE; ACTIVATION; MUTATIONS	Oncogenic variants of the receptor tyrosine kinase, Ret, cause formation of tumors of neuroendocrine derivation in the multiple endocrine neoplasia type 2 and, thus, likely interfere with antiproliferative and/or differentiative extracellular signals. Here we took advantage of two rat pheochromocytoma-derived cell lines (PC12/MEN2A and PC12/MEN2B) to investigate whether Bet-induced nerve growth factor (NGF) unresponsiveness might involve impairment of ERK signaling. In fact, these cells, stably transfected with distinct forms of the active ret oncogene, fail to block proliferation, even upon NGF stimulation. In these cells we show the presence of both chronic ERKs activity and high expression levels of MKP-3, an ERK-specific phosphatase, Despite the presence of MKP-3, ERK activity can be further stimulated by NGF, but it fails to translocate into the nucleus and consequently to induce immediate-early gene transcription. Because of the presence of MKP-3, our results suggest the existence of a negative regulatory feedback acting on ERKs as a mechanism responsible for the abrogation of NGF-induced terminal differentiation. Indeed, MKP-3 seems to be implicated in the persistence of ERKs in cell cytoplasm, This interpretation is further supported by the observation that in ret-transfected cells, forced expression of an active form of MEK-1 may overcome this block; it restores transcription from the c-fos promoter, induces translocation of ERKs into the nucleus, and inhibits cell proliferation.	Univ Naples Federico II, CNR G Salvatore,Fac Med & Chirurg, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fdn G Pascale, Ist Nazl Tumori, I-80131 Naples, Italy	University of Naples Federico II; IRCCS Fondazione Pascale	de Franciscis, V (corresponding author), Univ Naples Federico II, CNR G Salvatore,Fac Med & Chirurg, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	defranci@unina.it	Califano, Daniela/Y-6313-2018	Califano, Daniela/0000-0001-6945-3209	Telethon [A.097] Funding Source: Medline	Telethon(Fondazione Telethon)		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1994, ONCOGENE, V9, P3379; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Missale C, 1998, P NATL ACAD SCI USA, V95, P5366, DOI 10.1073/pnas.95.9.5366; Missale C, 1996, MOL ENDOCRINOL, V10, P272, DOI 10.1210/me.10.3.272; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PONDER BAJ, 1996, GENETIC MECHANISMS M, P21; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Powers JF, 1998, ENDOCR PATHOL, V9, P325, DOI 10.1007/BF02739692; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SMITH DP, 1994, J CELL SCI, P43; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	47	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19306	19314		10.1074/jbc.275.25.19306	http://dx.doi.org/10.1074/jbc.275.25.19306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858459	hybrid			2022-12-25	WOS:000087815900090
J	Williams, DL; de la Llera-Moya, M; Thuahnai, ST; Lund-Katz, S; Connelly, MA; Azhar, S; Anantharamaiah, GM; Phillips, MC				Williams, DL; de la Llera-Moya, M; Thuahnai, ST; Lund-Katz, S; Connelly, MA; Azhar, S; Anantharamaiah, GM; Phillips, MC			Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic alpha-helix as a recognition motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; SELECTIVE UPTAKE; CHOLESTERYL ESTER; STEROIDOGENIC CELLS; TARGETED MUTATION; ADRENAL-CELLS; RAT; METABOLISM; EXPRESSION	Scavenger receptor, class B, type I (SR-BI) mediates the selective uptake of high density lipoprotein (HDL) cholesteryl ester without the uptake and degradation of the particle. In transfected cells SR-BI recognizes HDL, low density lipoprotein (LDL) and modified LDL, protein-free lipid vesicles containing anionic phospholipids, and recombinant lipoproteins containing apolipoprotein (apo) A-I, apoA-II, apoE, or apoCIII, The molecular basis for the recognition of such diverse ligands by SR-BI is unknown. We have used direct binding analysis and chemical cross-linking to examine the interaction of murine (m) SR-BI with apoA-I, the major protein of HDL. The results show that apoA-I in apoA-I/palmitoyl-oleoylphosphatidylcholine discs, HDL3, or in a lipid-free state binds to mSR-BI with high affinity (K-d congruent to 5-8 mu g/ml). ApoA-I in each of these forms was efficiently cross-linked to cell surface mSR-BI, indicating that direct protein-protein contacts are the predominant feature that drives the interaction between HDL and mSR-BI. When complexed with dimyristoylphosphatidylcholine, the N-terminal and C-terminal CNBr fragments of apoA-I each bound to SR-BI in a saturable, high affinity manner, and each cross-linked efficiently to mSR-BI. Thus, mSR-BI recognizes multiple sites in apoA-I, A model class A amphipathic alpha-helix, 37pA, also showed high affinity binding and cross-linking to mSR-BI. These studies identify the amphipathic alpha-helix as a recognition motif for SR-BI and lead to the hypothesis that mSR-BI interacts with HDL via the amphipathic cw-helical repeat units of apoA-I. This hypothesis explains the interaction of SR-BI with a wide variety of apolipoproteins via a specific secondary structure, the class A amphipathic alpha-helix, that is a common structural motif in the apolipoproteins of HDL, as well as LDL.	SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19129 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Univ Alabama, Med Ctr, Arteriosclerosis Res Unit, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Drexel University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Alabama System; University of Alabama Birmingham	Williams, DL (corresponding author), SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, P01HL022633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049705] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58012, HL 22633] Funding Source: Medline; NIDDK NIH HHS [DK 49705] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1989, J LIPID RES, V30, P1799; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1990, J BIOL CHEM, V265, P12217; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; REAVEN E, 1989, J LIPID RES, V30, P1551; Reaven E, 1999, BBA-MOL CELL BIOL L, V1436, P565, DOI 10.1016/S0005-2760(98)00169-6; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2000, J LIPID RES, V41, P343; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; VANLOO B, 1991, J LIPID RES, V32, P1253; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Xu SZ, 1997, J LIPID RES, V38, P1289	48	94	98	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18897	18904		10.1074/jbc.M002411200	http://dx.doi.org/10.1074/jbc.M002411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858447	hybrid			2022-12-25	WOS:000087815900039
J	Tee, AR; Proud, CG				Tee, AR; Proud, CG			DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling	ONCOGENE			English	Article						DNA damage; apoptosis; mTOR; p70 S6 kinase; initiation factor; mRNA translation	DEPENDENT PROTEIN-KINASE; INITIATION-FACTOR 4G; P70 S6 KINASE; MESSENGER-RNA TRANSLATION; INDUCED APOPTOSIS; CELL-PROLIFERATION; SIGNALING PATHWAY; FACTOR 4E; FACTOR SUBUNIT; PHAS-I	Treatment of cells with DNA-damaging agents, such as etoposide, can cause growth arrest or apoptosis, Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E, These effects were not prevented by the general caspase inhibitor, Z-VAD.FMK, These findings indicate caspase-independent inhibition of signalling pathways that involve the mammalian target of rapamycin (mTOR), Similar effects were observed in response to two other DNA-damaging agents, cisplatin and mitomycin-C, These events preceded apoptosis, which was assessed by caspase-3 activity assays and FAGS analysis, This shows that inhibition of mTOR signalling is not a consequence of apoptosis, although it may play a role in the events that precede cell death. 4E-BP1 was cleaved during apoptosis yielding a fragment that retained the ability to bind eIF4E. Cleavage of 4E-BP1 was inhibited by treatment of the cells with Z-VAD.FMK, indicating it is caspase-dependent. Insulin elicited full activation of p70 S6 kinase and phosphorylation of 4E-PB1 in etoposide-treated cells prior to the onset of apoptosis, but not during cell death. This suggests that mTOR signalling becomes irreversibly inhibited only after entry into apoptosis.	Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Wellcome Trust Bldg Complex,Dow St, Dundee DD1 5EH, Scotland.			Proud, Christopher/0000-0003-0704-6442; Tee, Andrew/0000-0002-5577-4631				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, CANCER SURV, V27, P293; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Ishizuka T, 1997, BIOCHEM BIOPH RES CO, V230, P386, DOI 10.1006/bbrc.1996.5967; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meyuhas Oded, 1996, V30, P363; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Palom Y, 1998, ONCOL RES, V10, P509; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Proud CG, 1997, BIOCHEM J, V328, P329; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SHI YF, 1995, CANCER RES, V55, P1982; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; SULLIVAN D M, 1987, NCI (National Cancer Institute) Monographs, P73; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takizawa T, 1999, J BIOCHEM-TOKYO, V125, P391, DOI 10.1093/oxfordjournals.jbchem.a022299; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Tronov VA, 1999, BIOCHEMISTRY-MOSCOW+, V64, P345; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451	68	106	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3021	3031		10.1038/sj.onc.1203622	http://dx.doi.org/10.1038/sj.onc.1203622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871854				2022-12-25	WOS:000087581400009
J	Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P				Chami, M; Gozuacik, D; Saigo, K; Capiod, T; Falson, P; Lecoeur, H; Urashima, T; Beckmann, J; Gougeon, ML; Claret, M; le Maire, M; Brechot, C; Paterlini-Brechot, P			Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis	ONCOGENE			English	Article						SERCA1; Hepatitis B Virus; calcium; apoptosis; cancer	NF-KAPPA-B; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; SARCOPLASMIC-RETICULUM; TRANSGENIC MICE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; DNA-BINDING; IN-VITRO	We have used the Hepatitis B Virus DIVA genome as a probe to identify genes clonally mutated in vivo, in human liver cancers. In a tumor, HBV-DNA mas found to be integrated into the gene encoding Sarco/Endoplasmic Reticulum Calcium ATPase (SERCA), which pumps calcium, an important intracellular messenger for cell viability and growth, from the cytosol to the endoplasmic reticulum. The HBV X gene promoter cis-activates chimeric HBV X/SERCA1 transcripts, with splicing of SERCA1 exon II, encoding C-terminally truncated SERCA1 proteins. Two chimeric HBV X/SERCA1 proteins accumulate in the tumor and form dimers. III vitro analyses have demonstrated that these proteins localize to the ER, determine its calcium depletion and induce cell death. We have also shown that these biological effects are related to expression of the SERCA, rather than of the viral moiety. This report involves for the first time the expression of mutated SERCA proteins in vivo in a tumor cell proliferation and in vitro in the control of cell viability.	Necker Inst, U370 INSERM, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Chiba 2638852, Japan; Univ Paris Sud, U442 INSERM, F-91405 Orsay, France; CEA, URA CNRS 2096, F-91191 Gif Sur Yvette, France; Inst Pasteur, F-75015 Paris, France; Ctr Natl Genotypage, F-91057 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay	Paterlini-Brechot, P (corresponding author), Necker Inst, U370 INSERM, 156 Rue Vaugirard, F-75015 Paris, France.		CAPIOD, Thierry/K-4234-2017; Chami, Mounia/S-6471-2019; Beckmann, Jacques S/A-9772-2008; Devrim, Gozuacik/C-3330-2008	CAPIOD, Thierry/0000-0002-8448-7041; Chami, Mounia/0000-0003-1498-7187; Beckmann, Jacques S/0000-0002-9741-1900; Devrim, Gozuacik/0000-0001-7739-2346; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; Falson, Pierre/0000-0002-9760-4577				Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chung DC, 1998, CANCER RES, V58, P3706; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GRAEF E, 1994, ONCOGENE, V9, P81; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; HEILMANN C, 1985, J BIOL CHEM, V260, P788; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KEKULE AS, 1994, PRIMARY LIVER CANC E, V13; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOHN EC, 1995, CANCER RES, V55, P1856; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Koike K, 1998, HEPATITIS B VIRUS, P133; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN MH, 1989, BIOCHEM BIOPH RES CO, V164, P14, DOI 10.1016/0006-291X(89)91676-8; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; MacLennan DH, 1998, ACTA PHYSIOL SCAND, V163, P55; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PATERLINI P, 1994, PRIMARY LIVER CANC E, V12, P167; PATERLINI P, 1990, VIRAL HEPATITIS LIVE, P556; Peacocke M, 1999, NAT GENET, V21, P252, DOI 10.1038/6758; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pineau P, 1996, J VIROL, V70, P7280, DOI 10.1128/JVI.70.10.7280-7284.1996; PircDanoewinata H, 1996, WIEN KLIN WOCHENSCHR, V108, P752; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Raney AK, 1991, MOL BIOL HEPATITIS B, P1; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259	70	55	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2877	2886		10.1038/sj.onc.1203605	http://dx.doi.org/10.1038/sj.onc.1203605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871838				2022-12-25	WOS:000087544500001
J	Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW				Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW			Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR	ONCOGENE			English	Article						apoptosis; BCL-XL; PAX transcription factors; rhabdomyosarcoma	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; MUSCLE DEVELOPMENT; CELL-SURVIVAL; GENES; EXPRESSION; DIFFERENTIATION; DOMAIN; MYOD; DNA	The aberrant expression of the transcription factors PAN3 and PAX3/FKHR associated with rhabdomyosarcoma (RMS), solid tumors displaying muscle cell features, suggests that these proteins play an important role in the pathogenesis of RMS. We could previously demonstrate that one of the oncogenic functions of PAS3 and PAX3/FKHR in RMS is protection from apoptosis, BCL-XL is a prominent anti-apoptotic protein present in normal skeletal muscle and RMS cells. In the present study, we establish that BCL-XL is transcriptionally modulated bai PAX3 and PAX3/FMHR, since enhanced expression of both PAX proteins stimulates transcription of endogenous BCL-XL mRNA in a cell type specific manner. Further, we present evidence that both PAX3 and PAX3/FKHR can transcriptionally activate the Bcl-x gene promoter in cotransfection assays. Using electrophoretic mobility shift assays, an ATTA binding site for PAX3 and PAX3/FKHR could be localized in the upstream promoter region (position -42 to -39), Finally, ectopic overexpression of either PAY3, PAX3/FKHR or BCL-XL can rescue tumor cells from apoptosis induced by antisense treatment. These results suggest that at least part of the anti-apoptotic effect of PAX3 and PAX3/FKHR is mediated through direct transcriptional modulation of the prominent anti-apoptotic protein BCL-XL.	Univ Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biochem, Zurich, Switzerland; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Pennsylvania	Schafer, BW (corresponding author), Univ Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.		Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/C-6734-2008; Bernasconi, Michele/A-1588-2008	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Schafer, Beat/0000-0001-5988-2915				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2969; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Frascella E, 1998, CANCER GENET CYTOGEN, V102, P104, DOI 10.1016/S0165-4608(97)00352-X; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SCHAFER BW, 1998, GEN PHYSL BIOPHYS, V17, P1; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wang W, 1998, CANCER RES, V58, P4426; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	42	86	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2921	2929		10.1038/sj.onc.1203607	http://dx.doi.org/10.1038/sj.onc.1203607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871843				2022-12-25	WOS:000087544500006
J	Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH				Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - II. Analysis of Leu-rich repeat 4 of human luteinizing hormone/chorionic gonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; CHORIONIC-GONADOTROPIN; EXTRACELLULAR DOMAIN; BINDING; ACTIVATION; AFFINITY; SEQUENCE; GENE; RAT	The luteinizing hormone receptor (LHR) consists of an similar to 350-amino acid-long N-terminal extracellular exodomain and a membrane-associated endodomain of similar size. Human chorionic gonadotropin (hCG) binds to the exodomain, and then hCG/exodomain complex is thought to make a secondary contact with the endodomain and generate hormone signals. The sequence alignment of the exodomain shows imperfectly matching eight to nine Leu-rich repeats (LRRs), In the preceding article (Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T, (2001) J. Biol. Chem. 276, 3426-3435), we have shown that LRR2 and LRR4 are crucial for hormone binding. In this work, we have examined the residues of LRR4, in particular Leu(103) and Ile(105) in the putative beta strand. Our data show that Leu(103) and Ile(105) are involved in the specific, hydrophobic interaction of the LRR4 loop, likely to form the hydrophobic core. This loop is crucial for the structural integrity of all of the LRRs. In contrast, the downstream sequence consisting of Asn(107), Thr(108), Gly(109), and Ile(110) of LRR4 is crucial for cAMP induction but not for hormone binding, folding, and surface expression. This implicates, for the first time, its involvement in the interaction with the endodomain and signal generation. The evidence for the interaction is presented in the following article.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	University of Kentucky; Seoul National University (SNU); University of Glasgow	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GRISWOLD MD, 1993, SERTOLI CELLS, P496; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; HSUEH AJW, 1983, J REPROD FERTIL, V69, P325, DOI 10.1530/jrf.0.0690325; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI L, 1991, ENDOCRINOLOGY, V128, P2648; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411	25	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3436	3442		10.1074/jbc.M003773200	http://dx.doi.org/10.1074/jbc.M003773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10884391	hybrid			2022-12-25	WOS:000166784900059
J	Kuwasako, K; Shimekake, Y; Masuda, M; Nakahara, K; Yoshida, T; Kitaura, M; Kitamura, K; Eto, T; Sakata, T				Kuwasako, K; Shimekake, Y; Masuda, M; Nakahara, K; Yoshida, T; Kitaura, M; Kitamura, K; Eto, T; Sakata, T			Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; GREEN FLUORESCENT PROTEIN; GASTRIN-RELEASING PEPTIDE; AORTIC ENDOTHELIAL-CELLS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; ENDOCYTIC PATHWAY; LIGAND; ADRENOMEDULLIN	Expression of the calcitonin receptor-like receptor (CRLR) and its receptor activity modifying proteins (RAMPs) can produce calcitonin gene-related peptide (CGRP) receptors (CRLR/RAMP1) and adrenomedullin (AM) receptors (CRLR/RAMP2 or -3), A chimera of the CRLR and green fluorescent protein (CRLR-GFP) was used to study receptor localization and trafficking in stably transduced HEK 293 cells, with or without cotransfection of RAMPs, CRLR-GFP failed to generate responses to CGRP or AM without RAMPs, Furthermore, CRLR-GFP was not found in the plasma membrane and its localization was unchanged after agonist exposure. When stably coexpressed with RAMPs, CRLR-GFP appeared on the cell surface and was fully active in intracellular cAMP production and calcium mobilization, Agonist-mediated internalization of CRLR-GFP was observed in RAMP1/CGRP or AM, RAMP2/AM, and RAMP3/AM, which occurred with similar kinetics, indicating the existence of ligand-specific regulation of CRLR internalization by RAMPs. This internalization was strongly inhibited by hypertonic medium (0.45 M sucrose) and paralleled localization of rhodamine-labeled transferrin, suggesting that CRLR endocytosis occurred predominantly through a clathrin-dependent pathway. A significant proportion of CRLR was targeted to lysosomes upon binding of the ligands, and recycling of the internalized CRLR was not efficient. In HER 293 cells stably expressing CRLR-GFP and Myc-RAMPs, these rhodamine-labeled RAMPs were co-localized with CRLR-GFP in the presence and absence of the ligands, Thus, the CRLR is endocytosed together with RAMPs via clathrin-coated vesicles, and both the internalized molecules are targeted to the degradative pathway.	Shionogi & Co Ltd, Shionogi Inst Med Sci, Settsu, Osaka 5660022, Japan; Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Natl Cardiovasc Res Inst, Dept Struct Anal, Osaka 5658565, Japan	Shionogi & Company Limited; University of Miyazaki; National Cerebral & Cardiovascular Center - Japan	Sakata, T (corresponding author), Shionogi & Co Ltd, Shionogi Inst Med Sci, 2-5-1 Mishima, Settsu, Osaka 5660022, Japan.		Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOODMAN EC, 1986, LIFE SCI, V38, P2169, DOI 10.1016/0024-3205(86)90568-0; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; GUON XM, 1992, J BIOL CHEM, V267, P21995; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kitamura K, 1997, CURR OPIN NEPHROL HY, V6, P80, DOI 10.1097/00041552-199701000-00015; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KRUGER L, 1988, BRAIN RES, V463, P223, DOI 10.1016/0006-8993(88)90395-2; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PERKINS JP, 1991, BETA ADRENERGIC RECE, P125; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; Samson WK, 1998, FRONT NEUROENDOCRIN, V19, P100, DOI 10.1006/frne.1998.0164; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZIMMERMANN U, 1995, PEPTIDES, V16, P421, DOI 10.1016/0196-9781(94)00195-C	41	138	145	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29602	29609		10.1074/jbc.M004534200	http://dx.doi.org/10.1074/jbc.M004534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882736	hybrid			2022-12-25	WOS:000089439800057
J	Morris, MC; Heitz, A; Mery, J; Heitz, F; Divita, G				Morris, MC; Heitz, A; Mery, J; Heitz, F; Divita, G			An essential phosphorylation-site domain of human cdc25C interacts with both 14-3-3 and cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MITOTIC INDUCER; PROTEIN-KINASE; CELL-CYCLE; DNA-DAMAGE; CHECKPOINT CONTROL; DEPENDENT KINASES; CHEMICAL-SHIFTS; HUMAN HOMOLOG; PHOSPHATASE	Human cdc25C is a dual-specificity phosphatase involved in the regulation of cell cycle progression in both unperturbed cells and in cells subject to DNA damage or replication checkpoints. In this study, we describe the structure-function relationship of an essential domain of human cdc25C that interacts with 14-3-3 proteins. We show that this domain is a hi-functional interactive motif that interacts with cyclins primarily through their P-box motif in addition to 14-3-3 proteins. Characterization of the structural features of this domain by NMR and circular dichroism reveals two distinct cu helical moieties interconnected by a loop carrying the 14-3-3 binding site. Moreover, the helical folding is induced upon binding to 14-3-3, suggestive of a conformational regulation of this domain of cdc25C through interactions with partner proteins in vivo. Combining our structural and biochemical data, we propose a detailed model of the molecular mechanism of cdc25C regulation by differential association with 14-3-3 and cdc2-cyclin B.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Fac Pharm Montpellier, INSERM U414, F-34060 Montpellier, France; CNRS, UMR 9955, Ctr Biochim Struct, F-34060 Montpellier, France; CNRS UPR 1086, Ctr Rech Biochim Macromol, Biophys Unit, F-34293 Montpellier 5, France	Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Divita, G (corresponding author), Scripps Res Inst, Dept Mol Biol, MB4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gilles@scripps.edu	MORRIS, May/ABB-2629-2021; MORRIS, May C/J-5940-2016	MORRIS, May/0000-0001-8106-9728; MORRIS, May C/0000-0001-8106-9728				Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; KONTAXIS G, 1994, J MAGN RESON SER A, V111, P70, DOI 10.1006/jmra.1994.1227; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAMB NJC, 1994, ADV PROTEIN PHOSPHAT, V8, P133; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris MC, 1999, J MOL BIOL, V286, P475, DOI 10.1006/jmbi.1998.2475; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAGATA A, 1991, NEW BIOL, V3, P959; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; THANABAL V, 1994, J BIOMOL NMR, V4, P47; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wuthrich K., 1996, NMR PROTEINS NUCL AC; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	51	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28849	28857		10.1074/jbc.M002942200	http://dx.doi.org/10.1074/jbc.M002942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864927	Green Published, hybrid			2022-12-25	WOS:000089330700068
J	Koide, T; Aso, A; Yorihuzi, T; Nagata, K				Koide, T; Aso, A; Yorihuzi, T; Nagata, K			Conformational requirements of collagenous peptides for recognition by the chaperone protein HSP47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL PEPTIDES; BINDING STRESS PROTEIN; X-Y TRIPLETS; MOLECULAR CHAPERONE; ENDOPLASMIC-RETICULUM; MODEL PEPTIDES; PROCOLLAGEN; STABILITY; RESIDUES; LIBRARY	The collagen binding chaperone HSP47 interacts with procollagen in the endoplasmic reticulum and plays a crucial role in the biosynthesis of collagen. We recently demonstrated that typical collagen model peptides, (Pro-Pro-Gly)(n), possess sufficient structural information for interaction with HSP47 (Koide, T., Asada, S., and Nagata, K. (1999) J. Biol. Chem. 274, 34523-34526). Here we show that binding of (Gly-Pro-Pro), peptides to HSP47 can be detected using the two-hybrid system in yeast if a trimerizing domain is fused to the C termini of the peptides. Some peptides interacted with HSP47 at a lowered assay temperature at 24 degrees C but not at 30 degrees C, indicating the importance of conformational change of the substrate peptides, To analyze the spectrum of HSP47 substrate sequences, we performed two-hybrid screening of collagen-like peptides in designed random peptide libraries using HSP47 as a bait. In selected peptides, the enrichment ratio calculated for each amino acid residue correlated strongly with the contribution of the residue to triple-helix stability independently determined using synthetic collagen model peptides. Taken together, our results suggest that HSP47 preferentially recognizes collagenous Gly-X-Y repeats in triple-helical conformation. We also demonstrated that screening of combinatorial peptide libraries is a powerful strategy to determine conformational requirements as web as the elucidation of binding motifs in primary structure.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan	Kyoto University	Nagata, K (corresponding author), Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto, Japan.	nagata@frontier.kyoto-u.ac.jp						Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Asada S, 1999, CELL STRUCT FUNCT, V24, P187, DOI 10.1247/csf.24.187; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Feng YB, 1997, BIOCHEMISTRY-US, V36, P8716, DOI 10.1021/bi962980z; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Hegyi H, 1997, J PROTEIN CHEM, V16, P545, DOI 10.1023/A:1026382032119; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27957	27963						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862616				2022-12-25	WOS:000089197100059
J	Tsuji, Y; Shimada, Y; Takeshita, T; Kajimura, N; Nomura, S; Sekiyama, N; Otomo, J; Usukura, J; Nakanishi, S; Jingami, H				Tsuji, Y; Shimada, Y; Takeshita, T; Kajimura, N; Nomura, S; Sekiyama, N; Otomo, J; Usukura, J; Nakanishi, S; Jingami, H			Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; PERIPLASMIC BINDING-PROTEINS; LIGAND-BINDING; DIMERIZATION; EXPRESSION; COMPLEX; HETERODIMERIZATION; IDENTIFICATION; PURIFICATION; LOCALIZATION	Previously, we produced the whole extracellular region of metabotropic glutamate receptor subtype 1 (mGluR1) in a soluble form. The soluble receptor retained a ligand affinity comparable with that of the full-length membrane-bound receptor and formed a disulfide-linked dimer, Here, we have identified a cysteine residue responsible for the intermolecular disulfide bond and determined domain organization of the extracellular region of mGluR1, A mutant, C140A, was a monomer under nonreduced conditions by SDS-polyacrylamide gel electrophoresis; however, C140A was eluted at the position similar to that of mGluR113, the wild type soluble receptor, by size exclusion column chromatography, Furthermore, C140A bound a Ligand, [H-3]quisqualate, with an affinity similar to that obtained by mGluR113, Oocytes injected with RNA for full-length mGluR1 containing C140A mutation showed responses to ligands at magnitudes similar to those with wild type full-length RNA. Thus, elimination of the disulfide linkage did not perturb the dimer formation and ligand signaling, suggesting that cryptic dimer interface(s) possibly exist in mGluR1, Limited proteolysis of the whole extracellular fragment (residue 33-592) revealed two trypsin-sensitive sites, after the residues Arg(139) and Arg(521). A 15-kDa NH2-terminal proteolytic fragment (residue 33-139) was associated with the downstream part after the digestion. Arg(521) was located before a cysteine-rich stretch preceding the transmembrane region. A new shorter soluble receptor (residue 33-522) lacking the cysteine-rich region was designed based on the protease-sensitive boundary. The purified receptor protein gave a K-d value of 58.1 +/- 0.84 nM, which is compatible to a reported value of the full-length receptor. The B-max value was 7.06 +/- 0.82 nmol/mg of protein. These results indicated that the ligand-binding specificity of mGluR1 is confined to the NH2-terminal 490-amino acid region of the mature protein.	Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Nagoya Univ, Sch Med, Dept Anat, Showa Ku, Nagoya, Aichi 4668550, Japan; Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan	Hitachi Limited; Nagoya University; Kyoto University	Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.		Kajimura, Naoko/R-9267-2019	Usukura, Jiro/0000-0003-2286-5403				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Costantino G, 1999, J MED CHEM, V42, P5390, DOI 10.1021/jm990353c; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Miyazaki J, 1999, BIOCHEM J, V340, P687, DOI 10.1042/0264-6021:3400687; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Neki A, 1996, NEUROSCI LETT, V202, P197, DOI 10.1016/0304-3940(95)12248-6; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Ohashi H., 1997, Society for Neuroscience Abstracts, V23, P2023; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	35	115	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28144	28151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874032				2022-12-25	WOS:000089197100081
J	Kirschnek, S; Paris, F; Weller, M; Grassme, H; Ferlinz, K; Riehle, A; Fuks, Z; Kolesnick, R; Gulbins, E				Kirschnek, S; Paris, F; Weller, M; Grassme, H; Ferlinz, K; Riehle, A; Fuks, Z; Kolesnick, R; Gulbins, E			CD95-mediated apoptosis in vivo involves acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; SECRETORY SPHINGOMYELINASE; SIGNALING PATHWAY; CELL-DEATH; CERAMIDE; MICE; LYMPHOBLASTS; TRAFFICKING; GENE	Acid sphingomyelinase (ASM) is reported to have an essential function in stress-induced apoptosis although the physiological function of ASM in receptor-triggered apoptosis is unknown. Here, we delineate a pivotal role for ASM in CD95-triggered apoptosis of peripheral lymphocytes or hepatocytes in vivo. We employed intravenous injection of anti-CD4 antibodies or phytohemagglutinin that was previously shown to result in apoptosis of peripheral blood lymphocytes or hepatocytes via the endogenous CD95/CD95 ligand system. Our results demonstrate a high susceptibility in normal mice whereas ASM knock-out mice fail to immunodeplete T cells or develop autoimmune-like hepatitis. Likewise, ASM-deficient mice or hepatocytes and splenocytes ex vivo manifest resistance to anti-CD95 treatment. These results provide in vivo evidence for an important physiological function of ASM in CD95-induced apoptosis.	Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.		Gulbins, Erich/L-6989-2014; Paris, francois E/L-4915-2015	Gulbins, Erich/0000-0002-3117-1342; Paris, francois E/0000-0002-0176-7348; Weller, Michael/0000-0002-1748-174X	NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Ni HT, 1999, J IMMUNOL, V162, P5183; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SANDHOFF K, 1994, FEBS LETT, V346, P103, DOI 10.1016/0014-5793(94)00282-7; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Simarro M, 1999, J IMMUNOL, V162, P5149; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	30	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27316	27323						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867001				2022-12-25	WOS:000089144800087
J	Barbagallo, RP; Breyton, C; Finazzi, G				Barbagallo, RP; Breyton, C; Finazzi, G			Kinetic effects of the electrochemical proton gradient on plastoquinone reduction at the Qi site of the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER CHAIN; IRON-SULFUR PROTEIN; OPEN READING FRAME; CHLAMYDOMONAS-REINHARDTII; B/F COMPLEX; BC(1) COMPLEX; BF COMPLEX; OXYGENIC PHOTOSYNTHESIS; REDOX REACTIONS; PHOTOSYSTEM-I	We have investigated the effects of the light-induced thylakoid transmembrane potential on the turnover of the b(6)f complex in cells of the unicellular green alga Chlamydomonas reinhardtii. The reduction of the potential by either decreasing the light intensity or by adding increasing concentrations of the ionophore carbonylcyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) revealed a marked inhibition of the cytochrome b(6) oxidation rate (10-fold) without substantial modifications of cytochrome f oxidation kinetics. Partial recovery of this inhibition could be obtained in the presence of ionophores provided that the membrane potential was re-established by illumination with a train of actinic flashes fired at a frequency higher than its decay. Measurements of isotopic effects on the kinetics of cytochrome b(6), oxidation revealed a synergy between the effects of ionophores and the H2O-D2O exchange. We propose therefore, that protonation events influence the kinetics of cytochrome b(6) oxidation at the Qi site and that these reactions are strongly influenced by the light-dependent generation of a transmembrane potential.	CNR, Ctr Studio Biol Cellulare & Mol Piante, I-20133 Milan, Italy; Max Planck Inst Biophys, Dept Biol Struct, D-60528 Frankfurt, Germany	Consiglio Nazionale delle Ricerche (CNR); Max Planck Society	Finazzi, G (corresponding author), CNR, Ctr Studio Biol Cellulare & Mol Piante, Via Celoria 26, I-20133 Milan, Italy.	giovanni.finazzi@unimi.it						Barbagallo RP, 1999, BIOCHEMISTRY-US, V38, P12814, DOI 10.1021/bi990424+; Barzda V, 1996, BIOCHEMISTRY-US, V35, P8981, DOI 10.1021/bi960114g; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Brugna M, 1998, J BACTERIOL, V180, P3719, DOI 10.1128/JB.180.14.3719-3723.1998; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Connors K. A, 1990, CHEM KINETICS STUDY; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1989, ENERGY TRANSDUCTION, P79; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Deniau C, 2000, BIOCHEMISTRY-US, V39, P3304, DOI 10.1021/bi992445+; DINER B, 1973, BIOCHIM BIOPHYS ACTA, V305, P329, DOI 10.1016/0005-2728(73)90180-1; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Finazzi G, 1998, BIOCHEMISTRY-US, V37, P9999, DOI 10.1021/bi980320j; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P355, DOI 10.1016/S0005-2728(89)80343-3; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; JUNGE W, 1968, Z NATURFORSCH B, V24, P1038; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KLUGHAMMER C, 1993, FEBS LETT, V336, P491, DOI 10.1016/0014-5793(93)80862-O; Klughammer C, 1998, PHOTOSYNTH RES, V56, P117, DOI 10.1023/A:1005998729041; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P193, DOI 10.1016/0005-2728(94)90223-2; LANCASTER CR, 1995, REACTION CTR PHOTOSY; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; Matsuno-Yagi A, 1999, J BIOL CHEM, V274, P9283, DOI 10.1074/jbc.274.14.9283; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; ROBERTSON DE, 1984, FEBS LETT, V178, P343, DOI 10.1016/0014-5793(84)80630-4; RUMBERG B, 1968, Z NATURFORSCH PT B, VB 23, P239; SELAK MA, 1984, PHOTOCHEM PHOTOBIOL, V39, P485; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; SvenssonEk M, 1996, BIOCHEMISTRY-US, V35, P13673, DOI 10.1021/bi961466q; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAM R, 1991, BIOPHYS J, V59, P4, DOI 10.1016/S0006-3495(91)82192-0; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1998, BIOCHEMISTRY-US, V37, P10395, DOI 10.1021/bi980238o	61	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26121	26127		10.1074/jbc.M002299200	http://dx.doi.org/10.1074/jbc.M002299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10866998	hybrid			2022-12-25	WOS:000088999700034
J	Rodriguez-Pascual, F; Hausding, M; Ihrig-Biedert, I; Furneaux, H; Levy, AP; Forstermann, U; Kleinert, H				Rodriguez-Pascual, F; Hausding, M; Ihrig-Biedert, I; Furneaux, H; Levy, AP; Forstermann, U; Kleinert, H			Complex contribution of the 3 '-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene - Involvement of the RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR PROMOTER; 3' UNTRANSLATED REGION; T-CELL ACTIVATION; HUMAN DLD-1 CELLS; AU-RICH ELEMENTS; MESSENGER-RNA; CYTOKINE INDUCTION; STABILITY; TRANSCRIPTION	Cytokine stimulation of human DLD-1 cells resulted in a marked expression of nitric-oxide synthase (NOS) II mRNA and protein accompanied by only a moderate increase in transcriptional activity. Also, there was a basal transcription of the NOS II gene, which did not result in measurable NOS II expression. The 3'-untranslated region (3'-UTR) of the NOS II mRNA contains four AUUUA motifs and one AUUUUA motif, known to destabilize the mRNAs of proto-oncogenes, nuclear transcription factors, and cytokines. Luciferase reporter gene constructs containing the NOS II 3'-UTR showed a significantly reduced luciferase activity. The embryonic lethal abnormal vision (ELAV)-like protein HuR was found to bind with high affinity to the adenylate/uridylate-rich elements of the NOS II 3'-UTR. Inhibition of HuR with antisense constructs reduced the cytokine-induced NOS II mRNA, whereas overexpression of HuR potentiated the cytokine-induced NOS II expression. This provides evidence that NOS II expression is regulated at the transcriptional and post-transcriptional level. Binding of HuR to the 3'-UTR of the NOS II mRNA seems to play an essential role in the stabilization of this mRNA.	Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel	Johannes Gutenberg University of Mainz; Memorial Sloan Kettering Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinert, H (corresponding author), Univ Mainz, Dept Pharmacol, Obere Zahlbacher STr 67, D-55101 Mainz, Germany.		Rodríguez-Pascual, Fernando/Q-5100-2019; Kleinert, Hartmut/M-2988-2018	Rodríguez-Pascual, Fernando/0000-0002-9765-9578; Kleinert, Hartmut/0000-0003-2202-3548; furneaux, henry/0000-0003-2212-1017				Atasoy U, 1998, J CELL SCI, V111, P3145; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Erondu NE, 1999, MOL ENDOCRINOL, V13, P495, DOI 10.1210/me.13.3.495; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; GENG Y, 1995, J CELL BIOL, V129, P1651, DOI 10.1083/jcb.129.6.1651; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1991, J IMMUNOL, V146, P1843; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; Linscheid P, 1998, BIOCHEM BIOPH RES CO, V243, P137, DOI 10.1006/bbrc.1998.8072; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nunokawa Y, 1997, BIOCHEM BIOPH RES CO, V233, P523, DOI 10.1006/bbrc.1997.6471; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; Schutte BC, 1997, BIOTECHNIQUES, V22, P40, DOI 10.2144/97221bm06; Seiler-Tuyns A, 1999, J BIOL CHEM, V274, P21714, DOI 10.1074/jbc.274.31.21714; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	152	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26040	26049		10.1074/jbc.M910460199	http://dx.doi.org/10.1074/jbc.M910460199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10859327	hybrid			2022-12-25	WOS:000088999700023
J	Kurata, S				Kurata, S			Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; BINDING; ALPHA; CELLS	Apoptosis induced by high level oxidative stress accompanies diverse cellular biochemical events including activation of the stress signal cascades of JNK and NF-kappa B, We report here selective activation of p38 MAPK cascade and mitotic arrest under a low level oxidative stress that lacks apoptosis induction. U937 human lymphoid cells treated with low dose (0.02 mM) H2O2 rapidly caused p38 MAPK cascade activation detectable by phosphorylation of MKK3/6, p38 MAPK, activating transcription factor-a, and cAMP-responsive element-binding protein, leaving the JNK and NF-KB cascades unaffected. The p38 kinase activation was sustained for 24 h under the low level stress conditions and led to formation of polyploid nuclei. N-Acetyl-L-cysteine, a precursor of anti-oxidant glutathione, canceled both p38 MAPK activation and abnormal cell cycle progression, whereas blockage of the kinase by specific inhibitor SB203580 allowed the appearance of apoptotic cells. Thus, mimicking the effects of nocodazole, the low level oxidative stimulus caused inhibition of cell division in the M phase through p38 MAPK activation. The kinase cascade may serve as a primary transducer of cytoplasmic oxidative signals to nucleus for stress-relieving gene expression and cell cycle control before apoptosis-inducing signals are transduced, This is the first report demonstrating that oxidative stress can participate in cell cycle control by induction of a signal cascade.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Kurata, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kurata SI, 1996, J BIOL CHEM, V271, P21798, DOI 10.1074/jbc.271.36.21798; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAWN MC, 1995, SCIENCE, V267, P1353; SHULL S, 1991, J BIOL CHEM, V266, P24398; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; YAN MH, 1994, NATURE, V372, P798	28	170	175	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23413	23416		10.1074/jbc.C000308200	http://dx.doi.org/10.1074/jbc.C000308200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10856288	hybrid			2022-12-25	WOS:000088564200002
J	Vertommen, D; Rider, M; Ni, YP; Waelkens, E; Merlevede, W; Vandenheede, JR; Van Lint, J				Vertommen, D; Rider, M; Ni, YP; Waelkens, E; Merlevede, W; Vandenheede, JR; Van Lint, J			Regulation of protein kinase D by multisite phosphorylation - Identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; C-MU; PHORBOL ESTERS; D ACTIVATION; PROTEOLYTIC ACTIVATION; CATALYTIC DOMAIN; STRUCTURAL BASIS; PKD ACTIVATION; INTACT-CELLS	Activation of the serine/threonine kinase, protein kinase D (PKD/PKC mu) via a phorbol ester/PKC-dependent pathway involves phosphorylation events. The present study identifies five in vivo phosphorylation sites by mass spectrometry, and the role of four of them was investigated by site-directed mutagenesis. Four sites are autophosphorylation sites, the first of which (Ser(916)) is located in the C terminus; its phosphorylation modifies the conformation of the kinase and influences duration of kinase activation but is not required for phorbol ester-mediated activation of PKD. The second autophosphorylation site (Ser(203)) lies in that region of the regulatory domain, which in PKC mu interacts with 14-3-3 tau. The last two autophosphorylation sites (Ser(744) and Ser(748)) are located in the activation loop but are only phosphorylated in the isolated PKD-catalytic domain and not in the full-length PKD; they may affect enzyme catalysis but are not involved in the activation of wildtype PKD by phorbol ester. We also present evidence for proteolytic activation of PKD. The fifth site (Ser(255)) is transphosphorylated downstream of a PKC-dependent pathway after in vivo stimulation with phorbol ester, In vivo phorbol ester stimulation of an S255E mutant no longer requires PKC-mediated events. In conclusion, our results show that PKD is a multisite phosphorylated enzyme and suggest that its phosphorylation may be an intricate process that regulates its biological functions in very distinct ways.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	KU Leuven; Universite Catholique Louvain	Van Lint, J (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Herestr 49, B-3000 Louvain, Belgium.	johan.vanlint@med.kuleuven.ac.be	Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALLEN G, 1989, SEQUENCING PROTEINS, P140; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; INOUE M, 1977, J BIOL CHEM, V252, P7610; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PARKER PJ, 1997, PROTEIN KINASE C; PEERSON RT, 1999, CURR BIOL, V9, pR521; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; TAN JL, 1990, J BIOL CHEM, V265, P13818; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	55	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19567	19576		10.1074/jbc.M001357200	http://dx.doi.org/10.1074/jbc.M001357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867018	hybrid			2022-12-25	WOS:000087941300020
J	Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA				Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA			E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes	ONCOGENE			English	Article						keratinocyte; E2F-1; differentiation; carcinogenesis	HUMAN PAPILLOMAVIRUS TYPE-16; SKIN TUMOR-DEVELOPMENT; CARCINOMA CELL-LINE; S-PHASE ENTRY; WILD-TYPE P53; TRANSCRIPTION FACTOR; DNA-BINDING; EPITHELIAL-CELLS; IN-VIVO; TERMINAL DIFFERENTIATION	Squamous differentiation of keratinocytes is associated with decreases in E2F-1 mRNA expression and E2F activity, and these processes are disrupted in squamous cell carcinoma cell lines. We now show that E2F-1 mRNA expression is increased in primary squamous cell carcinomas of the skin relative to normal epidermis, To explore the relationship between E2F-1 and squamous differentiation further, we examined the effect of altering E2F activity in primary human keratinocytes induced to differentiate. Promoter activity for the proliferation-associated genes, cdc2 and keratin 14, are inhibited during squamous differentiation. This inhibition can be inhibited by overexpression of E2F-1 in keratinocytes, Overexpression of E2F-1 also suppressed the expression of differentiation markers (transglutaminase type 1 and keratin 10) in differentiated keratinocytes, Blocking E2F activity by transfecting proliferating keratinocytes with dominant negative E2F-1 constructs inhibited the expression of cdc2 and E2F-1, but did not induce differentiation. Furthermore, expression of the dominant negative construct in epithelial carcinoma cell lines and normal keratinocytes decreased expression from the cdc2 promoter. These data indicate that E2F-1 promotes keratinocyte proliferation-specific marker genes and suppresses squamous differentiation-specific marker genes. Moreover, these data indicate that targeted disruption of E2F-1 activity may have therapeutic potential for the treatment of squamous carcinomas.	Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia	University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia.		saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010; Dicker, Tony/F-6007-2010; Frazer, Ian/A-1137-2007	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529; Dicker, Tony/0000-0001-8539-2960; Frazer, Ian/0000-0002-8002-4680				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Arany I, 1997, IN VIVO, V11, P157; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BETZ NA, 1995, MOL CARCINOGEN, V12, P66, DOI 10.1002/mc.2940120203; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; Chiang SY, 1997, P NATL ACAD SCI USA, V94, P2811, DOI 10.1073/pnas.94.7.2811; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GILLES C, 1994, INT J CANCER, V58, P847, DOI 10.1002/ijc.2910580617; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HILDITCHMAGUIRE PA, 1998, THESIS U QUEENSLAND, P275; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JETTEN AM, 1989, CANCER RES, V49, P3990; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kikuchi Arata, 1992, Journal of Dermatological Science, V4, P83, DOI 10.1016/0923-1811(92)90063-H; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; MOORE GE, 1975, CANCER RES, V35, P2684; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEUMAN T, 1995, EXP CELL RES, V217, P363, DOI 10.1006/excr.1995.1098; PAGANO M, 1992, ONCOGENE, V7, P1681; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rook A, 1998, TXB DERMATOLOGY; Saunders N, 1999, CANCER RES, V59, P399; Saunders NA, 1998, CANCER RES, V58, P1646; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHARPE GR, 1994, ARCH DERMATOL RES, V286, P476, DOI 10.1007/BF00371575; Sladek TL, 1996, CELL PROLIFERAT, V29, P579, DOI 10.1111/j.1365-2184.1996.tb00973.x; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUDA K, 1994, NEUROREPORT, V5, P1749, DOI 10.1097/00001756-199409080-00015; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wang J, 1996, J CELL BIOCHEM, V62, P405; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welter JF, 1996, J BIOL CHEM, V271, P11034; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	84	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2887	2894		10.1038/sj.onc.1203610	http://dx.doi.org/10.1038/sj.onc.1203610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871839				2022-12-25	WOS:000087544500002
J	Lim, J; Wong, ESM; Ong, SH; Yusoff, P; Low, BC; Guy, GR				Lim, J; Wong, ESM; Ong, SH; Yusoff, P; Low, BC; Guy, GR			Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation - Identification of a novel translocation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASES; FUNCTIONS DOWNSTREAM; CELL-MIGRATION; PC12 CELLS; DROSOPHILA; FGF; SEVENLESS; HOMOLOG; PATHWAYS	Sprouty (Spry) was first identified in a genetic screen in Drosophila to be an antagonist of fibroblast growth factor and epidermal growth factor (EGF) signaling, seemingly by inhibiting the Ras/MAP kinase pathway. Data base searches lead to the identification and cloning of, to date, four mammalian sprouty genes. The primary sequences of the mammalian sprouty gene products share a well conserved cysteine-rich C-terminal domain with the Drosophila protein, The N-terminal regions, however, do not exhibit significant homology, This study aimed at determining the disposition of Spry proteins in intact cells before and after stimulation of the EGF receptor tyrosine kinase, Full-length or deletion mutants of Spry, tagged at the N termini with the FLAG-epitope, were expressed in COS-1 cells by transient transfection and analyzed by immunofluorescence microscopy before and after EGF stimulation of the cells. In unstimulated cells, the Spry proteins were distributed throughout the cytosol except for human Sprouty2 (hSpry2), which, although generally located in the cytosol, co-localized with microtubules. In all cases, the Spry proteins underwent rapid translocation to membrane ruffles following EGF stimulation. The optimal translocation domain was identified by deletion and immunofluorescence analysis to be a highly conserved 105-amino acid domain in the C-terminal half of the hSpry2 protein. The translocation of this conserved domain, based on hSpry2 data, was independent of the activation of phosphatidylinositol-3 kinase.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/H-8049-2012; Lim, Jormay/A-7257-2011; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Lim, Jormay/0000-0001-7191-545X; Low, Boon Chuan/0000-0003-0756-096X				AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; DELAAT SW, 1985, BIOCHEM SOC SYMP, P205; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JIANG WG, 1995, EXP CELL RES, V220, P424, DOI 10.1006/excr.1995.1334; Kramer S, 1999, DEVELOPMENT, V126, P2515; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Minowada G, 1999, DEVELOPMENT, V126, P4465; MIYATA Y, 1989, EXP CELL RES, V181, P454, DOI 10.1016/0014-4827(89)90102-X; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Stenmark H, 1999, J CELL SCI, V112, P4175; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; Weed SA, 1998, J CELL SCI, V111, P2433; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	38	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32837	32845		10.1074/jbc.M002156200	http://dx.doi.org/10.1074/jbc.M002156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10887178	hybrid			2022-12-25	WOS:000090003800064
J	Ferguson, DJ; Gorlatova, N; Grahame, DA; Krzycki, JA				Ferguson, DJ; Gorlatova, N; Grahame, DA; Krzycki, JA			Reconstitution of dimethylamine : coenzyme M methyl transfer with a discrete corrinoid protein and two methyltransferases purified from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; METHIONINE SYNTHASE; ENCODING GENES; ISOENZYME-II; METHANOL; TRIMETHYLAMINE; PURIFICATION; ISOZYMES; MONOMETHYLAMINE; METABOLISM	Methyl transfer from dimethylamine to coenzyme M was reconstituted in vitro for the first time using only highly purified proteins. These proteins isolated from Methanosarcina barkeri included the previously unidentified corrinoid protein MtbC, which copurified with MtbA, the methylcorrinoid:Coenzyme M methyltransferase specific for methanogenesis from methylamines, MtbC binds 1.0 mel of corrinoid cofactor/mol of 24-kDa polypeptide and stimulated dimethylamine:coenzyme M methyl transfer 3.4-fold in a cell extract. Purified MtbC and MtbA were used to assay and purify a dimethylamine:corrinoid methyltransferase, MtbB1. MtbB1 is a 230-kDa protein composed of 51-kDa subunits that do not possess a corrinoid prosthetic group. Purified MtbB1, MtbC, and MtbA were the sole protein requirements for in vitro dimethylamine:coenzyme M methyl transfer. An MtbB1:MtbC ratio of 1 was optimal for coenzyme M methylation with dimethylamine, MtbB1 methylated either corrinoid bound to MtbC or free co-b(I)alamin with dimethylamine, indicating MtbB1 carries an active site for dimethylamine demethylation and corrinoid methylation. Experiments in which different proteins of the resolved monomethylamine:coenzyme M methyl transfer reaction replaced proteins involved in dimethylamine:coenzyme M methyl transfer indicated high specificity of MtbB1 and MtbC in dimethylamine: coenzyme M methyl transfer activity. These results indicate MtbB1 demethylates dimethylamine and specifically methylates the corrinoid prosthetic group of MtbC, which is subsequently demethylated by MtbA to methylate coenzyme M during methanogenesis from dimethylamine.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA	Krzycki, JA (corresponding author), Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA.			Ferguson, Donald/0000-0002-0595-3033				Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; Daas PJH, 1996, J BIOL CHEM, V271, P22339, DOI 10.1074/jbc.271.37.22339; DANGEL W, 1987, ARCH MICROBIOL, V148, P52, DOI 10.1007/BF00429647; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; Harms U, 1996, EUR J BIOCHEM, V235, P653, DOI 10.1111/j.1432-1033.1996.00653.x; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; KING GM, 1984, APPL ENVIRON MICROB, V48, P719, DOI 10.1128/AEM.48.4.719-725.1984; KREFT JU, 1994, EUR J BIOCHEM, V226, P945, DOI 10.1111/j.1432-1033.1994.00945.x; KREMER JD, 1993, J BACTERIOL, V175, P4824, DOI 10.1128/JB.175.15.4824-4833.1993; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClerc GM, 1996, J BIOL CHEM, V271, P18725, DOI 10.1074/jbc.271.31.18725; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; Sauer K, 1997, EUR J BIOCHEM, V243, P670, DOI 10.1111/j.1432-1033.1997.t01-1-00670.x; Sauer K, 1999, EUR J BIOCHEM, V261, P674, DOI 10.1046/j.1432-1327.1999.00355.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; Vannelli T, 1999, P NATL ACAD SCI USA, V96, P4615, DOI 10.1073/pnas.96.8.4615; Wassenaar RW, 1998, EUR J BIOCHEM, V253, P692, DOI 10.1046/j.1432-1327.1998.2530692.x; Wassenaar RW, 1996, J BACTERIOL, V178, P6937, DOI 10.1128/jb.178.23.6937-6944.1996; Wassenaar RW, 1998, EUR J BIOCHEM, V258, P597, DOI 10.1046/j.1432-1327.1998.2580597.x; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031	33	68	72	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29053	29060		10.1074/jbc.M910218199	http://dx.doi.org/10.1074/jbc.M910218199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852929	hybrid			2022-12-25	WOS:000089330700092
J	Hanada, T; Lin, LH; Tibaldi, EV; Reinherz, EL; Chishti, AH				Hanada, T; Lin, LH; Tibaldi, EV; Reinherz, EL; Chishti, AH			GAKIN, a novel kinesin-like protein associates with the human homologue of the Drosophila discs large tumor suppressor in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; SYNAPTIC BOUTON STRUCTURE; KINASE-LIKE DOMAIN; POSTSYNAPTIC DENSITY; GUANYLATE KINASES; PDZ DOMAINS; GENE DLG; CHROMOSOME SEGREGATION; ORGANELLE TRANSPORT; BINDING INTERFACE	Reorganization of the cortical cytoskeleton is a hallmark of T lymphocyte activation, Upon binding to antigen presenting cells, the T cells rapidly undergo cytoskeletal re-organization thus forming a cap at the cell-cell contact site leading to receptor clustering, protein segregation, and cellular polarization. Previously, we reported cloning of the human lymphocyte homologue of the Drosophila Discs Large tumor suppressor protein (hDlg), Here we show that a novel protein termed GAKIN binds to the guanylate kinase-like domain of hDlg, Affinity protein purification, peptide sequencing, and cloning of GAKIN cDNA from Jurkat J77 lymphocytes identified GAKIN as a novel member of the kinesin superfamily of motor proteins. GAKIN mRNA is ubiquitously expressed, and the predicted amino acid sequence shares significant sequence similarity with the Drosophila kinesin-73 motor protein. GAKIN sequence contains a motor domain at the NH, terminus, a central stalk domain, and a putative microtubule-interacting sequence called the CAP-Gly domain at the COOH terminus, Among the MAGUK superfamily of proteins examined, GAKIN binds to the guanylate kinase-like domain of PSD-95 but not of p55. The hDlg and GAKIN are localized mainly in the cytoplasm of resting T lymphocytes, however, upon CD2 receptor cross-linking the hDlg can translocate to the lymphocyte cap. We propose that the GAKIN-hDlg interaction lays the foundation for a general paradigm of coupling MAGUKs to the microtubule-based cytoskeleton, and that this interaction may be functionally important for the intracellular trafficking of MAGUKs and associated protein complexes in vivo.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Med, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Anat, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Cellular Biol, Boston, MA 02135 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chishti, AH (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Sect Hematol Oncol Res,Dept Med, CBR 404,736 Cambridge St, Boston, MA 02135 USA.	achishti@semc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adey NB, 2000, CANCER RES, V60, P35; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brenman JE, 1998, J NEUROSCI, V18, P8805; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Chishti A H, 1998, Curr Opin Hematol, V5, P116; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOONIN EV, 1992, NAT GENET, V2, P256, DOI 10.1038/ng1292-256; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li HP, 1997, P NATL ACAD SCI USA, V94, P1086, DOI 10.1073/pnas.94.4.1086; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Seiler S, 1997, EMBO J, V16, P3025, DOI 10.1093/emboj/16.11.3025; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	90	119	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28774	28784		10.1074/jbc.M000715200	http://dx.doi.org/10.1074/jbc.M000715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10859302	hybrid			2022-12-25	WOS:000089330700059
J	Li, GH; Lee, EM; Blair, D; Holding, C; Poronnik, P; Cook, DI; Barden, JA; Bennett, MR				Li, GH; Lee, EM; Blair, D; Holding, C; Poronnik, P; Cook, DI; Barden, JA; Bennett, MR			The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; SMOOTH-MUSCLE CELLS; RAT URINARY-BLADDER; GATED ION CHANNELS; NERVE VARICOSITIES; ATP; PURINOCEPTORS; ADENOVIRUSES; EXPRESSION; RELEASE	The distribution of P2X receptors on neurons in rat superior cervical ganglia and lability of P2X receptors on exposure to agonists were determined, Antibody labeling of each P2X subtype P2X(1)-P2X(7) showed neurons isolated into culture possessed primarily P2X, subunits with others occurring in order P2X(7) > P2X(6) > P2X(3) > P2X(1) > P2X(5) > P2X(4). Application of ATP and alpha,beta-meATP to neurons showed they possessed a predominantly nondesensitizing P2X receptor type insensitive to alpha,beta-meATP, consistent with immunohistochemical observations. P2X(1)-green fluorescent protein (GFP) was used to study the time course of P2X, receptor clustering in plasma membranes of neurons and internalization of receptors following prolonged exposure to ATP, At 12-24 h after adenoviral infection, P2X(1)-GFP formed clusters about 1 mu m diameter in the neuron membrane, Application of ATP and alpha,beta-meATP showed these neurons possessed a predominantly desensitizing P2X receptor type sensitive to alpha,beta-meATP. Infection converted the major functional P2X receptor type in the membrane to P2X,, Exposure of infected neurons to alpha,beta-meATP for less than 60 s led to the disappearance of P2X(1)-GFP fluorescence from the cell surface that was blocked by monensin, indicating the chimera is normally endocytosed into these organelles on exposure to agonist.	Univ Sydney, Biomed Res Inst, Dept Physiol, Neurobiol Lab, Sydney, NSW 2006, Australia; Univ Sydney, Biomed Res Inst, Dept Physiol, Exocrine Physiol & Biophys Labs, Sydney, NSW 2006, Australia; Univ Sydney, Biomed Res Inst, Dept Anat & Histol, Prot Struct Lab, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	Bennett, MR (corresponding author), Univ Sydney, Biomed Res Inst, Dept Physiol, Neurobiol Lab, Sydney, NSW 2006, Australia.	maxb@physiol.usyd.edu.au		Poronnik, Philip/0000-0002-6246-528X				Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barden JA, 1999, J NEUROCYTOL, V28, P469, DOI 10.1023/A:1007053004771; Boehm S, 1999, J NEUROSCI, V19, P737; BOEHM S, 1994, N-S ARCH PHARMACOL, V350, P454; Bueno OF, 1998, MOL BRAIN RES, V59, P165, DOI 10.1016/S0169-328X(98)00129-6; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHEMASCHI D, 1996, BIOCHIM BIOPHYS ACTA, V1280, P27; Collo G, 1996, J NEUROSCI, V16, P2495; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; Dutton JL, 1999, J NEUROCYTOL, V28, P3, DOI 10.1023/A:1007043132537; DUTTON JL, 2000, IN PRESS NEUROPHARMA, V39; Evans RJ, 1996, NEUROSCI LETT, V212, P212, DOI 10.1016/0304-3940(96)12804-4; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Hansen MA, 1998, J NEUROCYTOL, V27, P529, DOI 10.1023/A:1006908010642; Hansen MA, 1999, J AUTONOM NERV SYST, V75, P147, DOI 10.1016/S0165-1838(98)00189-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Poronnik P, 1998, CELL CALCIUM, V24, P97, DOI 10.1016/S0143-4160(98)90077-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Worthington RA, 1999, ELECTROPHORESIS, V20, P2065; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5	26	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29107	29112		10.1074/jbc.M910277199	http://dx.doi.org/10.1074/jbc.M910277199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10869366	hybrid			2022-12-25	WOS:000089330700099
J	Sidovar, MF; Kozlowski, P; Lee, JW; Collins, MA; He, YQ; Graves, LM				Sidovar, MF; Kozlowski, P; Lee, JW; Collins, MA; He, YQ; Graves, LM			Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATES MAP KINASE; NIH 3T3 CELLS; B-RAF; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; THREONINE KINASE; CYCLIC-AMP; PC12 CELLS; PATHWAY; CASCADE	The activity of the serine/threonine kinase c-Raf (Raf) is inhibited by increased intracellular cAMP. This is believed to require phosphorylation with the cAMP-dependent protein kinase (PKA), although the mechanism by which PRA inhibits Raf is controversial. We investigated the requirement for PKA phosphorylation using Raf mutants expressed in HEK293 or NIH 3T3 cells. Phosphopeptide mapping of P-32-labeled Raf (WT) or a mutant lacking a putative PKA phosphorylation site (serine to alanine, S43A) confirmed that serine 43 (Ser(43)) was the major cAMP (forskolin)-stimulated phosphorylation site in vivo. Interestingly, the EGF-stimulated Raf kinase activity of the S43A mutant was inhibited by forskolin equivalently to that of the WT Raf. Forskolin also inhibited the activation of an N-terminal deletion mutant Delta 5-50 Raf completely lacking this phosphorylation site. Although WT Raf was phosphorylated by PKA, phosphorylation did not inhibit Raf catalytic activity in vitro, nor did forskolin treatment inhibit the activity of an N-terminally truncated Raf protein (Raf 22W) or a full-length Raf protein (Raf-CAAX) expressed in NIH 3T3 cells. In contrast, forskolin inhibited the EGF-dependent activation of a Raf isoform (B-Raf), lacking an analogous phosphorylation site to Ser43. Thus, these results demonstrate that PKA exerts its inhibitory effects independently of direct Raf phosphorylation and suggests instead that PKA prevents an event required for the EGF-dependent activation of Raf.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.		Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012; Graves, Lee/AAG-5470-2021	Lee, Jung Weon/0000-0003-2722-8200; 	NIGMS NIH HHS [GM54010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; RAY LB, 1988, J BIOL CHEM, V263, P12721; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28688	28694		10.1074/jbc.M909351199	http://dx.doi.org/10.1074/jbc.M909351199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862777	Green Published, hybrid			2022-12-25	WOS:000089330700048
J	Ali, N; Pruijn, GJM; Kenan, DJ; Keene, JD; Siddiqui, A				Ali, N; Pruijn, GJM; Kenan, DJ; Keene, JD; Siddiqui, A			Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANS-ACTING FACTORS; 5' NONCODING REGION; MESSENGER-RNA; AUTOANTIGEN-LA; LEADER RNA; HEPATOCELLULAR-CARCINOMA; PROTEIN INTERACTIONS; 5'-NONCODING REGION; POLIOVIRUS RNA	The 5'-noncoding region (5'-NCR) of the hepatitis C virus (HCV) RNA genome serves as an internal ribosome entry site (IRES) and mediates translation initiation in a cap-independent manner. Previously, we reported the interaction between La antigen and the HCV IRES, which appeared to occur in the context of initiator AUG, It was further shown that HCV IRES-mediated translation was stimulated in the presence of human La antigen. In this study, we have defined the cis- and transacting elements responsible for La-5'-NCR interactions and established the dependence of the HCV IRES efficiency on cellular La antigen. During the La-IRES interaction, initiator AUG but not the neighboring codons was found to be the direct target of La binding. The C terminus effector domain-dependent modulation of La binding to the HCV IRES is demonstrated by deletion and substitution mutagenesis of the protein. An RNA systematic evolution of ligands by exponential enrichment (SELEX), generated against La protein that selectively binds La in HeLa lysates and competes for the protein binding to the 5'-NCR, was used to demonstrate the requirement of La for the HCV IRES function in the context of mono- and dicistronic mRNAs. Sequestration of La antigen by the RNA SELEX in HeLa translation lysates blocked the HCV and poliovirus IRES-mediated translation in vitro. The functional requirement of La protein for the HCV IRES activity was further established in a liver-derived cell line and in an add-back experiment in which the inhibited IRES was rescued by recombinant human La. These results strongly argue for the novel role of La protein during selection of the initiator AUG and its participation during internal initiation of translation of the HCV RNA genome.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Duke Univ, Med Ctr, Combinatorial Sci Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Radboud University Nijmegen; Duke University; Duke University	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA.	aleem.siddiqui@uchsc.edu	Pruijn, Ger/D-6664-2012	Ali, Naushad/0000-0002-0058-7396				ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; Barton DJ, 1996, METHOD ENZYMOL, V275, P35; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Collier AJ, 1998, J GEN VIROL, V79, P2359, DOI 10.1099/0022-1317-79-10-2359; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duncan RC, 1997, GENE, V201, P137, DOI 10.1016/S0378-1119(97)00438-1; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; Grolz D, 1997, J BIOL CHEM, V272, P12076, DOI 10.1074/jbc.272.18.12076; HARADA F, 1984, NUCLEIC ACIDS RES, V12, P9263, DOI 10.1093/nar/12.24.9263; Honda M, 1996, RNA, V2, P955; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Jackson RJ, 1995, RNA, V1, P985; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; KENAN DJ, 1995, THESIS DUKE U RALEIG; KURILLA MG, 1984, J VIROL, V50, P773, DOI 10.1128/JVI.50.3.773-778.1984; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; Morley SJ, 1997, RNA, V3, P1085; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; PRUIJN GJM, 1994, MANUAL BIOL MARKERS, P1; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wang C, 1995, CURR TOP MICROBIOL, V203, P99; WANG CY, 1994, J VIROL, V68, P7301, DOI 10.1128/JVI.68.11.7301-7307.1994; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; XIAO QR, 1994, NUCLEIC ACIDS RES, V22, P2512	56	140	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27531	27540						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10856291				2022-12-25	WOS:000089197100005
J	Haas, M; Askari, A; Xie, ZJ				Haas, M; Askari, A; Xie, ZJ			Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT CARDIAC MYOCYTES; SMOOTH-MUSCLE CELLS; C-SRC; TYROSINE KINASES; RESPONSE GENES; HYPERTROPHY; PATHWAYS; EXPRESSION; OUABAIN	Nontoxic concentrations of ouabain, causing partial inhibition of the cardiac myocyte Na+/K+-ATPase, induce hypertrophy and several growth-related genes through signal pathways that include the activation of Ras and p42/44 mitogen-activated protein kinase (MAPK). The aim of this work was to examine the ouabain-induced events upstream of the Ras/MAPK cascade. Treatment of myocytes with genistein antagonized ouabain-induced activation of the MAPK, suggesting that protein tyrosine phosphorylation has a role. Tyrosine phosphorylation of several myocyte proteins was increased rapidly upon cell exposure to ouabain, Lowering of extracellular K+ had a similar ouabain-like effect. Ouabain also increased protein tyrosine phosphorylation in A7r5, HeLa, and L929 cells. In cardiac myocytes and A7r5 cells, herbimycin A antagonized the ouabain-induced increase in protein tyrosine phosphorylation and MAPK activation. In both cell types, ouabain stimulated Src kinase activity, Src translocation to the Triton-insoluble fraction, Src association with the epidermal growth factor receptor, and the tyrosine phosphorylation of this receptor on site(s) other than its major autophosphorylation site, Tyr(1173). The findings suggest that (a) the ouabain-induced activation of Src and the Src-induced phosphorylation of the growth factor receptor provide the scaffolding for the recruitment of adaptor proteins and Ras and the activation of Ras/MAPK cascade; and (b) the activation of such pathways may be a common feature of the signal-transducing function of Na+/K+-ATPase in most cells.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-63238, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL063238] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARYSTARKHOVA E, 1994, SODIUM PUMP, P230; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Haas MS, 2000, BIOPHYS J, V78, p78A; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; MCCALL D, 1985, CIRC RES, V56, P370, DOI 10.1161/01.RES.56.3.370; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; RUSANESCU G, 1995, BIOPHYS J, V78, pA79; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TIRUPATTUR PR, 1993, AM J HYPERTENS, V6, P626, DOI 10.1093/ajh/6.7.626; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	34	287	301	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27832	27837						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874030				2022-12-25	WOS:000089197100043
J	Hossain, MA; Bouton, CML; Pevsner, J; Laterra, J				Hossain, MA; Bouton, CML; Pevsner, J; Laterra, J			Induction of vascular endothelial growth factor in human astrocytes by lead - Involvement of a protein kinase c/activator protein-1 complex-dependent and hypoxia-inducible factor 1-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; DNA-BINDING ACTIVITY; C-FOS; NERVOUS-SYSTEM; PC12 CELLS; INORGANIC LEAD; MESSENGER-RNA; RAT; GENE; JUN	The mechanism(s) underlying lead neurotoxicity are not fully elucidated. cDNA expression microarray analysis identified lead-sensitive genes in immortalized human fetal astrocytes (SV-FHA), Of the represented genes expressed, vascular endothelial growth factor (VEGF) was one of the most sensitive, Lead induced VEGF mRNA 3-fold and VEGF protein similar to 2-fold with maximum mRNA induction following incubation with 10 mu M lead acetate for 24 h. Phorbol 12-myristate 13-acetate (PMA), a potent protein kinase C (PKC) activator, increased VEGF mRNA 2-fold and PKC inhibition by GF-109203 completely blocked VEGF induction by lead. Expression of dominant-negative PKC-epsilon, but not PKC-alpha, completely inhibited VEGF mRNA induction by lead. Lead activated the transcription factor AP-1 and increased AP-1-dependent luciferase expression >2-fold. Transfection of cells with a c-jun dominant-negative effectively inhibited both AP-1 activation and VEGF mRNA induction by lead. Hypoxia-inducible factor 1 (HIF-1) activity in SV-FHAs was moderately increased by lead (86%) and PMA (96%). Pretreatment with GF-109203 completely inhibited these effects of lead and PMA. However, lead did not alter HIF-1-dependent luciferase expression and a HIF-1 alpha dominant-negative had no effects on the induction of VEGF mRNA by lead. These findings indicate that lead induces VEGF expression in SV-FHAs via a PKC/AP-1-dependent and HIF-1-independent signaling pathway.	Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Hossain, MA (corresponding author), Kennedy Krieger Res Inst, Dept Neurol, 707 N Broadway, Baltimore, MD 21205 USA.	hossain@kennedykrieger.org			NIEHS NIH HHS [P01 ES08131-02] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES008131] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 1992, TOX PROF LEAD, P105; AUDESIRK G, 1989, IN VITRO CELL DEV B, V25, P1121; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; BelloniOlivi L, 1996, BIOCHEM J, V315, P401, DOI 10.1042/bj3150401; BRADBURY MWB, 1984, FED PROC, V43, P186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressler J, 1999, NEUROCHEM RES, V24, P595, DOI 10.1023/A:1022596115897; BRESSLER JP, 1991, BIOCHEM PHARMACOL, V41, P479, DOI 10.1016/0006-2952(91)90617-E; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BROWN PH, 1994, ONCOGENE, V9, P791; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; Chakraborti T, 1999, J NEUROCHEM, V73, P187, DOI 10.1046/j.1471-4159.1999.0730187.x; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; CLASEN RA, 1974, AM J PATHOL, V74, P215; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEBHART AM, 1988, TOXICOL APPL PHARM, V94, P191, DOI 10.1016/0041-008X(88)90261-X; GOLDSTEIN GW, 1983, LIFE SCI, V33, P1001, DOI 10.1016/0024-3205(83)90757-9; GOLDSTEIN GW, 1974, ARCH NEUROL-CHICAGO, V31, P382, DOI 10.1001/archneur.1974.00490420048005; GOLDSTEIN GW, 1991, HUMAN LEAD EXPOSURE, P125; GOLDSTEIN GW, 1988, ANN NY ACAD SCI, V25, P31; HABERMANN E, 1983, ARCH TOXICOL, V54, P61, DOI 10.1007/BF00277816; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; HOLTZMAN D, 1987, TOXICOL APPL PHARM, V89, P211, DOI 10.1016/0041-008X(87)90042-1; Hossain MA, 1998, EUR J NEUROSCI, V10, P2490, DOI 10.1046/j.1460-9568.1998.00259.x; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAZANIETZ MG, 1996, CELLULAR MOL PATHOGE, P389; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Kim FA, 2000, J NEUROCHEM, V74, P1140; Kim K, 1997, INT J DEV NEUROSCI, V15, P175, DOI 10.1016/S0736-5748(96)00085-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATERRA J, 1992, P NATL ACAD SCI USA, V89, P10748, DOI 10.1073/pnas.89.22.10748; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; LONG GJ, 1994, J BIOL CHEM, V269, P834; LUBRAN MM, 1980, ANN CLIN LAB SCI, V10, P402; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nriagu JO, 1996, SCIENCE, V272, P223, DOI 10.1126/science.272.5259.223; PRESS MF, 1977, J NEUROPATH EXP NEUR, V36, P169, DOI 10.1097/00005072-197701000-00014; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ramesh GT, 1999, TOXICOL APPL PHARM, V155, P280, DOI 10.1006/taap.1999.8624; SAMBROOK J, 1996, MOL CLONING; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SINGH AK, 1993, NEUROTOXICOLOGY, V14, P417; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOMSIG JL, 1995, J NEUROCHEM, V64, P2667; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WHO, 1995, ENV HLTH CRIT, P165; Winneke G, 1996, ARCH TOX S, V18, P57; Ying Z, 1996, MOL BRAIN RES, V39, P109, DOI 10.1016/0169-328X(96)00015-0; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	60	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27874	27882						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882716				2022-12-25	WOS:000089197100049
J	Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Brown, EM; Hediger, MA				Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Brown, EM; Hediger, MA			A rat kidney-specific calcium transporter in the distal nephron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CATION CHANNEL; CA2+ CHANNELS; FACILITATED DIFFUSION; PARATHYROID-HORMONE; FEEDBACK INHIBITION; CAPSAICIN-RECEPTOR; CONVOLUTED TUBULE; ENTRY CHANNEL; ION-CHANNEL	Active absorption of calcium from the intestine and reabsorption of calcium from the kidney are major determinants of whole body calcium homeostasis. Two recently cloned proteins, CaT1 and ECaC, have been postulated to mediate apical calcium uptake by rat intestine and rabbit kidney, respectively. By screening a rat kidney cortex library with a CaT1 probe, we isolated a cDNA encoding a protein (CaT2) with 84.2 and 73.4% amino acid identities to ECaC and CaT1, respectively. Unlike ECaC, CaT2 is kidney-specific in the rat and was not detected in intestine, brain, adrenal gland, heart, skeletal muscle, liver, lung, spleen, thymus, and testis by Northern analysis or reverse transcription polymerase chain reaction. The expression pattern of CaT2 in kidney was similar to that of calbindin D-28K and the sodium calcium exchanger 1, NCX1, by in situ hybridization of adjacent sections. Furthermore, the mRNAs for CaT2 and calbindin D-28K were colocalized in the same cells. CaT2 mediated saturable calcium uptake with a Michaelis constant (K-m) of 0.66 mM when expressed in Xenopus laevis oocytes, Under voltage clamp condition, CaT2 promoted inward currents in X. laevis oocytes upon external application of Ca2+. Sr2+ and Ba2+ but not Mg2+ also evoked inward currents in CaT2-expressing oocytes. Similar to the alkaline earth metal ions, application of Cd2+ elicited inward current in CaT2-expressing oocytes with a K-m of 1.3 mM. Cd2+, however, also potently inhibited CaT2-mediated Ca2+ uptake with an IC50 of 5.4 mu M. Ca2+ evoked currents were reduced at low pH and increased at high pH and were only slightly affected by the L-type voltage-dependent calcium channel antagonists, nifedipine, verapamil, diltiazem, and the agonist, Bay a 8644, even at relatively high concentrations, In conclusion, CaT2 may participate in calcium entry into the cells of the distal convoluted tubule and connecting segment of the nephron, where active reabsorption of calcium takes place via the transcellular route. The high sensitivity of CaT2 to Cd2+ also provides a potential explanation for Cd2+-induced hypercalciuria and resultant renal stone formation.	Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hediger, MA (corresponding author), Harvard Inst Med, Room 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052005, R01DK041415, R01DK048330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48330, DK52005, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Berger UV, 1998, ANAT EMBRYOL, V198, P13, DOI 10.1007/s004290050161; BINDELS RJM, 1993, J EXP BIOL, V184, P89; BINDELS RJM, 1991, J AM SOC NEPHROL, V2, P1122; BIRGE SJ, 1987, CLIN DISORDERS MEMBR, P121; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BORKE JL, 1990, PFLUG ARCH EUR J PHY, V417, P120, DOI 10.1007/BF00370781; Bronner F., 1997, Handbook of nutritionally essential mineral elements., P13; BRONNER F, 1992, J NUTR, V122, P641, DOI 10.1093/jn/122.suppl_3.641; Bronner F, 1998, J NUTR, V128, P917, DOI 10.1093/jn/128.5.917; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CHRISTAKOS S, 1992, J NUTR, V122, P678, DOI 10.1093/jn/122.suppl_3.678; Colbert HA, 1997, J NEUROSCI, V17, P8259; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; EDWARDS NA, 1965, CLIN SCI, V29, P143; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; Fierro L, 1999, J MEMBRANE BIOL, V168, P9, DOI 10.1007/s002329900493; FRIEDMAN PA, 1994, TOXICOL APPL PHARM, V128, P257, DOI 10.1006/taap.1994.1205; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FULLMER CS, 1992, J NUTR, V122, P644, DOI 10.1093/jn/122.suppl_3.644; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; JARUP L, 1993, BRIT J IND MED, V50, P598; Johnson J A, 1994, Curr Opin Nephrol Hypertens, V3, P424, DOI 10.1097/00041552-199407000-00008; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KARBACH U, 1992, J NUTR, V122, P672, DOI 10.1093/jn/122.suppl_3.672; Kazantzis G, 1979, Contrib Nephrol, V16, P161; KUMAR R, 1995, J CELL BIOCHEM, V57, P392, DOI 10.1002/jcb.240570304; KUROKAWA K, 1994, KIDNEY INT, V45, pS97; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; LITZOW JR, 1967, J CLIN INVEST, V46, P280, DOI 10.1172/JCI105530; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC157, DOI 10.1152/ajpcell.1994.267.1.C157; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PONCET V, 1992, PFLUG ARCH EUR J PHY, V422, P112, DOI 10.1007/BF00370410; SCOTT R, 1978, Urology, V11, P462, DOI 10.1016/0090-4295(78)90157-7; SCOTT R, 1980, UROLOGY, V15, P356, DOI 10.1016/0090-4295(80)90469-0; STACY BD, 1970, J PHYSIOL-LONDON, V210, P549, DOI 10.1113/jphysiol.1970.sp009226; STEIN WD, 1992, J NUTR, V122, P651, DOI 10.1093/jn/122.suppl_3.651; SUKI WN, 1996, KIDNEY, P472; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; TAN S, 1993, J CLIN INVEST, V92, P2731, DOI 10.1172/JCI116890; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; VanBaal J, 1996, AM J PHYSIOL-RENAL, V271, pF985, DOI 10.1152/ajprenal.1996.271.5.F985; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; WASSERMAN RH, 1995, J NUTR, V125, pS1971, DOI 10.1093/jn/125.suppl_7.1971S; WASSERMAN RH, 1992, J NUTR, V122, P662, DOI 10.1093/jn/122.suppl_3.662; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494; YU ASL, 1995, AM J PHYSIOL-RENAL, V268, pF525, DOI 10.1152/ajprenal.1995.268.3.F525; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	71	118	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28186	28194						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875938				2022-12-25	WOS:000089197100087
J	Price, B; Dennison, C; Tschesche, H; Elliott, E				Price, B; Dennison, C; Tschesche, H; Elliott, E			Neutrophil tissue inhibitor of matrix metalloproteinases-1 occurs in novel vesicles that do not fuse with the phagosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-BONE-MARROW; RHEUMATOID SYNOVIAL-FLUID; GRANULE CONSTITUENTS; CYTOPLASMIC GRANULES; BIOLOGICAL FUNCTIONS; POLYACRYLAMIDE GELS; ELECTRON-MICROSCOPY; SECRETORY VESICLES; AZUROPHIL GRANULES	The human neutrophil granule location of precursors of matrix metalloproteinases (MMPs), MMP-8 and -9, has been established, but that of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) has not. In this study, labeling for TIMP-1, pro-MMP-8, pro-MMP-9, and established granule marker proteins reveals that TIMP-1 is mainly located in distinct oval, electron translucent organelles, a little larger than azurophil granules. A lack of labeling for the fluid phase endocytic marker, bovine serum albumin-gold, the lysosome-associated membrane protein markers, and for glycosylphosphatidylinositol-linked proteins, which are enriched in secretory vesicles, indicates the nonendosomal, non-lysosomal, and non-secretory nature of this organelle. Density gradient cofractionation with the least dense, secretory population and some pleomorphism of the organelle suggest it is a "vesicle" rather than a "granule" population. Colocalization with pro-MMP-9 or pro-MMP-8, in minor subpopulations, suggests that TIMP-1 vesicle biogenesis occurs between metamyelocytic and terminal differentiation and before secretory vesicle synthesis. Pulse-chased IgG-coated latex beads and immunolabeling show that specific and azurophil granules fuse with the phagosome whereas TIMP-1 and pro-MMP-9-containing organelles do not. This suggests that these play no role in phagosomal destruction of IgG-opsonized bacteria. Separate localization and colocalization of these proteins may, however, facilitate fine regulation of extracellular proteolysis.	Univ KwaZulu Natal, Dept Biochem, Sch Mol & Cellular Biosci, ZA-3209 Pietermaritzburg, South Africa; Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany	University of Kwazulu Natal; University of Bielefeld	Elliott, E (corresponding author), Univ KwaZulu Natal, Dept Biochem, Sch Mol & Cellular Biosci, Private Bag X01, ZA-3209 Pietermaritzburg, South Africa.	elliott@unpsunl.cc.unp.ac.za		Price, Brendon/0000-0001-8894-6666				Absolom D R, 1986, Methods Enzymol, V132, P95; Andrews P C, 1986, Methods Enzymol, V132, P369; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; BAINTON DF, 1973, J CELL BIOL, V58, P249, DOI 10.1083/jcb.58.2.249; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BAKOWSKI B, 1992, BIOL CHEM H-S, V373, P529; BENTWOOD BJ, 1980, J IMMUNOL, V124, P855; BERGER M, 1994, J CLIN INVEST, V94, P1113, DOI 10.1172/JCI117426; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOLLAG DM, 1991, PROTEIN METHODS, P173; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1995, BLOOD, V85, P812, DOI 10.1182/blood.V85.3.812.bloodjournal853812; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BRETONGORIUS J, 1980, AM J PATHOL, V99, P413; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CAWSTON TE, 1986, BIOCHEM J, V238, P677, DOI 10.1042/bj2380677; CAWSTON TE, 1986, PROTEINASES INFLAMMA, P189; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; CRAMER E, 1985, BLOOD, V65, P423; DAVIS GE, 1991, ARCH BIOCHEM BIOPHYS, V286, P551, DOI 10.1016/0003-9861(91)90078-W; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; Dennison C, 1997, PROTEIN EXPRES PURIF, V11, P149, DOI 10.1006/prep.1997.0779; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DROUIN L, 1988, J PERIODONTAL RES, V23, P370, DOI 10.1111/j.1600-0765.1988.tb01615.x; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; EGESTEN A, 1994, BLOOD, V83, P2985, DOI 10.1182/blood.V83.10.2985.2985; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; ISHIBASHI H, 1988, METHOD ENZYMOL, V163, P485; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; JOST CR, 1990, BLOOD, V75, P144; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1993, BLOOD, V82, P3183; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; LeCabec V, 1996, P NATL ACAD SCI USA, V93, P6454, DOI 10.1073/pnas.93.13.6454; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; Mackarel AJ, 1999, AM J RESP CELL MOL, V20, P1209; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; MATSUDAIRA P, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P1; MERCER E, 1985, BIOCHEM J, V231, P505, DOI 10.1042/bj2310505; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MURPHY G, 1980, BIOCHEM J, V192, P517, DOI 10.1042/bj1920517; NITSCH M, 1990, BIOL CHEM H-S, V371, P611, DOI 10.1515/bchm3.1990.371.2.611; ODA T, 1995, MEDIAT INFLAMM, V4, P133, DOI 10.1155/S0962935195000238; Oda T, 1992, Mediators Inflamm, V1, P403, DOI 10.1155/S0962935192000619; OREN A, 1995, J LAB CLIN MED, V125, P340; OSTHUES A, 1992, FEBS LETT, V296, P16, DOI 10.1016/0014-5793(92)80393-U; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; POLSON A, 1964, BIOCHIM BIOPHYS ACTA, V82, P463, DOI 10.1016/0304-4165(64)90438-6; POLSON A, 1985, IMMUNOL INVEST, V14, P323, DOI 10.3109/08820138509022667; PRYZWANSKY KB, 1985, LAB INVEST, V53, P664; RICE WG, 1987, BLOOD, V70, P757; ROBERTS IM, 1975, J MICROSC-OXFORD, V103, P113, DOI 10.1111/j.1365-2818.1975.tb04542.x; Roos D, 1986, Methods Enzymol, V132, P225; ROTHWELL SW, 1989, J CELL BIOL, V108, P2313, DOI 10.1083/jcb.108.6.2313; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; SEGAL AW, 1980, J CELL BIOL, V85, P42, DOI 10.1083/jcb.85.1.42; SENGELOV H, 1995, J IMMUNOL, V154, P4157; Sengelov H, 1996, EUR J HAEMATOL, V57, P6; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Steadman R, 1997, INT J BIOCHEM CELL B, V29, P993, DOI 10.1016/S1357-2725(97)00038-1; Stricklin G P, 1992, Matrix Suppl, V1, P325; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEBEL S, 1995, EUR J BIOCHEM, V231, P714, DOI 10.1111/j.1432-1033.1995.tb20752.x; Uesugi M, 1998, J IMMUNOL, V161, P1422; Weibel E.R., 1979, STEREOLOGICAL METHOD, VI, P1; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zhao WQ, 1998, J CELL SCI, V111, P1147; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	89	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28308	28315						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869345				2022-12-25	WOS:000089197100103
J	Ippoliti, R; Lendaro, E; Benedetti, PA; Torrisi, MR; Belleudi, F; Carpani, D; Soria, MR; Fabbrini, MS				Ippoliti, R; Lendaro, E; Benedetti, PA; Torrisi, MR; Belleudi, F; Carpani, D; Soria, MR; Fabbrini, MS			Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism	FASEB JOURNAL			English	Article						plasminogen activator; ribsome-inactivating proteins; receptors; ligand-passing; cancer	RIBOSOME-INACTIVATING PROTEINS; RECEPTOR-RELATED-PROTEIN; PLASMINOGEN-ACTIVATOR; CELL-SURFACE; SIGNAL-TRANSDUCTION; INHIBITOR COMPLEX; SERPIN COMPLEXES; TRANSPORT; SYSTEM; CANCER	A fluorescent derivative of a chimeric toxin between human pro-urokinase and the plant ribosome-inactivating protein saporin (p-uPA-Sap(TRITC)), has been prepared in order to study the endocytosis of this potentially antimetastatic conjugate in the murine model cell line LB6 clone19 (Cl19) transfected with the human urokinase receptor gene. The physiological internalization of urokinase-inhibitor complexes is triggered by the interaction of plasminogen inhibitors (PAIs) with receptors belonging to the low density lipoprotein-related receptor protein (LRP) family, and involves a macro-quaternary structure including uPAR, LRP, and PAIs. However, in contrast to this mechanism, we observed a two-step process: first, the urokinase receptor (uPAR) acts as the anchoring factor on the plasma membrane; subsequently, LRP acts as the endocytic trigger. Once the chimera is bound to the plasma membrane by interaction with uPAR, we suggest that a possible exchange may occur to transfer the toxin to LRP via the saporin moiety and begin the internalization. So an unusual endocytic process is described, where the toxin enters the cell via a receptor different from that used to bind the plasma membrane.	Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; CNR, Inst Biophys, I-56100 Pisa, Italy; Univ Rome La Sapienza, Dept Expt Med & Pathol, Rome, Italy; San Raffaele Sci Inst, DIBIT, Dept Biol & Technol Res, I-20132 Milan, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Sapienza University Rome; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ippoliti, R (corresponding author), Univ Rome La Sapienza, Dept Biochem Sci, P Aldo Moro 5, I-00185 Rome, Italy.			IPPOLITI, RODOLFO/0000-0003-0652-3470				ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BLASI F, 1998, BIOCHIM BIOPHYS ACTA, V1423, pR35; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; CONESE M, 1995, BIOL CHEM H-S, V376, P143; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DEVRIES TJ, 1995, J PATHOL, V175, P59, DOI 10.1002/path.1711750110; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; Fabbrini MS, 2000, FASEB J, V14, P391, DOI 10.1096/fasebj.14.2.391; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; IPPOLITI R, 1995, FASEB J, V9, P1220, DOI 10.1096/fasebj.9.12.7672515; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Lord JM, 1998, J CELL BIOL, V140, P733; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Reiter Y, 1998, TRENDS BIOTECHNOL, V16, P513, DOI 10.1016/S0167-7799(98)01226-8; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	39	36	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1335	1344		10.1096/fj.14.10.1335	http://dx.doi.org/10.1096/fj.14.10.1335			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877826				2022-12-25	WOS:000087932200008
J	Gomez-Angelats, M; Bortner, CD; Cidlowski, JA				Gomez-Angelats, M; Bortner, CD; Cidlowski, JA			Protein kinase C (PKC) inhibits Fas receptor-induced apoptosis through modulation of the loss of K+ and cell shrinkage - A role for PKC upstream of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBELLAR GRANULE CELLS; JURKAT T-CELLS; MEDIATED APOPTOSIS; DNA FRAGMENTATION; PROTEOLYTIC ACTIVATION; INTRACELLULAR SIGNALS; SELECTIVE-INHIBITION; IMMUNE-SYSTEM; ICE-LIKE	Cell shrinkage and loss of intracellular K+ are early requisite features for the activation of effector caspases and apoptotic nucleases in Fas receptor-mediated apoptosis of Jurkat cells, although the mechanisms responsible for both process remain unclear (Bortner, C. D., Hughes, F. M., Jr., and Cidlowski, J. A. (1997) J. Biol Chem, 272, 32436-32442), We have now investigated the role of protein kinase C (PKC)-dependent signaling in the regulation of Fas-induced cell shrinkage and loss of KC during apoptosis, Anti-Fas induced cell shrinkage was blocked during PKC stimulation by the phorbol ester 12-O-tetradecanoylphorbol-3-acetate (PMA) and by bryostatin-1. Conversely, inhibition of PKC with Go6976, enhanced the anti-Fas-mediated loss of cell volume. Analyses of mitochondrial membrane potential and DNA fragmentation revealed that the PKC-mediated effect observed in cell volume is propagated to these late features of apoptosis, Flow cytometric analyses and Rb-86 efflux experiments revealed that a primary effect of PKC appears to be on the modulation of Fas-induced K+ efflux, since both PMA and bryostatin-1 inhibited extrusion of K+ that occurs during Fas-mediated cell death, and Go6976 exacerbated the effect of anti-Fas. Interestingly, high extracellular K+ significantly blocked the effect of anti-Fas alone or anti-Fas combined with Go6976, suggesting an underlying effect of PKC on K+ loss. Western blot analyses showed the caspase-dependent proteolysis of PKC isotypes delta, epsilon, and theta in whole cell extracts from anti-Fas treated Jurkat T cells. However, stimulation of PKC by PMA or bryostatin-1 prevented this isotypic-specific PKC cleavage during apoptosis, providing further evidence that PKC itself exerts an upstream signal in apoptosis and controls the caspase-dependent proteolytic degradation of PKC isotypes, Finally, we show that PMA or bryostatin-1 prevents the activation of caspase-3 and caspase-8, Thus, this study shows that the protective effect that PRC stimulation exerts in the Fas-mediated apoptotic pathway occurs at a site upstream of caspases-3 and -8.	NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAIER G, 1993, J BIOL CHEM, V268, P4997; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang JY, 1997, NEUROCHEM RES, V22, P43, DOI 10.1023/A:1027373220133; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chevaile A, 1998, CONTRIB NEPHROL, V123, P110, DOI 10.1159/000059924; Chung I, 1997, J MEMBRANE BIOL, V156, P73, DOI 10.1007/s002329900189; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; IMBODEN JB, 1988, IMMUNOL TODAY, V9, P17, DOI 10.1016/0167-5699(88)91350-3; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kawiak J, 1989, Postepy Biochem, V35, P265; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moustakas A, 1998, CONTRIB NEPHROL, V123, P121, DOI 10.1159/000059925; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAYET MD, 1992, J BIOL CHEM, V267, P18270; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Suda T, 1997, J ALLERGY CLIN IMMUN, V100, pS97, DOI 10.1016/S0091-6749(97)70013-7; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	91	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19609	19619		10.1074/jbc.M909563199	http://dx.doi.org/10.1074/jbc.M909563199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867019	hybrid			2022-12-25	WOS:000087941300025
J	Ishijima, J; Nakai, T; Kawaguchi, S; Hirotsu, K; Kuramitsu, S				Ishijima, J; Nakai, T; Kawaguchi, S; Hirotsu, K; Kuramitsu, S			Free energy requirement for domain movement of an enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES; ESCHERICHIA-COLI; ACTIVE-SITE; TYROSINE AMINOTRANSFERASE; CONFORMATIONAL-CHANGES; SUBSTRATE RECOGNITION; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; SPECIFICITY	Domain movement is sometimes essential for substrate recognition by an enzyme. X-ray crystallography of aminotransferase with a series of aliphatic substrates showed that the domain movement of aspartate aminotransferase was changed dramatically from an open to a closed form by the addition of only one CH2 to the side chain of the C4 substrate CH3(CH2)C(alpha)H(NH3+)COO-. These crystallographic results and reaction kinetics (Kawaguchi, S., Nobe, Y., Yasuoka, J., Wakamiya, T., Kusumoto, S., and Kuramitsu, S. (1997) J. Biochem. (Tokyo) 122, 55-63; Kawaguchi, S, and Kuramitsu, S, (1998) J. Biol. Chem. 273, 18353-18364) enabled us to estimate the free energy required for the domain movement.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Osaka City Univ, Grad Sch Sci, Dept Chem, Sumiyoshi Ku, Osaka 5588585, Japan; RIKEN, Genom Sci Ctr, Wako, Saitama 3510198, Japan	Osaka University; Osaka Metropolitan University; RIKEN	Kuramitsu, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, 1-1 Machikaneyama Cho, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp	Nakai, Tadashi/F-8047-2010	Nakai, Tadashi/0000-0001-9770-8168				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BIRCHMEIER W, 1973, J BIOL CHEM, V248, P1751; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CHRISTEN P, 1985, TRANSAMINASE; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KARPLUS M, 1983, ANNU REV BIOCHEM, V52, P263, DOI 10.1146/annurev.bi.52.070183.001403; Kasper P, 1996, EUR J BIOCHEM, V240, P751, DOI 10.1111/j.1432-1033.1996.0751h.x; Kawaguchi S, 1998, J BIOL CHEM, V273, P18353, DOI 10.1074/jbc.273.29.18353; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; Ko TP, 1999, ACTA CRYSTALLOGR D, V55, P1474, DOI 10.1107/S0907444999006630; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; Okamoto A, 1999, BIOCHEMISTRY-US, V38, P1176, DOI 10.1021/bi981921d; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; PFISTER K, 1985, J BIOL CHEM, V260, P1414; Pugmire WJ, 1998, J MOL BIOL, V281, P285, DOI 10.1006/jmbi.1998.1941; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; RYU K, 1992, BIOCHEMISTRY-US, V31, P2588, DOI 10.1021/bi00124a020; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; Takezawa Y, 1999, BIOPHYS J, V76, P1770, DOI 10.1016/S0006-3495(99)77338-8; WANGIKAR PP, 1995, BIOCHEMISTRY-US, V34, P12302, DOI 10.1021/bi00038a026; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	39	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18939	18945		10.1074/jbc.275.25.18939	http://dx.doi.org/10.1074/jbc.275.25.18939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858450	hybrid			2022-12-25	WOS:000087815900045
J	Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P				Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P			Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1	ONCOGENE			English	Article						proteasome; cDNA microarray; gene expression; ATF3; GADD153; MAD1	PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; UBIQUITIN/PROTEASOME PATHWAY; DNA MICROARRAY; CANCER-CELLS; PROTEIN; STRESS; APOPTOSIS; GROWTH; MYC	The ubiquitin/proteasome pathway has been implicated in a wide variety of cellular processes and the number of substrates degraded by the proteasome is impressive. Most prominently, the stability of a large number of transcription factors is regulated by ubiquitination. To elucidate pathways regulated by the proteasome, gene expression profiles were generated, comparing changes of mRNA expression of 7900 genes from the UniGene collection upon exposure of cells to the proteasome inhibitors Lactacystin, Lactacystin-beta-lactone or MG132 by means of microarray based cDNA hybridization, The three profiles were very similar, but differed significantly from a gene expression profile generated with the histone deacetylase inhibitor Trapoxin A, indicating that the observed alterations were indeed due to proteasome inhibition, Two of the most prominently induced genes encoded the growth arrest and DNA damage inducible protein Gadd153 and the activating transcription factor ATF3, both transcription factors of the CCAAT/enhancer binding protein (C/EBP) family. ii third gene encoded for the transcriptional repressor and c-Myc antagonist Mad1. Our results suggest that proteasome inhibition leads to upregulation of specific members of transcription factor families controlling cellular stress response and proliferation.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis	Furst, P (corresponding author), Novartis Pharma AG, Oncol Res, WKL-125-13-14, CH-4002 Basel, Switzerland.							Adams J, 1999, CANCER RES, V59, P2615; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAI JPF, 1995, J PHARM PHARMACOL, V47, P674, DOI 10.1111/j.2042-7158.1995.tb05858.x; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bush KT, 1997, J BIOL CHEM, V272, P9086; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen CH, 1996, ONCOGENE, V13, P1659; Drexler HCA, 1998, APOPTOSIS, V3, P1, DOI 10.1023/A:1009604900979; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Goodbourn S, 1997, BIOCHEM SOC T, V25, P498, DOI 10.1042/bst0250498; Han S, 1999, ONCOL REP, V6, P569; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; ICHIHARA A, 1995, MOL BIOL REP, V21, P49, DOI 10.1007/BF00990970; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Machiels BM, 1997, CYTOMETRY, V28, P243; MASUMOTO M, 1996, FEBS LETT, V395, P143; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; *PE APPL BIOS, US B ABI PRISM 7700, V2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang X, 1998, J IMMUNOL, V160, P788; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wolfe B, 1997, ISSUES SCI TECHNOL, V13, P17; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2913	2920		10.1038/sj.onc.1203606	http://dx.doi.org/10.1038/sj.onc.1203606			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871842				2022-12-25	WOS:000087544500005
J	Liu, C; Yang, ZY; Yang, J; Xia, ZX; Ao, SH				Liu, C; Yang, ZY; Yang, J; Xia, ZX; Ao, SH			Regulation of the yeast transcriptional factor PHO2 activity by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ACID-PHOSPHATASE; CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENE; PHO80-PHO85; EXPRESSION; ACTIVATION; SYSTEM; INTERACT	The induction of yeast Saccharomyces cerevisiae gene PHO5 expression is mediated by transcriptional factors PHO2 and PHO4. PHO4 protein has been reported to be phosphorylated and inactivated by a cyclin-CDK (cyclin-dependent kinase) complex, PH080-PH085. We report here that PHO2 can also be phosphorylated. A Ser-230 to Ala mutation in the consensus sequence (SPIK) recognized by cdc2/CDC28-related kinase in PHO2 protein led to complete loss of its ability to activate the transcription of PHO5 gene. Further investigation showed that the Pro-231 to Ser mutation inactivated PHO2 protein as well, whereas the Ser-230 to Asp mutation did not affect PHO2 activity. Since the PHO2 Asp-230 mutant mimics Ser-230-phosphorylated PHO2, we postulate that only phosphorylated PHO2 protein could activate the transcription of PHO5 gene. Two hybrid assays showed that yeast CDC28 could interact with PHO2. CDC28 immunoprecipitate derived from the YPH499 strain grown under low phosphate conditions phosphorylated GST-PHO2 in vitro. A phosphate switch regulates the transcriptional activation activity of PHO2, and mutations of the (SPIK) site affect the transcriptional activation activity of PHO2 and the interaction between PHO2 and PHO4. BIAcore(R) analysis indicated that the negative charge in residue 230 of PHO2 was sufficient to help PHO2 interact with PHO4 in vitro.	Chinese Acad Sci, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Ao, SH (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	aosz@sunm.shcnc.ac.cn						ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; BURKHOLDER PR, 1943, AM J BOT, V29, P459; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GILLIQUET V, 1993, FEMS MICROBIOL LETT, V108, P333, DOI 10.1016/0378-1097(93)90564-I; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; MATSUMOTO K, 1984, GENETICS, V108, P53; MEASDAY V, 1994, SCIENCE, V266, P1392; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; OSHIMA Y, 1981, MOL BIOL YEAST SACCH, P159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SENGSTAG C, 1988, GENE, V67, P223, DOI 10.1016/0378-1119(88)90399-X; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Shao DL, 1996, MOL GEN GENET, V251, P358, DOI 10.1007/BF02172527; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wu JS, 1996, ACTA BIOCH BIOPH SIN, V28, P507; YANG J, 1995, ACTA BIOCH BIOPH SIN, V27, P165; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31972	31978		10.1074/jbc.M003055200	http://dx.doi.org/10.1074/jbc.M003055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10884387	hybrid			2022-12-25	WOS:000089858900059
J	de Kreij, A; Venema, G; van den Burg, B				de Kreij, A; Venema, G; van den Burg, B			Substrate specificity in the highly heterogeneous M4 peptidase family is determined by a small subset of amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOLYSIN-LIKE PROTEASES; BACILLUS NEUTRAL PROTEASES; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; THERMAL-STABILITY; ACTIVE-SITE; SEQUENCE; GENE; SUBTILIS; CEREUS	The members of the M4 peptidase family are involved in processes as diverse as pathogenicity and industrial applications. For the first time a number of M4 family members, also known as thermolysin-like proteases, has been characterized with an identical substrate set and a uniform set of assay conditions. Characterization with peptide substrates as well as high performance liquid chromatography analysis of p-casein digests shows that the M4 family is a homogeneous family in terms of catalysis, even though there is a significant degree of amino acid sequence variation. The results of this study show that differences in substrate specificity within the M4 family do not correlate with overall sequence differences but depend on a small number of identifiable amino acids. Indeed, molecular modeling followed by site-directed mutagenesis of one of the substrate binding pocket residues of the thermolysin-like proteases of Bacillus stearothermophilus converted the catalytic characteristics of this variant into that of thermolysin.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotecchnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Venema, G (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotecchnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							Banbula A, 1998, STRUCTURE, V6, P1185, DOI 10.1016/S0969-2126(98)00118-X; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY; Dhanaraj V, 1996, Drug Des Discov, V13, P3; DOMANN E, 1991, INFECT IMMUN, V59, P65, DOI 10.1128/IAI.59.1.65-72.1991; EIJSINK VGH, 1995, NAT STRUCT BIOL, V2, P374, DOI 10.1038/nsb0595-374; EIJSINK VGH, 1992, PROTEINS, V14, P224, DOI 10.1002/prot.340140209; FEDER J, 1971, BIOCHIM BIOPHYS ACTA, V251, P74, DOI 10.1016/0005-2795(71)90061-4; FEDER J, 1970, BIOCHEMISTRY-US, V9, P2784, DOI 10.1021/bi00816a005; FEDER J, 1968, BIOCHEMISTRY-US, V6, P2088; FUJII M, 1983, J BACTERIOL, V154, P831, DOI 10.1128/JB.154.2.831-837.1983; Gaucher JF, 1999, BIOCHEMISTRY-US, V38, P12569, DOI 10.1021/bi991043z; HARDY F, 1994, PROTEIN ENG, V7, P425, DOI 10.1093/protein/7.3.425; HAUSRATH AC, 1994, J BIOL CHEM, V269, P18839; HOLMES MA, 1983, BIOCHEMISTRY-US, V22, P236, DOI 10.1021/bi00270a034; HOLT C, 1988, PROTEIN ENG, V2, P251, DOI 10.1093/protein/2.4.251; HUNTER A, 1945, J BIOL CHEM, V157, P427; Jin YH, 1998, BIOORG MED CHEM LETT, V8, P3515, DOI 10.1016/S0960-894X(98)00643-X; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KUBO M, 1988, J GEN MICROBIOL, V134, P1883; Kunugi S, 1996, EUR J BIOCHEM, V241, P368, DOI 10.1111/j.1432-1033.1996.00368.x; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MARIECLAIRE C, 1997, BIOCHEMISTRY-US, V36, P13984; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MORIHARA K, 1970, EUR J BIOCHEM, V15, P374, DOI 10.1111/j.1432-1033.1970.tb01018.x; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; Sabat A, 2000, INFECT IMMUN, V68, P973, DOI 10.1128/IAI.68.2.973-976.2000; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STARK W, 1902, EUR J BIOCHEM, V984, P1; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TRAN L, 1991, J BACTERIOL, V173, P6364, DOI 10.1128/jb.173.20.6364-6372.1991; Van den Burg B, 1999, BIOTECHNOL APPL BIOC, V30, P35; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; VANAALTEN DMF, 1995, PROTEINS, V22, P45, DOI 10.1002/prot.340220107; VANDENBURG B, 1989, J BIOCHEM BIOPH METH, V18, P209, DOI 10.1016/0165-022X(89)90005-5; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; Veltman OR, 1997, EUR J BIOCHEM, V248, P433, DOI 10.1111/j.1432-1033.1997.00433.x; Veltman OR, 1997, FEBS LETT, V405, P241, DOI 10.1016/S0014-5793(97)00193-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; Vriend G, 1998, J BIOL CHEM, V273, P35074, DOI 10.1074/jbc.273.52.35074; WEAVER LH, 1977, J MOL BIOL, V114, P119, DOI 10.1016/0022-2836(77)90286-8; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x	47	38	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31115	31120		10.1074/jbc.M003889200	http://dx.doi.org/10.1074/jbc.M003889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10869357	hybrid			2022-12-25	WOS:000089762700053
J	Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ				Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ			Rb-independent induction of apoptosis by bovine papillomavirus type 1 E7 in response to tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; OPEN READING FRAME; CYTOSOLIC PHOSPHOLIPASE A(2); EARLY REGION TRANSFORMATION; CELL-CYCLE; ADENOVIRUS E1A; HPV-16 E7; HUMAN KERATINOCYTES; ARACHIDONIC-ACID; GROWTH ARREST	Bovine papillomavirus type 1 (BPV-1) is a small DNA virus that causes fibropapillomas of the host. BPV-1 has served as the prototype for studies of the molecular biology of the papillomaviruses. BPV-1 efficiently induces anchorage-independent growth and focus formation in murine C127 cells, The transforming properties of BPV-1 primarily reside in two genes, E5 and E6. Each of these genes is sufficient to transform cells. Although no independent transformation activity has been detected for E7, it was shown to be required for full transformation of C127 by BPV-1. We investigated the biological activities of BPV-1 E7 in several assays. Our results indicate that expression of BPV-1 E7 sensitizes cells to tumor necrosis factor alpha (TNF)-induced apoptosis. The TNF-induced apoptosis in E7-expressing cells was accompanied by increased release of arachidonic acid, indicating that phospholipase A(2) was activated. Unlike the E7 proteins from the cancer-related human papillomaviruses, the BPV-1 E7 protein does not associate efficiently with the retinoblastoma protein (pRB) in vitro, nor does it significantly affect the pRB levels in cultured cells. Furthermore, BPV-1 E7 sensitizes Rb-null cells to TNF-induced apoptosis. These studies indicate that BPV-1 E7 can sensitize cells to apoptosis through mechanisms that are independent of pRB.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Chen, JJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St,Box 166, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R01 CA73558] Funding Source: Medline; PHS HHS [F32] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BANKS L, 1990, ONCOGENE, V5, P833; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BERG LJ, 1986, MOL CELL BIOL, V6, P859, DOI 10.1128/MCB.6.3.859; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferlini C, 1996, CELL PROLIFERAT, V29, P427, DOI 10.1111/j.1365-2184.1996.tb00985.x; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; JAREBORG N, 1992, J VIROL, V66, P4957, DOI 10.1128/JVI.66.8.4957-4965.1992; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; LASTER SM, 1988, J IMMUNOL, V141, P2629; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Munger K, 1997, HUMAN PAPILLOMAVIRUS, P17; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SATO H, 1989, VIROLOGY, V168, P196; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	90	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30894	30900		10.1074/jbc.M000640200	http://dx.doi.org/10.1074/jbc.M000640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887172	hybrid			2022-12-25	WOS:000089762700025
J	Li, B; Fuh, G; Meng, G; Xin, XH; Gerritsen, ME; Cunningham, B; de Vos, AM				Li, B; Fuh, G; Meng, G; Xin, XH; Gerritsen, ME; Cunningham, B; de Vos, AM			Receptor-selective variants of human vascular endothelial growth factor - Generation and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; KINASE DOMAIN RECEPTOR; HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; FLT-1 RECEPTOR; ANGSTROM RESOLUTION; KDR/FLK-1 RECEPTOR; TYROSINE KINASE; FACTOR VEGF; ORF VIRUS	Vascular endothelial growth factor (VEGF) is a pleiotropic factor that exerts a multitude of biological effects through its interaction with two receptor tyrosine kinases, fms-like tyrosine kinase (Flt-1) or VEGF receptor 1 and kinase insert domain-containing receptor (KDR) or VEGF receptor 2. Whereas it is commonly accepted that KDR is responsible for the proliferative activities of VEGF, considerable controversy and uncertainty exist about the role of the individual receptors in eliciting many of the other effects. Based on a comprehensive mutational analysis of the receptor-binding site of VEGF, an Flt-1-selective variant was created containing four substitutions from the wild-type protein. This variant bound with wild-type affinity to Flt-1, was at least 470-fold reduced in binding to KDR, and had no activity in cell-based assays measuring autophosphorylation of KDR or proliferation of primary human vascular endothelial cells. Using a competitive phage display strategy, two KDR-selective variants were discovered with three and four changes from wild-type, respectively. Both variants had approximately wild-type affinity for KDR, were about 2000-fold reduced in binding to Flt-1, and showed activity comparable with the wild-type protein in KDR autophosphorylation and endothelial cell proliferation assays. These variants will serve as useful reagents in elucidating the roles of Flt-1 and KDR.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Vos, AM (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	devos@gene.com						Bauters C, 1997, CLIN CARDIOL, V20, P52; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29823	29828		10.1074/jbc.M002015200	http://dx.doi.org/10.1074/jbc.M002015200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10878003	hybrid			2022-12-25	WOS:000089439800088
J	Porat, A; Elazar, Z				Porat, A; Elazar, Z			Regulation of intra-Golgi membrane transport by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; FUSION; RELEASE; BUFFERS; COMPARTMENTS; CHANNEL; CALNUC; STEP	Calcium cations play a critical role in regulating vesicular transport between different intracellular membrane-bound compartments. The role of calcium in transport between the Golgi cisternae, however, remains unclear. Using a well characterized cell-free intra-Golgi transport assay, we now show that changes in free Ca2+ concentration in the physiological range regulate this transport process. The calcium-chelating agent 1,2-bis(2-aminophenoxy)ethane-N,N,N,N'-tetraacetic acid blocked transport with an IC50 of approximately 0.8 mM. The effect of 1,2-bis(2- aminophenoxy)ethane-N,N,N',N'-tetraacetic acid was reversible by addition of fresh cytosol and was irreversible when performed in the presence of a Ca2+ ionophore that depletes calcium from lumenal stores, We demonstrate here that intra-Golgi transport is stimulated by low Ca2+ concentrations (20-100 nM) but is inhibited by higher concentrations (above 100 nM). Further, we show that calmodulin antagonists specifically block intra-Golgi transport, implying a role for calmodulin in mediating the effect of calcium. Our results suggest that Ca2+ efflux from intracellular pools may play an essential role in regulating intra-Golgi transport.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; LLINAS R, 1995, NEUROPHARMACOLOGY, V34, P1443, DOI 10.1016/0028-3908(95)00150-5; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P14457, DOI 10.1074/jbc.275.19.14457; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; SCHELLER RH, 1995, NEURON, V14, P893; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Wang SSH, 1995, BIOPHYS J, V69, P1683, DOI 10.1016/S0006-3495(95)80086-X	33	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29233	29237		10.1074/jbc.M005316200	http://dx.doi.org/10.1074/jbc.M005316200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871627	hybrid			2022-12-25	WOS:000089439800009
J	Blanchard, F; Duplomb, L; Wang, YP; Robledo, O; Kinzie, E; Pitard, V; Godard, A; Jacques, Y; Baumann, H				Blanchard, F; Duplomb, L; Wang, YP; Robledo, O; Kinzie, E; Pitard, V; Godard, A; Jacques, Y; Baumann, H			Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-II RECEPTOR; MOUSE ONCOSTATIN-M; PHASE PLASMA-PROTEINS; DI-LEUCINE MOTIF; GROWTH-FACTOR; HEPATIC CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; DOWN-REGULATION	Leukemia inhibitory factor (LIF) signals via the heterodimeric receptor complex comprising the LIF receptor alpha subunit (LIFR alpha) and the common signal transducing subunit for interleukin-6 cytokine receptors, gp130. This study demonstrates that in different cell types, the level of LIFR alpha decreases during treatment with LIF or the closely related cytokine oncostatin M (OSM). Moreover, insulin and epidermal growth factor induce a similar LIFR alpha down-regulation. The regulated loss of LIFR alpha is specific since neither gp130 nor OSM receptor beta shows a comparable change in turnover. LIFR alpha downregulation correlates with reduced cell responsiveness to LIF. Using protein kinase inhibitors and point mutations in LIFR alpha, we demonstrate that LIFR alpha downregulation depends on activation of extracellular signal-regulated kinase 1/2 and phosphorylation of the cytoplasmic domain of LIFR alpha at serine 185. This modification. appears to promote the endosomal/lysosomal pathway of the LIFR alpha. These results suggest that extracellular signal-regulated kinase-activating factors like OSM and growth factors have the potential to lower specifically LIF responsiveness in vivo by regulating LIFR alpha half-life.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Inst Biol, INSERM U463, F-44035 Nantes 01, France; Univ Bordeaux 2, CNRS UMR 5540, F-33076 Bordeaux, France	Roswell Park Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Blanchard, F (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	frederic.blanchard@roswellpark.org	Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NCI NIH HHS [CA16056, CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; BOWER J, 1995, J CELL PHYSIOL, V164, P93, DOI 10.1002/jcp.1041640112; BROWN MA, 1994, CYTOKINE, V6, P300, DOI 10.1016/1043-4666(94)90027-2; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLOWES GHA, 1988, TRAUMA SEPSIS SHOCK, P1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; FRAYN KN, 1976, BRIT J EXP PATHOL, V57, P316; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAEMURA JR, 1993, LYMPHOKINE CYTOK RES, V12, P187; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; Richards CD, 1997, J IMMUNOL, V159, P2431; Sasaoka T, 1999, ENDOCRINOLOGY, V140, P3826, DOI 10.1210/en.140.8.3826; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Strous GJ, 1999, J CELL SCI, V112, P1417; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; WANG Y, 2000, IN PRESS J BIOL CHEM, V275; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318	53	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28793	28801		10.1074/jbc.M003986200	http://dx.doi.org/10.1074/jbc.M003986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10858440	hybrid			2022-12-25	WOS:000089330700061
J	Lopez-Rovira, T; Chalaux, E; Rosa, JL; Bartrons, R; Ventura, F				Lopez-Rovira, T; Chalaux, E; Rosa, JL; Bartrons, R; Ventura, F			Interaction and functional cooperation of NF-kappa B with Smads - Transcriptional regulation of the junB promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; TGF-BETA; SIGNAL-TRANSDUCTION; DNA-BINDING; TUMOR-SUPPRESSOR; GENE; ACTIVATION; IDENTIFICATION; ELEMENTS	The transforming growth factor-beta (TGF-beta) family of cytokines regulates diverse cellular processes through control of the expression of target genes. Smad proteins are a recently identified family of signal transducers for members of the TGF-beta family. Smads act as transcriptional regulators through binding to DNA and interacting with a variety of transcription factors. Here, we identified a ICE Site as a TGF-beta-responsive region in the 3'-downstream junB promoter region. We also demonstrate that kappa B sites alone are sufficient to mediate immediate transcriptional activation by TGF-beta. Transactivation of kappa B Sites by TGF-beta requires an intact NF-kappa B pathway, cooperates with known activators of this pathway, and is mediated by Smad family members. Furthermore, we show that Smads interacts with p52 in vivo. These data expand the model in which Smad proteins undergo multiple interactions with several transcription factors that could induce either activation or repression of gene expression.	Univ Barcelona, Dept Ciencies Fisiol 2, E-08907 Lhospitalet De Llobregat, Spain	University of Barcelona	Ventura, F (corresponding author), Univ Barcelona, Unitat Bioquim, Campus Bellvitge,Feixa Llarga S-N, E-08907 Lhospitalet De Llobregat, Spain.	fventura@bellvitge.bvg.ub.es	Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Bartrons, Ramon/0000-0001-9349-5847				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	55	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28937	28946		10.1074/jbc.M909923199	http://dx.doi.org/10.1074/jbc.M909923199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874048	Green Published, hybrid			2022-12-25	WOS:000089330700079
J	Ramakers, GMJ; Heinen, K; Gispen, WH; de Graan, PNE				Ramakers, GMJ; Heinen, K; Gispen, WH; de Graan, PNE			Long term depression in the CA1 field is associated with a transient decrease in pre- and postsynaptic PKC substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALMODULIN-BINDING DOMAIN; ADULT-RAT BRAIN; B-50 GAP-43; AREA CA1; SYNAPTIC TRANSMISSION; NERVOUS-SYSTEM; MULTIPLE FORMS; VISUAL-CORTEX; POTENTIATION	Induction of homosynaptic long term depression (LTD) in the CA1 field of the hippocampus is thought to require activation of N-methyl-D-aspartate receptors, an elevation of postsynaptic Ca2+ levels, and a subsequent increase in phosphatase activity. To investigate the spatial and temporal changes in protein phosphatase activity following LTD induction, we determined the in situ phosphorylation state of a pre- (GAP-43/B-50) and postsynaptic (RC3) protein kinase C substrate during N-methyl-D-aspartate receptor-dependent LTD in the CA1 field of rat hippocampal slices. We show that LTD is associated with a transient (<30 min) and D-APS-sensitive reduction in GAP-43/B-50 and RC3 phosphorylation and that LTD is prevented by the phosphatase inhibitors okadaic acid and cyclosporin A. Our data provide strong evidence for a transient increase in pre- and postsynaptic phosphatase activity during LTD. Since the in situ phosphorylation of the calmodulin-binding proteins GAP-43/B-50 and RC3 changes during both LTD and long term potentiation, these proteins may form part of the link between the Ca2+ signal and Ca2+/calmodulin-dependent processes implicated in long term potentiation and LTD.	Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Ramakers, GMJ (corresponding author), Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	g.m.j.ramakers@med.uu.nl		Ramakers, Geert/0000-0001-7499-6996				Arancio O, 1996, J PHYSIOLOGY-PARIS, V90, P321, DOI 10.1016/S0928-4257(97)87907-7; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BAUDIER J, 1991, J BIOL CHEM, V266, P229; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPAGNE MV, 1990, J NEUROCYTOL, V19, P948, DOI 10.1007/BF01186822; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DANIELSON PE, 1994, GENOMICS, V19, P454, DOI 10.1006/geno.1994.1094; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; Gage AT, 1997, HIPPOCAMPUS, V7, P286; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; Hansel C, 1997, EUR J NEUROSCI, V9, P2309, DOI 10.1111/j.1460-9568.1997.tb01648.x; Hens JJH, 1996, J NEUROCHEM, V66, P1933; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Hjelmstad GO, 1997, NEURON, V19, P1309, DOI 10.1016/S0896-6273(00)80421-3; Hrabetova S, 1996, J NEUROSCI, V16, P5324; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; INIGUEZ MA, 1992, J CLIN INVEST, V90, P554, DOI 10.1172/JCI115894; Kamal A, 1999, EUR J NEUROSCI, V11, P3512, DOI 10.1046/j.1460-9568.1999.00769.x; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; McNamara RK, 1997, J COMP NEUROL, V379, P48; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Oliet SHR, 1996, SCIENCE, V271, P1294, DOI 10.1126/science.271.5253.1294; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Ramakers GMJ, 1999, J NEUROCHEM, V73, P2175; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; Reyes M, 1996, J NEUROSCI, V16, P5951; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SEKI K, 1995, ARCH BIOCHEM BIOPHYS, V316, P673, DOI 10.1006/abbi.1995.1090; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.0.CO;2-6; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; Wu J, 1997, NEUROSCIENCE, V78, P393, DOI 10.1016/S0306-4522(97)84911-1; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	58	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28682	28687		10.1074/jbc.M003068200	http://dx.doi.org/10.1074/jbc.M003068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867003	hybrid			2022-12-25	WOS:000089330700047
J	Elberg, G; Gimble, JM; Tsai, SY				Elberg, G; Gimble, JM; Tsai, SY			Modulation of the murine peroxisome proliferator-activated receptor gamma 2 promoter activity by CCAAT/enhancer-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; NF-KAPPA-B; C/EBP-BETA; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; P21(WAF1/CIP1) GENE; ECTOPIC EXPRESSION; DNA-BINDING	Peroxisome proliferator-activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding proteins (C/EBPs) are transcriptional regulators essential for adipocyte differentiation and function. Previous findings indicate that PPAR gamma 2 transcription is regulated by members of the C/EBP family. We demonstrate here that C/EBP alpha and C/EBP delta, but not C/EBP beta, induce the activity of the PPAR gamma 2 promoter in transiently transfected 3T3-L1 preadipocytes and bind to two juxtaposed low affinity C/EBP binding sites. Results obtained with chimeras containing interchanged C/EBP alpha-C/EBP beta N-terminal transactivation domain and C-terminal DNA binding dimerization domain indicate that the N-terminal part of C/EBP beta prevents it from binding to the PPAR gamma 2 promoter. Indeed, deletion mutants of C/EBP beta lacking the N-terminal part of the molecule are able to bind to the PPAR gamma 2 promoter. We further demonstrate that deletion of a region located between amino acids 184-212, upstream of the DNA binding domain, permits C/EBP beta binding to the PPAR gamma 2 promoter, implicating an inhibitory region in C/EBP beta for modulating DNA binding specificity to the PPAR gamma 2 promoter. In summary, this study indicates that C/EBP beta but not C/EBP alpha or C/EBP delta is unable to bind to C/EBP binding sites in the mouse PPAR gamma 2 promoter. The lack of binding is due to a region N-terminal of the C/EBP beta DNA binding domain. Our findings illustrate a mechanism by which C/EBP isoforms differentially modulate the transactivation of the PPAR gamma 2 promoter.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73190 USA	Baylor College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA050898, R01CA050898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055636, R01DK044988] Funding Source: NIH RePORTER; NCI NIH HHS [CA50898] Funding Source: Medline; NIDDK NIH HHS [DK44988, DK55636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Catron KM, 1998, CELL GROWTH DIFFER, V9, P949; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gimble JM, 1998, BIOCHEM BIOPH RES CO, V253, P813, DOI 10.1006/bbrc.1998.9858; GRUNDY SM, 1990, DM-DIS MON, V36, P641; Hansen AJ, 1998, MOL PHARMACOL, V53, P1027; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Krishnan V, 1997, MOL ENDOCRINOL, V11, P1458, DOI 10.1210/me.11.10.1458; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; POLL V, 1990, CELL, V63, P643; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128	43	91	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27815	27822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862621				2022-12-25	WOS:000089197100041
J	Ghirlando, R; Trainor, CD				Ghirlando, R; Trainor, CD			GATA-1 bends DNA in a site-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID TRANSCRIPTION FACTOR; BINDING DOMAIN; FINGER; PROMOTER; COMPLEX; ZINC; EXPRESSION; PROTEINS; CGATA-1; FAMILY	The DNA binding domain of GATA-1 consists of two adjacent homologous zinc fingers, of which only the C-terminal finger binds DNA independently. Solution structure studies have shown that the DNA is bent by about 15 degrees in the complex formed with the single C-terminal finger of GATA-1, The N-terminal finger stabilizes DNA binding at some sites. To determine whether it contributes to DNA bending, we have performed circular permutation DNA bending experiments with a variety of DNA-binding sites recognized by GATA-1, By using a series of full-length GATA-1, double zinc finger, and single C-terminal finger constructs, we show that GATA-1 bends DNA by about 24 degrees, irrespective of the DNA-binding site. We propose that the N- and C-terminal fingers of GATA-1 adopt different orientations when bound to different cognate DNA sites. Furthermore, we characterize circular permutation bending artifacts arising from the reduced gel mobility of the protein-DNA complexes.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ghirlando, R (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Ghirlando, Rodolfo/A-8880-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036121] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; Hagerman PJ, 1996, P NATL ACAD SCI USA, V93, P9993, DOI 10.1073/pnas.93.19.9993; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SHARROCKS AD, 1995, NUCLEIC ACIDS RES, V23, P2442, DOI 10.1093/nar/23.13.2442; SHULEMOVICH K, 1995, NUCLEIC ACIDS RES, V23, P811, DOI 10.1093/nar/23.5.811; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZWEIB C, 1994, METHOD MOL BIOL, V30, P281	26	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28152	28156						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862761				2022-12-25	WOS:000089197100082
J	Robyr, D; Gegonne, A; Wolffe, AP; Wahli, W				Robyr, D; Gegonne, A; Wolffe, AP; Wahli, W			Determinants of vitellogenin B1 promoter architecture - HNF3 and estrogen responsive transcription within chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; XENOPUS-LAEVIS; CRYSTAL-STRUCTURE; IN-VIVO; HISTONE ACETYLTRANSFERASE; INDEPENDENT ACTIVATION; INVITRO TRANSCRIPTION; GLOBULAR DOMAIN; DISTAL PROMOTER; LINKER HISTONES	The liver-specific vitellogenin B1 promoter is efficiently activated by estrogen within a nucleosomal environment after microinjection into Xenopus laevis oocytes, consistent with the hypothesis that significant nucleosome remodeling over this promoter is not a prerequisite for the activation by the estrogen receptor (ER alpha). This observation lead us to investigate determinants other than ER alpha of chromatin structure and transcriptional activation of the vitellogenin B1 promoter in this system and in vitro. We find that the liver-enriched transcription factor HNF3 has an important organizational role for chromatin structure as demonstrated by DNase I-hypersensitive site mapping. Both HNF3 and the estrogen receptor activate transcription synergistically and are able to interact with chromatin reconstituted in vitro with three positioned nucleosomes. We propose that HNF3 is the cellular determinant which establishes a promoter environment favorable to a rapid transcriptional activation by the estrogen receptor.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	University of Lausanne; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, Batiment Biol, CH-1015 Lausanne, Switzerland.		Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Wahli, Walter/0000-0002-5966-9089				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BATES AD, 1993, FOCUS; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; BURCH JBE, 1986, MOL CELL BIOL, V6, P1886, DOI 10.1128/MCB.6.6.1886; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG TC, 1990, J BIOL CHEM, V265, P8176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORTHESY B, 1990, MOL CELL BIOL, V10, P3926, DOI 10.1128/MCB.10.8.3926; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; FORTUNE JE, 1983, DEV BIOL, V99, P502, DOI 10.1016/0012-1606(83)90299-3; GERBERHUBER S, 1981, NUCLEIC ACIDS RES, V9, P2475, DOI 10.1093/nar/9.11.2475; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marilley D, 1998, MOL CELL ENDOCRINOL, V141, P79, DOI 10.1016/S0303-7207(98)00090-2; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MCKENZIE EA, 1990, MOL CELL BIOL, V10, P6674, DOI 10.1128/MCB.10.12.6674; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; TATA JR, 1979, RECENT PROG HORMONE, V35, P95; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tsai-Pflugfelder M, 1998, MOL ENDOCRINOL, V12, P1525, DOI 10.1210/me.12.10.1525; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; WAHLI W, 1979, CELL, V16, P535, DOI 10.1016/0092-8674(79)90028-X; Wahli W, 1985, Oxf Surv Eukaryot Genes, V2, P96; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; WATSON CS, 1991, J STEROID BIOCHEM, V38, P423, DOI 10.1016/0960-0760(91)90330-8; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WILLIAMS JL, 1983, NUCLEIC ACIDS RES, V11, P1151, DOI 10.1093/nar/11.4.1151; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zaret K, 1998, CURR OPIN GENET DEV, V8, P526, DOI 10.1016/S0959-437X(98)80006-3; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	69	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28291	28300						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10854430				2022-12-25	WOS:000089197100101
J	Vacratsis, PO; Gallo, KA				Vacratsis, PO; Gallo, KA			Zipper-mediated oligomerization of the mixed lineage kinase SPRK/MLK-3 is not required for its activation by the GTPase cdc 42 but is necessary for its activation of the JNK Pathway - Monomeric SPRK L410P does not catalyze the activating phosphorylation of Thr(258) of murine mitogen-activated protein kinase kinase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; COILED-COIL; MOLECULAR-CLONING; HUMAN BRAIN; MAP KINASE; C-JUN; DOMAIN; RESIDUES; BINDING; PROLINE	Src homology 3 domain-containing proline-rich kinase (SPRK)/mixed lineage kinase-3 is a serine/threonine kinase that has been identified as an upstream activator of the c-Jun NH2-terminal kinase (JNK) pathway. SPRK is capable of activating MKK4 by phosphorylation of serine and threonine residues, and mutant forms of MKK4 that lack the phosphorylation sites Ser(254) and Thr(258) block SPRK-induced JNK activation. A region of 63 amino acids following the kinase domain of SPRK is predicted to form a leucine zipper. The leucine zipper domain of SPRK has been shown to be necessary and sufficient for SPRK oligomerization, but its role in regulating activation of SPRK and downstream signaling remains unclear. In this study, we substituted a proposed stabilizing leucine residue in the zipper domain with a helix-disrupting proline to abrogate zipper-mediated SPRK oligomerization. We demonstrate that constitutively activated Cdc42 fully activates this monomeric SPRK mutant in terms of both autophosphorylation and histone phosphorylation activity and induces the same in vivo phosphorylation pattern as wild type SPRK. However, this catalytically active SPRK zipper mutant is unable to activate JNK. Our data show that the monomeric SPRK mutant fails to phosphorylate one of the two activating phosphorylation sites, Thr(258), of MKK4. These studies suggest that zipper-mediated SPRK oligomerization is not required for SPRK activation by Cdc42 but instead is critical for proper interaction and phosphorylation of a downstream target, MKK4.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 108 Giltner Hall, E Lansing, MI 48824 USA.				NATIONAL CANCER INSTITUTE [R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA76306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLONDEL A, 1991, PROTEIN ENG, V4, P457, DOI 10.1093/protein/4.4.457; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Butch ER, 1996, J BIOL CHEM, V271, P4230; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hirai S, 1996, ONCOGENE, V12, P641; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KATOH M, 1995, ONCOGENE, V10, P1447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	46	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27893	27900						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862766				2022-12-25	WOS:000089197100051
J	Abu-Amer, Y; Erdmann, J; Alexopoulou, L; Kollias, G; Ross, FP; Teitelbaum, SL				Abu-Amer, Y; Erdmann, J; Alexopoulou, L; Kollias, G; Ross, FP; Teitelbaum, SL			Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ESTROGEN DEFICIENCY; STROMAL CELLS; TNF RECEPTOR; MICE LACKING; BONE LOSS; ALPHA; MACROPHAGES; APOPTOSIS; PROTEIN	The potent osteoclastogenic agent, tumor necrosis factor-alpha (TNF), exerts its biological effects via two receptors, namely TNF receptors 1 (p55r) and 2 (p75r), each present on osteoclast precursors. Thus, we asked if p55r and p75r differentially impact the osteoclastogenic process. Marrow derived from mice expressing only p55r generates substantially more osteoclasts, in the basal state, than does wild type, while marrow expressing only p75r, produces substantially fewer. Reflecting its preferential activation of pb5r, exogenous TNF stimulates osteoclast formation by p55r(+/+)p75r(-/-), but not p65r(-/-)p76r(+/+), marrow. Consistent with the fact that NF-kappa B is essential for osteoclastogenesis, this transcription complex is activated, relative to wild type, in p55r(+/+)p75r(-/-) osteoclast precursors and suppressed in those expressing only p75r. Because p55r enhances, and p75r suppresses, osteoclastogenesis, we asked if their principal ligands, namely soluble and membrane-residing TNF, respectively, differrentially impact basal osteoclast recruitment. We find, in contrast to the significant level of osteoclast formation in wild type marrow, osteoclastogenesis by that derived from mice expressing membrane, but not soluble, TNF, is negligible. Thus, optimal therapeutic inhibition of bone resorption may entail selective TNF receptor modulation and/or arrested cleavage of membrane TNF to its soluble form.	Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Hellenic Pasteur Inst, Dept Mol Genet, Athens 11521, Greece	Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Jewish Hosp Plaza,11300 W Pavil,Campus B, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu	Kollias, George/A-7079-2012; Alexopoulou, Lena/A-5041-2017	Kollias, George/0000-0003-1867-3150; Alexopoulou, Lena/0000-0003-4619-697X; Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413, DE13754] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; ABUAMER Y, 1998, BONE, V23, pS190; Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; BJORNBERG F, 1994, LYMPHOKINE CYTOK RES, V13, P203; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Douni E, 1996, J INFLAMM, V47, P27; DROUET C, 1991, J IMMUNOL, V147, P1694; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Horie T, 1999, EXP HEMATOL, V27, P512, DOI 10.1016/S0301-472X(98)00058-7; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Kassem Moustapha, 1996, P691; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Pacifici R, 1996, J BONE MINER RES, V11, P1043; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260	32	161	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27307	27310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874036				2022-12-25	WOS:000089144800085
J	Barbosa-Tessmann, IP; Chen, C; Zhong, C; Siu, F; Schuster, SM; Nick, HS; Kilberg, MS				Barbosa-Tessmann, IP; Chen, C; Zhong, C; Siu, F; Schuster, SM; Nick, HS; Kilberg, MS			Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; LIGATION-MEDIATED PCR; TRANSCRIPTIONAL REGULATION; EXPRESSION; CELLS; CHOP; IDENTIFICATION; DEPRIVATION; INDUCTION; BINDING	The human asparagine synthetase (AS) gene is transcriptionally regulated by amino acid deprivation (amino acid response, AAR) and the endoplasmic reticulum stress response (ERSR), also known as the unfolded protein response pathway. The results reported here document the novel observation that induction of the AS gene by the AAR and ERSR pathways occurs via the same set of genomic elements. Data supporting this conclusion include transient transfection of AS promoter/reporter gene constructs that illustrate that the transcriptional control elements used by both pathways are contained with nucleotides -111 to -34 of the AS pro meter. In vivo footprinting analysis of this region identified six specific protein-binding sites. Within two of these sites, altered footprinting was observed following amino acid or glucose deprivation, but the patterns were identical for both the AAR and the ERSR pathway. Site-directed mutation of individual nucleotides within these two binding sites confirmed their importance for regulated transcription, and none of the mutations resulted in loss of response of only one pathway, Neither of these two sites corresponds to a recently identified ERSR cis-element, nor do they contain consensus sequences for known transcription factors, Collectively, the data document that there are at least two independent transcriptional mechanisms for gene activation by the ERSR pathway, one of which terminates at the same genomic elements used by the AAR pathway.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.		Barbosa-Tessmann, Ione Parra/H-3856-2012	Barbosa-Tessmann, Ione Parra/0000-0001-9860-378X	NIDDK NIH HHS [DK-51064] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; Heal R, 1998, BIOCHEM J, V329, P389, DOI 10.1042/bj3290389; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERRIGAN LA, 1994, CURRENT PROTOCOLS MO; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1981, P NATL ACAD SCI-BIOL, V78, P4922, DOI 10.1073/pnas.78.8.4922; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZHANG YP, 1989, GENOMICS, V4, P259, DOI 10.1016/0888-7543(89)90329-7; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	43	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26976	26985						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856289				2022-12-25	WOS:000089144800042
J	Yan, SD; Zhu, YC; Stern, ED; Hwang, YYC; Hori, O; Ogawa, S; Frosch, MP; Connolly, ES; McTaggert, R; Pinsky, DJ; Clarke, S; Stern, DM; Ramasamy, R				Yan, SD; Zhu, YC; Stern, ED; Hwang, YYC; Hori, O; Ogawa, S; Frosch, MP; Connolly, ES; McTaggert, R; Pinsky, DJ; Clarke, S; Stern, DM; Ramasamy, R			Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL-ARTERY OCCLUSION; COENZYME-A DEHYDROGENASE; CULTURED RAT ASTROCYTES; C-13 NMR-SPECTROSCOPY; ALZHEIMERS-DISEASE; BOVINE LIVER; END-PRODUCTS; PROTEIN; HEART; BRAIN	Amyloid beta-peptide-binding alcohol dehydrogenase (ABAD) is a member of the family of short chain dehydrogenase/reductases whose distinctive properties include the capacity to bind amyloid beta-peptide and enzymatic activity toward a broad array of substrates including n-isopropanol and beta-estradiol, In view of the wide substrate specificity of ABAD and its high activity on L-beta-hydroxyacyl-CoA derivatives, we asked whether it might also catalyze the oxidation of the ketone body D-3-hydroxybutyrate. This was indeed the case, and oxidation proceeded with K-m of similar to 4.5 mM and V-max of similar to 4 nmol/min/mg protein. When placed in medium with D-beta-hydroxybutyrate as the principal energy substrate, COS cells stably transfected to overexpress wild-type ABAD (COS/wtABAD) better maintained 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, cellular energy charge, and morphologic phenotype compared with COS/vector cells. Using a severe model of metabolic perturbation, transgenic mice with targeted neuronal expression of ABAD subjected to transient middle cerebral artery occlusion showed strokes of smaller volume and lower neurologic deficit scores in parallel with increased brain ATP and decreased lactate, compared with nontransgenic controls. These data suggest that ABAD contributes to the protective response to metabolic stress, especially in the setting of ischemia.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg & Med, New York, NY 10032 USA; Kanazawa Med Univ, Dept Neuroanat, Kanazawa, Ishikawa, Japan; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Columbia University; Columbia University; Columbia University; Columbia University; Kanazawa Medical University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles	Yan, SD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St,P&S 17-401, New York, NY 10032 USA.	sdy1@columbia.edu	Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861; Ramasamy, Ravichandran/0000-0002-3666-3346	NATIONAL INSTITUTE ON AGING [R01AG016736, R01AG014103] Funding Source: NIH RePORTER; NIA NIH HHS [AG16736, AG14103, AG00690] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; BOCK HG, 1975, J BIOL CHEM, V250, P5774; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Du YS, 1997, J NEUROCHEM, V69, P1382; Evertsen F, 1999, ACTA PHYSIOL SCAND, V167, P247; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FREDERIKS WM, 1995, J PATHOL, V175, P339, DOI 10.1002/path.1711750312; Furuta S, 1997, BBA-GENE STRUCT EXPR, V1350, P317, DOI 10.1016/S0167-4781(96)00171-6; GOLDGABER D, 1993, ANN NY ACAD SCI, V695, P139, DOI 10.1111/j.1749-6632.1993.tb23042.x; HARDY J, 1997, TRENDS NEUROSCI, V296, P28570; He XY, 1999, J BIOL CHEM, V274, P15014, DOI 10.1074/jbc.274.21.15014; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; Imuta N, 1998, J NEUROCHEM, V70, P550; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; Jones JG, 1997, ANAL BIOCHEM, V249, P201, DOI 10.1006/abio.1997.2172; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kang DE, 1999, J NEUROSCI, V19, P4229; King LM, 1998, MOL CELL BIOCHEM, V180, P3, DOI 10.1023/A:1006870419309; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LAMPRECHT W, 1995, METHOD ENZYMATIC ANA; LEHNINGER AL, 1960, J BIOL CHEM, V235, P2450; LEVITSKY LL, 1977, PEDIATR RES, V11, P298, DOI 10.1203/00006450-197704000-00008; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MARK R, 1996, MOL NEUROBIOL, V12, P915; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MCCANN WP, 1957, J BIOL CHEM, V226, P15; MCINTYRE JO, 1988, ARCH BIOCHEM BIOPHYS, V262, P85, DOI 10.1016/0003-9861(88)90171-3; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PETERSSON B, 1972, ACTA PAEDIATR SCAND, V61, P273; Roses AD, 1998, ANN NY ACAD SCI, V855, P738, DOI 10.1111/j.1749-6632.1998.tb10653.x; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Segel IH, 1975, ENZYME KINETICS BEHA; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELLEVOLD OFM, 1986, J MOL CELL CARDIOL, V18, P517, DOI 10.1016/S0022-2828(86)80917-8; SONNEWALD U, 1993, DEV NEUROSCI-BASEL, V15, P351, DOI 10.1159/000111355; St George-Hyslop PH, 1998, NEUROBIOL AGING, V19, P133, DOI 10.1016/S0197-4580(98)00020-7; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; UEDA H, 1988, J BIOCHEM, V104, P81, DOI 10.1093/oxfordjournals.jbchem.a122427; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Yan SD, 1997, NATURE, V389, P689; YAN SD, 1998, J BIOL CHEM, V274, P2145	61	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27100	27109						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869339				2022-12-25	WOS:000089144800059
J	Chen, L; Trujillo, K; Sung, P; Tomkinson, AE				Chen, L; Trujillo, K; Sung, P; Tomkinson, AE			Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; XRCC4 PROTEIN; GENE-PRODUCT; I GENE; KU; IDENTIFICATION	The DNA-dependent protein kinase (DNA-PK), consisting of Ku and the DNA-PK catalytic subunit (DNA-PKcs), and the DNA ligase IV-XRCC4 complex function together in the repair of DNA double-strand breaks by non-homologous end joining. These protein complexes are also required for the completion of V(D)J recombination events in immune cells, Here we demonstrate that the DNA ligase IV-XRCC4 complex binds specifically to the ends of duplex DNA molecules and can act as a bridging factor, linking together duplex DNA molecules with complementary but non-ligatable ends. Although the DNA end-binding protein Ku inhibited DNA joining by DNA ligase IV-XRCC4, it did not prevent this complex from binding to DNA, Instead, DNA ligase TVXRCC4 and Ku bound simultaneously to the ends of duplex DNA molecules. DNA ligase TV-XRCC4 and DNA-PKcs also formed complexes at the ends of DNA molecules, but DNA-PKcs did not inhibit ligation, Interestingly, DNA-PKcs stimulated intermolecular ligation by DNA ligase TV-XRCC4, In the presence of DNA-PK, the majority of the joining events catalyzed by DNA ligase IV-XRCC4 were intermolecular because Ku inhibited intramolecular ligation, but DNA-PKcs still stimulated intramolecular ligation, We suggest that DNA-PKcs-containing complexes formed at DNA ends enhance the association of DNA ends via protein-protein interactions, thereby stimulating intermolecular ligation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047251, R01GM047251] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM47251] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; GOTTESMA.ME, 1966, J BIOL CHEM, V241, P4339; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SODERHALL S, 1973, BIOCHEM BIOPH RES CO, V53, P910, DOI 10.1016/0006-291X(73)90178-2; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEBSTER ADB, 1992, LANCET, V339, P1508, DOI 10.1016/0140-6736(92)91266-B; WEI YF, 1995, MOL CELL BIOL, V15, P3206; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034	45	174	182	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26196	26205		10.1074/jbc.M000491200	http://dx.doi.org/10.1074/jbc.M000491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10854421	hybrid			2022-12-25	WOS:000088999700044
J	Hayne, C; Tzivion, G; Luo, ZJ				Hayne, C; Tzivion, G; Luo, ZJ			Raf-1/MEK/MAPK pathway is necessary for the G(2)/M transition induced by nocodazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SPINDLE ASSEMBLY CHECKPOINT; XENOPUS EGG EXTRACTS; CELL-CYCLE; MAP KINASE; M-PHASE; RAF-1 ACTIVATION; 3T3 CELLS; RAS; PHOSPHORYLATION	The dynamic balance between polymerization and depolymerization of microtubules is critical for cells to enter and exit mitosis, and drugs that disrupt this balance, such as taxol, colchicine, and nocodazole, arrest the cell cycle in mitosis. Although the Raf/MEK/MAPK pathway can be activated by these drugs, its role in mitosis has not been addressed. Here, we characterize activation of Raf/MEK/MAPK by nocodazole when mitosis is induced. We find that at early time points (up to 3 h) in nocodazole induction, Raf/MEK/MAPK is activated, and inhibition of MAPK activation by a MEK inhibitor, PD98059 or U0126, reduces the number of cells entering mitosis by creating a block at G(2). At later time points and in mitosis, activation of MEK/MAPK is severely inhibited, even though Raf-l activity remains high and can be further increased by growth factor. This inhibition is reversed when cells are released from metaphase and enter G(0)/G(1) phase. In addition, we find that binding of Raf-1 to 14-3-3 is progressively induced by nocodazole, reaching a maximum in mitosis, and that this binding is necessary to maintain mitotic Raf-l activity. Our present study indicates that activation of the Raf/MEK/MAPK pathway is necessary for the G(2)/M progression.	Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Med Serv, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Luo, ZJ (corresponding author), Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, 650 Albany St,Rm 820, Boston, MA 02118 USA.		Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; 	NIGMS NIH HHS [GM 57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lovric J, 1996, ONCOGENE, V12, P1109; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Murakami MS, 1998, DEVELOPMENT, V125, P237; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Torres K, 1998, CANCER RES, V58, P3620; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Winston JT, 1996, ONCOGENE, V12, P127; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	50	93	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31876	31882		10.1074/jbc.M002766200	http://dx.doi.org/10.1074/jbc.M002766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10884385	hybrid			2022-12-25	WOS:000089858900047
J	Coulson, EJ; Reid, K; Baca, M; Shipham, KA; Hulett, SM; Kilpatrick, TJ; Bartlett, PF				Coulson, EJ; Reid, K; Baca, M; Shipham, KA; Hulett, SM; Kilpatrick, TJ; Bartlett, PF			Chopper, a new death domain of the p75 neurotrophin receptor that mediates rapid neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; ZINC-FINGER PROTEIN; FACTOR-ALPHA; CASPASE ACTIVATION; SENSORY NEURONS; TRUNCATED FORM; SCHWANN-CELLS; NGF RECEPTOR	The cytoplasmic juxtamembrane region of the p75 neurotrophin receptor (p75(NTR)) has been found to be necessary and sufficient to initiate neural cell death. The region was named "Chopper" to distinguish it from CD95-like death domains. A 29-amino acid peptide corresponding to the Chopper region induced caspase- and calpain-mediated death in a variety of neural and nonneural cell types and was not inhibited by signaling through Trk (unlike killing by full-length p75(NTR)). Chopper triggered cell death only when bound to the plasma membrane by a lipid anchor, whereas non-anchored Chopper acted in a dominant-negative manner, blocking p75(NTR)-mediated death both in vitro and in vivo. Removal of the ectodomain of p75(NTR) increased the potency of Chopper activity, suggesting that it regulates the association of Chopper with downstream signaling proteins.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Coulson, EJ (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Coulson, Elizabeth J./C-8766-2009; Bartlett, Perry/F-3813-2012	Coulson, Elizabeth J./0000-0003-3783-6197; Kilpatrick, Trevor/0000-0003-3999-085X				Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Brann AB, 1999, J NEUROSCI, V19, P8199; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Cheema SS, 1996, J NEUROSCI RES, V46, P239, DOI 10.1002/(SICI)1097-4547(19961015)46:2<239::AID-JNR12>3.0.CO;2-Y; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Coulson EJ, 1999, MOL NEUROBIOL, V20, P29, DOI 10.1007/BF02741363; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1991, ANN NEUROL, V29, P13, DOI 10.1002/ana.410290105; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferri CC, 1998, J NEUROBIOL, V34, P1; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1997, DEVELOPMENT, V124, P3313; Frade JM, 1996, NATURE, V383, P166; Gu CH, 1999, J NEUROSCI, V19, P3043; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; Hileman MR, 1997, FEBS LETT, V415, P145, DOI 10.1016/S0014-5793(97)01113-7; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Ladiwala U, 1998, J NEUROSCI, V18, P1297; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LINDNER MD, 1993, ARCH NEUROL-CHICAGO, V50, P1054, DOI 10.1001/archneur.1993.00540100049013; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Majdan M, 1997, J NEUROSCI, V17, P6988; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	80	92	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30537	30545		10.1074/jbc.M005214200	http://dx.doi.org/10.1074/jbc.M005214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882742	hybrid			2022-12-25	WOS:000089577900085
J	Keller, G; Gross, C; Kelleher, M; Winge, DR				Keller, G; Gross, C; Kelleher, M; Winge, DR			Functional independence of the two cysteine-rich activation domains in the yeast Mac1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT PROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE; EXPRESSION; IDENTIFICATION; REPRESSION; OXIDASE; CTR1P	Mac1 is a transcriptional activator whose activity is inhibited by copper ions. Mutagenesis studies were carried out to map residues important in the copper inhibition of Mac1 activity. Seven new missense mutations were identified that resulted in copper-independent Mac1 transcriptional activation. All seven mutations were clustered in one of two C-terminal cysteine-rich motifs, designated the C1 motif. All but one of the constitutive Mac1 mutations occurred in one of the conserved six residues in the (CXC)-C-264(X)(4)CXC(X)(2)C(X)(2)H-279 C1 motif. The lone exception was a L260S substitution. Two additional MAC1 mutations exhibiting constitutive activity were in-frame deletions encompassing portions C1, Engineered mutations in the second cysteine-rich motif did not yield a constitutively active Mac1. These results are consistent with the C1 motif being the copper-regulatory switch. Both cysteine-rich motifs exhibited transactivation activity, although the C1 activator was weak relative to the C2 activator. Limited copper metalloregulation of Mac1 was observed with only the C1 activator fused to the N-terminal DNA binding domain. Thus, the two Cys-rich motifs appear to function independently. The C1 motif appears to be a functional copper-regulatory domain.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NATIONAL CANCER INSTITUTE [P30CA042014, R01CA061286] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA 42014, CA 61286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1997, METHOD ENZYMOL, V283, P141; BAKERBRACHMANN C, 1998, YEAST, V14, P115; Borghouts C, 1998, MOL GEN GENET, V260, P492, DOI 10.1007/s004380050922; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1998, J PEDIAT, V12, P24; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; MARTINS L, 1997, J BIOL CHEM, V273, P23716; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	29	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29193	29199		10.1074/jbc.M001552200	http://dx.doi.org/10.1074/jbc.M001552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887177	hybrid			2022-12-25	WOS:000089439800004
J	Nagai, T; Kawabata, S				Nagai, T; Kawabata, S			A link between blood coagulation and prophenol oxidase activation in arthropod host defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; HORSESHOE-CRAB; CDNA CLONING; PROCLOTTING ENZYME; GROWTH-FACTOR; INSECT; HEMOCYANIN; PROTEINS; TYROSINASE; HEMOLYMPH	Phenol oxidase, a copper-containing enzyme, is widely distributed not only in animals but also in plants and fungi, which is responsible for initiating the biosynthesis of melanin. Activation of prophenol oxidase in arthropods is important in host defense. However, the prophenol oxidase-activating system remains poorly understood at the molecular level. Here we show that the coagulation cascade of the horseshoe crab Tachypleus tridentatus is linked to prophenol oxidase activation, with the oxygen carrier hemocyanin functioning as a substitute for prophenol oxidase. Tachypleus clotting enzyme functionally transforms hemocyanin to phenol oxidase, and the conversion reaches a plateau at 1:1 stoichiometry without proteolytic cleavage. The active site-masked clotting enzyme also has the same effect, suggesting that complex formation of the clotting enzyme with hemocyanin is critical for the conversion. The two systems of blood coagulation and prophenol oxidase activation may have evolved from a common ancestral protease cascade.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp						Ashida M., 1990, P239; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hyuk T, 1997, MOL CELLS, V7, P90; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; RZEPECKI LM, 1989, ANAL BIOCHEM, V179, P375, DOI 10.1016/0003-2697(89)90148-6; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SEKI N, 1994, J BIOL CHEM, V269, P1370; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; SMITH CL, 1992, PROTEIN SCI, V1, P1225, DOI 10.1002/pro.5560010915; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; TAKAGI T, 1980, J BIOCHEM, V87, P1785, DOI 10.1093/oxfordjournals.jbchem.a132923; Terwilliger NB, 1999, AM ZOOL, V39, P589; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	31	134	151	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29264	29267		10.1074/jbc.M002556200	http://dx.doi.org/10.1074/jbc.M002556200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10880508	hybrid			2022-12-25	WOS:000089439800013
J	Furdui, C; Ragsdale, SW				Furdui, C; Ragsdale, SW			The role of pyruvate ferredoxin oxidoreductase in pyruvate synthesis during autotrophic growth by the Wood-Ljungdahl pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-BARKERI FUSARO; CATALYTIC ELECTRON-TRANSPORT; IRON-SULFUR PROTEIN; CLOSTRIDIUM-THERMOACETICUM; PYROCOCCUS-FURIOSUS; SUCCINATE-DEHYDROGENASE; CARBON-MONOXIDE; PURIFICATION; ENZYME; VOLTAMMETRY	Pyruvate:ferredoxin oxidoreductase (PFOR) catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA and CO2. The catalytic proficiency of this enzyme for the reverse reaction, pyruvate synthase, is poorly understood. Conversion of acetyl-CoA to pyruvate links the Wood-Ljungdahl pathway of autotrophic CO2 fixation to the reductive tricarboxylic acid cycle, which in these autotrophic anaerobes is the stage for biosynthesis of all cellular macromolecules. The results described here demonstrate that the Clostridium thermoaceticum PFOR is a highly efficient pyruvate synthase. The Michaelis-Menten parameters for pyruvate synthesis by PFOR are: V-max = 1.6 unit/mg (k(cat) = 3.2 s(-1)), K-m(Acetyl-CoA) = 9 mu M, and K-m(CO2) = 2 mM. The intracellular concentrations of acetyl-CoA, CoASH, and pyruvate have been measured. The predicted rate of pyruvate synthesis at physiological concentrations of substrates clearly is sufficient to support the role of PFOR as a pyruvate synthase in vivo. Measurements of its k(cat)/K-m values demonstrate that ferredoxin is a highly efficient electron carrier in both the oxidative and reductive reactions. On the other hand, rubredoxin is a poor substitute in the oxidative direction and is inept in donating electrons for pyruvate synthesis.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.			Furdui, Cristina M./0000-0003-3771-7999	NIGMS NIH HHS [GM-39451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039451, R29GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MWW, 1996, ADV PROTEIN CHEM, V48, P101; BAHL H, 1983, THESIS U GOETTINGEN; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; Bock AK, 1996, EUR J BIOCHEM, V237, P35, DOI 10.1111/j.1432-1033.1996.0035n.x; BOCK AK, 1995, J BACTERIOL, V177, P2002, DOI 10.1128/jb.177.8.2002-2007.1995; Bock AK, 1997, FEBS LETT, V414, P209, DOI 10.1016/S0014-5793(97)00998-8; Butt JN, 1997, EUR J BIOCHEM, V245, P116, DOI 10.1111/j.1432-1033.1997.00116.x; CHEN JS, 1979, ANAL BIOCHEM, V93, P216, DOI 10.1016/S0003-2697(79)80140-2; DANIEL SL, 1990, J BACTERIOL, V172, P4464, DOI 10.1128/jb.172.8.4464-4471.1990; ELLIOTT JI, 1982, J BACTERIOL, V151, P328, DOI 10.1128/JB.151.1.328-333.1982; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; GRUPE H, 1991, THESIS U GOETTINGEN; HIRSCH CA, 1963, J BIOL CHEM, V238, P3770; Hirst J, 1996, J AM CHEM SOC, V118, P5031, DOI 10.1021/ja9534361; Hirst J, 1997, J AM CHEM SOC, V119, P7434, DOI 10.1021/ja9631413; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; LAPADO J, 1990, P NATL ACAD SCI USA, V87, P5598; LeJohn H B, 1975, Methods Enzymol, V41, P293; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Menon AL, 1998, BIOCHEMISTRY-US, V37, P12838, DOI 10.1021/bi980979p; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; NEUER G, 1982, BIOCHIM BIOPHYS ACTA, V716, P358, DOI 10.1016/0304-4165(82)90028-9; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; RAEBURN S, 1971, ARCH BIOCHEM BIOPHYS, V146, P21, DOI 10.1016/S0003-9861(71)80037-1; RAEBURN S, 1971, ARCH BIOCHEM BIOPHYS, V146, P9, DOI 10.1016/S0003-9861(71)80036-X; RAGSDALE SW, 1984, J BACTERIOL, V157, P1; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAGSDALE SW, 2000, BIOL INORGANIC CHEM; RAGSDALE SW, 1998, VITAMIN B12 B12 PROT, P167; RAGSDALE SW, 1997, BIOFACTORS, V9, P1; RAJAGOPAL BS, 1994, CURR MICROBIOL, V28, P307, DOI 10.1007/BF01573211; SHIEH JS, 1987, J BACTERIOL, V169, P5327, DOI 10.1128/jb.169.11.5327-5329.1987; Simpson Peter G., 1993, P445; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; UYEDA K, 1971, J BIOL CHEM, V246, P3120; UYEDA K, 1971, J BIOL CHEM, V246, P3111; WAHL RC, 1987, J BIOL CHEM, V262, P10489; Yakunin AF, 1998, BBA-BIOENERGETICS, V1409, P39, DOI 10.1016/S0005-2728(98)00145-5; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	49	120	163	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28494	28499		10.1074/jbc.M003291200	http://dx.doi.org/10.1074/jbc.M003291200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878009	hybrid			2022-12-25	WOS:000089330700022
J	Zhao, T; Heyduk, T; Allis, CD; Eissenberg, JC				Zhao, T; Heyduk, T; Allis, CD; Eissenberg, JC			Heterochromatin protein 1 binds to nucleosomes and DNA in Vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; RESONANCE ENERGY-TRANSFER; DROSOPHILA HETEROCHROMATIN; HISTONE ACETYLATION; SACCHAROMYCES-CEREVISIAE; CHROMODOMAIN PROTEINS; CHROMATIN STRUCTURE; SELF-ASSOCIATION; RNA-POLYMERASE	Heterochromatin protein 1 (HP1) is a nonhistone chromosomal protein primarily associated with the pericentric heterochromatin and telomeres in Drosophila, The molecular mechanism by which HP1 specifically recognizes and binds to chromatin is unknown. The purpose of this study was to test whether HP1 can bind directly to nucleosomes. HP1 binds nucleosome core particles and naked DNA. HP1-DNA complex formation is length-dependent and cooperative but relatively sequence-independent. We show that histone H4 aminoterminal peptides bind to monomeric and dimeric HP1 in vitro. Acetylation of lysine residues had no significant effect on in vitro binding. The C-terminal chrome shadow domain of HPI specifically binds H4 N-terminal peptide. Neither the chrome domain nor chrome shadow domain alone binds DNA; intact native HP1 is required for such interactions. Together, these observations suggest that HP1 may serve as a cross-linker in chromatin, linking nucleosomal DNA and nonhistone protein complexes to form higher order chromatin structures.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Biol, Charlottesville, VA 22908 USA	Saint Louis University; University of Virginia	Eissenberg, JC (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIGMS NIH HHS [GM50514, GM53512, GM57005] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R01GM053512, R55GM057005, R37GM053512, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; BELYAEVA ES, 1993, CHROMOSOMA, V102, P583, DOI 10.1007/BF00368351; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; Cowell IG, 1997, BBA-PROTEIN STRUCT M, V1337, P198, DOI 10.1016/S0167-4838(96)00165-3; Cryderman DE, 1998, CHROMOSOMA, V107, P277, DOI 10.1007/s004120050309; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Frankel S, 1997, J CELL SCI, V110, P1999; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KELLUM R, 1995, J CELL SCI, V108, P1407; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; Lu BY, 2000, GENETICS, V155, P699; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Matlock DL, 1999, ANAL BIOCHEM, V270, P140, DOI 10.1006/abio.1999.4078; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Spofford J., 1976, GENET BIOL DROSOPHIL, VVolume 1, P955; Sugimoto K, 1996, J BIOCHEM, V120, P153; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; Zhao T, 1999, J BIOL CHEM, V274, P15095, DOI 10.1074/jbc.274.21.15095	56	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28332	28338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882726				2022-12-25	WOS:000089197100106
J	Iwamoto, S; Suganuma, H; Kamesaki, T; Omi, T; Okuda, H; Kajii, E				Iwamoto, S; Suganuma, H; Kamesaki, T; Omi, T; Okuda, H; Kajii, E			Cloning and characterization of erythroid-specific DNase I-hypersensitive site in human rhesus-associated glycoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; TRANSCRIPTION FACTOR GATA-1; BLOOD-GROUP ANTIGENS; RED-CELL MEMBRANE; CONTROL REGION; MOLECULAR-CLONING; CHROMATIN STRUCTURE; PROMOTER REGION; RH POLYPEPTIDE; EXPRESSION	fRhesus-associated glycoprotein is a critical co-factor in the expression of rhesus blood group antigens. We identified and cloned an erythroid-specific major DNase I-hypersensitive site located about 10 kilobases upstream from the translation start site of the RHAG gene. A short core enhancer sequence of 195 base pairs that corresponded with the major hypersensitive site and possessed position- and orientation-independent enhancer activity in K562 cells. In vitro DNase I footprint analysis revealed four protected regions in the core enhancer; two GATA motifs, an Ets-like motif and an unknown motif. The GATA motifs bound GATA-1 and mutagenesis analysis revealed that the proximal one is critical for the enhancing activity. Homology plot analysis using the 5' sequence of the mouse RHAG gene revealed four homologous stretches and multiple insertions of repetitive sequences among them; four LINE/L1 and four Alu in the human and as well as one LINE/L1 and one LTR/MaLR in the mouse gene. The highly conservative enhancer region was flanked by SINE and LINE/L1 in both species. These results suggest that the 5'-flanking sequence of RHAG gene is a preferable target sequence for retroviral transposition and that the enhancer was inserted in the same manner, resulting in the acquisition of erythroid dominant expression.	Jichi Med Sch, Dept Legal Med & Human Genet, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Med Ctr, Dept Surg, Omiya, Saitama 3308503, Japan	Jichi Medical University; Jichi Medical University	Iwamoto, S (corresponding author), Jichi Med Sch, Dept Legal Med & Human Genet, 3311-1 Minamikawachi Machi, Minami Kawachi, Tochigi 32904, Japan.			Omi, Toshinori/0000-0001-9303-2746				AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ARCE MA, 1993, BLOOD, V82, P651; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; Huang CH, 1998, J BIOL CHEM, V273, P2207, DOI 10.1074/jbc.273.4.2207; Ikuta T, 1996, J BIOL CHEM, V271, P14082, DOI 10.1074/jbc.271.24.14082; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Iwamoto S, 1998, BIOCHEM BIOPH RES CO, V243, P233, DOI 10.1006/bbrc.1997.8023; KAJII E, 1993, HUM GENET, V91, P157; Kawano M, 1998, ANN HUM GENET, V62, P107, DOI 10.1046/j.1469-1809.1998.6220107.x; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LEONARD M, 1993, BLOOD, V82, P1071; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; Li QL, 1999, GENOMICS, V61, P183, DOI 10.1006/geno.1999.5954; Liu Z, 1999, BIOCHEM GENET, V37, P119, DOI 10.1023/A:1018726303397; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; MOLLISON PL, 1993, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seack J, 1997, IMMUNOGENETICS, V46, P493, DOI 10.1007/s002510050310; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; Tippett P, 1990, Transfus Med Rev, V4, P56, DOI 10.1016/S0887-7963(90)70248-9; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; Vyas P, 1999, DEVELOPMENT, V126, P2799; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG TP, 1987, MOL CELL BIOL, V7, P2994, DOI 10.1128/MCB.7.8.2994; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428	50	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27324	27331						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862620				2022-12-25	WOS:000089144800088
J	Jones, CE; Mueser, TC; Nossal, NG				Jones, CE; Mueser, TC; Nossal, NG			Interaction of the bacteriophage T4 gene 59 helicase loading protein and gene 41 helicase with each other and with fork, flap, and cruciform DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR BRANCH MIGRATION; DOUBLE-STRAND BREAKS; 4-WAY JUNCTION DNA; REPLICATION COMPLEX; ASSEMBLY PROTEIN; PRIMASE-HELICASE; BINDING; RECOMBINATION; POLYMERASE; PURIFICATION	Bacteriophage T4 gene 59 helicase loading protein accelerates the loading of T4 gene 41 DNA helicase and is required for recombination-dependent DNA replication late in T4 phage infection. The crystal structure of 59 protein revealed a two-domain alpha-helical protein, whose N-terminal domain has strong structural similarity to the DNA binding domain of high mobility group family proteins (Mueser, T. C., Jones, C. E., Nossal, N. G., and Hyde, C, C, (2000) J. Mel. Biol, 296, 597-612), We have previously shown that 59 protein binds preferentially to fork DNA, Here we show that 59 protein binds to completely duplex forks but cannot load the helicase unless there is a single-stranded gap of more than 5 nucleotides on the fork arm corresponding to the lagging strand template. Consistent with the roles of these proteins in recombination, we find that 59 protein binds to and stimulates 41 helicase activity on Holliday junction DNA, and on a substrate that resembles a strand invasion structure. 59 protein forms a stable complex with wild type 41 helicase and fork DNA in the presence of adenosine 5'-O-(thiotriphosphate). The unwinding activity of 41 helicase missing 20 C-terminal amino acids is not stimulated by 59 protein, and it does not form a complex with 59 protein on fork DNA.	NIDDKD, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Nossal, NG (corresponding author), NIDDKD, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.		Jones, Charles/GVS-9497-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BARRY J, 1994, J BIOL CHEM, V269, P33049; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; CHA TA, 1989, J BIOL CHEM, V264, P12220; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; CUNNINGHAM RP, 1978, VIROLOGY, V88, P62, DOI 10.1016/0042-6822(78)90110-1; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; Fenley MO, 1998, BIOPHYS CHEM, V74, P135, DOI 10.1016/S0301-4622(98)00171-9; Gariglio M, 1997, EXP CELL RES, V236, P472, DOI 10.1006/excr.1997.3742; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; George JW, 1996, GENETICS, V143, P1507; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P89; Kuroki E, 1999, MOL GEN GENET, V262, P525, DOI 10.1007/s004380051114; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO, V3; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	51	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27145	27154						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871615				2022-12-25	WOS:000089144800065
J	Taheri, M; Saragovi, U; Fuks, A; Makkerh, J; Mort, J; Stanners, CP				Taheri, M; Saragovi, U; Fuks, A; Makkerh, J; Mort, J; Stanners, CP			Self recognition in the Ig superfamily - Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERGENE FAMILY; HUMAN-TUMOR-MARKER; CELL-ADHESION; 3-DIMENSIONAL STRUCTURE; HOMOPHILIC BINDING; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; HUMAN CD4; DOMAINS; CEA	The homophilic binding of extracellular domains of membrane-bound immunoglobulin superfamily (IgSF) molecules is often required for intercellular adhesion and signaling. Carcinoembryonic antigen (CEA), a member of the IgSF, is a widely used tumor marker that functions in vitro as a homotypic intercellular adhesion molecule, CEA has also been shown to contribute to tumorigenicity by inhibiting cellular differentiation, an effect that requires the hemophilic binding of its extracellular domains, It was of interest, therefore, to identify small subdomain sequences In CEA that could serve as a focus in the design of peptides that disrupt CEA-mediated intercellular adhesion. Three subdomains in the N-terminal domain of CEA, identified by site-directed deletions and point mutations, were shown to be required for intercellular adhesion. Cyclized peptides representing two of these subdomains, (42)NRQII and (80)QNDTG, were found to be effective in blocking CEA-mediated cellular aggregation when added to CEA-expressing transfectants in suspension. Intermolecular binding involving each of these subdomains is therefore essential for intercellular adhesion and cannot be compensated for by known binding contributions of other regions in the CEA molecule. In further support of this assumption, the binding epitope of an anti-CEA monoclonal antibody (monoclonal antibody A20) known to block CEA-mediated adhesion, was shown to bridge two of the three required subdomains: (42)NRQII and (30)GYSWYK.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Shriners Hosp Children, Montreal, PQ H3G 1A6, Canada	McGill University; McGill University; McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir Williams Osler, Montreal, PQ H3G 1Y6, Canada.	stanners@med.mcgill.ca						AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BATES PA, 1992, FEBS LETT, V301, P207, DOI 10.1016/0014-5793(92)81249-L; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Boehm MK, 1996, J MOL BIOL, V259, P718, DOI 10.1006/jmbi.1996.0353; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HIGUCHI R, 1989, USING PCR ENG DNA PC, P177; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; JESSUP JM, 1993, INT J CANCER, V55, P262, DOI 10.1002/ijc.2910550216; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leahy DJ, 1997, ANNU REV CELL DEV BI, V13, P363, DOI 10.1146/annurev.cellbio.13.1.363; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LEVIN LV, 1991, CANCER LETT, V60, P143, DOI 10.1016/0304-3835(91)90221-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P634, DOI 10.1016/S0006-291X(87)80013-X; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU H, 1993, CANCER RES, V53, P3817; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951; ZHOU H, 1990, CELL GROWTH DIFFER, V1, P209	49	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26935	26943						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864933				2022-12-25	WOS:000089144800037
J	Wooten, DK; Xie, XL; Bartos, D; Busche, RA; Longmore, GD; Watowich, SS				Wooten, DK; Xie, XL; Bartos, D; Busche, RA; Longmore, GD; Watowich, SS			Cytokine signaling through Stat3 activates integrins, promotes adhesion, and induces growth arrest in the myeloid cell line 32D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; DEPENDENT KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TARGETED DISRUPTION; T-CELLS; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS	Hematopoietic cell development and function is dependent on cytokines and on intercellular interactions with the microenvironment. Although the intracellular signaling pathways stimulated by cytokine receptors are well described, little is known about the mechanisms through which these pathways modulate hematopoietic cell adhesion events in the microenvironment. Here we show that cytokine-activated Stats stimulates the expression and function of cell surface adhesion molecules in the myeloid progenitor cell line 32D. We generated an erythropoietin receptor (EpoR) isoform (ER343/401-S3) that activates Stats rather than Stat5 by substituting the Stats binding/activation sequence motif from gp130 for the sequences surrounding tyrosines 343 and 401 in the receptor cytoplasmic region, Activation of Stats leads to homotypic cell aggregation, increased expression of intercellular adhesion molecule 1 (ICAM-1), CD18, and CD11b, and activation of signaling through CD18-containing integrins. Unlike the wild type EpoR, ER343/401-S3 is unable to support long term Epo-dependent proliferation in 32D cells. Instead, Epo-treated ER343/401-S3 cells undergo G(1) arrest and express elevated levels of the cyclin-dependent kinase inhibitor p27(Kip1). Sustained activation of Stats in these cells is required for their altered morphology and growth properties since constitutive SOCS3 expression abrogates homotypic cell aggregation, signaling through CD18-containing integrins, G(1) arrest, and accumulation of p27(Kip1). Collectively, our results demonstrate that cytokine-activated Stats stimulates the expression and function of cell surface adhesion molecules, indicating that a role for Stats is to regulate intercellular contacts in myeloid cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Watowich, SS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 178,1515 Holcombe Blvd, Houston, TX 77030 USA.			Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [R01 CA077447-03, CA 77447, R01 CA077447-02, CA 75315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447, R01CA075315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan ASH, 1997, J IMMUNOL, V159, P934; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENBERGER JS, 1980, VIROLOGY, V105, P425, DOI 10.1016/0042-6822(80)90043-4; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nielsen M, 1996, J IMMUNOL, V157, P5350; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; StCroix B, 1996, NAT MED, V2, P1204; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zamorano J, 1998, J IMMUNOL, V160, P3502	65	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26566	26575		10.1074/jbc.M003495200	http://dx.doi.org/10.1074/jbc.M003495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10858439	hybrid, Green Accepted			2022-12-25	WOS:000088999700094
J	Cherepanov, P; Pluymers, W; Claeys, A; Proost, P; De Clercq, E; Debyser, Z				Cherepanov, P; Pluymers, W; Claeys, A; Proost, P; De Clercq, E; Debyser, Z			High-level expression of active HIV-1 integrase from a synthetic gene in human cells	FASEB JOURNAL			English	Article						complementation; expression; human immunodeficiency virus type 1	IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL DNA INTEGRATION; NONDIVIDING CELLS; PREINTEGRATION COMPLEXES; MESSENGER-RNA; NUCLEAR-LOCALIZATION; CDNA INTEGRATION; PROTEIN INVITRO; MATRIX PROTEIN; SARCOMA VIRUS	A synthetic gene encoding for HIV-1 integase was designed to circumvent the intrinsic instability and the repressor elements present in the wild-type gene. High-level expression of HIV-1 integrase was obtained in various human cell lines independently of viral accessory proteins. A human 293T cell line was selected that stably expresses HIV-1 integrase and has growth kinetics comparable to the parental cell line. The enzyme was localized in the nucleus and remained stably associated with the chromosomes during mitosis. Lentiviral vector particles carrying the inactivating D64V mutation in the integase gene were capable of stably transducing 293T cells when complemented in the producer cells with integrase expressed from the synthetic gene. When the cell line that stably expresses integase was infected with the defective viral particles, complementation of integrase activity was detected as well. Expression of active HIV-1 integase in human cells will facilitate the study of the interplay between host and viral factors during integation.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven	Debyser, Z (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Proost, Paul/V-3052-2017; Cherepanov, Peter P/F-6859-2010	Proost, Paul/0000-0002-0133-5545; Cherepanov, Peter P/0000-0002-0634-538X; De Clercq, Erik/0000-0002-2985-8890				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Brown P. O., 1997, P161; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Caumont AB, 1996, CURR GENET, V29, P503; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Faust EA, 1995, BIOCHEM MOL BIOL INT, V36, P745; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gaur M, 1998, J VIROL, V72, P4678, DOI 10.1128/JVI.72.6.4678-4685.1998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hennigan AN, 1996, MOL CELL BIOL, V16, P3833; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kukolj G, 1997, J VIROL, V71, P843, DOI 10.1128/JVI.71.1.843-847.1997; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MORRISVASIOS C, 1989, J VIROL, V62, P349; MUMM SR, 1992, VIROLOGY, V189, P500, DOI 10.1016/0042-6822(92)90574-9; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	55	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1389	1399		10.1096/fj.14.10.1389	http://dx.doi.org/10.1096/fj.14.10.1389			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877832				2022-12-25	WOS:000087932200014
J	Parsons, M; Young, L; Lee, JE; Jacobson, KA; Liang, BT				Parsons, M; Young, L; Lee, JE; Jacobson, KA; Liang, BT			Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D	FASEB JOURNAL			English	Article						ischemia; ventricular myocyte; PKC activity; cardioprotection	SENSITIVE POTASSIUM CHANNELS; CARDIAC MYOCYTES; A(3) RECEPTORS; RABBIT HEART; ISCHEMIA; STIMULATION; ACTIVATION; PROTECTION; MUSCLE; INJURY	Adenosine released during cardiac ischemia exerts a marked protective effect in the heart that is mediated by the A(1) and A(3) subtypes of adenosine receptors, The signaling pathways activated by these adenosine receptors have now been characterized in a chick embryo ventricular myocyte culture model of cardioprotection against ischemia. Selective A(1) and A(3) receptor agonists were shown to activate phospholipases C and D, respectively, to achieve their distinct cardioprotective effects. The specificity of the A(3) receptor-phospholipase D interaction was also demonstrated in chick embryo atrial myocytes (which do not express endogenous A(3) receptors) that had been transfected with a vector encoding the human A(3) receptor. Activation of both endogenous A(1) and A(3) receptors in ventricular myocytes resulted in a protective response greater than that induced by stimulation of either receptor alone, Agonists that activate both adenosine A(1) and A(3) receptors may thus prove beneficial for the treatment of myocardial ischemia.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; NIDDKD, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 956 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [R01 HL48225, R01 HL048225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117, Z01DK031116] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali H, 1996, J PHARMACOL EXP THER, V276, P837; Auchampach JA, 1997, CIRC RES, V80, P800; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; Cohen MV, 1996, CIRCULATION, V94, P1713, DOI 10.1161/01.CIR.94.7.1713; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liang BT, 1997, AM J PHYSIOL-HEART C, V273, pH847, DOI 10.1152/ajpheart.1997.273.2.H847; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURTHY KS, 1995, MOL PHARMACOL, V48, P293; Podrasky E, 1997, AM J PHYSIOL-HEART C, V273, pH2380, DOI 10.1152/ajpheart.1997.273.5.H2380; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	26	78	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1423	1431		10.1096/fj.14.10.1423	http://dx.doi.org/10.1096/fj.14.10.1423			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877835	Green Accepted			2022-12-25	WOS:000087932200017
J	Polly, P; Herdick, M; Moehren, U; Baniahmad, A; Heinzel, T; Carlberg, C				Polly, P; Herdick, M; Moehren, U; Baniahmad, A; Heinzel, T; Carlberg, C			VDR-Alien: a novel, DNA-selective vitamin D-3 receptor-corepressor partnership	FASEB JOURNAL			English	Article						gene regulation; repression; NCoR	NUCLEAR HORMONE-RECEPTOR; LIGAND-BINDING DOMAIN; STIMULATING FACTOR GENE; RETINOIC ACID; THYROID-HORMONE; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; FUNCTIONAL-CHARACTERIZATION; BASAL TRANSCRIPTION; SIGNALING PATHWAYS	The vitamin D receptor (VDR) is a transcription factor that transmits incoming 1,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) signaling via combined contact with coactivator proteins and specific DNA binding sites (VDREs), which ultimately results in activation of transcription. In contrast, the mechanisms of transcriptional repression via the VDR are less well understood. This study documents VDR-dependent transcriptional repression largely via histone deacetylase (HDAC) activity. Direct, ligand-sensitive protein-protein interaction of the VDR with the nuclear receptor corepressor (NCoR) and a novel corepressor, called Alien, was demonstrated to be comparable but independent of the VDR AF-2 transactivation domain. Functional assays indicated that Alien, but not NCoR, displays selectivity for different VDRE structures for transferring these repressive effects into gene regulatory activities. Moreover, superrepression via Alien was found to be affected only in part by HDAC inhibitors such as trichostatin A. Finally, for a dissociation of VDR-Alien complexes in vitro and in vivo, higher ligand concentrations were needed than for a dissociation of VDR-NCoR complexes. This suggests that Alien and NCoR are using different interfaces for interaction with the VDR and different pathways for mediating superrepression, which in turn characterizes Alien as a representative of a new class of corepressors. Taken together, association of the VDR with corepressor proteins provides a further level of transcriptional regulation, which is emerging as a complex network of protein-protein interaction-mediated control.	Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany; Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Heinrich Heine University Dusseldorf; Justus Liebig University Giessen	Carlberg, C (corresponding author), Univ Dusseldorf, Inst Physiol Chem 1, Postfach 10 10 07, D-40001 Dusseldorf, Germany.		Carlberg, Carsten/C-9075-2011; Heinzel, Thorsten/B-1013-2015	Carlberg, Carsten/0000-0003-2633-0684; 				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C., 1997, P 10 INT VIT D WORKS, P268; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANAGI Y, 1999, J BIOL CHEM, V274, P12971; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Jimenez-Lara AM, 1999, ENDOCRINOLOGY, V140, P2898, DOI 10.1210/en.140.6.2898; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li Q, 1999, TRENDS ENDOCRIN MET, V10, P157, DOI 10.1016/S1043-2760(98)00141-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MORRISON J, 1989, ANN CLIN PSYCHIATRY, V1, P25; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nayeri S, 1996, NUCLEIC ACIDS RES, V24, P4513, DOI 10.1093/nar/24.22.4513; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; OZONO K, 1990, J BIOL CHEM, V265, P21881; Polly P, 1997, J CELL BIOCHEM, V67, P287, DOI 10.1002/(SICI)1097-4644(19971201)67:3<287::AID-JCB1>3.0.CO;2-S; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400	47	149	151	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1455	1463		10.1096/fj.14.10.1455	http://dx.doi.org/10.1096/fj.14.10.1455			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877839				2022-12-25	WOS:000087932200021
J	Yang, PF; Sale, WS				Yang, PF; Sale, WS			Casein kinase I is anchored on axonemal doublet microtubules and regulates flagellar dynein phosphorylation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLAMYDOMONAS-REINHARDTII IDENTIFY; CENTRAL-PAIR MICROTUBULES; INNER ARM DYNEIN; RADIAL SPOKES; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; INTERMEDIATE CHAIN; BENDING PATTERNS; SPERM FLAGELLA	Flagellar dynein activity is regulated by phosphorylation, One critical phosphoprotein substrate in Chlamydomonas is the 138-kDa intermediate chain (IC138) of the inner arm dyneins (Habermacher, G., and Sale, W. S. (1997) J. Cell Biol. 136, 167-176). In this study, several approaches were used to determine that casein kinase I (CKI) is physically anchored in the flagellar axoneme and regulates IC138 phosphorylation and dynein activity. First, using a videomicroscopic motility assay, selective Chi inhibitors rescued dynein-driven microtubule sliding in axonemes isolated from paralyzed flagellar mutants lacking radial spokes. Rescue of dynein activity failed in axonemes isolated from these mutant cells lacking IC138, Second, CKI was unequivocally identified in salt extracts from isolated axonemes, whereas casein kinase II was excluded from the flagellar compartment, Third, Western blots indicate that within flagella, CKI is anchored exclusively to the axoneme, Analysis of multi pie Chlamydomonas motility mutants suggests that the axonemal CKI is located on the outer doublet microtubules. Finally, CKI inhibitors that rescued dynein activity blocked phosphorylation of IC138, We propose that CKI is anchored on the outer doublet microtubules in position to regulate flagellar dynein.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Sale, WS (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 1648 Pierce Dr, Atlanta, GA 30322 USA.	win@cellbio.emory.edu			NIGMS NIH HHS [GM51173, GM17666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051173, R37GM051173] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROKAW CJ, 1985, CELL MOTIL CYTOSKEL, V5, P195, DOI 10.1002/cm.970050303; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; CHAUDHRY PS, 1995, CELL MOTIL CYTOSKEL, V32, P65, DOI 10.1002/cm.970320108; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P221, DOI 10.1016/0167-4838(91)90005-K; DUTCHER SK, 1995, TRENDS GENET, V11, P398, DOI 10.1016/S0168-9525(00)89123-4; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fu Z, 1999, J NEUROCHEM, V73, P830, DOI 10.1046/j.1471-4159.1999.0730830.x; GARDNER LC, 1994, J CELL BIOL, V127, P1311, DOI 10.1083/jcb.127.5.1311; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Habermacher G, 1996, J CELL SCI, V109, P1899; HAMASAKI T, 1989, CELL MOTIL CYTOSKEL, V12, P1, DOI 10.1002/cm.970120102; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HASEGAWA E, 1987, CELL MOTIL CYTOSKEL, V8, P302, DOI 10.1002/cm.970080403; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P308, DOI 10.1016/0076-6879(83)99066-3; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HOSOKAWA Y, 1987, J CELL BIOL, V105, P1297, DOI 10.1083/jcb.105.3.1297; HOWARD DR, 1994, J CELL BIOL, V127, P1683, DOI 10.1083/jcb.127.6.1683; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SJ, 1997, J CELL BIOL, V136, P177, DOI 10.1083/jcb.136.1.177; KING SM, 1994, J BIOL CHEM, V269, P5452; Kuret J, 1997, J NEUROCHEM, V69, P2506; Mitchell DR, 2000, J PHYCOL, V36, P261, DOI 10.1046/j.1529-8817.2000.99218.x; Mitchell DR, 1999, J CELL BIOL, V144, P293, DOI 10.1083/jcb.144.2.293; Myster SH, 1999, J CELL BIOL, V146, P801, DOI 10.1083/jcb.146.4.801; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; Omoto CK, 1999, MOL BIOL CELL, V10, P1; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1994, J CELL BIOL, V125, P1109, DOI 10.1083/jcb.125.5.1109; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PORTER ME, 1992, J CELL BIOL, V118, P1163, DOI 10.1083/jcb.118.5.1163; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Roush AM, 1999, MOL BIOL CELL, V10, p388A; San Agustin JT, 1998, J BIOL CHEM, V273, P24874, DOI 10.1074/jbc.273.38.24874; SANAGUSTIN JT, 1994, CELL MOTIL CYTOSKEL, V27, P206, DOI 10.1002/cm.970270303; SHUGAR D, 1994, CELL MOL BIOL RES, V40, P411; SMITH EF, 1992, J CELL BIOL, V117, P573, DOI 10.1083/jcb.117.3.573; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; Smith EF, 1997, CELL MOTIL CYTOSKEL, V38, P1; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALCZAK CE, 1993, BIOCHEM J, V296, P729, DOI 10.1042/bj2960729; WALCZAK CE, 1994, CELL MOTIL CYTOSKEL, V27, P101, DOI 10.1002/cm.970270202; WARNER FD, 1974, J CELL BIOL, V63, P35, DOI 10.1083/jcb.63.1.35; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; Yang PF, 1998, MOL BIOL CELL, V9, P3335, DOI 10.1091/mbc.9.12.3335; Yang PF, 2000, J CELL SCI, V113, P91; Yoshimura M, 1999, CELL STRUCT FUNCT, V24, P43, DOI 10.1247/csf.24.43	63	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18905	18912		10.1074/jbc.M002134200	http://dx.doi.org/10.1074/jbc.M002134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858448	hybrid			2022-12-25	WOS:000087815900040
J	Moon, NS; Berube, G; Nepveu, A				Moon, NS; Berube, G; Nepveu, A			CCAAT displacement activity involves CUT repeats 1 and 2, not the CUT homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGION; CELL TYPE SPECIFICATION; NEGATIVE REGULATORY ELEMENT; DNA-BINDING SPECIFICITY; SENSORY ORGAN IDENTITY; DROSOPHILA WING MARGIN; HISTONE H4 GENE; GLUTATHIONE TRANSFERASE; PROGESTERONE-RECEPTOR; TRANSCRIPTION FACTORS	The CCAAT displacement protein, the homolog of the Drosophila melanogaster CUT protein, contains four DNA-binding domains: three CUT repeats (CR1, CR2, and CR3) and the CUT homeodomain (HD). Using a panel of fusion proteins, we found that a CUT repeat cannot bind to DNA as a monomer, but that certain combinations of domains exhibit high DNA-binding affinity: CR1+2, CR3HD, CR1HD, and CR2HD. One combination (CR1+2) exhibited strikingly different DNA-binding kinetics and specificities. CR1+2 displayed rapid on and off rates and bound preferably to two C(A/G)AT sites, organized as direct or inverted repeats. Accordingly, only CR1+2 was able to bind to the CCAAT sequence, and its affinity was increased by the presence of a C(A/G)AT site at close proximity. A purified CCAAT displacement protein/CUT protein exhibited DNA-binding properties similar to those of CR1+2; and in nuclear extracts, the CCAAT displacement activity also required the simultaneous presence of a C(A/G)AT site. Moreover, CR1+2, but not CR3HD, was able to displace nuclear factor Y, Thus, the CCAAT displacement activity requires the presence of an additional sequence (CAAT or CGAT) and involves CR1 and CR2, but not the CUT homeodomain.	McGill Univ, Mol Oncol Grp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University	Nepveu, A (corresponding author), McGill Univ, Mol Oncol Grp, Ctr Hlth, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain@lan1.molonc.mcgill.ca	/AAB-8315-2020	Moon, Nam-Sung/0000-0002-0455-927X				ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blanc Richard, 1942, UNIV CALIFORNIA PUBL ZOOL, V49, P1; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Braun W, 1940, J EXP ZOOL, V84, P325, DOI 10.1002/jez.1400840302; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Catt D, 1999, CELL MOL BIOL, V45, P1149; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; JACK J, 1992, GENETICS, V131, P353; JACK J, 1991, DEVELOPMENT, V113, P735; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; PRENDERGAST P, 1994, J STEROID BIOCHEM, V48, P1, DOI 10.1016/0960-0760(94)90245-3; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Teerawatanasuk N, 1999, J NEUROCHEM, V72, P29, DOI 10.1046/j.1471-4159.1999.0720029.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang ZY, 1999, MOL CELL BIOL, V19, P284; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	57	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31325	31334		10.1074/jbc.M002912200	http://dx.doi.org/10.1074/jbc.M002912200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10864926	hybrid			2022-12-25	WOS:000089762700082
J	Sapranauskas, R; Sasnauskas, G; Lagunavicius, A; Vilkaitis, G; Lubys, A; Siksnys, V				Sapranauskas, R; Sasnauskas, G; Lagunavicius, A; Vilkaitis, G; Lubys, A; Siksnys, V			Novel subtype of type IIs restriction enzymes - BfiI endonuclease exhibits similarities to the EDTA-resistant nuclease Nuc of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; PHOSPHOLIPASE-D FAMILY; PLASMID DNA; HAEMOPHILUS-PARAHAEMOLYTICUS; ALKALINE EXTRACTION; SINGLE-TURNOVER; FOKI; SUPERFAMILY; MECHANISM; SYNTHASES	The type IIs restriction enzyme BfiI recognizes the non-palindromic nucleotide sequence 5'-ACTGGG-3' and cleaves complementary DNA strands 5/4 nucleotides downstream of the recognition sequence. The genes coding for the BfiI restriction-modification (R-M) system were cloned/sequenced and biochemical characterization of BfiI restriction enzyme was performed. The BfiI R-M system contained three proteins: two N4-methylcytosine methyltransferases and a restriction enzyme, Sequencing of bisulfite-treated methylated DNA indicated that each methyltransferase modifies cytosines on opposite strands of the recognition sequence. The N-terminal part of the BfiI restriction enzyme amino acid sequence revealed intriguing similarities to an EDTA-resistant nuclease of Salmonella typhimurium. Biochemical analyses demonstrated that BfiI, like the nuclease of S. typhimurium, cleaves DNA in the absence of Mg2+ ions and hydrolyzes an artificial substrate bis(p-nitrophenyl) phosphate. However, unlike the nonspecific S. typhimurium nuclease, BfiI restriction enzyme cleaves DNA specifically. We propose that the DNA-binding specificity of BfiI stems from the C-terminal part of the protein. The catalytic N-terminal subdomain of BfiI radically differs from that of type II restriction enzymes and is presumably similar to the EDTA-resistant nonspecific nuclease of S. typhimurium; therefore, BfiI did not require metal ions for catalysis. We suggest that BfiI represents a novel subclass of type IIs restriction enzymes that differs from the archetypal KokI endonuclease by the fold of its cleavage domain, the domain location, and reaction mechanism.	Inst Biotechnol, LT-2028 Vilnius, Lithuania	Vilnius University	Siksnys, V (corresponding author), Inst Biotechnol, Graiciuno 8, LT-2028 Vilnius, Lithuania.		Vilkaitis, Giedrius/AAI-9157-2021; Sasnauskas, Giedrius/AAE-8191-2019	Vilkaitis, Giedrius/0000-0003-2427-3997				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GordonBeresford RMH, 1996, PROTEINS, V25, P180, DOI 10.1002/(SICI)1097-0134(199606)25:2<180::AID-PROT4>3.0.CO;2-M; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; Gunn JS, 1997, NUCLEIC ACIDS RES, V25, P4147, DOI 10.1093/nar/25.20.4147; KITA K, 1992, NUCLEIC ACIDS RES, V20, P618, DOI 10.1093/nar/20.3.618; KITA K, 1992, NUCLEIC ACIDS RES, V20, P4167, DOI 10.1093/nar/20.16.4167; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; Lubys A, 1996, NUCLEIC ACIDS RES, V24, P2760, DOI 10.1093/nar/24.14.2760; MARKO MA, 1982, ANAL BIOCHEM, V121, P382, DOI 10.1016/0003-2697(82)90497-3; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POHLMAN RF, 1993, NUCLEIC ACIDS RES, V21, P4867, DOI 10.1093/nar/21.21.4867; Ponting CP, 1996, PROTEIN SCI, V5, P914; Roberts R, 1993, NUCLEASES, P35; Sambrook J., 2002, MOL CLONING LAB MANU; Sasnauskas G, 1999, BIOCHEMISTRY-US, V38, P4028, DOI 10.1021/bi982456n; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; SUGISAKI H, 1981, GENE, V16, P73; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TIMINSKAS A, 1995, GENE, V157, P3, DOI 10.1016/0378-1119(94)00783-O; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; Vilkaitis G, 1999, ANAL BIOCHEM, V271, P116, DOI 10.1006/abio.1999.4116; Vitkute J, 1998, NUCLEIC ACIDS RES, V26, P3348, DOI 10.1093/nar/26.14.3348; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WHITEHEAD PR, 1985, ARCH MICROBIOL, V141, P70, DOI 10.1007/BF00446742; WINANS SC, 1983, J BACTERIOL, V154, P1117, DOI 10.1128/JB.154.3.1117-1125.1983; Wright DJ, 1999, J BIOL CHEM, V274, P31896, DOI 10.1074/jbc.274.45.31896; Zhao Y, 1997, PROTEIN SCI, V6, P2655	35	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30878	30885		10.1074/jbc.M003350200	http://dx.doi.org/10.1074/jbc.M003350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10880511	hybrid			2022-12-25	WOS:000089762700023
J	Grzeskowiak, R; Amin, J; Oetjen, E; Knepel, W				Grzeskowiak, R; Amin, J; Oetjen, E; Knepel, W			Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; CELL-SPECIFIC EXPRESSION; PANCREATIC-ISLET CELLS; RESPONSE ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE; NUCLEAR-PROTEIN; MEMBRANE DEPOLARIZATION; PROGLUCAGON GENE; PATHO-PHYSIOLOGY; CYCLOSPORINE-A	Regulation of gene transcription is an important aspect of insulin's action. However, the mechanisms involved are poorly understood. Insulin inhibits glucagon gene transcription, and insulin deficiency is associated with hyperglucagonemia that contributes to hyperglycemia in diabetes mellitus. Transfecting glucagon-reporter fusion genes into a glucagon-producing pancreatic islet cell line, a 5'-, 3'-, and internal deletion analysis, and oligonucleotide cassette insertions failed in the present study to identify a single insulin-responsive element in the glucagon gene. They rather indicate that insulin responsiveness depends on the presence of both proximal promoter elements and more distal enhancer-like elements. When the paired domain transcription factor Pax6 binding sites within the proximal promoter element G1 and the enhancer-like element G3 were mutated into GAL4 binding sites, the expression of GAL4-Pax6 and GAL4-VP16 restored basal activity, whereas only GAL4-Pax6 restored also insulin responsiveness. Likewise, GAL4-CBP activity was inhibited by insulin within the glucagon promoter context. The results suggest that insulin responsiveness is conferred to the glucagon gene by the synergistic interaction of proximal promoter and more distal enhancer-like elements, with Pax6 and its potential coactivator the CREB-binding protein being critical components. These data thereby support concepts of insulin-responsive element-independent mechanisms of insulin action to inhibit gene transcription.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert-Koch-Str 40,Postfach 3742, D-37070 Gottingen, Germany.							ALEXANDERBRIDGES M, 1992, BIOCHEM SOC T, V20, P691, DOI 10.1042/bst0200691; Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Barroso I, 1999, J BIOL CHEM, V274, P17997, DOI 10.1074/jbc.274.25.17997; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Eckner R, 1996, BIOL CHEM, V377, P685; Freyse EJ, 1997, DIABETES, V46, P824, DOI 10.2337/diabetes.46.5.824; Furstenau U, 1999, J BIOL CHEM, V274, P5851, DOI 10.1074/jbc.274.9.5851; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jin TR, 1996, MOL CELL BIOL, V16, P19; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KNEPEL W, 2000, IN PRESS MOL BASIS E; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kruger M, 1997, N-S ARCH PHARMACOL, V356, P433, DOI 10.1007/PL00005073; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; LEFEBVRE PJ, 1995, DIABETES CARE, V18, P715, DOI 10.2337/diacare.18.5.715; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Pierreux CE, 1999, MOL CELL ENDOCRINOL, V147, P1, DOI 10.1016/S0303-7207(98)00238-X; Pierreux CE, 1998, MOL ENDOCRINOL, V12, P1343, DOI 10.1210/me.12.9.1343; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Wrege Antje, 1995, Gene Expression, V4, P205; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	70	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30037	30045		10.1074/jbc.M000984200	http://dx.doi.org/10.1074/jbc.M000984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862760	hybrid			2022-12-25	WOS:000089577900017
J	Henderson, JM; Wells, L; Fridovich-Keil, JL				Henderson, JM; Wells, L; Fridovich-Keil, JL			Covalent heterogeneity of the human enzyme galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST EXPRESSION SYSTEM; URIDYLYL TRANSFERASE; ESCHERICHIA-COLI; MOLECULAR-BASIS; UDP-GALACTOSE; URIDYLTRANSFERASE; SITE; PURIFICATION; MUTATIONS; IDENTIFICATION	Galactose-1-phosphate uridylyltransferase (GALT) acts by a double displacement mechanism, catalyzing the second step in the Leloir pathway of galactose metabolism. Impairment of this enzyme results in the potentially lethal disorder, galactosemia. Although the microheterogeneity of native human GALT has long been recognized, the biochemical basis for this heterogeneity has remained obscure. We have explored the possibility of covalent GALT heterogeneity using denaturing two dimensional gel electrophoresis and Western blot analysis to fractionate and visualize hemolysate hGALT, as well as the human enzyme expressed in yeast. In both contexts, two predominant GALT species were observed. To define the contribution of uridylylated enzyme intermediate to the two-spot pattern, we exploited the null allele, H186G-hGALT. The Escherichia coli counterpart of this mutant protein (H166G-eGALT) has previously been demonstrated to fold properly, although it cannot form covalent intermediate. Analysis of the H186G-hGALT protein demonstrated a single predominant species, implicating covalent intermediate as the basis for the second spot in the wild-type pattern. In contrast, three naturally occurring mutations, N314D, Q188R, and S135L-hGALT, all demonstrated the two-spot pattern. Together, these data suggest that uridylylated hGALT comprises a significant fraction of the total GALT enzyme pool in normal human cells and that three of the most common patient mutations do not disrupt this distribution.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA.		Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	NIDDK NIH HHS [DK46403] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046403, R01DK046403] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARABSHAHI A, 1986, BIOCHEMISTRY-US, V25, P5583, DOI 10.1021/bi00367a036; BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; BANROQUES J, 1983, BIOCHIMIE, V65, P7, DOI 10.1016/S0300-9084(83)80023-6; Crews C, 2000, J BIOL CHEM, V275, P22847, DOI 10.1074/jbc.M001053200; DALE GL, 1976, J BIOL CHEM, V251, P1057; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHODS ENZYMOLOGY; HOLTON JB, 2000, IN PRESS METABOLIC M; KELLEY RI, 1983, HUM GENET, V63, P274; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lai K, 1999, J BIOL CHEM, V274, P6559, DOI 10.1074/jbc.274.10.6559; Lai K, 1996, J PEDIATR-US, V128, P89, DOI 10.1016/S0022-3476(96)70432-8; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; REICHARDT JKV, 1992, BIOCHEMISTRY-US, V31, P5430, DOI 10.1021/bi00139a002; REICHARDT JKV, 1991, P NATL ACAD SCI USA, V88, P2633, DOI 10.1073/pnas.88.7.2633; SCHAPIRA F, 1978, BIOCHEM BIOPH RES CO, V80, P291, DOI 10.1016/0006-291X(78)90675-7; Segal S, 1995, METABOLIC MOL BASIS, P967; SHIN YS, 1995, EUR J PEDIATR, V154, pS75, DOI 10.1007/BF02143808; SHIN YS, 1987, CLIN CHIM ACTA, V166, P27, DOI 10.1016/0009-8981(87)90191-4; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Wells L, 1997, J INHERIT METAB DIS, V20, P633, DOI 10.1023/A:1005314207513; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032	34	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30088	30091		10.1074/jbc.M005259200	http://dx.doi.org/10.1074/jbc.M005259200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10884393	hybrid			2022-12-25	WOS:000089577900025
J	Ratti, S; Curnis, F; Longhi, R; Colombo, B; Gasparri, A; Magni, F; Manera, E; Metz-Boutigue, MH; Corti, A				Ratti, S; Curnis, F; Longhi, R; Colombo, B; Gasparri, A; Magni, F; Manera, E; Metz-Boutigue, MH; Corti, A			Structure-activity relationships of chromogranin A in cell adhesion - Identification of an adhesion site for fibroblasts and smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MONOCLONAL-ANTIBODIES; TERMINAL FRAGMENTS; ENDOCRINE-CELLS; PROTEIN FAMILY; A FRAGMENT; IN-VITRO; VASOSTATINS; SECRETION; PITUITARY	Previous studies showed that chromogranin A (CgA), a glycoprotein stored and co-released with various hormones by neuroendocrine cells and neurons, can modulate cell adhesion. We have investigated the structure-activity relationships of CgA using fibroblasts and coronary artery smooth muscle cells in adhesion assays. A recombinant CgA fragment 1-78 and a peptide 7-57 containing reduced and alkylated cysteines (Cys(17) and Cys(38)) induced cell adhesion after adsorption onto solid phases at 50-100 nM. Peptides lacking the disulfide loop region, including residues 47-68, 39-59, and 39-68, induced cell adhesion, either bound to solid phases at 200-400 nM or added to the liquid phase at 5-10 mu M, whereas peptide 60-68 was inactive, suggesting that residues 47-57 are important for activity. The effect of CgA-(1-78) was blocked by anti-CgA antibodies against epitopes including residues Arg(53), His(54), and Leu(57). Substitutions of residues His(54) Gln(55), and Asn(56) with alanine decreased the cell adhesion activity of peptide 47-68. These results suggest that the region 47-57 (RILSILRHQNL) contains a cell adhesion site and that the disulfide bridge is not necessary for the proadhesive activity. The ability of soluble peptides to elicit proadhesive effects suggests an indirect mechanism. The high sequence conservation and accessibility to antibodies suggest that this region is important for the physiological role of CgA.	San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; CNR, IRBM, I-20132 Milan, Italy; INSERM, Unite Biol Commun Cellulaire 338, F-67084 Strasbourg, France	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Corti, A (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Corti, Angelo/F-7046-2012; Gasparri, Anna Maria/AAN-5071-2020; Curnis, Flavio/AAK-3542-2020; Colombo, Barbara/AAN-5045-2020; Magni, Fulvio/A-7340-2014	Corti, Angelo/0000-0002-0893-6191; Gasparri, Anna Maria/0000-0002-1757-8699; Curnis, Flavio/0000-0002-7231-9569; Colombo, Barbara/0000-0002-5887-5868; Subba, Rajkrishna/0000-0003-0051-0062; Magni, Fulvio/0000-0002-8663-0374				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Corti A, 1998, CANCER RES, V58, P3866; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 1996, BRIT J CANCER, V73, P924, DOI 10.1038/bjc.1996.183; DEFTOS LJ, 1990, BONE MINER, V9, P169, DOI 10.1016/0169-6009(90)90035-E; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; PELAGI M, 1989, MOL CELL PROBE, V3, P87, DOI 10.1016/0890-8508(89)90039-X; QIAN J, 1988, J NEUROIMMUNOL, V17, P159, DOI 10.1016/0165-5728(88)90023-9; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1989, BIOCHEM J, V262, P1; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; Soriano JV, 1999, BIOCHEM BIOPH RES CO, V259, P563, DOI 10.1006/bbrc.1999.0826; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025	40	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29257	29263		10.1074/jbc.M003796200	http://dx.doi.org/10.1074/jbc.M003796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875933	hybrid			2022-12-25	WOS:000089439800012
J	Stevens, J; Jones, RC; Bordoli, RS; Trowsdale, J; Gaskell, SJ; Butcher, GW; Joly, E				Stevens, J; Jones, RC; Bordoli, RS; Trowsdale, J; Gaskell, SJ; Butcher, GW; Joly, E			Peptide specificity of RT1-A1(c), an inhibitory rat major histocompatibility complex class I natural killer cell ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; SEQUENCE-DERIVED PEPTIDES; HLA-E BINDS; NK CELLS; MASS-SPECTROMETRY; LEADER PEPTIDE; RECOGNITION; IDENTIFICATION; MOLECULES; ANTIGEN	The rat major histocompatibility complex class Ia allelomorph RT1-A1(c) is a potent ligand for the recently identified inhibitory rLy-49 receptor, STOK-2. With the ultimate objective of studying the interactions of these molecules using structural and functional methods, we undertook a detailed study of its peptide specificity. The study revealed that designing an "ideal peptide" by choosing the most abundant residues in the "binding motif" obtained by pool sequencing does not necessarily yield an optimal binding peptide. For RT1-A1(c), as many as four positions, P2, P4, P5, and P9, were detected as putative anchors. Since this molecule displays a preference for highly hydrophobic peptides, we tested binding of peptides derived from the known leader peptide sequences of other rat histocompatibility complex class I molecules. One such peptide, found to bind well, requiring 1.6 mu M peptide to achieve 50% stabilization, was searched for in vivo. Natural RT1-A1(c) binding peptides were purified from rat splenocytes and characterized by mass spectrometry using a combined matrix-assisted laser desorption ionization/time-of-flight and quadrupole time-of-flight approach. Results showed that the signal sequence-derived peptide was not detectable in the purified peptide pool, which was composed of a complex spectrum of peptides. Seven of these self-peptides were successfully sequenced.	Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Univ Manchester, Inst Sci & Technol, Dept Chem, Manchester M60 1QD, Lancs, England; Micromass UK Ltd, Manchester M23 9LE, Lancs, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Manchester	Stevens, J (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC206,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Backman-Petersson E, 2000, INT IMMUNOL, V12, P843, DOI 10.1093/intimm/12.6.843; Bhuyan PK, 1997, J IMMUNOL, V158, P3753; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brooks AG, 1999, J IMMUNOL, V162, P305; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DeCloux A, 1997, J IMMUNOL, V158, P2183; Dohring C, 1997, CRIT REV IMMUNOL, V17, P285, DOI 10.1615/CritRevImmunol.v17.i3-4.20; Engh E, 1998, TRANSPLANTATION, V65, P319, DOI 10.1097/00007890-199802150-00005; Fogli A, 1999, CYTOGENET CELL GENET, V86, P225, DOI 10.1159/000015344; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; Joly E, 1996, J IMMUNOL, V157, P1551; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kraus E, 1996, EUR J IMMUNOL, V26, P2582, DOI 10.1002/eji.1830261107; Lanier LL, 1998, CELL, V92, P705, DOI 10.1016/S0092-8674(00)81398-7; Lau P, 2000, IMMUNOGENETICS, V51, P148, DOI 10.1007/s002510050023; Llano M, 1998, EUR J IMMUNOL, V28, P2854, DOI 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; Manilay JO, 1998, CURR OPIN IMMUNOL, V10, P532, DOI 10.1016/S0952-7915(98)80219-7; Murphy WJ, 1997, IMMUNOL REV, V157, P167, DOI 10.1111/j.1600-065X.1997.tb00981.x; Naper C, 1996, INT IMMUNOL, V8, P1779, DOI 10.1093/intimm/8.11.1779; Naper C, 1999, EUR J IMMUNOL, V29, P2046, DOI 10.1002/(SICI)1521-4141(199906)29:06&lt;2046::AID-IMMU2046&gt;3.0.CO;2-Z; Naper C, 1998, J IMMUNOL, V160, P219; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Ozaki T, 1997, DNA CELL BIOL, V16, P985, DOI 10.1089/dna.1997.16.985; PARKER KE, 1991, IMMUNOGENETICS, V34, P211, DOI 10.1007/BF00205827; Peruzzi M, 1996, J EXP MED, V184, P1585, DOI 10.1084/jem.184.4.1585; Peruzzi M, 1996, J IMMUNOL, V157, P3350; POWIS SJ, 1993, TRANSPLANT P, V25, P2752; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rolstad B, 1997, IMMUNOL REV, V155, P91, DOI 10.1111/j.1600-065X.1997.tb00942.x; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; Stevens J, 1998, EUR J IMMUNOL, V28, P1272, DOI 10.1002/(SICI)1521-4141(199804)28:04<1272::AID-IMMU1272>3.0.CO;2-E; Stevens J, 1998, J BIOL CHEM, V273, P2874, DOI 10.1074/jbc.273.5.2874; VAAGE JT, 2000, IN PRES SJ IMMUNOL; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	45	15	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29217	29224		10.1074/jbc.M002565200	http://dx.doi.org/10.1074/jbc.M002565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10856297	hybrid			2022-12-25	WOS:000089439800007
J	Dirksen, WP; Li, XL; Mayeda, A; Krainer, AR; Rottman, FM				Dirksen, WP; Li, XL; Mayeda, A; Krainer, AR; Rottman, FM			Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; PROTEIN-PROTEIN INTERACTIONS; T ALTERNATIVE EXON; SR-PROTEINS; PREMESSENGER RNA; RECOGNITION MOTIFS; 5'-SPLICE-SITE RECOGNITION; FACTORS ASF/SF2; FACTOR SF2	Splicing of the last intron (intron D) of the bovine growth hormone pre-mRNA requires the presence of a downstream exonic splicing enhancer (ESE). This enhancer is contained within a 115-nucleotide FspI-PvuII (FP) fragment located in the middle of the last exon (exon 5). Previous work showed that the splicing factor SF2/ASF binds to this FP region and stimulates splicing of intron D in vitro. However, the precise sequences recognized by SF2/ASF within the FP region had not been determined. Here we used multiple strategies to map the SF2/ASF binding sites and determine their importance for ESE function. Taking advantage of the fact that SF2/ASF ultraviolet (UV) cross-links specifically to RNA containing the FP sequence, we first mapped a major SF2/ASF binding site by UV cross-linking and reverse transcription. This strategy identified a 29-nucleotide SF2/ASF binding region in the middle of the FP sequence containing the 7-nucleotide purine-rich motif described previously. Interestingly, this binding region is neither sufficient, nor absolutely required for SF2/ASF-mediated splicing, suggesting that additional SF2/ASF binding sites are present. The location of these additional sites was determined by electrophoretic mobility shift analysis of various subfragments of the FP sequence, Antisense 2'-O-methyl oligoribonucleotides complementary to selected SF2/ASF binding sites block bovine growth hormone intron D splicing. Thus, multiple SF2/ASF binding sites within the exonic splicing enhancer contribute to maximal enhancer activity.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, OH 44106 USA; Novartis Agribusiness Biotechnol Res Inc, Res Triangle Pk, NC 27709 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Case Western Reserve University; Case Western Reserve University; Novartis; University of Miami; Cold Spring Harbor Laboratory	Rottman, FM (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Sch Med, Wood Bldg W235,10900 Euclid Ave, Cleveland, OH 44106 USA.	fmr@po.cwru.edu	Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501	NIDDK NIH HHS [DK32770] Funding Source: Medline; NIGMS NIH HHS [GM42699] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DIRKSEN WP, 1995, J BIOL CHEM, V270, P5346, DOI 10.1074/jbc.270.10.5346; DOMINSKI Z, 1994, MOL CELL BIOL, V14, P7445, DOI 10.1128/MCB.14.11.7445; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gontarek RR, 1996, MOL CELL BIOL, V16, P2325; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; Hanamura A, 1998, RNA, V4, P430; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAMOND AI, 1990, MOL BIOL REP, V14, P201, DOI 10.1007/BF00360473; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1990, J BIOCHEM-TOKYO, V108, P399, DOI 10.1093/oxfordjournals.jbchem.a123213; Nagel RJ, 1998, RNA, V4, P11; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; SMITH KC, 1976, RAD INDUCED ADDITION; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SUN Q, 1993, J BIOL CHEM, V268, P15659; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zheng ZM, 1997, J VIROL, V71, P9096, DOI 10.1128/JVI.71.12.9096-9107.1997; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	63	22	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29170	29177		10.1074/jbc.M001126200	http://dx.doi.org/10.1074/jbc.M001126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880506	hybrid			2022-12-25	WOS:000089330700107
J	Mair, G; Ullu, E; Tschudi, C				Mair, G; Ullu, E; Tschudi, C			Cotranscriptional cap 4 formation on the Trypanosoma brucei spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; CAPPING ENZYME; TRANSCRIPTION; INVITRO; BINDING; SYSTEM; GENE	mRNA cap formation in trypanosomatid protozoa is mediated through trans-splicing of the capped spliced leader (SL) sequence of the SL RNA onto the 5' end of all mRNAs. The SL RNA cap structure in Trypanosoma brucei is unique among eukaryotes and consists of 7-methylguanosine (m(7)G) followed by four methylated nucleotides (cap 4): m(7)Gpppm(2)(6)AmpAmpCmpm(3)Um. Using transcriptional arrest in permeable T. brucei cells, we have analyzed the temporal progression of cap 4 formation on the 140-nucleotide-long SL RNA. m7G capping of the SL RNA could be detected on prematurely terminated SL RNA transcripts of 56 nucleotides in length and longer. Subsequent modifications characteristic of the SL RNA cap 4 were added successively in a 5' to 3' direction and appeared to be independent of core ribonucleoprotein formation. Transcripts between 56 and 67 nucleotides in length were partially modified and carried methyl groups on the first two adenosine residues, whereas a fully modified cap 4 structure was present on transcripts arrested at position 117 and beyond, Taken together, our results are consistent with a cotranscriptional mechanism for generating the cap 4 structure on the SL RNA.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Tschudi, C (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208022,333 Cedar St, New Haven, CT 06520 USA.			Mair, Gunnar/0000-0002-5187-3691	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043594] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43594] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1992, J BIOL CHEM, V267, P9805; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; JOVE R, 1984, J BIOL CHEM, V259, P8513; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Silberklang M, 1979, Methods Enzymol, V59, P58; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1995, J BIOL CHEM, V270, P20365, DOI 10.1074/jbc.270.35.20365; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; Varani G, 1997, STRUCTURE, V5, P855, DOI 10.1016/S0969-2126(97)00239-6; Yu MC, 1998, MOL BIOCHEM PARASIT, V94, P265, DOI 10.1016/S0166-6851(98)00083-8; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	21	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28994	28999		10.1074/jbc.M004193200	http://dx.doi.org/10.1074/jbc.M004193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880518	hybrid			2022-12-25	WOS:000089330700086
J	Duffieux, F; Van Roy, J; Michels, PKM; Opperdoes, FR				Duffieux, F; Van Roy, J; Michels, PKM; Opperdoes, FR			Molecular characterization of the first two enzymes of the pentose-phosphate pathway of Trypanosoma brucei - Glucose-6-phosphate dehydrogenase and 6-phosphogluconolactonase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MEXICANA MEXICANA; BLOOD-STREAM FORMS; GLYCOLYTIC-ENZYMES; ESCHERICHIA-COLI; SUBCELLULAR-DISTRIBUTION; PURIFICATION; GENE; LOCALIZATION; GLYCOSOMES; SEQUENCE	Trypanosomatids are parasitic protists that have part of their glycolytic pathway sequestered inside peroxisome-like organelles: the glycosomes. So far, at least one enzyme of the pentose-phosphate pathway has been found to be associated partially with glycosomes. Here, we describe how two genes from Trypanosoma brucei, coding for the first two enzymes of the pentose-phosphate pathway, i.e. glucose-8 phosphate dehydrogenase and 6-phosphogluconolactonase, were identified by in silico screening of trypanosome genome project data bases. These genes were cloned and sequenced. Analysis of the lactonase sequence revealed that it contained a C-terminal peroxisome targeting signal in agreement with its subcellular localization in the bloodstream form trypanosome (15% glycosomal and 85% cytosolic), However, the dehydrogenase sequence did not reveal any targeting signal, despite its localization inside glycosomes, The corresponding enzymes have been overexpressed in Escherichia coli and purified, and their biochemical characteristics have been determined.	Christian De Duve Inst Cellulat Pathol, Trop Dis Res Unit, Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium	Universite Catholique Louvain	Opperdoes, FR (corresponding author), Christian De Duve Inst Cellulat Pathol, Trop Dis Res Unit, Brussels, Belgium.	opperdoes@trop.ucl.ac.be	Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009	Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Duffieux, Francis/0000-0003-4906-0314				Adje CA, 1997, MOL BIOCHEM PARASIT, V90, P155, DOI 10.1016/S0166-6851(97)00152-7; ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTONENKOV VD, 1989, EUR J BIOCHEM, V183, P75, DOI 10.1111/j.1432-1033.1989.tb14898.x; Au SWN, 2000, STRUCTURE, V8, P293, DOI 10.1016/S0969-2126(00)00104-0; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; BARRETT MP, 1993, MOL BIOCHEM PARASIT, V57, P89, DOI 10.1016/0166-6851(93)90247-U; BARRETT MP, 1994, PROTEIN EXPRES PURIF, V5, P44, DOI 10.1006/prep.1994.1006; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; Beutler E, 1996, BLOOD REV, V10, P45, DOI 10.1016/S0268-960X(96)90019-3; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DEWALQUE S, 1996, ARCH PHYSIOL BIOCHEM, V104, pB49; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Hanau S, 1996, EUR J BIOCHEM, V240, P592, DOI 10.1111/j.1432-1033.1996.0592h.x; HANKOGLU I, 1989, EUR J BIOCHEM, V180, P479; HANNAERT V, 2000, IN PRESS RES REV PAR, V59; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Heise N, 1999, MOL BIOCHEM PARASIT, V99, P21, DOI 10.1016/S0166-6851(98)00176-5; Heise N, 1997, MOL BIOCHEM PARASIT, V89, P61, DOI 10.1016/S0166-6851(97)00101-1; KAGAWA Y, 1964, J BIOCHEM-TOKYO, V56, P364, DOI 10.1093/oxfordjournals.jbchem.a128003; KOHL L, 1994, EUR J BIOCHEM, V220, P331, DOI 10.1111/j.1432-1033.1994.tb18629.x; KUPOR SR, 1972, J BIOL CHEM, V247, P1904; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LUPIANEZ JA, 1987, INT J BIOCHEM, V19, P1085, DOI 10.1016/0020-711X(87)90310-7; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; MICHELS PAM, 1991, EUR J BIOCHEM, V198, P421, DOI 10.1111/j.1432-1033.1991.tb16031.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NYAME K, 1994, MOL BIOCHEM PARASIT, V67, P269, DOI 10.1016/0166-6851(94)00139-1; OBRIEN E, 1994, MOL BIOCHEM PARASIT, V64, P313, DOI 10.1016/0166-6851(94)00028-X; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; OPPERDOES FR, 1984, FEBS LETT, V169, P35, DOI 10.1016/0014-5793(84)80284-7; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; Peterson GC, 1997, EXP PARASITOL, V85, P16, DOI 10.1006/expr.1996.4114; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; Rakitzis ET, 1998, CHEM-BIOL INTERACT, V113, P205, DOI 10.1016/S0009-2797(98)00026-X; ROSEMEYER MA, 1987, CELL BIOCHEM FUNCT, V5, P79, DOI 10.1002/cbf.290050202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD PJ, 1976, BIOCHEM BIOPH RES CO, V71, P1313, DOI 10.1016/0006-291X(76)90798-1; SMITH K, 1991, MOL BIOCHEM PARASIT, V48, P109, DOI 10.1016/0166-6851(91)90170-B; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VISSER N, 1981, EUR J BIOCHEM, V118, P521, DOI 10.1111/j.1432-1033.1981.tb05550.x; WIERENGA RK, 1987, EMBO J, V6, P215, DOI 10.1002/j.1460-2075.1987.tb04741.x; Zomer AWM, 1999, MOL BIOCHEM PARASIT, V104, P55, DOI 10.1016/S0166-6851(99)00141-3	49	64	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27559	27565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10867008				2022-12-25	WOS:000089197100008
J	Xu, YX; Liu, L; Michaeli, S				Xu, YX; Liu, L; Michaeli, S			Functional analyses of positions across the 5 ' splice site of the trypanosomatid spliced leader RNA - Implications for base-pair Interaction with U5 and U6 snRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; LEPTOMONAS-COLLOSOMA; U1 SNRNA; CRITHIDIA-FASCICULATA; MUTATIONAL ANALYSIS; PREMESSENGER RNA; GU DINUCLEOTIDE; CLEAVAGE SITE; ACTIVE-SITE	In this study, we have used a genetic compensatory approach to examine the functional significance of the previously proposed interaction of spliced leader (SL) RNA with U5 small nuclear RNA (snRNA) (Dungan, J. D., Watkins, K. P., and Agabian, N. (1996) EMBO J. 15, 4016-4029; Xu, Y.-X., Ben Shlomo, H., and Michaeli, S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 8473-8478) and the interaction of the SL RNA intron with U6 snRNA analogous to cis-splicing. Mutations were introduced at positions -4, -1, +1, +4, +5, and +7/+8 relative to the SL RNA 5' splice site that were proposed to interact with U5 and U6 snRNAs, All mutants exhibited altered splicing phenotypes compared with the parental strain, showing the importance of these intron and exon positions for transsplicing. Surprisingly, mutation at invariant +1 position did not abolish splicing completely, unlike cia-splicing, but position +2 had the most severe effect on transsplicing. Compensatory mutations were introduced in U5 and U6 snRNAs to examine whether the defects resulted from failure to interact with these snRNAs by base pairing, Suppression was observed only for positions +5 and +7/+8 with U5 compensatory mutations and for position +5 with a U6 compensatory mutation, supporting the existence of a base pair interaction of U5 and U6 with the SL RNA intron region. The failure to suppress the other SL RNA mutants by the U5 compensatory mutations suggests that another factor(s) interacts with these key SL RNA positions.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022; Xu, Yu-Xin/G-4041-2010	Xu, Yu-Xin/0000-0002-0200-4633; Liu, Li/0000-0002-3733-6961				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; GOLDRING A, 1995, EXPT PARASITOLOGY, V80, P333; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; Goncharov I, 1998, NUCLEIC ACIDS RES, V26, P2200, DOI 10.1093/nar/26.9.2200; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; PALFI Z, 1994, J BIOL CHEM, V269, P30620; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Reyes J, 1996, RNA, V2, P213; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; Sambrook J., 2002, MOL CLONING LAB MANU; Schnare MN, 1999, FEBS LETT, V459, P215, DOI 10.1016/S0014-5793(99)01235-1; Schnare MN, 1999, J BIOL CHEM, V274, P23691, DOI 10.1074/jbc.274.34.23691; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, J BIOL CHEM, V274, P19361, DOI 10.1074/jbc.274.27.19361; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; ULLU E, 1997, MOL BIOL PARASITIC P, P115; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	49	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27883	27892						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875928				2022-12-25	WOS:000089197100050
J	Piserchio, A; Usdin, T; Mierke, DF				Piserchio, A; Usdin, T; Mierke, DF			Structure of tuberoinfundibular peptide of 39 residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PARATHYROID-HORMONE; PTH-RELATED PEPTIDE; NMR-SPECTROSCOPY; RECEPTOR INTERACTIONS; COUPLING-CONSTANTS; AMINO-TERMINUS; CROSS-LINKING; PROTEIN; LIGAND; AGONIST	The recently identified natural peptide ligand, tuberoinfundibular peptide of 39 residues (TIP39) for the parathyroid hormone-2 (PTHS) receptor has been structurally characterized by high resolution NMR, circular dichroism, and computer simulations. The structural features of TIP39, determined in the presence of a zwitterionic lipid to mimic the membrane environment of the G-protein-coupled PTH2 receptor, consist of two a-helices, Ala(5)-Arg(21) and Leu(26)-Val(35). Although TIP39 shares limited sequence homology with parathyroid hormone (PTH), a comparison of the structural features of TIP39 and PTH illustrates a similar topological display of residues of the N-terminal helix important for PTH2 receptor activation. The C-terminal helix of TIP39 differs from that of PTH with respect to size and amphipathicity, suggesting an altered mode of binding for TIP39, consistent with the receptor chimera and ligand truncation studies presented in the accompanying paper (Hoare, S. R. J., Clark, J, A, and Usdin, T. B. (2000) J. Biol. Chen. 275, 27274-27283). The structural characterization of TIP39 also provides some insight into the lack of affinity of this novel ligand for the PTH1 receptor.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Div Biol & Med, Providence, RI 02912 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA; NIMH, Genet Lab, Cell Biol Unit, Bethesda, MD 20892 USA	Brown University; Brown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Mierke, DF (corresponding author), Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Box G-B4, Providence, RI 02912 USA.	dale_mierke@brown.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054082, R01GM054082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002685, ZIAMH002685] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00995] Funding Source: Medline; NIGMS NIH HHS [GM54082] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BROWN LR, 1981, BIOCHIM BIOPHYS ACTA, V642, P296, DOI 10.1016/0005-2736(81)90447-8; CARTER PH, 1998, ASBMR IBMS 2 JOINT M, pSA178; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Crippen G, 1988, DISTANCE GEOMETRY MO; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fasman G.D., 1996, CIRCULAR DICHROISM C; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; Hoare SRJ, 2000, J BIOL CHEM, V275, P27274; Hoare SRJ, 1999, ENDOCRINOLOGY, V140, P4419, DOI 10.1210/en.140.10.4419; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; Hull KL, 1998, COMP BIOCHEM PHYS C, V119, P389, DOI 10.1016/S0742-8413(98)00010-3; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; MIERKE DF, 1994, INT J PEPT PROT RES, V44, P325, DOI 10.1111/j.1399-3011.1994.tb01016.x; MIERKE DF, 1994, BIOPOLYMERS, V34, P559, DOI 10.1002/bip.360340411; MORODER L, 1993, BIOCHEMISTRY-US, V32, P13551, DOI 10.1021/bi00212a022; Moroder L, 1997, J PEPT SCI, V3, P1; MULLER L, 1979, J AM CHEM SOC, V101, P4481; PAPAVOINE CHM, 1994, BIOCHEMISTRY-US, V33, P12990, DOI 10.1021/bi00248a007; Peggion E, 1999, BIOPOLYMERS, V50, P525; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Pellegrini M, 1999, BIOPOLYMERS, V51, P208, DOI 10.1002/(SICI)1097-0282(1999)51:3<208::AID-BIP4>3.0.CO;2-U; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SCHWYZER R, 1991, BIOPOLYMERS, V31, P785, DOI 10.1002/bip.360310624; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Usdin TB, 2000, TRENDS PHARMACOL SCI, V21, P128, DOI 10.1016/S0165-6147(00)01455-3; Usdin TB, 1999, NAT NEUROSCI, V2, P941, DOI 10.1038/14724; Usdin TB, 1999, ENDOCRINOLOGY, V140, P3363, DOI 10.1210/en.140.7.3363; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	54	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27284	27290						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10856302				2022-12-25	WOS:000089144800082
J	Zhao, J; Grafi, G				Zhao, J; Grafi, G			The high mobility group I/Y protein is hypophosphorylated in endoreduplicating maize endosperm cells and is involved in alleviating histone H1-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; CHROMATIN STRUCTURE; DNA INTERACTIONS; GENE-EXPRESSION; GAMMA-ZEIN; HMG-I/Y; BINDING; H1; PROMOTER; PHOSPHORYLATION	During maize endosperm development, cells shift from a mitotic cycle to endoreduplication, driving the massive synthesis of storage proteins (zeins) and starch. In this developmental context, we studied changes in expression levels of histone H1 and high mobility group I/Y (HMG-YY), two chromatin architectural proteins that are known to affect gene transcription. Almost no change was found in the level of histone H1 during endosperm development, despite a dramatic increase in DNA content (endoreduplication); hence, the histone H1/DNA ratio decreased substantially. Concurrently with a reduction in the Cdc2 kinase activity at the shift to endoreduplication, significant changes were found in the level and mobility of the HMG-I/Y protein; the faster migrating forms were, at least partly, hypophosphorylated. Purified maize HMG-I/Y protein was found to be phophorylated in vitro by the Cdc2 kinase and bound efficiently to the gamma-zein promoter AT-rich tract (gamma Z-AT). Using an in vitro transcription assay, we demonstrated the capability of the maize HMG-I/Y protein to relieve the inhibitory effect exerted by histone H1 on templates containing the gamma Z-AT sequence, These data suggest that during maize endosperm development transcription and perhaps replication are controlled, at least partly, by the activity of the Cdc2 kinase and the interplay between histone H1 and HMG-I/Y proteins.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Grafi, G (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.							Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARTWRIGHT IL, 1988, ARCHITECTURE EUKARYO, P283; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GOODWIN G, 1988, ARCHITECTURE EUKARYO, P187; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HUTH JR, 1997, NAT STRUCT BIOL, V4, P122; IVACHENKO MG, 1988, ELECTROPHORESIS, V9, P812; JACOBSEN K, 1990, PLANT CELL, V2, P85, DOI 10.1105/tpc.2.1.85; KAHL G, 1988, ARCHITECTURE EUKARYO, P301; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kowles R.V., 1988, INT REV CYTOL, P97, DOI [10.1016/s0074-7696(08)62007-0, DOI 10.1016/S0074-7696(08)62007-0]; Krech AB, 1999, GENE, V230, P1, DOI 10.1016/S0378-1119(99)00067-0; LAUX T, 1991, NUCLEIC ACIDS RES, V19, P4768, DOI 10.1093/nar/19.17.4768; Lu ZH, 1998, MOL BIOL CELL, V9, P1163, DOI 10.1091/mbc.9.5.1163; Martinez-Garcia JF, 1999, PLANT J, V18, P173, DOI 10.1046/j.1365-313X.1999.00440.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NIETOSOTELO J, 1994, NUCLEIC ACIDS RES, V22, P1115, DOI 10.1093/nar/22.6.1115; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OR E, 1993, PLANT CELL, V5, P1599, DOI 10.1105/tpc.5.11.1599; PEDERSEN TJ, 1991, PLANT MOL BIOL, V16, P95, DOI 10.1007/BF00017920; PrymakowskaBosak M, 1996, P NATL ACAD SCI USA, V93, P10250, DOI 10.1073/pnas.93.19.10250; PWEE KH, 1994, PLANT MOL BIOL, V26, P1907, DOI 10.1007/BF00019502; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; SINGER DS, 1978, BIOCHEMISTRY-US, V17, P2086, DOI 10.1021/bi00604a011; SO JS, 1991, MOL CELL, V1, P145; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPIKER S, 1988, ARCHITECTURE EUKARYO, P143; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; WALLACE JC, 1990, PLANT PHYSIOL, V92, P191, DOI 10.1104/pp.92.1.191; Wang ZD, 1998, GENE, V223, P321, DOI 10.1016/S0378-1119(98)00244-3; Yamamoto S, 1997, PLANT MOL BIOL, V33, P537, DOI 10.1023/A:1005791728975; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	43	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27494	27499						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864924				2022-12-25	WOS:000089144800109
J	Dienz, O; Hehner, SP; Droge, W; Schmitz, ML				Dienz, O; Hehner, SP; Droge, W; Schmitz, ML			Synergistic activation of NF-kappa B by functional cooperation between Vav and PKC theta in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-THETA; SIGNAL-TRANSDUCTION PATHWAYS; IL-2 PROMOTER; DEPENDENT ACTIVATION; CELL ACTIVATION; REL PROTEINS; JNK/SAPK; EXCHANGE; ISOFORMS; UV	Here we identified PKC theta as an activator of transcription factor NF-kappa B in T cells. PK theta-induced NF-kappa B activation was synergistically augmented by Vav, Several experimental approaches revealed that PKC theta is located downstream from Vav in the control of the pathway leading to synergistic NF-kappa B activation. In addition to the synergistic activation cascade, Vav also triggered NF-kappa B activity on a separate route. CD3/CD28-induced activation of NF-kappa B was inhibited by dominant negative forms of Vav or PKC theta, revealing their essential role in this activation pathway. The Vav/PKC theta-mediated signals preferentially activated I kappa B kinase P. Vav and PRC theta were found to be constitutively associated in unstimulated T cells. Only the ligation of the costimulatory CD28 receptor, but not of the T cell receptor, resulted in the transient dissociation of the Vav-PKC theta complex. In contrast, T cell receptor/CD28 costimulation resulted in faster dissociation and slower reassociation kinetics.	German Canc Res Ctr, Dept Immunochem G0200, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem G0200, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				BAIER G, 1993, J BIOL CHEM, V268, P4997; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Portoles P, 1999, CELL IMMUNOL, V195, P96, DOI 10.1006/cimm.1999.1529; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Vespa GNR, 1999, J IMMUNOL, V162, P799; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101	35	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24547	24551		10.1074/jbc.C000177200	http://dx.doi.org/10.1074/jbc.C000177200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10862755	hybrid			2022-12-25	WOS:000088683300043
J	Sengenes, C; Berlan, M; De Glisezinski, I; Lafontan, M; Galitzky, J				Sengenes, C; Berlan, M; De Glisezinski, I; Lafontan, M; Galitzky, J			Natriuretic peptides: a new lipolytic pathway in human adipocytes	FASEB JOURNAL			English	Article						human fat cells; ANP; BNP; lipolysis; microdialysis	FAT-CELL FUNCTION; ADIPOSE-TISSUE; CLEARANCE RECEPTOR; PROTEIN-KINASE; CYCLIC-AMP; PHOSPHODIESTERASES; INSULIN; LOCALIZATION; ACTIVATION; EXPRESSION	Atrial natriuretic peptide (ANP) receptors have been described on rodent adipocytes and expression of their mRNA is found in human adipose tissue. However, no biological effects associated with the stimulation of these receptors have been reported in this tissue. A putative lipolytic effect of natriuretic peptides was investigated in human adipose tissue. On isolated fat cells, ANP and brain natriuretic peptide (BNP) stimulated lipolysis as much as isoproterenol, a nonselective beta-adrenergic receptor agonist, whereas C-type natriuretic peptide (CNP) had the lowest lipolytic effect. In situ microdialysis experiments confirmed the potent lipolytic effect of ANP in abdominal s.c. adipose tissue of healthy subjects. A high level of ANP binding sites was identified in human adipocytes. The potency order defined in lipolysis (ANP > BNP > CNP) and the ANP-induced cGMP production sustained the presence of type A natriuretic peptide receptor in human fat cells. Activation or inhibition of cGMP-inhibited phosphodiesterase (PDE-3B) (using insulin and OPC 3911, respectively) did not modify ANP-induced lipolysis whereas the isoproterenol effect was decreased or increased. Moreover, inhibition of adenylyl cyclase activity (using a mixture of alpha(2)-adrenergic and adenosine A1 agonists receptors) did not change ANP- but suppressed isoproterenol-induced lipolysis. The noninvolvement of the PDE-3B was finally confirmed by measuring its activity under ANP stimulation. Thus, we demonstrate that natriuretic peptides are a new pathway controlling human adipose tissue lipolysis operating via a cGMP-dependent pathway that does not involve PDE-3B inhibition and cAMP production.	Fac Med Toulouse, INSERM, U317, Lab Pharmacol Med & Clin, F-31073 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Galitzky, J (corresponding author), Fac Med Toulouse, INSERM, U317, Lab Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France.	galizky@cict.fr	Sengenes, Coralie/GSN-0709-2022; Galitzky, Jean/R-6599-2017	de Glisezinski, Isabelle/0000-0002-3166-549X; Sengenes, Coralie/0000-0002-4820-6660				ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ATHONSEN MW, 1998, J BIOL CHEM, V273, P215; BERLAN M, 1980, J PHYSIOL-PARIS, V76, P133; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DELEON H, 1995, CIRC RES, V77, P64, DOI 10.1161/01.RES.77.1.64; GSKE R, 1989, BIOMED RES, V10, P463; JEANDEL L, 1989, MOL CELL ENDOCRINOL, V62, P69, DOI 10.1016/0303-7207(89)90114-7; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; Maack Thomas, 1995, P1001; MANGANIELLO V, 1988, METHOD ENZYMOL, V159, P504; MANGANIELLO VC, 1992, ADV SEC MESS PHOSPH, V25, P147; Manganiello VC, 1996, CURR TOP CELL REGUL, V34, P63, DOI 10.1016/S0070-2137(96)80003-3; Millet L, 1998, J APPL PHYSIOL, V85, P181, DOI 10.1152/jappl.1998.85.1.181; Pandey KN, 1996, ENDOCRINOLOGY VASCUL, P255, DOI [10.1007/978-1-4612-0231-8_19, DOI 10.1007/978-1-4612-0231-8_19]; Patel AI, 1997, J PHARMACOL EXP THER, V283, P894; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sarzani R, 1996, J ENDOCRINOL INVEST, V19, P581; Sarzani R, 1995, J HYPERTENS, V13, P1241, DOI 10.1097/00004872-199511000-00004; SCAVONE C, 1995, J PHARMACOL EXP THER, V272, P1036; STRALFORS P, 1985, FEBS LETT, V180, P280, DOI 10.1016/0014-5793(85)81086-3; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Thibault G, 1996, LIFE SCI, V58, P2345, DOI 10.1016/0024-3205(96)00235-4; UEHLINGER DE, 1986, J CARDIOVASC PHARM, V8, P1122, DOI 10.1097/00005344-198611000-00005	30	380	395	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1345	1351		10.1096/fj.14.10.1345	http://dx.doi.org/10.1096/fj.14.10.1345			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877827				2022-12-25	WOS:000087932200009
J	Chomyn, A; Enriquez, JA; Micol, V; Fernandez-Silva, P; Attardi, G				Chomyn, A; Enriquez, JA; Micol, V; Fernandez-Silva, P; Attardi, G			The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNA(Leu(UUR)) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-SYNTHESIS; POINT MUTATION; NADH DEHYDROGENASE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; TERTIARY STRUCTURE; MELAS SUBGROUP; AMINO-ACIDS; HUMAN-CELLS	The pathogenetic mechanism of the mitochondrial tRNA(Leu(UUR)) A3243G transition associated with the mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome has been investigated in transmitochondrial cell lines constructed by transfer of mutant mitochondrial DNA (mtDNA)-carrying mitochondria from three genetically unrelated MELAS patients or of isogenic wild-type mtDNA-carrying organelles into human mtDNA-less cells. An in vivo footprinting. analysis of the mtDNA segment within the tRNA(Leu(UUR)) gene that binds the transcription termination factor failed to reveal any difference in occupancy of sites or qualitative interaction with the protein between mutant and wild-type mtDNAs, Cell lines nearly homoplasmic for the mutation exhibited a strong (70-75%) reduction in the level of aminoacylated tRNA(Leu(UUR)) and a decrease in mitochondrial protein synthesis rate. The latter, however, did not show any significant correlation between synthesis defect of the individual polypeptides and number or proportion of UUR codons in their mRNAs, suggesting that another step, other than elongation, may be affected. Sedimentation analysis in sucrose gradient showed a reduction in size of the mitochondrial polysomes, while the distribution of the two rRNA components and of the mRNAs revealed decreased association of mRNA with ribosomes and, in the most affected cell line, pronounced degradation of the mRNA associated with slowly sedimenting structures. Therefore, several lines of evidence indicate that the protein synthesis defect in A3243G MELAS mutation-carrying cells is mainly due to a reduced association of mRNA with ribosomes, possibly as a consequence of the tRNA(Leu(UUR)) amino-acylation defect.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Chomyn, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Silva, Patricio Fernandez/U-2256-2017; Micol, Vicente/K-6841-2014; Enríquez, J.A./M-8468-2016	Silva, Patricio Fernandez/0000-0001-8971-7355; Enríquez, J.A./0000-0002-3671-2961; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P427; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; El Meziane A, 1998, NAT GENET, V18, P350; Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHELGHODSIAN N, 1995, AM J OTOLARYNG, V16, P403, DOI 10.1016/0196-0709(95)90078-0; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233; GOLDMAN E, 1982, J MOL BIOL, V158, P619, DOI 10.1016/0022-2836(82)90252-2; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; ICHIKI T, 1988, ANN NEUROL, V23, P287, DOI 10.1002/ana.410230312; Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744; JOHNS DR, 1991, LANCET, V337, P927, DOI 10.1016/0140-6736(91)90272-Q; KING MP, 1993, J BIOL CHEM, V268, P10228; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI M, 1987, J PEDIATR-US, V110, P223, DOI 10.1016/S0022-3476(87)80158-0; KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; Maxam A M, 1980, Methods Enzymol, V65, P499; Micol V, 1997, J BIOL CHEM, V272, P18896, DOI 10.1074/jbc.272.30.18896; Micol V, 1996, Methods Enzymol, V264, P3, DOI 10.1016/S0076-6879(96)64003-8; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; OJALA D, 1972, J MOL BIOL, V65, P273, DOI 10.1016/0022-2836(72)90282-3; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PUGLISI JD, 1993, NUCLEIC ACIDS RES, V21, P41, DOI 10.1093/nar/21.1.41; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Senger B, 1996, BIOCHIMIE, V78, P597, DOI 10.1016/S0300-9084(96)80006-X; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Soll D., 1993, RNA WORLD, P157; TANAKA M, 1986, BIOCHEM BIOPH RES CO, V140, P88, DOI 10.1016/0006-291X(86)91061-2; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANVENRO.WJ, 1972, BIOCHIM BIOPHYS ACTA, V259, P127, DOI 10.1016/0005-2787(72)90480-7; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	58	159	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19198	19209		10.1074/jbc.M908734199	http://dx.doi.org/10.1074/jbc.M908734199			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858457	Green Accepted, hybrid			2022-12-25	WOS:000087815900077
J	Ogawa, H; Muramatsu, H; Kobayashi, T; Morozumi, K; Yokoyama, I; Kurosawa, N; Nakao, A; Muramatsu, T				Ogawa, H; Muramatsu, H; Kobayashi, T; Morozumi, K; Yokoyama, I; Kurosawa, N; Nakao, A; Muramatsu, T			Molecular cloning of endo-beta-galactosidase C and its application in removing alpha-galactosyl xenoantigen from blood vessels in the pig kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE ENDOTHELIAL-CELLS; MAJOR SWINE XENOANTIGEN; HYPERACUTE REJECTION; EXPRESSION; EPITOPES; GENE; ANTIBODIES; XENOTRANSPLANTATION; GAL-ALPHA-1->3GAL; TRANSFECTION	Gal alpha 1-3Gal is the major xenoantigenic epitope responsible for hyperacute rejection upon pig to human xenotransplantation. Endo-beta-galactosidase C from Clostridium perfringens destroys the antigenic epitope by cleaving the beta-galactosidic linkage in the Gal alpha 1-3Gal beta 1-4GlcNAc structure. Based on partial peptide sequences of the enzyme, we molecularly cloned the enzyme gene, which encodes a protein with a predicted molecular mass of about 93 kDa, The deduced protein sequence of the enzyme has limited homology in the C-terminal half with endo-beta-galactosidase from Flavobacterium keratolyticus and beta-1,3-glucanases, The enzyme expressed in Escherichia coli removed the alpha-galactosyl epitope nearly completely from pig erythrocytes and from pig aortic endothelial cells. The enzyme-treated endothelial cells in culture were greatly reduced in cell surface antigens, which were recognized by IgM, IgG, or IgA in human sera, and became much less susceptible to complement-mediated cytotoxicity caused by human sera. When the pig kidney was perfused with the enzyme, the vascular endothelial cells became virtually devoid of the alpha-galactosyl epitope, with concomitant decrease in binding to IgM in human plasma. These results demonstrated that the recombinant endo-beta-galactosidase C is a valuable aid in xenotransplantation.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya City Univ, Dept Internal Med 3, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya University; Nagoya University; Nagoya City University	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			Ogawa, Haruko/0000-0001-5889-499X; Kurosawa, Nobuyuki/0000-0002-1548-4541				ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; BACH FH, 1991, TRANSPL P, V23, P205; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; FUSHUKU N, 1987, J BIOL CHEM, V262, P10086; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GOOD AH, 1992, TRANSPL P, V24, P559; KAMADA Y, 1988, J BIOCHEM-TOKYO, V104, P738, DOI 10.1093/oxfordjournals.jbchem.a122543; KAMADA Y, 1988, CARBOHYD RES, V176, P237, DOI 10.1016/0008-6215(88)80135-6; Kobayashi T, 1999, Subcell Biochem, V32, P229; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVECCHIO JA, 1995, TRANSPLANTATION, V60, P841, DOI 10.1097/00007890-199510270-00014; Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; Luo Y, 1999, XENOTRANSPLANTATION, V6, P238, DOI 10.1034/j.1399-3089.1999.00035.x; Nagasaka T, 1997, BIOCHEM BIOPH RES CO, V232, P731, DOI 10.1006/bbrc.1997.6360; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SHIMIZU T, 1991, INFECT IMMUN, V59, P137, DOI 10.1128/IAI.59.1.137-142.1991; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPILLIAERT R, 1994, EUR J BIOCHEM, V224, P923, DOI 10.1111/j.1432-1033.1994.00923.x; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; Tanemura M, 1998, J BIOL CHEM, V273, P16421, DOI 10.1074/jbc.273.26.16421; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; Watier H, 1996, TRANSPLANTATION, V62, P105, DOI 10.1097/00007890-199607150-00020; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8	35	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19368	19374		10.1074/jbc.M001888200	http://dx.doi.org/10.1074/jbc.M001888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10858461	hybrid			2022-12-25	WOS:000087815900097
J	Langlais, P; Dong, LQ; Hu, DR; Liu, F				Langlais, P; Dong, LQ; Hu, DR; Liu, F			Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family	ONCOGENE			English	Article						Grb10; Src; IR; SH2	ADAPTER PROTEIN GRB10; RECEPTOR-BINDING-PROTEIN; FACTOR-I RECEPTORS; INSULIN-RECEPTOR; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAIN; SHC PROTEINS; V-SRC; GROWTH	Treatment of cells with insulin and protein tyrosine phosphatase inhibitors such as vanadate and pervanadate resulted in the tyrosine phosphorylation of Grb10, a Src homology 2 (SH2) and pleckstrin homology domain-containing adaptor protein,which binds to a number of receptor tyrosine kinases including the insulin receptor (IR), Although Grb10 binds directly to the kinase domain of the IR, our data show that Grb10 is not a direct substrate for the IR tyrosine kinase. Consistent with this finding, Grb10 tyrosine phosphorylation in cells was inhibited by herbimycin A, a relatively specific inhibitor for members of the Src tyrosine kinase family, and by the expression of dominant negative Src or Fyn. In addition, Grb10 tyrosine phosphorylation was stimulated by expression of constitutively active Src or Fyn in cells and by incubation with purified Src or Fyn in vitro. The insulin stimulated or Src/Fyn-mediated tyrosine phosphorylation iir vivo was significantly reduced when Grb10 tyrosine 67 was changed to glycine. This mutant form of Grb10 bound with higher affinity to the IR in cells than that of the wild-type protein, suggesting that tyrosine phosphorylation of Grb10 may normally negatively regulate its binding to the IR, Our data show that Grb10 is a new substrate for members of the Src tyrosine kinase family and that the tyrosine phosphorylation of the protein may play a potential role in cell signaling processes mediated by these kinases.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DELALUNA S, 1988, GENE, V62, P121; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Wang J, 1999, MOL CELL BIOL, V19, P6217; WENG Z, 1994, MOL CELL BIOL, V14, P509; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHANG B, 1991, J BIOL CHEM, V266, P990	45	34	34	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2895	2903		10.1038/sj.onc.1203616	http://dx.doi.org/10.1038/sj.onc.1203616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871840				2022-12-25	WOS:000087544500003
